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Abstract N° A1
Length remodeling study of sarcomeres by uniform
strain via microtextured surfaces
H. Mansour a, M. Vracar-Grabar a, Y. Koshman a,
J. Martin b, A.M. Samarel b, B. Russell a. a Department of
Physiology, UIC, Chicago, IL, USA. b Cardiovascular
Institute, Loyola University Chicago Stritch School of
Medicine, Maywood, IL, USA
Our goal was to investigate remodeling of sarcomere
length in response to mechanical strain. To do so, we cultured
neonatal rat cardiomyocytes on microfabricated peg- and-
groove, laminin-coated silicone surfaces and rapidly applied
a uniaxial static strain of 10%. We found uniform lengthe-
ning of sarcomeres as determined by fast Fourier transform
analysis of images. The time course peaked in length in
minutes and had a half time of recovery of 2 h. Focal adhe-
sion kinase (FAK) is located in the costamere where the
cardiac myocyte is anchored to the extracellular matrix. A
quick strain caused increases in FAK autophosphorylation at
Y397 lasting over 30 min, as detected with phosphospecific
antibody both in confocal images and in Westerns (increased
54+/–18%, n = 3). To assess the importance of FAK, cardio-
myocytes were infected with an Adv encoding a dominant-
negative inhibitor containing the focal adhesion targeting
sequence, but lacking the Y-397 auto-phosphorylation site
and the kinase domain (Adv-GFP-FRNK). Adv-GFP-FRNK
prevented resting sarcomere length recovery, whereas a
control Adv encoding only GFP did not. To assess the loca-
tion of newly synthesized proteins we infected cells with
adenoviruses of alpha-tropomyosin with a FLAG epitope or
CapZ with a green fluorescent protein tag. Both are first
detectable under 12 h. A sudden strain applied at 10, 12 or
14 h after infections timed to catch incorporation of newly
synthesized and labeled Adv-proteins showed uniform labe-
ling throughout all sarcomeres suggesting the process of new
sarcomere addition or dynamic exchange occurs throughout
the myocyte. In conclusion, using our novel culture system,
we provide evidence indicating that the length remodeling
process requires FAK and occurs throughout the myocyte.
Funded by NIH HL 64956, HL 62426, HL 07692.
Abstract N° A2
Effects of myosin binding protein C on contractile
efficiency and oscillatory work production
Le Winter. University of Vermont, USA
We examined the effect of cardiac myosin binding
protein-C (cMyBP-C) on contractile efficiency in isovolumi-
cally contracting left ventricle (LV) and on internal viscosity
and oscillatory work production in skinned myocardial
strips. Propyl-2-thiouracil (PTU) was fed to wild-type
(+/+PTU) and homozygous truncated cMyBP-C (t/tPTU) mice,
leading to a myosin isoform profile of ~10% a-myosin heavy
chain (MHC) vs. 90% b-MHC in both groups. Western blot
analysis confirmed that cMyBP-C was present in the +/+PTU
and effectively absent in the t/tPTU. Total LV mechanical
energy per beat was quantified as pressure-volume area
(PVA). O2 consumption (VO2) per beat was plotted against
PVA at varying LV volumes. The reciprocal of the slope of
the linear VO2–PVA relation represents the efficiency of
conversion of O2 to mechanical energy (contractile effi-
ciency). Contractile efficiency was significantly enhanced in
t/tPTU (26.1 ± 2.6%) compared to +/+PTU (17.1 ± 1.6%). In
maximally calcium-activated skinned myocardial strips,
isometric tension was similar between groups. Sinusoidal
length perturbations applied from 0.125 to 250 Hz
demonstrated that maximum oscillatory work occurred at
higher frequencies and was more sensitive to phosphate
concentration in the t/tPTU. Under rigor conditions the
internal elastic stiffness and viscous load was significantly
reduced in the t/tPTU. These results collectively suggest that
contractile efficiency is most likely enhanced in t/tPTU
through reduced loss of mechanical energy by a viscous load
normally provided by cMyBP-C and through a gain of
phosphate-dependent oscillatory work normally inhibited by
cMyBP-C.
Abstract N° A3
Differential roles of estrogen and insulin in cardiac
myofilament activation
Ariyaporn Thawornkaiwong, Jonggonnee
Wattanapermpool. Department of Physiology, Faculty of
Science, Mahidol University, Bangkok 10400, Thailand
Alterations in cardiac function in postmenopausal and
diabetic (Diab) conditions result in the final outcome of heart
failure. No additive effect of insulin and estrogen on suppres-
sing maximum myofibrillar Ca2+ ATPase activity points to a
similar effect of the hormones on myosin heavy chain
(MHC) isoform expression. Electrophoretic analyses of car-
diac MHC in ovariectomized (Ovx), Diab, and Diab–Ovx
rats were then examined. With the same magnitude of sup-
pressed myofibrillar ATPase activity among the groups, le-
vels of a-MHC was found to be highest in Ovx and Diab–
Ovx but lowest in Diab hearts. These results indicate that the
mechanistic regulation of estrogen on cardiac myofilament
activity is not solely dependent on MHC. The dominant
effect of estrogen on changes in myofilament Ca2+ sensitivity
and intracellular Ca2+ transients through suppressions of
both the activity and content of SR Ca2+ ATPase (SERCA)
proteins in Diab–Ovx and Ovx hearts, respectively, led to a
proposed change in SERCA activity by estrogen but not
insulin. Surprisingly, a significant decrease in maximum
SERCA activity with an increase in Ca2+ sensitivity was also
demonstrated in Diab group in the same manner as those
detected in Ovx and Diab–Ovx groups. Supplementation of
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the hormone in each group completely abolished the changes
in SERCA activity. These results thus imply a differential
role of estrogen and insulin in cardiac myofilament activa-
tion.
Abstract N° A4
Genomic structure and functional characterization of
the promoters of mouse ssTnI
C. Zhang, J. Du, X.P. Huang. Department of Biomedical
Science, Center for Molecular Biology and Biotechnology,
Florida Atlantic University, Boca Raton, FL 33431, USA
Two major troponin I (TnI) genes are expressed in the
mammalian heart under the control of a developmentally
regulated program. Fetal TnI, which is identical to slow
skeletal TnI (ssTnI), is expressed first and predominates
throughout embryonic and fetal development. After birth,
ssTnI is downregulated and eventually disappears in the adult
heart. Meanwhile cardiac TnI (cTnI) is upregulated and be-
comes predominant in the adult heart. In our previous stu-
dies, we have demonstrated that ssTnI cannot re-express in
adult mouse heart even in the case of hypertrophy. In this
study, the up-stream part (~1800 bp) of mouse ssTnI has been
identified by PCR of genomic DNA. There is a high homo-
logy in this ssTnI region between mouse and rat. Analysis of
the sequence with a Genomatix software package has revea-
led several potential regulatory domains and binding sites
such as GA-rich sequences (Sp-1 binding sites), GATA bin-
ding site, SMAD4, MEF2, AP1 NFkB, etc. The results from
transfection assays have indicated that conserved GA-rich
sequences, an Oct binding site and a CCAAT box within the
first 300 bp upstream of the transcription start site are critical
for the gene expression. An inhibitory domain has been
revealed within the sequence between –1700 and –1780. The
inhibitory effect seems more significant in C2C12 Myoblast
cells than that in CHO cells, suggesting that some inhibitory
factors existed inside of muscle type cells. In summary, the
up-stream regulatory domain of mouse ssTnI has, at the first
time, been identified and characterized. This provides us with
a useful tool to investigate the expression regulation of this
gene during heart development (Supported partly by a Grant-
in-Aid from AHA-Florida and a research grant from the
Center of Excellence for Biomedical and Marine Biotechno-
logy (P200310) at FAU).
Abstract N° A5
Studies on the interactions between calpain1 and
cytoskeletal proteins of the heart
Liqun Jiang, Chuanjue Cui, Lan-Ying Chen. Division of
Biochemistry, Cardiovascular Institute and Fu Wai Hospital,
Chinese Academy of Medical Science & Peking Union
Medical College, Beijing 100037, PR China
In order to study the relations between calpain1 and cytos-
keletal proteins of heart, we screened the proteins interacted
with calpain1 using yeast two-hybrid system, then sequen-
cing the positive clones and BLAST analysis the DNA frag-
ments. The sequences of clone No. 12 and 22 (pACT2-12 and
pACT2-22) have the 99% and 100% similarity to cardiac
muscle alpha-actin (ACTC), respectively. The sequences of
clone No. 16 (pACT2-16) have the 100% similarity to car-
diac myosin-binding protein C (MyBP-C3). The sequences
of clone No. 37 (pACT2-37) have the 100% similarity to
cardiac alpha 2 actinin (ACTN2). To further confirm which
domain of calpain1 was contained during interactions, posi-
tive clones were transformed into the AH109 with the do-
main II, III or IV of calpain1. pACT2-12(ACTC) could
interact with domain II or III of human calpain1; pACT2-
16(MYBPC3) could interact with domain II, III or IV of
calpain1; while pACT2-37(ACTN) could not interact with
domain II, III or IV of human calpain1. Colorimetry to
quantitative analysis the activities of b-galactosidase (b-
Gal). The stronger of the interaction, the higher of the b-Gal.
When pACT2-12, 16 or 37 interacted with calpain1, the
activities of b-Gal (units/mg) are 122.28, 142.23, 110.26,
respectively. Actin and actinin participate cardiomyocyte
contraction. Our results showed calpain1 could interact with
actin or actinin. If calpain1, as proteinase, could hydrolyze
actin or actinin during physiological or pathological states, it
will affect the cardiomyocytes contraction. MyBP-C3 is
cardiac-specific subtypes and one of the necessary conditions
forming normal thick filaments in the cardiomyocyte. Our
results showed the interaction between calpain1 and MyBP-
C3, and the interaction is relatively strong. It takes a clue that
calpain1 is concerned with the regulation of cardiomyocyte
contraction through MyBP-C3.
Abstract No A6
Post-infarct ventricular rupture is due to matrix
collagen damage in mice
Gao X.M.a, Kiriazis H.a, Samuel C.S.b, Dart A.M.a,
Du X.J.a. aBaker Heart Research Institute and bHoward
Florey Research Institute, Melbourne, Australia
Ventricular rupture occurs in mice with acute myocardial
infarct (AMI). We studied the role of extracellular matrix
(ECM) collagen in the risk of rupture in mice. After coronary
artery occlusion, rupture occurred during days 2-6 in mice.
Collagen content in the infarcted tissue, as determined by
hydroxyproline assay, was unchanged at Day-2 but increased
by 60 % at Day-4 after AMI, indicating de novo collagen
synthesis. We then determined in vitro tension-to-rupture
(TTR) using left ventricular (LV) rings of hearts with AMI
for 4 days. There was a 60 % reduction in TTR of infarcted
vs. non-infarcted LV rings either from the same animal or
from sham-operated mice, indicating a reduced muscle ten-
sile strength. We previously showed that mice with cardiac
overexpression of a2-adrenoceptors had a reduced risk of
rupture (J Cardiovasc Res 2002 ;40 :632). The transgenic
mouse heart had a 30-40 % higher TTR than that of wildtype
mice with or withoutAMI, in keeping with a 55 % increase in
collagen content (2.63 ± 0.18 vs 1.61 ± 0.07 µg/mg d.w.,
p < 0.01, n = 6 each). To compare these findings with a non-
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rupture rodent, we also similarly studied Spraque-Dawley
rats. In rat hearts with AMI for 4-days, TTR was unchanged
relative to non-infarcted LV rings. Collagen content in the
heart was 50 % higher in rats than that in mice
(2.32 ± 0.04 vs 1.38 ± 0.04 µg/mg d.w., p < 0.01,
n = 6 each). We then determined levels of matrix metallopro-
tenase (MMP)-2 and -9 by zymography in mouse and rat
hearts with AMI at Day-4. The major form of MMP that
increased by AMI was MMP-9 in mice but MMP-2 in rats
with a MMP-9 :MMP-2 ratio of 6 in the mouse and 0.6 in the
rat. In summary, ECM collagen content correlates to the
myocardial tensile strength which is significantly reduced in
mice. Following AMI, MMP-9 activation likely degrades
collagen and lowers mechanical strength leading to rupture.
Differences in the mouse and rat in altered tensile strength,
subtypes of MMPs and collagen levels, imply collagen da-
mage in rupture pathogenesis.
Abstract N° A7
Post-infarct ventricular rupture is due to matrix
collagen damage in mice
X.M. Gao a, H. Kiriazis a, C.S. Samuel b, A.M. Dart a,
X.J. Du a. a Baker Heart Research Institute, Melbourne,
Australia. b Howard Florey Research Institute, Melbourne,
Australia
Ventricular rupture occurs in mice with acute myocardial
infarct (AMI). We studied the role of extracellular matrix
(ECM) collagen in the risk of rupture in mice. After coro-
nary artery occlusion, rupture occurred during days 2–6 in
mice. Collagen content in the infarcted tissue, as determined
by hydroxyproline assay, was unchanged at day-2 but in-
creased by 60% at day 4 after AMI, indicating de novo
collagen synthesis. We then determined in vitro tension-to-
rupture (TTR) using left ventricular (LV) rings of hearts with
AMI for 4 d. There was a 60% reduction in TTR of infarcted
vs. non-infarcted LV rings either from the same animal or
from sham-operated mice, indicating a reduced muscle ten-
sile strength. We previously showed that mice with cardiac
overexpression of b2-adrenoceptors had a reduced risk of
rupture (J Cardiovasc Res 2002;40:632). The transgenic
mouse heart had a 30–40% higher TTR than that of wildtype
mice with or withoutAMI, in keeping with a 55% increase in
collagen content (2.63 ± 0.18 vs. 1.61 ± 0.07 mg/mg d.w.,
P < 0.01, n = 6 each). To compare these findings with a
non-rupture rodent, we also similarly studied Spraque–
Dawley rats. In rat hearts with AMI for 4 d, TTR was
unchanged relative to non-infarcted LV rings. Collagen
content in the heart was 50% higher in rats than that in mice
(2.32 ± 0.04 vs. 1.38±0.04 mg/mg d.w., P < 0.01, n = 6 each).
We then determined levels of matrix metalloprotenase
(MMP)-2 and -9 by zymography in mouse and rat hearts with
AMI at day-4. The major form of MMP that increased by
AMI was MMP-9 in mice but MMP-2 in rats with a MMP-
9:MMP-2 ratio of 6 in the mouse and 0.6 in the rat. In
summary, ECM collagen content correlates to the myocar-
dial tensile strength which is significantly reduced in mice.
Following AMI, MMP-9 activation likely degrades collagen
and lowers mechanical strength leading to rupture. Differen-
ces in the mouse and rat in altered tensile strength, subtypes
of MMPs and collagen levels, imply collagen damage in
rupture pathogenesis.
Abstract N° A8
Changes in cardiac function and beta adrenoceptors
are not dependent upon cardiac remodeling
Rajat Sethi, Harjot K. Saini, Naranjan S. Dhalla. Institute of
Cardiovascular Sciences, St. Boniface General Hospital
Research Centre and University of Manitoba, Winnipeg,
Canada
Cardiac function and beta-adrenoceptors are either upre-
gulated or downregulated in the failing heart. Although car-
diac remodeling has been shown to be responsible for heart
failure, its relation with subcellular remodeling needs to be
understood. Heart dysfunction in rats was induced by myo-
cardial infarction (MI), aortocaval shunt (AV shunt) or pres-
sure overload (PO). Cardiac remodeling was determined by
changes in heart weight whereas hemodynamic parameters
were used to determine changes in left ventricle function.
Since beta-adrenergic receptor signal transduction plays an
important role in the regulation of cardiac function, we exa-
mined the status of beta-adrenergic receptors in this study.
Our results show that cardiac remodeling was evident at both
early (4 week) and later (24 week) stages of heart failure but
changes in left ventricular function, isoproterenol-induced
positive inotropic effect on cardiac performance and
isoproterenol-induced increase in intracellular calcium were
dependent on the type and stage of heart failure. Further-
more, beta-adrenergic receptor density in left ventricles was
downregulated, upregulated or unchanged in crude membra-
nes at 4 week due to MI, AV shunt or PO rats; this parameter
was downregulated in all heart failure types at the later
stages. These results thus support the view that changes in
cardiac function and beta-adrenoceptor due to different sti-
muli are not dependent upon cardiac remodeling during the
development of heart failure.
(Supported by CIHR Group in Experimental Cardio-
logy)
Abstract N° A9
Norepinephrine-induced changes in the rat cardiac
TGF-beta isoform expression pattern: studies in male
rats
Wilfried Briest, Henning Meier, Barbara
Ziegelhöffer-Mihalovicova, Heinz-Gerd Zimmer.
Carl-Ludwig-Institute of Physiology, University of Leipzig,
Germany
Transforming growth factor-beta (TGF-b) is a ubiquitous
growth-regulating protein with an essential role in tissue
repair and formation of the extracellular matrix (ECM). To
better understand the role of different isoforms of TGF-b in
the remodelling process induced by norepinephrine (NE), the
expression of TGF-b1, TGF-b2 and TGF-b3 as well as of
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collagen I and III and of matrix metalloproteinase 2
(MMP-2) and its inhibitor TIMP-2 was studied in hearts of
male rats. NE (0.1 mg/kg per h) was i.v. infused in male
Sprague–Dawley rats for 1, 3 and 4 d, and freshly obtained
ventricular myocardium after 1 d was dissociated into myo-
cyte and nonmyocyte fractions. After NE infusion the three
isoforms of TGF-b were differentially induced as far as the
magnitude and the time course is concerned. The increased
expression of TGF-b2 was more pronounced (16-fold eleva-
tion) than that of the two other isoforms, with a clear speci-
ficity for the left ventricle (LV) after 1 d of NE treatment. The
increase of TGF-b1 and TGF-b2 was significant only in the
myocyte fraction. TGF-b3 was decreased in non-myocytes
and not changed in myocytes after 1 d of NE treatment. The
expression of collagens I and III was elevated about 13-fold
after 3–4 d predominantly in the LV. The expression of
MMP-2 and TIMP-2 was increased about fivefold also pre-
dominantly in the LV. All three isoforms of TGF-b showed a
positive correlation with the mRNA of collagen I and III as
well as with MMP-2 and TIMP-2. However, the different
time course and different cell specificity of the NE-induced
elevation of the expression of TGF-b isoforms implicate a
different role of TGF-b isoforms in the NE-induced remodel-
ling process of the rat heart.
Abstract N° A10
Antisense oligoribonucleotide-induced exon skipping in
cardiac myocytes from dystrophin deficient mice
Ronita Sharma a, Sue Fletcher b, Stephen Wilton b,
Andrew Hoey a. a Centre for Biomedical Research,
University of Southern Queensland, Toowoomba, Qld,
Australia. b Centre for Neurological and Neuromuscular
Disorders, University of Western Australia, Perth, Australia
Duchenne muscular dystrophy (DMD) results from the
absence of a functional dystrophin protein from the mem-
brane of muscle cells. The severe skeletal muscle wasting in
DMD patients has previously overshadowed cardiac abnor-
malities. However, these now play a more prominent role as
patients are surviving beyond their 20s with improved pallia-
tive care. The administration of small synthetic RNA-like
molecules into murine skeletal muscle has been shown to
restore dystrophin in mdx mice, which carry a nonsense
mutation in exon 23. The antisense oligoribonucleotides
(AOs) used targeted the donor splice site of exon 23 and
induced the removal of this mutation-containing exon during
pre-mRNA splicing. This AO-induced exon-skipping has
been shown to produce a shorter but functional, non-
immunogenic protein in skeletal muscle. This investigation
therefore focussed on the potential application of AOs in
cardiac tissue to induce functional dystrophin. Fluorescently
labelled AOs were first used to test a range of transfection
reagents to visually confirm uptake by neonatal mdx cardiac
myocytes. AOs of different lengths and chemistries, pre-
viously efficient in skeletal myocytes, were then transfected
into cardiac myocytes at different doses. These were able to
induce exon-skipping, detectable by RT-PCR, however, the
level of exon-skipping in cardiac myocytes was less than that
previously observed in skeletal myocytes. If greater levels of
exon-skipping can be induced in cardiac myocytes, it is
anticipated that sufficient dystrophin may be produced, to
allow for systemic delivery of the treatment and thus delay
the development of dilated cardiomyopathy in DMD pa-
tients.
Abstract N° A11
Abnormal cardiac wall motion and matrix
metalloproteinase activity
Ricardo Garcia, James Covell, Francisco Villarreal.
Department of Medicine, University of California,
San Diego, CA, USA
Activation of matrix metalloproteinases (MMPs) in the
heart is known to facilitate cardiac remodeling and progres-
sion to failure. We hypothesized that regional dyskinetic wall
motion of the left ventricle would stimulate activation of
MMPs. Abnormal wall motion at a target site on the anterior
lateral wall of the left ventricle was induced by pacing atrial
and ventricular sites of five open-chest anesthetized dogs.
Changes in shortening at the left ventricular (LV) pacing site
and at a remote site at the anterior base of the left ventricle
were monitored with piezoelectric crystals. Simultaneous
atrial–ventricular pacing resulted in abnormal wall motion at
the LV pacing site yielding early shortening and late systolic
lengthening, while shortening at the remote site was essenti-
ally unaffected. Global myocardial MMP activity showed a
sevenfold increase in substrate cleavage at the LV pacing site
relative to the remote site. Gelatin zymography revealed
increases of 50-fold in 92 kDa MMP-9 activity and 10-fold in
84 kDa MMP-9 at the LV pacing site relative to the remote
site, whereas MMP-2 activity was unaffected.Abnormal wall
motion was associated with a twofold increase in collagen
degradation and with increases in plasmin activity and in-
flammatory infiltrate relative to the remote site. Results indi-
cate that regional dyskinesis by epicardial activation is suffi-
cient to stimulate significant MMP activity in the heart,
suggesting that abnormal wall motion is a major stimulus for
MMP activation.
Abstract N° A12
Doxycycline flanks the zinc-binding domains of
matrilysin: a putative mode of inhibition
Ricardo A. Garcia, Dennis Pantazatos, Virgil Woods Jr.,
Francisco Villarreal. Department of Medicine, University of
California, San Diego, CA, USA
Matrix metalloproteinases (MMPs) play an essential role
in normal and pathological collagen matrix degradation.
Here, we report on the effects of a broad-spectrum MMP
inhibitor, doxycycline, on the structure of the MMP matrily-
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sin. Deuterium exchange mass spectrometry studies on ma-
trilysin reveal two putative doxycycline-binding sites (resi-
dues 145–155; residues 231–243) of similar affinity that
flank the zinc-binding domains of the enzyme. Examination
of the X-ray crystal structure of matrilysin shows that the
doxycycline-binding site at residues 231–243 is positioned
within the active site cleft adjacent to the catalytic zinc atom.
Comparisons of drug-bound vs. drug-free forms of matrily-
sin show discrete changes in deuterium exchange suggesting
that drug binding induces alterations in structure. In addition,
fluorescence-quenching studies of matrilysin shown minor
changes in conformation induced by doxycycline. In the
absence of doxycycline, tryptophan fluorescence is comple-
tely accessible to quencher, whereas in the presence of doxy-
cycline, accessibility decreases by approximately 8%. These
results suggest a mode of MMP inhibition by doxycycline
that could involve interactions with the catalytic zinc atom.
Abstract N° A13
Reduction of infarct size by doxycycline: a role for
plasmin inhibition
Michael O. Griffin, Francisco Villarreal. Department of
Medicine, University of California, San Diego, CA, USA
Reperfusion of ischemic myocardium leads to the upregu-
lation of several extracellular matrix (ECM)-degrading pro-
teases. The purpose of this study was to determine whether
doxycycline (DOX), a matrix metalloproteinase (MMP) in-
hibitor, would reduce infarct size following ischemia–reper-
fusion injury and to identify potential mechanisms for its
effects. Results showed that DOX treatment reduced infarct
size by ~37% in the rat. DOX did not reduce acute inflamma-
tion (i.e. neutrophil infiltration) but did attenuate increases in
92 kDa MMP-9 and plasmin levels observed in the infarct
region. To investigate the role of these proteases in mediating
myocardial injury, we utilized cultures of neonatal rat ventri-
cular myocytes (NRVMs). NRVMs stimulated with physio-
logical levels of plasminogen generated the active plasmin
form of the protease in a dose-dependent manner. Stimula-
tion with plasminogen (or plasmin), but not active MMP-9,
caused cell detachment and death (i.e. anoikis). Plasminogen
stimulation did not activate endogenous MMPs, and co-
treatment with GM6001 did not preserve cell attachment
suggesting MMP activity was not responsible for cell deta-
chment. Interestingly, co-treatment with DOX preserved
NRVM attachment and viability, and DOX inhibited plasmin
activity in culture with an apparent IC50 of ~18 µg/ml. Howe-
ver, inhibition of plasmin was an indirect effect, as DOX
displayed no dose-dependent or time-dependent inhibition of
plasmin in an in vitro test. These results suggest a novel role
for DOX in preserving cardiomyocyte cell–matrix interac-
tions by indirectly inhibiting plasmin activity.
Abstract N° A14
Cardiovascular changes in the ageing growth hormone
deficient rat
Andrew Fenning a, Andrew Hoey b, Lindsay Brown a.
a School of Biomedical Sciences, The University of
Queensland, QLD 4072, Australia. b Department of
Biological and Physical Sciences, The University of
Southern Queensland, Toowoomba, Australia
Exogenous growth hormone has been implicated as a
potential novel therapy for patients with congestive heart
failure. This project has characterised the Lewis Dwarf (LD)
growth hormone deficient rat model from 6 to 18 months (M)
of age using echocardiography, isolated Langendorff heart
preparations, single-cell microelectrode electrophysiological
recordings and responses from isolated thoracic aortic rings
to determine if growth hormone deficiency initiates heart
failure. LD rats were moderately hypertensive (6 M, 148 ±
3*; 12 M, 157 ± 4*; 15 M, 162 ± 3*; 18 M, 161 ± 4* mmHg)
compared to age-matched Wistar (W) controls (6 M, 121 ± 3;
12 M, 126 ± 3; 15 M, 133 ± 2; 18 M, 129 ± 6 mmHg) with
decreased left ventricular internal dimensions in diastole
(LD: 6 M, 5.4 ± 0.3*; 12 M, 5.3 ± 0.1*; 15 M, 6.1 ± 0.1*;
18 M, 6.8 ± 0.2* mm; W: 6 M, 7.1 ± 1; 12 M, 8.2 ± 0.2; 15 M,
7.8 ± 0.3; 18 M, 7.9 ± 0.3 mm) and increased left ventricular
posterior wall thicknesses (LD: 6M – 1.87 ± 0.08*; 12M –
1.87 ± 0.07*; 15M – 1.89 ± 0.08*; 18M – 1.76 ± 0.1* mm; W:
6M – 1.76 ± 0.08; 12M – 1.72 ± 0.07; 15M – 1.77 ± 0.08;
18M – 1.89 ± 0.08 mm) indicative of concentric cardiac
hypertrophy. Fractional shortening, ejection fraction, maxi-
mum ascending aortic blood flow velocity and maximum
+dP/dt were all increased in the LD rat showing improved
systolic function. LD rats showed prolonged action potential
duration (APD90: LD: 6M – 47.5 ± 5.9*; 12M – 52.9 ± 4.3;
15M – 60.2 ± 5.3*; 18M – 76.5 ± 7.2* ms; W: 6M – 33.1 ±
3.7; 12M – 47.8 ± 5.9; 15M – 49.9 ± 4.1; 18M – 53.7 ±
5.6 ms). Additionally, maximal responses to noradrenaline,
acetylcholine and sodium nitroprusside were significantly
reduced in LD rats. Diastolic stiffness was unaltered between
the groups but increased with age. Thus, chronic growth
hormone deficiency produces compensated concentric car-
diac hypertrophy with improved left ventricular function
without symptoms of heart failure but vascular function is
dramatically reduced in the LD rat.
Abstract N° A15
PKCe-mediated phosphorylation of Cx43 of cardiac
gap junction in the diabetic heart
Lin Hai a, Issei Imanaga a, Koichi Ogawa b. a Department of
Physiology, School of Medicine, Fukuoka University,
Fukuoka 814 0180, Japan. b Department of Anatomy,
School of Medicine, Fukuoka University,
Fukuoka 814 0180 Japan
Cardiac arrhythmias have been extensively documented in
experimental and clinical diabetes. We studied abnormalities
of the gap junction function in the streptozotocin-induced
diabetic rat heart, since impairment of electrical cell-to-cell
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coupling is one of factors inducing arrhythmias. Impulse
conductivity and the intercellular coupling were impaired.
Immunoblot for Cx43 and co-immunoprecipitation of Cx43
and PKC isoforms, PKCe-mediated phosphorylation of
Cx43 was augmented despite of reduction of Cx43 protein. It
was observed in immunohistochemistry image analysis that
expression of Cx43 at the intercalated disk was reduced.
These alterations were ameliorated by lysosomal inhibitors.
In GK/Jcl DM model rat (hereditary, NIDDM), an activation
of PKC was also observed. We concluded that disturbances
of intercellular communication in the diabetic heart is possi-
bly caused by deterioration of the gap junction due to PKCe-
mediated phosphorylation of Cx43.
Abstract N° A16
Identification of four small molecules that increase
alpha myosin heavy chain protein levels in rat neonatal
cardiomyocytes
Jody Kronlage, Lisa Hollingsworth, Larry Melvin,
Kathy Schreiber. Myogen, Inc., Westminster, CO, USA
A diverse group of cardiovascular diseases, including val-
vular dysfunction, cardiomyopathies, hypertension, and is-
chemic heart disease, eventually result in chronic heart
failure (CHF). During the course of disease progression,
changes in fetal gene and contractile protein gene expression
are frequently observed. One of these contractile proteins,
alpha myosin heavy chain (a-MyHC), is severely downregu-
lated in human heart failure. Importantly, these changes are
associated with an impairment in cardiac pump function.
These findings raise the possibility that one potential treat-
ment to enhance contractile performance in CHF patients is
to increase a-MyHC protein levels. In addition, improvement
of cardiac contractility in CHF patients by increasing
a-MyHC protein levels may also reverse cardiac remodelling
and improve cardiac pump function even further. In order to
identify small molecules that upregulate a-MyHC protein
levels in the heart, we have developed a high throughput
screening assay in rat neonatal cardiac myocytes that detects
small changes in (a-MyHC) protein levels. This assay has
been used to screen a 20,000 compound library of small
molecules. Four compounds were identified in this screen
that increase levels of a-MyHC and decrease levels of
b-MyHC. The effect of these compounds on a-MyHC levels
is quite dramatic, with two- to threefold increases in protein
expression levels typically observed. The effect of these
compounds is almost, or in some cases, of equal magnitude
to the increase in a-MyHC induced by thyroid hormone, the
most potent regulator of a-MyHC both in vitro and in vivo.
Further studies are currently underway to examine how these
compounds affect other aspects of cardiac hypertrophy in the
rat neonatal cardiomyocyte model system, and to determine
the mechanism of action of these small molecular regulators
of a-MyHC expression.
Abstract N° A17
Atrial osteopontin expression is not elevated in patients
who develop postoperative atrial fibrillation
Joachim B. Grammer, Johannes Böhm, Csaba Balogh,
Rüdiger Lange, Robert Bauernschmitt. German Heart
Center, Munich, Germany
Osteopontin (OPN), an extracellular matrix protein, has
been shown to play an important role in the development of
heart failure and post-myocardial infarction remodeling by
promoting collagen synthesis and accumulation. Its plasma
levels were found to be associated with the presence and
extent of coronary artery disease and its expression is stimu-
lated by angiotensin II. In chronic atrial fibrillation (AF),
angiotensin-converting enzyme (ACE) mRNA expression is
upregulated, and it has also been shown that angiotensin II
increases OPN mRNA expression in human heart. Therefore,
we were now interested whether OPN expression is elevated
in atria of patients with no history of AF but who develop AF
early after cardiac surgery. Ten patients (68.5 ± 9.2 years;
seven males/three females; ACE inhibitor treatment 40%)
who did not develop postoperative AF were compared to
eight patients (66.3 ± 9.9; six males/two females; ACE inhi-
bitor treatment 62.5%) who experienced AF within 6 d pos-
toperatively. Right atrial appendages were obtained during
cardiac surgery and OPN mRNA and protein expression was
assessed by RT-PCR and western blots, respectively. The
medians of OPN/HPRT mRNA ratios were 1.142 (range
0.429–17.555) and 1.376 (range 0.732–5.287; postoperative
AF vs. postoperative sinus rhythm). The medians of
OPN/GAPDH ratios on the western blots were 0.318 (range
0.140–0.475) and 0.243 (range 0.195–0.408). OPN mRNA
as well as protein expression was not significantly different
between groups (U-test). Our data suggest that the occur-
rence of AF in the early period after cardiac surgery is not
correlated with the amount of atrial OPN expression at the
time of surgery in the affected patients. Hence, plasma OPN
determination will not be adequate to estimate the risk for
postoperative AF.
Abstract N° A18
Expression pattern of troponin C and troponin T
isoforms in developing and pathological heart
A. Stoutamyer, P.J. Barton, L.E. Felkin, M. Koban,
M. Cullen, N. Brand, G.K. Dhoot. The Royal Veterinary
College, University of London, London UK. Heart Science
Centre, Royal Brompton and Harefield Hospital, UK
During heart development, contractile and regulatory pro-
tein genes show characteristic patterns of activation and
subsequent modulation of expression resulting in the forma-
tion of a mature four-chambered organ. Myocardial gene
expression is also altered in the adult in response to patholo-
gical stimuli and this is thought to contribute to the altered
contractile characteristics of the diseased heart. We have
examined the expression of different isoforms of troponin I,
T and C in the developing avian heart as well as the changes
in slow skeletal muscle troponin T in the human heart during
168 2004 ISHR World Congress / Journal of Molecular and Cellular Cardiology 37 (2004) 161-375
development and in disease using whole mount in situ hybri-
disation and real time quantitative (TaqMan) PCR analyses.
Slow skeletal muscle troponin T mRNA shows transitory and
regional expression in the early fetal heart, which occurs at
different times in atria and ventricles. In ventricular myocar-
dium, expression is seen in the outer epicardial layer at a time
when the coronary circulation is being established. Expres-
sion was also detected at quite low levels in the adult human
heart that was significantly increased in end-stage heart
failure. Similarly, expression was readily detectable during
early rat heart development and was up regulated in pressure
overload hypertrophy in adult. These data thus show that
slow skeletal muscle troponin T mRNA is readily detectable
during early human heart development and further suggest
that slow skeletal muscle troponin T may be responsive to
myocardial stress and that elevated levels may contribute to
myocardial dysfunction in adult disease. There have been
virtually no reports of the changes occurring in the isoforms
of troponin C in the developing heart. In this communication,
we will also describe the expression patterns of troponin C
isoforms in developing avian heart.
Abstract N° A19
Regulation of scaffold protein expression during
ischemia/reperfusion
Y.L. Siow a,b,c, K.K.W. Au-Yeung a,c, O.K. a,c,d. a National
Centre for Agri-Food Research in Medicine, University of
Manitoba, Winnipeg, MB, Canada. b Centre for Research
and Treatment for Atherosclerosis, University of Manitoba,
Winnipeg, MB, Canada. c Department of Physiology,
University of Manitoba, Winnipeg, MB, Canada.
d Department of Animal Science, University of Manitoba,
Winnipeg, MB, Canada
The apoptotic death of cardiomyocytes due to
ischemia/reperfusion is one of the major complications of
heart disease. One of the molecular mechanisms leading to
apoptosis is the activation of c-Jun N-terminal kinase (JNK).
The specificity of the activation of JNK cascade may be
determined partly by scaffold proteins, which bind several
kinases of a signaling cascade to form a multimolecular
complex. JIP-1 and JSAP-1 are two recently identified scaf-
fold proteins that are involved in the JNK signaling pathway.
The objectives of the present study were to investigate the
expressions of JIP-1 and JSAP-1 in ischemia/reperfusion and
the effect of magnesium tanshinoate B, a compound purified
from a Chinese medicinal herb Danshen (Radix Salvia mil-
tiorrhizae) on their expressions. Isolated rat hearts were per-
fused in the Langendorff mode and subjected to 30 min
global ischemia followed by reperfusion for various time
periods. The expression of JIP-1 mRNA was significantly
reduced in the heart after ischemia/reperfusion. In contrast,
the expression of JSAP-1 mRNA was elevated. The addition
of magnesium tanshinoate B reversed changes in the expres-
sion of both JIP-1 and JSAP-1 induced by ischemia/
reperfusion. A decrease in JIP-1 expression might reduce the
retention of JNK in the cytoplasm while JSAP-1 at a high
level would facilitate the activation of JNK. In conclusion,
our results suggest that JIP-1 and JSAP-1 can act in concert
to facilitate JNK activation during ischemia/reperfusion. Ma-
gnesium tanshinoate B can exert differential effects on the
expressions of JIP-1 and JSAP-1 indicating its potential
therapeutic role in cardiovascular disorders.
Abstract N° A20
Resveratrol attenuates cardiac remodelling
in DOCA-salt hypertensive rats
Guyan Weerasinghe, Vincent Chan, Lindsay Brown. School
of Biomedical Sciences, The University of Queensland,
QLD 4072, Australia
Chronic cardiovascular disease induces cardiac remodel-
ling including hypertrophy and fibrosis, the excessive depo-
sition of collagen. Reactive oxygen species such as supe-
roxide and hydroxyl radicals are increased in hypertension
and may initiate cellular damage. To test the hypothesis that
an increased oxidant stress is important in cardiac remodel-
ling, we have determined the changes in cardiac structure and
function in DOCA-salt hypertensive rats, which show in-
creased superoxide production, after treatment with the an-
tioxidant resveratrol (R, 1 mg/kg/d p.o. starting 4 d before
uninephrectomy). DOCA-salt rats were uninephrectomied,
given 1% NaCl in their drinking water and deoxyxorticoste-
rone acetate (25 mg every 4th d s.c.) for 4 weeks; uninephrec-
tomied rats (UNX) were used as controls (n = 6–12; *P <
0.05 vs. DOCA). R attenuated the hypertension (UNX 133 ±
5, DOCA 176 ± 4, DOCA + R 154 ± 7* mmHg) and left
ventricular hypertrophy (wet weight: UNX 1.97 ± 0.04,
DOCA 3.17 ± 0.07, DOCA + R 2.76 ± 0.11* mg/g bwt) and
prevented both the increased stiffness (UNX 22.2 ± 1.2,
DOCA 30.1 ± 1,2, DOCA + R 25.5 ± 0.4*) and decreased
contractility (+dP/dt: UNX 2080 ± 70, DOCA 1610 ± 130,
DOCA + R 2170 ± 100* mmHg/s). Further, the increased left
ventricular interstitial collagen deposition was prevented by
R treatment. In isolated thoracic aortic rings, the decreased
endothelial-mediated relaxation in DOCA-salt rats was pre-
vented (maximal response to acetylcholine: UNX 5.8 ± 0.9,
DOCA 1.0 ± 0.2, DOCA + R 3.9 ± 0.7* mN). In addition,
maximal responses to noradrenaline and sodium nitroprus-
side were improved. Thus, administration of R prevented or
attenuated the changes in cardiovascular structure and func-
tion in the DOCA-salt hypertensive rat, indicating that reac-
tive oxygen species are likely to be involved in these changes.
Abstract N° A21
Covalently bound synthetic peptides of fibronectin and
laminin facilitate good cellular attachment but
abnormal physiology in neonatal cardiac myocytes
Samuel Boateng a, Syed Lateef b, Thomas Hartman a,
William Moseley a, Luke Hanley b, Brenda Russell a.
a Department of Physiology and Biophysics, University of
Illinois, Chicago, MI, USA. b Department of Chemistry,
University of Illinois, Chicago, MI, USA
Cell growth, adhesion and migration can be regulated by
the extracellular matrix and play an important role in cardiac
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adaptation to stress. In cell culture, a significant number of
cells become detached in response to mechanical stimula-
tion, limiting the scope of such studies. Here, we have adhe-
red synthetic peptides, RGD (fibronection) and YIGSR (la-
minin) onto silicone. We examined the morphology, gene
expression of neonatal cardiac myocytes cultured on these
peptides and in response to mechanical stimulation. At
100 µM peptide reaction concentration, we achieved the
same degree of cellular adhesion as their respective native
proteins. After 48 h of culture, cells were stained with phal-
loidin and visualized to assess cell morphology. The number
of striated cells on the peptide surfaces was significantly
reduced compared to those on native proteins. Western blot
analysis showed that focal adhesion kinase (FAK) was redu-
ced by 50% in myocytes cultured on YIGSR peptide compa-
red with laminin (laminin vs. YIGSR P < 0.05 n = 3).
B1-integin was unchanged in all groups. Connexin 43 was
more phosphorylated in cells from RGD and YIGSR pepti-
des, similar to levels found in the adult atrium. Myocytes
were subjected to cyclic strain at 20% maximum strain, 1 Hz
for 48 h. Cell attachment on laminin was reduced to about
50% compared to the unstretched (P < 0.05 n = 6). In cells
cultured on the synthetic peptides, there was no significant
cellular detachment. Following mechanical stimulation myo-
sin protein was decreased by about 50% in cells cultured on
YIGSR peptide (P < 0.05 n = 3). However, total myosin was
unchanged in cells stretched on laminin. These results sug-
gest that synthetic peptides promote the same degree of
cellular adhesion has their native proteins. However, they are
unable to promote the signaling required for normal FAK
expression and complete cytosketetal formation in myocytes.
In addition, although these covalently adhered peptides pro-
vide improved cellular adhesion in response to mechanical
stimulation, they promote aberrant myocytic gene expres-
sion. HL 64956 and HL 62426.
Abstract N° A22
N-cadherin determined the localization of connexin 43
through Rho pathway in cardiac myocytes
Takahisa Matsuda, Kyoko Takahashi, Tetsurou Nariai,
Takashi Ito, Tomoka Takatani, Mayo Hirata, Yasushi Fujio,
Junichi Azuma. Department of Clinical Evaluation of
Medicines and Therapeutics, Graduate School of
Pharmaceutical Sciences, Osaka University, Osaka, Japan
Gap junction formation is a critical event for normal heart
development. To reveal the involvement of N-cadherin in the
distribution of connexin 43 (Cx43) at the intercalated disk,
the distribution of the cell–cell adhesion molecules,
N-cadherin and Cx43, was analyzed in the aligned cardiac
myocytes induced by mechanical stretch. Neonatal rat car-
diac myocytes were plated for 3 h and exposed to 20% cyclic
stretch for 24 h on silicone chambers. Stretch stimulation
promoted cell orientation running in parallel to tension direc-
tion. After cultivation for 5 d, the Cx43 was co-localized with
N-cadherin at the intercalated disk-like longitudinal oriented
cell termini. Next, adenoviral gene transfer of dominant
negative N-cadherin significantly attenuated the localization
of Cx43 at cell termini. Furthermore the inhibition of Rho
family pathways, downstream of cadherin, significantly can-
celled the accumulation of Cx43, but not N-cadherin. Collec-
tively, it is suggested that N-cadherin determined the locali-
zation of Cx43 through Rho pathway in cardiac myocytes.
These findings provide pathophysiological insights into ar-
rhythmogenesis resulting from the disturbance of cell–cell
adhesion.
Abstract N° A23
Differential expression of the extracellular matrix
(ECM) components mimecan and elastin during
arteriogenesis
R. Zimmermann a, A. Kampmann a, T. Kubin a, S. Boehm b,
B. Fernandez b, W.-J. Cai b, F. Pipp b, D. von der Ahe a,
J. Schaper b, W. Schaper b. a Kerckhoff-Clinic,Bad Nauheim,
Germany. b Max-Planck Institute, Bad Nauheim, Germany
Arteriogenesis, the enlargement of collateral vessels, is
induced by fluid shear stress to compensate for the loss of
blood flow in an occluded artery. The molecular analysis of
this process identified the proteoglycan mimecan/
osteoglycin (M) and elastin (E), the main component of the
arterial wall, as participating molecules. Northern and wes-
tern blot analysis showed a significant downregulation of M
after 3, 7 d and 3 weeks of occlusion. Vascular SMC of the
media were the main source of M in growing collaterals.
TGF-b1 in combination with MCP-1 as well as FGF-2 and
Oncostatin M (OSM) attenuated M mRNA levels in in vitro
studies. Unlike M the protein levels of E were reduced only at
early time points of arteriogenesis, indicative of an outward
remodeling of the arteries, but increased during maturation,
supported by elevated mRNA levels at 7 d and 3 weeks.
Similar to M vascular SMC are the main source of E. In in
vitro studies mRNA levels of E could be increased by stimu-
lation with TGF-b1, PDGF-AB and IGF-I, while FGF-2 and
OSM nearly completely abolished its expression. MCP-1
had no effect on E mRNA levels in vascular SMC. Our results
implicate an extensive remodeling of the ECM during colla-
teral growth, characterized by early downregulation of M and
late upregulation of E. Arteriogenic growth factors like
PDGF-AB, FGF-2 or TGF-b1, alone or in combination with
MCP-1, are potent modulators of the expression of these
ECM proteins and potential pharmaceutical agents for modu-
lating arteriogenesis.
Abstract N° A24
Effect of l-arginine on cardiac function in mdx mice
Christel van Erp, Andrew Hoey. Centre for Biomedical
Research, University of Southern Queensland, Toowoomba,
Queensland, Australia
Duchenne muscular dystrophy (DMD) is a fatal condition
occurring in approximately one in 3500 live male births
caused by lack of the dystrophin protein. Initially DMD was
considered a skeletal myopathy, however, improved care has
caused an increased incidence and acknowledgement of car-
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diomyopathy as a contributor to mortality. The dystrophin
deficient mdx mouse is used as a model of DMD and in both
mdx and DMD biopsy samples, deficiencies of neuronal
nitric oxide synthase (nNOS) are evident. Without dystro-
phin, nNOS is misdirected reducing nitric oxide (NO) syn-
thesis, possibly contributing to the muscle necrosis and fibro-
sis. On this basis l-arginine, a NO donor, was investigated for
its potential to restore muscle function and reduce fibrosis.
The mdx mice were treated for 6 months with 10% l-arginine
in their drinking water while untreated mdx and
C57BL10ScSn (C57) mice were used as controls. Subse-
quently the Langendorff technique was used to measure
cardiac function. Control mdx hearts had reduced left ventri-
cular contractility (dP/dt), and increased end diastolic pres-
sure (EDP) and end systolic pressure (ESP) (P < 0.05) and an
increase in hydroxyproline (HP) content (P < 0.001) relative
to C57 hearts. Hearts from l-arginine treated mdx had a
decreased stiffness and increased contractility relative to
control mdx (P < 0.04 and P < 0.06) without affecting HP
content in the left ventricle. l-arginine treatment may have
potential to improve cardiac function significantly in the
nNOS deficient dystrophic heart, thereby possibly improving
prognosis for DMD patients.
Abstract N° A25
A novel mechanism of regulation of cardiac
contractility by mitochondrial functional state
Allen Kaasik, Frederic Joubert, Renée Ventura-Clapier,
Vladimir Veksler. Inserm U-446, Université Paris-Sud,
Châtenay-Malabry, France
It is generally considered that mitochondria regulate car-
diac cell contractility by providing ATP for cellular ATPases
and by participating in Ca2+ homeostasis. However, besides
these well-documented functions, other possible mecha-
nisms by which mitochondria can influence contractility
have been largely overlooked. The densely packed subcellu-
lar architecture of the cardiomyocyte favors direct interac-
tions between cellular structures such as mitochondria, sar-
coplasmic reticulum and myofibrils. Functional studies using
fibers with selectively permeabilized sarcolemma provide an
excellent means to investigate the mitochondria–myofibrils
interactions while maintaining the cellular architecture and
controlling the intracellular medium, which mimics the ionic
composition of cytosol. Here, we demonstrate that inhibition
of the mitochondrial electron-transport chain strongly in-
creases (by 39 ± 10%) Ca2+-dependent and independent
isometric force in permeabilized ventricular fibers. This ef-
fect is unrelated to the ATP-generating activity of mitochon-
dria or Ca2+ homeostasis. Furthermore, various conditions
that increase K+ accumulation in the mitochondrial matrix
(activation of ATP- or Ca2+-dependent K+ channels as well as
inhibition of the K+ efflux pathway via the K+/H+ exchanger)
induce a similar mechanical response. Replacement of K+ by
another cation, tetraethylammonium, considerably dimi-
nished the mechanical response to mitochondrial de-
energization. All modulators of mitochondrial function that
augment isometric force also cause swelling of mitochondria
in the vicinity of myofibrils in situ, as shown by confocal
microscopy. Osmotic compression of intracellular structures
abolishes the effect of mitochondria-induced force modula-
tion, thus confirming the mechanical nature of interaction
between the organelles. These findings suggest a novel me-
chanism for cellular regulation of myofibrillar function by
mitochondrial K+ homeostasis. Modulation of mitochondrial
volume that imposes mechanical constraints within the cell,
leading to an increase in force developed by myofibrils,
might be involved.
Abstract N° A26
Inotropic responses to muscarinic stimulation of
ventricular myocardium from developing chick and
duck
Shigenobu. School of Pharmaceutical Sciences, Koki Tocho
University, USA
In mammalian ventricular myocardium, acetylcholine
(ACh) shows negative inotropy only when the contractile
force is elevated by stimulated adenylate cyclase. In the
present study inotropic effects of ACh and carbachol (CCh)
were examined in isolated ventricular preparations from em-
bryonic and hatched chick and duck hearts. ACh and CCh
produced positive inotropic response in the embryonic chick
and duck ventricles, while both negative and positive inotro-
pic responses in the hatched ventricles. Thus, positive inotro-
pic effect was observed in both species at developing stages.
Negative inotropic effect was observed only in hatched
hearts and was not accompanied by action potential shorte-
ning. Experiments with specific antagonists and inhibitors
revealed that the positive inotropy is mediated through M1
receptors and PLC, and the negative inotropy through M4
receptors and inhibition of adenylate cyclase. In conclusion,
we found that ACh produces positive and negative inotropy
in developing chick and duck ventricular myocardium,
which is different from mammalian ventricle.
Abstract N° A27
Diastolic dysfunction is as bad as systolic dysfunction
in heart failure on long-term basis
Adarsh Kumar, Harharpreet Kaur, Sunil Kumar,
Varun Mohan. Government Medical College, Amritsar,
India
Patients hospitalised for heart failure (HF) with normal
left ventricular ejection fraction (LVEF) are mostly due to
hypertension, LVH, DM and CAD and have mostly myocar-
dial stiffness and relaxation abnormalities with increased
Left Ventricular End Diastolic Pressures. The long-term out-
come of these patients after initial hospitalisation is not very
well defined. Hence 106 patients admitted with decompensa-
ted HF (NYHA class II–IV), diagnosed by pulmonary
congestion on chest X-ray and evidence of volume overloa-
ding on physical examination with presence of normal LVEF
and evidence of dominant diastolic dysfunction with abnor-
malities in E/A ratio, Deceleration time and isovolumetric
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relaxation time on echocardiographic evaluation were taken
as the study group. The survivors of indexed admissions were
followed up for a period of 1.5–3.1 years (mean of 2.3 years).
Mean age was 67.3 years. M/F ratio was 61/45 (57.5/42.5%);
53% patients were hypertensives, 44% had CAD, 39% were
diabetics and 4.6% cases had HCM. Endpoints were annua-
lised re-hospitalisation rate and mortality. Thirty deaths oc-
curred with annualised mortality rate of 15.6% and annua-
lised re-hospitalisation rate was 67% and these rates are
comparable to those reported in patients of HF with systolic
LV dysfunction (NYHA class II–IV). To conclude, patients
of HF with normal EF and isolated Diastolic LV dysfunction
have similar outcome especially in relation to mortality and
re-hospitalisations as is the case with LV systolic dysfunc-
tion.
Abstract N° A28
Heart failure as a syndrome caused by instability of
higher order process control
John J. Allan. Piedmont Heath Care, Statesville, NC, USA
Heart failure is a complex syndrome of left ventricular
systolic dysfunction, neurohormonal, inflammatory and en-
dothelial dysfunction. Treatment focuses on neurohormonal
blockade.As evidence accumulates, it is becoming increasin-
gly apparent that the “neurohormonal theory” of heart failure
is incomplete. The human cardiovascular system is under
feedback control. These control loops are typically nonlinear
and therefore referred to as higher order. I hypothesize that
heart failure is a malfunction of process control. Specifically,
heart failure is a syndrome in which feedback loops becomes
unstable. The response of a control loop to a given input can
be represented by the following equation: c(t) = b1e
r1t +
b2e
r2t + … + bne
rt + (input terms); where c(t) is the loop
output or controlled variable and r1, r2, …, rn are the eigen-
values or roots of the characteristic equation. Assuming that
the input terms are bound as time increases, the loop’s stabi-
lity requires the following: for real roots r = r; r has to be <0
because ert approaches 0 as t approaches infinity if r < 0; for
complex roots: r = a + ib; ert = eat(cos bt + i sin bt) where i is
an imaginary number; a has to be <0, for eat(cos bt + i sin bt)
to approach 0 as t approaches infinity. Factors affecting the
eigenvalues include loop delays, changes in control gain, and
structural changes of the system. Translating this to the
human cardiovascular system, changes in the myocardium
(MI, cardiomyopathy), vascular bed (afterload, preload)
could result in an unstable control loop as shown the in
example below.
Therapeutic changes including drugs and mechanical
events could restore the stability of the control loop.
Abstract N° A29
Blood pressure generating capacity is a critical
component in measuring overall cardiac function
P.D. Chantler a, R.E. Clements a, L. Sharp a, L.-B. Tan b,
D.F. Goldspink a. a Sports and Exercise Sciences, Liverpool
John Moores University, Liverpool, UK. b Molecular and
Vascular Medicine, University of Leeds, Leeds, UK
Peak exercise cardiac power (CPmax) incorporates both
the pressure (BP) and flow (cardiac output, CO) generating
capacities of the heart and is a measure of overall cardiac
function (CF). Past research has tended to ignore the BP
generating capacity of the heart, focusing mainly on measu-
ring CO. CP was measured in healthy sedentary 20 and
60-year old subjects, and 60-year old heart failure (HF;
NYHA III) patients. Cardiac output (CO) and mean arterial
pressure (MAP) were measured non-invasively at rest and at
maximal exercise, and CP (watts) calculated as (MAP × CO)
× 2.2 × 10–3. COmax significantly (P < 0.05) declined (–21%)
over these 40 years of healthy ageing (Fig. 1). In contrast
MAPmax was significantly increased (+9%). Therefore, the
true decline in overall function (i.e. CPmax) was not as great
(–14%) as that predicted using COmax alone (–21%). That is,
the overall decline in CF was overestimated when BP was
ignored. In contrast, in HF patients the decline in CF was
underestimated by COmax, because a significant (P < 0.05)
decline in both COmax (34%) and MAPmax (22%) contributed
to a 61% decline in CPmax. These data stress the importance
of measuring both BP and CO as both change in ageing and
failing hearts.
Abstract N° A30
Cardiac power in the ageing, trained and failing heart
P.D. Chantler a, R.E. Clements a, L. Sharp, L.-B. Tan b,
D.F. Goldspink a. a Sports and Exercise Sciences, Liverpool
John Moores University, Liverpool, UK. b Molecular and
Vascular Medicine, University of Leeds, Leeds, UK
Overall cardiac function, measured as cardiac power (CP)
incorporates both the pressure and flow generating capacities
of the heart. When measured in men at rest, CPrest is around
1 W. However, to discriminate between the effects of age,
disease or fitness levels the heart must be maximally stimu-
lated, thereby revealing differences in CPmax and cardiac
reserve (CR). Hence, the effects on CP of healthy ageing,
with or without endurance training (Tr), and heart failure
(HF) were studied. Except for the HF patients (NYHA III) all
subjects were free from known diseases and medications.
Cardiac output (CO) and mean arterial pressure (MAP) were
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CP calculated as (MAP×CO) × 2.22 × 10–3, and CR =
CPmax–CPrest. Older (60–70 years) sedentary (Sed) subjects
had significantly (P < <0.05) lower (14–17%) CPmax than
20-year olds (Fig. 1). This decline in CPmax was further
accentuated in HF patients (56%). In contrast, veteran athle-
tes (Tr) demonstrated significantly higher CPmax (15%) and
CR (17%) values than age-matched controls, with similar
values to Sed 20-year olds (Fig. 1). These results indicate that
CP declines with healthy ageing, and in HF. The age-related
changes in CP can however be ameliorated by long-term
training.
Abstract N° A31
Age-and gender-related changes in cardiac power
P.D. Chantler a, L. Sharp a, R.E. Clements a, L.-B. Tan b,
D.F. Goldspink a. a Sports and Exercise Sciences, Liverpool
John Moores University, Liverpool, UK. b Molecular and
Vascular Medicine, University of Leeds, Leeds, UK
A 33% loss of cardiomyocytes has been reported between
20 and 70 years of age in men, whereas the equivalent loss in
women has been much less. We tested whether these gender
differences are reflected in overall cardiac function, when
measured as cardiac power (CP) and incorporating both
pressure and flow generating capacities of the heart. All male
and female subjects were healthy and free from known di-
seases and medications. In all subjects at rest, CPrest is around
1 Watt. However, to discriminate between the effects of age
and gender the heart has to be maximally stimulated, thereby
revealing differences in CPmax and cardiac reserve (CR).
Cardiac output (CO) and mean arterial pressure (MAP) were
measured non-invasively at rest and at maximal exercise, and
CP was calculated as (MAP × CO) × 2.22 × 10–3, with CR =
CPmax–CPrest. The rate of decline in CPmax and CR between
20 and 70 years for men and women were similar. However,
the CR was approx 29% greater in men than women, al-
though this was less after adjusting for body size. These data
indicate that CR declines with healthy ageing in both sexes at
a similar rate, despite reported greater losses of cardiomyco-
tyes in men.
Abstract N° A32
Reduced expression of the sodium–calcium exchanger
by RNAi decreases action potential duration in
neonatal rat cardiomyocytes
B.P. Ander, C. Hurtado, A. Lukas, G.N. Pierce. Division of
Stroke and Vascular Disease and Institute of Cardiovascular
Sciences, Department of Physiology, Faculties of Medicine
and Pharmacy, University of Manitoba, Winnipeg, MB,
Canada
The sodium–calcium exchanger (NCX) is an electrogenic
mechanism important for clearance of calcium that enters
during the contraction cycle of the heart and is considered
essential for heart function. Adenovirally delivered siRNA
constructs were used to inhibit NCX expression in primary
cultured neonatal rat cardiomyocytes. Following 3–6 d infec-
tion, the perforated patch clamp technique was used to record
action potentials in cardiomyocytes stimulated at rates of
0.25–2 Hz. Expression of the NCX was only 5.6% in the
knocked down cells relative to controls containing a scram-
bled sequence. Both cell types responded to electrical stimu-
lation. Peak amplitude of the action potential was signifi-
cantly lower in the NCX silenced cells compared to the
scrambled controls, but there was no difference in the resting
membrane potential between the two groups. Action poten-
tial durations were calculated at both 50% (APD50) and 90%
(APD90) repolarization. No significant difference in APD90
was observed between the two groups at any stimulation rate
tested. However, APD50 was significantly less in the NCX
knock down cells when stimulated at 0.25–1.25 Hz compa-
red to scrambled controls. In control cells, APD50 was inver-
sely related to stimulation frequency, whereas no relation
was observed in NCX silenced cells. Our data suggests the
NCX is an important contributor to the shape of the cardiac
action potential. This may suggest that the NCX is important
in modifying L-type Ca2+ current. We have also shown that
NCX activity is not required for beating of heart cells, raising
importance of other calcium extrusion mechanisms.
Supported by the Heart and Stroke Foundation of Canada
and CIHR.
Abstract N° A33
Inhibition of 4-AP sensitive transient outward
potassium channel current (Ito) induced T-wave
alternans in isolated rat heart model
Xi Wang, Weihong Liu, David A. Saint
T-wave alternans (TWA) is characterized as the beat-to-
beat alternation of the morphology, amplitude and/or polarity
of T-wave. TWA has been considered to be a marker of
myocardial electrical instability and a predictor of lethal
ventricular arrhythmias. Action potential duration alternans
(APD alternans) of single myocytes is the primary basis of
TWA, and block of repolarization currents such as rapid and
slow delayed rectifier potassium currents are associated with
TWA. However, the role of 4-AP sensitive Ito in TWA forma-
tion has not been determined as yet. In eight Langendorff
perfused isolated rat hearts, ECG signals and monophasic
action potentials (MAP) from epicardium, mid-myocardium
and endocardium were simultaneously recorded. The heart
was paced at basic cycle length (BCL) of 200 ms, and the
effects of 4-AP at rapid pacing were investigated. Neither
TWA nor alternation of MAP was induced in rat hearts
without 4-AP perfusion. In the presence of 4-AP (2 mmol/l),
increase in pacing rate with cycle length (CL) of 100 to 76 ms
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Fig. 1. Values = Mean ± SEM (n =10–15 per group).
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TWA and MAP alternans were induced at CLs ranging from
100 to 90 ms, while acceleration of CL to 86–76 ms resulted
in more marked beat-to-beat alternation of T-wave and MAP.
The alternation of MAP duration in epicardium was more
prominent than that in mid-myocardium and endocardium.
At CL of 76 ms, marked TWA and alternation of MAP were
induced, followed by Torsade de pointes (Tdp) in one rat
heart. Our results suggest that the blockade of Ito causes TWA
and APD alternans in rat heart at rapid pacing and is associa-
ted with ventricular arrhythmia following acceleration of
heart rate.
Abstract N° A34
Absence of mechano-electric feedback in isolated rat
atrial tissue
Douglas R. Kelly, David A. Saint. University of Adelaide,
Adelaide, SA, Australia
Mechano-electric feed back (MEF) is the process by
which stretch directly affects the electrophysiology of the
myocardium. Its physiological role is not clear although it
has been suggested that changes in action potential morpho-
logy in stretched myocardium are important in minimising
dispersion of repolarisation. Strips of isolated left ventricular
and left atrial tissue from male Sprague–Dawley rats were
stretched and action potentials recorded with intracellular
electrodes using both repeat impalement and continuous re-
cording. Even in the absence of stretch, action potential
duration (APD), AP amplitude and resting membrane poten-
tial (RMP) were found to be surprisingly variable in closely
neighbouring areas of the tissue. Repeat impalements within
small regions gave more consistent results. However, even
within a confined region, application of stretch produced
either inconsistent changes (n = 7) or no discernable change
in APD or RMP (n = 10). On a few occasions we achieved
stable sustained impairments in rat left atrial tissue during
stretch: in these recordings there was no change in RMP,
action potential amplitude or APDs at tensions exceeding the
peak of the Frank–Starling relation (n = 4). We conclude that
MEF was not present in isolated rat atrial tissue under our
experimental conditions.
Abstract N° A35
NIP-142 prolongs myocardial action potential duration
through direct inhibition of GIRK1/4 channel
H. Lida Tanaka a, M. Ito b, R. Yamagishi a, N. Tanaka a,b,
T. Matsuda a,c, N. Hashimoto c, N. Fujikura c, T. Yamashita
c, Namekata, N. Tsuruzoe c, K. Shigenobu a. a Department
of Pharmacology, Toho University School of
Pharmaceutical Sciences, Funabashi, Chiba 274 8510,
Japan. b Department of Food Science, Otsuma Woman’s
University, Chiyoda-ku, Tokyo 101 0062, Japan.
c Biological Research Laboratories, Nissan Chemical
Industries, Ltd., Shiraoka, Saitama 349 0294, Japan
NIP-142 is a novel benzopyran compound with antiar-
rhythmic activity against vagally induced atrial fibrillation in
canine models (Circ. J. 66 (2002) 185). In anesthetized dogs,
NIP-142 prolonged atrial refractory period under vagal sti-
mulation. NIP-142 reversed carbachol- or adenosine-
induced shortening of action potential. Binding assay with
[3H]AF-DX384 showed lack of NIP-142 binding to M2-
receptors. In isolated guinea-pig ventricular muscles, CCh
showed a negative inotropic effect in the presence of forsko-
lin, but not in its absence. NIP-142 had no effect on this
negative inotropic effect of CCh indicating lack of effect on
the M2-receptor and Gi-protein. In HEK293 cells expressing
hGIRK1/4 channels (IKACh channel), NIP-142, as well as
tertiapin, concentration-dependently inhibited hGIRK1/4
current. In conclusion, NIP-142 prolongs atrial action poten-
tial duration and refractory period through direct inhibition
of the GIRK1/4 channel.
Abstract N° A36
The aging mdx mouse as a model of cardiomyopathy
for Duchenne muscular dystrophy
Andrew Hoey, Christel van Erp, Nicki Laws. Sai Lu Centre
for Biomedical Research, University of Southern
Queensland, Toowoomba, Queensland, Australia
The absence of the myocyte protein dystrophin causes
Duchenne muscular dystrophy (DMD), an X-linked myopa-
thy affecting one in 3500 live male births. The incidence of
cardiomyopathy has increased over the last decade as impro-
ved respiratory care has prolonged the lifespan of boys with
DMD. The dystrophin deficient mdx mouse has been widely
used for skeletal muscle research, but as a model of cardio-
myopathy it has been poorly characterised. Male mdx mice
and control C57BL10ScSn (C57) mice at 12 months of age
showed increased sympathetic and decreased parasympathe-
tic activity relative to both age and sex matched C57s and
12 week old male C57s (P < 0.05). In tissue bath studies,
(—)-isoprenaline had a lowered efficacy and potency (P <
0.05) associated with a reduced affinity to the b1-selective
antagonist CGP20712A. Other manifestations of cardiac
dysfunction include an increased incidence of arrhythmias in
vivo as recorded by electrocardiography and in vitro in
spontaneously beating right atria (P < 0.05). In left atria, a
reduced potency and efficacy to calcium was evident (P <
0.05), associated with a delayed relaxation in spite of a
shorter action potential at 90% repolarisation (P < 0.05).
Similarly, ventricular contractility measured using the Lan-
gendorff technique reveals impaired contractility, and eleva-
ted end systolic and end diastolic pressure (P < 0.05). Finally,
ventricles from mdx mice showed increased collagen levels
evident by hydroxyproline measurements and picrosirius red
staining of ventricular sections (P < 0.05). Thus the mdx
mouse exhibits many features of cardiomyopathy that are
similar to those evident in patients with DMD.
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Abstract N° A37
Cardiac electro-mechanics: from CellML to the whole
heart
D.P. Nickerson, P.J. Hunter. Bioengineering Institute,
The University of Auckland, Auckland, New Zealand
We have developed a computational modelling framework
for cardiac electromechanics. The framework has been ap-
plied to the simulation of electrical activation and mechani-
cal contraction of cardiac cells, myocardial tissue and anato-
mically based models of ventricular geometry. Detailed
tissue microstructure is included in the tissue and ventricular
models. Cellular models are specified using CellML
(http://www.cellml.org), an XML language designed to store
and exchange computer-based biological models. The
CMISS (http://www.cmiss.org) computational package is
used to integrate and describe the tissue and ventricular
models. The integration of CellML into CMISS has been an
important aspect of this work, resulting in the development of
the open source C++ implementation of the CellML 1.0
Application Program Interface (API) available at
http://cellml.sourceforge.net/. The framework we have im-
plemented provides the ability to specify not only spatial
variation of cellular material parameters (e.g. transient
outward channel density through the ventricular wall), but
also spatial variation of the cellular models themselves (e.g.
Purkinje fibre models coupled to ventricular myocytes). By
using CellML as the standard format for the cellular models,
we have allowed for the models to be defined by any piece of
cellular modelling software capable of exporting the model
to CellML, and gained access to public model repositories.
This work is one of the first steps in the development of a
simulation environment for the IUPS Physiome Project
(http://www.physiome.org.nz), aimed at providing a fra-
mework for the simulation of models describing organisms
from proteins through to whole organ systems.
Abstract N° A38
Involvement of death receptor signaling in mechanical
stretch-induced cardiomyocyte apoptosis
Lan-Ying Chen a, Xu Dong Liao a,b, Quan Chen b.
a Cardiovascular Institute and Fu Wai Hospital, Chinese
Academy of Medical Sciences, Beijing 100037, PR China.
b State Key Laboratory of Biomembrane and Membrane
Biotechnology, Chinese Academy of Sciences, Beijing
100080, PR China
Mechanical overload associated with hypertension causes
cardiomyocyte apoptosis, yet the intracellular signaling me-
chanism leading to apoptosis has not been fully characteri-
zed. In the present study, we presented evidences suggesting
the involvement of death receptor signaling in mechanical
stretch-induced apoptosis. The major finding are as fol-
lowing: (1) the stretch-induced activation of caspases 8, 9
and 3, upregulation of Fas, FasL expression and cell surface
trafficking of death ligands (FasL and TRAIL); (2) exoge-
nous death ligand (TRAIL) enhanced while soluble death
receptor (sDR5) neutralized stretch-induced apoptosis; (3)
adenovirus delivered dominant negative FADD significantly
decreased apoptosis and caspases 8, 9, and 3 activation; (4)
moreover, it also attenuated stretch-induced cytochrome c
release from mitochondria. These data demonstrated the in-
volvement of death receptor signaling in cardiomyocyte
apoptosis-induced by mechanical stretch and further sugges-
ted the crosstalk between the death receptor signaling and
mitochondria-dependent apoptotic signaling. Our data pro-
vide novel clues for further understanding the mechanism of
mechanical overload-induced cardiomyocyte apoptosis.
Abstract N° A39
Improvement of vasorelaxation by endothelin receptor
antagonist CPU 0213 is mediated by suppression on
preproET-1 of the vascular wall in diabetic rats
De-Zai Dai, Li Sun Min Ji. China Pharmaceutical
University, Nanjing 210009, China
Aim. – The endothelial lesion in diabetes could be related
to an excess of endothelin (ET)-1 which causes dysfunction
of vasorelaxation. A novel ET receptor antagonist CPU 0213
a dual blockader is tested to recover the impairment of
vasorelaxation in the STZ-induced diabetes.
Methods. – Rats were injected with STZ 60 mg/kg i.p.
developed sustained hyperglycemia in 4 weeks and treated
with CPU0213 80 mg/kg p.o. and aminoguanidine (AGD)
100 mg/kg p.o. for 28 d, separately. The vasorelaxation to
acetylcholine, measurement of ET-1, mRNA of preproET-1
in myocardium and thoracic aorta, iNOS and NO in serum
were conducted.
Results. – ET-1 raised significantly in serum in diabetic rat
by 39.5% and a reduction in ET-1 level was significant by
CPU 0213 (–40.4%) and AGD (–30.0%). In the diabetic
model the mRNA abundance of preproET-1 was increased
dramatically in the myocardium (104%) and aortic wall
(581%), respectively. CPU 0213 and AGD reduced
preproET-1mRNA in myocardium (–42% and –28%, respec-
tively) and thoracic aorta (–83% and –80%). The iNOS
mRNA increased in diabetic aorta (305%) and was reduced
by 0213 and AGD (–70% and –38%). The iNOS activity in
serum was elevated in the model (865%), and reduced by
0213 and AGD (–81% and –51%). The NO in serum was
increased in model significantly (96%) and reduced by 0213
and AGD (–16% and –18%). The maximal vasorelaxation
was reduced in the model (–69%), and improved by 0213 and
AGD(151% and 125%).
Conclusion. – The novel endothelin receptor antagonist
CPU 0213 which improves significantly vasorelaxation of
the diabetic thoracic aorta is more effective to suppress over-
expression of preproET-1 mRNA in thoracic wall.
Supported by a key project of National Science Founda-
tion of China No. 30230170.
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Abstract N° A40
Alterations in cardiac dihydropyridine receptors and
calcium channel function in mdx mice
Xiao Hui Xiao, Peter Woolf, Michael Watson, Sai Lu,
Andrew Hoey. Centre for Biomedical Research, University
of Southern Queensland, Toowoomba, Queensland,
Australia
Duchenne muscular dystrophy (DMD) is a fatal neuro-
muscular condition affecting approximately one in 3500 live
male births resulting from the lack of the myocyte protein
dystrophin. The absence of dystrophin in cardiac myocytes is
associated with calcium overload which in turn activates
calcium-dependent proteolytic enzymes contributing to
congestive heart failure, muscle necrosis and fibrosis. To
date, the basis for the calcium overload has not been deter-
mined. Since L-type calcium channels are a major mediator
of calcium influx we determined their potential contribution
to the calcium overload. Male muscular dystrophy (mdx)
mice and control C57BL10ScSn (C57) mice aged 12–
16 weeks were used in all experiments. In tissue bath studies,
isolated contracting left atria from mdx revealed a reduced
potency to the dihydropyridine (DHP) agonist BayK8644
and antagonist nifedipine (P < 0.05). Similarly, radioligand
binding studies using the DHP antagonist [3H]-PN 200-110
showed a reduced potency (P < 0.05) in isolated membranes,
associated with an increased receptor density (P < 0.05). The
increased receptor density was supported by RT-PCR expe-
riments revealing increased RNA for the DHP receptor. Patch
clamp studies revealed the presence of a diltiazem sensitive
calcium current that showed delayed inactivation in isolated
mdx myocytes (P < 0.01). In conclusion, the increased num-
ber of DHP binding sites and the delay in L-type current
inactivation may both contribute to increased calcium influx
and hence calcium overload in the dystrophin deficient mdx
cardiac myocytes.
Abstract N° A41
Testing AKT modulation of ICAL by gene transfection
in HEK293 cells
M. Bondesan a, V. Perego a, M. Rocchetti a,
G.L. Condorelli b, A. Zaza a. a University Milano-Bicocca
Milano, Italy.
b Istituto SanRaffaele, Rome, Italy
The kinase AKT mediates antiapoptotic/hypertrophic si-
gnaling downstream to phosphatidilinositol kinase PI3K, a
pathway activated by numerous growth factors and involved
in “compensatory” cardiac hypertrophy. This study tests
whether the DHP-sensitive Ca2+ channel a-subunit (DHPR)
is a target of AKT-mediated modulation.
Methods. – HEK293 cells were transfected with the rele-
vant plasmid vectors and the current/voltage relation of
DHP-sensitive Ca2+ current (ICaL) was evaluated by patch-
clamp; Ba2+ was substituted to Ca2+ as charge carrier.
Results. – Transfection with a vector encoding DHPR and
the reporter GFP under the same promoter (DHPR/GFP) led
to expression of ICaL in all GFP + cells (peak density at 25.6
± 3 mV = 29.3 ± 2.8 pA/pF; n = 17). Co-transfection of these
cells with constitutively active AKT isoform (AKT+) led to
complete suppression of ICaL in 83% (10/12) of cells. A
similar result was obtained with inactive AKT isoform
(AKT–), which suppressed ICaL in 83% (5/6) of cells. In both
cases, co-transfection of AKT isoforms markedly enhanced
GFP fluorescence signal. In cells with stable expression of
AKT+, DHPR/GFP transfection induced ICaL in 43% of
GFP+ cells only (3/7, peak density = 8.0 pA/pF). A similar
result was obtained in cells with stable AKT–.
Summary. – Co-transfection with AKT inhibited DHPR
functional expression irrespective of whether its kinase acti-
vity was enhanced or inhibited. Since DHPR-bound GFP
signal was enhanced, DHPR/GFP gene transcription was
probably stimulated, rather than inhibited by AKT co-
transfection. Thus, a mechanism downstream to regulation of
gene transcription and independent of AKT kinase activity is
likely to account for AKT-induced inhibition of DHPR func-
tional expression in HEK293 cells. While biochemical as-
says are required to confirm this view, our preliminary data
suggest that this experimental model may be unsuitable to
test DHPR modulation by AKT-mediated phosphorylation.
Abstract N° A42
Role of the L-type Ca current in the dissociation
between systolic Ca and sarcoplasmic reticulum Ca
content observed at physiological stimulation
frequencies in the rat
K.M. Dibb, D.A. Eisner, A.W. Trafford. Unit of Cardiac
Physiology, The University of Manchester, Manchester, UK
Previously, we have investigated systolic Ca and
sarcoplasmic reticulum (SR) Ca content under conditions of
physiological temperature and stimulation rates using cur-
rent clamp control. Here on increasing stimulation frequency
between 4 and 6 Hz SR Ca content and Ca transient
amplitude increased in parallel. However at 8 Hz SR content
was increased yet Ca transient amplitude decreased
compared to 6 Hz data. This was not due to changes in action
potential duration. Thus, we have investigated the role of the
L-type Ca current. Changes in [Ca]i were measured using
Fluo-3 AM. Data are presented as mean ± SEM from n
experiments. Peak L-type Ca current amplitude decreased
with stimulation frequency at 1, 4, 6 and 8 Hz (7.2 ± 1.3, 5.1
± 1.0, 3.6 ± 0.7 and 2.3 ± 0.5 pA pF–1; P < 0.05, n = 5). The
time constant of decay of the L-type Ca current increased
with stimulation frequency (1 Hz, 8.1 ± 0.7; 4 Hz, 8.7 ± 0.4;
6 Hz, 9.7 ± 0.3 and 8 Hz, 11.3 ± 0.5 ms, n = 5). Under these
conditions, Ca transient amplitude decreased with increasing
stimulation frequency (285 ± 45, 243 ± 41, 181 ± 31 and
116 ± 24 nmol l–1; P < 0.05 between 4, 6 and 8 Hz, n = 5–6).
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This was partly due to a rise in diastolic Ca (P < 0.05
between all frequencies). We suggest that a decrease in trig-
ger Ca for Ca-induced Ca release, brought about by a reduc-
tion in peak L-type Ca current at high stimulation frequen-
cies, may contribute to the dissociation between systolic Ca
and SR Ca content observed under current clamp conditions.
The associated decrease in Ca transient amplitude may be
responsible for the increasing time constant of inactivation of
the L-type channel due to a reduction in Ca-dependent inac-
tivation.
Abstract N° A43
Reverse engineering the L-type Ca channel a1c subunit
in adult cardiac myocytes using novel adenoviral
vectors
Anand Ganesan, David C. Johns, Henry Colecraft,
Christoph Maack, Agnieszka Sidor, Brian O’Rourke. Johns
Hopkins University, Baltimore, MD, USA
The a1c subunit is the main component of the cardiac
L-type Ca2+ channel, containing the channel pore, voltage-
and Ca2+-dependent gating structures, and drug binding si-
tes. Although well-studied in heterologous expression sys-
tems, many questions regarding the biophysical properties of
cardiac L-type channels in intact cardiomyocytes remain
unanswered, including the physiological sites of channel
phosphorylation, and which structures influence cardiac ex-
citation–contraction coupling. The latter has been impossible
to study due to the inability to reconstitute the spatial organi-
zation of the dyad. To overcome these problems, we develo-
ped adenoviral constructs with E1, E3 and fiber gene dele-
tions, to permit incorporation of full length, a1c gene
cassettes into the adenovirus backbone. Full-length wild type
(a1c-wt) and mutant (a1c-qm), as well as a C-terminal truncated
a1c subunit (a1c-dm) adenoviruses were constructed; the two
latter viruses were mutated at residues critical for dihydropy-
ridine binding. a1c-wt, a1c-qm and a4.19 pA/pF n = 5; a1c-qm
3.2 pA/pF n = 30; a1c-dm 19.36 pA/pF, n = 5), and, as
expected, ICa carried by a1c-dm (Ki 10.8 µM) was markedly
less sensitive to nitrendipine than a1c-wt (Ki 80 nM); a feature
exploited to discriminate between engineered- and native-
channel currents in transduced guinea-pig myocytes. Ten
micromolar nitrendipine blocked only 51 ± 5% (n = 9) of ICa
in a1c-dm-transduced myocytes, in comparison to 86 ± 8% (n
= 9) of ICa in control myocytes. Further, evoked calcium
transients, measured with indo-1, were observed in a1c-dm
-transduced cells, but were largely blocked in control myo-
cytes, in the presence of 10 µM nitrendipine, indicating that
the engineered channels were coupled to sarcoplasmic reti-
cular Ca2+ release. These novel a1c adenoviruses provide an
unprecedented method for structure-function studies of car-
diac excitation–contraction coupling and L-type channel re-
gulation in the native myocyte background.
Abstract N° A44
Age associated alterations in the cardiac L-type
calcium current: role in excitation–contraction
coupling
K.M. Dibb a, U. Rueckschloss b, G. Isenberg b,
D.A. Eisner a, A.W. Trafford a. a University of Manchester,
Manchester, UK. b Martin Luther University, Halle,
Germany
Ageing is the greatest risk factor for the development of
heart failure. We have investigated whether ageing is associa-
ted with alterations in cardiac excitation–contraction cou-
pling that may predispose the aged myocardium to heart
failure. Experiments were performed on left ventricular mid-
myocardial myocytes from young (<1.5 years) and aged
(>8 years) sheep. Cells were voltage clamped and Fluo-3AM
used to measure changes in intracellular calcium concentra-
tion. Cells from aged animals exhibited a 26% increase in
membrane capacitance, 21% increase in width and 4% in-
crease in length (P < 0.005) indicating cellular hypertrophy
with ageing. The systolic calcium (Ca2+) transient amplitude
increased in aged myocytes (115 ± 16 vs. 178 ± 17, P < 0.05).
This was not due to a difference in sarcoplasmic reticulum
Ca2+ content (43 ± 4 vs. 45 ± 3 µmol/l, P > 0.6). In aged
myocytes peak L-type Ca2+ current increased by 175% (–40
to 8 mV, P < 0.001) and integrated Ca2+ entry during the
voltage clamp pulse increased by 55% (P < 0.01). In addi-
tion, there were also slight changes in the properties of
activation and voltage-dependent inactivation of the L-type
Ca2+ current such that the window current increased by 20%
in the ageing myocytes. We conclude that together, the in-
crease in peak Ca2+ current (that which triggers release of
Ca2+ from the sarcoplasmic reticulum) and the increased
total Ca2+ entry via the L-type Ca2+ current, will serve to
produce the observed increase in the systolic Ca2+ transient
in aged hearts without the need to change sarcoplasmic
reticulum calcium content. Furthermore the greater window
current will facilitate a larger Ca2+ entry to support contrac-
tion under normal physiological conditions where the aged
cells have a longer action potential duration.
Supported by the British Heart Foundation.
Abstract N° A45
Differences in L-type calcium current between infant
and adult human atrial myocytes
Ronald W. Joyner, Mary B. Wagner, Srinivas M. Tipparaju,
Yanggan Wang, Rajiv Kumar. The Todd Franklin Cardiac
Research Laboratory, Department of Pediatrics, Emory
University School of Medicine, 2040 Ridgewood Drive NE,
Atlanta, GA 30322, USA
Developmental differences in the amplitude of L-type
calcium current (ICa) and its regulation by sympathetic tone
have been demonstrated in several animal studies. We inves-
tigated differences in b-adrenergic regulation of ICa between
infant (INF, 1–12 months), young adult (YAD, 14–18 years),
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and older adult (AD) human atrial myocytes. Atrial myocytes
were dissociated from biopsies of right atrial appendages of
patients undergoing open-heart surgery. Basal ICa in INF
atrial myocytes (1.2 ± 0.1 pA/pF) was significantly smaller
than YAD (2.5 ± 0.2 pA/pF) or AD (2.6 ± 0.3 pA/pF) myo-
cytes. The maximal ICa produced by isoproterenol was simi-
lar for INF (8.4 ± 1.1 pA/pF),YAD (9.6 ± 1.0 pA/pF), andAD
(9.2 ± 1.3 pA/pF) cells. The efficacy of isoproterenol was
larger for INF (Emax 607 ± 50%), than for YAD (Emax 371 ±
29%) or AD (Emax 455 ± 12%) myocytes. The potency was
higher for AD (EC50 0.82 ± 0.09 nM) or YAD (EC50 0.41 ±
0.14 nM) than for INF myocytes (EC50 7.6 ± 3.5 nM).
Western blotting showed similar levels of Gia2 but much
greater levels of Gia3 for INF vs. AD or YAD atrial tissue.
When we inhibited the activity of Gia3, by including the
C-terminal peptide of Gia3 in the pipette, both basal ICa and
the response to 10 nM isoproterenol were increased for INF
cells but not for YAD cells. In summary, there are significant
differences in the properties of ICa between INF and either
YAD or AD human atrial myocytes. We propose that basal
ICa and response to low-dose isoproterenol are inhibited in
INF (but not YAD or AD) cells by constitutive inhibitory
effects of Gia3.
Abstract N° A46
NADP+/NADPH plays a role in regulating K+- and
Ca2+ channels in vascular smooth muscle and cardiac
myocytes
Sachin A. Gupte, Michael S. Wolin, Rikuo Ochi,
Takao Okada. Department of Physiology, New York
Medical College, NY, USA. Juntendo University School of
Medicine, Tokyo, Japan
Recent studies from our laboratory have demonstrated
that inhibition of pentose phosphate pathway (PPP) by
6-aminonicotinamide, epiandrosterone and dihydroepian-
drosterone dilates aorta, coronary (CA) and pulmonary (PA)
artery, and inhibits myocardial contractility. In the CA, PPP
inhibitors have been found to suppress intracellular Ca2+
release and influx, and in the PA inhibition of PPP decreases
Kv channel currents. Evidences in the smooth muscle indi-
cate that neither cAMP nor cGMP mediates relaxation indu-
ced by the PPP inhibition. In the isolated rat hearts, inhibition
of PPP decreases ±dp/dt and suppresses myocardial contrac-
tility. Electrophysiological evidences further suggested that
PPP inhibitor epiandrosterone decreases L-type Ca2+ chan-
nel activity, since PPP inhibition decreases activation and
accelerates decay of the Ca2+ currents. Furthermore, steady-
state inactivation curve is shifted to more negative potentials
by PPP antagonist, this indicates that PPP inhibition stabili-
zed channels in inactivated state as well as inactivated open
channels. Therefore, these results suggest that PPP-derived
NADPH and/or NADP+ may be involved in directly regula-
ting ion channel function.
Abstract N° A48
Proteomics approach to the study of cardiovascular
disease
Youngsuk Lee a,b, Nari Kim a,b, Euiyong Kim a, Jin Han a,b.
a Department of Physiology & Biophysics, College of
Medicine, Inje University, Busan 614 735, Korea. b
Molecular and Cell Physiology Research Group, College of
Medicine, Inje University, Busan 614 735, Korea
Heart failure is not a uniform disease entity, but a syn-
drome with various causes, including hypertension, ischemia
and congenital heart disease, cardiomyopathy, myocarditis
and intoxication. The characterization of biological proces-
ses on the basis of alterations in the cellular proteins, or
“proteomic” analysis, is a powerful approach that may be
adopted to decipher the signaling mechanisms that underlie
various pathophysiological conditions, such as ischemic
heart disease. The application of proteomics provides major
opportunities to elucidate disease mechanisms and to iden-
tify new diagnostic markers and therapeutic targets. The
purpose of the present study was to evaluate difference of the
cardiac marker protein expression in three types of heart
tissue (control, ischemic preconditioning (IPC), and ische-
mia–reperfusion) using two-dimensional gel electrophoresis
(2DE) and matrix-assisted laser desorption ionization mass
spectrometry (MALDI-MS). We have compared rabbit
control heart 2DE gel with ischemia preconditioning and
ischemia 2DE gels, respectively. Appearances in expression
of some proteins were observed in ischemia–reperfusion
heart gel, but this spots were not detected or decreased in
control and IPC heart gels. For further examination of mole-
cular characteristics, this spots in 2DE were isolated and
subjected to trypsin digestion followed by MALDI-MS ana-
lysis. We were able to identify this spots, and which was
confirmed by western immunoblot. Our result was consistent
with previous studies of cardiac marker in ischemic heart
disease and showed that proteins are suitable cardiac marker
as measure of myocardial injury. In addition, through the
multiple techniques, including 2DE, MALDI-MS, and wes-
tern immunoblot, proteomic analysis is appropriate means of
the identification of cardiac marker in study of IPC and
ischemia–reperfusion.
Abstract N° A49
Pivotal role of gp91phox-containing NADPH oxidase in
early ischemic preconditioning
R.M. Bell a, A.C. Cave b, S. Johar b, D.J. Hearse a,
A.M. Shah b, M.J. Shattock a. a Centre for Cardiovascular
Biology & Medicine, King’s College, London, UK. b
Department of Cardiology, GKT, London, UK
Reactive oxygen species (ROS) signaling is implicated in
early ischemic preconditioning (PC). A gp91phox-containing
NADPH oxidase is a recognised source of ROS in cardiac
myocytes, whose activity is augmented by preconditioning-
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mimetics such as angiotensin II. We hypothesised that this
oxidase is an essential source of ROS in PC. Hearts from
wild-type (WT) and gp91phox knockout (KO) mice were
Langendorff perfused and subjected to 35 min
ischemia/reperfusion with or without preceding PC or drug
treatment. Infarct size was measured by triphenyl tetrazolium
chloride staining and NADPH oxidase activity by lucigenin
chemoluminescence. PC significantly attenuated infarct size
in WT (26 ± 2% vs. WT control, 38 ± 2%, P < 0.05), yet was
ineffective in KO hearts (33 ± 3% vs. KO control, 34 ± 3%).
Concomitantly, PC significantly increased NADPH oxidase
activity in WT (+41 ± 13%; P < 0.05), but not in KO (+1 ±
28%, P = NS). The ROS scavenger N-2-mercaptopropionyl
glycine (MPG, 300 nmol/l) abrogated PC in WT (39 ± 2% vs.
33 ± 1%). 2-Chloro-N6-cyclopentyl adenosine (CCPA
200 nmol/l), a putative ROS-independent PC trigger, signifi-
cantly attenuated infarct size in WT, MPG-treated WT and
KO hearts (24 ± 2%, 23 ± 1% and 20 ± 3%, respectively, P <
0.05). Furthermore, CCPA did not augment NADPH oxidase
activity over control (+22 ± 11%, P = NS). Inhibition of
protein kinase C (PKC) with chelerythrine (CHE, 2 nmol/l),
completely abrogated both PC (36 ± 2% vs. CHE alone, 33 ±
3%) and associated increases in oxidase activity (+3 ± 10%,
P = NS). Thus, we have demonstrated PKC-dependent acti-
vation of a gp91phox-containing NADPH oxidase is pivotally
involved in early ischemic PC. However, adenosine receptor
activation is able to trigger a ROS and gp91phox independent
PC pathway.
Abstract N° A50
Ischemic postconditioning reduced infarct size in
normal and hypercholesterolemic rabbit hearts
M. Donato, V. D´Annunzio, M. Sabán, L. Flor, R.J. Gelpi.
Institute of Cardiovascular Physiopathology, Faculty of
Medicine, University of Buenos Aires
Brief episodes of ischemia/reperfusion performed imme-
diately after a prolonged ischemia episode (ischemic post-
conditioning) reduce infarct size in dogs. The objective was
to determine if this mechanism was present not only in
normal rabbit hearts, but in hypercholesterolemic animal
hearts as well. Isolated and isovolumic rabbit hearts were
perfused according to Langendorff technique and subjected
to 30 min of global ischemia followed by a 30 min reperfu-
sion (G1, n = 9). In G2 (n = 8) the protocol of G1 was
repeated, but immediately after ischemia an ischemic post-
conditioning protocol was performed that consisted of two
episodes of ischemia/reperfusion of 30 s each one. In G3 (n =
6) and G4 (n = 6) protocols of G1 and G2 were, respectively,
repeated but the animals were previously fed with 1% cho-
lesterol enriched diet, during 4 weeks. The left ventricular
developed pressure (LVDP, mmHg), end diastolic pressure
(LVEDP), and infarct size were measured using TTC after
30 min of reperfusion. Plasma cholesterol levels were deter-
mined as 47.3 ± 9.3 mg/dl in normal animals and 340 ±
128.8* mg/dl in animals fed with cholesterol enriched diet.
Ischemic postconditioning reduced infarct size in normal
and hypercholesterolemic rabbit hearts without modifying
postischemic ventricular function. Although infarct was
greater in hypercholesterolemic animals, the protection rea-
ched was similar in both groups.
Abstract N° A51
Ischemic preconditioning induced by coronary
angioplasty in patients: effect of hyperlipidemia
I. Ungi a, E. Nagy a, Z. Ruzsa a, Z. Zimmermann a,
T. Ungi b, T. Csont b, P. Ferdinandy b. a Second Department
of Internal Medicine, Cardiology Center, University of
Szeged, Hungary. b Cardiovascular Research Group,
Department of Biochemistry, University of Szeged, Hungary
Although ischemic preconditioning provides a remarkable
cardioprotection in animals and humans, its effectiveness is
limited in some disease states, such as hyperlipidemia. We
studied ischemic preconditioning induced by coronary angio-
plasty in hyper- and normocholesterolemic patients by means
of beat-to-beat analysis of intracoronary ST-segment eleva-
tion. Thirty patients of significant single-vessel coronary di-
sease were divided into normocholesterolemic and hypercho-
lesterolemic (n = 15 each) groups. Intracoronary ECG and
intra-aortic pressure were continuously recorded during three
2 min balloon inflations with 5 min intervals. In normocholes-
terolemic patients, ST-segment was continuously increasing
during occlusions. Repeated occlusions significantly attenua-
ted ST-elevation from 1.28 ± 0.67 to 0.88 ± 0.51 mV (P <
0.001) when measured at the end of the last occlusion,
showing the effect of preconditioning. In hypercholesterole-
mic patients, ST-segment rapidly increased in the initial 30 s
of the first occlusion. However, in these patients, repeated
occlusions did not attenuate ST-segment elevation at the end
of the last occlusion (1.24 ± 1.11 mV vs. 1.21 ± 1.09 mV,
non-significant). We conclude that (i) beat-to-beat analysis of
ST-segment shift is a suitable method for the fine assessment
of the evolution of the severity of ischemia; (ii) hypercholes-
terolemia attenuates the anti-ischemic effect of preconditio-
ning in patients, and leads to an early, rapid increase in ST-
segment elevation during the first ischemic challenge. These
results show that the ability of the heart to adapt to ischemic
stress is diminished in hypercholesterolemic patients.
LVDP LVEDP Infarct size
G1 39.8 ± 4.1 48.2 ± 4.5 16.6 ± 2.1
G2 37.6 ± 4.4 66.6 ± 12.5 4.2 ± 1.5 *
G3 29.2 ± 5.3 56.1 ± 6.1 30.6 ± 2.6 *
G4 35.1 ± 8.1 61.5 ± 8.8 5.5 ± 1.1**
X ± SEM.
*P < 0.05 vs. G1.
**P < 0.05 vs. G3.
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Abstract N° A52
Hypoxia-inducible factor-1a mediates anti-apoptosis of
hypoxic preconditioning in cardiomyocytes from
neonatal rats
Xiuhua Liu a, Feifei Xu, Lirong Cai. Department of
Pathophysiology, PLA General Hospital, Beijing, China
Ischemic preconditioning (IPC) is a term that is used to
describe the phenomenon that brief ischemic episodes can
attenuate tissue injury caused by subsequent sustained
ischemia/reperfusion. The cardioprotection of IPC including
anti-apoptosis has been demonstrated in hypoxic precondi-
tioning model of cardiomyocytes. To investigate whether
hypoxia-inducible factor-1a (HIF-1a) mediates anti-
apoptosis of hypoxic preconditioning in cardiomyocyte, we
measured the apoptosis rate of cardiomyocytes at 6 or 12 h
after hypoxia/reoxygenation, activities of extracellular
signal-regulated protein kinases (ERKs), and expression of
HIF-1a in cultured cardiomyocyte from neonatal S.D. rats.
We found that the apoptosis rate of cardiomyocytes in hy-
poxic preconditioning group decreased 10.92% and 14.34%
at 6 and 12 h after hypoxia/reoxygenation (n = 6, P < 0.05),
respectively. We also found that hypoxic preconditioning
increased the abundance of phospho-ERK1/2 by 3-folds and
expression of HIF-1a by onefold in whole cell extracts from
hypoxic preconditioned cardiomyocytes. PD98059, an inhi-
bitor of the upstream kinase of ERKs, abolished the anti-
apoptosis effect, ERKs activation, and expression of HIF-1a
induced by hypoxic preconditioning. We concluded that hy-
poxic preconditioning protects cardiomyocytes from
hypoxia/reoxygenation-induced apoptosis and upregulation
of HIF-1a through ERKs pathway mediates the cardiopro-
tection of hypoxic preconditioning.
Keywords: Hypoxia-inducible factor–1a; Hypoxic pre-
conditioning; Apoptosis
Abstract N° A53
ERKS-mediated phosphorylation of HIF-1a is
associated with cardioprotection of hypoxic
preconditioning
Xiuhua Liu, Xudong Wu, Lirong Cai. Department of
Pathophysiololy, PLA General Hospital, Beijing, China
Hypoxia-inducible factor-1a (HIF-1a) is a heterodimer
composed by HIF-1a and HIF-1b. The phosphorylation of
HIF-1a is upregulated upon hypoxia and regulates transcrip-
tion of the hypoxia-inducible genes and cellular survival fol-
lowing hypoxia. To determine whether the cardioprotection of
hypoxic preconditioning (HPC) is mediated by
phosphorylation of HIF-1a through extracellular signal-
regulated protein kinases (ERKs) pathway, neonatal
cardiomyocytes from Sprague–Dawley rats were divided into
HPC, hypoxia/reoxygenation (H/R), PD98059 + HPC, BDM
+ HPC, and control groups. We measured viability of cardio-
myocytes, lactate dehydrogenase (LDH) release, ERKs acti-
vity, and phosphorylation of HIF-1a in HPC neonatal cardio-
myocytes. We found that the HPC cardiomyocytes showed an
increase by 22% in survival, a decrease by 52% in LDH
release from cardiomyocytes subjected to lethal H/R 24 h after
HPC. The protective effects of HPC were abolished either by
PD98059 which inhibits ERKs, or by BDM (an activator of
protein phosphatase). Western blot analysis showed activated
ERKs in whole cell extracts from HPC cardiomyocytes. SDS-
PAGE mobility shift experiments showed increased phospho-
rylation level of HIF-1a in HPC group, and the phosphoryla-
tion was blocked by PD98059 or BDM. We conclude that
ERKs-induced phosphorylation of HIF-1a is associated with
cardioprotection of HPC.
Keywords: Hypoxic preconditioning; Cardiomyocyte;
Hypoxia-inducible factor-1
Abstract N° A54
Different mechanisms contribute to preconditioning vs.
d-myo-inositol trisphosphate-induced cardioprotection
Karin Przyklenk, Michelle Maynard, Chad E. Darling,
Ronald A. Ignotz, Peter Whittaker. University of
Massachusetts, Worcester, MA, USA
Recent studies from our group revealed that: (1) concen-
trations of the second messenger inositol trisphosphate
(IP3) are increased in hearts ‘preconditioned’ (PC) with
brief antecedent ischemia; and (2) pretreatment with a syn-
thetic analog of IP3 (d-myo-IP3) elicits a significant reduc-
tion of infarct size (IS). The mechanisms by which d-myo-
IP3 evokes cardioprotection are unknown; but may involve
cardiac gap junctions (a site at which external IP3 receptors
are purportedly located), and protein kinase C (PKC: a
mediator of PC, also reportedly co-localized and involved
with gap junction phosphorylation). To assess these
potential candidates, isolated buffer-perfused rabbit hearts
underwent 30 min of coronary artery occlusion and 3 h of
reflow, with IS delineated by tetrazolium staining and ex-
pressed as a percentage of the risk region (RR). In Protocol
1, hearts were randomized to receive d-myo-IP3 (6 µM),
5 min brief PC ischemia or a matched control period.
Protocols 2, 3, and 4 were identical, except all hearts were
treated with the PKC inhibitor chelerythrine, the classic but
non-specific gap junction blocker heptanol, and the novel
and selective peptide-based gap junction inhibitor, Gap 27,
respectively. Protocol 1 confirmed that IS/RR was reduced
in both PC and d-myo-IP3-treated groups vs. controls (29*
+ 4% and 31* + 7% vs. 52 + 6%; *P < 0.05). Chelerythrine,
at a dose known to block translocation of PKC, had no effect
on IS in controls (49 + 6%), abrogated the benefits of PC
(IS/RR: 48 + 6%), but failed to block d-myo-IP3-induced
protection (IS/RR: 29 + 4%; P < 0.05 vs. matched controls).
Conversely, heptanol and Gap 27, at doses confirmed to
block gap junctions, abrogated d-myo-IP3-induced protec-
tion (IS/RR: 45–54%; P = ns vs. matched controls), but did
not block PC (IS/RR: 14–21%; P < 0.05 vs. matched
controls). Thus, while both d-myo-IP3 and PC limit IS, this
comparable protection is achieved via different cellular me-
chanisms.
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Abstract N° A55
Bcl-2 levels are increased in endothelial cells
by antioxidant supplementation but not exercise
training
Sue Marsh, Paul Laursen, Jeff Coombes.
School of Human Movement Studies,
The University of Queensland, Queensland, Australia
Atherosclerotic plaque contains apoptotic cells of endo-
thelial origin with oxidative stress implicated in this process.
The dietary supplements vitamin E and a-lipoic acid have
been shown to be a potent antioxidant combination with the
potential to prevent endothelial apoptosis. Furthermore, re-
gular exercise is known to increase myocardial protection
however little research has investigated the effects on the
endothelium. Therefore, the purpose of this study was to
examine the effect of antioxidant supplementation and/or
exercise training on Bcl-2 (anti-apoptotic) and Bax (pro-
apoptotic) proteins in coronary endothelial cells.Young male
rats received either a control or antioxidant-supplemented
diet (vitamin E and a-lipoic acid) and were assigned to
sedentary or exercise-trained groups for 14 weeks. Left ven-
tricular endothelial cells were isolated and Bcl-2 and Bax
protein levels were measured. Antioxidant supplementation
alone caused a fourfold increase in Bcl-2 (P < 0.05) with no
significant change in Bax (P > 0.05). Consequently, Bcl-
2:Bax, a marker of cellular protection, was increased sixfold
with antioxidant supplementation compared to non-
supplemented animals (P < 0.05). Exercise training had no
significant effect on Bcl-2, Bax or Bcl-2:Bax either alone or
combined with antioxidant supplementation (P > 0.05). An-
tioxidant supplementation did not affect myocardial Bcl-2
compared to non-supplemented animals (P > 0.05). We
conclude that dietary supplementation of vitamin E and
a-lipoic acid increases endothelial cell Bcl-2 whereas exer-
cise training has no such effect.
Abstract N° A56
Intermittent hypoxic training protects canine
myocardium from infarction
P. Zong, S. Setty, R. Martinez, W. Sun, J.D. Tune,
I.V. Ehrenburg, E. Tkatchouk, R.T. Mallet, H.F. Downey.
Department of Integrated Physiology,
University of North Texas, Health Sciences Center,
3500 Camp Bowie Blvd., Fort Worth, TX 76107,
USA
This investigation examined cardiac protective effects of
intermittent hypoxia training (IHT). Six dogs underwent IHT
for 20 d in a normobaric chamber ventilated intermittently
with N2 to reduce O2 to 9.5–10%. To assess resistance of
ventricular myocardium to infarction, after anesthesia the left
anterior descending coronary artery (LAD) was occluded for
60 min and then reperfused for 5 h. Radioactive microspheres
were injected systemically to assess coronary collateral flow
into the ischemic region. After 5 h reperfusion, the heart was
dyed to delineate the area at risk (AAR), and stained to
identify infarcted myocardium (IS). During LAD occlusion
and reperfusion, systemic hemodynamics and global left
ventricular function were stable. Average collateral flow in
the inner 2/3 of the center of the AAR was 0.20 ±
0.09 ml/min/g (four hearts had collateral flow
<0.12 ml/min/g). In four hearts no infarcted tissue was
detected, and in two hearts, infarction equaled 0.5 g (1.4% of
AAR). In contrast, four sham trained dogs and five untrained
dogs subjected to similar periods of LAD occlusion and
reperfusion had large infarctions (see Fig. 1). In conclusion,
IHT protects canine myocardium from infarction.
Abstract N° A57
BAX ablation protects against myocardial infarction
E. Hochhauser a, E. Birk b, Y. Cheporko a, N. Yasovich a,
L. Pinchas b, D. Offen a, Y. Barhum a, H. Pannet a,
A. Tobar a, A.D. Vidne a. a FMRC, Rabin Medical Center,
Petah Tikva, and Tel Aviv University, Israel. b Schneider
Children’s Medical Center, Petah Tikva, and Tel Aviv
University, Israel
Isolated hearts lacking the bax gene demonstrated more
cardioprotection than wild type, following myocardial
ischemia/reperfusion injury. To explore the effect of the bax
gene in vivo following myocardial infarction (MI), two
groups were studied: homozygotic bax gene deficient (–/–)
knockout and matched wild type mice, which underwent left
anterior descending coronary artery (LAD) ligation. Echo-
cardiography was performed before surgery and at 1 or
4 weeks after MI. Left ventricular end diastolic diameter
(LVEDd), end systolic diameter (LVESd), and fractional
shortening (FS), infarct size and caspase 3 activity were
measured. Post-infarct mortality was 25% in both groups.
The progressive increase in LVEDd and LVESd in Bax (–/–)
was significantly smaller compared to the wild type, 28 d
following MI (P < 0.03). Concomitantly, FS was higher in
Bax (–/–), (35 ± 4.1% and 27 ± 2.5%, P < 0.001). Infarct size
was smaller in the Bax (–/–) than wild type (24 ± 3.7% and 37
± 3.3%, P < 0.001). Caspase 3 activity was elevated at 2 h
after MI only in the wild type, but reduced to baseline values
at 1 and at 28 d post-MI. Hearts of Bax knockout mice
demonstrated reduced infarct size and superior myocardial
function. Further investigation is required concerning the bax
gene and its intracellular mechanisms that appear to play a
significant role in the post-MI response.
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Abstract N° A58
Role of Erk-mediated suppression of gap junction
permeability in cardioprotection afforded by mitoKATP
channel activation
Yoshihiko Ichikawa, Tetsuji Miura, Takayuki Miki,
Toshiyuki Yano, Yuichi Nakamura, Kazuaki Shimamoto.
The Second Department of Internal Medicine, Sapporo
Medical University School of Medicine
Our recent study showed that suppression of gap junction
(GJ) permeability during myocardial ischemia significantly
limited infarct size (IS) (Am. J. Physiol. 286 (2004) H214).
In the present study, we examined the hypothesis that cardio-
protection afforded by activation of the mitochondrial ATP-
sensitive K+ channel (mitoKATP) is mediated by ERK-
induced suppression of GJ permeability. To assess GJ
permeability in the ischemic myocardium, rabbit ventricular
myocardium was incubated in anoxic buffer containing Luci-
fer yellow (2.5 µg/ml). A mitoKATP opener, diazoxide
(100 µM), induced phosphorylation of ERK1/2 and reduced
transport of Lucifer yellow during 20-min ischemia by 70%.
PD98059 (10 µM), a MEK1/2 inhibitor, abolished suppres-
sion of GJ permeability and ERK phosphorylation by dia-
zoxide. In isolated perfused rabbit hearts, IS after 30-min
global ischemia was 57.1 ± 3.7% of the left ventricle. Pre-
treatments with 100 and 10 µM diazoxide reduced IS to 5.0 ±
1.3% and 21.5 ± 10.5% of the left ventricle, respectively.
PD98059 inhibited cardioprotection by 10 µM diazoxide (IS
= 55.8 ± 7.3%) but not by 100 µM (IS = 6.8 ± 0.3%). These
results suggest that ERK-mediated suppression of GJ per-
meability is crucial for cardioprotection by a low level of
mitoKATP activation and that additional mechanisms play
roles in protection by a high level of mitoKATP activation.
Abstract N° A59
Detection of Ca2+-activated and ATP-sensitive
potassium channels in the rat cardiac mitochondria
Youngsuk Lee a,b, Dang Van Cuong a,b, Nari Kim a,b,
Euiyong Kim a, Jin Han a,b. a Department of Physiology and
Biophysics, College of Medicine, Inje University, Busan
614-735, Korea. b Department of Molecular and Cell
Physiology Research Group, College of Medicine, Inje
University, Busan 614-735, Korea
Ion channels on the mitochondrial membrane influence
cell function in specific ways that can be detrimental or
beneficial to cell survival. At least one type of potassium
channel, mitochondrial ATP-sensitive potassium (mitoKATP)
channels play a pivotal role in early and late ischemic pre-
conditioning. And another channel with properties similar to
the surface membrane calcium-activated K+ channel was
found on the mitochondrial inner membrane (mitoKCa) of rat
ventricular cells. In this study, we investigated the subunit
composition of the rat heart mitoKATP channels and Kca
channel proteins were present in mitochondrial membrane.
Mitochondria were isolated and purified by differential cen-
trifugation and visualized by confocal microscopy and visua-
lized mitoKATP channels by means of green fluorescence
probe BODIPY-glibenclamide labeling. Enriched mitochon-
drial protein was estimated by Bradford method. Western
blotting was performed with antibodies against the known
KATP channel subunits (the sulfonylurea receptor, SUR1, -2
and the inwardly rectifying potassium channel Kir6.1 or 6.2)
and KCa channel (the surface membrane BKCa channel). The
results showed that two known bands of ~44 and ~46 kDa
Kir6.2, and ~46 kDa Kir6.1 proteins was enriched in the
mitochondria. And we observed that heart mitochondria ap-
peared to be significantly enriched in SUR2-specific bands
found at ~140 kDa. We also observed that two major bands of
about 55 and 140 kDa, similar to the predicted size of the
a-subunit and b-subunit of KCa. Our results indicate that
mitoKATP channels compose of Kir6.1, Kir6.2 subunits and a
SUR2-related sulfonylurea binding protein in rat heart mito-
chondria. Also our results findings identify mitoKca in rat
cardiac mitochondria.
Abstract N° A61
Changes in myocardial protein expression in hypoxic
preconditioned rat heart
Xiuhua Liu, Lirong Cai, Sheng Sun, Feifei Xu. Department
of Pathophysiology, PLA General Hospital, Beijing, China
Two-dimensional gel electrophoresis (2-DE) is a powerful
tool for proteomic analysis, providing us with valuable infor-
mation on differential protein expression. The aim of the
present study is to detect the changes in myocardial protein
expression in hypoxic-preconditioned (HPC) rat heart. Male
Sprague–Dawley rats (200–220 g) were randomly divided
into either HPC or control group. Rats in HPC group were
subjected to systemic hypoxic exposure (10 ± 0.4 O2) for 4 h
followed by a 24-h period of normoxic reoxygenation. Rats
in control group were time matched with the preconditioned
group and maintained under normoxic conditions for 28 h.
Rats were euthanized and the hearts were removed. Whole
cell extracts were prepared from myocardium. 2-DE was
carried out with IPG-DALT systems and the protein spots
were stained and detected by ImageMaster 2D Elite
software. The results were that 1271 ± 93 protein spots were
resolved in HPC myocardium and the match rate is 82.2 ±
7.5%. The results also showed that 45 protein spots displayed
quantitative changes in HPC myocardium, among which 33
showed higher expression and 22 decreased in abundance.
Therefore, HPC induces differential expression of myocar-
dial proteins in rats. We suggest that the alteration of protein
expression may attribute to the cardioprotection of HPC.
Keywords: Hypoxic preconditioning; Two-dimensional
polyacrylamide gel electrophoresis; Myocardium
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Abstract N° A62
Preconditioning improves post-ischemic mitochondrial
function and diminishes oxidation of mitochondrial
proteins
Herzl Schwalb a, Igor Khaliulin a, Ping Wang b,
Ester Houminer a, Harvey Katzeff b, Joseph B. Borman a,
Saul R. Powell b. a Joseph Lunenfeld Cardiac Surgery
Research Center, Hadassah-Hebrew University Medical
Center, Jerusalem 91120, Israel. b Department of Medicine,
Long Island Jewish Medical Center, New Hyde Park,
NY 11040, USA
This study examined the hypothesis that preconditioning
improves post-ischemic mitochondrial function by attenua-
ting oxidation of mitochondrial proteins. Isolated rat hearts
were exposed to 25 min global ischemia (37 °C), and 60 min
reperfusion. Hearts were preconditioned by short ischemia
and reperfusion (IP); or by 50 µM nicorandil (Nic). IP and
Nic significantly (P < 0.05) improved post-ischemic hemo-
dynamic function. The respiratory control ratio (RCR) in
isolated mitochondria was depressed by 61% in control
hearts at the end of reperfusion. IP and Nic significantly (P <
0.05) improved post-ischemic RCR. Improvement was par-
tially abolished by 200 µM 5-hydroxydecoanate (5HD) or
300 µM N-(2-mercaptopropionyl)-glycine (MPG). Further-
more, mitochondria from ischemic hearts had significantly
(P < 0.05) less ability to resist swelling upon Ca2+ loading,
which was improved by both IP and Nic. Carbonyl content of
multiple mitochondrial proteins was elevated after ischemia;
and still elevated by the end of reperfusion. IP and Nic
attenuated the increased protein oxidation observed at the
end of ischemia. The protective effects of IP and Nic were
partially abolished by 5HD. These studies support the
conclusion that one mechanism for enhanced post-ischemic
function in the preconditioned heart is improved mitochon-
drial function as a result of decreased oxidation of mitochon-
drial proteins.
Abstract N° A63
Effects of nuclear factor-jB on inhibition of
cardiomyocyte apoptosis induced by hypoxic
preconditioning
Feifei Xu, Xiuhua Liu. Department of Pathophysiology,
PLA General Hospital, Beijing, China
Apoptosis is one of the characteristics of ischemia/
reperfusion injury. Hypoxic preconditioning (HPC) attenua-
tes cell apoptosis. In the present study, we investigated
whether protein kinase C (PKC)-mediated upregulation of
nuclear factor-jB (NF-jB) attributed to inhibition of apop-
tosis by HPC in neonatal cardiomyocytes subjected to
hypoxia/reoxygenation. Cultured cardiomyocytes from neo-
natal Sprague–Dawley rats were divided into four groups:
Hypoxia/reoxygenation, hypoxia preconditioning, hypoxia
preconditioning + PKC inhibitor H7, and control. Morpholo-
gical changes in apoptotic cardiomyocytes were detected by
the DNA specific fluorochrome Hoechst 33258 under the
invert microscope. The apoptotic rates of cardiomyocytes
were measured. Whole cell extracts were prepared for wes-
tern blotting analysis to measure the expression of PKC and
NF-jB. It was found that the HPC reduced apoptosis ratio of
cardiomyocytes subjected to sustained hypoxia/reoxy-
genation by 28.7% and upregulated nPKC e expression to
2.5-fold and NF-jB expression to 1.3-fold. The effects of
HPC on nPKC e, NF-jB expression, and cardioprotection
were abolished by H7, an inhibitor of PKC.We conclude that
HPC protects cardiomyocytes from apoptosis induced by
hypoxia/reoxygenation and PKC-mediated upregulation of
NF-jB is involve in the cardioprotection.
Keywords: NF-jB; Hypoxic preconditioning; Apoptosis
Abstract N° A64
Roles of microtubules in ischemic preconditioning
against myocardial infarction
Tetsuji Miura, Yuichi Nakamura, Atsushi Nakano,
Yoshihiko Ichikawa, Toshiyuki Yano, Hironori Kobayashi,
Yoshihiro Ikeda, Kazuaki Shimamoto. Second Department
of Internal Medicine, Sapporo Medical University, Sapporo,
Japan
The aim of this study was to determine roles of microtu-
bules in ischemic preconditioning (PC). Myocardial infarc-
tion was induced in isolated rabbit hearts by 30-min global
ischemia and 2-h reperfusion, and infarct size was expressed
as a percentage of the left ventricle (% IS/LV). Using sepa-
rate groups of rabbits, ventricular biopsies were taken before
and after PC for determination of protein kinase C (PKC)
translocation and p38-mitogen activated protein kinase
(p38MAPK) activation. To depolymerise microtubules, we
used two structurally different agents, colchicine (50 µM)
and nocodazole (1 µM). PC with two cycles of 5-min
ischemia/5-min reperfusion significantly reduced IS from
60.1 ± 5.0% to 20.0 ± 5.0%. Although neither colchicine nor
nocodazole modified IS in non-preconditioned hearts, these
agents abolished the IS-limiting effects of PC (% IS/LV =
56.8 ± 2.2% and 53.4 ± 2.5%, respectively). Colchicine
prevented PKC-e translocation and p38MAPK activation by
PC. Furthermore, PKC translocation by infusion of 1-oleyl-
2-acetyl-sn-glycerol was also prevented by colchicine.
However, colchicines did not interfere with negative inotro-
pic and chronotropic responses of the myocardium to adeno-
sine. These results suggest that microtubules play a crucial
role in transmission of signals from G proteins to PKC in the
mechanism of anti-infarct tolerance afforded by PC.
Abstract N° A66
Biochemical changes in cardiac myocytes obtained at
different stages of ischemic preconditioning from
rabbit model
Anil Grover a, Rajesh Vijayvergiya a, Ajay Bahl a,
Dipika Sharma b, S. Majumdar b, V.K. Bhargava c.
a Department of Cardiology, Post Graduate Institute of
Medical Education and Research, Chandigarh 160012,
India. b Department of Experimental Medicine, Post
Graduate Institute of Medical Education and Research,
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Chandigarh 160012, India. c Department of Pharmacology,
Post Graduate Institute of Medical Education and Research,
Chandigarh 160012, India
Various biochemical markers are associated with ischemic
preconditioning (IP) of cardiac myocytes. We studied the
role of various markers like superoxide dismutase (SOD),
glutathione peroxidase (GSH), malondialdehyde (MAD), in-
tracellular calcium (Ca2+), protein kinase C (PKC), norepi-
nephrine (NEp), and nitric oxide byproducts–(citrulline) and
reactive nitrogen intermediates (RNI) in IP of rabbit heart
using isolated cardiac myocyte preparation. Each of Sham
group (A) and five preconditioned groups (B–G) had eight
rabbits. Preconditioned groups were–as follows (B) 5 min
coronary ligation, (C) 5 min ligation → 10 min recovery, (D)
30 min ligation, (E) 5 min ligation → 10 min recovery →
30 min ligation, (F) 5 min ligation → 10 min recovery →
30 min ligation → 30 min recovery, and (G) adenosine
infusion → 30 min ligation → 30 min reperfusion. Following
anaesthesia, left anterior descending (LAD) was ligated.
Thereafter, myocytes were isolated from LAD, left circum-
flex (LCx) and right coronary artery (RCA) territory to esti-
mate various markers. SOD and GSH were significantly
increased in all three territories in Groups F and G. MAD
level in membranous fraction of myocytes showed signifi-
cant increase in Groups C and E in all three territories.
Intracellular Ca2+ was significantly increased in Groups F
and G in LAD territory only. In Groups F and G of LAD
territory, the translocation of PKC from cytosol to membrane
was significantly increased. Citrulline and RNI levels were
significantly increased in E, F and G Groups in all three
territories. Groups F and G did not show significant increase
in NEp level in any territory. Various biochemical markers
like SOD and GSH, membranous MAD, intracellular Ca2+,
citrulline, RNI, NEp, and PKC are contributing to IP in
Group F (preconditioned group) and adenosine treated group
(Group G).
Abstract N° A67
Effect of mechanical stress on myocardial anti-oxidant
enzymes and ischemic preconditioning in rabbit heart
Anil Grover a, Rajesh Vijayvergiya a, Ajay Bahl a,
Dipika Sharma b, V.K. Bhargava c, S. Majumdar b.
a Department of Cardiology, PGIMER, Chandigarh 160
012, India. b Department of Experimental Medicine,
PGIMER, Chandigarh 160 012, India. c Department of
Pharmacology, PGIMER, Chandigarh 160 012, India
We studied the contribution of mechanical stress in raising
anti-oxidant enzymes levels in cardiac myocytes during is-
chemic preconditioning in rabbit hearts. Eight rabbits in each
sham group and pulmonary artery ligation group were stu-
died. Following anaesthesia, pulmonary artery (PA) was liga-
ted partially for 2 min (till right ventricular dilatation was
visualized), followed by 30 min of reperfusion. In sham
group, the heart was directly removed without PA ligation.
Thereafter, cardiac myocytes were isolated from left anterior
descending (LAD), left circumflex (LCx), and right coronary
artery (RCA) territory to estimate enzymes namely supe-
roxide dismutase (SOD) and glutathione peroxidase (GSH).
Values of levels of SOD and GSH in two groups are presen-
ted in the table as mean ± SEM. Both SOD and GSH levels in
cardiac myocytes were significantly increased in PA ligation
group compared to sham group in RCA territory. The levels
were higher but not statistically significant in other territories
compared to sham group. The table denotes * P < 0.05 as
compared to sham. Mechanical stress can produce a rise in
the anti-oxidant enzyme levels and can play an important role
in ischemic preconditioning. Groerritory RCA territory
Abstract N° A68
Heat shock protein 70 mediates effects of metabolic
inhibition preconditioning or kappa opioid receptor
stimulation on calcium homeostasis in the rat
ventricular myocytes subjected to ischaemic insults
Jing Liu, Tak Ming Wong. Department of Physiology and
Institute of Cardiovascular Sciences, The University of
Hong Kong, HK SAR, China
Heat shock protein 70 (HSP70) plays an important role in
delayed cardioprotection of preconditioning. Attenuation of
cytosolic calcium ([Ca2+]i) overload is believed to be respon-
sible for cardioprotection. There is evidence suggesting a
link between HSP70 and [Ca2+]i homeostasis. We hypothe-
size that activation of HSP70 by preconditioning may restore
[Ca2+]i homeostasis altered by ischaemic insults. To test the
hypothesis, we determined the effects of preconditioning
with metabolic inhibition or U50,488H (a j-opioid receptor
agonist) on viability and injury, HSP70 expression, and
[Ca2+]i alterations in ventricular myocytes subjected to is-
chaemic insults (MI and anoxia, MI/A), with blockade of the
synthesis of HSP70. In myocytes with vehicle pretreatment,
the percentage of dead cells detected by trypan blue exclu-
sion, the injury reflected by release of lactate dehydrogenase
(LDH) and the resting [Ca2+]i significantly increased, while
the amplitude of electrically induced [Ca2+]i transient de-
creased, after 10 min incubation with 10 mM 2-deoxy-d-
glucose (2-DOG) and 10 mM sodium dithionite, known to
cause MI/A. However, when the myocytes were subjected to
30 min pretreatment with either 20 mM lactate and 10 mM
2-DOG (MIP) or 30 µM U50,488H (UP) 20 h before MI/A,
the changes in viability and injury, and [Ca2+]i responses
were significantly attenuated. These were accompanied by a
Groups LAD territory LCx territory RCA territory
SOD (Enzyme U/mg
protein)
Sham group 0.56 ± 0.09 0.52 ± 0.11 0.57 ± 0.06
PA Group 0.61 ± 0.02 0.70 ± 0.04 1.06 ± 0.02 *
GSH (nmol/mg protein)
Sham group 3.07 ± 0.26 2.93 ± 0.40 3.03 ± 0.40
PA group 3.72 ± 0.26 3.10 ± 0.13 6.71 ± 0.20 *
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significant increase in HSP70 expression. Furthermore, bloc-
kade of the synthesis of HSP70 with a selective antisense
oligonucleotides abolished the beneficial effects of MIP or
UP on cellular viability and [Ca2+]i responses. This study
provides evidence that activation of HSP70 induced by pre-
conditioning, which conferred delayed cardioprotection, res-
tored, at least partially, the [Ca2+]i homeostasis altered by
ischaemic insults. The observations also suggest that activa-




Cardioprotective actions of melatonin:
receptor-mediated or due to its reactive oxygen species
scavenging?
Genade A. Lochner. Department of Medical Physiology,
University of Stellenbosch, Republic of South Africa
Melatonin (mel), a hormonal product of the pineal gland,
is a powerful cardioprotectant, probably due to its reactive
oxygen species (ROS) scavenging properties. Mel receptors
have been identified in the myocardium, but it is unknown
whether they participate in mel-induced cardioprotection. In
contrast, mel may counteract the protective effects of ischae-
mic preconditioning (IP), a process dependent on ROS re-
lease. The aims of this study were to investigate the effect of
(a) mel on IP as well as NO-induced preconditioning and (b)
mel antagonists on mel-induced cardioprotection. Isolated
perfused rat hearts were subjected to either 20 min global
ischaemia or 35 min regional ischaemia preceded by (i) no
interventions (non-IP), (ii) 3 × 5 min IP in the presence or
absence of mel 50 µM, (iii) 3 × 5 min NO preconditioning
(induced by sodium nitroprusside (SNP) 100 µM), in the
presence or absence of mel 50 µM. The effect of mel 50 µM
on infarct size was studied after 35 min regional ischaemia in
the presence or absence of the mel-receptor blockers, Luzin-
dole 5 µM or N-acetyl tryptamine (NAT) 5 µM.
Conclusions. – Mel-induced cardioprotection is partially
receptor mediated. Due its ROS scavenging properties it
attenuates IP, but has no effect on NO preconditioning.
Abstract N° A70
Possible involvement of changes in mitochondrial
calcium uptake in cardio-protection by ischemic
preconditioning
Shi-zhong Zhang, Chun-mei Cao, Qin Gao, Qiang Xia.
Department of Physiology, Zhejiang University School of
Medicine, Hangzhou 310031, China
Intensive studies have demonstrated that the mechanism
of cardioprotection by ischemic preconditioning (IPC) is
closely related to mitochondria. It was reported that IPC can
reduce mitochondrial calcium content in ischemic myocar-
dium. However, whether mitochondrial calcium uniporter
participates in the cardiac effect of IPC has not been elucida-
ted. The aim of this study is to determine whether mitochon-
drial calcium uniporter plays a role in the cardioprotection by
IPC and its relationship to mitochondrial permeability tran-
sition pore (MPTP). Isolated rat hearts were subjected to
30 min regional ischemia (ligation of left anterior descending
artery) followed by 120 min reperfusion. We found that IPC
(5 min global ischemia + 5 min reperfusion, two cycles)
reduced the infarct size (IPC vs. control, 13.09 ± 3.65% vs.
44 ± 3.6%, P < 0.01), which was associated with improved
recovery of left ventricular developed pressure (LVDP) and
left ventricular end-diastolic pressure (LVEDP) at 30 min of
reperfusion (P < 0.01). Spermine, an activator of mitochon-
drial calcium uniporter, which was administrated at 20 µM
during first 10 min of reperfusion, attenuated IPC-induced
decrease of infarct size (IPC + spermine vs. IPC, 35.6 ± 4.0%
vs. 13.09 ± 3.65%, P < 0.01), and preserved recovery of
LVDP and LVEDP (P < 0.01). Release of lactate dehydroge-
nase from coronary effluent in spermine-treated IPC heart
was more than that in the IPC heart. During first 10 min of
reperfusion, application of ruthenium red (5 µM), an inhibi-
tor of mitochondrial calcium uniporter, had similar effect
with IPC. Treatment with cyclosporin A (CsA, 0.2 µM, an
inhibitor of MPTP opening) during last 5 min of ischemia
and first 15 min of reperfusion also showed similar cardiac
effect with IPC. Co-administration of spermine (20 µM) with
CsA (0.2 µM) during reperfusion abolished the effect of
spermine. The results indicate that inhibition of mitochon-
drial calcium uptake is involved in the cardioprotection of
IPC via inhibiting MPTP.
Abstract N° A71
University of Wisconsin vs. Celsior for donor heart
preservation with cyclosporin A
Thomas N. Masters, Alexander A. Fokin,
Geoffrey G. Gong, Francis Robicsek. Heineman Medical
Research Laboratory, Carolinas Medical Center, Charlotte,
North Carolina 28232
In previous studies, 12 h of heart preservation using Uni-
versity of Wisconsin solution (UW) at 4 °C and micro perfu-
sion (1 ml/min) in a canine heart model resulted in 100%
functional recovery. Eighteen hours of preservation resulted
in 50–60% functional recovery with no necrosis but signifi-
cant amounts of apoptotic cells (TUNEL). Blocking apopto-
Aortic output (ml/min) during reperfusion
Non-IP IP IP + Mel SNP SNP + Mel
6.25 ± 1.70 19.1 ± 1.7 * 7.1 ± 2.88 14.10 ± 1.31 * 16.6 ± 3.06 *
P < 0.05 vs. non-IP
Effect of melatonin on infarct size
Non-IP Mel Mel+Luzindole Mel+NAT
34.8 ± 1.8 16.8 ± 2.6 * 27.2 ± 2.1 ** 21.4 ± 2.8
* Non-IP vs. Mel P < 0.001.
** Luzindole vs. Mel P < 0.001.
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sis with cyclosporin A (CsA) by treating the donor animal
(10 mg/Kg) and adding CsA to preservation solution (10-
5 mol/l), resulted in functional recoveries of 100% after 18
and 24 h of preservation. The viscosity of UW at 4 °C may
prevent adequate perfusion during preservation. In the pre-
sent experiments, Celsior (Cs) was used, (less viscous) to
determine the efficacy of heart preservation with and without
CsA. After preservation for 24 h, hearts were heterotopically
transplanted and studied biochemically, morphologically and
functionally during 6 h of reperfusion. When combined with
CsA, both preservation solutions were equally effective with
100% functional recovery (Cs hearts reached this level
faster-between 2 and 3 h while 5–6 h for UW). Apoptosis was
less with Cs and CsA preservation. In conclusion, Cs was a
better solution for extended periods of heart preservation.
Although the destructive processes are not blocked or elimi-
nated by CsA, their delay through mitochondrial mecha-
nisms (permeability transition pore blockade) provides a
viable heart graft after 18–24 h of preservation.
Abstract N° A72
Anti-infarct effect of magnesium is not mediated by
adenosine A1 receptor in the globally ischemic isolated
rat heart
S. Ebrahimi, M. Faghihi. Department of Physiology, Faculty
of Medicine Tehran Medical Sciences University, Tehran,
Iran
Attention is growing for a potential role of magnesium
(Mg) in the pathophysiology of cardiovascular disease. Cli-
nical impact of Mg therapy remains controversial in acute
myocardial infarction. The present study investigated the
infarct size. Isolated rat hearts (n = 28) were used for Lan-
gendorff perfusion. Control hearts were perfused at 37 °C for
180 min, global ischemia (GI) hearts received 30 min of
global ischemia and 120 min reperfusion, Mg hearts received
a bolus injection of magnesium sulfate (MgSO4) 15 min
before the global ischemia, Mg/DPCPX, a selective antago-
nist adenosine A1 receptor, hearts received DPCPX
(200 nM) 5 min before the MgSO4. Infarct size was measu-
red by triphenyltetrazolium chloride method. The rate pres-
sure product (RPP) was calculated as an index of ventricular
contractile function and RPP 120 min after reperfusion was
taken as an endpoint of functional protection. Infarct size was
significantly smaller in Mg group (0.2 ± 0.13%) compared to
GI group (43.41 ± 1.63%) P < 0.001. The infarct size limiting
effects of Mg was not abolished by DPCPX. Mg enhanced
post-ischemic functional recovery. RPP was significantly
enhanced to 88.34 ± 3.1% (P < 0.001 vs. GI). The present
findings raise the possibility that reduction of infarct size
with Mg dose not involve enhanced adenosine-mediated car-
dioprotection but adenosine mediate protection action of Mg
on post-ischemic function recovery. Another important fin-
ding of this study is that Mg administration has an infarct size
limiting effect independently its effect on post-ischemic
functional recovery in rats.
Abstract N° A73
Adenosine A1 and opioid receptor cross-talk in the
isolated murine heart
Jason N. Peart, Eric R. Gross, Garrett J. Gross. Medical
College of Wisconsin, WI, USA
We have previously shown cross-talk between adenosine
and opioid receptors in vivo. As there is evidence supporting
an interaction between opioids and adenosine in the CNS, we
sought to examine if the cross-talk observed in vivo was
present in a model devoid of CNS innervation. To this end,
we employed an isolated mouse heart model where hearts
were subjected to 25 min global ischemia followed by 45 min
reperfusion. Following reperfusion, untreated hearts exhibi-
ted an elevated end-diastolic pressure (EDP) of 29 ±
3 mmHg, while rate–pressure product (%RPP) returned to 40
± 5% of baseline. Treatment with CHA (1 µM) or morphine
(30 µM) significantly reduced EDP (17 ± 1 and 15 ± X
mmHg, respectively, P < 0.05) and improved contractile
function (62 ± 2.2% and 66 ± 2% RPP, respectively, P <
0.05). Lactate dehydrogenase (LDH) release was signifi-
cantly reduced in both agonist-treated groups. Pretreatment
with opioid antagonist naloxone (100 µM) effectively redu-
ced the recovery of %RPP in CHA-treated hearts (50 ± 3%)
implying a role for the adenosine A1 receptor. Furthermore,
200 nM of the A1 adenosine receptor antagonist, DPCPX,
abrogated the cardioprotective effects of morphine. Phosph-
porylation of GSK-beta and ERK1/2 was also significantly
increased in morphine-treated hearts. This increase in phos-
phorylation was completely blocked by DPCPX. Thus,
cross-talk between adenosine A1 and opioid receptors ap-
pears to exist in a model lacking intact CNS innervation, and
may provide novel approaches to cardioprotective therapeu-
tics.
Abstract N° A74
The delta opioid agonist fit is protective 48–120 h after
administration via PI3K
Eric R. Gross, Jason N. Peart, Anna K. Hsu,
John A. Auchampach, Garrett J. Gross. Department of
Pharmacology and Toxicology, Medical College of
Wisconsin, Milwuakee, WI, USA
Chronically administered morphine achieves an enhanced
cardioprotective effect, however, the mechanism of protec-
tion, including the opioid receptor subtype and protein kina-
ses involved, are unknown. Recent evidence suggests that the
phosphatidylinositol-3 kinase (PI3k) pathway is involved in
acute opioid-induced cardioprotection (OIC), however, it is
unknown whether PI3k is involved in chronic OIC. Hence,
we analyzed the efficacy and window of cardioprotection
provided by FIT, a novel irreversible d opioid agonist, and
whether PI3k mediates chronic OIC. Male Sprague–Dawley
rats were administered FIT either acutely or chronically and
then subjected to 30 min ischemia and 2 h of reperfusion
followed by infarct size (IS) assessment (Mean ± SEM%,
significance, *P < 0.01 or **P < 0.001). Acute doses of FIT
showed greatest IS reduction at 0.01 mg/kg given either
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10 min before ischemia or 5 min before reperfusion compa-
red to control (41.7 ± 1.0*, 45.9 ± 1.8* vs. 60.0 ± 1.1%,
respectively). Chronic IS reduction was also present with FIT
(0.01 mg/kg) 48, 72, 96, and 120 h vs. control (45.4 ± 1.3*,
42.4 ± 3.1**, 30.0 ± 3.3**, 46.2 ± 0.7*, vs. 60.0 ± 1.1%,
respectively). Wortmannin (WORT, 15 µg/kg), an irreversi-
ble PI3k inhibitor, given 1 h prior to FIT, abolished IS
reduction at 96 h (55.3 ± 4.9%). Data obtained from H9C2
cells showed that FIT (1 µM) phosphorylates GSKb, a kinase
downstream of PI3k, 10 min after stimulation. This effect
was abolished by pretreatment with WORT (100 nM). These
data suggest that chronic OIC via the d opioid receptor
occurs via PI3k.
Abstract N° A75
Cardioprotection of k-opioid receptor stimulation with
interleukin-2 or U50,488H involves inhibition of MPTP
opening
Chunmei Cao, Qiang Xia, Takming Wong. Department of
Physiology, Zhejiang University, Hangzhou and Department
of Physiology, The University of Hong Kong, Hong Kong
SAR, China
Previous study demonstrated that kappa opioid receptor
stimulation with a kappa opioid receptor (j-OR) agonist,
U50,488H (U50), or interleukin-2 (IL-2) confers cardiopro-
tection. Inhibiting mitochondrial permeability transition
pore (MPTP) opening at reperfusion has also been shown to
confer cardioprotection of ischaemic preconditioning. We
tested the hypothesis that stimulation with U50 or IL-2 also
confers cardioprotection by inhibiting MPTP opening. Car-
diac injury was evaluated by measuring infarct size and
lactate dehydrogenase (LDH) release in response to 30 min
ischemia and 120 min reperfusion in the isolated rat heart.
The MPTP opening was observed in calcein-loaded isolated
myocytes and isolated mitochondria. Intracellular Ca2+
([Ca2+]i) also was determined in the isolated ventricular
myocytes suffered from 5 min anoxia and 10 min reoxyge-
nation by spectrofluorometry. Pretreatment of the isolated
perfused heart with IL-2 (50 U/ml) or U50 (10 µM) de-
creased the infarct size and LDH release, effects blocked by
blockade of j-OR with a selective j-OR antagonist, nor-
BNI. Moreover, blockade of protein kinase C (PKC) with its
inhibitor, GF109203X (GF, 10 µM), also attenuated the pro-
tective effect of both IL-2 and U50. The infarct and LDH
reducing effects of IL-2 or U50 or PMA were blocked by
atractyloside (Atr, 20 µM), a MPTP opener. Inhibition of the
MPTP opening with cyclosporin A (CsA, 0.2 µM) reduced
both infarct size and LDH release, which could not be bloc-
ked by GF. In isolated ventricular myocytes subject to anoxia
and reperfusion, the end diastolic [Ca2+]i increased while the
amplitude of [Ca2+]i transient decreased. These changes
were attenuated by either IL-2 or U50. The effects of IL-2
and U50 were abolished with opening of the MPTP with Atr.
Finally we showed that IL-2 and U50 decreased MPTP
opening in calcein-loaded myocytes, and reduce calcium-
induced mitochondrial swelling. The present study provides
the first evidence that j-OR stimulation with IL-2 and U50
protects the myocardium by inhibiting of MPTP opening.
PKC may be one of the upstream components of signal
transduction pathway.
Supported by The Research Grants Council, Hong Kong.
Abstract N° A76
The delta opioid agonist fit is protective 48-120 hours
after administration via PI3k
Eric R. Grossa, Jason N. Pearta, Anna K. Hsua, John A.
Auchampacha and Garrett J. Grossa.
aDepartment of Pharmacology and Toxicology, Medical
College of Wisconsin, Milwuakee, WI, USA
Chronically administered morphine achieves an enhanced
cardioprotective effect, however, the mechanism of protec-
tion, including the opioid receptor subtype and protein kina-
ses involved, are unknown. Recent evidence suggests that the
phosphatidylinositol-3 kinase (PI3k) pathway is involved in
acute opioid-induced cardioprotection(OIC), however, it is
unknown whether PI3k is involved in chronic OIC. Hence,
we analyzed the efficacy and window of cardioprotection
provided by FIT, a novel irreversible d opioid agonist, and
whether PI3k mediates chronic OIC. Male Sprague Dawley
rats were administered FIT either acutely or chronically and
then subjected to 30 minutes ischemia and 2 hours of reper-
fusion followed by infarct size (IS) assessment
(Mean ± SEM %, significance = *P < 0.01 or **P < 0.001).
Acute doses of FIT showed greatest IS reduction at
0.01mg/kg given either 10 minutes before ischemia or 5 mi-
nutes before reperfusion compared to control (41.7 ± 1.0*,
45.9 ± 1.8* vs. 60.0 ± 1.1 %, respectively). Chronic IS re-
duction was also present with FIT (0.01mg/kg) 48, 72,
96 and 120 hours versus control (45.4 ± 1.3*, 42.4 ± 3.1**,
30.0 ± 3.3**, 46.2 ± 0.7*, vs.60.0 ± 1.1 %,respectively).
Wortmannin (WORT, 15µg/kg), an irreversible PI3k inhibi-
tor, given 1 hour prior to FIT, abolished IS reduction at
96 hours (55.3 ± 4.9 %). Data obtained from H9C2 cells
showed that FIT(1µM) phosphorylates GSKb, a kinase
downstream of PI3k, 10 minutes after stimulation. This ef-
fect was abolished by pretreatment with WORT(100nM).
These data suggest that chronic OIC via the d opioid receptor
occurs via PI3k.
Abstract N° A77
Sarcolemmal Na/Ca exchange and mitochondria are
both involved in Ca paradox induced cell injury:
effects on [Ca]i and [Ca]m
Masaki Matsunaga, Masao Saotome, Hiroshi Satoh,
Hideki Katoh, Akihiko Uehara, Hajime Terada,
Hideharu Hayashi. Internal medicine III, Hamamatsu
University School of Medicine, Hamamatsu, Japan
The Ca paradox results in marked Ca overload and cell
damage. Recently, it has been reported that mitochondrial
KATP channel (mitoKATP) and mitochondrial permeability
transition pore (mPTP) could be involved in the cardiopro-
tective effects against Ca overload. We investigated the un-
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derlying mechanisms of protective effects by monitoring
[Ca]i (by fura-2 ratio:R) and the cell death during Ca paradox
protocol in intact rat myocytes, and [Ca]m (by rhod-2) in
saponin-permeabilized myocytes. (1) On Ca repletion fol-
lowing 15 min Ca depletion, 90 of 210 cells (43%) died, and
R increased in these cells (DR; 1.51 ± 0.06, means ± S.E., P
< 0.01). (2) KB-R7943 (10 µM; an inhibitor of Na/Ca ex-
change) completely inhibited both the cell death and increase
in R (0%, 0.14 ± 0.02, n = 30, P < 0.01). (3) Diazoxide (Dz;
100 µM, a mitoKATP opener), ruthenium red (RR; 10 µM, an
inhibitor of Ca uniporter) and cyclosporin A (CsA; 1 µM, an
inhibitor of mPTP) prevented cell death (26%, 15%, 17%, n
= 81–125, P < 0.05), and the protective effects of Dz were
abolished by 5-hydroxydecanoate (100 µM; a mitoKATP inhi-
bitor). (4) Dz and RR decreased [Ca]m, but CsA did not. (5)
Dz decreased NADH fluorescence whereas RR or CsA did
not alter it. In conclusion, (1) a rapid increase in cytosolic Ca
concentration via Na/Ca exchange causes cell damage in Ca
paradox, (2) the protective effects of Dz could be ascribed to
altered Ca regulation by decreasing [Ca]m and by modifying
oxidative phosphorylation, and (3) the protective effects of
CsA could be directly associated with mPTP.
Abstract N° A78
Cardioprotection with diazoxide and pinacidil:
protonophoric mechanism of action
E.L. Holmuhamedov, A. Jahangir, A. Oberlin, N. Ashfaque,
A. Komarov, M. Colombini, A. Terzic. Mayo Clinic,
Rochester, MN and University of Maryland, College Park,
MD, USA
Excessive build-up of mitochondrial protonic potential is
harmful to cellular homeostasis, and modulation of inner
membrane permeability a proposed countermeasure. Here,
we demonstrate that structurally distinct potassium channel
openers, diazoxide (D) and pinacidil (P), facilitated trans-
membrane proton translocation generating H+-selective cur-
rent. Both openers depolarized mitochondria, activated state
4 respiration and reduced oxidative phosphorylation, recapi-
tulating the signature of mitochondrial uncoupling (Fig. 1).
This effect was maintained in K+-free conditions, and shared
with the prototypic protonophore 2,4-dinitrophenol (DNP).
D, P, and 2,4-DNP (Fig. 2), but not 2,4-dinitrotoluene lacking
protonophoric properties, preserved functional recovery of
ischemic heart. The identified protonophoric property of po-
tassium channel openers, thus, implicates a previously unre-
cognized component in their mechanism of cardioprotection.
Abstract N° A79
Antimycin A (AA) a mitochondrial free radical
generator mediates cardioprotection via p38 mapkinase
(p38)
Alamgir M.N. Kabir a, Xuebin Cao a, Diana A. Gorog a,
Masaya Tanno a, Michael J. Shattock b,
Michael S. Marber a. a Department of Cardiology, Rayne
Institute, St Thomas’ Hospital, UK. b Department of
Cardiovascular Research, Rayne Institute, St Thomas’
Hospital, UK
Low concentration free radicals may have a role in cell
signalling. Antimycin A (AA) is a mitochondrial free radical
generator thought to work at site III of the electron transport
chain. The p38 has a controversial role in cardioprotection.
We examined the effect of AA on p38 activation. We also
examined whether AA is cardioprotective and if so whether
SB203580 (SB), a p38 inhibitor has any effect on cardiopro-
tection. C57Blk/6 or MKK3 knockout (KO) mice were trea-
ted in a Langendorff model with 3 min AA (0.1 µg/ml)
followed by 5 min perfusion then freeze clamped for protein
analysis by western blotting. Also C57Blk/six hearts were
perfused with AA for 3 min and 10 min washout followed by
30 min global ischaemia and 2 h reperfusion. A similar
protocol was performed but with theAA bracketed with 1 µM
SB. Controls of SB alone and DMSO were used. Infarct size
(IS) was analysed in all groups. AA caused activation of p38
and HSP27. This was similar in the MKK3 KO mice. AA
caused a significant reduction in infarct size and this reduc-
tion was lost when AA was bracketed with SB. The p38
appears to be activated by AA independently of MKK3 and
inhibition of p38 blocks AA cardioprotective effect. Infarct
size/left ventricle size (%IS/LV) P < 0.05:
Abstract N° A80
LPS treatment of neonatal rat cardiomyocytes alters
mitochondrial membrane potential and increases
uncoupling protein expression
Diane Hickson-Bick, Chad Jones, L. Maximilian Buja. The
University of Texas Medical School, Houston, TX, USA
Cardiac myocyte cell death is a clinically important
consequence of endotoxic shock. Our studies have identified
an innate protective phenotype of the neonatal rat heart
against LPS-induced cell death. Using deconvolution laser
microscopy we have demonstrated that LPS treatment of
neonatal rat ventricular myocytes (NRVM) leads to a tran-
sient change in the mitochondrial membrane potential (DX).
This loss of DX is temporally associated with an increase in
the expression of mitochondrial uncoupling proteins, UCP2
and UCP3, and a decrease in cellular ATP levels. Thus,
implying that LPS treatment of NRVM’s can reversibly un-
Group (n = 6 in each group) % IS/LV ± SEM
DMSO 48.3 ± 5.2
SB 48 ± 4.5
AA 22.8 ± 6.1
SB + AA 60.7 ± 6.5
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couple oxidative phosphorylation, facilitating a proton leak
across the mitochondrial membrane, decreasing DX, and
thereby reducing the production of cell-damaging reactive
oxygen species. LPS treatment has been reported to reduce
fatty acid oxidation and decrease the levels of fatty acid
binding protein. In our LPS treated cell model we observed a
rapid decrease in the level of phosphorylated AMP-activated
protein kinase (AMPK). Decreasing active AMPK leads to
increases in cardiac malonyl CoA levels and a concomitant
decrease in fatty acid oxidation. In this situation the intrami-
tochondrial levels of long chain fatty acid anions, which
cannot be metabolised, may increase. UCP3 may act as an
anion transporter, protecting the mitochondrion by removing
long chain fatty acids, which are not esterified to acetyl-CoA,
from the mitochondrial matrix.
Supported by the US Army (TATRC) DREAMS Project.
Abstract N° A81
Cardioprotection by pretreatment of tumor necrosis
factor-alpha: role of mitochondrial permeability
transition pore
Q. Gao, C.M. Cao, S.Z. Zhang, L.Y. Zou, Q. Xia.
Department of Physiology, Zhejiang University School of
Medicine, Hangzhou 310031, China
It is known that brief exposure to tumor necrosis factor-
alpha (TNF-alpha) triggers subsequent cardioprotection.
TNF-alpha can activate multiple downstream signaling cas-
cades related to mitochondria. However, it is not clear if
mitochondrial permeability transition pore is involved in
TNF-alpha-induced cardioprotection. In the present study,
we examine whether TNF-alpha can inhibit mitochondrial
permeability transition pore opening. In isolated rat hearts
subjected to 30 min regional ischemia (occlusion of left
anterior descending artery) and 120 min reperfusion, pre-
treatment with TNF-alpha at 10 U/ml for 7 min followed by
10 min washout reduced the infarct size (TNF vs. control,
15.9 ± 4.5% vs. 44.86 ± 4.4%, P < 0.01) and lactate dehydro-
genase (LDH) release (P < 0.01). The pretreatment of TNF-
alpha also improved the recovery of the left ventricular per-
formance (left ventricular developed pressure and +
dP/dtmax) during reperfusion as well as the left ventricular
end-diastolic pressure (LVEDP). Administration of atracty-
loside (Atr), an opener of mitochondrial permeability transi-
tion pore, at 20 µmol/l for 20 min (last 5 min of ischemia and
first 15 min of reperfusion) attenuated the reduction of infarct
size (Atr + TNF vs. TNF, 51.56 ± 1.03% vs. 15.9 ± 4.5%, P <
0.01), LDH release and LVEDP induced by TNF-alpha (P <
0.01). In addition, treatment of paxilline (Pax, 1 µmol/l), a
calcium-activated potassium channel antagonist, for 5 min
before ischemia, diminished the decreasing effect of TNF-
alpha on infarct size (Pax + TNF vs. TNF, 44.69 ± 3.08% vs.
15.9 ± 4.5%, P < 0.01) and LDH release (P < 0.01). The
findings suggest that in the isolated heart model, TNF-alpha
protect myocardium against ischemia and reperfusion injury
via inhibiting mitochondrial permeability transition pore
opening as well as activating calcium-activated potassium
channel (*Department of Neurology, Harbin Medical Uni-
versity First Clinical College, China).
Abstract N° A82
Attenuated mitochondrial calcium uptake as
mechanism of protection on heart reperfusion injury.
Study with an oxygen-bridged dinuclear amine
ruthenium complex (Rth360)
Gerardo de Jesús García-Rivas, Karla Carvajal,
Cecilia Zazueta. Instituto Nacional de Cardiología “Ignacio
Chávez”, Departamento de Bioquı́mica, Mexico City 14080
A growing body of evidence has demonstrated that reper-
fusion injury is mediated by mitochondria. Mitochondrial
oxidative damage is enhanced during reperfusion, probably
due to an increased mitochondrial calcium uptake. Mito-
chondrial calcium overload occurs via the calcium-uniporter;
high [Ca2+]m induces the onset of a highly permeable state of
the mitochondrial inner membrane, called the mitochondrial
permeability transition. Oxygen-bridged dinuclear amine
ruthenium complex (Rth360) is the most potent and specific
inhibitor of the mitochondrial calcium uniporter. This study
reports the effect of Rth360 in isolated and in vivo rat hearts
after ischemic–reperfusion injury. Rth360 completely abo-
lished post-reperfusion arrhythmias in the whole animal mo-
del. Also, it was observed a decrease in tissue injury marker
enzymes and an intact mitochondrial phosphorylating capa-
city was observed. In isolated hearts subjected to global
ischemia a threefold recovery of mechanical performance at
20 min of reperfusion was found. Isolated mitochondria
obtained from reperfused hearts previously treated with
Rth360 showed 18% inhibition in calcium transport. Possible
Ruth360 interactions with another calcium transport systems
were evaluated. We measured Rth360 effect on calcium re-
lease and uptake of sarcoplasmic reticulum vesicles (SRV).
SRV showed a very low affinity for the inhibitor. These data
demonstrated that the main protection mechanism of Rth360
on reperfusion injury is by direct attenuation of mitocondrial
calcium transport.
Abstract N° A83
Blocking electron transport during cardiac ischemia
protects mitochondria
Edward J. Lesnefsky, Qun Chen, Shadi Moghaddas,
Maria S.K. Stoll, Charles L. Hoppel Louis Stokes. VAMC
and Case Western Reserve University, Cleveland,
OH 44106, USA
Mitochondria are sources and targets of injury during
cardiac ischemia (isch). In the isolated rabbit heart, 45 min
isch decreases the content of the oxidatively sensitive phos-
pholipid cardiolipin (CL) in subsarcolemmal mitochondria
(SSM) located beneath the plasma membrane. The decrease
in CL is accompanied by a decrease in the content of cyto-
chrome c (cyt c) and decreased respiration through cyto-
chrome oxidase (complex IV, CIV). Isch did not alter CIV,
CL, or cyt c in interfibrillar mitochondria located between the
myofibrils. The contents of CL and cyt c, and oxidation
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through CIV, did not further decrease further during reperfu-
sion in SSM. We thus focused on isch, and asked if electron
leak from sites in the electron transport chain (ETC) proxi-
mal to CIV depletes CL, predisposing to loss of cyt c and the
defect in CIV. Isolated rabbit hearts were treated immedia-
tely before isch with rotenone (ROT), an irreversible inhibi-
tor of complex I to block electron flow in the ETC during
isch. ROT treatment preserved CL (nmol/mg pr) and cyt c
(nmol/mg pr). CIV, measured as TMPD-ascorbate respira-
tion (nAO/min/mg), was also preserved. Inhibition of the
proximal ETC during isch preserves CL, cyt c, and improves
respiration through CIV in SSM. During isch, the ETC me-
diates damage to mitochondria, probably via electron leak
that produces reactive oxygen species. Limitation of electron
flow during isch is a novel approach to limit mitochondrial
damage and possibly limit subsequent mitochondrial-derived
cardiomyocyte injury during ischemia and reperfusion.
Abstract N° A84
Blockade of electron transport before cardiac ischemia
with the reversible inhibitor amytal protects rat heart
mitochondria
Qun Chen, Charles L. Hoppel, Edward J. Lesnefsky. VAMC
and Case Western Reserve University, Cleveland,OH, USA
Ischemia (ISCH) damages the electron transport chain
(ETC). Irreversible blockade of the ETC at complex I by
rotenone blunts ischemic damage to mitochondria at cyto-
chrome oxidase (complex IV, CIV) in the distal ETC. Howe-
ver, eventual therapeutic intervention to protect myocardium
during ISCH and reperfusion (R) requires the use of a rever-
sible inhibitor that allows resumption of oxidative metabo-
lism during R. Interestingly, R does not worsen oxidative
function through CIV. Thus, we propose that if protection of
oxidative function during ISCH can be achieved with rever-
sible inhibitors of ETC, then R can occur in the setting of
preserved mitochondrial oxidative function. Amytal is a re-
versible inhibitor at the rotenone site of complex I. We asked
if amytal administered immediately before ISCH protects
mitochondria. Isolated rat hearts were perfused for 15 min
followed by 25 min global ISCH at 37 °C. Non-ISCH hearts
were only perfused for 15 min. Amytal-treated hearts recei-
ved drug for 1 min before ISCH. Subsarcolemmal (SSM) and
interfibrillar (IFM) populations of mitochondria were isola-
ted after ISCH and oxidation through CIV measured. ISCH
decreased respiration through CIV. Amytal decreased da-
mage at CIV in both SSM and IFM in a dose-dependent
manner. Peak protection occurred at doses of 2 or 2.5 mM (n
= 3 each, combined below). Lower or higher doses provided
suboptimal protection. Thus, blockade of the ETC during
ISCH with a reversible agent protects oxidative function.
Thus, R with relatively preserved mitochondrial function is a
feasible goal.
Abstract N° A85
Impact of imidapril on cardiac mitochondrial function
in an ex vivo animal model of global myocardial
ischemia
P. Monteiro, R. Carreira, L. Gonçalves, L.A. Providência.
Cardiology Department, Basic Research Unit in Cardiology,
Coimbra University Hospital, Coimbra, Portugal
Myocardial ischemia has a negative impact on both car-
diac mitochondria structure and function; it is thought that
the main cause of this deleterious affect is mediated by the
induction of the mitochondrial permeability transition. This
phenomenon is believed to be triggered by the oxidative
stress that occurs within the mitochondria as a result of
calcium overload. It is, therefore, clinically relevant to iden-
tify drugs capable of reverting or preventing these altera-
tions. Angiotensin converting enzyme (ACE) inhibitors, due
to its modulation of the renin-angiotensin-aldosterone sys-
tem, are a pharmacological class that already showed in
several clinical trials to have an important role in the treat-
ment of heart failure and coronary artery disease patients.
However, their impact on the cardiac mitochondrial function
during ischemia is not fully understood. Our aim was to
assess the impact of imidapril, an ACE inhibitor, on the
calcium-induced mitochondrial damage during myocardial
ischemia. We used an ex vivo animal model of global myo-
cardial ischemia, with a Langendorff perfusion system.
Thirty Wistar rat hearts were divided in to three groups: A
(75 min of perfusion with a Krebs-modified solution), B
(15 min of perfusion, followed by 60 min of ischemia), and C
(as in B, but in the presence of imidapril 4 µM). Several
parameters of mitochondrial function were assessed: velo-
city of the respiratory state 3 (using a Clark-type electrode),
membrane electrical potential (TPP+-electrode) and rate and
amplitude of mitochondrial swelling (by turbidimetry). Re-
garding the velocity of the respiratory state 3, no significant
differences were observed between ischemic and imidapril
groups. However, imidapril significantly increased mem-
brane electrical potential and prevented, in cardiac mitochon-
dria submitted to ischemia, the calcium-induced increase on
the rate and amplitude of mitochondrial swelling (P < 0.05,
see Fig. 1). These results demonstrate that imidapril has a
positive impact on the calcium-induced mitocondrial-





45 min isch + ROT
(n = 6)
CIV 484 ± 32 324 ± 20 * 436 ± 37 **
CL 41 ± 2 34 ± 1 * 43 ± 2 **
Cyt c 0.17 ± 0.01 0.10 ± 0.01 * 0.15 ± 0.02 **
±SEM.
* P < 0.05 vs. pre-isch.
** P < 0.05 vs. 45 min isch.
Respiration through CIV (nAO/min/mg protein (mean ± S.D.)
SSM IFM
Non-ischemia (n = 7) 550 ± 76 829 ± 103
Ischemia alone (n = 3) 354 ± 34 * 583 ± 101 *
2 or 2.5 mM amytal (n = 6) 536 ± 91 ** 817 ± 99 **
* P < 0.05 vs. non-ischemia.
** P < 0.05 vs. ischemia.
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ACE inhibitors have already demonstrated in the treatment of
heart failure and coronary artery disease patients.
Abstract N° A86
Carvedilol protects ischemic cardiac mitochondria
from oxidative stress-induced injuries
P. Monteiro a, R. Carreira a, A. Duarte b, M.S. Santos b,
A.C. Rego b, C.R. Oliveira b, L. Gonçalves a,
L.A. Providência a. a Cardiology Department, Basic
Research Unit in Cardiology, Coimbra University Hospital,
Coimbra, Portugal. b Center for Neuroscience and Cell
Biology of Coimbra, Coimbra, Portugal
During ischemia, there is an increase in production of
reactive oxygen species (ROS), due to the decrease of an-
tioxidant defenses and to the reduced state of several respira-
tory chain components, thus increasing electron escape and
ROS production, leading to higher oxidative damage. Oxida-
tive stress can cause mitochondrial dysfunction and, ultima-
tely, lead to cell death. The use of drugs capable of reversing
this mitochondrial dysfunction can be clinically relevant.
This work aimed to assess the impact of carvedilol, a beta
adrenoreceptor blocker with antioxidant properties, on the
activation level of the apoptotic cascade induced by oxidative
stress during global myocardial ischemia. Twenty-one Wis-
tar rat hearts were divided in three groups: A, 75 min of
perfusion with a Krebs-modified solution; B, 15 min de
perfusion, followed by 60 min of global ischemia; C, as in B,
but in the presence of carvedilol 40 µM. Oxidative stress was
measured by the thiobarbituric acid reactive substances test
(TBARS) and the activities of caspases 1, 3, 8, and 9 was
determined by using their respective colorimetric assays. In
cardiac mitochondria from ischemic hearts, carvedilol de-
creased oxidative stress levels (P < 0.05, see Table 1). Ische-
mia increased the activity of caspase 8, without significant
differences on the activities of caspases 1, 3, and 9 (see
Table 1). Regarding this parameter, carvedilol did not signi-
ficantly change the activity of the caspases evaluated. Our
results show that carvedilol decreases oxidative stress.
However, under these experimental conditions, carvedilol
showed no impact on the apoptotic cascade.
Abstract N° A87
Carvedilol protects cardiac mitochondria submitted to
ischemia–reperfusion from oxidative stress-induced
injuries
P. Monteiro a, R. Carreira a, A. Duarte b, M.S. Santos b,
A.C. Rego b, C.R. Oliveira b, L. Gonçalves a,
L.A. Providência a. a Cardiology Department, Basic
Research Unit in Cardiology, Coimbra University Hospital,
Coimbra, Portugal. b Center for Neuroscience and Cell
Biology of Coimbra, Coimbra, Portugal
In an ischemia–reperfusion setting, there is a marked
increase in reactive oxygen species (ROS) production in
mitochondria, as a result of the sudden availability of oxygen
in the cardiac tissue. This phenomenon can cause oxidative
damage in the inner mitochondrial membrane, thus resulting
in mitochondrial dysfunction and, ultimately, cell death
(oxygen paradox). Our aim was to assess the impact of
carvedilol, a beta adrenoreceptor blocker with antioxidant
properties, on the activation level of the apoptotic cascade
induced by oxidative stress during global myocardial ische-
mia–reperfusion. Twenty-one Wistar rat hearts were divided
in three groups: A, 90 min of perfusion with a Krebs-
modified solution; B, 15 min de perfusion, followed by
60 min of global ischemia and 15 min of reperfusion; C, as in
B, but in the presence of carvedilol 40 µM. Oxidative stress
was measured by the thiobarbituric acid reactive substances
test (TBARS) and the activities of caspases 1, 3, 8, and 9 was
determined by using their respective colorimetric assays.
Carvedilol decreased TBARS levels (an indicator of oxida-
tive stress) in cardiac mitochondria submitted to ischemia–
reperfusion (P < 0.001, see Fig. 1). Ischemia followed by
reperfusion induced an increase in the activity of caspase 1,
without altering the activity of caspases 3, 8, and 9. Carvedi-
lol significantly decreased the activity of caspases 1 and 8
(see Fig. 1). In this ischemia–reperfusion model, carvedilol
significantly decreased the oxidative stress and caspase cas-
cade activity. These findings may explain some of the pre-
viously reported cytoprotective effects of carvedilol under
ischemia–reperfusion conditions.
Abstract N° A88
Auranofin increases apoptosis and
ischemia–reperfusion injury in the isolated rat heart
K. Venardos, G. Harrison, J. Headrick, A. Perkins. Heart
Foundation Research Centre, School of Health Science,
Griffith University Gold Coast Campus, QLD, Australia
Auranofin, an anti-rheumatic gold compound is an inhibi-
tor of selenocysteine enzymes such as thioredoxin reductase
and glutathione peroxidase. These antioxidant enzymes play
an important role in protecting cardiac tissue from oxidative
stress generated during ischemia–reperfusion.Auranofin was
administered to rats by suspending in corn oil and gavaging
with an oral dosing needle 24 h prior to sacrifice. We chose to
use 100 mg auranofin/kg bodyweight to selectively down-
regulate thioredoxin reductase activity without altering glu-
tathione peroxidase. Sham controls were gavaged with corn
oil only. Hearts were then isolated and perfused using the
Langendorff model where they were subjected to 22.5 min
ischemia and 45 min reperfusion. The activity of thioredoxin
reductase and glutathione peroxidase was determined in
heart extracts subjected to normoxic perfusion and ischemia–
reperfusion. Caspase-3, a marker of apoptosis, was also
measured in heart extracts post-ischemia–reperfusion. There
was significantly less thioredoxin reductase activity in nor-
Parameters/groups Ischemic Carvedilol P
TBARS (% control) 90 ± 5 45 ± 12 <0.05
Caspase 1 activity (% control) 127 ± 7 102 ± 10 <0.05
Caspase 3 activity (% control) 121 ± 3 103 ± 12 n.s.
Caspase 8 activity (% control) 110 ± 6 76 ± 11 n.s.
Caspase 9 activity (% control) 102 ± 20 101 ± 18 n.s.
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moxic auranofin treated hearts whilst the level of glutathione
peroxidase remain unchanged, demonstrating that the dose
of auranofin was able to selectively inhibit one of these
enzymes. Rats treated with auranofin displayed significantly
impaired recovery from ischemia–reperfusion with elevated
end diastolic pressures and decreased contractile function.
The level of caspase-3 activity was also significantly in-
creased in the auranofin treated hearts suggesting auranofin is
pro-apoptotic. Given that auranofin is prescribed as an anti-
rheumatic drug, often to older patients at risk of cardiovascu-
lar disease, this data would suggest that these patients would
recover poorly from an ischemic insult such as myocardial
infaction or related clinical procedures.
Abstract N° A89
Age-related changes in purine catabolism in normoxic
and ischemic–reperfused hearts
Laura Willems, John P. Headrick. Heart Foundation
Research Centre, Griffith University Gold Coast, Q 4217,
Australia
Impaired tolerance to ischemia–reperfusion with age may
stem in part from altered purine catabolism. This study cha-
racterized potential changes in adenosine/purine catabolism
in young (2–4 months) and aged (18 months) C57/B16 mice.
To interrogate purine metabolism we employed 10 µM
EHNA to block adenosine deaminase (ADA), and 5 µM
iodotubercidin to block adenosine kinase (AK), individually
or in combination. Datya revealed that absolute adenosine
formation (with deamination and rephosphorylation bloc-
ked) under normoxic conditions was 12 nmol/min/g in young
vs. 9 nmol/min/g in aged hearts. Of this, 4.5 nmol/min/g was
rephosphorylated and 5.2 nmol/min/g deaminated in young
hearts vs. 1.5 nmol/min/g rephophorylated and 3.5 nmol/
min/g deaminated in aged hearts. This was consistent with
50% reductions in measured adenosine deaminase and AMP-
specific 5′nucleotidase activities with age. Effects of
ADA/AK inhibition reveal 45% of normoxic purine efflux
occurs via 5′-AMP catabolism and 55% via IMP catabolism
in young hearts vs. 50% for each in aged hearts. Young and
aged hearts exhibited similar purine efflux following 20 min
ischemia and 30 min reperfusion, approximating
1800 nmol/g. Data indicate ~1100 nmol/g of 5′-AMP is
hydrolysed in both age groups, with 200 nmol/g of the
adenosine formed being rephosphorylated, giving a net was-
hout of 800 nmol/g 5′-AMP-derived metabolites in both
ages. An equal quantity (800 nmol/g) of purine washout was
derived from IMP. Thus, 50% of purines lost during ische-
mia–reperfusion are derived from 5′-AMP hydrolysis and
50% from IMP hydrolysis. In summary, our data reveal IMP
and 5′-AMP are equally important sources of extracellular
purines (and potentially damaging xanthine-oxidase derived
radicals) during normoxic and ischemic conditions, and that
minor differences in purine handling are unlikely to account
for substantial differences in ischemic tolerance with age.
Abstract N° A90
Age-related changes in ischemic tolerance and
adenosinergic cardioprotection in mouse hearts
Laura Willems, John P. Headrick. Heart Foundation
Research Centre, Griffith University Gold Coast, Q 4217,
Australia
The genesis of ischemia intolerance with age is poorly
understood. We examined effects of aging on ischemic tole-
rance and adenosinergic protection with adenosine, adeno-
sine deaminase blockade (10 µM EHNA), adenosine kinase
blockade (5 µM iodotubercidin) in C57/Bl6 mouse eharts
subjected to 20 min ischemia and 45 min reperfusion. Post-
ischemic contractility was impaired by aging with elevated
ventricular diastolic contracture (32 ± 3 mmHg vs. 19 ±
2 mmHg in young) and reduced ventricular developed pres-
sure (39 ± 4 mmHg vs. 83 ± 5 mmHg in young). Lactate
dehydrogenase (LDH) loss, indicative of necrotic damage,
was also enhanced (27 ± 2 IU/g vs. 16 ± 2 IU/g). Treatment
with 50 µM adenosine improved diastolic (8 ± 2 mmHg) and
developed pressures (132 ± 6 mmHg), and LDH loss (8 ±
2 IU/g) in young hearts, yet failed to modify outcomes in
aged hearts. This was despite the presence of functional A1
and A2 receptor mediated responses to 50 µM adenosine in
both age groups. Similarly, while enhanced endogenous ade-
nosine with EHNA and iodotubercidin exerted protective
effects comparable to adenosine in young hearts, both agents
failed to modify outcome in aged hearts (despite 3- to 4-fold
elevations in endogenous extracellular adenosine levels). In
contrast to adenosinergic treatment, direct mitochondrial
KATP activation with 50 µM diazoxide reduced ischemic
injury in both age groups. Effects of PKC activation with
PMA were also assessed. Reduced protection is not the result
of impaired A1 receptor transcription or expression (compa-
rable in both ages), but may involve reduced A3 receptor
transcription with both aging and ischemia–reperfusion (po-
tentially limiting adenosinergic protection in older hearts).
Data collectively reveal failure of adenosinergic cardiopro-
tection, potentially involving a “lesion” in signaling proxi-
mal to mitochondrial KATP channels, together with changes
in A3 receptor expression.
Abstract N° A91
The effects of dietary hempseed on cardiac
ischemic-reperfusion injury
A. Al-Khalifa a, T.G. Maddaford b, A.L. Edel b,
M.N. Landry b, R. Ganguly b, B.P. Ander b, N. Gavel b,
G.N. Pierce b. a College of Medicine and Medical Science,
Arabian Gulf University, Bahrain. b National Centre for
Agri-Food Research and Medicine, St Boniface Hospital
Research Ctr, University of Manitoba, Winnipeg, Canada
Polyunsaturated fatty acids (FA) are known to possess
significant cardioprotective effects. For example, n-3 FAs are
known to be anti-arrhythmic. However, n-6 FAs are sugges-
ted to have detrimental effects on the heart. Hempseed is a
unique food enriched in both linoleic acid (LA), an n-6 FA,
and alpha linolenic acid (ALA), an n-3 FA. The purpose of
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our study was to determine if chronic dietary supplementa-
tion with hempseed would provide beneficial cardioprotec-
tion vs. ischemic challenge. Sprague–Dawley rats were ad-
ministered a regular diet or one supplemented with 5%
hempseed, or 10% hempseed, or 10% hempseed cake (lipid
depleted) or 1% palm oil for 6 or 12 weeks. Global ischemia
was induced in Langendorff-perfused hearts for 10 min fol-
lowed by normal reperfusion. Plasma LA and ALA levels
were significantly increased at 6 and 12 weeks in the two
hempseed supplemented groups. After 6 weeks of dietary
intervention, there were no differences in the recovery of any
parameters of cardiac contractile performance in any of the
groups. The incidence of extra systoles was not statistically
different amongst the groups. After 12 weeks of dietary
intervention, hempseed supplementation induced a signifi-
cantly better recovery of post-ischemic cardiac contractile
tension in comparison to the seedcake supplemented group.
The dietary interventions did not influence the incidence of
extra systoles. In summary, our data would argue against a
detrimental effect of elevated n-6 fatty acids in ischemic/
reperfusion injury to the heart. Conversely, extended dietary
supplementation with hempseed provided a better recovery
of cardiac contractile performance after global ischemia.
This is likely due to the unique n-6/n-3 FA content.
This study was supported by CIHR, the Heart and Stroke
Foundation of Canada and Hemp Oil Canada.
Abstract N° A93
Significance of serum calcineurin activity and the
protective role of eugenol in isoproterenol-induced
cardiac hypertrophy
Rashmi Choudhary a, B.K.S. Sastry b, B.N. Pandey c,
K.P. Mishra c, C. Subramanyam a. a Department of
Biochemistry, Osmania University, Hyderabad, India. b
CARE Hospitals and CARE Foundation, Hyderabad, India.
c Division of Radiation Biology and Health Sciences,
Bhabha Atomic Research Centre, Mumbai 400 085, India
The role of calcineurin (CaN) in cardiac hypertrophy is
rapidly gaining importance since CaN inhibitors can reverse
this disease. We thus evaluated the significance of serum
calcineurin in heart disease patients. Oxidative stress in all
groups of patients was evidenced by (a) increase in lipid
peroxidation and activities of antioxidant enzymes and (b)
decreased glutathione contents. CaN activity was enhanced
in patients diagnosed for cardiac hypertrophy but not in other
cardiac disorders. Since we found that eugenol could inhibit
CaN activity in vitro, its in vivo effects on isoproterenol-
induced cardiac hypertrophy were evaluated in Wistar rats.
Intraperitonial (i.p.) administration of isoproterenol resulted
in tachycardia, increase in heart weight, accumulation of
reactive oxygen species, decreased total glutathione
contents, increased activities of CaN and protein kinase C
and enhanced percentage of apoptotic cells. Administering
eugenol alone for 3 d followed by simultaneous administra-
tion of isoproterenol with eugenol, resulted in reversal of
cardiac hypertrophy and normalization of the above changes,
even though it could only decrease the number of apoptotic
ventricular cells to a limited extent. These results suggest that
eugenol, a natural antioxidant, may offer potential benefits in
the management of cardiac hypertrophy.
Abstract N° A94
Activation of calcineurin in human failing heart
ventricle by endothelin-1, angiotensin II and urotensin
II
Joan Li, Jianchun Wang, Fraser D. Russell, Peter Molenaar
The calcineurin (CaN) enzyme-transcriptional pathway is
critically involved in the hypertrophy of heart muscle in some
animal models. Currently, there is no information concerning
the regulation of calcineurin (CaN) enzyme activation by
endogenous agonists in human heart. Therefore, we investi-
gated whether endothelin-1 (ET-1), angiotensin II (Ang II)
and human urotensin II (hUII) can directly activate calcineu-
rin in human heart in vitro.
Methods. – Human right ventricular trabeculae were ob-
tained from explanted human (14 males/one female) failing
hearts, set up in a tissue bath and electrically paced at
60 beats/min. Tissues were incubated with or without
100 nM ET-1, 10 µM Ang II or 20 nM hUII for 30 min.
Tissues from three patients were incubated with 200 nM
FK506 for 60 min and then incubated in the presence or
absence of ET-1 for a further 30 min. Tissues were then snap
frozen and used to determine calcineurin enzymatic activity
with detection of free phosphate released from a specific
phospho-substrate. SDS-PAGE was used to quantify calci-
neurin A protein level.
Results. – ET-1 (100 nM) increased contractile force in all
12 patients with an overall P < 0.001. Ang II (10 µM) and
hUII (20 nM) also increased contractile force in three of
seven and four of nine patients separately with overall insi-
gnificant P-value. FK506 (200 nM) had no effect on contrac-
tile force. ET-1, Ang II and hUII increased calcineurin acti-
vity by 26%, 92%, and 10%, respectively (P = 0.001, n = 12;
P = 0.03, n = 7; P = 0.04, n = 10). FK506 caused reduction in
basal calcineurin activity (basal 0.019 ± 0.003, FK506 0.013
± 0.003 nmol/µg protein/30 min, n = 3 patients, P = 0.001).
ET-1 stimulation in the presence of FK506 did not restore
calcineurin activity (ET-1 + FK506 0.014 ± 0.004, P = 0.1
FK506 vs. ET-1 + FK506). Despite the increase in calcineu-
rin activity there was no difference in calcineurin A protein
level in the right ventricle in different patients.
Conclusion. – Endogenous cardiostimulants which cou-
ple to Gaq-proteins can directly activate calcineurin in hu-
man heart. There is not correlation between calcineurin acti-
vity and muscle contractile force.
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Abstract N° A95
Failure of the calcineurin enzymatic assay to detect
calcineurin activation in left ventricular hypertrophy
V.L. Benson, A.C. McMahon, S.H. Kesteven, M.P. Feneley.
Department of Cardiology, St Vincent’s Hospital and Victor
Chang Cardiac Research Institute
Translocation of NFAT to the nucleus by the enzyme
calcineurin is thought to mediate induction of left ventricular
hypertrophy (LVH), based on published animal models that
mimic renal artery stenosis by tightly banding the abdominal
aorta, resulting in large pressure gradients. Whether calci-
neurin activity in the heart is increased by such models is
controversial. We measured LV calcineurin activity in a se-
lection of in vivo models where pressure-overload LVH was
induced by abdominal aortic banding (Ab) or thoracic aortic
banding–mild (TAC) and severe (TTAC). NFAT3 nuclear
content was also measured and used as an alternative index of
calcineurin activation. Male Wistar rats were either banded
(B) or sham-operated (Sh). These two groups were sub-
divided into treatment with vehicle (C) or FK506, a calcineu-
rin inhibitor (FK). Whilst the conventional enzymatic assay
could only detect significant inhibition of calcineurin activity
due to blockade, NFAT3 nuclear content was shown to be
increased over twofold at 1 d post-abdominal banding, but
not by thoracic banding. Plasma renin concentration was also
measured for these models, and was also only increased in
the abdominal CB group. A significant limitation of the
calcineurin assay is the absence of cardiac intracellular cal-
cium data. Measurement of NFAT3 provides information on
the downstream effect of calcineurin which circumvents this
issue.
Abstract N° A96
Selectivity of bisindolylmaleimides as inhibitors of
protein kinase C vs. p90 ribosomal S6 kinase (p90RSK)
isoforms in vitro and in cardiac myocytes
N.A. Roberts, R.S. Haworth, M. Avkiran. Cardiovascular
Research Division, King’s College London, The Rayne
Institute, St Thomas’ Hospital, London SE1 7EH
Bisindolylmaleimide inhibitors of protein kinase C
(PKC), such as GF109203X (GF) and Ro318220 (Ro), have
been used to investigate the roles of PKC isozymes in the
regulation of many cellular processes, including sarcolem-
mal Na+/H+ exchanger activity in cardiac myocytes. Howe-
ver, data from in vitro kinase assays suggest that GF and Ro
also inhibit the p90RSK family of enzymes (RSK1, 2 and 3).
We therefore investigated the selectivity of GF and Ro for
PKCa and PKCe vs. RSK2, the predominant p90RSK isoform
in the heart. GF and Ro inhibited the activities of recombi-
nant PKCa, PKCe and RSK2 in vitro (at 5 mM [ATP], IC50
values for inhibition of PKCa, PKCe and RSK2, respecti-
vely, were 0.31, 0.17 and 7.4 µM for GF, and 0.15, 0.14 and
0.93 µM for Ro). To determine the effects of GF and Ro on in
situ p90RSK activity in cultured adult rat ventricular myocy-
tes (ARVM), phosphorylation of the eukaryotic elongation
factor 2 kinase (eEF2K) at Ser366, a known p90RSK target,
was used as the index of such activity. Adenoviral expression
of a constitutively active form of mitogen activated protein
kinase kinase 1 (MEK1) induced p90RSK activation and
eEF2K phosphorylation 42 h post-infection. eEF2K phos-
phorylation was abolished by UO126 (1 µM), a selective
inhibitor of MEK1, and significantly reduced by GF (at
≥3 µM) and Ro (at ≥ 1 µM). Both agents significantly
inhibited PMA-induced PKC activity in ARVM (as indexed
by PKC substrate phosphorylation) at 1 µM. Thus, PKC
inhibitory concentrations of GF and Ro additionally inhibit
p90RSK, which may contribute to their cellular effects in
ARVM.
Abstract N° A97
Angiotensin II-induced phosphorylation of the SSXS
motif of R-SMAD 2 in cardiac myofibroblasts is
mediated by PKC and PI3K
T. Angelovska, B. Wang, D.H. Freed, V. Drobic, S.C. Jones,
I.M.C. Dixon. St. Boniface General Hospital Research
Centre, Winnipeg, Canada
Cardiac myofibroblasts contribute to remodeling of the
cardiac collagen matrix in failing hearts. Transforming
growth factor-b1 (TGF-b1) and angiotensin II (angiotensin)
both influence myofibroblast function. TGF-b1 signals
through Smads and other signaling pathways, including ki-
nases. We have previously determined that angiotensin type I
receptor activation led to rapid specific phosphorylation of
R-Smad 2 at Ser 465/467, and that this event is linked to
enhanced collagen deposition; however, the precise kinase
pathways mediating this phenomenon are unresolved. We
investigated angiotensin and TGF-b1-signaling in primary
cardiac myofibroblasts in vitro, using inhibitors of protein
kinase C (PKC) and phosphoinositide 3-kinase (PI3K). We
examined (i) phosphorylation of R-Smad 2 at Ser 465/467;
(ii) the effects of chelerythrine (PKC inhibitor), and LY
294002 (PI3K inhibitor) on such phosphorylation; (iii) the
nuclear translocation of phosphorylated R-Smad 2; and (iv)
the effects of TGF-b1 neutralizing and anti-TGF-b type II
receptor (TbRII) antibodies on the phosphorylation of
R-Smad 2. Angiotensin-mediated phosphorylation of
R-Smad 2 at Ser 465/467 is associated with nuclear translo-
cation in myofibroblasts and increased collagen type I syn-
thesis. Chelerythrine (1 µM) or LY294002 (10 µM) treatment
ablated angiotensin-induced phosphorylation of R-Smad 2
protein. Pretreatment of cells with either chelerythrine or LY
294002 decreased nuclear translocation of phosphorylated
R-Smad 2 in both TGF-b1 and angiotensin treatments. Abla-
tion of TGF-b1 signaling with either TGF-b1 neutralizing
antibody (TGF-b1 NA) or anti-TGF-b type II receptor neu-
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specific phosphorylation of R-Smad 2. We suggest that the
PKC and PI3K pathways in cardiac myofibroblasts partici-
pate in non-classic (i.e., non-TGF-b1 induced) phosphoryla-
tion of R-Smad 2 to enhance collagen deposition by myofi-
broblasts.
Abstract N° A98
Inhibition of phenylephrine-induced cardiomyocyte
hypertrophy by activation of multiple adenosine
receptor subtypes
X. Tracey Gan, James V. Haist, Venkatesh Rajapurohitam,
Peter Chidiac, Michael A. Cook, Morris Karmazyn
Plasma adenosine levels are elevated in cardiovascular
disease including hypertension and heart failure and the
nucleoside has been proposed to serve as an endogenous
anti-myocardial remodelling factor. We studied the modula-
tion of phenylephrine-induced hypertrophy by adenosine re-
ceptor activation in isolated neonatal cultured ventricular
myocytes. Phenylephrine (10 µM) increased cell size by 35%
and significantly increased expression of atrial natriuretic
peptide. These effects were completely prevented by the
stable adenosine analogue 2-chloro adenosine as well as the
adenosine A1 receptor agonist CPA (1 µM), the A2a receptor
agonist CGS21680 (100 nM) and the A3 receptor agonist
IB-MECA (100 nM). The antihypertrophic effects of all
three agonists were completely reversed by their respective
antagonists. Phenylephrine significantly upregulated expres-
sion of the immediate early gene c-fos especially within the
first 30 min of phenylephrine treatment. These effects were
almost completely inhibited by all adenosine receptor ago-
nists. Although phenylephrine also induced early stimulation
of both p38 and ERK, these responses were unaffected by
adenosine agonists. The expression of the G-protein regula-
tory factor RGS2 was increased fivefold by phenylephrine
treatment although this was completely prevented by adeno-
sine receptor agonists. These agents also blocked the ability
of phenylephrine to upregulate Na-H exchange isoform 1
(NHE1) expression in hypertrophied myocytes. Thus, our
results demonstrate an antihypertrophic effect of adenosine
acting via multiple receptor subtypes through a mechanism
involving downregulation of NHE1 expression. The ability to
prevent RGS2 upregulation further suggests that adenosine
receptor activation minimizes signalling which leads to hy-
pertrophic responses.
Abstract N° A99
Protective effects of A3 adenosine receptor activation
against doxorubicin induced cardiotoxicity in rats
A. Korkus a, E. Hochhauser b, V. Shneyvays a,
Y. Chepurko b, A. Sagie c, M. Mansur c, B.A. Vidne b,
A. Shainberg a. a Faculty of Life Sciences Bar-Ilan
University, Ramat-Gan. b Cardiac Research Laboratory,
FMRC. c Cardiology Department, Rabin Medical Center,
Petach Tikva, Tel Aviv University, Israel
Background. – Anthracycline antibiotic doxorubicin
(DOX) induced cardiotoxicity. We have previously shown
that activation of the A3 adenosine receptor (A3R) in new-
born cultured cardiomyocytes by highly selective agonist
Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)adenosine-5′-N-
methyluronamide) induced protection after treatment with
DOX.
Objectives. – To explore the effect of Cl-IB-MECA
against DOX cardiac injury in an in vivo model.
Methods. – Four groups of rats: control, DOX, Cl-IB-
MECA and DOX + Cl-IB-MECA were tested. DOX
2.5 mg/kg (i.p.) and Cl-IB-MECA 33 µg\kg (i.v.) were injec-
ted six times every alternate day. Left ventricular end diasto-
lic diameter (LVEDd), end systolic diameter (LVESd) and
fractional shortening (FS) were assessed by echocardiogra-
phy. A stress test with dobutamine was conducted. To deter-
mine whether DOX changed SR Ca2+ content and uptake, we
exposed cultured rat cardiomyocytes to 10 mM caffeine to
release SR calcium.
Results. – LVEDd, LVESd were higher and FS was smal-
ler in DOX treated animals than controls (P < 0.01). The
stress test showed superior contractility dP/dtmax at each dose
point in DOX and Cl-IB-MECA treated hearts vs. DOX.
Twenty micromolar DOX increased Ca2+i diastolic level,
decreased amplitude and Ca2+i transients following caffeine
treatment. Cl-IB-MECA significantly improved SERCA2a
efficiency.
Conclusions. – DOX+Cl-IB-MECA improved cardiac
hemodynamic function, partially caused through a decrease
in calcium overload and activation of SR Ca2+ uptake.
Abstract N° A100
The effect of chronic l-arginine on cardiac adenosine
receptor expression and function
Tamsin L. Jenner, Glenn J. Harrison, Andrew Fenning,
Bronwyn G. Garham, Lindsay Brown, Roselyn B.
Rose’Meyer
l-Arginine increases myocardial nitric oxide (NO)
production. NO mediates many cardiovascular actions of
adenosine and modulates adenosine metabolism. In this
study we examined the effect of chronic l-arginase (5%)
intake on adenosine receptor expression and b-adrenergic
induced stimulation of cardiac function and adenosine pro-
duction. Our results indicate that 4 week chronic ingestion
decreases the expression of all the cardiac adenosine recep-
tors, with reductions in adenosine A1 (20-fold), A2A (7.7-
fold), A2B (25.6-fold) and A3 (76-fold) mRNA. Stimulation
of b-adrenoceptors with noradrenaline induced an increase in
purine release in hearts from control and l-arginine treated
rats (P < 0.05). Chronic l-arginine treatment did not alter
catecholamine induced purine efflux (P > 0.05), it did howe-
ver reduce contractile responses to noradrenaline with a
significant decrease in left ventricular developed pressure
(LVDP) and dP/dtmax and myocardial oxygen consumption.
At basal and low noradrenaline concentrations a significant
increase in coronary resistance was observed in l-Arginine
treated hearts, however with an increase in contractility ob-
served at higher levels of noradrenaline, coronary perfusion
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pressure decreased to control values (P < 0.05). These results
indicate that chronic l-arginine treatment reduced the expres-
sion of all cardiac adenosine receptor and although it attenua-
tes b-adrenoceptor induced stimulation of the heart it does
not alter adenosine efflux. As a number of cardiac actions of
adenosine receptor work via NO-cGMP mediated mecha-
nisms, elevated NO production with chronic l-Arginine in-
take may result in down regulation of upstream stimulators of
nitric oxide synthase activity.
Abstract N° A101
A novel Ca2+-dependent Akt phosphorylation in
endothelial cells
Mariko Ozeki a, Hiroshi Watanabe b, Tomoyasu Nakano a,
Akihiko Uehara a, Hideki Katoh a, Hiroshi Satoh a,
Hajime Terada a, Kyoichi Ohashi b, Hideharu Hayashi a.
a Internal Medicine III, Hamamatsu University School of
Medicine, Hamamatsu, Japan. b Clinical Pharmacology and
Therapeutics, Hamamatsu University School of Medicine,
Hamamatsu, Japan
The protein kinase Akt participates in such important
functions of endothelial cells (ECs) as nitric oxide (NO)
production and angiogenesis, activities that involve changes
in cytosolic Ca2+ concentration ([Ca2+]i). However, it is not
known if Akt activity is linked to Ca2+ signaling in these
cells. Here we have investigated possible mutual interaction
between phosphatidylinositol 3-kinase (PI3-kinase)/Akt ac-
tivation and Ca2+ signaling during agonist stimulation in
cultured porcine aortic ECs. Intracellular Ca2+ concentration
was measured using fura-2/AM. Phosphorylation of Akt and
eNOS, known as a downstream substrate of Akt, was as-
sessed by western blotting. Thapsigargin (TG, 1 µM) and
bradykinin (BK, 10 nM) stimulated biphasic Ca2+ response
in ECs, which were not influenced by inhibition of PI3-
kinase/Akt using wortmannin or by expression of a
dominant-negative form of Akt. TG and A23187 (5 µM), a
Ca2+ ionophore, induced phosphorylation of both Akt and
eNOS. Wortmannin prevented phosphorylation of Akt but
not of eNOS. On the other hand, removal of extracellular
Ca2+ prevented both phosphorylation of Akt and eNOS. In
conclusion, PI3-kinase/Akt is not involved in the regulation
of agonist-stimulated Ca2+ signals in ECs. However, Akt
phosphorylation appears to require both Ca2+ entry and PI3-
kinase activity, while eNOS phosphorylation requires extra-
cellular Ca2+ but does not involve the PI3-kinase/Akt-linked
signaling pathway.
Abstract N° A102
Intracellular nitric oxide detection in adult
cardiomyocytes: assessment with a fluorescent probe
H. Strijdom a, C. Muller b, A. Lochner a,b. a Department of
Medical Physiology, University of Stellenbosch, South
Africa. b Department of Anatomy and Histology, University
of Stellenbosch, South Africa. c MRC Diabetes Research
Group, South Africa
The role of nitric oxide (NO) as a biological mediator of
cardioprotection during ischaemia–reperfusion injury and
ischaemic preconditioning is a fast growing field of interest
in heart research. Despite this, understanding NO’s exact
cellular mechanism remains elusive. Although measurement
of intracellular NO levels is essential for gaining more insi-
ght, many studies depend on indirect methods to assess NO
release. Diaminofluorescein-2/diacetate (DAF-2/DA), a NO-
specific fluorescent probe, provides an affordable method to
detect intracellular NO generation. DAF-2/DA has been
shown to detect NO production in endothelial cells by flow
cytometry, but this method has not yet been tested in adult
cardiomyocytes. We assessed whether intracellular NO re-
lease in these cells could be detected with DAF-2/DA by flow
cytometric analysis. Adult rat cardiomyocytes were isolated
by collagenase perfusion and incubated with 10 µM DAF-
2/DA for 180 min with or without (i) the NO-donor SNP
(100 µM), (ii) eNOS activator cyclosporine A (CsA, 10 µM),
and (iii) hypoxia (120 min). The NOS inhibitor l-NAME
(50 µM) was administered to groups (ii) and (iii). Incubation
was followed by FACS analysis. SNP increased mean fluo-
rescence by 36.4% (P < 0.05 vs. control), CsA by 42.4% (P <
0.05), and hypoxia by 16.6% (P < 0.05). l-NAME resulted in
a 16% attenuation of mean fluorescence in control cells (P <
0.05), 35% in CsA-treated cells (P < 0.05), and 13% in
hypoxic myocytes (P < 0.05). This study demonstrates a
method for the direct detection of intracellular NO in adult
cardiomyocytes by flow cytometry, using DAF-2/DA. CsA
and hypoxia both increase NO-production in cardiomyocytes
secondary to NOS activation. This method, not previously
described in isolated adult cardiomyocytes, could be used in
future studies to help elucidate intracellular NO mechanisms
in the myocardium.
Abstract N° A103
Nitric oxide does not significantly contribute to altered
pulse pressure amplification during aerobic exercise
J.E. Sharman a, C.M. McEniery b, R. Campbell c,
P. Pusalkar c, I.B. Wilkinson b, J.S. Coombes a,
J.R. Cockcroft c. a The University of Queensland, Brisbane,
Australia. b University of Cambridge, Addenbrookes
Hospital, Cambridge, UK. c University of Wales, College of
Medicine, Cardiff, UK
Nitric oxide modulates blood pressure and arterial stif-
fness at rest. Normally there is amplification of pulse pres-
sure from central (aorta) to peripheral (brachial) arteries,
which is increased during exercise. However, amplification is
significantly attenuated during exercise in people with hyper-
cholesterolemia, who also have reduced nitric oxide bioa-
vailability and increased arterial stiffness. The aim of the
present study was to determine the contribution of nitric
oxide to pulse pressure amplification and markers of arterial
stiffness during exercise in people free from cardiovascular
risk factors that may confound results. Twelve healthy males
aged 29 ± 1 years (mean ± SEM) exercised at 60% of their
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maximal heart rate on a bicycle ergometer. Non invasive
measures of central blood pressure, estimated aortic pulse
wave velocity (Tr) and systemic arterial stiffness (AIx) were
obtained by pulse wave analysis during iv infusion of saline
(control), NG-monomethyl-l-arginine (l-NMMA; a nitric
oxide-synthase inhibitor) at 6 mg/kg/h or noradrenaline (NE;
control vasoconstrictor) at 50 ng/kg/h. Pulse pressure ampli-
fication was defined as the ratio of peripheral to central pulse
pressure (PPP:CPP). Cardiac output and stroke volume was
determined by electrical bioimpedence. Both l-NMMA and
NE caused a significant increase in mean arterial pressure (7
and 8 mmHg, respectively; P < 0.01) and AIx (5% and 11%,
respectively; P < 0.01), a decline in PPP:CPP (–4% and –8%,
respectively; P<0.05) and a trend towards reducing Tr (–4
and –7 ms; P = 0.35 and 0.07, respectively) at baseline.
Exercise caused significant elevation of PPP:CPP (P <
0.001), whereas AIx and Tr declined (P < 0.05) during saline
and drug infusions. However, during exercise no significant
differences were observed in AIx, PPP:CPP or Tr between
infusion procedures (P > 0.50). Heart rate, peripheral vascu-
lar resistance and cardiac output did not differ during exer-
cise between saline, l-NMMA or NE. Nitric oxide contribu-
tes to systemic arterial stiffness and pressure amplification at
rest, but has no significant effect on these variables during
aerobic exercise.
Abstract N° A104
Central pressure during exercise is significantly
increased with age and hypercholesterolaemia
J.E. Sharman a, C.M. McEniery b, Z.R. Dhakam b,
J.S. Coombes a, I.B. Wilkinson b, J.R. Cockcroft c. a The
University of Queensland, Brisbane, Australia. b Clinical
Pharmacology Unit, University of Cambridge, Cambridge,
UK. c University of Wales College of Medicine, Cardiff, UK
Due to amplification of pulse pressure, central (aortic)
blood pressure may differ significantly from recordings at
peripheral (e.g. brachial artery) sites. Although, the brachial
blood pressure response to exercise and resting central blood
pressures are more powerful predictors of cardiovascular
outcome compared to resting peripheral measures alone, the
effect of exercise on central blood pressure in people with
risk factors for cardiovascular disease is unknown. This study
aimed to assess the central and peripheral haemodynamic
response to exercise with increasing age and hypercholeste-
rolaemia. Twenty healthy young subjects (aged 29 ± 5 years;
mean ± S.D.), 20 healthy older (aged 57 ± 5 years) and 10
matched hypercholesterolaemic (aged 59 ± 7 years) men
exercised at 60% of their predicted maximal heart rate on a
bicycle ergometer. Central blood pressure and augmentation
index (AIx), a marker of systemic arterial stiffness, were
obtained non-invasively using pulse wave analysis. Amplifi-
cation was calculated as the ratio of peripheral to central
pulse pressure. Resting haemodynamic measures were not
different between the hypercholesterolaemics and controls.
During exercise there was no difference in brachial systolic
blood pressure (SBP) (P = 0.7), but hypercholesterolaemics
had significantly higher mean arterial pressure, brachial dias-
tolic blood pressure (DBP), central SBP and AIx (P < 0.05
for all). Young subjects had significantly lower AIx and
central SBP during exercise (P < 0.001) compared to older
subjects. For the whole population, total cholesterol and
amplification during exercise were negatively correlated
(r=–0.60; P < 0.001). With increasing age, wave reflection is
augmented during exercise, resulting in elevated central pres-
sure. These effects are exacerbated by hypercholesterolae-
mia and would contribute to cardiovascular risk by mecha-
nisms associated with central hypertension.
Abstract N° A105
Role of nitric oxide and protein kinase C in the
tachyphylaxis to vasopressin in rat aortic rings
C. Hamel, E. Millette, D. Lamontagne. Faculty of
Pharmacy, University of Montreal, Que, Canada
The purpose of the present study was to assess the contri-
bution of nitric oxide (NO) and protein kinase C (PKC) in the
tachyphylaxis to arginine vasopressin (AVP) in the rat aorta.
Endothelium-intact (E+) and -denuded (E–) rings obtained
from the rat thoracic aorta were exposed to three repetitive
administrations of a supramaximal concentration of AVP
(100 nM) lasting 20 and 45 min apart. The first contraction to
AVP was 17 ± 2 mN in E+ and 27 ± 1 mN in E– rings.
Compared with the first, the third contraction to AVP was
equal to 15 ± 2% and 46 ± 8% in E+ and E– rings, respecti-
vely. NG-nitro-l-arginine (NNLA), a non-selective inhibitor
of all isoforms of NO synthase, led to a significant diminu-
tion of AVP tachyphylaxis in both E+ (67 ± 12%) and E–
rings (86 ± 6%). Inhibition of PKC by either bisindolylma-
leimide I-HCl (Bis I) or chelerythrine diminished signifi-
cantly the tachyphylaxis to AVP in E– rings only (125 ± 20%
and 95 ± 5%, respectively). Furthermore, activation of PKC
with phorbol-12-myristate-13-acetate (PMA) simulated ta-
chyphylaxis to AVP in E– rings only (12 ± 3% compared to
120 ± 17% in E+). This effect of PMA on AVP tachyphylaxis
in E– rings was antagonized by the NO donor, sodium nitro-
prusside. Results obtained suggest that NO modulates the
implication of PKC in the tachyphylaxis to AVP. Thus, PKC
plays a role in AVP tachyphylaxis only in E– rings, the
presence of NO probably diminishing the effects of this
kinase.
Abstract N° A106
Endothelial CB1 receptors confer cardiac protection
through nitric oxide production
P. Lépicier *, A. B-Poirier, C. Lagneux, M.G. Sirois,
M. Servant, D. Lamontagne. Faculty of Pharmacy,
University of Montreal, Que, Canada. * Corresponding
author.
Both cannabinoid receptor subtypes CB1 and CB2 have
been identified in the rat ventricles and selective agonists can
produce a significant cardiac protection against ischemia.
The aim of the study was therefore to identify differences in
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the localization of these receptors as well as their signaling
pathways and specific effectors. Isolated rat hearts were
perfused with Krebs–Henseleit buffer on a Langendorff se-
tup and submitted to severe ischemia and reperfusion. Some
hearts were formalin fixed and paraffin embedded for immu-
nohistochemical experiments, some were stained with 1%
TTC after reperfusion to measure infarct size and some
hearts were snap frozen at different time to extract protein
and RNA to perform biochemical assays. ACEA and
JWH133 (respectively, CB1 and CB2 agonists) as well as
SR141716A and SR144528 (respectively, CB1 and CB2
antagonists) were perfused before and throughout ischemia.
CB1 receptor was identified on capillary and arterial endo-
thelial cells only in control hearts but appeared as well on
myocytes in ischemic hearts. CB2 receptor was identified on
myocytes and arterial endothelial cells but ischemia did not
alter its expression. CB1 and CB2 agonists caused an inde-
pendent cardioprotection activating different signaling pa-
thway (respectively, ERK1/2 and p38 MAPK) as assessed by
phosphorylation and activity experiments. N-X-nitro-l-
arginine selectively inhibited CB1 mediated cardioprotec-
tion, and CB1 agonist caused a selective induction of iNOS
protein, thus suggesting a strong implication of nitric oxide
in the cardiac protection conferred by CB1 receptor.
Abstract N° A107
Practical and fundamental considerations in
quantification of nitrite as an index of nitric oxide
formation in vivo
Takaharu Ishibashi, Junko Yoshida, Matomo Nishio.
Department of Pharmacology, Kanazawa Medical
University, Uchinada, Ishikawa 920 0293, Japan
Nitrite is now assigned to be an alternative candidate for
an index of nitric oxide (NO) formation in vivo, as nitrate or
NOx (nitrite and nitrate) in plasma or in whole blood (inclu-
ding red blood cells) are not considered to be reliable index
of NO formation in vivo anymore. However, there is no
practical information available in handling for quantification
of the ion, though nitrite contamination from laboratory ware
or through whole procedure is anticipated. Therefore, we
explored nature of the contamination and way to avoid that
for accurate evaluation of nitrite. Nitrite was measured by
ENO10 or 20 (Eicom, Kyoto, Japan) with sensitivity of
~3 nM by loading volume of 100 µl. Every solution contained
small amount of nitrite. It was not possible to obtain nitrite-
free solution even by the usage of an ion exchange column
(Milli Q, Millipre). Degrees of nitrite contamination from
laboratory ware were variable. However, they were lower
than those of nitrate and were attenuated by pre-wash with
water containing lower nitrite. For pre-treatment of plasma,
use of some kinds of ultrafiltration units may be a cause of
severe nitrite contamination, however, a unit with negligible
contamination is available. As nitrite contamination is sus-
pected in methanol, attention has to be paid to the use of the
agent for deproteinization of plasma. A solution kept in room
air without seal absorbed nitrite and the concentration in-
creased time dependently, while solution sealed within a
gas-tight ware did not, regardless whether air of the dead
space was replaced with argon gas or not. These results
indicated that we should avoid nitrite contamination through
whole procedure in any way possible for accurate evaluation
of nitrite in biological samples.
Abstract N° A108
Identification of the nitroxyl anion as a coronary
vasodilator
Joanne L. Favaloro, Barbara K. Kemp-Harper. Department
of Pharmacology, Monash University, Clayton, Victoria,
Australia
Nitric oxide (NO) is a well-known endogenous vasodila-
tor molecule that can exist in several different redox forms,
including the free-radical form (NO•) and the nitroxyl anion
(NO–). Like NO• , NO– causes vasorelaxation and can be
produced endogenously. The role of NO– in the coronary
vasculature is currently unknown, so this study aimed to
examine the ability of NO– to cause vasodilation in the intact
rat coronary circulation. Hearts from male Sprague–Dawley
rats (350–550 gm) were excised and perfused by the Langen-
dorff method with Krebs’ solution containing EDTA
(26 µM). Perfusion pressure was monitored throughout the
experiments. Following a 15 min equilibration period, perfu-
sion pressure was raised to approximately 100 mmHg by
infusing phenylephrine (100 mM, 0.5–2 ml/min) and giving
bolus additions of the thromboxane mimetic U46619 (0.1–
10 nmol) as required. Concentration response curves to the
NO– donor, Angeli’s salt (1 pmol–100 nmol) were construc-
ted in the presence and absence of inhibitors that were added
to the perfusion solution. Angeli’s salt caused a
concentration-dependent vasodilation (EC50: 1.12 ±
3.4 nmol, maximum vasodilation: 36.7 ± 12.5 mmHg, n = 4)
that was reproducible over time. This response was unaffec-
ted by the NO scavenger, hydroxocobalamin (100 µM) but
significantly inhibited by the NO– scavenger l-cysteine (l-
cys) (3 mM) (Max dilation (mmHg) control 27.9 ± 4.8; l-cys
11.4 ± 4.7, P < 0.05, n = 6) indicating the response is
mediated via NO–. Vasodilator responses to Angeli’s salt
were significantly attenuated by ODQ (10 µM), and 30 mM
K+ Krebs. The response was unaffected by the Kv channel
blocker 4-aminopyridine (1 mM), but attenuated by the KATP
channel blocker glibenclamide (10 µM). This is the first
demonstration of vasodilation by NO– in the coronary
circulation. NO– mediates coronary vasodilation indepen-
dently of NO• and via the activation of sGC and K+ channels.
These findings raise the possibility that NO– donors may be
useful therapeutic agents for treating coronary vascular di-
sease.
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Abstract N° A109
A decrease in endothelium-derived hyperpolarizing
factor in femoral resistance arterioles of spontaneously
hypertensive rats
Yoshitomo Mori, Satsuki Koida, Atsunori Ueda,
Mitumasa Ohyanagi. Department of Internal Medicine,
Division of Coronary Heart Disease, Hyogo College of
Medicine, Nishinomiya, Japan
The aim of our study is to clarify the mechanism of
impairment of endothelium-dependent relaxation (EDR) in
the resistance arterioles of hypertensive rats. Femoral arterio-
les (75 ) of male spontaneously hypertensive rat (SHR) and
age matched Wistar-Kyoto rat (WKY) were isolated and
examined acetylcholine (ACh)-induced EDR with microvi-
deoscopy. ACh-induced dilatation in prehypertensive rat
(4 weeks) was not significantly decreased without any inhi-
bitor (control). Also there was no difference in nitric oxide
(NO)-mediated dilatation (difference between control and
dilatation with NG-monomethyl-l-arginine (l-NMMA) and
indomethacin (INDO)) and EDHF-mediated dilatation (dif-
ference between dilatation with l-NMMA, INDO and dilata-
tion with l-NMMA, INDO, CTX, apamin and 40 mM KCl)
between SHR and WKY. In the resistance arterioles
endothelium-derived hyperpolarizing factor (EDHF)-
mediated dilatation was more than NO-mediated dilatation
(45 ± 4% vs. 23 ± 3%, percentage of maximal dilatation by
nitroprusside). Blood pressure of 16 weeks SHR was signifi-
cantly higher than WKY. Control dilatation in 16 weeks SHR
was attenuated than that in WKY (64.5% vs. 100%). EDHF-
mediated dilatation is significantly decreased in SHR
(16 weeks) as compared to age matched WKY (46.5 ± 5% vs.
14.5 ± 3%). There were no differences in NO-mediated
dilatation between SHR and WKY. EDHF-mediated dilata-
tion was decreased in the smaller arterioles of established
hypertensive rats.
Abstract N° A110
Prostaglandin E1 induces vascular endothelial growth
factor-1 in human adult cardiac myocytes but not in
human adult cardiac fibroblasts via a cAMP-dependent
mechanism
T. Weiss, C. Kaun, G. Zorn, G. Maurer, K. Huber, J. Wojta.
Department of Internal Medicine II, Medical University
Vienna, Austria
Prostaglandin E1 (PGE1) has been used to treat pulmo-
nary hypertension and peripheral artery occlusive disease
and has been successfully employed for pharmacological
bridging to transplantation in patients with chronic end stage
heart failure. In addition to its vasoactive effects PGE1 was
shown to stimulate angiogenesis in animal models. Recently,
we showed that PGE1-induced angiogenesis in hearts of
patients with ischaemic heart disease. We proposed that the
angiogenic action of PGE1 is mediated by vascular endothe-
lial growth factor (VEGF). The purpose of this study is to
show a possible effect of PGE1 on the expression of VEGF-1
in cultured human adult cardiac myocytes (HACM) and
cultured human adult cardiac fibroblasts (HACFB), respecti-
vely, to identify a cellular source of VEGF-1 in patients
treated with PGE1. We also aimed to delineate mechanisms
involved in a possible regulation of VEGF-1 by PGE1 in
these cells. When HACM, isolated from human myocardial
tissue, were treated with PGE1, a significant up to threefold
increase in VEGF-1 production could be observed. These
results could be confirmed on the level of specific mRNA
expression as determined by real-time PCR. The effect of
PGE1 on VEGF-1 expression could be blocked by H089, an
inhibitor of cAMP-dependent protein kinase A. In HACFB,
also isolated from human myocardial tissue, no effect of
PGE1 on VEGF-1 production was seen. If this effect of
PGE1 is also operative in the in vivo situation, one could
speculate that cardiac myocytes could be a cellular source of
PGE1-induced VEGF-1 expression in patients treated with
this drug. This mechanism might lead to angiogenesis and
subsequently to better collateral blood flow in the hearts of
these patients and thus might offer an explanation of benefi-
cial effects of PGE1 treatment not attributable solely to its
vasodilative activity.
Abstract N° A111
Expression equilibrium between matrix
metalloproteinases and their inhibitors (TIMPs)
in human compensated left ventricular
hypertrophy
S. Bleiziffer a, F. Monticelli b, R. Lange a,
R. Bauernschmitt a, J. Grammer a. a German Heart Center,
TU, Munich. b Institute of Forensic Medicine, LMU,
Munich, Germany
The development of left ventricular hypertrophy (LVH) is
an adaptive response to pressure overload following aortic
stenosis, but chronic alterations may lead to heart failure.
Remodeling of myocardial extracellular matrix caused by a
disequilibrium between matrix metalloproteinase (MMP)
and tissue inhibitors of metalloproteinase (TIMP) activities
is likely to play a crucial role in the progression of LVH and
in the transition to heart failure. During aortic valve replace-
ment tissue samples from the interventricular septum were
obtained from patients with aortic stenosis and consecutive
LVH (n = 13). The hypertrophy was verified by echocardio-
graphy, while all patients were clinically in a compensated
stage of the disease. Equivalent autopsy samples from traffic
accident victims who had no heart disease, served as controls
(n = 12). mRNA and protein expression for MMP-2, MMP-9,
TIMP-1, TIMP-2, TIMP-3 and TIMP-4 was assessed by
semiquantitative RT-PCR and western blots. Additionally,
MMP activity was determined by gelatin zymography. We
did not find any significant differences in MMP and TIMP
expression between LVH patients and controls, neither on the
mRNA nor on the protein level. Correspondingly, MMP-2
and MMP-9 activity on zymogram gels were similar between
groups. Our data suggest, that in human compensated LVH,
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the expression and activity of MMPs and TIMPs is still
balanced, confirming recent results in a rat model. The res-
ponse to chronic pressure overload concerning MMPs and
their endogenous inhibitors might be more pronounced and
important during the transition from a compensated stage of
the disease to heart failure. It will be of great interest to
investigate whether the time period of transition could be
marked by plasma MMP and TIMP levels.
Abstract N° A112
Oncostatin M upregulates tissue inhibitors of
metalloproteinase-1 and 2 in human adult cardiac
myocytes
T.W. Weiss, C. Kaun, K. Huber, G. Maurer, J. Wojta.
Department of Internal Med II, Medical University of
Vienna, Austria
Myocardial infarction (MI), a leading cause of death,
results in pathological remodelling, thinning of ventricular
wall, dilation and heart failure. Following MI, however, a
reorganization of the extracellular matrix (ECM) and, conse-
quently, the myocytes occurs which contributes to loss of
heart function. Dynamic expression and activation of matrix
metalloproteinases (MMPs) may mediate many of the mor-
phological changes that occur after MI. Tissue inhibitors of
MMPs (TIMPs) function as an important regulatory control
on the activity of MMPs by stabilizing the proenzymes and
by inhibiting the active enzymes. Downregulation of TIMPs,
as shown in the failing heart, alters the ECM equilibrium
towards matrix degradation and leads to an increase in tissue
turnover and accelerated remodelling. In a recent publica-
tion, by showing that human adult cardiac myocytes
(HACM) in vitro express plasminogen activator inhibitor-1
(PAI-1) and that this expression is significantly upregulated
by the inflammatory mediator oncostatin M (OSM), we spe-
culate on a protective role of PAI-1 against excessive matrix
degradation by proteases during inflammation and cardiac
repair processes. To expand on these observations we studied
expression patterns and possible regulatory mechanisms of
MMPs and TIMPs in HACM. We could show that HACM
express MMP-1, -2, -3 and -9, and TIMP-1 and -2 constitu-
tively. Whereas TIMP-1 and -2 were upregulated threefold
and twofold, respectively, after treatment with OSM for 4 h
as determined by quantitative real-time PCR, no significant
changes were observed on the expression of MMPs studied.
Thus HACM might not only be indirectly involved in ECM
degradation—by production and dynamic expression of
components of the plasminogen system—but also directly
affect ECM equilibrium and consequently ventricular geo-
graphy and pump function by differential regulatory patterns
of MMPs and TIMPs.
Abstract N° A113
Matrix metalloproteinases-3 and -7 have differing
effects on atherosclerotic plaque stability
Jason Johnson, Sarah George, Andrew Newby,
Christopher Jackson. Bristol Heart Institute, University of
Bristol, UK
Matrix metalloproteinases (MMPs) are thought to be in-
volved in the destabilization and rupture of atherosclerotic
lesions. We have previously demonstrated that MMP-9 and
MMP-12 have divergent effects on atherosclerotic plaque
stability in the fat-fed apolipoprotein E (apoE) knockout
mouse model of plaque rupture: the former is protective,
whilst the latter is destructive. We aimed to evaluate the roles
of two further MMPs in the same model, focussing on
apoE/MMP-3 (stromelysin-1) and apoE/MMP-7
(matrilysin-1) double knockouts. Plaques in the proximal
150 µm of the brachiocephalic artery were substantially
larger in apoE/MMP-3 double knockouts (n = 26) than in
age-, strain- and sex-matched apoE knockout controls (n =
26) (31150 ± 7380 µm2 vs. 7060 ± 2860 µm2; P < 0.01). The
frequency of previous, now healed, plaque rupture (seen as
buried fibrous layers within the plaque) was sevenfold higher
in apoE/MMP-3 double knockouts than in controls (0.31 ±
0.11 vs. 0.04 ± 0.04; P < 0.05). Additionally, an 80% reduc-
tion in smooth muscle density was observed in plaques from
apoE/MMP-3 double knockouts (4.5 ± 1.6 vs. 0.9 ±
0.1 cell/mm2; P < 0.001). The effects of knocking out
MMP-7 were quite different. There was no significant diffe-
rence in plaque size (68660 ± 11210 µm2 vs. 63690 ±
8680 µm2 in apoE/MMP-7 double knockouts (n = 25) and
controls (n = 25), respectively). Also, there were no signifi-
cant differences in the frequency of healed plaque rupture or
smooth muscle cell density. These data indicate that, like
MMP-9, MMP-3 plays a protective role, limiting plaque
growth and promoting plaque stability. However, absence of
MMP-7 has no effect on plaque stability. This challenges the
concept that MMPs simply degrade matrix and thus destabi-
lize plaques, and suggests that members of the MMP family
have diverse effects on plaque stability. Selective MMP inhi-
bitors would allow further dissection and understanding of
the roles of MMPs in plaque rupture, and selective targeting
of MMPs will be essential if such drugs are to be developed
as plaque stabilizing agents.
Abstract N° A114
Changes in hearts of spontaneously hypertensive rats
induced by salt drinking
Barbara Ziegelhöffer-Mihalovicova, Wilfried Briest,
Heinz-Gerd Zimmer. Carl-Ludwig-Institute of Physiology,
University of Leipzig, Germany
Elevated blood pressure in spontaneously hypertensive rat
(SHR) leads to pathological changes in the myocardium that
ultimately may result in heart failure (HF) after 18 months of
age. To investigate the mechanisms contributing to the tran-
sition from cardiac hypertrophy to HF, adult SHR were given
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1% NaCl solution (SHR-Na) to drink for the period of
3 months. Control group of SHR (SHR-C) was given tap
water for drinking. At the age of 6 months hemodynamic
parameters were measured with Millar tip catheters, hearts
were then excised, and the changes in the mRNA for
cytokines and extracellular matrix were investigated using
ribonuclease protection assay (RPA). The hemodynamic
measurements showed high left ventricular systolic pressure
and high peripheral resistance in both groups. The hemody-
namic parameters were not significantly different between
the water-drinking (SHR-C) and NaCl-drinking (SHR-Na)
rats. Also the mRNA for cytokines showed no significant
differences between hearts of SHR-C and SHR-Na rats.
SHR-Na rats, however, had significant hypertrophy of the
right ventricle (RV) as compared to SHR-C (RV weight/body
weight ratio 0.56 ± 0.01 vs. 0.49 ± 0.01, P < 0.05). The
changes in RV were also prominent at the level of mRNA for
extracellular matrix proteins. There was significant increase
in the mRNA for atrial natriuretic peptide (ANP) (360% of
SHR-C, P < 0.001), collagen I (248% of SHR-C, P < 0.001),
collagen III (190% of SHR-C, P < 0.002), and colligin (150%
of SHR-C, P < 0.05) in the RV. This was accompanied by
changes in LV in mRNA for ANP (296% of SHR-C, P <
0.001), collagen III (144% of SHR-C, P < 0.002), and tissue
inhibitors of matrix metalloproteinases-2 (TIMP-2, 122% of
SHR-C, P < 0.01). These results suggest, that the 6-month-
old SHR rats compensate functionally the additional stress.
At the subcellular level there are changes that may contribute
to the increasing stiffness of the myocardium (increased
collagen I/collagen III ratio) possibly contributing to the
development of HF.
Abstract N° A115
Studies of the effects of IFN-c on proliferation and
apoptosis of smooth muscle cells and matrix
metalloproteinase activity
Qian Chen*, Zonggui Wu, Lingzhen Zhang, Hongtao Li.
Department of cardiology, Changzheng hospital, Second
Military Medical University, Shanghai 200003, China.
* Corresponding author.
The aim is to study the effects of interferon-c (IFN-c) on
proliferation and apoptosis of smooth muscle cells (SMCs)
and matrix metalloproteinases (MMPs) activity and its effect
on plaque stability. The SMCs from male Sprague–Dawley
rat thoracic aorta were primarily cultured in vitro. Different
IFN-c concentrations (10, 100, and 200 u/ml) were added
into plates to be co-incubated with the cells, respectively.
MTT method was used to detect the cell proliferation at 24,
48 and 72 h. After different IFN-c concentrations were incu-
bated with SMCs for 24 h, the cell cycle was detected by flow
cytometer to observe the effect of IFN-c on cell apoptosis.
Macrophages were isolated from rat abdomen and allowed to
grow in cell culture with different IFN-c concentrations (10,
100, and 200 u/ml). The supernatant of the macrophages
cultures was collected 24 h later. Zymography was perfor-
med by SDS-PAGE in 10% gels containing 0.1% (wt/vol)
gelatin. After destained gelatinolytic activity was established
by a clear white band against the blue background of stained
gelatin. The activities of MMPs could be detected by the grey
level of the band. IFN-c inhibited the proliferation and acce-
lerated apoptosis of SMC with dose depend. IFN-c increased
the activity of MMPs significantly with dose depend. IFN-c
in plaque is produced by active T-cells. IFN-c can increase
plaque instability by decreasing the amount of SMCs in
plaques and increasing the degradation of extracellular ma-
trix in fibrous cap.
Abstract N° A116
Transition from hypertrophy to heart failure
in patients with aortic stenosis is accompanied
by changes of MMP-2 level in plasma and pericardial
fluid
V. Polyakova a, S. Hein b, S. Kostin a, J. Schaper a.
a Max-Planck-Institute, Bad Nauheim. b Kerckhoff-Clinic,
Bad Nauheim
The transition from hypertrophy to heart failure (HF) in
human hearts is characterized by myocardial remodeling
where matrix metalloproteinases (MMPs) and their tissue
inhibitors (TIMPs) take an active part. We studied the expres-
sion of these enzymes in different stages of hypertrophy
progression. We investigated three groups of patients with
aortic stenosis (AS) (I group: ejection fraction (EF) > 50%,
II: 50–30%, III: <30%). Intraoperative biopsies (28 patients),
pericardial fluid (12 patients) and serum (11 patients) were
analyzed. Biopsies from five patients with mitral stenosis but
normal EF and two donor hearts; pericardial fluid of three
patients without valve pathology and serum of five healthy
volunteers were used as controls. Quantitative analysis by
confocal microscopy and western blotting showed upregula-
tion of MMP1, 2, 3, 9, 13, 14 already in group I and further
increase in later stages. TIMP1, 2 were enhanced, TIMP4
was decreased in comparison to control. Zymography de-
monstrated that MMP-2 significantly (P < 0.05) increased
1.2- (group I), 1.5- (group II) and 1.6-fold (group III) over
control. We found that gelatinolytic activity of MMP2 in
serum and pericardial fluid was increased in patients with AS
in comparison to control, but the content of MMPs in the
serum was lower than in pericardial fluid. Increased MMP2
levels in both serum and pericardial fluid correlated with
hypertrophy progression.
Conclusions. – (1) Changes in MMPs and TIMPs levels
indicate the ongoing left ventricular (LV) remodeling process
during the transition from hypertrophy to HF and finally lead
to an increased rate of fibrosis and a reduction of cardiac
function. (2) MMPs profiles in myocardial tissue are compa-
rable with serum and pericardial fluid levels. These measure-
ments may have a diagnostic and prognostic significance in
patients with AS.
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Abstract N° A117
Combined guanethidine and capsaicin administration:
effect on sensory and sympathetic innervation of the
rat heart
J. Slavíková, J. Kuncová. Department of Physiology,
Faculty of Medicine, Charles University, Plzeň, Czech
Republic
It has been well documented that lasting chemical sympa-
thetic and sensory denervation can be achieved by adminis-
tration of guanethidine (G) and capsaicin (C), respectively.
The aim of our study was to investigate the effect of combi-
ned G and C treatment on norepinephrine (NE), dopamine
(DA) and calcitonin gene-related peptide (CGRP) levels in
the rat heart compartments. Newborn rats were randomly
divided into five groups: G: rats treated with G 50 mg/kg
daily for 3 weeks after birth, C: animals given C 50 mg/kg on
postnatal days 2 and 3, CG: rats treated with both drugs in the
above mentioned scheme, C+G: animals given C as above
and G from postnatal day 10 for 3 weeks, Cont: rats injected
with saline only. The following table shows NE, DA and
CGRP concentrations in the right atria of 60-d-old rats as
determined by RIA:
Separate G and C administrations led to the expected
shifts in NE and CGRP levels in all heart compartments.
Interestingly, combined simultaneous administration of C
and G (CG) resulted in 84% decrease in NE level and in
significant increase in DA and CGRP concentrations (220%
and 250% of controls, respectively). Delayed administration
of G (C+G) led to more effective depletion of NE (5% Cont).
Nevertheless, CGRP levels were still increased to the same
extent as in G and CG protocols. In conclusion, the plasticity
of the cardiac sensory innervation seemed to exceed that of
the sympathetic neurons.
Supported by GACR, Grant No. 305/04/0144.
Abstract N° A119
Developmental changes in the action of moderate
hypoxia on intrinsic membrane properties of
intracardiac neurones
Katrina Rimmer, A.A. Harper. Molecular Physiology,
School of Life Sciences, University of Dundee, Dundee,
DD1 5EH, UK
The action of moderate hypoxia on the electrical proper-
ties of intracardiac neurones (ICNs) was investigated in an
intact ganglion preparation from adult (≥6 weeks), juvenile
(2–3 weeks) and neonatal (2–8 d) Wistar rats, maintained at
37 °C. Measurements were taken in normoxic Krebs (95%
O2/5% CO2, pO2 ~200 mmHg), after 20 min hypoxia (95%
argon/5% CO2, pO2 ~80 mmHg) and upon reversion to
normoxic Krebs (45 min). At each stage of development,
hypoxia hyperpolarized the Em by ~2 mV, and increased
input resistance by ~15% in neurones from neonates and
~40% in both juveniles and adult neurones. There were no
changes in action potential overshoot or after hyperpolariza-
tion (AHP) amplitude. Hypoxia increased theAHP50 (50% of
AHP maximum duration) from 19.2 ± 6.2 to 23.5 ± 7.5 ms
(n.s., n = 3) in adults; 11.4 ± 0.8 to 15.1 ± 1.7 mV P = 0.02, n
= 6) in juveniles and 12.4 ± 3.3 to 17.9 ± 4.5 ms (P = 0.01, n
= 4) in neonates. The reversal of these actions was dependent
on postnatal age. Differences in ion channel expression have
been reported for dissociated neonatal and adult ICN (Auton.
Neurosci. 98 (2002) 75). These alterations may contribute to
developmental changes in sensitivity to hypoxia in ICN.
Abstract N° A120
Developmental regulation of GABA-ergic responses in
intrinsic cardiac neurons of the rat heart
H. Fischer, D.J. Adams. School of Biomedical Sciences,
University of Queensland, Brisbane QLD 4072, Australia
The amino acids, c-aminobutyric acid (GABA) and tau-
rine, have been proposed to be neuromodulators in the mam-
malian heart. Intravenous administration of GABA has been
shown to lower blood pressure and to induce bradycardia in
several species. Furthermore, GABA has been shown to be
released from nerve endings terminating in the sinus node of
the guinea pig heart and directly modulate its function by
enhancing the release of acetylcholine via activation of GA-
BAA receptors. We investigated the effects of GABA and
taurine on acutely dissociated intracardiac ganglion neurons
from neonatal and adult rat hearts using whole-cell patch-
clamp recording technique. Focal application of GABA and
taurine evoke a depolarizing, excitatory response in neonatal
but not adult rat intracardiac neurons. Under voltage clamp,
both GABA and muscimol elicit inward currents in a
concentration-dependent manner with half-maximal activa-
tion (EC50) of 28.1 ± 1.2 µM (n = 8). The fast, desensitizing
currents could be inhibited by micromolar concentrations of
the GABA antagonists, bicuculline and picrotoxin. The GA-
BAC antagonist, (1,2,5,6-tetrahydropyridin-4-yl)methyl
phosphonic acid (TPMPA), had no effect on GABA-induced
currents, suggesting that GABAA receptor channels mediate
the response. The GABA-evoked current was age dependent
whereby the current density measured at a holding potential
of –80 mV was ~20 times higher in intracardiac neurons
obtained from neonatal rats (P5: –164.4 ± 7.3 pA/pF) com-
pared to adult rats (P49: –8.4 ± 1.8 pA/pF). The decrease in
GABA sensitivity occurs during the first 2 weeks post-natally
as maturation of the sympathetic innervation of the rat heart
occurs. Antibodies against GABA and taurine demonstrate
the presence of GABA-ergic innervation of the intracardiac
nerve plexus in the rat heart. These results suggest that
GABA and taurine may act as modulators of neurotransmis-
sion and cardiac function in the developing mammalian in-
trinsic cardiac nervous system.
Group NE (ng/g) DA (ng/g) CGRP (ng/g)
Cont 826 ± 67 8.7 ± 1.7 9.5 ± 0.6
G 24 ± 7 * 5.5 ± 1.4 20.2 ± 0.8 *
C 1278 ± 106 * 57 ± 9 * 1.4 ± 0.2 *
CG 130 ± 11 * 19 ± 2.3 * 23.8 ± 3.1 *
C+G 41 ± 4 * 14 ± 1.2 * 24.5 ± 1.1 *
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Abstract N° A122
CP-154,526, A CRF1 receptor antagonist, reduces
cardio-vascular responses during acute psychological
stress in rabbits
E. Nalivaiko, W.W. Blessing. Centre for Neuroscience,
Flinders University, Bedford Park, SA 5042, Australia
CP-154,526 is a selective non-peptide antagonist of CRF1
receptors, with anxiolytic properties (Proc. Natl. Acad. Sci.
USA 93 (1996) 10477; Psychopharmacol 138 (1998) 55). We
examined the effect of CP-154,526 on changes in heart rate
(HR) and mean arterial pressure (MAP) induced by salient
stimuli in conscious unrestrained rabbits with pre-implanted
telemetric probes. Stimuli were presented after administra-
tion, on different days, of CP-154,526 (30 mg/kg i.v.), pro-
pranolol (1.5 mg/kg i.v.) or vehicle. Neither treatment affec-
ted basal level of HR or MAP. CP-154,526 substantially
reduced pressor and HR responses (both brady- and tachy-
cardic) elicited by stressful stimuli. Propranolol inverted
tachycardia induced by a pinprick and reduced airjet-elicited
tachycardic and pinprick-elicited pressor responses.
Thus, CP-154526 reduced both vagally and sympatheti-
cally mediated cardiac effects. Blocking CRF1 receptors
attenuates cardiovascular responses to environmental sti-
muli, presumably by reducing the probability that a particu-
lar stimulus will prove salient.
Abstract N° A123
Disinhibition of the medullary raphe/parapyramidal
region increases cardiac contractility in anaesthetized
rabbits
E. Nalivaiko, Y. Ootsuka, W.W. Blessing. Centre for
Neuroscience, Flinders University, Bedford Park, SA 5042,
Australia
Recent studies (Brain Res. 980 (2003) 1; J. Physiol. 546
(2003) 243) suggest that medullary raphe may contain car-
diac presympathetic neurons. We further investigated this
possibility in anaesthetized, paralyzed and mechanically
ventilated rabbits (n = 6). We recorded changes in ECG,
mean arterial pressure (MAP), heart rate (HR) and left ven-
tricular pressure (LVP) elicited by pharmacological disinhi-
bition of raphe region by bicuculline. Local microinjection of
bicuculline (1 nmol/100 nl) increased MAP (from 99 ± 6 to
112 ± 7 mmHg, P < 0.01), arterial pulse pressure (from 59 ±
7 to 66 ± 8 mmHg, P < 0.05), LVdP/dT (from 3727 ± 348 to
4110 ± 398 mmHg/s, P < 0.01), and slightly decreased HR
(from 305 ± 5 to 295 ± 6 BPM, P < 0.05). The onset of
bradycardia was delayed compared to the increase in MAP
and ventricular contractility. Electrical stimulation (50 Hz,
50–200 µA, 5 s) of the same area produced similar haemody-
namic changes accompanied by ventricular ectopic beats.
Propranolol (1 mg/kg i.v.) caused sustained reduction in
MAP (92 ± 7 to 73 ± 9 mmHg, P < 0.05), pulse pressure (54
± 5 to 46 ± 4 mmHg, P < 0.05), LVdP/dT (3549 ± 330 to 1694
± 395 mmHg/s, P < 0.01) and HR (298 ± 3 to 206 ± 8 BPM,
P < 0.01). After propranolol, bicuculline injection evoked
only minor pressor responses, without affecting other hae-
modynamic parameters. Our data indicate that raphe area
participate in the sympathetic control of cardiac contractility.
Abstract N° A124
Evidence for the involvement of the opioidergic system
in the development of heart failure
Craig Bolte, Gilbert Newman, Jo El Schultz. University of
Cincinnati College of Medicine, Cincinnati, OH, USA
Opioid peptides and their receptors have been shown to be
present in the heart, with the j-opioid receptor the most
highly expressed, and to modulate normal cardiac function
by inducing bradycardia and a negative inotropic state, as
well as inhibiting b-adrenergic receptor signaling. It has also
been shown that levels of leu-enkephalin and dynorphin, two
endogenous opioid peptides, are altered in the spontaneously
hypertensive rat, a model of heart failure. However, the role
of the opioidergic system in the development and progression
towards heart failure has yet to be elucidated. To investigate
the functional capacity of the opioidergic system in heart
failure, a hamster model of spontaneous hypertension (H)
was employed. Previous characterization of these animals
found that hypertension is first observed at 8 weeks resulting
in a mean atrial pressure of 162 ± 3 mmHg for H and 94 ±
4 mmHg for control hamsters (C). Utilizing the isolated
work-performing heart, 1 months C and H hamsters, those
without a hypertensive phenotype, and 10 months C and H
hamsters, non-hypertensive controls and chronic hyperten-
sive hamsters, were employed to investigate the effect of
j-opioid receptor stimulation on cardiac function via a cum-
mulative concentration–response curve. Also, an immunoas-
say was utilized to investigate changes in endogenous opioid
peptide levels (b-endorphin, dynorphin-A, and leu-
enkephalin) as the animals progressed towards heart failure.
Administration of a j-selective opioid agonist led to a
concentration dependent decrease in systolic and diastolic
functional parameters that was similar in both 1 months C
and H hearts. However, the negative inotropic and lusitropic
response to opioid administration was markedly attenuated
in 10 months H hearts compared to age-matched C hearts (P
< 0.05). Cardiac opioid peptide levels also differed between
the normotensive and hypertensive lines. These observations
suggest that the opioidergic system may be a pivotal modu-
Sound Cage drop Pinprick Airjet
Effects on HR responses (BPM)
Vehicle –29 ± 8 –6 ± 9 62 ± 9 30 ± 3
CP154526 –9 ± 3 * 3 ± 3 21 ± 3 * 14 ± 4
*
Propranolol –26 ± 4 –20 ± 6 –16 ± 12 * 15 ± 3
*
Effects on MAP responses (mmHg)
Vehicle 4 ± 1 8 ± 1 16 ± 2 17 ± 1
CP154526 2 ± 1 2 ± 1 * 3 ± 1 * 6 ± 2 *
Propranolol 2 ± 1 7 ± 1 7 ± 2 * 14 ± 2
* Significantly different from control (P < 0.01, n = 6).
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lator in the etiology of heart failure as well as present a
possible mechanism for therapeutic intervention.
Abstract N° A125
Cardiac methionine-enkephalin levels are decreased in
a mouse model of primary hypertrophy
Olivier van den Brink a, Rachel Denver a, Anna Caldwell b,
Deahne Quick a, Thierry Pedrazzini a, Franklin Rosenfeldt a,
Lea Delbridge b, Salvatore Pepe a. a Cardiac Surgical
Research Unit, Alfred Hospital and Baker Heart Research
Institute, Australia. b Department of Physiology, University
of Melbourne, Melbourne, Australia. c University of
Lausanne, Switzerland
The opioid peptide methionine-enkephalin (ME) is produ-
ced by heart muscle cells and by neural afferents terminating
in the heart. Apart from countering the effects of
noradrenalin-mediated stimulation, ME can suppress DNA
synthesis and act as a ‘negative’ growth factor in cardiac
tissue. The transgenic AOGN mouse overproduces angioten-
sin II in the heart, which leads to primary cardiac hypertro-
phy. In this study we investigated whether alterations in ME
concentrations are altered during the development of hyper-
trophy in AOGN.
Methods. – Hearts were isolated from 14- and 28-week-
old AOGN and wild-type (WT) mice. Cardiac tissues were
immediately homogenised in acid mixture and boiled for
15 min to inactivate enkephalinases. Enkephalins were ex-
tracted and ME content was measured by radioimmunoassay.
Results. – An increase in atrial ME content with age was
seen in the WT group (from 3968 ± 627 to 9291 ± 2656 pg/g,
n = 7, P = 0.0748). In the AOGN group the increase in atrial
ME content was significantly attenuated compared to WT
(from 3745 ± 539 to 5833 ± 1071 pg/g, n = 7, P = 0.02). No
differences in ME were detected between ventricular and
atrial tissues.
Conclusion. – The growth promoting effects of elevated
cardiac angiotensin II levels in this model of hypertrophy are
linked with suppression of ME levels. The coincident regu-
latory shift in these mediators requires further exploration as
to their molecular interaction and contribution to the develo-
pment of primary cardiac hypertrophy.
Abstract N° A126
Met-enkephalin gradient across the heart decreases
with increased sympathetic activation in heart failure
van den Brink O, P. Gould, F. Rosenfeldt, D. Kaye, S. Pepe.
Cardiac Surgical Research Unit, Wynn Department
Metabolic Cardiology, Alfred Hospital and Baker Heart
Research Institute, Melbourne, Australia
Within the myocardium, two cellular production sources
of Met-enkephalin (ME) have been identified, these being
cardiomyocytes and sympathetic nerves. In the context of
neuronal release of ME, it appears that the opioid peptide is
co-released with noradrenaline (NA) and can oppose the
tachycardic, vasoconstrictive and positive inotropic effects of
NA. Our group has characterised the presence of cardiac
sympathetic nervous system overactivity in heart failure
(HF) patients, as indicated by heightened cardiac NA release
using radiotracer “spill-over” methodology. In the present
study we hypothesised that cardiac ME release correlates
with the NA “spill-over” and may be subject to similar
baroreceptor control.
Methods. – 3H NA was infused through a peripheral vein
in 10 HF patients undergoing cardiac catheterisation for
transplantation assessment. Baseline haemodynamic para-
meters, coronary sinus (CS) and arterial blood samples (9 ml)
were collected. Subjects were then tilted on a 20° angle for
10 min and measurements were repeated. ME levels were
measured via I125 radioimmunoassay, NA was determined
using high performance liquid chromatography, 3H NA was
measured by liquid scintillation spectroscopy.
Results. – Before upright tilt the CS-arterial gradient in
ME correlated with the high NA CS-arterial gradient (P =
0.052). The NA CS-arterial gradient increased during upright
tilt (427 ± 110 to 585 ± 117 pg/ml, P = 0.004). In contrast,
after upright tilt ME gradient across the heart decreased
significantly (8.8 ± 6.8 to –17.4 ± 9.3 pg/ml, P = 0.04),
suggesting significant cardiac uptake of ME. Upright tilt
invoked a reduction of ME in CS (44.8 ± 26.3 to 14.2 ±
6.4 pg/ml, P = 0.246) and arterial samples (36.0 ± 26.5 to
31.6 ± 11.5 pg/ml, P = 0.433).
Conclusion. – In HF, ME release appears to be subject to
similar baroreceptor control as NA. However, sympathetic
stimulation provoked by upright tilt increases NA CS-arterial
gradients but decreases ME gradients across the heart.
Abstract N° A127
Effects of peptide molecular mass and PEG chain
length on vasoactivity of VIP and PACAP1–38 in
PEGylated phospholipid micelles
I. Rubinstein, B. Ashok, T. Tsueshita, H. Önyüksel.
Colleges of Medicine and Pharmacy, University of Illinois
at Chicago, Chicago, Illinois 60612, USA
We have previously shown that vasoactive properties of
certain amphipathic peptides are amplified when self-
associated with sterically stabilized micelles (SSMs) com-
posed of polyethylene glycol (PEG)-conjugated phospholi-
pids. The purpose of this study was to determine the effects
of amphipathic peptide molecular mass and PEG chain
length on vasoreactivity evoked by vasoactive intestinal pep-
tide (VIP), a 28-amino acid neuropeptide, and pituitary ade-
nylate cyclase-activating peptide1–38 (PACAP1–38) associa-
ted with PEGylated phospholipid micelles in vivo. Both
peptides were incubated for 2 h with SSM composed of PEG
with molecular mass of 2000 or 5000 grafted onto distearoyl-
phosphatidylethanolamine (DSPE-PEG2000 or DSPE-
PEG5000) before use. We found that regardless of peptide
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molecular mass, PEG chain length had no significant effects
on peptide–SSM interactions. Using intravital microscopy,
VIP associated with DSPE-PEG5000 SSM incubated at
25 °C evoked similar vasodilation as VIP associated with
DSPE-PEG2000 SSM in the intact hamster cheek pouch
microcirculation. Likewise, PACAP1–38-induced vasodila-
tion was PEG chain length independent. However, SSM-
associated PACAP1–38 evoked significantly smaller vasodila-
tion than that evoked by SSM-associated VIP (P < 0.05).
When the incubation temperature was increased to 37 °C,
SSM-associated PACAP1–38-induced vasodilation that was
now similar to that of SSM-associated VIP. This response
was associated with a corresponding increase in a-helix
content of both peptides in the presence of phospholipids.
Collectively, these data indicate that for a larger amphipathic
peptide, such as PACAP1–38, greater kinetic energy and/or
longer incubation period is required to optimize peptide–
SSM interactions which, in turn, amplify its vasoactivity in
vivo.
Abstract N° A128
VIP and its receptors in diabetic heart
Magdalena Dvorakova a, Uwe Pfeil b, JitkaŠvı́glerová a,
Jana Slavı́ková a, Wolfgang Kummer b. a Department of
Physiology, Medical Faculty, Charles University, Plzen,
Czech Republic. b Institute for Anatomy and Cell Biology,
Justus Liebig University, Giessen, Germany
Vasoactive intestinal peptide (VIP) is a vasorelaxant pep-
tide. Its actions are mediated through G-protein-coupled re-
ceptors that also recognize pituitary adenylate cyclase-
activating peptide and are denoted VPAC1 and VPAC2
receptors. It stimulates insulin secretion and mediates anti-
inflammatory effects, and has been proposed for treatment of
type 2 and autoimmune diabetes. In the heart, VIP is produ-
ced and released primarily by intrinsic neurons and improves
cardiac perfusion and function. Here, we investigated the
involvement of this system in the events underlying develo-
pment of diabetic cardiomyopathy in the rat model of
streptozotocin-induced diabetes by real-time RT-PCR, and
VPAC1- and VPAC2-immunohistochemistry. Cardiac neuro-
pathy of VIP containing neurons manifests progressively
during the first 4 months of diabetes at both mRNA and
peptide level, and is accompanied by initial downregulation
of VPAC2 at one prime target of VIP containing axons, i.e.
smooth muscle cells of coronary arterioles.After initial chan-
ges that are specific for atria and ventricles, respectively, both
VPAC1 and VPAC2 expression return to control or slightly
elevated levels at 16 weeks, despite ongoing loss of VIP.
Given the cardioprotective role of the VIP signaling system,
this persistence of receptors has therapeutic implications, as
it can be expected that treatment with VPAC2 agonists will
also exert a beneficial effect on diabetic cardiomyopathy.
Granted by: GACR 305/03/D180, GACR 305/04/0144,
and by german-czech cooperation grant (WTZ CZE 01/014).
Abstract N° A129
Effect of atropine on vasoactive intestinal peptide
concentrations in the rat heart atria
J. Kuncová, J. Slavı́ková. Department of Physiology,
Faculty of Medicine, Charles University, Plzeň, Czech
Republic
The effects of acute and chronic atropine (ATR) adminis-
tration on vasoactive intestinal peptide (VIP) levels in the
separated rat heart atria were investigated.Young adult rats (n
= 30) received ATR 10 mg/kg daily for 10 d (A group) or
saline in corresponding volume (n = 30; C group). One day
after the last injection, all animals were anesthetized, pretrea-
ted with metipranolol and artificially ventilated. Ten animals
from each group were subjected to bilateral vagus nerve
stimulation lasting 30 min. Ten rats from each group were
pretreated with ATR and then subjected to bilateral vagus
nerve stimulation lasting 30 min. Remaining animals from
both C and A groups were ventilated for 30 min without any
other intervention and served as controls. ECG was recorded
throughout each experiment. After the end of experiment,
atria were excised and extracted for VIP determinations. The
following table shows VIP levels in the right atria (RA) and
left atria (LA) of experimental rats:
Abstract N° A130
Contractile effects of neurotensin in normal and
hypertrophic rat left ventricles
O. Osadchii, A. Woodiwiss, G. Norton. Cardiovascular
Pathophysiology and Genomics Research Unit, School of
Physiology, University of the Witwatersrand, South Africa
Although neurotensin (NT)-induced positive inotropic
responses on isolated rat atria have been reported in some
studies, its inotropic potency in ventricular myocardium has
not been determined. In the present study, we assessed ino-
tropic responses to NT (10–15–10–7 M) in isolated, isovolu-
mically contracting hearts from normal and isoproterenol
(ISO)-treated (0.04 mg/kg/d, intraperitoneally, 5 weeks)
Sprague–Dawley rats. The hearts were retrogradely perfused
with physiological saline solution (10 ml min–1 g of heart
weight) and paced at a frequency of 330 beats min–1. In
normal rats NT produced marked positive inotropic respon-
Group Intervention VIP (ng/g)—RA VIP
(ng/g)—LA
n
C 0 3.44 ± 0.3 4.33 ± 0.3 10
A 0 2.09 ± 0.2 * 2.67 ± 0.3 * 10
C Stimulation 2.16 ± 0.2* 3.48 ± 0.2 10
A Stimulation 1.94 ± 0.2* 2.72 ± 0.2 * 10
C Stimulation + ATR 1.88 ± 0.1 * 3.61 ± 0.3 10
A Stimulation + ATR 2.01 ± 0.2 * 2.45 ± 0.2 * 10
Chronic ATR administration led to a significant decrease in VIP levels in
both atria. Vagus nerve stimulation alone decreased VIP concentrations in
RA only. ATR administration before the stimulation had no further effect on
the tissue VIP levels. The present results suggest that chronic ATR treatment
might interfere rather with VIP synthesis than its release in the rat heart atria.
VIP releasable by the vagus nerve stimulation seemed to be located
preferentially in RA.
Supported by Grant Agency of CU, Grant No 75/2001.
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ses developing within 30 s after the beginning of peptide
infusion. The magnitude of NT-induced responses was equi-
valent to those of norepinephrine and histamine, but greater
than those for serotonin and angiotensin II. Comparisons of
the EC50 values revealed NT to be as potent as serotonin and
angiotensin II, but more potent than norepinephrine and
histamine at eliciting contractile responses. A comparison of
the inotropic activity of the NT (1–6) and (8–13) fragments,
and the NT analogue, [D-Trp11]-NT, showed that the
contractile effects of NT were largely attributed to the
C-terminal part of this peptide. ISO-induced left ventricular
hypertrophy was accompanied by a reduced contractile res-
ponse both to NT and norepinephrine. Indeed, the maximal
inotropic response achieved at a dose of 10–7 M of NT was
approximately halved in ISO-treated rats, although the EC50
value was not altered. Taken together, these findings suggest
that NT promotes ventricular contractility, an effect that is
downregulated in myocardial hypertrophy.
Abstract N° A131
Factors determining NT-proBNP levels in patients with
end-stage renal failure
L.H. Madsen a, S. Ladefoged b, P. Hildebrandt a,
F. Pedersen a, D. Atar c. a Department of Cardiology and
Endocrinology, Frederiksberg University Hospital,
Copenhagen, Denmark. b Department of Nephrology, State
University Hospital (Rigshospitalet), Copenhagen,
Denmark. c Division of Cardiology, Aker University
Hospital, Oslo, Norway
Introduction. – Serum N-terminal pro brain natriutretic
peptide (NT-proBNP) determination in the general popula-
tion can help identify patients with left ventricular systolic
dysfunction. NT-proBNP levels are, however, often elevated
in patients with end-stage renal failure (ESRF), the reason for
which is largely unknown. The present study aimed at (i)
identifying the factors that affect the concentrations of circu-
lating NT-proBNP in patients undergoing regular hemodia-
lysis and (ii) determining the effect of dialysis on NT-
proBNP levels.
Methods. – One hundred and nine patients (82 males,
mean age 62 years) on chronic hemodialysis underwent phy-
sical examination, ECG, echocardiography, cardiac MRI,
and measurement of 24-h ambulatory blood pressure. NT-
proBNP was measured before and after hemodialysis using
Elecsys 2010 (Roche Diagnostics, Germany).
Results. – Eighty percentage of the cohort had hyperten-
sion treated to a mean systolic blood pressure of 144 ±
22 mmHg, 50% had left ventricular hypertrophy and 27%
had documented CAD. The mean left ventricular ejection
fraction (LVEF) was 50 ± 13%. NT-proBNP was remarkably
elevated in these patients (predialysis 4079 pg/ml (median;
interquartile range 1893–14549); postdialysis 2773 pg/ml
(1073–10773), P < 0.001; normal value <334 pg/ml). Logis-
tic regression analysis demonstrated a strong correlation
between predialysis NT-proBNP and LVEF (P < 0.001),
systolic blood pressure (P = 0.008) and 24-h urine production
(P = 0.016). As opposed to the general population there was
no correlation between levels of NT-proBNP and age, sex,
BMI or volume overload (maximum weight above estimated
dry weight) in our cohort.
Conclusion. – Serum concentrations of NT-proBNP are
greatly elevated in patients with ESRF undergoing dialysis.
Hence they cannot be used as a marker of heart failure in this
population. Dialysis induces a significant decrease of NT-
proBNP levels, most likely due to loss during dialysis, howe-
ver, reduced synthesis may also contribute considering the
abrupt fall in intravascular volume occuring during dialysis.
Further, the correlation between 24-h urine production and
NT-proBNP levels can be explained by both increased renal
excretion of NT-proBNP and reduced synthesis.
Abstract N° A132
Thyroid hormone enhances calcification of vascular
smooth muscle cells in vitro
Yoji Sato a, Ryo Nakamura a, Hiromi Yoshida b,
Teruhide Yamaguchi a, Yasuo Ohno c, Taku Nagao d,
Kazuhide Inoue b. a Division of Cell and Gene Therapy
Production, Setagaya, Tokyo 158 8501, Japan. b Division of
Xenobiotic Metabolism and Disposition, Setagaya, Tokyo
158 8501, Japan. c Division of Pharmacology, Setagaya,
Tokyo 158 8501, Japan. d National Institute of Health
Sciences, Setagaya, Tokyo 158 8501, Japan
Thyroid hormones have marked effects on various tissues
and organs, including the cardiovascular system. Although
nuclear receptors for thyroid hormones are expressed in
vascular smooth muscle cells, their functional roles have
been unclear. As thyroid hormones play critical roles in bone
remodelling, and both smooth muscle cells and
chondrogenic/osteogenic cells are derived from mesenchy-
mal stem cells, we hypothesized that thyroid hormones are
also associated with vascular smooth muscle calcification. To
test this hypothesis, we examined the effects of 3′,3,5-
triiodo-l-thyronine (T3) on rat aortic smooth muscle cells,
which were cultured in the presence of 10% thyroid
hormone-depleted serum. As assessed by the colorimetric
method based on o-cresolphthalein complexion, the treat-
ment with a physiological concentration of T3 (15 pM free
T3, 5 d) significantly increased the calcium deposition in the
smooth muscle cells by 38.7%. The T3 treatment also in-
creased the alkaline phosphatase activity, a phenotypic mar-
ker of osteogenesis, by 14.2%. In contrast, aortic smooth
muscle tissues isolated from methimazole-induced hypothy-
roid rats (400 mg/l drinking water, 28 d) showed an increase
in the calcium content by 32.9%, compared with that of the
control euthyroid rats. Our findings suggest that hypothyroi-
dism directly attenuates vascular smooth muscle cell calcifi-
cation, but this effect is apparently masked in vivo, presuma-
bly due to atherosclerosis by abnormal cholesterol
metabolism in the hypothyroid liver. This is the first evidence
for the direct effect of thyroid hormone on the calcification of
vascular smooth muscle cells.
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Abstract N° A133
Overexpression of diacylglycerol kinase zeta inhibits
endotheline-1-induced cardiomyocyte hypertrophy
Hiroki Takahashi a, Yasuchika Takeishi a, Isao Kubota a,
Tim Seidler b, Gerd Hassenfuss b. a Yamagata University,
Yamagata, Japan. b George-August-University Goettingen,
Goettingen, Germany
Diacylglycerol kinase (DGK) is an enzyme that is respon-
sible for controlling the cellular level of diacylglycerol
(DAG) by converting it to phosphatidic acid, thus acting as a
regulator of protein kinase C (PKC). However, the functional
role of DGK has not been rigorously examined in cardiomyo-
cytes. Since DGK inactivates DAG, a strong activator of
PKC, we hypothesized that overexpression of DGK inhibited
endothelin-1 (ET-1)-induced activation of downstream si-
gnaling cascade and subsequent cardiomyocyte hypertrophy.
Since it was reported that DGK zeta (DGKf was predomi-
nant isoform in the heart, we overexpressed DGKf in neona-
tal rat cardiomyocytes using recombinant adenovirus that
encoded rat DGKf. The translocation of both PKCa and e by
ET-1 was inhibited by overexpression of DGKf. We next
examined the activator protein-1 (AP-1) DNA-binding acti-
vity by dual-luciferase assay. The increased AP-1 DNA-
binding activity by ET-1 was inhibited by overexpression of
DGKf (4.54 ± 0.23 vs. 1.36 ± 0.71-folds over control, P <
0.01) Furthermore, ET-1-induced increases in cell surface
area were attenuated by DGKf. We demonstrated for the first
time that overexpression of DGKf inhibited ET-1-induced
activation of subcellular signaling pathway and resultant
cardiomyocyte hypertrophy.
Abstract N° A134
S100B expression modulates left ventricular
hypertrophy and apoptosis following pressure overload
in mice
Thomas G. Parker, Alexander Marks, Fayez Dawood,
Peter P. Liu, James N. Tsoporis. St. Michael’s Hospital,
University of Toronto, Toronto, Canada
Myocardial hypertrophy is an adaptive response of the
heart to increased workload, but it is also associated with a
high risk of cardiac mortality. S100B, a 20 kDa, Ca2+-
binding dimer is an intrinsic negative regulator of myocardial
hypertrophy expressed following cardiac disease, suggesting
that S100B overexpressing transgenic (TG) and S100B
knock-out (KO) mice could be used to relate varying degrees
of hypertrophy to cardiac structure and function. We compa-
red 15 wild-type (WT) and 15 TG mice over 28 d following
aortic banding (AB) with similar matched sham-operated
controls. Of those, 6/15 TG-, 2/15 WT-banded mice and 0/30
sham-operated mice died during the observation period. KO
mice did not survive surgery. In both strains, AB increased
arterial pressure by approximately 40 mmHg. Echocardio-
graphy and postmortem examination indicated that the WT
group of banded mice mounted a hypertrophic response
(30% increase) accompanied by a program of fetal gene
re-expression including b-myosin heavy chain, skeletal
a-actin and atrial natriuretic factor, while the S100B overex-
pressing TG-banded group showed no detectable hypertro-
phy or the associated fetal gene expression, but marked
myocyte apoptosis, as evidenced by DNA fragmentation and
increased mRNA expression of the apoptotic related genes
Caspase-8, Fas-1. Our results suggest that the absence of
adaptive hypertrophy, and the marked apoptosis associated
with S100B expression in TG mice may contribute to the
poor survival in response to pressure-overload induced by
AB.
Abstract N° A135
Expression and functional consequences of RAGE
(receptor for advanced glycation end products)/S100B
expression in rat myocardium
James N. Tsoporis, Abraham Haddad, Alexander Marks,
Henri J. Huttunen, Thomas G. Parker. St. Michael’s
Hospital, University of Toronto, Toronto, Canada.
Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
RAGE and its ligands including the calcium-binding pro-
tein S100B have been implicated in a range of disorders
leading to diverse cellular responses varying from cytokine
expression to cell survival. We show here that RAGE mRNA
and protein is enhanced (approximately 10-fold) in ventricu-
lar tissue in a manner overlapping that of its ligand S100B in
a rat model of myocardial infarction, coronary artery liga-
tion. In addition, using a co-immunoprecipitation strategy we
demonstrated an interaction between S100B and RAGE in
ventricular myocardium following coronary artery ligation.
To determine the functional role of the RAGE/S100B inte-
raction, rat neonatal cardiac myocyte cultures co-transfected
with a full-length cDNA of the RAGE gene or a cytoplasmic
deletion mutant of RAGE plus a green fluorescent protein
(GFP) expression plasmid were stimulated with nanomolar
(1–100) concentrations of recombinant bovine brain S100B.
In RAGE/GFP expressing myocytes, S100B-induced myo-
cyte apoptosis in a concentration-dependent manner as evi-
denced by DNA fragmentation. This effect seems to be
RAGE dependent as myocytes expressing the cytoplasmic
deletion mutant of RAGE were not apoptotic. S100B also
induced RAGE-dependent increased mRNA expression of
the apoptotic related genes Caspase-8 (fivefold), and Fas-1
(threefold). Thus, the expression and engagement of RAGE
with its ligand S100B post myocardial infarction may play a







Control + LacZ 0.17 ± 0.04 0.52 ± 0.03 1.00 ± 0.07
Control + DGKf 0.24 ± 0.06 0.72 ± 0.20 0.95 ± 0.05
ET-1 + LacZ 0.54 ± 0.11 * 4.93 ± 0.35 * 1.42 ± 0.07 *
ET-1 + DGKf 0.31 ± 0.04 ** 1.31 ± 0.14 ** 1.23 ± 0.05 **
M/C ratio: membrane/cytosol ratio as indices for the translocation of PKC.
* P < 0.01 vs. control + LacZ.
** P < 0.01 vs. ET-1 + LacZ.
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Abstract N° A136
Regulation of the human S100A6 gene in myocardial
cells by trophic stimuli
James N. Tsoporis, Abraham Haddad, Jacek Kuznicki,
Thomas G. Parker. St. Michael’s Hospital, University of
Toronto, Toronto, Canada. Nencki Institute of Experimental
Biology, Warsaw, Poland
The calcium-binding protein S100A6 has been implicated
in the general regulation of distinct genetic programs known
to be activated in terminally differentiated non-dividing adult
myocytes by trophic stimuli both under physiological condi-
tions and during hypertrophy. To begin to define the regula-
tion of S100A6 expression under basal conditions, and in the
setting of trophic stimulation with the a1-adrenergic agonist
phenylephrine (PE), angiotensin II (AII), triiodothyronine
(T3), PDGF, TGFb, prostaglandin F2a, phorbol myristate
acetate (PMA) or the activated transcription factors, trans-
cription enhancer factor 1 (TEF-1) and activator protein-1
(AP-1), we characterized the human S100A6 promoter and
mapped its upstream regulatory elements in rat neonatal
cardiac myocytes in culture, using a luciferase reporter sys-
tem. The functional S100A6 promoter was localized to a
region –167/+134 containing 167 bp upstream of the trans-
cription initiation site of the gene. The human S100A6 pro-
moter is regulated by both positive and negative regulatory
elements located upstream in the 5′ flanking DNA regions.
The regions –361/–167 and –588/–361 contain strong posi-
tive regulatory elements. Negative regulatory elements were
mapped to the regions –1371/–1194 and –3000/–1371 of the
gene. PE, PMA, F2a, AII, T3, PDGF, TGFb, all induce the
basic S100A6 promoter approximately 1.25 to 3-fold. a1-
Adrenergic stimulation had no effect on promoter activity.
The transcription factors, TEF-1 and AP-1 influenced trans-
cription from the basic promoter, implicating active MCAT
and AP-1-binding sites, respectively. TEF-1 transrepressed
(0.35-fold) and AP-1 transactivated (fivefold) the basic
S100A6 promoter. Our results suggest that multiple signa-
ling pathways induce the S100A6 gene and that this induc-
tion is modulated by TEF-1 and AP-1.
Abstract N° A137
The signaling pathway of macrophage migration
inhibitory factor induces MMPs expression
XiYong Yu a, ShuGuang Lin a, ZhiXin Shan a,
QiuXiong Lin a, Xiao-Ru Huang b, Hui Y. Lan b.
a Guangdong Provincial Cardiovascular Institute,
Guangzhou, China.
b Department of Medicine, Baylor College of Medicine,
Houston, TX 77030, USA
The aim of this study is to investigate the potential role of
macrophage migration inhibitory factor (MIF) in the desta-
bilization of atherosclerotic plaques and the signal transduc-
tion pathways of MIF inducing matrix metalloproteinases
(MMPs) expression in macrophages in vitro. Real-time PCR
showed that constitutive expression of MMP-2, MMP-9 and
MT-MMP-1 mRNA was low in normal macrophages. Addi-
tion of MIF strongly induced MMP-2, MMP-9 and MT-
MMP-1 mRNA expression by macrophages in a time- and a
dose-dependent manner, being significant twofold increase
at 3 h after MIF stimulation. Similarly, western blot analysis
demonstrated MIF-induced MMP-2, MMP-9 and MT-
MMP-1 protein synthesis by macrophages in a time- and a
dose-dependent fashion, being significant at 12 h after MIF
stimulation. The specificity of MIF to induce MMPs mRNA
or protein expression in macrophages was further demonstra-
ted by the addition of a neutralizing MIF mAb. In addition,
the upregulation of MMPs by MIF stimulation can be bloc-
ked completely by MEK-1 inhibitor PD98059, partly by JNK
inhibitor SP600125, but not blocked by p38 inhibitor
SB203580. Induction of dominan-negative MEK1 by retro-
virus blocked MMPs expression significantly, but induction
of dominan-negative ERK by a replication-deficient adeno-
virus blocked MMPs synthesis slightly. Similarly, dominan-
negative MEK1, not dominan-negative ERK, blocked the
phosphorylation of transcription activators c-jun. This pro-
cess can be confirmed by c-jun trans-reporting system. Thus,
MIF may play a critical role in the destabilization of human
atherosclerotic plaques by upregulation of MMP-2, MMP-9
and MT-MMP-1 expressions by MER1–ERK–c-jun-
dependent pathways.
This work was supported by grants from National Natural
Science Foundation of China (30271287, 30300421) and
Guangdong Provincial Natural Science Foundation for Re-
search Team (015015).
Abstract N° A138
Using antisense RNA to inhibit the macrophage
migration inhibitory factor expression in human
umbilical vein endothelial cell
ZhiXin Shan, QiuXiong LIN, XiYong Yu, Min Yang,
Meng Zheng, XiaoYing Liu, YongHeng Fu, HongHong Tan,
ShuGuang Lin. Guangdong Provincial Cardiovascular
Institute, Guangzhou, China
Macrophage migration inhibitory factor (MIF) is a pro-
inflammatory cytokine involved in atherosclerosis. By bloc-
king new mRNA synthesis with antisense RNA, post-
transcriptional gene silencing phenomenon in human
umbilical vein endothelial cells (HUVECs) is reported in this
study. A vector (pcDNA3) was used that transcribed anti-
sense RNA and hairpin-double-stranded RNA (dsRNA) of
MIF gene separately to transfect HUVECs by using lipofec-
tamine 2000. By using G-418 sulfate, two HUVECs which
were transfected by antisense RNA or hairpin-dsRNA of
MIF separately were obtained and identified by PCR. The
apoptotic cells were visualized with the fluorescent DNA-
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binding dyes Hoechest 33258 and propidium iodide under
fluorescent microscope. The real-time PCR and western blot
analysis showed that MIF mRNA and MIF protein was upre-
gulated significantly by the stimulation of lipopolysaccha-
ride (LPS) at 10 ng/ml for 30 h. In the present of antisense
RNA or hairpin-dsRNA, the MIF expressions were both
significantly inhibited (P < 0.01), but the apoptosis was
observed only in the HUVECs which were transfected by
hairpin-dsRNA. The results indicate that antisense RNA can
specifically inhibit the MIF express, but the hairpin-dsRNA
(348 bp) can reduce the genes expression in HUVECs by
unspecific apoptosis. Thus, antisense RNA not full hairpin-
dsRNA (348 bp) is suitable for gene therapy, small interfe-
ring RNAs (siRNAs) may be more potential for RNA inter-
ference which will be performed in our further study.
This work was supported by grants from National Natural
Science Foundation of China (30271287, 30300421) and
Guangdong Provincial Natural Science Foundation for Re-
search Team (015015), and Guangdong Provincial Natural
Science Foundation (033189).
Abstract N° A139
PKC reduces sarcoplasmic reticulum calcium and
induces cardioprotection
Ken Yamamuraa, Charles Steenbergenb, Elizabeth Murphya.
aNIEHS, NIH, Research Triangle Park, North Carolina
27709. bDuke Med. Ctr, Durham, NC
Protein kinase C (PKC) activation has been shown to be
cardioprotective. We previously showed that activation of
PKC-epsilon reduced that rate of decline in ATP during
ischemia and improved postischemic contractile function.
We also found that reducing sarcoplasmic reticulum (SR)
calcium cycling during ischemia is cardioprotective. To exa-
mine the role of SR calcium in the cardioprotection associa-
ted with activation of PKC, we used freshly isolated single
myocytes from adult rat ventricular myocardium. To confirm
that PKC activation is protective in the myocyte model,
myocytes were exposed to 3 µM DOG for 10 min to activate
PKC. Myocytes were gently pelleted and covered with oil in
1.5 ml tubes to simulate ischemia and incubated at 37 de-
grees. Trypan blue was applied to assess myocyte viability.
Untreated (control) myocytes had increased cell death com-
pared to myocytes treated with DOG after simulated ische-
mia. Cell death was 57.9 % in controls vs 47.3 % in DOG
treated myocytes after 1 h of simulated ischemia, 65.5 % vs
48.3 % at 2 h, 68.0 % vs 50.2 % at 3 h, and 70.7 % vs 53.3 %
at 4 h. Once we confirmed that DOG was cardioprotective,
we examined the effect of DOG on SR calcium using fura-
2 fluorescence to monitor calcium transients and caffeine
releasable calcium as a measure of SR calcium content. At
10 min after addition of DOG, there was a decrease in the
amplitude of the [Ca2 + ]i transient, to 82 ± 22 % of the pre-
treatment level. Caffeine-releasable SR calcium measured
after 10 min of DOG treatment was reduced by 12 %. We
also analyzed the [Ca2 + ]i transient curve as an indicator of
SERCA and Ryanodine Receptor function. The relaxation
time after 2 min of DOG exposure was prolonged compared
with control, suggesting decreased SERCA activity. These
data suggest that activated PKC reduces SR Ca2 + content,
and that reduced SR Ca2 + may be important in cardioprotec-
tion.
Abstract N° A140
Vardenafil : a novel type 5 phosphodiesterase inhibitor
reduces myocardial infarct size following
ischemia/reperfusion injury via opening of
mitochondrial KATP channels in rabbit
Fadi Salloum, Ramzi Ockaili, Michael Wittkamp,
Vijay R. Marwaha and Rakesh C. Kukreja.
Virginia Commonwealth University Medical Center,
Richmond, USA
We previously demonstrated that sildenafil (Viagra), a
potent inhibitor of phosphodiesterase-5 (PDE-5) that enhan-
ces erectile function in men through upregulation of cGMP,
induces powerful preconditioning like cardioprotective ef-
fect following ischemia/ reperfusion (I/R) injury. In the pre-
sent study, we further investigated the effect of vardenafil
(Levitra), a more selective and biochemically potent inhibi-
tor of PDE5 in protection against I/R injury. Rabbits were
treated with vardenafil (0.014 mg/kg, iv) or equivalent vo-
lume of saline, 30 min prior to 30 min of sustained regional
ischemia followed by 3 hrs of reperfusion.
5-hydroxydecanoate (5-HD, 5 mg/kg, iv) or HMR 1098
(HMR, 3 mg/kg, IV), the respective specific blockers of
mitochondrial or sarcolemmal KATP channel were adminis-
tered 5 min before I/R. Infarct size was measured by compu-
ter morphometry of tetrazolium stained sections. Mean arte-
rial blood pressure decreased from 93.5 ± 2.6 to
82.2 ± 1.5 mmHg and heart rate increased from baseline
value of 151 ± 20 to 196 ± 4.6 (mean ± SEM, p < 0.05) wi-
thin 5 minutes after treatment with vardenafil. The infarct
size (% of risk area) was reduced from 33.8±1.3 in control
rabbits to 14.3±2.2 (58 % reduction, p < 0.05). 5-HD abo-
lished vardenafil-induced protection with increase in infarct
size to 34.5 ± 2.3 (p < 0.05, n-6/groups). In contrast, HMR
failed to block the protective effect of vardenafil (infarct size,
14.3 ± 2.2 versus 16.3 ± 1.0 in vardenafil + HMR, p > 0.05).
Both inhibitors of the KATP channel had no influence on
infarct size in the control rabbits, as shown by infarct size of
34.9 ± 1.1 and 33.3 ± 1.4 in animals treated with 5HD and
HMR, respectively. For the first time, we demonstrate that
vardenafil induces protective effect against I/R injury via
opening of mitochondrial KATP channel. These results further
support our hypothesis that novel class PDE-5 inhibitors, in
addition to their well known clinical effects in the treatment
of erectile dysfunction in men, also induce protective effects
in the ischemic heart.
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Abstract N° B1
Hypoxia/reoxygenation studies on mouse embryonic
stem cells
Chi Zhang a, Ramaswamy Narayanan b,
Larry F. Lemanski a. a Department of Biomedical Sciences,
Florida Atlantic University, Boca Raton, FL 33431, USA. b
Biological Sciences, Florida Atlantic University, Boca
Raton, FL 33431, USA
It is important to understand the cellular responses to
hypoxia since hypoxia conditions lead to serious human
disease such as ischemia and tumorigenesis. Hypoxia re-
cently has been shown as a factor that promotes the self-
renewal of murine and human normal hematopoietic stem
cells. We have recently cultured murine embryonic stem cells
(CCE27) in LIF maintained culture medium. The pluripo-
tency of these embryonic stem cells has been proven by
successfully differentiating into embryoid bodies (EBs) with
distinctive germ layers. About 50% of the induced EBs show
rhythmic beating after 12 d of culture in differentiation me-
dium. Two weeks cultures of EBs on gelatin-coated dishes
show abundant expression of cardiac troponin-T and organi-
zed myofibrils. The hypoxia/anoxia effects are being tested
by treating the cells with an anoxic environment in anoxic
chambers. Our results show that extensive exposure to anoxia
induces apoptosis in the embryonic stem cells. Western blot-
ting has shown clearly that BNIP3, a hypoxia-induced pro-
apoptosis protein in the stem cell, is expressed in the
hypoxia/reoxygenization-treated stem cells. In our differen-
tiated stem cell cultures, we have observed the translocation
of protein kinase C (PKC)-epsilon to myofibril structures
after phorbol ester treatment, indicating the involvement of
PKC-epsilon in the hypoxia response in stem cell-derived
cardiomyocytes. Hypoxia/reoxygenization treatment of stem
cells on potential differentiation ability into specific cell
types is being studied with emphasis on cardiomyocyte for-
mation. Our preliminary data suggest that hydrogen peroxide
is an inducing factor for cardiomyocyte differentiation from
embryonic stem cells; 10 nM H2O2 treatment on the EBs has
significantly increased the numbers of beating centers to
twice that of untreated or 1 µM H2O2 overtreated undifferen-
tiated cells. Microarray assays are used to elucidate the
genome level responses of embryonic stem cells to
hypoxia/reoxygenization during differentiation, apoptosis
and self-renewal processes.
Supported by NIH HL58435 and HL61246 and AHA
Grant-in-aid to LFL.
Abstract N° B2
Histone deacetylase inhibitors reverse hypertrophic
growth and gene expression in cultured neonatal
cardiomyocytes
Matthew Dreitz, Lisa Hollingsworth.
Hansjorg Rindt Myogen, Inc., Westminster, CO, USA
Cardiac hypertrophy is an independent risk factor for the
development of heart failure. Although it was originally
assumed that hypertrophy was a necessary compensatory
response of the heart to increased load, more recent evidence
suggests that contractile function can be maintained in the
absence of cardiomyocyte hypertrophy. Thus, inhibiting the
onset of hypertrophy, or reversing established hypertrophic
growth, may be of therapeutic value. Histone deacetylase
inhibitors (HDAC-I) are a novel class of antineoplastic
agents currently in clinical trials for various types of cancer.
It has been shown previously that hypertrophy of cultured
neonatal cardiomyoctyes is inhibited by HDAC-I. This was
correlated to increased levels of histone acetylation. We have
now extended this investigation to demonstrate that the hy-
pertrophic phenotype of cardiomyocytes can be at least par-
tially reversed by the administration of HDAC-I. Stimulation
of cardiomyocytes with phenylephrine for 48 h induced the
typical expression of fetal genes and led to increases in cell
size. An additional 48 h culture in the presence of pheny-
lephrine plus HDAC-I resulted in the repression of fetal gene
expression, reduction of protein accumulation, and decrease
of cell size. This phenotypic change was accompanied by a
reduction in global histone acetylation. Similar results were
obtained with different chemical classes of HDAC-I. These
results suggest that HDAC-I may be effective at modulating
cardiac hypertrophy both in a prophylactic as well as a
therapeutic setting.
Abstract N° B3
Occurrence of bone-marrow-derived cardiomyocytes in
transgenic mice with cardiac overexpression of
monocyte chemoattractant protein-1
A. Martire a, T. Ziegelhoeffer a, M. Heil a, B. Fernandez a,
S. Kostin a, I. Loeffler a, W. Schaper a, P. Kolattukudy b,
J. Schaper a. a Max-Plank Institute, Bad Nauheim, Germany.
b University of Central Florida, Orlando, Florida, USA
Only recently, it became apparent that in cardiac diseases
characterized by myocyte loss, cardiomyocytes die by mul-
tiple mechanisms and probably proliferate. We have studied
transgenic (TG) mice with prolonged cardiac overexpression
of monocyte chemoattractant protein-1 (MCP-1). These
slowly develop an autoimmune inflammatory cardiomyopa-
thy characterized by cardiomyocyte loss by autophagy, anti-
gen presentation, necrosis but not apoptosis, and low rate of
proliferation. In order to study whether myocyte loss might
be counteracted by myocyte replacement from bone-
marrow-derived cells (BMDCs), MCP-1 TG mice were
lethally irradiated and subsequently transplanted with
BMDCs from enhanced green fluorescent protein (eGFP)
ubiquitously expressing mice. At 4 months after transplanta-
tion the hearts were analyzed for detection of GFP cells using
confocal laser scanning microscopy, myocytes were identi-
fied by sarcomeric actin labeling, and nuclei by TOTO 3.
MCP-1 transplanted mice showed significant levels of hae-
matopoietic reconstitution (81–91% of nucleated blood cells
expressed eGFP), which was measured by flow cytometry. At
4 months after transplantation, GFP-BMDCs were found
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incorporated into the ventricular wall. The vast majority of
green cells were identified as interstitial cells. However,
several GFP-positive cells exhibited cross-striated actin labe-
ling and had a morphology and alignment that was indistin-
guishable from the surrounding cardiomyocytes, following
the orientation of the other fibres. These data indicate that in
MCP-1 TG mice myocyte loss is partially counteracted by
myocyte replacement from BMDCs.
Abstract N° B4
The study on gene transfer into different passages of
bone marrow mesenchymal stem cell
Yutao Guo *, Xiaoying Li. Geriatric Cardiology, Chinese
PLA General Hospital, Beijing, 100853, China. *
Corresponding author.
The efficiency and stability of adenovirus-medicated gene
transfer into different passages of bone marrow mesenchy-
mal stem cells (BMSCs) were investigated. BMSCs were
obtained from bone marrow of Sprague–Dawley rat and
cultured. Then P3 and P8 BMSCs were transfected with
Ad-CMV-green fluorescent protein (GFP), respectively. The
transfection ratio was evaluated by flow cytometer at 2, 4, 7
and 10 d after transfection. At the same time Coxsackie and
Ad receptor (CAR) of different passages of BMSCs was
estimated by RT-PCR and western blot. The green fluores-
cence could be observed 24 h after transfection, while the
strength of fluorescence were rising with time and the peak
was at 7 d. It was seen that the transfection ratio was over
80% and there was no difference between P3 and P8 BMSCs;
P > 0.05. Flow cytometer analysis by different gates showed
the transfection ratio was high in BMSCs in period of pro-
ductive metabolism. The gene expression of CAR in P3, P6,
and P8 was similar, and the same change was in the protein
expression of CAR in P3 and P8 BMSCs. Ad-CMV-GFP
could be transferred to BMSC effectively and sustained
about 28 d. It was suspected that BMSC in mitotic phase
were easy to be transferred by Ad-CMV-GFP and different
passages of BMSCs from P3 to P8 BMSCs could be as
high-effectively gene vehicle.
Abstract No B5
Induction of controlled therapeutic angiogenesis by
L-Lysine hydrochloride in ischaemic myocardium
Guhathakurta Sa, Cherian KM, Datta D, Nayar S,
Kurian VM, Kanagarajan N, Sriram P. Indian Institute of
Technology, Bombay, India
Acute and chronic ischemia in myocardium produce hi-
gher yield of angiogenic agents in situ as a normal response,
which is inadequate on demand. Simpler mode of therapy for
induction of controllable therapeutic angiogenesis, espe-
cially for myocardial salvage in ischemic heart disease are
under search. Based on the profound cellular expansion abi-
lities of L-Lysine hydrochloride, the molecule has been exa-
mined in the current experimental work, for its possible role
in reperfusing ischemic myocardium, in an acute mode of
experimentation. Two phasic sheep experiments were
conducted with Madras Red breed sheep of similar age group
and body weight. Four sheep hearts were accessed through
left anterolateral thoracotomy in the first phase and an upper
diagonal branch tied in each to induce myocardial infarction,
whereas in the second phase through median sternotomy the
apical diagonal branches were tied in 6 sheep. Injectable
L-Lysine (250mg), was used for various routes of injection,
such as locally at the infarcted area, and/or aortic root or
intravenously in a dose of 4gm per day for 10 days. One
control in each group had 1 ml normal saline injected locally.
Preoperative and post operative 2D echocardiography asses-
sment of the sheep hearts were done till the day of sacrifice ;
phase 1 sheep were sacrificed after 6 weeks and phase 2,
after 4 weeks. Macroscopic findings and histopathological
examinations of the infarcted area by various stains are no-
ted. Quantitative increase of neoangiogenesis is noticed in
the experimental animals having L-Lysine than the control.
Quantitation done by averaging the observation of five fields
of 200 magnification and confirmation done by immunohis-
tochemistry. L-Lysine creates considerable neoangiogenesis
in ischemic myocardium, even through intravenous adminis-
tration in sheep model ; being an essential amino acid it will
be easy to use clinically for human trial in ischemic heart
disease.
Abstract N° B6
The kelch family protein Nd1 and actin depolymerising
proteins are differentially expressed in growing
collateral arteries
S. Boehm a, O. Volger b, F. Pipp a, I. Eitenmueller a,
M. Granz a, T. Schmitz-Rixen c, R. Zimmermann d,
W. Schaper a. a Max-Planck-Institute, Frankfurt, Germany. b
Academic Medical Center, Amsterdam, The Netherlands. c
Goethe-University, Frankfurt, Germany. d Kerckhoff-Clinic,
Bad Nauheim, Frankfurt, Germany
Fluid shear stress (FSS) induces collateral growth (arterio-
genesis). To identify genes involved in this process, two
models of chronic high FSS were used. The femoral arteries
of rabbit or pig were ligated (LC) bilaterally and a unilateral
arteriovenous shunt (SC) was created. Genes differentially
expressed between LC and SC were identified by a combina-
tion of 2D-PAGE, array analysis and suppression subtractive
hybridisation. Northern blot analysis was used to verify the
results. Results showed differential expression of genes in-
volved in actin turnover and stabilisation. In particular, the
actin depolymerising proteins Cofilin1 (36% up-regulated)
and Cofilin2 (72% down-regulated on SC) are expressed
reciprocally (P < 0.05) in the porcine model. Additionally,
the kelch family protein Nd1, known to stabilise actin fila-
ments, is 69% downregulated on SC in the rabbit model (P <
0.009). Similar results were obtained in the porcine model.
Our results indicate an important role of proteins involved in
actin regulation during arteriogenesis. The reciprocal expres-
sion of the Cofilins and the reduced expression of Nd1 seem
to be responsible for the “switch” from the contractile to the
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synthetic phenotype and the restart of proliferation during
collateral growth. We hypothesise that actin depolymerisa-
tion and polymerisation are important events during arterio-
genesis, necessary for the migration of vascular smooth mus-
cle cells.
Abstract N° B 7
Hypoxic preconditioning induces myocardial
angiogenesis through ERKs-mediated HIF-1a
expression
Xiuhua Liu *, Yuzhen Li, Lirong Cai, Sheng Sun,
Fengying Liu. Department of Pathophysiology, PLA
General Hospital, Beijing, China. * Corresponding author.
Angiogenesis plays an important role in cardioprotection
of ischemic preconditioning. Hypoxia-inducible factor-1
(HIF-1) is involved in transcription of the hypoxia-inducible
genes including vascular endothelial growth factor (VEGF),
which is involved in angiogenesis. To determine whether
hypoxic preconditioning (HPC) induces myocardial angio-
genesis through extracellular signal-regulated protein kina-
ses (ERKs)-mediated HIF-1a expression, 12 male Sprague–
Dawley rats were divided into either HPC or control group.
Animals in HPC group were subjected to systemic hypoxic
exposure (10 ± 0.4 O2) for 4 h. Animals in control group were
time matched with the preconditioned group and maintained
under normoxic conditions for 4 h. Rats were euthanized and
the hearts were removed at 1, 7, and 21 d after HPC. The
myocardial samples were submitted for immunohistochemi-
cal analysis to detect microvascular density with the antibody
against factor-VIII-related antigen. Remaining samples were
submitted for western blot analysis to measure activities of
ERKs with phospho-specific antibody against ERK1/2 and
expression of HIF-1a with HIF-1a antibody. We found that
microvascular density appeared increased by 36.99% and
37.76% in myocardium 7 and 21 d after HPC, respectively.
Western blot analysis showed activated ERKs and expression
of HIF-1a in whole cell extracts from hypoxic preconditio-
ned cardiomyocytes. We conclude that upregulation of
HIF-1a by ERKs mediates angiogenesis of hypoxic precon-
ditioning.
Keywords: Angiogenesis; Hypoxic preconditioning;
Hypoxia-inducible factor-1
Abstract N° B 8
Gene transfer of stromal cell-derived factor-1a
enhances ischemic vasculogenesis and angiogenesis via
VEGF/eNOS-related pathway
Ken-ichi Hiasa, Minako Ishibashi, Kouta Funakoshi,
Yoshiko Ihara, Gang Zhao, Qingwei Zhao, Kisho Ohtani,
Shiro Kitamoto, Kensuke Egashira
Background. – Stromal cell-derived factor-1a (SDF-1a)
is implicated as a chemokine for endothelial progenitor cells
(EPCs). We, therefore, hypothesized that SDF-1a gene trans-
fer would induce therapeutic neovascularization in vivo by
functioning as a chemokine of EPC.
Methods and results. – To examine SDF-1a-induced
mobilization of EPC, we used bone marrow-transplanted
mice whose blood cells ubiquitously express b-galactosidase
(LacZ). We produced unilateral hindlimb ischemia in the
mice and transfected them with plasmid DNA encoding
SDF-1a or empty plasmids into the ischemic muscles.
SDF-1a gene transfer mobilized EPCs into the peripheral
blood, augmented recovery of blood perfusion to the ische-
mic limb, and increased capillary density associated with
partial incorporation of LacZ-positive cells into the capilla-
ries of the ischemic limb, suggesting that SDF-1a-induced
vasculogenesis and angiogenesis. SDF-1a gene transfer did
not affect ischemia-induced expression of vascular endothe-
lial growth factor (VEGF), but did enhance Akt and
endothelial-type nitric oxide synthase (eNOS) activity. Bloc-
kade of VEGF or nitric oxide synthesis prevented all such
SDF-1a-induced effects.
Conclusion. – SDF-1a gene transfer enhanced ischemia-
induced vasculogenesis as well as angiogenesis in vivo
through a VEGF/eNOS-related pathway. This strategy might
become a novel chemokine therapy for next generation the-
rapeutic neovascularization.
Abstract N° B 9
Augmentation of arteriogenesis via cell therapy
J. Herold a, F. Pipp b, Z. Xing c, B. Fernandez b, M. Heil b,
H. Tillmanns a, W. Schaper b, R.C. Braun-Dullaeus d.
a Department of Internal Medicine I/Cardiology, University
of Giessen, Germany. b Max Planck Institute, Bad Nauheim,
Germany. c Department of Pathology, Mc Master
University, Ontario, Canada. d Department of Internal
Medicine II/Cardiology, University of Dresden, Germany
The treatment of vascular occlusive disease is of tremen-
dous clinical importance for alleviation of morbidity and
mortality in the western world. Although some patients have
developed a collateral circulation, the net effect was rarely
adequate to return to normal blood flow. Instead of invasive
bypassing or catheter intervention, cell therapy via monocy-
tes (Mo) transplantation could be used for promotion of
collateral vessel growth. Mo play a key role for the remodel-
ling of a pre-existing arteriole into a collateral artery (ca) by
various arteriogenic cytokines. In this study, we test the
hypothesis that Mo transplantation is able to increase arterio-
genesis and demonstrate the homing of vehicle Mo for a gene
therapeutic approach histochemically. Therefore, Mo were
isolated and intravenously (i.v.) re-injected into rabbits 24 h
after ligation of their femoral artery (n = 6 for each condi-
tion). One week later collateral conductance (CC) was deter-
mined in vivo (CC = flow/mean central pressure–mean
peripheral pressure, ml/min/100 mmHg). Additionally an-
giographic evaluation of ca within the rabbit hind limbs was
done. Transplantation of allogenic Mo (same species) resul-
ted in a 83% rise of CC from 105 ± 20, ca = 11 ± 2 (ligation
without transplantation) to CC = 192 ± 18, ca = 16 ± 1,
P < 0.001 vs. autologous Mo (same animal) (CC = 130 ± 29,
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ca= 11±1). The homing of re-injected Mo was demonstrated
by visualization of LacZ-transduced Mo close to collateral
vessels. Their transplantation after ex vivo adenoviral trans-
duction with GM-CSF was able to efficiently augment arte-
riogenesis (CC = 211 ± 46, ca = 19 ± 2, P < 0.001) in
comparison to control-transduced cells (CC = 122 ± 7, ca =
14 ± 2) being close to values determined in unligated control
vessels (CC = 262 ± 31, ca = 5 ± 1). The observations derived
from our study have the potential to offer a method for
systemic cell administration for transplantation into areas of
arteriogenesis. Obtaining Mo is currently widely available,
all of which makes the ultimate goal of applying this strategy
to humans for therapy of vascular disease eminently attrac-
tive.
Abstract N° B10
Effects of hydrogen peroxide on proliferation and
messenger RNA of MMP-2 and TIMP-2 in vascular
smooth muscle cells
Xiaogang Guo, Junzhu Chen, Furong Zhang, Qianmin Tao,
Jianhua Zhu, Chunmei Cao, Qiang Xia. Department of
Cardiology, The First Affiliated Hospital, Zhejiang
University School of Medicine, Hangzhou, China
To determine whether hydrogen peroxide alters the acti-
vation of transcription of matrix metalloproteinases-2
(MMP-2) and tissue inhibitors of metalloproteinase-2
(TIMP-2) in rat vascular smooth muscle cells (VSMCs), we
measured the proliferation and messenger RNA (mRNA)
levels of MMP-2 and TIMP-2 by using MTT method and
RT-PCR, respectively. We found that hydrogen peroxide at
range of 0.01–200 µM did not, but at more than 300 µM
decreased viability of VSMCs. The OD value in MTT test
was increased by treatment of hydrogen peroxide at 10 µM,
which reached a peak at 24 h and maintained similar level to
48 h. Hydrogen peroxide induced transcription of mRNA of
MMP-2 in dose-dependent and time-dependent manner, and
the peak of MMP-2/beta-actin ratio occurred at 24 h of
incubation, but TIMP-2 mRNA levels were similar during
12–48 h incubation with hydrogen peroxide. The results
indicate that hydrogen peroxide acts as a stimulator for pro-
liferation and transcription of MMP-2 of VSMCs, suggesting
that it may play a role in the vascular remodelling.
Abstract N° B11
Estrogen modulates cardiac mast cell-mediated
extracellular matrix degradation
Jason D. Gardner, Amanda L. Chancey, Gregory L. Brower,
Joseph S. Janicki. Department of Anatomy, Physiology and
Pharmacology Auburn University, Auburn, Alabama, USA
There are fundamental differences between males and
females with regard to susceptibility to heart disease. Al-
though numerous animal models of heart failure have de-
monstrated that premenopausal females are afforded cardio-
protection and therefore fare better in the face of cardiac
disease than their male counterparts, many questions as to
how this occurs still exist. We have shown that increased mast
cell density is associated with adverse ventricular remode-
ling. Also, we have demonstrated that chemically induced
mast cell degranulation with compound 48/80 caused mar-
ked changes in matrix metalloproteinase (MMP) activity,
cardiac collagen structure, and cardiac diastolic function in
male rats. With the known gender differences in cardiac
disease in mind, we sought to examine the effects of chemi-
cally induced cardiac mast cell degranulation in isolated,
blood perfused, functioning hearts of intact females, ovariec-
tomized females (OX), and OX treated with 17b-estradiol
(OX + EST). In response to mast cell degranulation, no
change in cardiac function, MMP-2 activity, or collagen
volume fraction (CVF) was observed in intact females or OX
+ EST. However, a significant rightward shift in the pressure–
volume relationship occurred post-48/80 in OX hearts, ac-
companied by a significant reduction below control in CVF
(0.455 + 0.23 vs. 0.730 + 0.072, P < 0.05), and a significant
132.6% increase in active MMP-2 values over that seen in
intact female hearts post-48/80 (P < 0.05). These findings
indicate that estrogen’s cardioprotective role could be par-
tially mediated by its effects on cardiac mast cells, MMPs,
and the extracellular matrix.
Abstract N° B12
Development and evaluation of matrix-type
transdermal patch for controlled delivery
of carvedilol
S.S. Agrawal, Dipankar, Manoj P. Jadhav. Delhi Institute of
Pharmaceutical Sciences and Research (Formerly,
College of Pharmacy), Pushp Vihar Sector III, New Delhi
17, India
Matrix-type transdermal patches were fabricated using
Chitosan. Patches were fabricated by casting method using
lactic acid. The drug load was adjusted to 0.3%. Patches thus
fabricated were evaluated for drug release using modified
Franz diffusion cell using dorsal part of rattus skin and
Cadaver skin as rate limiting membrane. Patches were also
evaluated for their physico-chemical properties (i.e. thic-
kness, tensile strength, drug load, content uniformity and
physical appearance). The rate of drug release was calculated
as cumulated percentage of drug release and analysed for its
release kinetics. The rate of drug release was found to be
92–99% in 48 h. The release kinetics when statistically ana-
lysed, showed that drug releases from these patches fol-
lowing zero-order kinetics (R = 0.98). Therefore, it may be
possible that optimized patch containing Carvedilol can be
used to deliver Carvedilol in systemic circulation at a
controlled rate up to 48 h. The in vivo studies in rats and
rabbits to evaluate its pharmaco-kinetics parameters are in
progress.
Acknowledgements: Government of NCT of Delhi, India,
AIIMS, New Delhi, Cipla Ltd, Mumbai.
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Abstract N° B13
Cardioprotection in mast cell deficient rats with
chronic volume overload
G.L. Brower a, J.D. Gardner a, J.C. Florek a, M. Holland a,
M. Hauer-Jensen b, J.S. Janicki a. a Auburn University,
Auburn, Alabama, USA. b University of Arkansas for
Medical Sciences, Little Rock, Arkansas, USA
We have previously reported that cardiac mast cell-
mediated myocardial remodelling contributes to the develo-
pment of ventricular dilatation associated with heart failure.
We have also demonstrated that elevations in tumour necro-
sis factor (TNF)-alpha contribute to the adverse myocardial
remodelling in chronic volume overload. In order to further
characterize the role mast cells play in the initial myocardial
remodelling and subsequent development of heart failure,
8-week-old male mast cell deficient (Ws/Ws) and normal
wildtype (WT) rats were divided into three groups as
follows—Sham-operated control, 5 d aortocaval fistula and
56 d fistula groups. In contrast to the significant increase of
120% in left ventricular (LV) matrix metalloproteinase
(MMP) activity in the WT hearts at 5 d post-fistula, MMP-2
activity in the Ws/Ws hearts remained at control levels. LV
levels of TNF were significantly increased sixfold in the WT
hearts, while TNF levels in the Ws/Ws hearts were similar to
control. Consistent with these differences in MMP-2 activity
and TNF levels, serial echocardiography demonstrated signi-
ficant differences in the extent of ventricular dilatation indu-
ced by chronic volume overload. While the LV end diastolic
dimension (LVEDD) was significantly increased by 82%
above baseline in WT hearts at 8 weeks post-fistula, the
LVEDD in the mast cell deficient Ws/Ws hearts was only
37% larger than baseline measurements. These findings are
consistent with our previous observations that cardiac mast
cell degranulation is responsible for the MMP activation,
extracellular matrix degradation and ventricular dilatation
induced by chronic biventricular volume overload. These
findings also suggest that cardiac mast cells regulate activa-
tion of latent TNF in the myocardium and demonstrate that
the mast cells play a crucial role in regulating the myocardial
remodelling responsible for heart failure.
Abstract N° B14
Synthesis and evaluation of new chelators for use as
MMP inhibitors using cardiac cell cultures
David Puerta, Jana Lewis, Micheal Griffin, Ricardo Garcia,
Francisco Villarreal, Seth Cohen. Departments of Chemistry
and Medicine, University of California, San Diego,
California, USA
Matrix metalloproteinases (MMPs) are hydrolytic enzy-
mes involved in the breakdown of connective tissue. MMP
activity is associated with a number of illnesses including
arthritis, cancer, and cardiovascular disease. Compounds that
can inhibit MMP activity may prove to be useful therapeutic
agents. The MMP active site contains a Zn(II) ion bound to
three histidine ligands with open coordination sites for subs-
trate binding. Our research program is focused on developing
novel MMP inhibitors and exploring the binding modes of
known inhibitors. Using hydrotris(pyrazolyl)borate (Tp)
model complexes the interaction of MMP inhibitors with the
enzyme has been reproduced. This strategy has revealed
several chelators that may be promising compounds for
MMP inhibition. These lead compounds were evaluated in an
MMP activity assay that utilizes a fluorescent peptide subs-
trate. The results of these assays indicate that the newly
identified ligands have activities ranging from 3- to 600-fold
more potent than the hydroxamic acid ligands used in most
clinically tested MMP inhibitors. These activities and lack of
evidence for cytotoxicity were validated using cultures of rat
cardiac fibroblasts. We propose that these new chelators
represent a significant step toward producing improved, next-
generation MMP inhibitors.
Abstract N° B15
Recellularisation of photo-oxidised pericardium using
immature foreign body reaction in the construction of
a tissue engineered heart valve
G. De Visscher, E. Verbeken, C. Van Kerrebroeck,
P. Holvoet, W. Flameng. CEHA, KULeuven, Belgium
Foreign body reaction (FBR), a mechanism encapsulating
non-degradable implants, deposits a layered structure of
macrophages, fibroblasts and mesothelium. We hypothesise
that the immature stage of FBR can be used to repopulate
durable biological matrix material for construction of a tissue
engineered heart valve. Eight sheep received an intra-
peritoneal implant of an acellular photo-oxidised bovine pe-
ricardium patch suspended in a stainless steel cage. After 3 d,
the retrieved patch showed the presence of both macrophages
and a blast-like vimentin positive cell population. From this
material, a valve was constructed and immediately implanted
in the pulmonary artery. Additional sheep served as control,
receiving an identical valve construct without prior intra-
peritoneal cell seeding. Weekly echocardiography showed
normal functioning valves. The control and four sheep were
sacrificed at day 8, the remaining four at 1 month. The
explants were fixed for immunohistochemistry (IHC) and
matrix stability (sirius red) study. IHC shows a clear in- and
overgrowth of cells in/on the photo-oxidised pericardium
with a two- to fourfold increase in cell number with time in
situ. Positive for both vimentin and a-smooth muscle actin,
but negative for heavy chain myosin; we conclude that the
cells are of the (myo)fibroblast phenotype. Additionally IHC
showed a limited but progressive endothelialisation of the
valve surface. Specific IHC indicated a trivial presence of
macrophages in the overgrowth and complete absence in the
original matrix. The original matrix showed remodelling
over time: at 8 d the total collagen markedly increased in both
the wall and leaflet, but normalised at 1 month. The amount
of organised collagen diminished gradually in parallel with
the increased recellularisation. We conclude that by this
method we have repopulated the valve with (myo)fibroblast,
i.e. its original interstitial cells, and induced spontaneous
endothelialisation without causing chronic macrophage infil-
tration or matrix degeneration.
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Abstract N° B16
An attempt to develop an experimental model of
rheumatic heart valve in vitro using tissue engineering
techniques
Anil Grover a, Archana Bhatnagar a, Eva Medina b,
Manfred Rhode b, Shamim Ahmad a, G.S. Chhatwal b.
a Department of Cardiology (Division of Experimental
Medicine and Biotechnology), PGIMER, Chandigarh, India.
b Department of Microbial Pathogenesis, GBF, Germany
Tissue engineering of heart valve represents a new expe-
rimental concept to improve current mode of therapy in
rheumatic valvular heart disease and to develop an experi-
mental model of rheumatic heart disease (RHD) in vitro. For
the treatment of heart valve disease, mechanical or bio-
prostheses are currently in use. But the drawbacks of
glutaraldehyde-fixed tissue valves or mechanical valves in-
clude the short durability or the need for life-long anticoagu-
lation, respectively. Both have in common the inability to
grow, which makes valvular heart disease problematic espe-
cially in children. The aim of the present study is to develop a
new methodology for the tissue engineered heart valve com-
bining human cells and xenogenic acellularized matrix. Por-
cine aortic as well as pulmonary valves were acellularized by
deterging cell extraction using Triton. Endothelial cells as
well as myofibroblast cells were isolated in parallel from
human saphenous veins and expanded in vitro. Specimens of
the surface of the acellular matrix will be seeded with myo-
fibroblast cells and endothelial cells. Analysis of acellularity
was performed by light microscopy and scanning electron
microscopy. Cell viability following seeding will be assayed
by fluorescence staining of viable cells. The tissue-
engineered valve then will be cultured with sensitized serum
and lymphocytes of RF/RHD patients to see the pathological
lesion. The acellularization procedure resulted in almost
complete removal of the original cells while the 3D arrange-
ment of the matrix fibers was grossly maintained. The por-
cine matrix could be seeded with in vitro expanded human
myofibroblast and endothelial cells and maintained in culture
for up to 3 d to document the formation of confluent cultures.
The xenogenic matrix will be reseeded with human endothe-
lial and myofibroblast cells. This approach may eventually
lead to the engineering of tissue heart valves repopulated
with the patient’s own autologous cells.
Abstract N° B17
Different responses to inflammation of left- and
right-sided heart valves
Robert Bauernschmitt, Joachim B. Grammer, Bo Zhao,
Walter B. Eichinger, Rüdiger Lange. German Heart Center,
Munich, Germany
Infective endocarditis (IE) rarely involves right-sided
heart valves as compared to left-sided valves. One reason
may be lower haemodynamic stress; however, we hypothesi-
zed that there may be a difference in immune response. In our
established rabbit model of IE, surgically-induced valve in-
sufficiency and bacterial inoculation (Staphylococcus
aureus) were performed. Untreated animals, animals with
bacteraemia only and with surgery only served as controls.
Using semi-quantitative RT-PCR, mRNA expression of the
macrophage colony-stimulating factor (MCSF-1), the
MCSF-1 receptor c-fms and of b1-integrin on valve tissues
was analysed for comparison of left- and right-sided heart
valves. MCSF-1 increased on mitral and tricuspid valves
after the surgical procedure alone (P < 0.05). Bacterial ino-
culation resulted in a further increase of MCSF-1 on the
mitral (P < 0.05), but not on the tricuspid valve. Correspon-
ding data were obtained for the aortic and pulmonary valves
(analyses performed on pooled valves). Comparison of b1-
integrin-expression (pooled tissue) gave evidence of downre-
gulation in right-heart valves, while left-heart valves again
remained unaffected. c-fms was equally decreased on both
sides of the heart after the surgical trauma; bacteraemia did
not induce additional changes. Our results suggest a more
pronounced inflammatory response to endothelial trauma
and bacteraemia on left-sided heart valves. The lack of b1-
integrin downregulation on left-sided heart valves may faci-
litate fibronectin binding and bacterial growth, thus promo-
ting the formation of vegetations. We conclude, that there is a
different immune response to bacterial infection between
right and left heart.
Abstract N° B18
Impacts of hemodynamic factors on the myocardium
after intra-abdominal heart transplantation in mice
A. Gutsol, C. Scudamore, R. Guzman, M.H. Moghadasian.
Departments of Human Nutritional Sciences, Surgery and
NCARM, University of Manitoba, Winnipeg, Canada
Mouse intra-abdominal heart transplantation (IAHT) mo-
del is increasingly being used to understand the immunologic
bases of allograft rejection. However, little is reported on
myocardial adaptation to altered hemodynamic factors, par-
ticularly over a long period of time. IAHT was performed in
mice. Graft function was confirmed by palpation and perio-
dic echocardiography. At various time points, grafts were
removed for routine histological evaluation. After 3 months
of transplantation, some of the grafts had prominent concen-
trating hypertrophy of both right and left ventricles. Occasio-
nally, the left ventricle cavity contained fibrous tissue most
likely as a result of a thrombotic mass organization, which
often was complicated with calcification. In some cases,
fibrotic tissue was moderately spread into the myocardium.
Some hearts had dilatation of the right ventricle cavity with
or without thrombus formation and local aneurism. Accumu-
lation and infiltration of inflammatory cells were observed to
a different extent primarily at the level of pericardium, some-
times spreading into the myocardium and perivascular re-
gions. No advanced atherosclerotic lesion was observed in
the major coronary arteries. Altered hemodynamic parame-
ters after intra-abdominal heart transplantation may result in
myocardial alterations. More studies are needed to explore
the mechanisms of these tissue modifications.
Supported by the Heart and Stroke Foundation of Canada.
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Abstract N° B19
Successful repair of acute myocardial infarction by
skeletal muscle myoblasts
M. Horackova a,*, R. Arora a, R. Chen a, J.A. Armour a,
P.A. Cattini b, R. Livingston a, Z. Byczko a. a Faculty of
Medicine, Dalhousie University, Halifax, Canada. b
Department of Physiology, University of Manitoba,
Winnipeg, Canada. * Corresponding author.
The adult heart injured by an ischemic episode has a
limited capacity to regenerate. We administered skeletal
myoblasts to assess their suitability for repair of acute myo-
cardial infarction. Using confocal fluorescent microscopy
and a variety of specific immunomarkers and echocardiogra-
phy we have provided anatomical evidence for the viability
and the long-term survival of these cells and the possible
functional benefits of such implants. All cells were transfec-
ted with adenovirus containing b-galactosidase gene such
that their migration from the site of injections could be
traced. Skeletal myoblasts (Mb) isolated from adult guinea-
pigs and inbred rats (M. soleus) were expanded in vitro. Most
(95%) of the transfected Mb were identified 7 d post-
transplantation mainly in the infarcted area. During this time
and thereafter they proliferated and differentiated into myo-
tubes forming new regularly striated myofibers which occu-
pied most (50–70%) of the infarcted area by the 2–3 week.
These newly formed myofibers maintained their skeletal
muscle origin evidenced by their expression of myogenin
and fast skeletal myosin. With time, skeletal phenotype ap-
peared to downregulate, while the Mb partially transdifferen-
tiated into cardiac phenotype indicated by labeling for
cardiac-specific troponin T and cardiac myosin heavy chain
(MHC). At the third week post-transplantation, the new myo-
fibres formed apparent contacts with the native cardiomyo-
cytes via aputative gap-juntions@ expressing connexin 43.
The myocardial performance of the animals successfully
transplanted with myoblasts was significantly improved.
They remained anatomically and functionally unchanged for
12 weeks post-transplantation without any sign of atrophy.
Abstract N° B20
Fibre death and regeneration in skeletal
muscle following exposure to elevated catecholamines
G. Ellison a, L.-B. Tan b, D. Goldspink a. a Sports and
Exercise Sciences, John Moores University,
Liverpool, UK. b Vascular Medicine, University of Leeds,
Leeds, UK
High levels of catecholamines are found in patients with
heart failure and cachexia and may be causally linked to the
muscle wasting. We have recently shown that a single injec-
tion (s.c.) of adrenaline or isoprenaline (0.01–20 mmol/kg) in
vivo causes myocyte apoptosis and necrosis in the soleus
muscle of male Wistar rats (205 ± 7 g).Animals were killed at
various times over the next 28 d, the soleus muscle isolated,
cryosectioned and the total number of normal, dying and
regenerating fibres quantified using image analysis (Fig. 1).
Data were analysed using one-way ANOVA. Seventeen per-
cent of the total number of fibres were injured and lost 5 d
after exposure to the catecholamine. However, newly regene-
rating fibres (identified using an antibody against
embryonic/neonatal myosin) were soon evident (solid sym-
bols), with these restoring the full complement of fibres
within 28 d. The time course of these events, are shown
below.
Abstract N° B21
Obstruction of aortic valve using a left ventricular
catheter in a mouse model
Kushal J. Dighe, Mathew Faircloth, Gajen S.
Kanaganayagam, Michael S. Marber. Department of
Cardiology, St Thomas’ Hospital, King’s College London,
UK
Pressure volume loops generated using a conductance
catheter are increasingly used to measure cardiac contracti-
lity in mice. Catheters are introduced in the left ventricle
(LV) either by LV puncture or following carotid (ICA) can-
nulation by crossing the aortic valve (AV). We questioned
whether the catheter, although small (0.47 mm diameter,
0.17 mm2 cross-section area), might cause obstruction when
placed across the murine AV (0.88 + 0.05 mm diameter, 0.62
± 0.07 mm2 area in C57Bl/6 mice 25–33 g), using the ICA
route. We simultaneously measured aortic pressure (AP)
using left ICA cannulation and LV pressure (LVP) using
either direct LV puncture (uncrossed group, n = 6) or using
right ICA cannulation (crossed group, n = 6).
Results obtained:
Thus, no statistically significant differences were seen
between the groups. Furthermore, the trend toward an in-
crease AV gradient in the crossed group is of no functional
significance. We conclude that this technique does not com-
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Fig. 1. Fibre loss and regeneration with time. Viable ([) and regenerating
(■ ) fibres. Mean ± SEM, n = 5–6, *P < 0.05
Parameters Uncrossed Crossed P-value, t-test
Body weight (g) 28.8 ± 1.0 29.3 ± 1.0 NS
Heart rate (per min) 369 ± 16 373 ± 6 NS
Stroke volume (µl) 5.87 ± 0.86 4.14 ± 0.60 NS
Cardiac output (ml/min) 2.21 ± 0.40 1.54 ± 0.21 NS
LVP–AP (mmHg) 5.30 ± 1.53 11.19 ± 3.77 NS
NS: Not significant.
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Abstract N° B22
Sheng Mei for mild to moderate cardiorenal syndrome
in heart failure
Xianghong Zeng, Xiangji Zeng, Yunyun Li, Yunhuan
Huang, Yonghua Zeng, Wenzeng Wu. Chengdu University,
Chengdu No. 2 Hospital, Chengdu Red Cross Hospital and
Dujiangyan Municipal People’s Hospital, China
Cardiorenal syndrome in chronic heart failure is recently
recognized as the most common reason that symptoms can-
not be relieved despite aggressive management. Our previous
observation found that 1 month Sheng Mei therapy for car-
diorenal syndrome is safe (Circulation (2002) 106(19) II-
352). We hypothesised that short-time Sheng Mei treatment
for cardiorenal syndrome may show both efficacy and safety.
Methods and results. – The study in 127 patients with
mild to moderate cardiorenal syndrome and class III or VI
and LVEF <25 was performed. They were randomly divided
into Sheng Mei group (60 ml/d n = 64) and placebo (n = 63).
Sex, age, serum creatinine, LVEF, 6 min walking distance
and MLWHF scores between the two groups were similar.
Six minute walk test, LVEF, MLWHF score and serum crea-
tinine were assessed at beginning and after 6 months of
treatment. Serum creatinine level in Sheng Mei group de-
creased slightly but increased in placebo (P < 0.005). LVEF,
6 min walking distance and QOL in Sheng Mei group were
more remarkable than those in placebo (all P < 0.01). There
was a significant difference in mortality between two groups
(four patients in Sheng Mei died vs. nine died in placebo).
Conclusions. – Sheng Mei may improve cardiac function,
exercise capacity and QOL without increasing serum creati-
nine and decrease mortality in patients with mild to moderate
cardiorenal syndrome during 6 month treatment.
Abstract N° B23
Structural differences in stable and unstable coronary
artery atheromatous plaque
M. Lutaj, A. Lomakovsky, R. Abutalipov, O. Nemchyna.
Strazhesko Institute of Cardiology, Kiyiv, Ukraine
The aim of our study was the establishment of structural
differences between stable and unstable atheromatous plaque
(AP). Coronary segments (n = 146) were harvested from the
hearts of 94 patients who died of coronary artery disease. All
segments were studied by morphological and morphometri-
cal methods. Presence of erosion, dystrophic and necrotic
signs with fissure or rupture of fibrous cap (FC), intraplaque
hemorrhage, and parietal or obstructive thrombosis was
considered as morphological features of AP instability. We
estimated the intensity of inflammtory cell infiltration (CI) of
FC using ocular net with 280th magnification in 5–10 fields
of vision. Intensity of CI was divided into four types—mild,
moderate, intensive and severe. Thickness of FC was esta-
blished by ocular micrometer. It was considered that thick FC
formed >30% of the diameter of AP, and thin FC >20%.
Destruction of FC of instable AP with fissure from the direc-
tion of vessel lumen occurred in 36.5% of cases, with
rupture—in 50.0%, with fissure from the direction of lipid
core—in 8.5%. Our data suggest that severity of destruction
depends on FC thickness (P < 0.025), rupture was more
frequent in AP with thin FC (61.4%), and fissure was more
frequent for thick FC (56.0%). There was no correlation
between level of inflammatory CI and thickness of FC, both
for stable and unstable AP. Instable AP with thin FC revealed
mild and moderate CI in 51% of cases, intensive and
severe—in 49%, those with thick AP—in 48% and 52%
correspondently. Instability of AP was concerned with disor-
ganization of connective tissue and presence of necrotic
focuses in FC (P < 0.001). Disorganization of connective
tissue was not related to intensity of CI (P > 0.1). Reliable
difference in quality characteristic of CI (ratio
monocyte/lymphocyte) of FC for stable and instable AP was
discovered (P < 0.001). In FC of stable AP prevalence of
lymphocytes was observed in 51.4% of cases,
monocytes—in 5.7%. For instable AP monocyte prevalence
in 30.6%, and lymphocyte prevalence—in 26.1% of cases
was established.
Abstract N° B25
Total circulation time in heart failure patients
measured using an acetylene technique
N. Morris a, K. Beck b, E. Snyder b, K. O’Malley b,
L. Haseler a, D. Schneider a, B. Johnson b. a Heart
Foundation Research Centre, Griffith University, Gold
Coast, Australia. b Division of Cardiovascular Diseases,
Mayo Clinic, Rochester Minnesota, USA
While exercise testing represents an important prognostic
tool in patients with chronic heart failure (CHF) it provides
only a broad index of the cardiovascular response. Patients
with CHF have traditionally been thought to have a blunted
cardiovascular response to exercise. Circulation (circ) time
may provide a further index of the cardiovascular impairment
to exercise in CHF. Traditionally circ time has required
arterial blood sampling and the introduction of a labeled dye.
We hypothesized that a mean circ time could be estimated
from the reappearance of end tidal acetylene (PetC2H2) in the
expired air following a single inhalation. Moreover, we hypo-
thesized that there would be an attenuated fall in circ time
with progressive exercise in patients with CHF, relative to
healthy subjects. Four healthy subjects (39 ± 11 years,) and
four gender-matched CHF patients (46 ± 14 years) comple-
ted two exercise tests during which circ time (test 1) and
cardiac output (CO, test 2) were measured. The circ time and
CO were measured at four exercise intensities 25%, 50%,
75% and 100% of peak. CO was measured using the open
circuit C2H2 washing technique. In the healthy subjects, circ
time decreased and CO increased from rest (circ time = 42 ±
3 s, CO = 4.5 ± 0.5 l min–1) to peak exercise (circ time = 19 ±
1 s, CO = 19.2 ± 0.7 l min–1). Similarly, in CHF patients circ
time decreased and CO increased from rest (circ time = 48 ±
3 s, CO = 3.6 ± 0.7 l min–1) to peak exercise (circ time = 19 ±
1 s, CO = 8.8 ± 1.6 l min–1). At a matched CO, circ time was
longer in the healthy subjects (P < 0.05). This study demons-
trated that circ time can be measured using the reappearance
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of PetC2H2 and at a similar CO during exercise, CHF patients
had a faster circ time, possibly suggesting an enhanced peri-
pheral vasoconstriction.
Supported by HFRC, Griffith University and HL71478.
Abstract N° B26
Vascular smooth muscle role on right
ventricular-arterial coupling
J. Grignola a, D. Bia a, D. Craiem b, F. Ginés b,
R. Armentano b. a Department Physiology, Faculty of
Medicine, Uruguay. b Favaloro University, Argentina
We analyzed the effects of the vascular smooth muscle
(VSM) activation to right ventricular (RV) afterload and
ventricular–arterial coupling. Pulmonary flow, pressure and
diameter and biventricular pressures were measured in six
anesthetized sheep.Acute pulmonary hypertension was indu-
ced by phenylephrine (AH) and a high-pressure (PH) mecha-
nical occlusion. The pulmonary artery (PA) viscous/elastic
indexes ratio (g/E) was obtained to quantify the arterial wall
buffering function. Total vascular resistance (Zo) characteris-
tic impedance (Zc), and RV hydraulic power (total, WT and
oscillatory, WO) were quantified (flow-pressure curves). RV–
arterial coupling was assessed by the efficiency transmission
ratio (ETR) and transpulmonary efficiency (TPE). Total pul-
monary compliance (CT) was obtained by the diastolic time
constant.
During acute pulmonary hypertension the VSM activation
enhanced both, local and global buffering function of pulmo-
nary circulation and decreased the pulsatile component of the
RV hydraulic load, resulting in an improved coupling
between the RV and the hypertensive pulmonary circulation.
Abstract N° B27
Differences of coronary microvascular lesion in
coronary heart disease and hypertension alone
Xiaoying Li *, Rui Li, Wen Yu, Huaiyin ShI, Lixin Wei.
Department of Geriatric Cardiology, Chinese PLA General
Hospital, Beijing, 100853, China. * Corresponding author.
The purpose of this study is to observe the characteristics
and difference of coronary microvascular lesion (CML) in
the autopsied elderly cases with essential hypertension
(EHT) and coronary heart disease (CHD) with the same
degree of left ventricular wall thickness (LVWT). A retros-
pective study was performed in 246 cases over 60 year old of
EHT, CHD, EHT with CHD and 26 normal cases as control
(CTRL) out of 3195 consecutive autopsied cases. The arte-
riole with the diameter of 10–60µm and the capillary in
muscular layer were shown by the methods of HE, Elastic
fiber + VG staining and immunohistochemistry of CD31.
Quantitative measurements on the arteriole density (AD), the
ratio of arteriole wall and lumen (RWL), and the capillary
density (CD) were performed by light microscope observa-
tion and image analysis by computer. According to LVWT,
the cases were divided into four degrees from I to IV, which
were I–IV degrees in EHT, CHD and EHT with CHD groups
and I degree in CTRL group, respectively. SAS system was
used for the statistic analysis. The AD and RWL increased
while CD decreased significantly with the aggravation of
LVWT in EHT group (P < 0.05–0.0001); there was a
similar but more severe change in the group of EHT with
CHD (P < 0.001–0.0001); the AD increased (P < 0.001),
while RWL and CD did not change significantly in CHD
group. In EHT and CHD groups, the similar change of
CML appeared in AD and different changes appeared in
RWL and CD. The CML was much more severe in the group
of EHT with CHD. It was concluded that the CML might be
one of the main causes for decreased coronary flow reserve
and myocardial damage in EHT and EHT with CHD.
Abstract N° B28
Expression of a1-adrenoceptor mRNA in the human
cystic artery: correlation with functional responses
K. Bagot a, M. Mosley b, M. Holbrook b,
R. Chess-Williams a. a University of Sheffield, Sheffield,
UK. b Pfizer Sandwich Laboratories, Kent, UK
The a1-adrenoceptor (a1-AR) subtype (a1A,a1B,a1D), res-
ponsible for vasoconstriction is unclear since expression
varies between species and vascular bed. This study aims to
identify the a1-AR subtypes responsible for vasoconstriction
of the human cystic artery and look for correlation at the
mRNA expression level. Vessels obtained from cholecystec-
tomy operations were snap-frozen or used immediately. Iso-
lated tissue bath experiments were used to generate subtype
a1-AR selective antagonist affinities (pKB values), which
were determined from shifts in individual concentration–
response curves (CRCs) to phenylephrine (PE). RNA was
extracted from the vessels and mRNA expression levels were
obtained using quantitative real-time polymerase chain reac-
tion (qRT-PCR). The results are presented as mean ± SEM,
with n ≥ 3. a1-AR antagonists produced parallel rightward
shifts of PE CRCs without affecting maximum responses,
and with Schild slopes not differing from unity. The a1A-AR
antagonists RS100329 and 5-methylurapidil had high affi-
nity values of 9.88 ± 0.13, and 8.21 ± 0.26, respectively. The
CTL PH AH
PAmean pressure (mmHg) 14.5 ± 2 21.9 ± 1.5 a 19.9 ± 2.7 a
PAmean diameter (mm) 23.0 ± 2.3 23.9 ± 2.2 a 22.3 ± 2.4 a,b
E, (mmHg/mm) 5.5 ± 1.2 9.3 ± 3.5 a 6.4 ± 1.2 b
g, 10–2 (mmHg s/mm) 4.9 ± 0.6 4.7 ± 0.5 7.6 ± 0.7 a,b
g/E, 10–3 s 9.2 ± 1.7 5.4 ± 1.8 a 12 ± 1.4 a,b
Zo, (dyn s/cm5) 595 ± 137 934 ± 275 a 965 ± 230 a
Zc, (dyn s/cm5) 82 ± 21 231 ± 90 a 80 ± 26 b
CT, (ml/mmHg) 2.0 ± 0.2 1.0 ± 0.3
a 1.5 ± 0.1 a,b
WO/WT, (%) 11 ± 2.6 21 ± 2.2
a 13 ± 3.6 b
ETR, (%) 45 ± 8.9 69 ± 12 a 35 ± 16
TPE, (ml mW/min) 15.2 ± 1.2 10 ± 3 a 10 ± 2.7 a
Mean ± S.D., n = 6.
a P < 0.05 vs. CTL.
b P < 0.05 vs. PH, ANOVA.
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a1D-AR antagonist BMY7378 had a low affinity (5.90 ±
0.19). The a1-AR antagonist prazosin had a high affinity
(9.52 ± 0.12). The artery affinity values correlated best with
the values reported for the cloned a1A-AR. From the qRT-
PCR total mRNA copy number for the three a1-AR subtypes
was 1.734, 383 ± 561, 807 with the a1A mRNA making up
69.7 ± 19.7%, a1B 30.22 ± 18.7% and a1D 0.06 ± 0.02% of
the total a1-AR mRNA copy number. In conclusion the cystic
artery has high a1-AR mRNA levels with a predominance of
the a1A-AR subtype. The a1A-AR subtype was also found to
mediate vasoconstriction of this artery in vitro.
Abstract N° B30
Interstitial effects account for the ability of aldosterone
receptor blockade to prevent
b-adrenoreceptor-mediated cardiac dilatation
D. Veliotes, D. Badenhorst, O. Osadchii, A.J. Woodiwiss,
G.R. Norton. Cardiovascular Pathophysiology and
Genomics Research Unit, School of Physiology, University
of the Witwatersrand, South Africa
Cardiac dilatation is an important determinant of pump
dysfunction in cardiac disease. Although myocardial inters-
titial changes are suggested to be an important mechanism by
which aldosterone receptor blockade reduces cardiac cavity
dimensions in cardiac disease, there is no direct evidence to
support this hypothesis. We therefore evaluated the impact of
spironolactone (SPIRO), an aldosterone receptor antagonist,
on chamber remodelling and the potential mechanisms the-
reof in a rat model of cardiac dilatation (b-adrenoreceptor
mediated). The effect of SPIRO (80 mg kg–1 d–1) on left
ventricular (LV) cavity dimensions, myocardial function and
interstitial changes was assessed in 14 month old sponta-
neously hypertensive rats (SHR) receiving isoproterenol
(ISO) at 0.04 mg kg–1 d–1 for 4.5 months. ISO administration
resulted in an increase in 24 h urinary aldosterone excretion,
enlarged cavity dimensions, produced a right shift in LV
end-diastolic (LVED) pressure–internal diameter and LVE-
DP–LVED volume relations, decreased relative wall thic-
kness despite augmenting LV hypertrophy, reduced collagen
cross-linking and increased total and non-cross-linked myo-
cardial collagen concentrations. ISO altered neither cross-
linked collagen concentrations nor intrinsic myocardial sys-
tolic function in SHR. SPIRO prevented ISO-induced
increases in total and non-cross-linked myocardial collagen
concentrations and chamber remodelling, but failed to mo-
dify blood pressure, cross-linked collagen concentrations, or
intrinsic myocardial systolic function. These results suggest
that myocardial interstitial changes are important in media-
ting the beneficial effects of aldosterone receptor blockade
on LV dilatation.
Abstract N° B31
Interstitial changes are a critical mechanism mediating
b-adrenoreceptor-induced cardiac dilatation
A.J. Woodiwiss, D. Badenhorst, D. Veliotes, O. Osadchii,
G.R. Norton. Cardiovascular Pathophysiology and
Genomics Research Unit, School of Physiology, University
of the Witwatersrand, South Africa
b-Adrenoreceptor (b-AR) activation is an important deter-
minant of adverse chamber remodelling. The critical mecha-
nisms responsible for b-AR-mediated cardiac dilatation are
however unclear. We evaluated the mechanisms by which
chronic b-AR activation induces left ventricular (LV) dilata-
tion. The effect of isoproterenol (ISO, 0.04 mg kg–1 d–1 from
14 to 18.5 months of age) on LV cavity dimensions, systolic
chamber and intrinsic myocardial function, interstitial pro-
perties, diastolic pressure–volume relations, necrosis, apop-
tosis and myocardial noradrenaline (NA) release was as-
sessed in spontaneously hypertensive rats (SHR). At
18.5 months of age SHR had LV end-diastolic (LVED) dia-
meters, LVED pressure–internal diameter relations, LVED-
P–LVED volume relations, systolic chamber and myocardial
function similar to that noted in Wistar Kyoto controls
(WKY). However, myocardial stiffness, relative wall thic-
kness, myocardial NA release, collagen cross-linking, total
and non-cross-linked myocardial collagen concentrations,
pathological score and the percentage of myocytes with
apoptosis was increased in SHR at 18.5 months. ISO admi-
nistration to SHR, but not to WKY resulted in enlarged cavity
dimensions, a right shift in LVED pressure–internal diameter
and LVEDP–LVED volume relations, decreased relative wall
thickness despite augmenting LV hypertrophy, reduced col-
lagen cross-linking and increased total and non-cross-linked
myocardial collagen concentrations. However, ISO adminis-
tration to SHR failed to alter blood pressure, heart rate,
myocardial NA release, cross-linked myocardial collagen
concentration, pathological score, percentage of myocytes
with apoptosis, or intrinsic myocardial systolic function in
SHR. These results suggest that myocardial interstitial chan-
ges are a critical mechanism mediating b-AR-induced LV
dilatation.
Abstract N° B32
Effect of histamine on mesenteric microcirulation,
measured by intravital microscopy
M. Bajpai, N. Verma. Department of Physiology,
K.G. Medical University, Lucknow, India
Using in vivo intravital microscopy, we examined the role
of histamine on mesenteric microcirculation. The present
experiments were carried out on 25 male Sprague–Dawley
rats anaesthetized by subcutaneous administration of 1.25 ml
of 20% solution of Urethane per 100 g body weight of animal
(1) and prepared for in vivo intravital microscopy of mesen-
teric microcirculation. The internal diameter (i.d.) of the
terminal arterioles (TA) as measured through a precalibrated
micrometer eye-piece fitted to the binocular microscope
(Hertell and Reuss) was found to be 18–23 µm (microns),
these TA branch out to the capillaries of 4–9 µm. One milli-
molar solution of histamine in modified tyrode solution pH
7.4, was topically applied on the preparation and the i.d. of
the vessels was measured to know the latency and magnitude
of the response, any change in i.d. of the vessels was ex-
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pressed as the percentage of control, the vascular flow was
visually recorded. Soon after application (10–20 s) the arte-
rioles were found to be in dilated state, and the i.d. became
almost twice the control diameter between 80 and 100 s. This
gradually approached the control diameter in 5 min. In most
instances the number of dormant capillaries increased by
50–60%, the flow rate in the active capillaries also substanti-
ally increased. The effect presumably appears to be either a
direct effect on histamine receptors or on the specific ion-
channels, thus bringing about the relaxation of the smooth
muscles of the terminal arterioles. It seems that the local
regulatory mechanisms like the hormones and transmitters
are of greater value than the enteric neural regulation alone.
The possibility that the specific histaminergic receptors are
present on intestinal microcirculation has not been explored
in the current work, as it requires rather more comprehensive
experimental work.
Abstract N° B33
Increases in leukocyte CD antigen expression during
cardiopulmonary bypass in patients undergoing heart
transplantation
Rodney Lui a, Sean Lal a, Lisa Nguyen b, Peter Macdonald
c, Gareth Denyer b, Cristobal dos Remedios a. a Institute for
Biomedical Research, University of Sydney, Sydney, NSW,
Australia. b School of Microbial and Biochemical
Sciences,University of Sydney, Sydney, NSW, Australia. c
Heart and Lung transplant Unit, St. Vincent’s Hospital,
Darlinghurst, NSW, Australia
Cardiopulmonary bypass (CPB) is essential in heart trans-
plantation surgery and is also associated with a post-
operative inflammation (increases in IL-8, TNFa and cluster
of differentiation (CD) antigens) in coronary artery bypass
procedures. We have developed a novel antibody array that
can simultaneously measure the expression of 72 CD anti-
gens on isolated leukocytes. The array compares the changes
in leukocyte CDs isolated from a 5 ml blood samples from 12
heart transplant patients. A preoperative blood sample acted
as a baseline and was compared to a second sample taken
about 2 h at the end of CPB. Two samples from lung trans-
plantation patients where CPB was not used acted as
controls. No previous studies have examined changes in the
expression so many CD antigen during heart transplantation.
In effect, the array data comprise the immunophenotype of
the patient. We find increased expression of 10 CD antigens
in leukocytes from all patients between these two samples.
Detailed clinical data were obtained to evaluate the effects of
epigenetic factors (smoking, diet, drinking, and medications)
on the CD expression. This is the largest CD expression
profiling of patients with end-stage heart failure undertaken
so far. It provided us insights into the nature of inflammation
associated with CPB.
Abstract N° B34
Changes in CD antigen expression in on-pump and
off-pump coronary artery grafting surgery
Sean Lal a, Paul Bannon b, Lisa Nguyen a, Gareth Denyer a,
Cris dos Remedios a. a University of Sydney, Sydney, NSW,
Australia. b The Baird Institute, Sydney NSW, Australia
Coronary artery grafting surgery may be undertaken with
(on-pump) or without (off-pump) cardiopulmonary bypass.
Following on-pump surgery a systemic post-operative in-
flammatory response is often observed. This manifests as an
increase in pro-inflammatory proteins like interleukin-8 and
tumour necrosis factor accompanied by increases in neutro-
phil populations and increased expression of cluster of diffe-
rentiation (CD) antigens The cause of this inflammation has
been attributed to the activation of complement and leuko-
cyte mediated inflammatory pathways via the extracorporeal
circuit. However, following off-pump surgery a similar but
less intense systemic inflammatory response is also observed
despite the absence of cardiopulmonary bypass. Clearly
there is contention as to the cause of this inflammatory
response observed in both forms of cardiac surgery. Previous
studies have measured pro-inflammatory proteins in serum
as markers of inflammation following cardiopulmonary by-
pass. Others have measured the expression of CD antigens on
leukocytes as possible inflammatory indicators, though these
studies were limited to examining three–four CD antigens
simultaneously. We have developed a novel antibody array
that is able to measure changes in the expression of 72
different CD antigens simultaneously. The present study re-
presents the first large-scale analysis of changes in CD anti-
gen expression in on-pump and off-pump coronary artery
grafting surgery.
Abstract N° B35
Improved vein graft patency using a ‘no-touch’
technique is due to preserved endothelial nitric oxide
synthase
M.R. Dashwood a, R. Anand a, A. Dooley a,
Mats Karlsson b, D. Filbey b, DSR Souza b. a Royal Free and
University College Medical School, London, UK. b Örebro
University Hospital, Örebro, Sweden
The saphenous vein (SV) is the most commonly used
conduit for coronary artery bypass surgery (CABG) but over
50% of grafts fail within 10 years. In conventional CABG the
SV is exposed to surgical trauma during harvesting. A mar-
ked improvement in graft patency has recently been descri-
bed using a no-touch technique (NT) of CABG where the SV
is removed with minimal damage. Here, under local ethics
committee approval and patients’ informed consent we have
used segments of conventional and NT SV for the localisa-
tion and assessment of endothelial nitric oxide synthase
(eNOS) using immunohistochemistry and western blotting.
The ability of SV to release NO was also studied using the
citrulline assay. Western blot analysis revealed that eNOS
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expression in conventional SV was reduced compared to NT
vein segments (P < 0.05). Immunohistochemical studies
showed that this was due to denudation of the luminal endo-
thelium as well as damage to the tunica adventitia, both
structures that are unaffected in NT CABG. Using the citrul-
line assay the ability of conventional SV to release NO was
reduced by approximately 80% compared with NT SV. These
results show that eNOS associated with the luminal endothe-
lium and endothelial cells of microvessels and nerves within
the adventitia of SVs are removed or damaged during
conventional CABG. Since the NT technique is atraumatic
the SV retains its normal architecture. The preservation of
eNOS in such veins used for CABG maintains the vessel’s
ability to generate NO and plays a central role in the in-
creased graft patency described using NT surgery.
Abstract N° B36
Telomerase in end-stage heart failure
Shih-Chi Liu a, Shoei-Shen Wang a, Mu-Zon Wu a,
Deng-Chyang Wu b, Fang-Jung Yu b, Wen-Jone Chen a,
Meng-Fen Yu c. a National Taiwan University Hospital,
Taipei, Taiwan (S-C Liu; S-S Wang; M-Z Wu; S W-J Chen).
b Kaohsiung Medical University Hospital, Kaohsiung,
Taiwan (D-C Wu; F-J Yu). c Chang Gung
Heart failure can result from various cardiovascular di-
seases of ischemic, hypertensive, toxic or inflammatory ori-
gin. Animal studies have shown the potential role of telome-
rase, a ribonucleoprotein complex that stabilizes and extends
the chromosome telomeric ends and thereby regulates cell
replicative capacity and lifespan, in cardiac regeneration and
proliferation. However, the regulation of telomerase in the
failing human heart and associated coronary circulation re-
mains unclear. The study was aimed to uncover the patholo-
gical regulation of telomerase in chronic heart failure by
molecular and morphological approaches, with emphasis on
epicardial coronary arteries and myocardium of the end-
stage failing human heart. Forty discrete epicardial coronary
arterial segments and 12 explanted failing hearts were obtai-
ned from patients who underwent heart transplantation.
Functional bioactivity of the telomerase holoenzyme and
cellular expression of telomerase catalytic protein, human
telomerase reverse transcriptase (hTERT) were examined by
sensitive PCR-ELISA-based telomeric repeat amplification
protocol (TRAP) and immunocytochemical analyses, res-
pectively. In epicardial coronary arteries, we compared with
the telomerase expression in vascular tissues with or without
atherosclerotic lesions form ischemic or dilated cardiomyo-
pathy. The incidence of telomerase re-activation reached
70% in atherosclerotic coronary arteries, fourfold higher
than that of non-atherosclerotic controls (P = 0·007). hTERT-
immunoreactivities frequently distributed in the vascular
smooth muscle cells (VSMCs) with coronary atherosclerotic
lesions, coupled with the mitotic index of proliferating VS-
MCs proven by positive Ki67-staining. The level of hTERT
expression significantly correlated with telomerase bioacti-
vity (P = 0·017) and atherosclerotic severity (P < 0·001). In
the failing myocardial tissues, apparent telomerase bioacti-
vity was shown in all endomyocardial biopsies, whereas
most of the transverse myocardial slices of left ventricle
exhibited weak enzyme activity. Histopathologically, strong
hTERT-immunolabeling presented predominantly in endo-
cardium and epicardium, including the endothelial cells,
smooth muscle cells, connective tissues cells, mesothelial
cells and intramural vascular cells. Some damaged myocytes
or adjacent connective tissues cells showed moderate
hTERT-immunoreactivities in the injury zone of myocar-
dium. Our results indicate the unique active telomerase and
hTERT expression in the coronary atherosclerosis and myo-
cardial tissues may play a role in the cardiovascular events
leading to the development of chronic heart failure.
Abstract N° B37
No-touch saphenous veingraft for coronary artery
bypass grafting provides a high graft patency rate
Souza, Domingos. Department of Cardiothoracic Surgery,
Sweden
The aim of this study is to evaluate a new “no-touch”
harvesting technique where the vein is harvested with a
cushion of surrounding tissue, which protects the vein from
spasm and therefore obviating the need for distension. This is
a prospective and randomised study comparing the patency
of veingrafts harvested with three techniques: (I) Conventio-
nal technique: Adventitial stripping, manual distension and
storage in saline at room temperature. (II) Intermediate tech-
nique: Adventitial stripping, locally papaverine was used
instead of distension and storage in heparinized blood. (III)
“No-touch” technique: The vein was harvested with a
cushion of surrounding tissue. It was not dilated and stored in
heparinized blood. The patients demographics and the distri-
bution of the grafts to the target coronary arteries were
similar in the three groups. The patency rate for grafts har-
vested by the conventional technique was 113/127 (88.9%),
for grafts in the intermediate technique was 100/116 (86.2%)
and for grafts in the “no-touch” technique was 118/124
(95.4%). The statistical analysis showed a P-value of 0.035
for the “no-touch” technique. Futhermore, the preliminary
results of the long-term angiographic follow up has also
shown a high patency rate for the SV grafts that were prepa-
red with the “no-touch” technique. The use of refined techni-
que of harvesting SV for CABG is a prerequisite to achieve a
high early veingraft patency and this can be accomplished
when using our “no-touch” technique. The success of “no-
touch” graft might be due to preservation of endothelial
integrity and nitric oxide synthase (NOS) activity as we
demonstrated in previous studies.
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Abstract N° B38
C-Jun N-terminal kinase regulates pathological
extracellular matrix metabolism in abdominal aortic
aneurysm in vivo
Koichi Yoshimura a, Hiroki Aoki a, Norio Akiyama b,
Akira Furutani b, Kimikazu Hamano b,
Masunori Matsuzaki a. a Departments of Molecular
Cardiovascular Biologyand Surgery I. b Yamaguchi
University School of Medicine
We investigated the role of c-Jun N-terminal kinase (JNK)
in human abdominal aortic aneurysm (AAA) that is charac-
terized by proteolytic degradation of extracellular matrix
(ECM) by matrix metalloproteinases (MMPs). We observed
a significant increase in JNK activity showing a linear corre-
lation (r = 0.82) with MMP-9 expression in human AAA.
Active JNK and MMP-9 co-localized in macrophages and
vascular smooth muscle cells (VSMCs) in AAA. DNA mi-
croarray analysis in rat aortic VSMC culture revealed that
MMP-9 and five of its positive regulators were ranked within
top 20 JNK-induced genes, which was confirmed at protein
levels. In contrast, tissue inhibitor of metalloproteinase-3
(TIMP-3), a negative regulator of MMP activity, was sup-
pressed by JNK. In addition, collagen type III and biosynthe-
tic enzymes for collagen and elastin fibers were suppressed
by JNK, suggesting an important role of JNK in turnover of
ECM in the aortic wall. In fact, specific activation of JNK by
adenoviral expression of active MKK7 markedly suppressed
collagen biosynthesis as measured by [3H] proline incorpo-
ration in VSMCs. SP600125, a specific JNK inhibitor, elimi-
nated expression and secretion of MMP-9, recovered
TIMP-3 expression and prevented collagen degradation in ex
vivo culture of human AAA walls. Finally, specific inhibition
of JNK in vivo by SP600125 completely suppressed the
development of murine AAA that was induced by abluminal
application of calcium chloride. These findings demonstrate
the central role of JNK in the pathological ECM metabolism
in AAA. JNK represents a novel therapeutic target for abdo-
minal aortic aneurysm.
Abstract N° B39
Regression of pressure-overload induced left
ventricular hypertrophy in mice
Xiao-Ming Gao, Helen Kiriazis, Shirley Moore,
Anthony Dart, Xiao-Jun Du. Baker Heart Research
Institute, Melbourne, Australia
The aims of this study are to establish left ventricular
hypertrophy (LVH) and regression model in mice by surgical
interventions and to characterize the time-course for the deve-
lopment of LVH and a subsequent regression of established
LVH. Alterations in histology and certain genes expression
were studied as well. Mice with C57BL/6 genetic background
subjected to aortic banding, some of them followed by deban-
ding (release of aortic narrowing), and sham operation were
investigated for 10 or 14 weeks. Using echcardiography, we
observed a progressive increase in LV mass, gradual LV dila-
tation and dysfunction during the development of LVH fol-
lowing aortic banding. LVH was also associated with myocyte
enlargement, interstitial fibrosis, enhanced ANP and sup-
pressed a-MHC and SERCA2a expressions. Surgical unloa-
ding induced a reversal in myocardial hypertrophy, LV cham-
ber dilatation and dysfunction, which was accompanied with
restorations of histological changes and gene expressions.
Regression of LVH induced by pressure overload was very
sensitive to the alteration of arterial pressure. However, the
extent of LVH regression was not consistent in mice with
different duration of pressure overload. A complete restora-
tion in LV structure and function was observed in animals
undergone 4 weeks aortic banding followed by 6 weeks de-
banding, but not in those undergone 8 weeks banding fol-
lowed by 6 weeks debanding. Hypertrophied myocytes and
increased interstitial collagen content could not return to
control level even given a longer recovery period than pres-
sure overload. These findings demonstrated that the degree of
LVH regression was dependent on the duration and extent of
LVH and histological reversal was slower and lagged behind
the restoration in LV structure and function. The time courses
for the development and regression of LVH induced by pres-
sure overload and subsequent surgical unloading were clearly
delineated from different levels.
Abstract N° B40
The low oxygen-carrying capacity of Krebs buffer
causes a doubling in wall thickness in the isolated heart
R. Southworth a, S.C. Blackburn a, K.A.B. Davey a,
G.K. Sharland b, P.B. Garlick a. a Division of Imaging
Sciences. b Department of Foetal Cardiology,
GKT School of Medicine, Guy’s Hospital, London SE1
9RT, UK
The coronary flow of buffer-perfused hearts is known to be
higher than in vivo, due to the low oxygen-carrying capacity
of Krebs buffer. We postulated that this may result in changes
in cardiac dimensions that may impact on contractile effi-
ciency. Rats (n = 4/group) were anaesthetised and their heart
dimensions measured in vivo (closed chest) using a modified
ultrasound system. The hearts were then excised and buffer-
perfused in Langendorff mode at 100, 80, 60 or 40 cm H2O.
Two further groups of hearts were perfused at 100 cm H2O
and either given a bolus of endothelin 1 (ET1, 1 × 10–9M) or
infused with FC-43 (the perfluorochemical oxygen carrier);
another group was perfused in the “working” mode.
Left ventricular wall thickness (LVWT) in Langendorff
hearts (100 cm) was twice that of the same hearts in vivo, and




In vivo 2.1 ± 0.3 5.7 ± 0.4 –
Langendorff 100 cm 5.6 ± 0.5 * 2.0 ± 0.1 * 16.6 ± 0.5
Langendorff 40 cm 7.1 ± 0.7 * 1.3 ± 0.3 * 6.7 ± 0.8 †
Langendorff + ET1 3.8 ± 0.9 *,† 2.2 ± 0.4 * 7.9 ± 1.2 †
Langendorff + FC-43 4.1 ± 0.4 *, † 1.8 ± 0.7 * 8.5 ± 0.6 †
Working heart 4.9 ± 0.5 * 3.9 ± 0.6 † 18.2 ± 0.7
* P < 0.05 vs. in vivo.
† P < 0.05 vs. Langendorff 100 cm.
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increased further with lower perfusion pressures. The in-
creased LVWT was attenuated by ET1 or FC-43. The col-
lapse of the LV lumen in Langendorff hearts was reversed by
switching to the “working” mode, but was unaffected by ET1
or FC-43. We conclude that the increased wall thickness in
buffer-perfused hearts is due to vasodilation induced by the
low oxygen carrying capacity of Krebs buffer.
Abstract N° B41
Ventricular function and remodelling in hypertensive
cardiomyopathy
Adèle Pope, Bruce Smaill, Ian LeGrice. Department of
Physiology/Bioengineering Institute, University of
Auckland, New Zealand
Myocardial remodelling as a result of chronic hyperten-
sion includes progressive changes in cellular architecture and
extracellular matrix collagen organisation. These changes
have the potential to interfere with the mechanical and meta-
bolic properties of cardiac myocytes and affect left ventricu-
lar (LV) function. The objective of this study was to charac-
terise the time-course of changes in LV structure and
function through the progression of hypertensive cardiomyo-
pathy. Hearts were collected from spontaneously hyperten-
sive rats (SHRs) at different stages of hypertensive cardio-
myopathy development (early hypertension (3 months),
established hypertension (12 months), compensated heart
failure (18 months) and de-compensated heart failure (22–
24 months)) as well as from aged-matched controls, Wistar-
Kyoto rats (WKYs). Standard indices of LV geometry and
systolic function were determined using echocardiography
prior to excision and plasma samples stored for subsequent
brain natriuretic peptide assay. Passive LV pressure/volume
relations were then measured in the isolated hearts (eight per
group). Two further hearts from each group were fixed in
Bouin’s solution, stained for collagen with picrosirius red
and imaged using an automated confocal microscopy system
to produce detailed extended 3D images of myocardial struc-
ture spanning the LV free wall. All SHR hearts, including the
dilated failing hearts, demonstrated increased passive stif-
fness compared to age-matched controls. Structural analysis
revealed increased collagen volume fraction and density in
the myocardial intralaminar spaces, the increases being sys-
tematically associated with age and disease state. Long-term
hypertension causes loss of intralaminar spaces and thicke-
ning of collagen around individual myocytes, these effects
being exaggerated in failing hearts.
Abstract N° B42
Phosphodiesterase inhibition promotes the transition
from compensated hypertrophy to cardiac dilatation
D. Badenhorst, C. Anamourlis, M. Gibbs, R. Correira,
D. Veliotes, O. Osadchii, G.R. Norton, A.J. Woodiwiss.
Cardiovascular Pathophysiology and Genomics Research
Unit, Schools of Physiology and Medicine, University of
the Witwatersrand, South Africa
The cellular mechanisms responsible for the transition
from compensated left ventricular (LV) hypertrophy (LVH)
to LV dilatation (chamber remodeling) and heart failure are
unclear. As chronic administration of a b-adrenoceptor (b-
AR) agonist mediates the premature onset of cardiac remo-
deling without myocyte necrosis or myocardial dysfunction
in LVH, we suggest that the b-AR-cyclic adenosine mono-
phosphate (cAMP) system is critical in promoting cardiac
dilatation and hence the transition from compensated LVH to
heart failure. To determine the role of cAMP in promoting
adverse cardiac chamber remodeling, we evaluated whether
phosphodiesterase inhibition (PDEI) promotes LV dilatation
in rats with compensated LVH. The impact of chronic admi-
nistration of the PDEI, pentoxifylline (75 mg kg–1 d–1), on
LV remodeling and function was assessed in spontaneously
hypertensive rats (SHR) with compensated LVH. Inotropic
doses of the PDEI administered for 4 months to SHR failed to
modify LV weight or influence intrinsic myocardial systolic
function, but mediated the development of a right shift in LV
end-diastolic (LVED) pressure–internal diameter and LVED
pressure–volume relations, produced LV wall thinning, redu-
ced systolic chamber function and increased myocardial so-
luble (non-cross-linked) collagen concentrations. In conclu-
sion, chronic PDEI administration induces adverse
geometric and interstitial cardiac remodeling in SHR, a fin-
ding that supports the notion that the b-AR-cAMP system is
important in mediating the progression to heart failure by
promoting interstitial remodeling and LV dilatation in LVH.
Abstract N° B43
Lymphocyte adhesion to the artery wall is increased in
atherosclerosis
Karen Pugh a, John Waller b, Roger M. Wadsworth a,
Cherry L. Wainwright c. a Department of Physiology and
Pharmacology, University of Strathclyde, Glasgow,
Scotland, UK. b Section of Cardiovascular Pharmacology,
Organon Laboratories Ltd., Newhouse, Scotland, UK. c
School of Pharmacy, Robert Gordon University, Aberdeen,
Scotland, UK. karen.pugh@strath.ac.uk
Lymphocytes accumulate in atherosclerotic plaques and
may have a role in plaque instability and breakdown. The aim
of this study was to compare basal and thrombin-stimulated
adhesion of lymphocytes to vessel segments from 16 week-
old C57BL/6 and Apo-E–/– mice. Apo-E–/– received a high
fat diet from 4 weeks. Lymphocytes were isolated from
mouse spleen, labelled with 51Cr, and added in a droplet to
mouse aortic arch, thoracic aorta and abdominal aorta. After
30 min non-adherent lymphocytes were washed and the
adherent lymphocytes were counted. Basal lymphocyte ad-
hesion in Apo-E–/– mice (19.3 ± 2.4%) was significantly
increased compared to C57BL/6 mice (10.8 ± 1.4%). Throm-
bin pre-treatment of the artery segments increased lympho-
cyte adhesion, however Apo-E–/– mice were more sensitive
to thrombin (thrombin 1 U/ml 27.0 ± 1.7% adhesion) com-
pared to C57BL/6 mice (thrombin 1 U/ml 12.7 ± 1.9%
adhesion, thrombin 10 U/ml 27.0 ± 3.6% adhesion). Adhe-
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sion of C57BL/6 lymphocytes to Apo-E–/– arteries was in-
creased (40.0 ± 4.0% adhesion) compared to adhesion of
autologous lymphocytes to C57BL/6 arteries (10.8 ± 1.8%
adhesion). Adhesion of Apo-E–/– lymphocytes to C57BL/6
arteries was increased (25.0 ± 4.6% adhesion) compared to
adhesion of autologous lymphocytes to Apo-E–/– arteries
(19.3 ± 2.4% adhesion). These results suggest that in this
model of atherosclerosis there is enhanced adherence of both
the lymphocytes and the aortic wall. The greater responsive-
ness to thrombin suggests upregulation of thrombin receptor
signalling in atherosclerosis.
Abstract N° B44
Effect of OX-LDL on proliferation of vascular smooth
muscles and the promoter activities of human a2(I)
procollagen gene
Qian Chen a, Zong-Gui Wu a, Chun-Fang Gao b,
Hao Wang b. a Department of Cardiology, Changzheng
Hospital, Second Military Medical University, Shanghai
200003, China. b Department of laboratory Diagnosis,
Changzheng Hospital. * Corresponding authors.
To comprehend the role of OX-LDL in the formation and
progression of atherosclerosis. The smooth muscle cells ob-
tained from male Sprague–Dawley rat’s thoracic aorta were
primarily cultured in vitro. Different concentrations of OX-
LDL50, 100, 150 and 200 µg/ml were added into the plate to
co-incubated with the cells, respectively. MTT method was
used to detect the cell proliferation after 24, 48 and 72 h.
Smooth muscle cells were transiently transfected with
pCOLH22.4 and pCOLH21.6 containing –2.4 kb and –1.6 kb
of 5′flank sequence of human a2(I) procollagen gene, fused
to CAT reporter gene by FuGene transfectant reagent. The
effect of OX-LDL 150 µg/ml on the plasmid were determi-
ned by CAT-ELISA. OX-LDL could accelerate the prolifera-
tion of VSMC in dose-dependent manner. OX-LDL could
enhance the promoter activities of human a2(I) procollagen
gene significantly. OX-LDL can accelerate the proliferation
of VSMC and enhance production of typeacollagen and
accelerate the formation and progression of atherosclerosis.
Abstract N° B45
SR Ca release at transverse tubule and cell surface
dyads in cardiac myocytes
Fabien Brette, Clive H. Orchard. School of Biomedical
Sciences, University of Leeds, Leeds, UK
Introduction. – In cardiac ventricular myocytes, it is unk-
nown whether local Ca release from the sarcoplasmic reticu-
lum (SR) is the same at the transverse (t-) tubule and cell
surface dyads. We have addressed this question.
Methods. – Experiments were performed at room tempe-
rature on enzymatically isolated rat ventricular myocytes.
The perforated patch clamp technique and fura-2 were used
to record the Ca current (ICa) and whole cell Ca transient
(CaTr) simultaneously. CaTr was also recorded in field-
stimulated myocytes using fluo3 imaged by confocal micros-
copy. We compared control myocytes, in which Ca signalling
is dominated by the t-tubules, with detubulated myocytes, in
which Ca signalling occurs predominantly at the cell surface.
Results. – ICa and CaTr amplitude elicited at 0 mV were
significantly smaller in detubulated cells than in control cells
(n = 14 and 16, respectively). The gain of the Ca release
process (CaTr amplitude/ICa amplitude) was not significantly
different between control and detubulated cells (0.133 ±
0.015 vs. 0.122 ± 0.016, P > 0.05). This suggests that the
effectiveness of a given ICa in causing SR Ca release is the
same in control and detubulated myocytes, and therefore at
the t-tubules and surface membrane. To investigate this fur-
ther, we compared localised rates of rise of Ca (dF/dT) in
control and detubulated myocytes using confocal micros-
copy. dF/dT was the same at the cell surface and center in
control myocytes (3.4 ± 0.6 vs. 3.6 ± 0.7, P > 0.05, n = 11)
and at the cell surface in detubulated myocytes (3.6 ± 0.4, n =
15).
Discussion. – Structural studies using electron micros-
copy have shown no difference in the size of the dyadic space
at the cell surface and t-tubules (Am. J. Physiol. (1978) 235:
C147), and immunocytochemistry has shown similar co-
localization of ICa and RyR (J. Cell. Biol. (1995) 129 672) at
the two sites. In addition, computer simulation showed that
differences in the dyadic cleft would be expected to alter the
gain and the rate of rise of Ca (Biophys. J. (1997) 73 112).
Our data provide the first functional evidence that the geo-
metry and the structure of the dyadic cleft, and hence cou-
pling of Ca entry and release, is the same at the cell surface
and the t-tubules.
Supported by the Wellcome Trust.
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Abstract N° B46
Changes of spontaneous Ca2+ transients during
cardiomyocyte development: the role of type 2
ryanodine receptor
Ji-Dong Fu, Hui-Mei Yu, Rong Wang, Le Chen,
Huang-Tian Yang. Laboratory of Molecular Cardiology,
Health Science Center, SIBS, CAS and SSMU, Key
Laboratory of Stem Cell Biology, SIBS, Shanghai, China
In adult cardiomyocytes, type 2 ryanodine receptor
(RyR2), the cardiac sarcoplasmic reticulum Ca2+ release
channel, plays a critical role in the regulation of cytosolic
Ca2+ transients (CaTs), but the developmental changes of
CaTs and the contribution of RyR2 during cardiomyogenesis
are currently obscure. We have therefore systematically ana-
lyzed spontaneous CaTs in cardiomyocytes derived from
wild-type (RyR2+/+) and RyR2 deficient (RyR2–/–) embryo-
nic stem cells at early (EDS, 7 + 2–4 d), intermediate (IDS, 7
+ 6–8 d) and late developmental (LDS, 7+ 10–12 d) stages. In
RyR2+/+ cardiomyocytes, the frequency and amplitude of
spontaneous CaTs were increased significantly from EDS to
LDS, while the duration of CaTs was decreased gradually
upon development. Unexpectedly, RyR2–/– cardiomyocytes
showed similar amplitude of CaTs to these in RyR2+/+ cells
at three developmental stages, however, the duration of CaTs
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was significantly prolonged with slow contraction. The pro-
longed duration of CaTs was mimicked in RyR2+/+ cells by
10 µM ryanodine in a development-dependent manner. As
b-adrenergic stimulation is known to regulate CaTs, we fur-
ther analysed the role of RyR2 on CaTs with isoproterenol
(Iso, 3 × 10–8 M). Iso significantly increased in spontaneous
frequency and amplitude of CaTs in RyR2+/+ cardiomyocy-
tes, whereas these responses to Iso in RyR2–/– cardiomyocy-
tes were much weaker. We conclude that: (1) more rapid and
higher CaTs are developed gradually during cardiomyocyte
development; (2) RyR2 is essential for this rapid CaT via
acting as a functional Ca2+ release channel in spontaneous
beating and contracting cardiomyocytes and in b-adrenergic-
stimulated response throughout all developmental stages,
especially in terminally differentiated stage.
Acknowledgements: The study was supported in part by
grant of General Program of National Natural Science Foun-
dation (No. 30270656) and by grants of Major and Key
Programs (03DJ14019 and 01JC14048) from Science and
Technology Committee of Shanghai Municipality.
Abstract N° B47
PKA and CaMKII phosphorylation of ryanodine
receptors in canine heart failure
Nancy A. Benkusky, Ming-Tao Jiang, Emily F. Farrell,
Héctor H. Valdivia. University of Wisconsin, Madison, WI,
USA
Phosphorylation/dephosphorylation of ion channels and
transporters is an effective mechanism by which neurotrans-
mitters and hormones increase cardiac performance during
stress or exercise. This response is apparently altered in heart
failure (HF), as failing ventricular cells appear to be insensi-
tive to b-adrenergic stimulation. Perfusion of hearts with
isoproterenol results in activation of PKA and subsequent
phosphorylation of ryanodine receptors (RyR), the Ca2+ re-
lease channels of the sarcoplasmic reticulum (SR). However,
RyRs display a unique phosphorylation site for PKA
(S2809), and multiple Ca2+-, CaM-dependent protein kinase
II (CaMKII) sites. In principle, then, RyRs are better substra-
tes for CaMKII than for PKA, but the exact stoichiometry of
PKA/CaMKII phosphorylation of RyRs, and the extent of
RyR phosphorylation in HF remain unclear. We used [32Pc]-
ATP incorporation and an antibody against phospho-S2809
(P-S2809) to investigate the total level of RyR phosphoryla-
tion by CaMKII and PKA and the relative efficacy of these
kinases to phosphorylate S2809, in control and HF dogs.
Autoradiograms of SR proteins show that CaMKII is three-
to fivefold more efficient than PKA to phosphorylate RyRs in
vitro. The higher CaMKII stoichiometry cannot be ascribed
to lower PKA activity, as both kinases phosphorylated phos-
pholamban to similar levels. Phospho-S2809 signals were
low in native SR, suggesting low basal levels of S2809
phosphorylation, but increased with PKA or CaMKII phos-
phorylation. A dephospho-S2809 antibody (deP-S2809) si-
gnal is diminished by PKA or CaMKII, indicating equal
access of both kinases to this site. Neither autoradiogram nor
P-S2809 signals in untreated, PKA-, or CaMKII-
phosphorylated RyRs were significantly different in control
and HF dogs. These results suggest that CaMKII is potenti-
ally a more effective modulator of RyRs than PKA, but that
phosphorylation of RyRs does not appear to play a central
role in the blunted response of cardiac myocytes to
b-adrenergic stimulation.
Abstract N° B49
Vasodilation via Cl– Channel blockade-induced Ca2+
flux reduction
Heng Ma, Shi S. Zhou, Xiao D. Zhang, Feng Gao.
Department of Physiology, Fourth Military Medical
University, Xi’an, China
Cl– channels are expressed in vascular smooth muscles
(VSM), but their role in VSM contraction remains poorly
understood. In order to investigate these roles, isometric
tension of isolated rat aortic ring was measured with an organ
bath perfusion technique. The data were reported as mean ±
S.D. and were analyzed by Student’s unpaired t-test. The Cl–
channel blockers niflumic acid (NFA) and 5-nitro-2-(3-
phenylpropylamino)benzoic acid (NPPB) completely inhibi-
ted high K+(60 mM)-induced aorta contraction. Glt– substi-
tution for extracellualar Cl– mimicked the inhibitory effects
of Cl– channel blockers (81.3 ± 2.9%, n = 8, P < 0.01), but
depletion of internal Ca2+ stores with thapsigargin (10 µM)
did not affect this inhibitory action (n = 5). Blockade of
L-type Ca2+ channels (ICa,L) with nifedipine(1 µM) preven-
ted the contraction. In contrast, high K+ induced a transient
contraction pretreated with NFA and NPPB, and the half
inhibition time (T1/2) for NFA and NPPB were16.3 ± 3.9 (n =
7) and 16 ± 4.3 min (n = 6) respectively, which were signifi-
cantly longer than that of nifedipine (2 ± 0.8 min, n = 10). In
addition, in Ca2+-free Krebs solution, NFA and NPPB com-
pletely suppressed norepinephrine-induced contractions (n =
5). Taken together, these data indicated that the inhibitory
effect of Cl– channel blockers on VSM contraction was due
to Cl– channel inhibition and the resulting decreased Ca2+
entry carried by ICa,L, and Cl
– channel blockade also preven-
ted sarcoplasmic reticulum Ca2+ release in VSM.
Abstract N° B50
Dispersion of RYR2 and ICA.L associated with
exacerbated arrhythmias and cardiac failure is
regressed by propranolol and CPU86017, a
multi-channel blocker
Hong-Lan Wang, De- Zai Dai. China Pharmaceutical
University, Nanjing, China
It was intended to explore if the downregulated ryanodine
2 receptor and upregulated ICa.L could be dispersed in an
infarcted heart associated with arrhythmogenesis and cardiac
failure by over phosphorylation and in response to proprano-
lol and CPU86017, a multi-channel blocker.
Methods. – The coronary artery in rats was ligated to
develop myocardial infarction, then, isoproterenol (Isop) was
medicated during d 16–20 for 5 d in parallel with interven-
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tions with propranolol and three doses of CPU 86017. Car-
diac arrhythmias were assessed by reperfusion mounting on
Langendorff’s apparatus and hemodynamics was evaluated
under pentobarbital anesthesia. The severity of arrhythmias
and cardiac failure was exaggerated in the MI rat with iso-
proterenol together with significant cardiac remodeling. The
mRNA abundance of RyR2, SERCA2, NCX and ICa.L cur-
rent were not changed markedly in the MI group vs. normal.
Downregulation of RyR2 and SERCA2 was significant in
infarcted hearts stimulated with isoproterenol (P < 0.01) and
much more depressed RyR2 and SERCA2 were presented in
the LV against the right (P < 0.01). An upregulation of the
ICa.L current and mRNA of NCX were evident and a disper-
sion was presented by showing a more upregulated in the LV
in the infarcted plus isoproterenol against the MI. The chan-
ges in channels were associated with exacerbation of arrhyth-
mias and hemodynamics in MI plus isoproterenol group.
Propranolol was effective to regress these changes. The re-
gression was also significant in responses to CPU 86017 2
and 4 mg/kg i.p., however, no effect with 1 mg/kg. This is the
first time to show dispersion of depressed RyR2, SERCA2
and upregulated ion channels NCX and ICa.L in an affected
heart associated with enhancement of arrhythmias and car-
diac failure, resulting from the hyperphosphorylation by iso-
proterenol in MI heart. These were regressed completed by
propranolol. Regression of exacerbation of arrhythmias and
cardiac failure by hyperphosphorylation can also be achieved
by CPU86017 which possessing a blockade on ICa.L, IKR,
IKS a-receptors and a potent antioxidant effect is derived
from berberine.
Abstract N° B51
Dissociation of [Ca2+]i and force in trabeculae from an
animal model of hypertensive failure
Marie-Louise Ward, Denis S. Loiselle, Mark B. Cannell.
Department of Physiology, University of Auckland,
Auckland, New Zealand
We have used an animal model of hypertensive heart
failure to examine the relationship between intracellular cal-
cium ([Ca2+]i) and contractile force for a range of different
stimulus frequencies. Simultaneous measurements were
made of isometric force and [Ca2+]i (measured as the ratio of
fura-2/AM fluorescence), in left-ventricular (LV) trabeculae
from spontaneously hypertensive rats (SHR, mean age 21.8 ±
0.5 months) in heart failure, and their age-matched, normo-
tensive, Wistar-Kyoto controls (WKY, mean age 23.6 ±
0.5 months). In addition, the force–frequency relationship
was also examined in right ventricular (RV) trabeculae from
healthy Wistar rats (mean age 3.0 ± 0.4 months) to allow
comparison with other studies. At 37 °C, and with an extra-
cellular calcium concentration of 2 mM, peak stress was
lower for SHR trabeculae in comparison to WKY for all
stimulus frequencies examined, whereas, paradoxically,
peak [Ca2+]i was higher. At low frequencies, peak [Ca
2+]i and
peak stress both decreased with increasing frequency for all
rat strains. However, for frequencies above 2 Hz, although
peak [Ca2+]i increased, there was no parallel frequency-
dependent increase in peak stress for either SHR or WKY. A
bi-phasic force–frequency response was obtained for Wistar
trabeculae, with peak stress increasing at higher frequencies
in a similar manner to peak [Ca2+]i. The dissociation of stress
and [Ca2+]i suggest that altered excitation–contraction cou-
pling does not explain the apparent contractile dysfunction,
but that differences in the extracellular matrix might be a
contributing factor.
Abstract N° B52
Suppression in sarcoplasmic reticulum calcium uptake
activity underlies changes in intracellular calcium
mobilization in ovariectomized rat hearts
Tepmanas Bupha-Intr, Jonggonnee Wattanapermpool.
Department of Physiology, Faculty of Science, Mahidol
University, Rama 6 Rd. Bangkok, 10400, Thailand
The hypothesis that ovarian sex hormone deficiency may
suppress cardiac contraction through modification of intra-
cellular calcium mobilization was tested here. The sarcoplas-
mic reticulum (SR) calcium uptake activity was determined
using both left ventricular homogenate and SR membrane
vesicular preparations from 10-week ovariectomized rat
hearts. A significant decrease in the maximum SR Ca2+
uptake rate but an increase in Ca2+ sensitivity was demons-
trated in ovariectomized hearts. Measurements of SR Ca2+-
ATPase (SERCA) activity also substantially revealed sup-
pression in maximum activity but an increase in SERCA
sensitivity to Ca2+ in ovariectomized hearts. Reductions in
the SR Ca2+ uptake and SR Ca2+-ATPase activity were cor-
related well with a significant downregulation of SERCA
proteins detected by immunoblot analyses. Either estrogen
(5 µg/rat) or progesterone (1 mg/rat) supplementation after
ovariectomy completely reversed changes in the uptake acti-
vity as well as the SERCA protein expression. On the other
hand, there was no effect of ovarian sex hormone deficiency
on the expression of phospholamban protein. These results
thus indicate a significant cardioregulatory effect of ovarian
sex hormones on intracellular Ca2+ homeostasis through the
function of SR Ca2+ uptake especially the SERCA activity
and protein expression.
Abstract N° B53
Calmodulin triggers Ca2+ Pump function in native
cardiac sarcoplasmic reticulum by disrupting
Ca2+-ATPase–phospholamban interaction
Njanoor Narayanan, Ande Xu. Department of Physiology,
The University of Western Ontario, London, Ontario,
Canada
A pivotal role for calmodulin (CaM) in supporting the
Ca2+-ATPase function in cardiac sarcoplasmic reticulum
(CSR) was suggested by our recent observation that a high
affinity CaM-binding peptide (CaM BP) strongly inhibits
CSR Ca2+ pump function by scavenging membrane-
associated CaM (Xu, A., Narayanan, N., 2000. J Biol Chem
275, 4407–4416). The present study investigated the mecha-
226 2004 ISHR World Congress / Journal of Molecular and Cellular Cardiology 37 (2004) 161-375
nism of CaM regulation of CSR Ca2+ pump function by
determining the influence of CaM BP and CaM on the inter-
mediate steps in Ca2+-ATPase catalytic cycle and Ca2+-AT-
Pase–phospholamban (PLN) interaction in rabbit CSR. Pa-
rallel studies were also performed using rabbit fast skeletal
muscle SR (FMSR) lacking PLN. Under identical assay
conditions, CaM BP (5 µM) strongly inhibited decomposi-
tion of the Ca2+-induced phosphoenzyme (EP) intermediate
in the catalytic cycle of Ca2+-ATPase in CSR but not FMSR.
CaM (3 µM) reversed the CaM BP-induced blockade EP
decomposition in CSR. CaM BP and CaM did not influence
EP formation in CSR or FMSR. Co-immunoprecipitation
studies revealed that CaM BP promoted association of Ca2+-
ATPase with PLN in native CSR whereas as CaM promoted
dissociation of the Ca2+-ATPase-PLN complex. This action
of CaM was Ca2+-dependent and was accompanied by CaM–
Ca2+-ATPase interaction. CaM BP (2.5 µM) caused relaxa-
tion failure in the intact beating rabbit heart. These findings
imply that (a) PLN-bound Ca2+-ATPase is catalytically inert,
and (b) endogenous CaM serves to trigger CSR Ca2+ pump
function and cardiac relaxation by dissociating Ca2+-ATPase
from PLN and by accelerating the rate limiting step of EP
decomposition in the enzyme’s catalytic cycle.
Supported by CIHR and HSFO.
Abstract N° B54
Target-dedicated function of
calcium/calmodulin-dependent protein kinase in
cardiac sarcoplasmic reticulum
Ande Xu, Hagit Bergman, Njanoor Narayanan. Department
of Physiology and Pharmacology, The University of
Western Ontario, London, Ontario, Canada
In the cardiac sarcoplasmic reticulum (SR), a membrane-
associated CaMK is known to phosphorylate the ryanodine
receptor-Ca2+ release channel (RyR), Ca2+-ATPase and
phospholamban (PLN). RyR phosphorylation results in en-
hanced Ca2+ release whereas phosphorylation of the Ca2+-
ATPase and PLN results in enhanced Ca2+ uptake. To be
physiologically meaningful, the Ca2+ release and uptake
events must occur sequentially and in concert with the
contraction–relaxation cycle of the heart. The mechanism
that governs the sequential activation and temporal segrega-
tion of these events is unknown. This study investigated our
hypothesis that, spatial segregation of SR-CaMK as target-
dedicated molecules provides a mechanistic framework for
the temporal segregation of Ca2+ release and uptake events.
As a first step, the target specificity of SR-CaMK was deter-
mined from its ability to discriminate between endogenous
and exogenous substrates. SR vesicles were isolated from
rabbit cardiac muscle and the phosphorylation reaction by
endogenous CaMK was performed in the absence and pre-
sence of Ca2+/CaM and the exogenous substrates troponin,
myosin light chain (MLC), and myelin basic protein (MBP).
The results showed that SR-CaMK phosphorylated the endo-
genous substrates RyR, Ca2+-ATPase and PLN but not the
exogenous substrates troponin and MLC. MBP was phos-
phorylated in the absence and presence of Ca2+/CaM, sug-
gesting that its phosphorylation is CaMK-independent. Ca2+-
ATPase in the junctional SR, but not in the longitudinal SR,
underwent phosphorylation by endogenous CaMK. These
findings suggest target-dedicated spatial segregation of
CaMK in cardiac SR.
Supported by CIHR and HSFO.
Abstract N° B55
The frequency-induced relaxant effect is mediated by a
camkii independent pathway
J. Palomeque, C. Valverde, C. Mundiña-Weilenmann,
M. Vila-Petroff, A. Mattiazzi. Centro de Investigaciones
Cardiovasculares, La Plata, Argentina
An increase in stimulation frequency (ISF) causes an
acceleration of relaxation (FDAR). Several mechanisms
have been postulated to explain this effect: a CaMKII-
phosphorylation of Thr17 site of PLB (PThr17) and/or of
Ser38 site of SERCA, or a CaMKII-independent mechanism,
whereby ISF-induced Ca2+ elevation would disrupt the
SERCA-PLB interaction. We examined these mechanisms in
Indo-1-loaded isolated cat myocytes. The ISF significantly
reduced time to half Ca2+ transient decay, (t1/2CaiT), and
increased PThr17. Comparison of the time course of FDAR
with the increase in PThr17, produced by ISF from 10 to
50 ppm, showed that the t1/2CaiT was maximally decreased
after 2.5 s of ISF, whereas the increase in PThr17 became
significant only after 15 s of ISF (Fig. 1). Additionally, the
CaMKII-inhibitor KN-93, significantly decreased the PThr17
evoked by ISF, but failed to affect FDAR. The results would
indicate that CaMKII-phosphorylation pathways are not in-
volved in FDAR in cat myocytes. More likely, a direct effect
of the increase in Ca2+ on SERCA-PLB interaction, promo-
ting its dissociation, would lead to an increase in SR Ca2+
uptake and myocardial relaxation.
Abstract N° B56
Overexpression of sarcoplasmic reticulum calcium
atpase in isolated rat myocytes mediated by
recombinant adenovirus
Xiaochun Lu *, Xiaoying Li *, Zhen-hua Yuan, Xin Ma,
Xiao-bing Wu. Department of Geriatric Cardiology,
Chinese PLA General Hospital, Beijing 100853, China.
*Corresponding authors.
To assess value of SERCA2a in the gene therapy of
congestive heart failure, furthermore to analysis the effect of
transfection to pathophysiology. A recombinant adenovirus,
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named rAd-trSERCA2a, was constructed with AdEasy sys-
tem, in which the SERCA2a cDNA was inserted under the
control of CMV promoter. The cardiac myocytes of newborn
rat were cultured, and were transfected with rAd-
trSERCA2a. RTPCR and western blotting were performed to
detect the expression of SERCA2a in cardiac myocytes.
Results. – The sequence of SERCA2a was stably existed
in rAd-trSERCA2a, which was tested by PCR and Southern
blot. The quantity of mRNA of SERCA2a in cardiac myocy-
tes increased 3.6 times compared with the control, and the
protein level is 1.5 times of the control, 72 h after the
transfection.
Conclusion. – This recombinant virus, rAd-trSERCA2a,
can effectively deliver the SERCA2a gene into cultured car-
diac myocytes and may become a feasible tool to modulate
myocyte Ca2+ homeostasis in the failure heart.
Keywords: Heart failure; Recombinant adenovirus;
SERCA2a; Gene therapy
Abstract N° B57
Inhibition of phosphoamban expression in cultured rat
myocardial cells by adeno-associated virus plasmid
mediated RNA interference
Xiaochun Lu *, Xiaoying Li *, Xin Ma, Zhen-hua Yuan,
Xiao-bing Wu. Department of Geriatric Cardiology,
Chinese PLA General Hospital, Beijing 100853, China. *
Corresponding authors.
Construct three plasmids containing the shRNA of phos-
pholamban to suppress the expression of phospholamban in
rat myocardial cell. A 334-bp human U6snRNA promoter
was amplified from human genomic DNA by PCR and liga-
ted to a 21 or 20 nt reverse repeated motif of phospholamban
target sequence with 9 nt spacer and AAV plasmid pSNAV,
pSNAV-phRis. We transfected those three plasmids into cul-
tured rat myocardial cells to detect the effect of e phospho-
lamban expression separately. pSNAV-phR is suppresses the
phospholamban mRNA expression 15, 25 and 30 by RT-
PCR. pSNAV-phRis suppresses the phospholamban protein
expression 10%, 14.5% and 23.6% by western blot, whereas
the control GFP express efficency was 32.4%. The results
showed that the short hairpin RNA of PLN can suppress it’s
expression in cultured rat myocardial cell.
Abstract N° B58
Knock down phospholamban to improve heart function
by AAV- and adenovirus-mediated RNAi
Xiaochun Lu *, Xiaoying Li, Zhenhua Yuan, Xin Ma,
Xiaobing Wu. Department of Geriatristic Cardiology,
Chinese PLA General Hospital, Beijing, 100853, China. *
Corresponding author.
We developed serials of methods to introduce RNAi into
cultured mammal cell by adenoassistant virus (AAV) and
adenovirus for improving heart function by AAV- and
adenovirus-mediated RNAi.
Methods. – (1) We constructed three AAV plasmids, na-
med pSNAVpRi1, 2 and 3, in which short 21nt stem hairpin
RNA duplexes under the control of the U6 snRNA promoter
were cloned into pSNAV-1. After generation of AAV cell
lines by G418 chosen, the AAV-pRi vectors were saved out
by HSV1-rc/DUL2. (2) The long hairpin duplexes were
constructed by linkage two 657 and 541 bp segments cloned
from phospholamban mRNA with 5′-5′ mode, which trans-
criptional RNA would form to a 541 bp stem and 116 bp loop
structure. Then the duplexes were inserted into the pTract-
CMV plasimd under CMV promoter to product recombina-
tion adenovirus AV-lpRi. (3) Cultured rat cardiac myocytes
were transfected with these siRNA plasmids or infected with
AAV-pRis and AV-lpRi. The cells were collected in 72 h after
infections. Western blot were performed to compare the
difference between the expression of phospholamban. RT-
PCR were used to quantified the mRNA levels.
Results and conclusion. – Western blot and RT-PCR were
shown that two virus could inhibit phospholamban expres-
sion no more than 50%. And three AAV plasmids pSNAV-
pRi1, pSNAV-pRi2 and pSNAV-pRi3, could inhibit phospho-
lamban expression about 10%, 14.5% and 23.6%.
Considering the low transfections efficiency of control plas-
mids (about 20–30%) into cultured rat cardiac myocytes, we
will finish the other two AAV-pRis virus vectors in the further
study. On the other hand, it has shown that the cardiac
myocytes infected with AV-lpRi virus did not show the nons-
pecific mRNA degradation and translation inhibition. We
thought this long hairpin RNA duplexes with long-short
mode introduce RNAi weakly. Next we would construct the
long duplexes adenovirus with an additional loop.
Abstract N° B59
Endoplasmic reticulum Ca2+ depletion induces
apoptosis independent of caspase-12 signaling pathway
T. Nakano a, M. Ozeki a, H. Katoh a, A. Uehara a, H. Satoh a,
H. Terada a, H. Hayashi a, H. Watanabe b, K. Ohashi b.
a Division Of Cardiology, Department Of Medicine,
Hamamatsu University School of Medicine. b Clinical
Pharmacology and Therapeutics, Hamamatsu University
School Of Medicine
Apoptosis of endothelial cells (ECs) is now regarded to be
an initial step inducing atherosclerosis. Recent study repor-
ted that the depletion of endoplasmic reticulum (ER) Ca2+
stores plays an important role of apoptosis. Caspase-12 is a
key signal to lead ER stress-induced apoptosis. However, it is
not known if the depletion of ER Ca2+ is linked to caspase-12
signaling in ECs. Here, we have investigated the interaction
of Ca2+ signaling and caspase-12 cleavage in apoptosis of
cultured porcine aortic ECs. Cytosolic Ca2+ concentration
([Ca2+]i) was measured using fura-2/AM. Apoptosis was
assessed by DNA ladder formation and cleavage of
caspase-12 by western blotting. Thapsigargin (2 µM), an
inhibitor of the ER-associated Ca2+-ATPase, increased
[Ca2+]i and induced persistent ER calcium depletion, clea-
vage of caspase-12 and apoptosis. Bradykinin (10 nM) in-
creased [Ca2+]i but induced neither cleavage of caspase-12
nor apoptosis. However, when ECs were treated with
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BAPTA/AM, BK caused the Ca2+ depletion of ER and apop-
tosis without the cleavage of caspase-12. These results sug-
gested that the increase of [Ca2+]i did not play an important
role to cause apoptosis in ECs and ER Ca2+ depletion-
induced apoptosis independent from caspase-12 linked si-
gnaling pathway.
Abstract N° B60
Regulatory myosin light chain signaling pathways in
urotensin-II-mediated positive inotropic effect in
human right atrium
F.D. Russell, P. Molenaar. Department of Medicine,
University of Queensland, Qld 4032
Urotensin-II (UII) is the most potent endogenous car-
diostimulant yet identified, however the signaling mecha-
nism is not known. Phosphorylation of regulatory myosin
light chain (MLC-2) increases force by sensitisation of myo-
filaments to Ca2+, and this may be modulated by protein
kinase C (PKC) and myosin light chain kinase (MLCK).
RhoA/Rho kinase may prevent dephosphorylation of MLC-2
by inhibition of myosin light chain phosphatase. The role of
these pathways on the UII response was investigated using
human right atrial trabeculae in a tissue bath preparation. UII
increased phosphorylation of MLC-2 (1.76 ± 0.40-fold, n =
6, P < 0.05), and PKCabII (1.42 ± 0.18-fold, n = 7, P < 0.05).
UII increased force of contraction and this was attenuated by
desensitisation of PKC with phorbol 12-myristate 13-acetate
(PMA) but not 4a-phorbol, which does not desensitise PKC
(Table 1). The cardiostimulatory effect was inhibited by the
PKC inhibitor chelerythrine, but not the MLCK inhibitor,
wortmannin.
Although the Rho kinase inhibitor Y-27632 (10 µM) inhi-
bited the UII response, basal force of contraction was also
reduced. No detectable activation of RhoA was observed by
affinity immunoprecipitation. The findings indicated that UII
increased phosphorylation of MLC-2 and that the positive
inotropic effect involved activation of PKC, and was inde-
pendent of MLCK and RhoA-Rho kinase signaling pa-
thways.
Abstract N° B61
Both b1- and b2-adrenoceptors mediate increases in
contractile force and hastening of relaxation in human
atrium
E.-G. Krause a, S. Bartel a, D. Vetter a, P. Karczewski a,
F.D. Russell b, A.J. Kaumann c, P. Molenaar b.
a Max-Delbrück Center of Molecular Medicine, Berlin,
Germany. b University of Queensland, Brisbane, Australia.
c University of Cambridge, UK
Right atrial emptying initially occurs passively when the
tricuspid valve opens and then by contraction of atrial mus-
cle. Ensuing relaxation allows venous filling of the right
atrium. Right atrial muscle contraction and relaxation is
modulated by activation of b1- and b2-ARs. We therefore
investigated the effects of stimulation of b1- and b2-ARs and
phosphorylation of proteins that affect contractile function in
right atrium from non-failing and failing hearts. Both (–)-
noradrenaline in the presence of 50 nM ICI 118,551 (NA,
selective b1-AR activation) and (–)-adrenaline in the pre-
sence of 300 nM CGP 20712A (ADR, selective b2-AR acti-
vation) caused increases in contractile force and hastening of
relaxation associated with increases in cyclic AMP, phospho-
rylation of phospholamban, troponin I and C-protein in tra-
beculae taken from right atrial appendages of patients under-
going coronary artery bypass surgery, not taking b-blockers
(non BB) prior to surgery. Further studies also investigated
trabeculae dissected from human right atrial appendages
obtained from coronary artery bypass surgery from patients
with non-failing hearts (NF) receiving BB
(atenolol/metoprolol) and trabeculae from right atrium of
explanted hearts from patients with terminal heart failure
(HF). There was no difference in basal contractile force
between trabeculae from the three groups, however, the time
to reach peak force (TPF) was longer in heart failure patients
(non BB 102.3 ± 1.4 ms; BB 104.8 ± 1.6 ms; HF 113.0 ±
3.7 ms, P = 0.0021, n = 37—115 trabeculae) with a similar
trend for time to reach 50% relaxation. The difference was
not related to endogenous cyclic AMP, phospho-serine16-
phospholamban (P-Ser16PLB) or phospho-threonine17-
PLB (P-Thr17PLB) content. NA and ADR caused
concentration-dependent increases in contractile force (NA
–log EC50 NF BB 7.4 > NF non BB 7.0 > HF 6.4 P < 0.0001;
ADR NF BB 7.95 > NF non BB 7.24 ≅ HF 6.95, P < 0.0001)
and hastening of relaxation in right atrium associated with
increases in phosphorylation of PLB. These studies empha-
size the importance of b2-AR in addition to b1-AR coupling
to Gsa-protein-cyclic AMP and phosphorylation of proteins
implicated in hastening of relaxation.
Abstract N° B62
Different types of heart failure induced by
overexpression of cardiac NCX1.1 or its mutant in
transgenic mice
Satomi Kita a, Takahiro Iwamoto a, Yuji Arai b,
Hajime Takamatsu c, Satomi Adachi-Akahane c,
Noriko Uesugi d, Noriyuki Sakata d, Takeshi Katsuragi a. a
Department of Pharmacology, School of Medicine, Fukuoka
University, Fukuoka. b Department of Bioscience, National
Cardiovascular Center Research Institute, Osaka. c
Laboratory of Cell Signaling, Graduate School of
Pharmaceutical Sciences, University of Tokyo, Tokyo,
Japan. d Department of Pathology, School of Medicine,
Table 1
Effect of inhibitors on inotropic response of UII
Treatment Control (mN) Treated (mN) n, P values
10 µM PMA 1.81 ± 0.46 0.21 ± 0.15 6, P = 0.008
10 µM 4a-phorbol 1.22 ± 0.19 1.24 ± 0.36 5, P = 0.968
10 µM chelerythrine 1.56 ± 0.31 0.61 ± 0.13 7, P = 0.016
10 µM Wortmannin 1.93 ± 0.75 3.90 ± 1.03 5, P = 0.159
Developed force (mean ± SEM). P < 0.05, significance (Student’s t-test).
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Fukuoka University, Fukuoka, Japan
Na+/Ca2+ exchange is the primary mechanism of Ca2+
extrusion from cardiac myocytes during diastole. There are
many reports indicating that NCX1 expression levels are
elevated in heart failure; however, the role of NCX1 in the
pathophysiology of cardiac disease is not well understood.
To determine the in vivo cardiac function of NCX1, we
generated transgenic mice with cardiac-specific overexpres-
sion of NCX1.1, and also mice where the exchanger had a
mutated XIP region (Y224W/Y226W/Y228W/Y231W), de-
void of Na+-dependent inactivation. Cardiac-specific overex-
pression of exchangers in these transgenic mice was confir-
med by western blotting and immunohistochemistry with an
anti-NCX1 antibody. Increased Na+/Ca2+ exchange activities
were also demonstrated by measuring 45Ca2+ uptake into
membrane vesicles and exchange currents in whole cell
patch-clamp myocytes. We found that homozygous NCX1.1-
transgenic mice, but not heterozygous mice, develop cardiac
hypertrophy, and heterozygous NCX1.1 mutant-transgenic
mice produce dilated cardiomyopathy. These models will be
useful for understanding the role of NCX1 in cardiac disease.
Abstract N° B63
The reverse mode of vascular Na+/Ca2+ exchanger
type-1 is essential for the development of salt-sensitive
hypertension
Takahiro Iwamoto a,c, Satomi Kita a,e, Jin Zhang b,
Mordecai P Blaustein b, Yuji Arai d, Shigeru Yoshida e,
Koji Wakimoto f, Issei Komuro g, Takeshi Katsuragi a. a
Department of Pharmacology, School of Medicine,
Fukuoka University, Fukuoka, Japan. b Department of
Physiology, University of Maryland School Medicine,
Maryland, USA. c Departments of Molecular Physiology,
National Cardiovascular Centre Research Institute, Osaka,
Japan. d Bioscience, National Cardiovascular Centre
Research Institute, Osaka, Japan. e Taisho Pharmaceutical
Co., Saitama, Japan. f Tanabe Seiyaku Co., Osaka, Japan.
g Department of Cardiovascular Science and Medicine,
Chiba University, Chiba, Japan
Excessive salt intake is a major risk factor for hyperten-
sion. Here, we studied the role of Na+/Ca2+ exchanger type 1
(NCX1) in salt-sensitive hypertension using SEA0400 (Mat-
suda et al. 2001), a specific inhibitor for the reverse mode of
NCX1, and genetically engineered mice. SEA0400 lowered
arterial blood pressure in salt-induced hypertensive rat mo-
dels, but not in spontaneously hypertensive or normotensive
rats. Infusion of SEA0400 into the femoral artery in salt-
induced hypertensive rats increased the arterial blood flow,
indicating direct vasodilation. SEA0400 reduced the
ouabain-induced vasoconstriction or cytosolic Ca2+ eleva-
tion in mesenteric and femoral arteries. Furthermore,
NCX1+/– mice showed low salt-sensitivity to blood pressure,
whereas vascular NCX1.3-transgenic (NCX1.3Tg/Tg) mice,
but not cardiac NCX1.1Tg/Tg mice, displayed salt hypersen-
sitivity. SEA0400 drastically lowered salt-induced hyperten-
sion in NCX1.3Tg/Tg mice, but not in NCX1.3-G833CTg/Tg
mice which overexpress an SEA0400-insensitive mutant.
Our findings indicate that the reverse mode of vascular
NCX1 is involved in the development of salt-sensitive hyper-
tension and that it may be a new target for anti-hypertensive
drug.
Abstract N° B64
Strong inhibition of Na+–Ca2+ exchanger expression by
RNAi does not prevent cardiac contraction
Cecilia Hurtado, Thane G. Maddaford, Grant N. Pierce. St.
Boniface Research Center, University of Manitoba,
Winnipeg, Canada
The Na+–Ca2+ exchanger (NCX) is the main mechanism
for calcium efflux in the heart and is thought to be essential in
cardiac excitation–contraction coupling. NCX1 gene disrup-
tion for the generation of knock-out mice is lethal during
development. An alternative approach to study the lack of
function of the exchanger in postnatal cardiomyocytes is the
use of RNA interference (RNAi) for NCX silencing. The
purpose of the present study, therefore, was to deplete NCX
expression to directly evaluate the hypothesis that NCX plays
a critical role in excitation–contraction coupling. We genera-
ted adenoviruses to deliver short hairpin RNAs (Ad-R) targe-
ting different regions of NCX and one scrambled control.
Protein levels were analyzed by Western blot and immuno-
cytochemistry. NCX activity was measured using a 45Ca
uptake assay. Transduction of neonatal cardiomyocytes with
Ad-R resulted in a ~94% decrease in NCX protein level
compared to control. Surprisingly, cardiomyocytes with
nearly depleted NCX still show spontaneous contractions
(although at lower frequency) and respond to electrical sti-
mulation. Intracellular calcium measurements in electrically
stimulated cells showed that Na+–Ca2+ exchanger depleted
cells have depressed Ca2+ transient amplitude, depressed rate
of Ca2+ rise and decline and, elevated diastolic [Ca2+] com-
pared to control cells. We observed a three times increase in
sarcolemmal Ca2+ pump expression (the other calcium extru-
sion mechanism in the cells) as an adaptative mechanism to
the lack of NCX. Thus, our data support an important but not
critical role for the Na+–Ca2+ exchanger in excitation–con-
traction coupling in the heart and demonstrates that RNA
interference is a valuable tool for efficient downregulation of
cardiac proteins.
This work was supported by the Heart and Stroke Foun-
dation of Canada.
Abstract N° B65
Replacement of the endogenous NCX1.1 isoform of the
Na–Ca exchanger by the NCX1.3 isoform in neonatal
rat cardiomyocytes
Cecilia Hurtado, Michele Prociuk, Grant N. Pierce. The
Division of Stroke and Vascular Disease and the University
of Manitoba, Winnipeg, Canada
The sodium calcium exchanger NCX1 gene undergoes
alternative splicing in a region that corresponds to a small
region of the intracellular loop of the protein. NCX1.1, the
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isoform found in the heart, contains exons A, C, D, E, F.
NCX1.3, found in kidney cells, contains exons B,D. These
two isoforms show different response to intracellular regula-
tory Na+ and Ca2+. To study the differences in calcium
handling and regulation of both isoforms we designed a
series of experiments that allow us to replace the endogenous
1.1 isoform by the 1.3 isoform in neonatal rat cardiomyocy-
tes. First, we generated adenovirus constructs to downregu-
late the endogenous protein (NCX1.1 isoform) by RNAi. We
observed a 94% decrease in protein level respect to control.
We subsequently transduced the cells with another adenovi-
rus expressing the NCX1.3 isoform (canine) or the NCX1.1
(canine) for control. We show that RNAi targeting a region
142 nucleotides from the start codon (where there are seven
nucleotides in difference between rat and canine cDNA se-
quence) interferes with the expression of the exogenous 1.3
isoform and does not allow isoform replacement. However,
RNAi targeting exon F (present in the 1.1 but not 1.3, either
rat or canine) can successfully be used to perform the isoform
replacement. We used adenoviruses coding NCX1.1/3 pro-
tein fussed to EGFP, the fusion protein runs at a different size
respect to the endogenous protein in western blots and allows
us to differentiate them. Characterization of calcium tran-
sients in cells expressing the 1.1 and 1.3 isoform show no
differences in diastolic or systolic calcium. We found diffe-
rences in the response of the cells to treatment with ouabain.
This work was supported by the Heart and Stroke Foun-
dation of Canada.
Abstract N° B66
Response to simulated ischemia–reperfusion of
HEK-293 cells expressing the cardiac or kidney
isoform of the Na+–Ca2+ exchanger
Cecilia Hurtado, Thane G. Maddafford, Annette Kostenuk,
Grant N. Pierce. The Division of Stroke and Vascular
Disease, and the University of Manitoba, Winnipeg, Canada
The Na+Ca2+ exchanger (NCX1) gene can generate diffe-
rent isoforms of the protein by alternative splicing. NCX1.1
is the isoform found in the heart whereas NCX1.3 is found in
kidney cells. These isoforms show different response to in-
tracellular regulatory Na+ and Ca2+. An increase in Ca2+i is
known to activate the Ca2+ entry mode and eliminate Na+
inactivation in NCX1.1 but not in NCX1.3. Due to the intra-
cellular [Na+] and [Ca2+] change during ischemia, the
purpose of the present study was to determine if cells expres-
sing either of the two isoforms respond in a different way to
an ischemic insult. We generated stable transfected clones of
293 cells expressing similar levels of the NCX1.1 or
NCX1.3. Protein levels were measured by western blot. We
performed a protocol of simulated ischemia and reperfusion
on the cells and measured changes in intracellular calcium
and pH. We also studied non-transfected 293 cells that do not
contain endogenous (NCX1). We found no differences in
intracellular pH between groups before or during the ische-
mia–reperfusion protocol. Intracellular calcium was lower in
the NCX1.1 before ischemia. During the ischemic insult, the
not-transfected cells showed a small increase in Ca2+i that
has to take place through mechanisms other than the
(NCX1). Ca2+i was higher during ischemia in the NCX1.3
group compared to the non-transfected group and even hi-
gher in the NCX1.1 group. In summary, [Ca2+]i was greater
during simulated ischemia in HEK-293 cells when the 1.1
isoform of the NCX was present. The 1.3 NCX isoform was
not as effective in inducing an increase in [Ca2+]i during
ischemia. Our results demonstrate that ionic regulation of
NCX plays a role in calcium overload during ischemia–
reperfusion. This work was supported by the Heart and
Stroke Foundation of Canada.
Abstract N° B67
Cyanide inhibits Na+–Ca2+ exchanger in single
pacemaker cells isolated from sinus venosus of cane
toad
Yue-Kun Ju, David G. Allen. Department of Physiology
(F13), University of Sydney, NSW 2006, Australia
Dysfunction of the sinoatrial node is well recognised,
particularly in ischaemic heart disease, and can cause a
variety of arrhythmias. Recent studies have suggested that
Ca2+ release from the sarcoplasmic reticulum plays an im-
portant role in determination of pacemaker rhythm by modu-
lating Na+–Ca2+ exchange current. To study whether Na
+
–
Ca2+ exchanger activity might be affected by ischaemia, we
examined the effects of cyanide on Na+–Ca2+ exchanger
activity in isolated toad pacemaker cells. The reverse mode of
exchanger activity was estimated by measuring the ampli-
tude of [Ca2+]i rise in response to extracellular Na
+ removal.
After application of 2 mM NaCN for 3–5 min, the rise of
[Ca2+]i was significantly decreased from 377 ± 42 to 260 ±
46 nM (n = 8, P < 0.01). To study the forward mode of
exchanger activity, we recorded the Li-sensitive tail current
by using nystatin-perforated patch technique. The amplitude
of tail currents was also significantly decreased by CN– by 36
± 2.6%. To investigate the intrinsic properties of Na+–Ca2+
exchange during the metabolic inhibition, we simultaneously
recorded [Ca2+]i and Na
+–Ca2+ exchange current by using
rapid caffeine application. Caffeine induced [Ca2+]i signals
were reduced from 741 ± 106 to 509 ± 57 nM, while the
average inward current reduced from –121 ± 29 to –52 ±
12 pA. When current was plotted against [Ca2+], the slope of
the decay phase was decreased in the present of CN–, indica-
ting that for a given [Ca2+], there was less current produced.
The average slope was reduced to 44 ± 8% of control (n = 7,
P < 0.02). These results indicate that CN– inhibits Na+–Ca2+
exchanger activity, and such inhibition is at least partially
through the inhibition of the intrinsic properties of exchan-
ger. Therefore, the heart rate changes during the ischaemia
might be related to the changes of activity of Na+–Ca2+
exchanger.
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Abstract N° B68
Rise of intracellular Na2+ during cardiac ischaemia:
the underlying mechanisms
Iwan A. Williams, X.-H. Xiao, Yue-Kun Ju, D.G. Allen.
Department of Physiology (F13), University of Sydney,
NSW 2006, Australia
The importance of the intracellular sodium concentration
([Na+]i) in cardiac cells during and after ischaemia arises
because the increase in [Na+]i during ischaemia is removed
by the Na+–Ca2+ exchanger, which in turn increases [Ca2+]i,
thereby promoting myocardial damage. There is a dispute
over the mechanisms responsible for the increase of [Na+]i in
cardiac cells during ischaemia. One proposal is that the
cardiac Na+–H+ exchanger 1 (NHE1) causes Na+ entry in
exchange for H+ extrusion. Another proposal is that Na+
entry is via the tetrodotoxin (TTX)-sensitive persistent Na+
current. To distinguish these hypotheses, whole rat hearts
were isolated and perfused. [Na+]i was measured before,
during and after ischaemia. In control experiments, [Na+]i
increased slowly during ischaemia and rapidly upon reperfu-
sion. It was found that the rise of [Na+]i during ischaemia was
abolished by TTX (a Na+ channel blocker; 0.3 µM) and
amiloride (a low affinity NHE1 blocker; 0.1 mM), but not by
zoniporide (a high affinity NHE1 blocker; 1 µM). The rise of
[Na+]i following reperfusion was blocked by amiloride and
zoniporide. We propose that the rise of [Na+]i during ischae-
mia is due to a TTX- and amiloride-sensitive inward Na+
current. To test this hypothesis, single ventricular myocytes
were isolated from rat hearts and prepared for patch clam-
ping. Metabolic inhibition was produced by adding 2 mM
CN– to the pipette solution. Cells were then subjected to a
voltage-step protocol, which allowed both transient inward
Na+ current and an inward Na+ tail current to be measured.
All other currents were suppressed. Inward tail currents of
–15.6 ± 1.5 and –15.6 ± 1.7 pA were blocked by TTX and
amiloride, respectively. However, the tail current blocked by
zoniporide was significantly smaller (–6.9 ± 1.9 pA; P <
0.005). These results indicate that an inward tail current
allows the entry of Na+ into ventricular myocytes during
ischaemia, which is a major cause of the rise in [Na+]i.
Abstract N° B69
Effects of NCX inhibitor on underperfusion injury in
diabetic rat hearts
Makie Higuchi, Naoko Kouzuma. Division of
Pharmacology, Kyushu University of Nursing & SW,
Tamana, Kumamoto, Japan
We have reported that the diabetic (DM) than non-DM rat
hearts were more susceptible to flow reduction and readily
exhibited abnormal myocardial energy metabolism and in-
crease in the left ventricular (LV) diastolic stiffness. Norepi-
nephrine (NE) during underperfusion exacerbated the injury.
In non-DM hearts, a pathophysiological role of the Na+/Ca2+
exchanger (NCX) in myocardial ischemia–reperfusion in-
jury has been proposed. In DM hearts, depression in NCX
activity is reported. In the present study, therefore, the effect
of a NCX inhibitor on the underperfusion injury was exami-
ned in isolated paced DM rat hearts without or with NE.
KB-R7943 (3 × 10–6 M) was infused for 15 min before as
well as during 60-min underperfusion (2 ml/min/g heart
weight), and NE (10–6 M) during 55-min underperfusion.
The abnormal transmural energy metabolism and the in-
crease in LV stiffness during underperfusion without or with
NE both were not definitely improved by KB-R7943. It
rather tended to enhanced the injury with NE, particularly in
the LV subendocardium. The results indicate that at least an
increase in the outward Na+/Ca2+ exchange may not appre-
ciably contribute to the LV dysfunctions during 60-min un-
derperfusion with NE in DM rat hearts.
Abstract N° B70
Engagement of Na+–Ca2+ exchanger and Na+–K+
ATPase in the coronary artery relaxation induced by
isosorbide dinitrate
Jun Yamanaka, Junji Nishimura, Katsuya Hirano,
Hideo Kanaide. Div. Mol. Cardiol., Res. Inst. Angiocardiol.,
Grad. Sch. Med. Sci., Kyushu University, Fukuoka, Japan
Isosorbide dinitrate (ISDN) is widely prescribed in mana-
gement of ischemic heart diseases. Its vasodilating mecha-
nism still remains to be elucidated. We investigated a role of
Na+–Ca2+ exchanger (NCX) and Na+–K+ ATPase in the
ISDN-induced vasorelaxation, by simultaneously monito-
ring [Ca2+]i and tension in the fura-2 loaded medial strips of
porcine coronary artery. ISDN induced sustained decreases
in [Ca2+]i and tension during the contraction induced by
U46619 (a thromboxane A2 analogue) in the normal saline
(137.3 mM Na+). These decreases in [Ca2+]i and tension
were reduced by lowering [Na+]o or by two different NCX
inhibitors, KB-R7943 and 2′,4′-dichlorobenzamil. When
Ca2+ was replaced by Ba2+ (which is not extruded by Ca2+
pumps but by NCX), ISDN also decreased [Ba2+]i in the
normal saline but not in low [Na+] saline. A large part of the
ISDN induced decreases in [Ca2+]i and tension were reversed
by ouabain. This effect of ouabain was attenuated by either
lowering [Na+]o or diltiazem, and abolished by their combi-
nation. The ISDN-induced decreases in [Ca2+]i and tension
were abolished by ODQ (an inhibitor for guanylate cyclase).
Rp-8-Br-cGMPs (an inhibitor of PKG) substantially inhibi-
ted the ISDN-induced decreases in [Ca2+]i and tension, while
Rp-8-Br-cAMPs (an inhibitor of PKA) was only partially
effective. These results suggest that ISDN activates NCX
mainly by activating Na+–K+ ATPase through a cGMP–PKG
pathway and thereby induce vasorelaxation in the coronary
artery.
Abstract N° B71
The value of heart-type fatty acid-binding protein for
early detection of acute myocardial infarction
Y.I. Zhi-yong *, Xiao-ying Li Zhi-xin Jiang. Chinese PLA
General Hospital, Beijing 100853, China. * Corresponding
author.
To evaluate the diagnostic value of heart-type fatty acid-
binding protein (H-FABP) for early detection of acute myo-
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cardial infarction. Serum H-FABP of 126 healthy individuals
and 53 AMI patients were measured by self-development
ELISA. MYO, cTnI and CK-MB, traditional biochemistry
diagnostic markers, were estimated in the same time. The
dynamic changes of these myocardial indicators for AMI
patients were analyzed, and the diagnostic sensitivity and
specificity of them in the earlier period of AMI onset were
evaluated. The plasma concentration of H-FABP began to
increase at 1.84 ± 0.64 h, earlier than CK-MB and cTnI, after
AMI onset. The time–concentration dynamic curves of
H-FABP was similar to that of MYO and was in left compa-
red with both CK-MB and cTnI. The sensitivity and specifi-
city of H-FABP were 76.47% and 80.41% at 2 h after AMI;
89.16% and 91.26% at 4 h after AMI, respectively. H-FABP
seems more sensitive and specificity in diagnosis of AMI
early stage within 2 or 4 h after the onset. H-FABP probably
will become an important myocardial marker for diagnosis of
AMI in early stage.
Abstract N° B72
The effects of cholesterol on nuclear pore density
M.N. Landry, R.S. Faustino, A.L. Kostenuk, E. Dibrov,
G.N. Pierce. Division of Stroke and Vascular Disease, St.
Boniface Research Centre, University of Manitoba,
Winnipeg, Canada
The nuclear pore complexes (NPC) are channels found in
the nuclear envelope through which proteins are carried.
Protein movement into the nucleus can affect gene expres-
sion, cell proliferation and growth. Very little is known about
factors involved in altering NPC density. In view of the
altered cell proliferation that occurs under atherosclerotic
conditions, we investigated the possibility that cholesterol
may alter NPC density. New Zealand white rabbits were fed
a 0.5% cholesterol diet for 8 weeks and control groups were
fed a regular diet. Hepatic nuclei were isolated and nuclear
protein was analyzed by western blots and immunocytoche-
mistry using the antibody mAb414 that reacts to p62, an
integral NPC protein. Immunostaining of the isolated nuclei
for p62 displayed a high degree of punctate, fluorescent
staining in the control group. The cholesterol fed rabbits
showed a comparative decrease in immunostaining intensity.
Western blotting for the nuclear pore protein showed a de-
crease in band intensity in the cholesterol group as compared
to the control. These observations indicate a significant de-
crease in nuclear pore density in nuclei isolated from livers of
cholesterol-fed rabbits when compared to a control group.
Our data demonstrate that NPC expression is a dynamic
adaptable structure. Changes in pore density may have im-
portant implications for nuclear protein import and, ultima-
tely, gene expression.
Abstract N° B73
Cholesterol diet-induced hyperlipidemia influences
gene expression pattern of rat hearts: a DNA
microarray study
L.G. Puskás a, Z.B. Nagy a, Z. Giricz b, A. Onody b,
C. Csonka b, L. Hackler Jr a, A. Zvara a, P. Ferdinandy a.
a Laboratory of Functional Genomics, Institute of
Biochemistry, Biological Research Center, Hungarian
Academy of Sciences, Szeged, Hungary. b Cardiovascular
Research Group, Department of Biochemistry, University of
Szeged, Hungary
Hyperlipidemia influences myocardial function and car-
diac adaptation to ischemic stress via a yet unidentified,
direct action on the myocardium (see for reviews: TIPS
(1998); Br. J. Pharmacol. (2003)). To profile gene expression
patterns involved in the direct myocardial effect of
cholesterol-enriched diet-induced hyperlipidemia, we moni-
tored global gene expression changes by DNA microarray
analysis of 3200 genes in rat hearts. Twenty-six genes exhi-
bited significant upregulation and 25 showed downregulation
in hearts of rats fed 2% cholesterol-enriched diet for 8 weeks
as compared to age-matched controls. The expression chan-
ges of 12 selected genes were also assessed by real-time
quantitative PCR. Genes with altered expression in the heart
due to hyperlipidemia included procollagen type III,
cofilin/destrin, tensin, transcription repressor p66, synaptic
vesicle protein 2B, Hsp86, chaperonin subunit 5-epsilon,
metallothionein, glutathione S-transferase, protein kinase C
inhibitor, ATP synthase subunit c, creatin kinase, chloride
intracellular channel 4, NADH oxidoreductase and dehydro-
genase, fibronectin receptor beta-chain, CD81 antigen, farne-
syltransferase, calreticulin, disintegrin, p120 catenin,
Smad7, etc. Although some of these genes have been suspec-
ted to be related to cardiovascular diseases, none of the genes
have been previously shown to be involved in the mechanism
of the cardiac effect of hyperlipidemia.
Abstract N° B74
The antiatherogenic effect of mouse recombinant leptin
on high-fat diet induced oxidative stress
N. Nalini, J. Kalaivani Sailaja. Department of biochemistry,
Annamalai University, Tamil Nadu, India
Obesity, characterized by an excess of fat mass, is clearly
associated with an increased risk of cardiovascular patho-
logy. The link between increased adipogenesis, oxidative
stress and development of atherosclerosis is still not well
understood. Our aim in this study was to explore the tissue
lipid peroxidation and antioxidant status in mice administe-
red exogenous leptin along with high-fat diet (2% choleste-
rol, 0.125% bile salts and 5% peanut oil) for a period of
6 weeks. Significantly (P < 0.05) elevated levels of tissue
thiobarbituric acid reactive substances (TBARS), conjugated
dienes (CD) and significantly lowered levels of superoxide
dismutase (SOD), catalase (CAT), glutathione and its related
enzymes were observed in the heart, liver and kidney of mice
fed high-fat diet as compared with the control mice fed
standard pellet diet. Subsequent to the treatment with high-
fat diet (i.e. the initial period of 30 d) exogenous leptin
(230 µg/kg body weight) was simultaneously administered
every alternate day for 15 d along with the high-fat diet.
Leptin administration significantly lowered the tissue levels
of TBARS, CD and elevated the activities of SOD, CAT,
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reduced glutathione (GSH), glutathione peroxidase (GPX)
and glutathione S-transferase (GST) in both the control and
high-fat diet fed mice. Food intake and average body weight
at the end of the experimental period was significantly de-
creased on leptin administration. Thus, leptin administration
was found to be effective in attenuating high-fat induced
oxidative stress.
Abstract N° B75
Leptin downregulates lipid profile in mice fed a
high-fat diet
V. Balasubramaniyan, J. Kalaivani Sailaja, N. Nalini.
Department of biochemistry, Annamalai University, Tamil
Nadu, India
Dyslipidemia, atherosclerosis, diabetes, and obesity are
among the many risk factors associated with coronary artery
disease. The aim of our present study was to evaluate the
effect of leptin on plasma and tissue lipids in an experimental
model of atherosclerosis. Feeding a high-fat diet (2% choles-
terol, 0.125% bile salts and 5% peanut oil) to 4-week-old
healthy mice for a period of 45 d resulted in significantly
elevated levels of plasma and tissue total cholesterol, phos-
pholipids, free fatty acids and triglycerides as compared to
control mice fed the standard pellet diet. Subsequently after
30 d, exogenous leptin (230 µg kg–1 body weight i.p.) was
administered every alternate day for 15 d along with the
high-fat diet to another group. Leptin administration signifi-
cantly reduced body weight as well as the levels of total
cholesterol, phospholipids, free fatty acids and triglycerides
in the plasma, heart, liver and kidney of both the control and
high-fat fed mice. Moreover leptin administration markedly
reduced the levels of plasma low-density lipoprotein (LDL),
very low-density lipoprotein (VLDL) and elevated plasma
high-density lipoprotein (HDL) and the activity of lipopro-
tein lipase as compared with the untreated control and high-
fat fed mice. Thus, leptin administration was found to reduce
the risk of atherosclerosis markedly by virtue of its lipid
lowering effects.
Abstract N° B76
Effect of obesity and hydralazine treatment on diurnal
rhythms of blood pressure and heart rate
J.F. Carroll, J.W. King, A.M. Wright, J.J. Thaden.
University of North Texas Health Science Center, Fort
Worth, TX, USA
Obesity results in both hypertension and loss of heart rate
(HR) and blood pressure (BP) diurnal rhythms. Hypertension
itself is associated with loss of HR and BP diurnal rhythms.
Whether BP control in obesity restores diurnal rhythms is
unknown. We tested whether BP control using hydralazine
reversed loss of diurnal patterns during 12 weeks of deve-
loping obesity in rabbits. Female New Zealand white rabbits
were divided into lean control (LC, n = 8), lean hydralazine
treated (LH, n = 10), obese control (OC, n = 8) and obese
hydralazine-treated (OH, n = 11) groups. Obese rabbits ate
an ad lib high-fat diet; lean rabbits ate a maintenance diet. BP
was monitored from 1100 to 0700 h daily using telemetry.
Hydralazine treatment (6–14 mg/kg/d) began during week 2
of the dietary protocol. To evaluate diurnal rhythms, night
(0200–0700 h) values were subtracted from day (1100–
0400 h) values; groups were compared using one-way
ANOVA.
Abstract N° B77
The relationship between angiotensin-converting
enzyme gene polymorphism and peripheral arterial
occlusive disease
Xiaoying Li, Jin Chen, Jinsheng Li. Department of Geriatric
Cardiology, Chinese PLA General Hospital, Beijing
100853, China
To investigate the relationship between angiotensin-
converting enzyme (ACE) gene insertion/deletion (I/D) poly-
morphism and peripheral arterial occlusive disease (PAOD).
ACE genotypes of 100 patients with hypertension complica-
ted with PAOD and 150 hypertensive patients and 126 heal-
thy people were detected by polymerase chain reaction
(PCR) methods. To compare the differences of the distribu-
tion of ACE gene I/D polymorphism among the three groups.
The frequencies of ACE DD genotype and deletion allele in
hypertension complicated with PAOD group (0.23 and 0.44)
were significantly higher than those in hypertension group
(0.11 and 0.34, P < 0.05) and those in normal control group
(0.10 and 0.33, P < 0.01). There was no significant differen-
ces between hypertension group and normal control group (P
< 0.05). The D allele of ACE gene may be a susceptible gene
to presence of PAOD. ACE gene I/D polymorphism may be
not associated with presence of hypertension.
Abstract N° B78
The relationship between 4G/5G polymorphism located
in the promoter region of plasminogen activator
inhibitor-1 gene and peripheral arterial occulsive
disease
Xiaoying Li *, Lan Kang, Jinsheng Li. Department of
Geriatric Cardiology, Chinese PLA General Hospital,
Beijing 100853 China. * Corresponding author.
To explore the relationship between a single nucleo
deletion/insertion (4G/5G) polymorphis located in the pro-
Table 1
Day–night values
Group Control Week 12
BP HR BP HR
LC 2.8 ± 1.2 49.0 ± 9.7 4.9 ± 0.9 53.5 ± 7.5
LH 5.8 ± 1.3 56.5 ± 3.5 3.6 ± 0.9 41.9 ± 7.7
OC 6.5 ± 1.7 59.1 ± 4.9 –0.6 ± 1.2 25.3 ± 10.5
OH 4.0 ± 1.2 45.0 ± 6.9 –0.8 ± 0.5 15.1 ± 5.1
Groups did not differ in day–night BP or HR during the control period. After
12 weeks of high-fat feeding, day–night BP was reduced in OC and OH,
suggesting that there was no nighttime dipping of BP. Day–night HR was
lower in OH compared with LC and LH. These data suggest that obesity’s
role in the loss of HR and BP diurnal rhythms is independent of
hypertension.
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moter region of plasminogen activator inhibitor-1 (PAI-1)
gene and peripheral arterial occulsive diseases (PAOD). The
polymorphism of PAI-1 gene was analyzed by allele-specific
polymerase chain reaction (AS-PCR) technique in 100 pa-
tients with hypertension, 100 patients with hypertension with
PAOD, and 100 people as control subjects. In the meantime,
blood glucose, blood lipids, blood pressure and blood fibri-
nogen, body mass index (BMI), and ankle-arm index (AAI)
were studied. The frequency of 4G/4G genotype and 4G
allele frequency of PAI-1 gene significantly increased in
patients with hypertension with PAOD in comparison with
patients with hypertension and control subjects (P < 0.05,
respectively). While no significant difference was found
between the patients with hypertension and control subjects.
The levels of cholesterol and LDL were significantly in-
creased in patients with hypertension with PAOD group
compared with the other two groups (P < 0.05, respectively).
In patients with hypertension with PAOD group, the 4G/4G
genotype showed that the blood glucose, blood lipids (cho-
lesterol, low-density lipoprotein, LDL and triglyceride, TG),
blood fibrinogen, and BMI were higher than the 4G/5G
genotype and the 5G/5G genotype, but there was no diffe-
rence among them. The frequency of 4G/4G genotype and
4G allele frequency of PAI-1 gene were higher in patients
with hypertension PAOD than that in patients with hyperten-
sion and control subjects, which suggest that 4G allele fre-
quency of PAI-1 gene might be a risk factor of hypertension
with PAOD.
Abstract N° B79
The prevalence of peripheral arterial occlusive disease
and cardiovascular diseases in elderly population in
Beijing
Xiaoying Li *, Jie Wang, Yao He, Li Fan. Department of
Geriatric Cardiology, Chinese PLA General Hospital,
Beijing 100853, China
To determine the prevalence of cardiovascular diseases
(CVD) with peripheral arterial occlusive disease (PAOD) in
elderly population. A cross-sectional survey for PAOD was
made on the Wanshoulu area, Beijing. A total of 2124 sub-
jects, males 943, females 1183, aged 60–95 (68.54 ± 5.43)
years, were studied. PAOD was defined as an ankle–arm
index (AAI) ≤ 0.9. The prevalence of PAOD was 15.91%,
standardized 16.42% in Wanshoulu area. The prevalences of
essential hypertension, hyperlipidemia, coronary heart di-
sease (CHD) and diabetes in the population with PAOD were
55.8%, 54.3%, 41.0% and 25.4%, respectively, among which
the prevalences of hypertension (P < 0.01), CHD (P < 0.05)
and diabetes (P < 0.05) were significantly higher in the
population with PAOD than those without PAOD, respecti-
vely. And the prevalences of hypertension in female PAOD
(P < 0.001) and that of CHD in male PAOD population (P <
0.01) were higher than those without PAOD, respectively.
The prevalence of CVD in the population with PAOD was
1.36–1.63 times higher than those in the population without
PAOD. The prevalence of PAOD was 17.55% in the elderly
population with single CVD risk factor U = 3.8661, P <
0.001, 20.33% in those with double risk factors and 22.14%
in those with triple factors (v2 = 7.2408, P < 0.05), respecti-
vely. The prevalence of PAOD in this study was similar to
that in the developed countries and was increased signifi-
cantly with the increase of cardiovascular risk factors. The
prevalence of CVD in the population with PAOD was signi-
ficantly higher than that without PAOD.
Abstract N° B81
Heart rate variability, parasympathetic action and
cardiovascular risk
György Járos. School of Health Sciences, Bond University,
Gold Coast, Q 4229 and Barry Baker, Central Clinical
School, Sydney University, NSW 2006, Australia
Heart rate variability has been gaining increasing clinical
importance during the last three decades. Its presence has
been assumed to be an indication of appropriate adaptability
of the organism to external challenges. Its absence or dimi-
nution on the other hand, is understood to indicate parasym-
pathetic malfunction and to provide an indication of cardio-
vascular morbidity and mortality. However, the exact
mechanism of parasympathetic action is not entirely clear. It
is also not clear whether the relationship between the para-
sympathetic activity and the cardiovascular risk is causal or
simply correlational. Although many authors still regard pa-
rasympathetic involvement as being achieved through a di-
minished parasympathetic tone, it is becoming increasingly
clear that reflex parasympathetic mechanisms are involved.
Evidence is available from both scientific and medical litera-
ture to show that parasympathetic reflex activity is complex
and involves not only nervous reflexes, but also the spatio-
temporal regulation of nitric oxide, production and release of
insulin, glucose and hepatic insulin sensitizing substance
(HISS) as well as regulation of mineral metabolism in the
kidneys. Contrary to conventional belief, parasympathetic
reflex activity becomes of great importance during increased
states of activity, such as exercise or stress, when the para-
sympathetic tone is generally completely withdrawn. The
neuronal pathways that are involved comprise intrinsic car-
diac receptors and local neuronal circuits. There exist several
positive feedback pathways within this complex system that
includes the parasympathetic and sympathetic nerves, the
vascular endothelium, the liver, pancreas and the kidneys.
The presence of positive feedback reflexes may explain the
relationship between parasympathetic activity and cardio-
vascular morbidity and mortality can be explained.
Abstract N° B82
Using of the controlled breath for studying the
mechanisms of respiratory arrhythmia
A.R. Kiselev a, O.M. Kolizhirina a, V.F. Kirichuk a,
V.I. Gridnev b, P.Y. Dovgalevsky b. a State Medical
University, Chair of Normal Physiology, Saratov, Russia. b
Research Institute of Cardiology, Saratov, Russia
The aim is the studying of using the controlled-frequency
breath for investigation of mechanisms of respiratory ar-
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rhythmia. Twenty men and 15 women without the signs of
cardiovascular and respiratory pathology were involved in
the study. All the volunteers underwent tilt-test with control-
led frequency of breathing (period of breath was 4–12 s). The
depth and the phases ratio of controlled breathing did not
differ from those under the spontaneous breathing. During
the tilt-test the tachograms were registered for 3 min on each
stage of the controlled breath. Spectrum of the heart rhythm
was estimated using autoregressive algorithm. The intensity
of frequency modulation of heart rhythm depends on the
period of controlled breathing. More apparent modulation
was observed under 8, 10 and 12 s period of breath. The
maximal synchronization of the heart rhythm fluctuations
and the phases of respiration was observed under 10 s period
of breath. Supposing that there is the feedback system
between the control centers of cardiac and respiratory
rhythms, the coincidence of breathing frequency of internal
oscillatory process may provoke resonance amplification of
oscillations on the present frequency in the heart rhythm. In
accordance with our data, the oscillation frequency in the
feedback system between the control centers of heart and
respiratory rhythms is about 0.1 Hz. The intensity of the
frequency modulation of heart rhythm depends on the period
of breathing. The frequency of synchronization mechanism,
the respiratory phases and the heart rate fluctuations is about
0.1 Hz.
Abstract N° B83
Prevalence of diabetic retinopathy in diabetic
populations: evaluating the ethnic differences
J. Chellappah, C. Reid. Department of Epidemiology and
Preventive Medicine, Monash University, Alfred Hospital,
Prahran, Australia
Diabetic retinopathy (DR) is the fourth leading cause of
world blindness, and is an ever-increasing problem in deve-
loping nations. The relative importance of genetic heritage,
socio-economic status, culture, language and access to health
care among ethnic groups, in relation to the prevalence of DR
in diabetic populations, has remained unclear in the litera-
ture. This review aims to identify interacting or confounding
variables associated with ethnic differences, and the trends in
the prevalence of DR in diabetic populations of the United
States (US), United Kingdom (UK), Southern India (SI), and
Singapore. A MEDLINE search from 1975 to 2003 was
conducted through the PubMed search system. Data extrac-
tion was based on risk factors, prevalence, determination of
DR, and treatment strategies, followed by written critical
appraisal of the literature. In the US, PIMA Indians, African
Americans and Hispanics were at higher risk compared to
their Caucasian counterparts. Migrant Asians, in particular,
Indo-Chinese, were identified as high-risk groups in the UK.
Certain communities in SI reportedly exhibited higher risk
than other communities. Singaporean Indians and Malays
were also found to be in the high-risk category. There is a
strong evidence of ethnic disparities in the prevalence of DR
in diabetic populations, and this has been found to be closely
associated with variables such as socio-economic status, cul-
ture, genetic heritage, poor health education and awareness,
and language barriers. It is now important for researchers and
policy makers to better the causes of these disparities, to
evaluate programs, and to then implement programs and
policies necessary to address these disparities.
Abstract N° B84
A clustered randomised-controlled school community
intervention to improve the dietary habits and
cardiovascular risk factors of children and young
adults: pilot study
J. Chellappah, C. Reid, A. Tonkin. Department of
Epidemiology and Preventive Medicine, Monash
University, Alfred Hospital, Prahran, Australia
Multiple studies of children have demonstrated clearly
that systolic blood pressure, total- and LDL-cholesterol,
plasma insulin and obesity tend to cluster. A high likelihood
exists that such cardiovascular risk factors present in obese
children tend to track with age. Poor dietary habits developed
in childhood have been found to contribute to obesity in
children, and continue into adulthood. By aiming an inter-
vention at children, whose dietary habits are in the process of
being ingrained, the long-term benefits to adiposity and
health overall are likely to be optimised. This study involved
the participation of both parents and schools in (1) an inter-
vention of providing healthy eating information, and serves
of fruit daily in the classroom, over 8 weeks, (2) an assess-
ment of children’s dietary choices using 3-d-weighted food
diaries, food frequency and lifestyle questionnaires adminis-
tered during the intervention and post-intervention period,
(3) measures of body mass index, lipid and glucose levels,
and assessment of fitness levels of children, to evaluate any
changes in children’s adiposity and cardiovascular risk fac-
tors, which may have resulted during the course of this
intervention and post-intervention. Results have suggested
that baseline dietary habits were associated with cardiovas-
cular risk factors in this younger aged population. Baseline
dietary habits were also associated with parental demogra-
phic and dietary patterns. An increased number of children
meeting Australian Dietary Guidelines would contribute to
improvement in the overall health of the intervention popu-
lation, and may help reduce the incidence of obesity and
related disease burden.
Abstract N° B85
Atherogenic burden of hypertensive, diabetic and
hypertensive–diabetic patients seen in Jos Nigeria
B.A. Okeahialam a, Damaris A. Osunkwo b C.O. Isichei c.
a Department of Medicine, Faculty of Medical Sciences,
University of Jos, Nigeria. b Department of Medicine,
National Hospital, Abuja, Nigeria. c Department of
Chemical Pathology, Faculty of Medical Sciences,
University of Jos, Nigeria
The study set out to determine the atherogenic burden of
hypertensive, diabetic and diabetic–hypertensive patients.
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These diseases are known to accelerate atherosclerosis,
which puts patients at risk for ischaemic events. Twenty-four,
28 and 24 diabetic, hypertensive and diabetic-hypertensive
patients, respectively, were recruited. Fourteen apparently
healthy subjects served as controls. Blood samples were
collected and subjected to full lipid profile estimation. The
patients were significantly older than the controls (diabetic
vs. normal P < 0.001, hypertensive vs. normal P < 0.001,
diabetic-hypertensive vs. normal P < 0.001). The mean body
mass index (BMI) was significantly raised in diabetic-
hypertensive patients compared with the control (37.4 kg/m2
vs. 26.2 kg/m2 P < 0.001). Both the diabetics and hyperten-
sives did not significantly differ from the normals regarding
BMI. All the patient groups had significantly raised total
cholesterol levels (diabetic 6.0 mmol/l, hypertensive
6.4 mmol/l, diabetic-hypertensive 6.7 mmol/l). For the HDL
fraction, which is protective, the hypertensives and diabetic-
hypertensives had significantly higher levels than normals
(hypertensive vs. normal P < 0.02, diabetic-hypertensive vs.
normal P < 0.02). The diabetics had similar HDL levels with
the normal subjects. For the LDL atherogenic sub fraction,
only the diabetic-hypertensive had significantly raised levels
(4.7 vs. 3.5 mmol/l P < 0.05). All groups are at risk of
atherosclerosis given the high total cholesterol. The high
HDL levels would seem to protect the hypertensives and
diabetic-hypertensives. The diabetics from their low HDL
levels are therefore at the greatest risk. This is also borne out
by their TC/HDL ratio, which was the highest of all the
groups.
Abstract N° B86
Peripartum cardiomyopathy: correlation between
cholesterol, C-reactive protein and left ventricular
dysfunction
O. Forster, E. Libhaber, J. Kachope, H. Abbasi,
A. Pappachan, F. Peters, M.R. Essop, K. Sliwa. Department
of Cardiology, Chris Hani Baragwanath Hospital Soweto,
University of the Witwatersrand, Johannesburg, South Africa
Heart failure is characterised by activation of inflamma-
tory cytokines possibly due to increased endotoxin levels.
Lipoproteins are non-specific endotoxin buffers. We ana-
lysed the correlation between serum cholesterol level,
C-reactive protein (CRP) level and left ventricular dysfunc-
tion in patients with peripartum cardiomyopathy (PPCM).
Single centre, prospective study of 100 patients with newly
diagnosed PPCM. Clinical assessment, echocardiography
and cardiac scintigraphy were done at baseline and after
6 months of treatment. CRP and serum cholesterol were
measured at baseline only. Fifteen patients died and eight
were not available for follow-up. Total serum cholesterol was
4.2 ± 0.9 mmol/l, while CRP was 10.8 ± 13.2 mg/l with 45%
of patients having values >10 mg/l. We documented an in-
verse correlation between CRP and total serum cholesterol
(rs = –0.29, P = 0.01). Total serum cholesterol also correlated
inversely with left ventricular end-diastolic diameter (rs =
–0.35, P = 0.0009) and end-systolic diameter (rs = –0.38, P =
0.0001). The correlation between baseline serum cholesterol
and ejection fraction was positive (rs = 0.36, P = 0.0006). In
PPCM low serum cholesterol levels are associated with ele-
vated CRP levels at baseline and more severe left ventricular
dysfunction after 6 months of treatment.
Abstract N° B87
Predictors of mortality in 100 prospectively studied
patients with peripartum cardiomyopathy
O. Forster, E. Libhaber, C. Libhaber, A. Becker, A. Yip,
M.R. Essop, K. Sliwa. Department of Cardiology, Chris
Hani Baragwanath Hospital Soweto, University of the
Witwatersrand, Johannesburg, South Africa
Peripartum cardiomyopathy (PPCM) is a disorder of unk-
nown etiology. This analysis aims to identify predictors of
death in PPCM. Single centre prospective study of 100 pa-
tients with newly diagnosed PPCM. Clinical assessment,
echocardiography, cardiac scintigraphy and blood analysis
were done at baseline and after 6 months of therapy. All
patients received diuretics, angiotensin-converting enzyme
inhibitors and carvedilol. Fifteen patients died and eight were
not available for follow-up. Univariate analysis (Table 1)
showed significant differences in New York Heart Associa-
tion functional class (NYHA FC), systolic blood pressure
(SBP), end-diastolic dimension (EDD), end-systolic dimen-
sion (ESD), left ventricular ejection fraction (EF),
FAS/Apo-1 and aspartate aminotransferase (AST) between
non-survivors (Group 1) and survivors (Group 2).
Abstract N° B88
Troponin levels in patients with end-stage renal failure:
assessment by three different assays
L.H. Madsen a, S. Ladefoged b, A. Hodt c, F. Pedersen a,
P. Hildebrandt a, D. Atar c. a Department of Cardiology and
Endocrinology, Frederiksberg University Hospital,
Copenhagen, Denmark. b Department of Nephrology, State
University Hospital (Rigshospitalet), Copenhagen,
Denmark. c Division of Cardiology, Aker University
Hospital, Oslo, Norway
Introduction. – ESRF has long been known as a confoun-
ding factor for the assessment of cardiac troponin (cTn),
hampering the interpretation of cTn elevations for diagno-
Table 1
Group 1
(n = 15) *
Group 2
(n = 77) **
P
NYHA FC 3.3 ± 0.7 2.0 ± 0.8 0.04
SBP (mmHg) 102 ± 22 112 ± 17 0.002
EDD (mm) 64.9 ± 5.8 61.2 ± 7.2 0.032
ESD (mm) 57.7 ± 7.3 53.4 ± 8.0 0.032
EF (%) 22.8 ± 8.0 26.2 ± 8.3 0.04
FAS/apo-1 (U/ml) 9.8 ± 4.2 5.9 ± 3.9 0.002
AST (U/l) 50.4 ± 34.4 34.8 ± 24.0 0.036
* Non-survivors presented with higher NYHA FC and lower EF at baseline
than survivors.
** FAS/apo-1 (a marker of programmed cell death) and higher NYHA FC at
baseline were independent predictors of mortality.
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sing myocardial infarction. We performed a study in a cohort
of patients undergoing chronic haemodialysis in order to (i)
compare three commercially available and widely used cTn
assays in a population with ESRF and (ii) determine the
effect of dialysis on cTn levels.
Methods. – Ninety-seven patients (71 males, mean age
62 years) on chronic haemodialysis were analyzed with
blood samples on standardized time-points 1 h before and
after haemodialysis. Eighty percent of the cohort had known
hypertension (treated to 142 ± 22 mmHg), 34% had diabetes,
and 24% had documented coronary artery disease, but none
had symptoms, clinical signs or ECG alterations suggestive
of myocardial ischemia. Fifty-two percent had left ventricu-
lar hypertrophy, and mean left ventricular ejection fraction
was 51 ± 13%. The three cTn tests utilized were cTnT
(Elecsys 2010, Roche Diagnostics), cTnI (AxSYM, Abbott
Laboratories (Abb)) and cTnI (Access AccuTnI, Beckman
Coulter (B-C)).
Results. – cTnT (Upper Reference Limit URL =
0.01 ng/ml) was elevated to 0.023 pre-dialysis and 0.017
post-dialysis (all median, P < 0.001; mean: 0.061 vs. 0.046);
cTnI (Abb) (URL = 0.6 ng/ml) was 0.0 pre-dialysis and 0.0
post-dialysis (P = ns; mean: 0.196 vs. 0.20), and cTnI (B-C)
(URL 0.02 ng/ml) was 0.017 pre-dialysis and 0.014 post-
dialysis (P = 0.007; mean: 0.034 vs. 0.032). In expressing the
measurements as percentage of patients reaching cTn eleva-
tions above the diagnostic cut-off for myocardial infarction
(AMI), it was found that cTnT (cut-off > 0.1 ng/ml) dia-
gnosed 16.5% of the pre-dialysis patients as AMI, cTnI
(Abb) (cut-off > 1.0 ng/ml) diagnosed 5.9% as AMI, and
cTnI (B-C) (cut-off >0.1 ng/ml) diagnosed only 4.0% of the
patients as AMI. The corresponding post-dialysis numbers
were 14.4% for cTnI, 4.9% for cTnI (Abb), and 5.0% for
cTnI (B-C).
Conclusion. – In our cohort with no evidence suggestive
of myocardial ischemia or myocardial infarction, cTnT le-
vels were significantly more often false-positive than cTnI
levels as assessed by two different cTnI assays. While the
elevation of cTnT has been claimed to be a prognostic marker
for cardiovascular events and mortality, the cTnI assays seem
clearly superior for ruling out acute myocardial infarction in
this population (with no difference found between the two
assays). Dialysis decreases cTnT levels substantially, but
does not seem to alter cTnI levels in a clinically relevant
manner.
Abstract N° B90
High prevalence of chronic kidney disease in patients
undergoing elective coronary angiography
Arman Babajanyan, Robert A. Short, Katherine R. Tuttle.
The Heart Institute of Spokane, Spokane, WA, USA
Chronic kidney disease (CKD) is one of the strongest
predictors of outcomes in patients with coronary artery di-
sease (CAD). In clinical cardiology practice serum creatinine
measurement is the primary tool for assessment of kidney
function, but it may underestimate the true prevalence of
kidney disease. The aim of the study was estimation of the
prevalence of CKD among patients referred for elective coro-
nary angiography by using serum creatinine to calculate
glomerular filtration rate (GFR) and assessing urine albumin-
to-creatinine ratio. Data from study of 303 patients referred
for elective coronary angiography selected to have appa-
rently normal kidney function (serum creatinine <1.5 mg/dl
and normal urinalysis) is presented. Medical history, clinical
and laboratory tests, and angiographic severity of CAD were
also evaluated. Presence and stages of CKD were assessed
according to National Kidney Foundation Clinical Practice
Guidelines. Average age at admission was 62 (±10) years;
male/female ratio was 2.2:1. Overall prevalence of CKD (as
defined by GFR < 60 ml/min/1.73 m2 or presence of albumi-
nuria) was 37% (95% confidence intervals (CI), 31–42%).
Unadjusted for age, this value is 3.3 times higher than the
National Health and Nutrition Examination Survey III esti-
mate for adult population in the US (11%). Prevalence of
albuminuria standardized by age was 1.4 times higher than
for the general population (13% vs. 9%). Severity of CAD
was positively associated with prevalence of CKD. The risk
of having CKD in patients with angiographic presence of
CAD was 2.4 (95% CI, 1.4–4.3, P = 0.0003) times higher
compared to those without CAD. Moreover, 34% (95% CI,
29%–39%) of all patients with “normal” creatinine level
(<1.5 mg/dl) had CKD. CKD is a very common condition in
patients referred for elective coronary angiography even if
markers (serum creatinine and urinalysis) of kidney function
are normal by traditional criteria. It is important to recognize
the high prevalence of CKD in adult cardiac patients, as this
may allow better management strategies to avoid complica-
tions of cardiac procedures, as well as achieve better outco-
mes of treatment.
Abstract N° B92
Nuclear factor jB (NF-jb) inhibition reduces
myocardial expression of macrophage
colony-stimulating factor and of cell adhesion
molecules after mitral valve surgery
Joachim B. Grammer, Walter Eichinger, Rüdiger Lange,
Robert Bauernschmitt. German Heart Center, Munich,
Germany
Transcription factors have become an increasingly attrac-
tive target for potential therapeutic intervention. Since
NF-jB regulates gene expression of cell adhesion molecules
(CAMs) and inflammatory mediators such as the macro-
phage colony-stimulating factor (MCSF-1), we studied
whether pharmacological inhibition of NF-jB can prevent
CAM upregulation after mitral valve surgery. Seven untrea-
ted rabbits were compared to 14 animals which underwent
surgery, with a patch being sewed onto the mitral valve.
Thirty minutes prior to surgery, seven of the latter animals
had received 20 mg/kg pyrrolidine dithiocarbamate (PDTC)
i.p. an NF-jB inhibitor. Six hours after surgery, left ventricu-
lar tissue was collected and relative mRNA levels were ana-
lyzed by RT-PCR using 18S RNA as internal control. Expres-
sion levels (% of control ± SD) were as follows:
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Abstract N° B93
Coenzyme QI0 and l-carnitine alone and in
combination in CHF
D.M. Adarsh Kumar, Harharpreet Kaur,
Pushpa Devi Varun Mohan. Government Medical College,
G.N.D. Hospital, Amritsar, Punjab, India
Congestive heart failure (CHF) patients have a high mor-
tality. l-Carnitine and coenzyme Q10 (CoQ10) both improve
cardiac function by improving bioenergetics in failing heart.
Both are known to benefit heart failure (HF) cases indivi-
dually, but their combined long-term beneficial effect in CHF
has not been fully evaluated. Over the last 4 years, 309 CHF
cases (due to CAD, DCM and valvular lesions: NYHA Class
II–IV), with global LVEF ≤30% on echocardiography were
taken up for the study to evaluate and compare effects of
long-term treatment in HF patients in the control group I (on
conventional therapy of digoxin, diuretics, ACE inhibitors,
etc.: group I, 150 cases) and the treatment group II (159 cases
comprising three subgroups: subgroup IIa, 52 cases with
addition of oral carnitine alone (3 g); subgroup IIb, 53 cases
of CoQIO alone (120 mg), and addition of both drugs;
subgroup IIc, 54 cases in addition to conventional treatment.
Mean follow-up period was 18.9 months. As compared to the
control group, patients on combined drug treatment, showed
significant improvement in quality of life—68% vs. 34% in
group II/I. Functional class improvement was 68% vs. 46%
and reduction in hospitalizations 46% vs. 25%. There was
insignificant reduction in incidence of mortality and SCD.
Response was marginally better with addition of CoQ10
alone: group IIb, as compared to l-carnitine alone: group IIa.
To conclude, both CoQ10 and l-carnitine improve cardiac
contractile status in CHF. Their combination has additional
beneficial effect on survival in HF as they act at different
sites.
Abstract N° B94
Statins alone and in combination with coenzyme Q10
in dyslipidemias
Adarsh Kumar, H. Kaur, Varun Mohan, Pushpa Attri,
Sunil Attri. Government Medical College, Amritsar, India
Statins reduce coenzyme Q10 (CQ10) blood levels by
inhibiting mevalonoate synthesis, which is a substrate for
synthesis of both cholesterol and CQ10.The ‘statin-induced
cardiomyopathy’ and some other undesirable effects may be
prevented by simultaneous use of CQ10. Diastolic LV func-
tion is highly ATP dependant. The statins induced diastolic
LV dysfunction, fatigue, myalgia and myopathy and abnor-
mal transaminases appear to be due to their CQ10 depletion
effect. With this background 86 cases aged 37–74 years
(mean 51.2 years) and male/female 62/24 (72.1%/27.9%) of
hyperlipidemia were studied. Forty-nine/eighty-six (56.9%)
were given 20–40 mg atorvastatin alone and 47/86 (43.1%)
were given capsule CQ10—30 mg bd in addition. HF and
unstable angina cases were excluded. Duration of study was
6 months. Reduction in cholesterol/LDL and levels of global
LVEF were same in the two groups (P = 0.02). Baseline peak
E, peak A, E/A ratio, deceleration time, IVRT (ms); and
colour M-mode propagation velocity (cm/s) were much more
affected with atorvastatin alone than when it was used with
CQ10 (P < 0.05). Fatigue/myalgias and deranged liver func-
tion tests (LFTs) were seen in 10/49 (20.4%) vs. 3/47 (6.4%)
cases (P < 0.05) in atorvastatin alone/combination therapy.
No patient in either group developed myopathy or rhabdo-
myalinosis. Hence addition of CQ10 to statins may signifi-
cantly reduce their undesirable effects particularly diastolic
dysfunction, myalgic symptoms and abnormalities of LFTs.
Abstract N° B96
Impact of exercise training on plasma ET-1, BNP and
TNF-alpha and automatic balance and quality of life in
patients with severe heart failure and cor pulmonale
Xianghong Zeng, Xiangji Zeng, Yunyun Li,
Yuanhua Huang. Yongnhua Zeng Chengdu University,
Chengdu No 2 Hospital and Chengdu Red Cross Hospital,
China
Many studies have demonstrated that exercise training
represents a safe and effective therapy and reduces brain
natriuretic peptide (BNP), tumor necrosis factor-alpha (TNF-
alpha), endothelin-1 (ET-1), and improves automatic balance
in moderate heart failure. It remains unclear whether patients
with severe ischemic heart failure and cor pulmonale
(NYHA IIIb) also benefit from a training intervention. The
aim of the present study was to evaluate the effect of an
individual tailored exercise and ventilatory muscle training
on cytokines. BNP and ET-1, heart rate variability (HRV) and
quality of life score (QOL) in patients with severe ischemic
heart failure (IHF) and cor pulmonale. Forty-two patients
with stable IHF and cor pulmonale were randomized into an
exercise training group (four times daily bicycle ergometer
and ventilatory muscle training n = 21) or inactive control
group (n = 21). Plasma rest and peak exercise BNP, TNF-
alpha and ET-1, 24 h Holter monitoring for heart rate varia-
bility (HRV), a symptom-limited spiroegometry, left ventri-
cular ejection fraction (LVEF) by echocardiography and
Minnesota quality of life score (QOL) were assessed at
randomization and after 6 months. In the exercise group,
HRV analysis showed significant changes in SDNN and
SDANN index (P < 0.05), but not in pNN50 and rMSSD,
suggesting sympathetic activity reduction rather than para-
ELAM-1 PECAM-1 VCAM-1 MCSF-1
Control 100.0 ± 28.5 100.0 ± 41.9 100.0 ± 41.0 100.0 ± 25.0
Mitral valve
surgery




* P = 0.29
81.5 ± 13.5;
* P < 0.001
53.5 ± 40.7;
* P = 0.29
576.3 ± 211.5;
* P = 0.165
* Compared to mitral valve surgery group. PDTC pre-treatment clearly
reduced CAM and MCSF expression in the left ventricle. Our data confirm
that transcription of CAM and MCSF-1 mRNAs is controlled by NF-jB and
suggest that in our animal model NF-jB inhibition effectively suppresses
their transcription. Thus, NF-jB may be a promising target for
pharmacological intervention in order to limit inflammatory processes
during and after cardiac surgery.
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sympathetic activity increase. Decrease in rest and peak
BNP, TNF-alpha and ET-1, increase of exercise capacity and
improvement of QOL in exercise group were greater than
those in control group (P < 0.01). Our data suggest that a
carefully designed and individually tailored aerobic exercise
and ventilatory muscle training in patients with stable ische-
mic heart failure and cor pulmonale is not only associated
with an increase in exercise tolerance and improvement of
QOL and autonomic balance but also decreased plasma rest
and peak BNP, TNF-alpha and ET-1 levels.
Abstract N° B97
Impact of berberine on TNF-alpha and activity of
aldose reductase in cardiorenal syndrome secondary to
diabetic heart failure
Xianghong Zeng, Xiangji Zeng, Yunyun Li. Chengdu
University, Chengdu No. 2 Hospital, China
Circulating plasma TNF-alpha level and activity of aldose
reductase (AR) is associated with development of heart
failure and diabetic nephropathy. In our previous studies,
berberine may decrease plasma TNF-alpha levels in patients
with chronic heart failure and inhibit activity of AR of red
cells in diabetic patients. We hypothesized that short-term
berberine therapy may have beneficial effects in patients with
cardiorenal syndrome in diabetic heart failure.
Methods and results. – Sixty-nine patients with cardiore-
nal syndrome in diabetic heart failure were randomly divided
into berberine (B 0.2 three times a day n = 35) or placebo (P
n = 34). Clinical characteristics between two groups were
same. Fasting blood glucose, plasma TNF-alpha, activity of
AR in red cell.beta 2-MG, urine albumin excretive rate
(UAER), 6 min walking distance and Minnesota Living with
Heart Failure (MLWHF) score were assessed before rando-
mization and 6 months after treatment. Plasma TNF-
alpha.beta 2-MG in blood, activity of AR in red cell and
UAER in B group decreased remarkably than in P group.
Increase of 6 min walking distance and improvement of
MLWHF in patients receiving B were remarkable than in P.
Serum creatinine in B group had slightly lower but had
increase in P.
Conclusions. – B may decrease plasma TNF-alpha and
activity of AR and improve renal function, exercise capacity
and quality of life in patients with cardiorenal syndrome
secondary to diabetic heart failure during 6 month treatment.
Abstract N° B98
Clinical observations of effects of sheng mei for patient
with profile L in chronic heart failure
Xianghong Zeng, Xiangji Zeng, Yunyun Li, Yuanhua
Huang. Wenzhen Wu Chengdu University, Chengdu Second
People’s Hospital, Chengdu Red Cross Hospital and
Dujianyan Municipal People’s Hospital, China
Patients with profile L, those with low cardiac output
without clinical evidence of elevated filling pressure, often
do not improve acutely with adjustments of oral therapy. No
trials have targeted this small group. The aim of present study
was to observe efficacy and safety of sheng mei for profile L
in chronic heart failure.
Methods and results. – Clinical effects and safety of
sheng mei in 112 patients with class II–III symptomatic and
LVEF <40% with profile L of chronic heart failure secondary
to coronary heart disease or dilated cardiomyopathy were
observed by five medical centers in China. The patients were
divided into sheng mei group (60 ml/d n = 57) and placebo (n
= 55). Clinical characteristics between two groups were
similar. Six minute walking test (6MWT), LVEF and Minne-
sota Living with Heart Failure (MLWHF) score were as-
sessed at randomization and after 6 months. 6MWT, LVEF
and MLWHF score in sheng mei group improved more re-
markably than those in placebo group (see Table 1). There
were no significant differences in side-effects between the
two groups.
Conclusions. – Sheng mei may improve quality of life and
increase LVEF and exercise tolerance without side effects
during 6 month of treatment in patients with profile L of
chronic heart failure.
Abstract N° B99
Beneficial efficacy of losartan for ischemic heart failure
with cor pulmonale
Zeng Xianghong, Li Yunyun. Chengdu University, Chengdu
Second People’s Hospital, 610017 China
Objective. – The aim of study was to ascertain safety and
efficacy of long-term losartan therapy on ischemic heart
failure with cor pulmonale.
Methods and results. – Two hundred seventeen patients
with ischemic heart failure with cor pulmonale (CPHA) were
randomly divided into two groups. All patients were given
conventional therapy for CHF and anti-inflammatory drugs
consisting of digoxin, nitrates and spironolactone. Patients in
the treatment group (n = 109) were also given losartan
50 mg/day. The other 108 patients were given diltiazem.
Symptoms, 6 min walk testing, left ventricular ejection frac-
tion (LVEF), quality of life, and TNF-a, IL-1b, IL-6 and ET
were assessed after 8 weeks of treatment and during a mean
of 12 and 24 months follow-up. Improvement quality of life
and exercise tolerance, decrease in plasma TNF-a, IL-I b,
IL-6 and ET-I level and mortality in losartan group were
more significant than those in diltiazem. And there were no
apparent side effects in the treatment group.
Conclusions. – Losartan may improve quality of life,
exercise tolerance, decrease plasma cytokines and ET level
and mortality during 2 years treatment.
Table 1
MLWHF 6MWT LVEF
Sheng mei (%) –16.4 16.6 5.6
Placebo (%) –1.1 5.9 5.6
P <0.005 <0.01 <0.05
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Abstract N° B100
Atorvastatin for severe ischemic heart failure with cor
pulmonale
Xianghong Zeng, Yunyun Li, Xiangji Zeng. Yunhuan Zeng,
Chengdu University, Chengdu Second People’s Hospital,
Chengdu 610017, China
Heart failure and cor pulmonale are associated with in-
flammation and neurohormonal imbalance. The 3-hydroxy-
3-methylglutaryl-3-CoA reductase inhibitors (statins) pos-
sess anti-inflammatory and vascular protective effects. We
hypothesized that atorvastatin may be beneficial effect for
severe ischemic heart failure with cor pulmonale since these
diseases both cause inflammation and vascular endothelial
dysfunction.
Methods and results. – One hundred twenty-three pa-
tients with severe ischemic heart failure combined with cor
pulmonale were randomly divided into groups. One group
received atorvastatin 10 mg/day (n = 62), and the other group
received placebo (n = 61). The initial dose of atorvastatin was
5 mg/day, which was increased to 10 mg/day after 1 month.
After 6 months, patients receiving atorvastatin exhibited a
modest reduction in low-density lipoprotein (LDL)-C level
compared with patients receiving placebo (126 ± 11 vs. 141 ±
17 P < 0.01), improvement of New York health association
(NYHA) functional class in atorvastatin group was more
remarkably than that in placebo group (2.16 ± 0.06 vs. 2.42 ±
0.08 P < 0.01). This corresponded to improved left ventricu-
lar ejection fraction (LVEF) in treatment group (21 ± 3 to 32
± 5 P < 0.01) but not in the placebo group. And plasma
TNF-alpha, interleukin (IL)-6, IL-18, ET-1 and brain natriu-
retic peptide were significantly lower than those in the ator-
vastatin group compared with the placebo group.
Conclusions. – Atorvastatin may improve cardiac func-
tion, neurohormonal imbalance, symptoms associated with
severe ischemic heart failure and cor pulmonale and decrease
circulating pro-inflammatory cytokine levels.
Abstract N° B101
Sulfaphenazole reduces post-ischemic vascular
dysfunction
Nicola Bai, Arwen L. Hunter, Ismail Laher,
David J. Granville, James Hogg. iCAPTURE Centre for
Cardiovascular and Pulmonary Research, St. Paul’s
Hospital, University of British Columbia, Vancouver, BC,
Canada
We recently demonstrated that cytochrome p450 2C
(CYP2C) inhibitors significantly reduce infarct size caused
by cardiac ischemia and reperfusion (I/R) using a rat Langen-
dorff perfusion model of global ischemia and a rabbit LAD
occlusion model of regional ischemia (Proc. Natl. Acad. Sci.
USA 101 (2004) 1321–1326). CYP2C inhibition reduced
superoxide generation and augmented coronary flow. In this
study, we hypothesize that CYP2C-mediated superoxide pro-
duction results in nitric oxide scavenging, production of
peroxynitrite and reduced endothelial-dependent, nitric
oxide-mediated vasodilation. To test this hypothesis, rat
hearts were perfused in Langendorff mode for 20 min in the
presence, or absence, of the specific CYP2C9 inhibitor sul-
faphenazole (10 µM) and then subjected to 30 min global
no-flow ischemia followed by 15 min reperfusion. Septal
coronary resistance arteries were isolated and mounted on
glass cannulae for measurements of luminal diameter. Arte-
rial tone was increased with U-46619 and tissues were ex-
posed to increasing concentrations of acetylcholine (1–
10 µM) to elicit endothelial-dependent, nitric oxide-
mediated vasodilation. Acetylcholine caused near maximal
dilation in control tissues not subjected to I/R. Following
30 min global ischemia and 15 min reperfusion, endothelial-
dependent vasodilation occurred with reduced sensitivity and
the maximal effect of acetylcholine was also attenuated.
Pretreatment with sulfaphenazole restored both the sensiti-
vity and maximal effect of acetylcholine. In summary, sulfa-
phenazole restored post-ischemic endothelium-dependent,
nitric oxide-mediated vasodilation. This work was supported
by grants from the CIHR and Michael Smith Foundation
(MSF) DJG is a Tier II Canada Research Chair and MSFHR
Scholar.
Abstract N° B102
Characterization of vascular reactivity of human
umbilical artery in normal and reduced oxygen
conditions
S.W.S. Leung a, A. Quan a, T.T. Lao b, R.Y.K. Man a. a
Departments of Pharmacology, The University of Hong
Kong, HKSAR, China. b Obstetrics and Gynecology, The
University of Hong Kong, HKSAR, China
This study investigates the responses of the human umbi-
lical artery to various contracting and relaxing agents in order
to determine the mechanisms involved in the regulation of
the umbilical cord vascular tone. Rings of human umbilical
arteries from full-term caesarian deliveries were suspended
in tissue baths containing warm Krebs–Henseleit buffer un-
der normal and reduced oxygen conditions. These rings were
contracted with cumulative additions of potassium chloride,
serotonin, bradykinin, endothelin-1, histamine and a throm-
boxane A2 mimetic, U46619. Among these vasoconstrictors,
only serotonin and U46619 elicited strong and sustained
contractions at physiological concentrations in both oxygen
conditions. Therefore, potassium chloride (50 mM), seroto-
nin (10 µM) or U46619 (1 µM) were used to contract human
umbilical arterial rings, which were then relaxed with the
nitrovasodilator sodium nitroprusside, the potassium channel
opener levcromakalim or the calcium antagonist amlodipine.
Our data suggest that the responses of the human umbilical
arteries to constricting agents, but not relaxing agents, were
greater in the condition with a reduced oxygen supply. The
nature of the constricting agents used did not affect the
potency or efficacy of sodium nitroprusside, levcromakalim
or amlodipine to relax human umbilical artery. While all
three relaxing agents had similar potencies in this tissue
preparation, sodium nitroprusside induced significantly
smaller relaxation compared to levcromakalim and amlodi-
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pine. These data suggest that serotonin and thromboxane A2
effectively constrict human umbilical artery at physiological
concentrations. Moreover, the smooth muscle of the human
umbilical artery is less responsive to vasodilators that act via
the nitric oxide pathway. As such, nitric oxide donors may
not be effective therapeutic agents to reduce the elevated
umbilical contractile tone in pathological conditions.
Abstract N° B103
Holistic preparation for cardiac surgery in high risk
and elderly patients utilising a combination of
metabolic, physical and mental therapy
F. Rosenfeldt *, A. Hadj, J. Lewin, S. Pepe, D. Esmore.
Department of Cardiothoracic Surgery, Alfred Hospital and
Baker Institute, Melbourne, Victoria, Australia
Cardiac surgery represents major stress, which in ageing
patients is associated with increased production of reactive
oxygen species. Previous studies examining individual ef-
fects of antioxidant therapy and physical and mental prepa-
ration have shown benefit but no studies investigated the
combined effect. The methods we evaluated were a preope-
rative metabolic, physical and mental program. Antioxidants
coenzyme Q10 (300 mg) and a-lipoic acid (300 mg), combi-
ned with magnesium orotate (1200 mg), and omega-3 fatty
acids (1 g) were given daily with exercise and stress reduc-
tion therapy. A quality of life (QOL) questionnaire (SF-36)
was administered before and after the program. A survey
gauged gave satisfaction and benefit. QOL assessments be-
fore and after the program (pre-surgery) (n = 16) showed
increase in: physical QOL from 33.5 ± 4.12 before, to 41.0 ±
4.5 after the program (P = 0.005); mental QOL from 44.3 ±
4.5 before, to 54.1 ± 5.3 afterwards (P = 0.006). QOL before
and 1 month after surgery, also showed improvement in
physical QOL in the MPM group from 37.7 ± 5.0 before, to
56.5 ± 7.0 afterwards (P = 0.01), the control group showed
deterioration (P = 0.05). Mental QOL was similar: improve-
ment in the MPM group from 48.4 ± 6.2 to 65.0 ± 5.7 (P =
0.048) and deterioration in the control group (P = 0.05).
Malondialdehyde levels decreased from 23.9 ± 2.5 before the
program to 13.2 ± 2.1 µM/ml afterwards (P = 0.026). The
survey (n = 11) showed that 100% of patients rated satisfac-
tion as excellent/very good with 68% and 60% benefiting
from the exercise and mental component, respectively. Com-
bined metabolic, physical and mental preparation prior to
major surgery is satisfying to the patient, reduces oxidative
stress and improves patient QOL.
Abstract N° B104
Beneficial effects of antioxidants on
catecholamine-induced arrhythmias
Ken S. Dhalla, Rajat Sethi, Vijayan Elimban,
Naranjan S. Dhalla. Institute of Cardiovascular Sciences, St.
Boniface General Hospital Research Centre and University
of Manitoba, Winnipeg, Canada
Oxidation products of catecholamines are known to cause
arrhythmias. Since the mechanisms of this action are not
clear, this study was designed to investigate the beneficial
effects of antioxidants on catecholamine-induced arrhyth-
mias. Rats were treated with or without different antioxidants
such as vitamin A (30 mg/kg), vitamin E (20 mg/kg), vitamin
C (100 mg/kg) and N-acetylcysteine (NAC, 200 mg/kg) for
2 d before studying the cumulative effects of epinephrine.
Our results show that the minimum dose of epinephrine
required for inducing arrhythmias in control was 4 µg/kg
whereas the dose of epinephrine was 16 µg/kg in the treat-
ment group. The onset time (s) of arrhythmias was 13.6 ± 1.1,
19.1 ± 0.6, 19.6 ± 1.3, 20.1 ± 0.8 and 21.4 ± 0.4 whereas the
duration (s) of arrhythmias was 149 ± 11, 41 ± 5, 40 ± 6, 87 ±
4 and 30 ± 2 in control, vitamin A, vitamin E, vitamin C and
NAC treated animals, respectively. In order to assess the
status of oxidative stress, changes in malondialdehyde
(MDA) (µmoles/l) were measured in the heart and plasma.
Cardiac MDA and catecholamine levels were not changed in
any of the groups; however, a significant difference in MDA
levels was seen in plasma from control and antioxidant trea-
ted animals. On the other hand, epinephrine induced changes
in hemodynamic parameters were not altered by any of the
antioxidant treatment. These results thus support the view
that epinephrine induced arrhythmias may be mediated by
oxidation products of catecholamines and the beneficial ef-
fects of antioxidants may not be due to their direct effect on
the heart.
(Supported by a grant from Heart and Stroke Foundation
of Manitoba).
Abstract N° B105
The ability of macrophages from the blood of patients
with ischaemic heart disease and healthy donors for
LDL oxidation and uptake
M.V. Bilenko, A.V. Khilchenko, N.A. Nikitina. Moscow,
Russia
It is known that the contents of cytokines and lipid peroxi-
dation products in the blood increase in the patients with
ischaemic heart disease (IHD), and our earlier studies have
shown that TNF-a promotes the priming or activation of
macrophages (MP) in vitro, increasing their ability to oxidize
low-density lipoprotein (LDL). The purpose of this work was
to find out if the same activation of MP with IHD (MPIHD)
would take place in vivo. LDL from the blood of donors with
low (LDLn) and high (LDLh) cholesterol (CH) levels were
incubated with MP with healthy donors (MPN) and MPIHD
cultures for 1–24 h under aerobic or ischaemic conditions. It
was shown that the sensitivity of MPIHD to LDLn and LDLh
was expressed to a greater extent than that of MPN, especially
under ischaemia. The contents of TBARS in LDLn and
LDLh gradually decreased after 1–24 h of incubation (to a
lower level in LDLh than in LDLn), whereas LDL electro-
phoretic mobility increased, reaching a peak after 24 h.
Accumulation of CH (ng/mg proteins) in MPN and MPIHD
after incubation with LDLn and LDLh increased by a factor
of 1.2–2.4 (to a higher level in LDL incubated with MPIHD).
Accumulation of CH in MPN (ng/10
3 viable cells) after incu-
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bation with LDLn and LDLh for 3–6 h increased by factors
of 3.0–4.0 under aerobic and 2.7–6.9 under ischaemic condi-
tions. The same parameter in MPIHD after incubation with
LDLn and LDLh for 3–6 h increased by factors of 4.7–7.8
and 5.7–9.1, under aerobic and ischemic conditions, respec-
tively. This parameter in MPIHD after incubation for 3–6 h
exceeded the same parameter in MPN in 1.5–3.4 times. Expe-
rimental data showed that IHD was accompanied by in vivo
activation of blood MP, leading to their increased ability for
LDL oxidation and uptake. This phenomenon was better
expressed in the case of LDLh than LDLn and under ischae-
mic rather than aerobic conditions. Therefore, IHD, local
ischaemia and high blood cholesterol stimulate LDL oxida-
tion and uptake by MP and, hence, are responsible for speci-
fic localized atherosclerotic plaque formation. The study was
supported by RFFR.
Abstract N° B106
Comparison of Cu2+-, endothelial cell - and
macrophage -induced oxidative modification of LDL
under aerobic and ischaemic conditions
M.V. Bilenko. Moscow, Russia
The main factors responsible for low-density lipoprotein
(LDL) oxidation in vivo are transition metals, endothelial
cell (EC), and macrophage (MP), but their effects on LDL
taken from healthy donors (LDLn) and patients with high
cholesterol (HC) levels (LDLh) and on LDL incubated under
aerobic or ischaemic conditions have not been compared. We
studied the effect of these three oxidant models on LDLn and
LDLh upon their co-incubation for 0.5–24 h. The accumula-
tion of lipid peroxidation (LPO) products: TBARS and Schiff
bases, and relative electrophoretic mobility (REM) in aga-
rose gel were used as indices of LDL oxidation, and the
accumulation of cholesterol in MP, as an index of LDL
uptake. MP was taken from the blood of healthy donors. The
results were as follows: (1) Incubation of LDLn and LDLh in
vitro with CuSO4, EC and MP resulted in the accumulation
of LPO products. Their content was higher in LDLh than in
LDLn, but this difference was significant only at the early
stage of incubation. (2) Incubation of LDLn and LDLh with
CuSO4, EC, and MP entailed an increase in their REM. In all
the models, the lag phase of change in REM was shorter in
LDLn than in LDLh, which could be explained by LDL
fragmentation and, in the MP model, also by more rapid LDL
uptake. (3) With respect to the potential for LDLn and LDLh
oxidation, the models could be arranged in the following
series: CuSO4 > EC > MP. (4) LDLn and LDLh oxidation by
EC and their oxidation and uptake by MP were enhanced
under ischaemia, compared to those under aerobic condition.
(5) TNF-a (one or two small doses) promoted the priming or
activation of MP, increasing their ability to oxidize LDL. (6)
Antioxidants, such as K-phenozane, desferal and probucol as
well as antihypoxant deltoran inhibited EC-, MP- and EC +
MP-induced LDL oxidation. Therefore all the three factors
caused LDL oxidation in vitro and in vivo; in the case of MP,
this was accompanied by rapid LDL uptake. These factors,
together with local ischaemia, and high cholesterol level,
represent a very high risk of atherosclerotic plague forma-
tion. The study was supported by RFFR.
Abstract No B107
Protective role of pentoxifylline in ischemia reperfsion
induced heart injury in rats
Ming Zhang, Yan-Jun Xu, Vijayan Elimban, and Naranjan
S. Dhalla. Institute of Cardiovascular Sciences, St. Boniface
General Hospital Research Center and University of
Manitoba, Winnipeg, Canada
Although, pentoxifylline (PTXF), a methylxanthine phos-
phodiesterase inhibitor, is clinically used to prevent ischemic
heart damage during cardiac surgery, the mechanism of its
effect on ischemia reperfusion (I/R) induced heart injury is
not clear. Since PTXF has been reported to prevent the
production of TNF-a in heart failure and cardiomyopathy, we
examined whether PTXF protected the heart from I/R injury
due to its effect on depressing TNF-a synthesis and blocking
NFjB activation. The isolated rat hearts were subjected to
global ischemia for 30 min, followed by 30 min of reperfu-
sion ; PTXF was given for 10 min before ischemia as well as
for 30 min during reperfusion period. I/R caused significant
change in cardiac contractile parameters, as indicated by a
decrease in the rate of contraction (+ dP/dt), rate of relaxa-
tion (—dP/dt) and left ventricular developed pressure
(LVDP), as well as an increase in left ventricular end diasto-
lic pressure (LVEDP) ; these changes were significantly im-
proved by PTXF treatment. An increase in TNF-a protein
levels and an activation of NFjB in I/R group were also
attenuated by PTXF treatment. In order to determine whether
the beneficial effect of PTXF is related to alteration in intra-
cellular Ca2 + concentration, Ca2 + paradox model was also
used. PTXF treatment partially prevented changes caused by
Ca2 + paradox in cardiac contractile parameter and TNF-a
production as well as the activation of NFjB. These observa-
tions indicate that PTXF rendered cardioprotection by Ca2 +
related mechanisms associated with reducing the TNF-a
synthesis and blocking the activation of NFjB. (Supported
by CIHR Group Experimental Cardiology).
Abstract N° B108
Involvement of LPA subtype-specific receptors
expression in heart remodeling of AMI rat
J.H. Chen, Y.F. Chen, Y.J. Yang, X. Chen Cardio-vascular
Institute of Peking Union Medical College, Beijing,
PR China
To investigate LPA receptor mediated signal transduction
in left ventricle remodeling process, the relationship between
the pattern of mRNA expression of LPA receptor subtypes
and the myocardial hypertrophy and apoptosis in rat hearts
after acute myocardial infarction (AMI) was studied. AMI
model was established with the ligation of anterior descen-
ding coronary artery in Sprague–Dawley (SD) rat. 24 h after
AMI, the 58 survivors were served as AMI (MI) group.
Sham-operated (S) group was selected as control. Each
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group was randomly divided to two subgroups, 48 hours
(48h) and 4 weeks (4w) groups according to the time point
observed. After the completion of hemodynamic study, pa-
thological examination on the thickness of ventricular sep-
tum performed. Cardiomyocyte apoptosis was detected by
TUNEL and DNA ladder assay. The mRNA expression of
LPA receptor subtypes was determined by RT-PCR. Compa-
red with S group, LVSP and ±dp/dt decreased and LVEDP
elevated significantly in 48h and 4w group. The thickness of
ventricular septum was obviously changed between MI and S
group in 4w group but not in 48h group. Numerous TUNEL-
positive cells and DNA ladder were found in tissue at 48h
after AMI but apoptosis was prone to decreased at 4w MI
group. Compared with S group, there was no remarkably
difference in mRNA expression of LPA type 1 and type 2
receptor (LPA1 and LPA2) whereas mRNA level of LPA3
was increased by 40% at 48h after AMI, and the mRNA
expression of LPA1 and LPA3 significantly increased by
98% and 120%, yet no difference was found in LPA2 mRNA
levels in 4w group. At 48h after AMI, a remarkable cardio-
myocyte apoptosis was accompanied with the notable in-
crease of LPA3 mRNA expression suggesting that LPA3 may
concern the signal pathway of apoptosis in early period after
AMI. At 4w after AMI, notable increase of LPA1 and LPA3
mRNA level came with obvious cardiomyocyte hypertrophy
and unconspicuous apoptosis, revealing that LPA1 may
mainly mediate the signal pathway of cardiomyocyte hyper-
trophy while LPA3 might involve in apoptosis in the process
of left ventricle remodeling after AMI in rats.
Abstract N° B109
Arachidonic acid inhibits
hypoxia/reoxygenation-induced injury by upregulation
of the phosphatase, MAPK-1, in cardiomyocytes
A.-M. Engelbrecht a, C. Page b, A. Lochner a. a Departments
of Physiological Sciences, University of Stellenbosch,
Stellenbosch, South Africa. b Department of Medical
Physiology and Biochemistry, University of Stellenbosch,
Stellenbosch, South Africa
We have previously demonstrated that hypoxia/
reoxygenation-injury induced MAPK activation in neonatal
cardiomyocytes and that arachidonic acid (ARA) protected
the myocytes via attenuation of p38-MAPK activation. The
aim of this study was to evaluate the putative role of the
phosphatases in this phenomenon. Cultured neonatal cardio-
myocytes were exposed to 20 µM ARA complexed to BSA
for an hour before the onset of 60 min of hypoxia (chemical
hypoxia was induced by deoxyglucose and KCN) followed
by 30 min reoxygenation. To further investigate the mecha-
nism of action of ARA on p38-MAPK inhibition, we em-
ployed okadaic acid (1 µM), an inhibitor of type 1 and type
2A serine/threonine phosphatases as well as orthovanadate
(100 µM), a specific inhibitor of tyrosine phosphatases (in-
cluding MAPK-1 (mitogen activated protein kinase phospha-
tase)). Vanadate, but not okadaic acid, significantly reduced
ARA-induced inhibition of p38-MAPK activation. Thus, our
data provide evidence for ARA-induced inhibition of p38-
MAPK through activation of a tyrosine phosphatase during
hypoxia/reoxygenation. We targeted MAPK-1 (a subclass of
the tyrosine specific protein phosphatases and a member of
the dual specific phosphatases, DSPs), and found ARA to
cause a sixfold activation of MAPK-1 during
hypoxia/reoxygenation. An in vitro dephosphorylation assay
was used to demonstrate that it was the phosphatase which
was responsible for inhibition of the kinase. We conclude that
ARA exerts its beneficial effect during hypoxia/
reoxygenation through activation of MAPK-1 causing de-
phosphorylation of p38-MAPK.
Abstract N° B110
Attenuation of isoproterenol-induced increase in
intracellular calcium in cardiomyocytes isolated from
ischemic–reperfused hearts
Harjot K. Saini, Vijayan Elimban, Naranjan S. Dhalla.
Institute of Cardiovascular Sciences, St. Boniface General
Hospital Research Centre and University of Manitoba,
Winnipeg, Canada
Although isoproterenol is known to cause an increase in
intracellular Ca2+ concentration ([Ca2+]i) in control hearts,
the status of Ca2+ mobilization by isoproterenol in ischemia–
reperfused hearts is not fully understood. In order to examine
the effect of ischemia–reperfusion on isoproterenol-
mediated increase in [Ca2+]i, cardiomyocytes were isolated
after 30 min of ischemia followed by 5, 15 and 30 min of
reperfusion. Viability of cells at each of these time points was
determined by tryphan blue exclusion assay. [Ca2+]i was
determined spectrofluorometrically in fura-2 loaded cardio-
myocytes. Both ischemia and ischemia–reperfusion caused
an increase in basal [Ca2+]i, which was associated with de-
creased cell viability and increased left ventricular end dias-
tolic pressure. Pre-treatment of cardiomyocytes with isopro-
terenol (100 µM) augmented the increase in [Ca2+]i due to
KCl (30 mM), a known depolarizing agent, S(-)-Bay K 8644
(2 µM), a dihydropyridine calcium channel activator and
ATP, (50 µM), a purinergic receptor agonist in control hearts.
On the other hand, isoproterenol-induced increase in [Ca2+]i
due to these agents was attenuated in cardiomyocytes isola-
ted from both ischemic and ischemic–reperfused hearts.
These findings indicate that global ischemia for 30 min
causes attenuation in isoproterenol-mediated augmentation
of [Ca2+]i, which was not reversed by reperfusion up to
30 min.
(Supported by the CIHR Group in Experimental Cardio-
logy).
Abstract N° B111
Modulation of doxorubicin-induced cardiac
dysfunction in toll-like receptor-2 knockout mice
Tetsuro Shishido, Naoki Nozaki, Hiroki Takahashi,
Yasuchika Takeishi. Isao Kubota Yamagata University,
Yamagata, Japan
Toll-like receptor (TLR)-2 is involved in inflammatory
response and expressed in the heart. Recent studies have
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demonstrated that TLRs are activated by endogenous signals
such as oxidative stress, which contributes to doxorubicin
(Dox)-induced cardiac dysfunction. Thus, we hypothesized
that TLR-2 had potential role for pathogenesis in Dox-
induced cardiac dysfunction. Myocardial lipid peroxidation
was significantly increased after Dox (20 mg/kg, intraperito-
neally injection), but no significant difference was found
between wild-type (WT) and knockout (KO) mice.After Dox
injection, NF-kappaB activation was decreased by 80% in
KO mice compared with WT mice. Production of pro-
inflammatory cytokines was attenuated in KO mice. Num-
bers of TUNEL positive nuclei and Dox-induced caspase-3
activation were decreased by 36.1% and 26.7%, respectively
(P < 0.01), in KO mice compared with WT mice. Cardiac
function evaluated by echocardiography was preserved in
KO mice compared with WT mice. Consequently, survival
rate was significantly higher in KO mice than in WT mice
10 d after Dox treatment (11% vs. 46%, P < 0.05). These
findings suggest that TLR-2 may play an important role in the
regulation of inflammatory and apoptotic mediators in the
heart following Dox.
Abstract N° B112
Oxidant species are less effective in modulating
pro-inflammatory cytokines turnover in ischemic heart
disease
Maqsood M. Elahi, Bashir M. Matata. Manuel Galiñanes
Integrative Human Cardiovascular Physiology & Cardiac
Surgery Unit, Glenfield Hospital, Leicester, UK
Objectives. – We have previously demonstrated during
blood recirculation that there is an increased production of
oxidant species that are associated with a reduction in an-
tioxidant capacity, and pro-inflammatory cytokines in blood
from patients with ischemic heart disease (IHD) in contrast
to that of healthy subjects. However, the effect of these
specific oxidant species on the inflammatory response is still
not well defined.
Methods. – To investigate the role of specific oxidant
species on the production of three different types of pro-
inflammatory cytokines in blood during extracorporeal cir-
culation, radical scavengers NG-nitro-l-arginine methyl ester
HCl (l-NAME), uric acid, SOD mimetic (manganese tetrakin
porphyrin) and hydroxyl radical scavenger (N-2 mercapto-
propinyl glycine) were used. Fifty milliliters of blood from
25 IHD patients with stable angina and 25 sex-age matched
healthy controls were treated with specific scavengers and
re-circulated at normothermia for 4 h. Samples were taken at
0 and 4 h and TNF-a, IL-6 and IL-8 were determined by
sensitive ELISA assays.
Results. – Results are presented as mean ± S.D. with
baseline levels of TNF-a, IL-6 and IL-8 found to be signifi-
cantly greater in IHD than healthy controls, a trend that
remained at 4 h. In all the scavengers only l-NAME and uric
acid had significant effect on pro-inflammatory cytokines
turnover. The inhibition of NO synthase activity by l-NAME
significantly reduced the levels of TNF-a, only in IHD (66.4
± 29.5 at 4 h; P < 0.05) in contrast to healthy controls (494.3
± 120.0 at 4 h). Interestingly, in IHD, ONOO– scavenging by
uric acid resulted in a significant elevation of IL-6 levels
(7586.7 ± 167.7 vs. 112.5 ± 17.4 at 4 h; P < 0.05) but not
TNF-a (342.6 ± 72.4 vs. 262.5 ± 98.6 at 4 h) and IL-8 levels
(691.71 ± 30.54 vs. 366.3 ± 98.8 at 4 h; P=NS in both the
cases).
Conclusion. – In conclusion, the blockade of NO metabo-
lism attenuates TNF-a but enhances IL-6 turnover in IHD,
suggesting a possible post-transcriptional regulation by these
oxidant species. These results contribute to the understan-
ding of the mechanism of extracorporeal blood circulation
induced tissue damage and may represent a potential in
targeting the inflammatory process in patients with IHD.
Abstract N° B113
Nitric oxide reduces ischemia-and reperfusion-induced
DNA damage in rat ventricular myocytes
Dang Van Cuong a,b, Nari Kim a,b, Euiyong Kim a,
Jin Han a,b. a Department of Physiology and Biophysics,
College of Medicine, Inje University, Busan 614 735,
Korea. b Molecular Cell Physiology Research Center,
College of Medicine, Inje University, Busan 614 735, Korea
Nitric oxide (NO) donors can mimic the protective effects
of ischemic preconditioning (IPC) in ischemia- and reperfu-
sion (I/R)-induced heart injury. Cardiac NO donors are syn-
thesized primarily from l-arginine in a reaction that is cata-
lyzed by endothelial and inducible NO synthases (eNOS and
iNOS, respectively). A common mechanism of action of NO
is the induction of a direct or indirect increase in tissue cGMP
content, which activates protein kinase G (PKG).
NO/cGMP/PKG signal transduction pathways are thought to
reduce I/R-induced injury by activating both sarcolemmal
and mitochondrial ATP-sensitive K+ (KATP) channels during
IPC. Here, we tested the hypothesis that intracellular signa-
ling pathways that involve iNOS and KATP channels function
in the reduction of I/R-induced oxidative damage during IPC.
We estimated DNA strand breaks and oxidative damage in rat
ventricular myocytes by means of single-cell gel electropho-
resis and digestion with endonuclease III. In the I/R model,
the level of DNA damage was significantly elevated. Three
different preconditioning treatments, namely anoxia (5 min),
diazoxide (100 µM), S-nitroso-N-acetylpenicillamine
(SNAP, 300 µM), or 8-(4-chlorophenylthio)-guanosine-3′,5′-
cyclic monophosphate (8-pCPT-cGMP, 100 µM) protected




1.0 ± 1.0 11.2 ± 3.3 ** 2.0 ± 0.4 ##
TNF-alpha (pg/mg protein) 0.2 ± 0.2 3.0 ± 0.4 ** 1.4 ± 0.8 *,##
Fractional shortening (%) 40.0 ± 0.4 27.7 ± 1.0 ** 34.1 ± 1.6 **,##
Data were expressed mean ± SEM.
*P < 0.05.
**P < 0.01 vs. WT-control.
#P < 0.05.
##P < 0.01 vs. WT-Dox.
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anoxia (30 min). The protective effects were blocked by the
concomitant presence of glibenclamide (50 µM),
5-hydroxydecanoate (5-HD, 100 µM), and an RP-isomer of
cyclic GMP (Rp-CPT-cGMP, 100 µM). These results suggest
that NO/cGMP/PKG signal transduction pathways contri-
bute to the cardioprotective effects of KATP channels in rat
ventricular myocytes. The increased expression of iNOS in
the IPC model supports a role for this molecule in NO
production wherein mitochondrial KATP channel opening is
maintained, reducing injury due to ischemia.
Key words: Ischemic preconditioning; Inducible NO syn-
thase; ATP-sensitive K+ channels
Abstract N° B114
Role for reactive oxygen species in TNFa induced
myocyte protection
L. Lacerda a, D. Yellon b, R.M. Smith a. a Hatter Institute,
UCT, South Africa. b Hatter Institute, UCL, UK
We have previously shown that TNFa is necessary and
sufficient to induce preconditioning (PC) in both cells and the
heart. However, the signalling pathways involved in this
protection remain incompletely understood. One potential
protective pathway involves the generation of reactive oxy-
gen species (ROS), which can be produced by TNFa. We
therefore hypothesized that TNFa promotes the production
of ROS, and this leads to the protection seen in PC. To test
this we measured TNFa-induced ROS production in C2C12
myotubes, using a concentration known to cause PC
(0.5 ng/ml). ROS production and cell viability were measu-
red in viable myotubes at 37 °C using a flow cytometer and
the fluorometric dyes 2′,7′-dichlorofluorescin diacetate and
propidium iodide, respectively. The ROS scavenger,
N-acetyl-l-cysteine (NAC) was used to try to abolish the
TNFa induced ROS production and PC. There was a rapid
increase in ROS (dichlorofluorescin signal), following TNFa
adminstration which peaked at 1 min (72.2 ± 23.8% in-
crease). This initial burst of ROS lasted on average 3 min. A
second increase in ROS was seen after 60 min. The antioxi-
dant NAC abolished the ROS production following TNFa
treatment. In addition the degree of protection afforded by
TNFa was reduced by 27.7 ± 3.7%. These results indicate
that TNFa treatment leads to a rapid burst of ROS produc-
tion, and that this ROS plays a minor role in the protection
afforded by TNFa.
Abstract N° B115
Asymptomatic myocardial ischemia in Mexican
patients with diabetes mellitus type 2 and coronary
artery disease
A. Unzueta, G. Ordoñez, A. Unzueta Jr, J. Escobedo,
N. Zamorano. Hospital of Cardiology, National Medical
Center “Siglo XXI”, Mexican Institute of the Social
Security, Mexico City, Mexico
Asymptomatic myocardial ischemia (AMI) is known to be
associated with a poor prognosis. Patients with diabetes are
at increased risk for coronary artery disease (CAD) and
perhaps also for silent ischemia. A cross-sectional study was
conducted to assess the effect of diabetes on the occurrence
of AMI. Patients were derived from a clinical trial f for AMI.
Two hundred and forty nine patients with CAD were scree-
ned with a 24-h Holter ECG, in order to diagnose silent
ischemia. AMI was diagnosed according to the American
Heart Association recommendations and diabetes according
to the American Diabetes criteria. Odds ratios (OR) with
95% confidence intervals (CI 95%) were estimated to assess
the strength of the association, and a chi-square for trend (v2
trend) was used to evaluate biologic gradient. Eighty-four
diabetic patients were included (71 males and 13 females),
mean age was 60.3 years. AMI was more frequent in diabe-
tics (51%, 43 patients). Diabetic patients with longer dura-
tion of disease had double-fold higher risk of AMI (OR 2.5;
CI 95% 2.7–9.2). Patients with triple-vessel disease had
twofold higher risk of AMI (OR 2; CI 95% 0.6–7.3). The
subjects with LVEF <40% had ninefold higher risk (OR 9.3;
CI 95% 1.6–64.7); whereas those with a LVEF between 40%
and 50% had a threefold higher risk of AMI (OR 2.6; CI 95%
0.6–12.8), due to a biologic gradient, major myocardial da-
mage was related to major risk (v2trend 8.4; P = 0.03) Patients
with more severe CAD, greater myocardial damage and
longer duration of diabetes had higher risk of AMI.
Abstract N° B116
The mechanism(s) of dexamethasone against ischemia
and reperfusion-induced damage in isolated working
hearts
Edit Varga a, Tamas Biro b, Arpad Tosaki a. a Department of
Pharmacology, University of Debrecen, Debrecen, Hungary.
b Department of Physiology, University of Debrecen,
Debrecen, Hungary
Dexamethasone (DX) treatment on the recovery of post-
ischemic cardiac function and the development of
reperfusion-induced ventricular fibrillation (VF) in isolated
rat hearts (n = 6 in each group) were studied. Rats were
treated with 2 mg/kg of intraperitoneal injection of DX, and
24 h later, hearts were isolated, and subjected to 30 min
global ischemia followed by 120 min reperfusion. Cardiac
function including heart rate (HR), coronary flow (CF), aor-
tic flow (AF), and left ventricular developed pressure
(LVDP) were recorded. In the DX treated hearts, a significant
recovery in AF and LVDP were observed during reperfusion.
Thus, after 60 and 120 min reperfusion, DX treatment impro-
ved the recovery of AF and LVDP from their control values
of 10.7 ± 0.3 ml/min and 10.5 ± 0.3 kPa to 22.2 ± 0.3 ml/min
(P < 0.05) and 14.3 ± 0.5 kPa (P < 0.05), 19.3 ± 0.3 ml/min (P
< 0.05) and 12.3 ± 0.5 kPa (P < 0.05), respectively. HR and
CF did not show a significant change during reperfusion. In
rats treated with 0.5 mg/kg of actinomycin D (ActD), a
protein synthesis inhibitor, injected i.v., 1 h before DX injec-
tion, suppressed the DX-induced cardiac protection. The
incidence of VF, and cytochrome c release from the mito-
chondria into the cytosol were also monitored. Data demons-
trate that DX pretreatment reduces the occurrence of VF.
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Cytochrome c release was observed in the cytoplasm in the
ischemic/reperfused and ActD-treated groups in contrast
with the DX-treated group. The results suggest that inhibi-




ischemia/reperfusion oxidative stress in the rat heart
Herzl Schwalb, Igor Khaliulin, Aviva Schneider,
Esther Houminer, Joseph B. Borman. Joseph Lunenfeld
Cardiac Surgery Research Center, Hadassah-Hebrew
University Medical Center, Jerusalem 91120, Israel
Apomorphine forms stable complexes with copper and
with iron, and inhibits the copper-induced ascorbate oxida-
tion. This study examined the hypothesis that low concentra-
tion of apomorphine improves post-ischemic hemodynamic
and mitochondrial functions in the isolated rat heart model
by attenuating oxidation of myocardial proteins. Control and
apomorphine-treated isolated hearts were subjected to
35 min of perfusion, 25 min of no-flow normothermic global
ischemia, and 60 min of reperfusion. Apomorphine (2 µM)
was introduced into the perfusate for 20 min starting from the
onset of reperfusion. Apomorphine significantly (P < 0.05)
improved post-ischemic hemodynamic function. In particu-
lar, work index of heart (product of LVDP and heart rate) was
twice as high in apomorphine-treated hearts as compared to
controls at the end of reperfusion. Following isolation of
cardiac mitochondria, the respiratory control ratio (RCR)
was calculated from oxygen consumption rate of State 3 and
State 4 respiration ratio. Apomorphine significantly impro-
ved post-ischemic RCR (87% of pre-ischemic value vs. 39%
in control, P < 0.05). Using an immunoblot technique, car-
bonyl content of multiple myocardial proteins was observed
to be elevated after global ischemia/reperfusion. Apomor-
phine significantly attenuated the increased protein oxidation
observed at the end of reperfusion. These results support the
conclusion that apomorphine is capable of preventing
ischemia/reperfusion-induced oxidative stress by attenuating
myocardial protein oxidation and preserving mitochondrial
respiration function.
Abstract N° B118
Oral administration of geranylgeranylacetone blunts
coronary endothelial dysfunction induced by
ischemia/reperfusion in rat hearts
Saikawa Prof. Tetsunori. Oita Medical University, Japan
Oral geranylgeranylacetone (GGA) induces expression of
heat shock protein 72 (HSP72) and exhibits protection
against ischemia/reperfusion injury in rat hearts. However, it
remains unclear whether GGA preserves endothelial dys-
function induced by ischemia/reperfusion. Rats were orally
administrated with GGA (200 mg/kg, GGA group) or vehicle
(control, CNT group), and hearts were isolated 24 h after
administration. We examined the effects of GGA on the left
ventricular contractility, coronary endothelium-dependent
vasodilation, and nitric oxide (NO) production before and
during the 30 min of low-flow ischemia and following 30 min
of reperfusion in Langendorff apparatus. Effects of a NO
synthase (NOS) inhibitor, NG-nitro-l-arginine methyl ester
(L-NAME), a phosphatidyinositol 3 kinase inhibitor,
LY294002, or a Rho kinase inhibitor, Y27632, were also
investigated. Our results were as follows: (1) GGA augmen-
ted the postischemic functional recovery, which was abo-
lished by L-NAME. (2) Ischemia/reperfusion caused a de-
crease in coronary perfusion pressure (CPP) in response to
acetylcholine (ACh), which was preserved in GGA group.
(3) The amount of NO in coronary effluents during the both
ischemia/reperfusion period was increased in GGA group.
(4) LY294002 abolished the preserved vasodilation in res-
ponse to ACh and attenuated the augmented NO production
by GGA while Y27632 augmented ACh-induced vasodila-
tion and increased NO production in CNT group to compa-
rable levels to those in GGA group. Our results indicate that
GGA blunts the coronary endothelial dysfunction induced by
ischemia/reperfusion injury, which may contribute, at least in
a part, to the cardioprotective effects induced by GGA.
Abstract N° B119
Protective mechanism of taurine on ischemia-induced
apoptosis in cultured cardiomyocytes
Kyoko Takahashi a, Tomoka Takatani a, Yoriko Uozumi a,
Takashi Ito a, Takahisa Matsuda a, Yasushi Fujio a,
Stephen W. Schaffer b, Junichi Azuma a. a Department of
Clinical Evaluation of Medicines and Therapeutics,
Graduate School of Pharmaceutical Sciences, Osaka
University, Osaka, Japan. b Department of Pharmacology,
School of Medicine, University of South Alabama, Mobile,
AL, USA
To reveal the mechanism for the attenuation of ischemic
injury by taurine in hearts, we examined the interaction
between taurine and mitochondrial-mediated apoptosis using
a cardiomyocyte model of simulated ischemia. Neonatal rat
cardiomyocytes were cultured for 24–72 h in sealed flask, a
condition that leads to simulated ischemia characterized by a
decrease in the pH and oxygen content of the medium and
catabolite accumulation. The frequency of apoptotic cells as
determined by both the Hoechst 33258 staining and TUNEL
method pattern was significantly reduced by 20 mM taurine
for 24–72 h. In absence of taurine treatment, simulated ische-
mia led to mitochondrial dysfunction resulting in both cyto-
chrome c releases from the mitochondria depolarization after
a 24-h ischemic insults. It also promoted the apoptotic cas-
cade initiated by the activation of caspase-9/-3 because their
active forms were detected after a 30 h ischemic insult. The
taurine loaded myocytes exhibited less mitochondrial dys-
function in response to ischemia. Interestingly, taurine inhi-
bit ischemia-induced cleavages of caspase-9/-3, completely.
Taurine loading also suppressed the formation of Apaf-
1/caspase-9 apoptosomes formation, as evidenced by the
immunoprecipitation study. These findings demonstrated
that taurine effectively prevents myocardial ischemia-
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induced apoptosis, by inhibiting Apaf-1/caspase-9 apopto-
some formation.
Abstract N° B120
Urotensin II protectes rat heart from
ischemia/reperfusion injury
Xudong Wu a, Xiuhua Liu b, Chaoshu Tang c, Jingyi Su c.
a Department of Special Medicine, PLA General Hospital
Beijing, Beijing, China. b Department of Pathophysiology,
PLA General Hospital Beijing, Beijing, China. c
Department of Physiology and Pathophysiology, Health
Center, Peking University, Beijing, China
Urotensin II (UII) is a cyclic neuropeptide initially isola-
ted from the caudal neurosecretory system of teleost fish and
confers potent cardiovascular effects including depression of
cardiac function and vessel contraction. The present study
investigated the effects of human urotensin II (hUII) on
myocardial ischemia/reperfusion (I/R) injury. In the I/R mo-
del of isolated perfused rat hearts, the effects of hUII on heart
rate, VEDP, and ±dP/dt max were monitored with cardiac
function software of MFL Lab200. ATP total calcium and
MDA content in myocardium were detected. The coronary
perfusion flow (CPF) was measured during reperfusion pe-
riod. The results were that hUII pretreatment reduced lea-
kage of LDH by 28% calcium overload by 27%, and lipid
peroxidation by 24% and increased ATP content by 73%.
hUII pretreatment also improved the cardiac function, and
increased natrite/natrate content in myocardium and CPF.
Thus, hUII attenuates I/R injury in isolated perfused rat
hearts. The protective mechanism may be associated with
NO-mediated coronary vasodilation.
Keywords: Peptide ischemic preconditioning; Myocar-
dium
Abstract N° B121
Sustained cardioprotection afforded by A2A adenosine
receptors increases Hsp27 expression and CREB
activation
M. Boucher, B.P. Wann, É. Schampaert, R. Cardinal,
G. Rousseau. Centre de Biomédecine, Hôpital Sacré-Cœur
de Montréal, Montréal, Québec, Canada. Department of
Pharmacology, GRSNA, Faculty of Medicine, University of
Montréal, Montréal, Québec, Canada
Introduction. – Stimulation of A2A adenosine receptors
(A2AR) during reperfusion reduces infarct size. However, it
has been shown that some therapeutic interventions may only
delay cell death and extension of the reperfusion period
results in loss of the cardioprotection.
Objective. – The objective of this study is to determine if
the cardioprotection induced by A2AR stimulation is sustai-
ned and if heat shock protein 27 (Hsp27) and cAMP-
response element binding (CREB) protein, known to be in-
volved in long-term cardioprotection, is modulated by this
therapeutic intervention.
Method. – Myocardial infarction was generated in rats by
LAD occlusion (40 min) and reperfusion (72 h). Two groups
were constituted: Control (Vehicle) and Treated (A2AR ago-
nist: CGS21680 at 0.2 µg/kg/min for 120 min, starting 5 min
prior to reperfusion). Infarct size is determined by triphenyl-
tetrazolium chloride staining and Hsp27 expression along
with CREB activation by western blotting.
Results. – Infarct size was reduced by 34% in the Treated
group (36.2 ± 2.3%) compared to Control (54.6 ± 3.0%; P
&ks; 0.001). Hsp27 expression and CREB activation were
significantly elevated in the Treated (305.7 ± 44.3% and
202.8 ± 34.1%, respectively, P &ks; 0.01) compared to
Control group.
Conclusion. – These results suggest that cardioprotection
by A2AR stimulation is sustained and is accompanied with an
enhanced Hsp27 expression and CREB activation.
Abstract N° B122
Atorvastatin at reperfusion attenuates myocardial
infarction by the induction of heat shock protein 27
and p38 MAPK in the isolated perfused mouse heart
Christopher A. Efthymiou, Mihaela M. Mocanu,
Kwabena Mensah, Derek M. Yellon. The Hatter Institute
and Centre For Cardiology, University College London
Hospitals and Medical School London, UK
Objectives. – Heat shock proteins (HSPs) are produced
when cells are exposed to biological stress such as heat stress
and chemical stress. This response is a highly conserved
defense mechanism that can result in the activation of HSPs
such as HSP27. This low-molecular weight HSP is reco-
gnised to act as a chaperone and can function in different
unrelated cytoprotective processes such as RNA stabilisa-
tion, molecular chaperoning, stabilization of the cytoskele-
ton and ultimately restoring redox balance and inhibiting
apoptosis. The phosphorylation of HSP27 is by the mitogen-
activated protein kinase-2 (MAPK-2), a stress-sensitive ki-
nase that is sequentially phosphorylated in a cascade of
kinases involving p38 mitogen-activated protein kinase (p38
MAPK). Our aim was therefore to discover if atorvastatin is
able to attenuate infarction via p38/HSP27 dependent pa-
thways.
Methods. – We subjected an isolated Langendorff per-
fused mouse heart to 35 min global ischaemia and 30 min
reperfusion, followed by either infarct size determination or
western blot analysis for the phosphorylation of p38 MAPK
and its down stream target HSP27. Fifty micromolars ator-
vastatin alone or atorvastatin with the specific inhibitor of
p38 MAPK, SB203580 (10 µM) were administered in the
perfusate at reperfusion.
Results. – There was a profound reduction of infarct size
in the atorvastatin treated group (32.96 ± 3.41% (n = 12) vs.
51.2 ± 2.79% (n = 11) in controls P < 0.005). This protection
was abrogated by the inhibitor of p38 SB203580. (49.37 ±
4.16% (n = 9) SB/Atorva vs. 49.40 ± 6.5% (n = 6) SB alone).
Western blot analysis revealed that atorvastatin at reperfu-
sion results in the rapid phosphorylation of p38MAPK which
mediates the subsequent phosphorylation HSP27.
Conclusion. – Atorvastatin attenuates lethal reperfusion
induced injury in an HSP27 dependent manner via the p38
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MAPK cascade. This protection may be conferred by the
ability of HSP27 to inhibit apoptosis.
Abstract N° B123
Reperfusion induced injury attenuated by atorvastatin
in an experimental model of myocardial
ischaemia/reperfusion: a role for p44/42 mapkinase
and PI3kinase
Christopher A. Efthymiou, Mihaela M. Mocanu,
Kwabena Mensah, Derek M. Yellon. The Hatter Institute
and Centre For Cardiology, University College London
Hospitals and Medical School London, London, UK
Objectives. – Statins are used in the treatment of hyper-
cholesterolaemia. Several studies including WOSCOP and
CARE suggest these compounds may have pleiotrophic ef-
fects including: plaque stabilisation, anti-inflammatory ef-
fects and stroke reduction, which are beyond their ability to
lower cholesterol. Our previous animal studies have shown
that atorvastatin attenuates lethal reperfusion injury via acti-
vation of the phosphatidyl inositol 3-kinase (PI3K) pro-
survival signalling pathway. Using other agents we have also
shown that phosphorylation of another pro-survival pathway,
i.e the p44/42 MAPKinase pathway can also protect the
myocardium from such injury. However this pathway has not
been investigated in relation to statins. Therefore our aim was
to elucidate if atorvastatin attenuates reperfusion injury not
only via PI3K but also via p44/42 phosphorylation.
Methods. – We used an experimental model of Langen-
dorff perfused mouse heart subjected to 35 min global is-
chaemia and 30 min reperfusion followed by either infarct
quantification or western blot analysis (AKT and p44/42
phosphorylation). Fifty millimolars atorvastatin were admi-
nistered during reperfusion. One hundred nanomolars Wort-
mannin were used to block PI3K, while 10 mM PD98059 or
10 mM U0126 were used to block the p44/42 pathway. The
hearts were randomised into eight groups (n = 5–10): (a)
control; (b) atorvastatin; (c) atorvastatin and Wortmannin; (d)
Wortmannin alone; (e) atorvastatin and PD98059; (f)
PD98059 alone; (g) atorvastatin and U0126; (h) U0126
alone.
Results. – Atorvastatin significantly reduced infarct size
in the treated group: (36.0 ± 4.0% vs. 51.2 ± 3.1% in controls
P < 0.05). This protection was abrogated by blocking PI3K
with Wortmannin (48.4 ± 4.3%) and p44/42 with U0126 or
PD98059 (52.6 ± 7.6% or 53.0 ± 8.0%), respectively. Wes-
tern blot analysis confirmed phosphorylation of AKT and
p44/42 by the administration of atorvastatin during reperfu-
sion.
Conclusions. – Our data demonstrate that atorvastatin,
given at reperfusion, significantly attenuated infarct size via
both p44/42 and PI3K pathways, implying that these pro-
survival pathways are involved in protection from reperfu-
sion induced lethal injury.
Abstract N° B124
Detection and purification of protein sulphenic acids in
H2O2 treated hearts
A.T. Saurin, P. Eaton. Department of Cardiology, KCL, The
Rayne Institute, St Thomas’ Hospital, London SE1 7EH,
UK
Although post-translational modification of proteins by
phosphorylation is well established, the reversible cysteine-
targeted modifications are less well characterised. The prin-
cipal product of the reaction between a protein cysteinyl thiol
and H2O2 is a protein sulphenic acid (PSOH). Since PSOH
formation is reversible, it provides a mechanism whereby
redox status can control protein function. The deleterious
effects of ischaemia and reperfusion in the heart have been
attributed in part to oxidative stress and H2O2. At lower
concentrations, however, H2O2 can act as a signalling mole-
cule, and is implicated in genesis of ischaemic preconditio-
ning. We have developed methods for the detection and
purification of PSOH. Control (30 min aerobic stabilisation)
or oxidised (0.05–1.00 mM H2O2 perfusion for 5 min) heart
muscle was homogenised in an argon-gassed buffer contai-
ning the thiol alkylating agent maleimide (100 mM). SDS
was added to denature proteins, allowing full access of the
alkylation reagent and efficient blocking of protein thiols.
Excess free maleimide was then removed by Superdex
FPLC. Purified proteins were then treated with water
(control) or 20 mM sodium arsenite for 30 min to specifically
reduce PSOHs back to the free thiol groups. These free thiol
groups were then labelled with 0.1 mM biotin–maleimide.
Thus, the sulphenic group on cysteine is ‘switched’ for bio-
tin, allowing detection by streptavidin–HRP and purification
with streptavidin–agarose. Initial studies illustrate a multi-
tude (possibly hundreds) of cardiac proteins form PSOH in
response to H2O2. We have affinity purified these proteins, as
a first step to their characterisation by LC-MS/MS. Cysteine
containing peptides modified with maleimide can be exclu-
ded as sites of sulphenic acid formation, whereas those modi-
fied with biotin pinpoint where oxidation occurs. Preliminary
experiments with a cysteine containing peptide control have
validated this oxidation site mapping method. The mapping
of cysteines that from sulphenic acid will enable more targe-
ted studies aimed at understanding the effect of oxidation on
protein function. An understanding of the physical conse-
quences of increased cellular H2O2 should provide new insi-
ghts into the mechanisms of injury, as well as stress adapta-
tion.
Abstract N° B125
Effects of aging on cardiac antioxidant enzyme systems
K. Venardos, K. Ashton, J. Headrick, A. Perkins. Heart
Foundation Research Centre, School of Health Science,
Griffith University Gold Coast Campus, Qld, Australia
Thioredoxin reductase (Txnrd) and glutathione peroxi-
dase (Gpx) are selenocysteine containing antioxidant enzy-
mes involved in limiting oxidative stress. We have previously
shown that upregulation of these enzymes is cardioprotective
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and downregulation leaves hearts more susceptible to ische-
mia–reperfusion injury. Given that oxidative stress and car-
diovascular disease are more prevalent in the older popula-
tion we chose to investigate the effect of aging on these
antioxidant enzyme systems. Hearts were isolated from
10 weeks (young) and 15 months (aged) male Wistar rats.
RNA was extracted for quantitative real-time PCR analysis
of gluatathione peroxidase (Gpx)-1and -4, glutathione reduc-
tase (Gsr), Txn, thioredoxin peroxidase-2 (Prdx2), and
Txnrd-1 and -2. Txnrd, Gpx, and superoxide dismutase
(SOD) activities were also measured in heart extracts. We
found no difference in Txnrd activity (96 ± 5 vs. 90 ±
4 mol/min/mg protein) or Txnrd-1 mRNA between young
and aged hearts, however there was a significant fourfold
increase in Txnrd-2 transcription in aged hearts. Prdx2
mRNA was also significantly increased in aged hearts (~2.5-
fold). Gpx activity was significantly reduced in aged hearts
(256 ± 36 vs. 417 ± 48 µmol/min/mg protein in young)
without changes in Gpx-1 or -4 transcription. There were no
differences in SOD activity between age groups. These re-
sults suggest a reduced ratio between enzyme activities in
relation to mRNA levels in aged hearts. This may result from
decreased protein translation, reduced selenium incorpora-
tion into the active sites, or increased turnover caused by
oxidative stress. This reduction in Gpx activity may also play
a role in impaired tolerance to oxidative stress that is obser-
ved in older hearts.
Abstract N° B126
Effects of dietary selenium on post-ischemic expression
of thioredoxin reductase and glutathione peroxidase
antioxidant systems
K. Venardos, K. Ashton, J. Headrick, A. Perkins. Heart
Foundation Research Centre, School of Health Science,
Griffith University Gold Coast Campus, Qld, Australia
Cardiac ischemia–reperfusion injury results in oxidative
stress and poor physiological recovery. Glutathione peroxi-
dase (Gpx) and thioredoxin reductase (Txnrd) are selenocys-
teine dependent enzymes that protect against oxidative in-
jury. Previously, we have shown selenium deficiency
downregulates Txnrd and Gpx activity, impairing recovery
from ischemia–reperfusion. Furthermore, selenium supple-
mentation was found to be cardioprotective and lessened
oxidative damage in reperfused rat hearts. We have now
investigated the role of selenium in the mRNA expression of
these and related antioxidant proteins post-ischemia–reper-
fusion. Male Wistar rats were fed varying doses of selenium
for 5 weeks. Hearts were then isolated and perfused using the
Langendorff method where they were subjected to 22.5 min
ischemia and 45 min reperfusion. RNA was extracted for
quantitative real-time PCR analysis of Gpx-1 and -4, gluta-
thione reductase (Gsr), thioredoxin (Txn), thioredoxin
peroxidase-2 (Prdx2) and Txnrd-1 and -2. Selenium defi-
ciency produced significant reductions in Gpx-1, Gpx-4,
Prdx2, Txnrd-1 and -2 gene expression. Conversely, sele-
nium supplementation of 1000 µg selenium/kg food signifi-
cantly upregulated Gpx-1, Gpx-4, Txn, Txnrd-1 and -2 trans-
cription. These results indicate dietary selenium modulates
the cardiac mRNA expression of antioxidant enzymes post-
ischemia–reperfusion. This also suggests those consuming a
low selenium diet may be less well equipped to cope with
oxidative injury and selenium supplementation may be an
effective method for reducing oxidative damage post-ische-
mia–reperfusion.
Abstract N° B127
PPAR agonists and vascular injury
D.B. McNamara, C.V. Desouza, S.N. Murthy, J. Diez,
B. Dunne, A.S. Matta, V.A. Fonseca. Departments of
Pharmacology, Medicine, and Surgery, Tulane Medical
School, New Orleans, LA, USA
Patients with type 2 diabetes have a higher rate of resteno-
sis following angioplasty. Peroxisome proliferator activator
receptors (PPAR) ∀ and ligands, such as fenofibrate and
rosiglitazone, have been shown to have protective effects on
the vessel wall. We studied the effects of fenofibrate and
rosiglitazone on intimal hyperplasia on the Zucker rat (a
model for insulin resistance and type 2 diabetes) post-balloon
catheter injury. Three groups of 13-week-old female fatty
Zucker rats were administered either 3 mg/kg rosiglitazone
(n = 7) or 150 mg/kg fenofibrate (n = 6) or served as controls
(n = 9). In addition, two groups of 13-week-old female lean
Zucker rats were either administered 3 mg/kg rosiglitazone
(n = 6) or served as controls (n = 6). Carotid balloon injury
was induced 1 week after starting drug administration, which
was continued for 3 weeks. A 2.0 mm balloon catheter was
introduced through the femoral artery to the left carotid. The
balloon was inflated to 4 atm for 20 s and then deflated to
2 atm and dragged down to the aorta. Rats were sacrificed
3 weeks after injury. The carotid intima/media (I/M) ratio
was calculated using Image-Pro software. Intimal hyperpla-
sia after carotid balloon injury in the fatty Zucker rats was
significantly reduced in the rosiglitazone treated (0.18∀ 0.29)
as compared to untreated animals (0.97 ± 0.13; P < 0.01).
Plasma glucose, triglyceride and insulin levels were elevated
indicative of the presence of insulin resistance; rosiglitazone
treatment significantly reduced insulin and triglyceride levels
without decreasing glucose. Rosiglitazone treatment also
reduced to a lesser extent the intimal hyperplasia in the lean
Zucker rats (0.57 ± 0.10 vs. 1.06 ± 0.12 treated and untreated,
respectively; P < 0.01). Rosiglitazone had no effect on insu-
lin, triglyceride and glucose levels in this group. The intimal
hyperplasia in the fenofibrate treated fatty Zucker rats was
not reduced as compared to controls (0.84 ± 0.26 vs. 0.97 ±
0.13, respectively); insulin and triglyceride but not glucose
levels were reduced by fenofibrate in these animals. The
PPAR ligand rosiglitazone, but not PPAR∀ ligand fenofi-
brate decreases intimal hyperplasia following balloon injury.
This effect of the PPAR ligand is independent of glycemia
and is more pronounced in insulin-resistant rats.
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Abstract N° B128
Estrogen induced changes in the b-adrenergic signal
transduction in rat heart
W.L. Kam, G.M. Kravtsov, M. Chen, T.M. Wong.
Department of Physiology, The University of Hong Kong,
Hong Kong SAR, China
We have previously shown that estrogen deficient cause
upregulation of b-adrenergic receptor (b-AR) which is cor-
related with higher susceptibility to ischemic damage in
ovariectomized rat heart. However, the effect of ovariectomy
on downstream b-AR signaling remains unknown. The
purpose of the present study was to examine the effects of
estrogen on the post receptor b-AR signaling cascade in the
rat hearts from: (i) sham operated female Sprague–Dawley
(SD) rats, (ii) female SD rats subjected to bilateral ovariec-
tomy (Ovx), (iii) estrogen replaced Ovx rats (Ovx+E2). It
was found that there were no differences in the amount of Gsb
and Gi1–3 proteins between the left ventricles in all groups of
rats. In contrast, forskolin stimulated increase in electrically
stimulated calcium transient (E[Ca2+]i ) was significantly
higher in Ovx than sham and Ovx+E2 rats. However, forsko-
lin stimulated increase in ventricular cAMP content was the
same in all groups of rats. Activation of b-AR with isoprote-
renol (Iso) and treatment of cardiomyocytes with N6, 2′-O-
dibutyryl adenosine cyclic monophosphate (DB-cAMP)
more strongly potentiated the E[Ca2+]i in the ventricular
myocytes of Ovx rats than in the sham rats suggesting an
enhanced Ca2+ response to cAMP in Ovx hearts. The basal
activity of protein kinase A (PKA) in Ovx heart was also
significantly higher than sham rats. The increased E[Ca2+]i in
Ovx rats was correlated with significantly higher 45Ca2+
uptake through L-type Ca2+ channels activated by either Iso
or DB-cAMP than in sham rats. Inhibition of PKA with its
inhibitor, H-7, eliminated differences in the activity L-type
Ca2+ channels between Ovx and sham rats. Taken together,
besides affecting b-AR expression estrogen deficiency also
impair reversibly one of the key stages of b-AR cascade in
heart namely the PKA enzymatic activity. This abnormality
is likely to target L-type Ca2+ channels and thereby modify
both the E[Ca2+]i and its potentiation by the agonist of b1-
AR. (Supported by the Research Grants Council, Hong
Kong.)
Abstract N° B129
Oxidative stress in the infarcted heart: role of de novo
angiotensin II production
Sun, Prof. Yao. The University of Tennessee Health Science
Centre, USA
A beneficial role for angiotensin (Ang) II blockade on
adverse structural remodeling of myocardium following in-
farction (MI) has been documented. During early stages of
tissue repair that follow MI, macrophages express renin,
ACE and AT1 receptors, thereby implicating locally genera-
ted AngII in the repair process. This possibility, however, has
not been fully explored. In the present study, we hypothesi-
zed AngII induces oxidative stress (OS) with reactive oxygen
species (ROS) production at the infarct site. Four groups (n =
12 rats/group) were studied: normal controls; MI; MI+AT1
receptor antagonist, losartan (Los, 10 mg/kg qd p.o.) and
MI+antioxidant, N-acetylcysteine (NAC, 200 mg/kg qd i.p.).
Hearts were collected on day 7 post-MI to monitor the ex-
pression of gp91phox (a subunit of NADPH oxidase involved
in ROS generation) by immunohistochemistry and western
blot; 3-nitrotyrosine (a marker of peroxynitrite formation) by
immunohistochemistry; superoxide dismutase (SOD) ex-
pression by microarray and western blot; and macrophages
by immunohistochemical ED1 labeling. We found: (1)
gp91phox and 3-nitrotyroxine were highly expressed in the
infarcted myocardium, but were not detected in normal myo-
cardium; (2) cells expressing gp91phox and 3-nitrotyrosine at
the infarct site were primarily macrophages; (3) compared to
normal myocardium, the expression of SOD was reduced (P
< 0.05) in infarcted myocardium in keeping with its
consumption by ROS; (4) Los or NAC treatment reduced (P
< 0.05) gp91phox expression in infarcted myocardium, while
gene expression and activity of SOD were increased (P <
0.05) in treated as compared to untreated group. Thus,
macrophage-derived AngII stimulates OS in an autocrine
fashion by enhancing ROS production that leads to the
consumption of antioxidant reserves. AT1 receptor blockade
has the potential to protect the infarcted heart from further
cardiac damage caused by OS and may reduce infarct size
and structural remodeling.
Abstract N° B130
Cardiovascular remodelling of aged rats during
chronic AT1 receptor blockade involves AT2 receptors
E.S. Jones a, M.J. Black b, R.E. Widdop a. a Department of
Pharmacology, Monash University, Melbourne. b
Department of Anatomy and Cell Biology, Monash
University, Melbourne, Vic., Australia
Chronic administration of the angiotensin type 1 receptor
(AT1R) antagonist, candesartan cilexetil, is associated with
increased circulating angiotensin II, and thus it has been
suggested that a component of the cardiovascular effects of
such drugs may be due to direct angiotensin type 2 receptor
(AT2R) stimulation. In addition, AT2R expression is upregu-
lated in hypertrophied hearts, and other components of the
local renin–angiotensin system are also dramatically in-
creased in the aging heart. Therefore the aim of this study
was to determine the contribution of the AT2R to the chronic
antihypertensive and cardiovascular effects of AT1R bloc-
kade in normotensive aged rats. Radiotelemetry probes were
implanted into senescent (20 months) male Wistar–Kyoto
(WKY) rats, and baseline recordings of mean arterial pres-
sure (MAP) were made for 1 week. Candesartan cilexetil
(2 mg/kg/d) was given in drinking water, while an additional
group simultaneously received the AT2R antagonist,
PD123319 (10 mg/kg/d). At the end of the 4 weeks treatment
period, animals were perfusion-fixed to enable histological
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analysis of cardiovascular structure. MAP was decreased by
candesartan cilexetil, however, this effect was not further
influenced by PD123319. Cardiac hypertrophy and fibrosis,
and aortic hypertrophy were all significantly reduced by
candesartan cilexetil. Most interestingly, these structural
changes were reversed by concomitant PD123319 adminis-
tration, despite the lack of AT2R-mediated effects on MAP.
These results suggest that the AT2R does not exert a signifi-
cant influence on the antihypertensive effect of chronic AT1R
blockade in aged rats. However, PD123319 did reverse
AT1R-mediated regression of cardiovascular hypertrophy
and fibrosis, highlighting the important role of the AT2R on
cardiovascular structure in the aging heart and vasculature.
Abstract N° B131
Angiotensin AT2 receptor contributes to cardiovascular
remodelling of aged SHR during chronic AT1 receptor
blockade
E.S. Jones a, M.J. Black b, R.E. Widdop a. a Department of
Pharmacology, Monash University, Melbourne, Vic.,
Australia. b Department of Anatomy and Cell Biology,
Monash University, Melbourne, Vic., Australia
Circulating angiotensin II levels rise as a consequence of
treatment with the angiotensin type 1 receptor (AT1R) anta-
gonist, candesartan cilexetil, and it has been suggested that a
component of the cardiovascular effects of such drugs may
be due to direct angiotensin type 2 receptor (AT2R) stimula-
tion. In addition, AT2R expression is upregulated with car-
diac hypertrophy, and other components of the local renin–
angiotensin system are also dramatically increased in the
aging heart. Therefore the aim of this study was to determine
the contribution of the AT2R to chronic antihypertensive and
remodelling effects of AT1R blockade in aged hypertensive
rats. Radiotelemetry probes were implanted into senescent
(20 months) male spontaneously hypertensive rats (SHR)
and baseline recordings of mean arterial pressure (MAP)
were made for 1 week. Animals were then treated with either
candesartan cilexetil (2 mg/kg/d), the AT2R antagonist,
PD123319 (10 mg/kg/d), or a combination of the two drugs.
At the end of the 4 weeks treatment period, animals were
perfusion-fixed to enable histological analysis of cardiovas-
cular structure. MAP was markedly decreased by candesar-
tan cilexetil, however, this effect was not further influenced
by PD123319. Cardiac hypertrophy and fibrosis were signi-
ficantly reduced by candesartan cilexetil, and interestingly,
these structural changes were reversed by concomitant
PD123319 administration. These results suggest that the an-
tihypertensive effect of chronic AT1R blockade is not signi-
ficantly influenced by AT2R stimulation in aged hypertensive
rats. However, PD123319 did reverse AT1R-mediated regres-
sion of cardiac hypertrophy and fibrosis, indicating that the
AT2R is involved in regulation of cardiovascular structure in
the aging hypertensive heart.
Abstract N° B132
Long QT syndrome and APD90 prolongation in the
cardiac Ang II-overproducing transgenic mouse model
of heart failure
A.A. Domenighetti a, C. Boixel b, H. Abriel b,
T. Pedrazzini a. a Division of Hypertension, University of
Lausanne, Switzerland. b Institute of Pharmacology and
Toxicology, University of Lausanne, Switzerland
Normotensive TG1306/1R (TG) mice, harbouring multi-
ple copies of a cardiac-specific angiotensinogen transgene,
develop dilated cardiomyopathy and exhibit a significant
increase in mortality, associated with mechanical dysfunc-
tion and downregulation of SERCA2 protein levels. Here, we
hypothesize that mechanical dysfunction is associated with
changes in cardiac electrical activity and cardiomyocyte ac-
tion potential (AP) duration in TG mice. Non-invasive
surface-limb ECG measurements were recorded on 15–20-
and 50–60-week-old male TG and WT mice under halothane
anaesthesia.At a constant heart rate of ~450 beats per minute,
QT and QTc intervals, but not P and QRS durations, were
significantly prolonged in TG hearts relative to WT (QTc =
60.5 ± 1.4 vs. 50.0 ± 1.4 ms, respectively, at 50–60 weeks, P
< 0.001). TG mice also showed an increased incidence of
dysrhythmogenic events (extra systole), when compared to
age-matched WT. Prolongation of the QT interval was asso-
ciated with increased AP duration as measured in isolated
ventricular myocytes by whole-cell patch clamp. While the
resting potential and the amplitude of the AP remained un-
changed, the APD90 was significantly increased in TG myo-
cytes relative to WT (APD90 = 67 ± 5.0 vs. 48 ± 3.6 ms,
respectively, at 50–60 weeks, P < 0.01). These data suggest
that chronic overproduction of Ang II in the heart induces a
long QT phenotype resulting from a prolongation of the
cardiac and myocyte repolarization period. Patch-clamp ana-
lysis of repolarizing currents will determine which chan-
nel(s) may be accountable for such electrophysiological mo-
difications.
Abstract N° B133
Impaired angiotensin II responses of cerebral artery in
catecholamine-induced cardiac hypertrophy
Nari Kim, Jin Han. Department of Physiology and
Biophysics, Molecular Cell Physiology Research Center,
College of Medicine, Inje University, Busan 614 735, Korea
Catecholamines that accompany acute physiological
stress are also involved in mediating the development of
cardiac hypertrophy. Cardiac hypertrophy is an independent
risk factor for cerebrovascular event. However, the cellular
mechanisms involved in cerebrovascular impairment during
cardiac hypertrophy are largely unknown. We therefore in-
vestigated the effects of cardiac hypertrophy, produced by
isoprenaline, on cerebrovascular contractility and Ca2+ han-
dling by angiotensin II (Ang II) in cerebral artery. We studied
the contractile response to Ang II in pressured middle cere-
bral artery in vitro using a video imaging system to record
diameter. Myocytes were also loaded with fura-2 to assess
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[Ca2+]i and SR Ca2+ content by Ang II. In control, vasomo-
tion, which was qualitatively similar to that observed in
hypertrophy. In contrast, the Ang II vasoconstrictor response
in cerebral artery with cardiac hypertrophy was decreased
compared to control. Ca2+ release from the SR was de-
creased, whereas resting [Ca2+]i was unchanged in cerebral
artery with cardiac hypertrophy compared to control. We
conclude that treatment with Ang II impairs cerebrovascular
contractility during cardiac hypertrophy through the modu-
lation of Ca2+ sensitivity of the contractile elements.
Keywords: Cardiac hypertrophy; Cerebral artery; Ang II
Acknowledgements: This work was supported by Grants
R05-2001-000-004113-0 and R05-2002-000-00905-0 and
by the Biohealth Products Research Center of the Korea
Science and Engineering Foundation.
Abstract N° B134
Angiotensin-related induction of immediate early genes
in ventricle and cerebral artery during cardiac
hypertrophy
Hyunju Kim a,b, Nari Kim a,b, Euiyong Kim a, Jin Hana a,b.
a Department of Physiology and Biophysics, College of
Medicine, Inje University, Busan 614 735, Korea.
b Molecular Cell Physiology Research Center, College of
Medicine, Inje University, Busan 614 735, Korea
Angiotensin II (Ang II) controls not only the peripheral
but also the brain circulation by stimulation of Ang II recep-
tors and its receptors are defined as Ang II type 1 receptor
(AT1 receptor) and Ang II type 2 receptor (AT2 receptor). In
contrast to peripheral tissues, little is known about the stimu-
latory effects of Ang II receptors on the expression of imme-
diately early genes (IEGs) in cerebral arteries. We have
assessed whether Ang II receptors (AT1 and AT2) and Ang
II-related biochemical signal pathways in cerebral arteries
were altered during cardiac hypertrophy. New Zealand white
rabbits were made cardiac hypertrophy by injection of iso-
proterenol (300 µg/kg body weight) for 7 d. In molecular
biological analysis, the expression of Ang II (AT1 and AT2)
receptors was lower in LVH than in control cerebral arteries.
In contrast to increased level of IEGs in ventricle, the expres-
sions of IEGs (c-fos, c-myc, and c-jun) were decreased in
cerebral arteries during cardiac hypertrophy. The expressions
of H-ras and raf-1 were significantly decreased in LVH
cerebral arteries compared to controls. The levels of cAMP
and PKA were decreased in LVH cerebral arteries compared
to controls. We demonstrated a possible molecular mecha-
nism that decreased expressions of H-ras/raf-1/c-fos and
activities of cAMP/PKA as well as Ang II receptor would
contribute to cerebrovascular dysfunction during cardiac hy-
pertrophy.
Abstract N° B135
Improved cardiovascular function in ageing female
SHR following chronic perindopril treatment
Michael Randall a, Vincent Chan a, Kathleen Wilson b,
Darryl Burstow b, Lindsay Brown a. a School of Biomedical
Sciences, The University of Queensland, Qld, Australia. b
The Prince Charles Hospital, Qld, Australia
The spontaneously hypertensive rat (SHR) is the most
common animal model of human disease. Ageing male SHR
develop cardiac hypertrophy and then heart failure from
about 18 months of age as shown by decreased contractility,
left ventricular dilatation, ventricular fibrosis and increased
stiffness. We have shown that low-dose chronic perindopril
(P) treatment (1 mg/kg/d po for 24 weeks) prevents the onset
of heart failure in 15-month-old male SHR. In contrast,
age-matched female SHR do not develop heart failure al-
though hypertrophy and fibrosis are similar. This study has
determined whether treatment of 15-month-old female SHR
with P (1 mg/kg/d po for 24 weeks) changes cardiac structure
and function using echocardiography and isolated Langen-
dorff hearts (n = 5–10; P < 0.05). Administration of perindo-
pril did not change systolic blood pressure (SHR: 189 ±
6 mmHg; SHR+P: 199 ± 5 mmHg) but decreased left ventri-
cular wet weight (SHR: 4.34 ± 0.16 mg/g body weight;
SHR+P: 3.42 ± 0.10* mg/g bodyweight). Left ventricular
wall thickness at diastole was decreased (SHR: 2.38 ±
0.1 mm; SHR+P: 2.07 ± 0.1* mm) while fractional shorte-
ning (SHR: 58.2 ± 3.3%; SHR+P: 55.3 ± 5.3%) and E/A ratio
(SHR: 1.68 ± 0.06; SHR+P: 1.73 ± 0.10) were unchanged. In
the isolated Langendorff heart, cardiac stiffness was unchan-
ged (SHR: 25.8 ± 1.0; SHR+P: 25.9 ± 0.9) but +dP/dt was
improved (SHR: 1830 ± 70 mmHg/s; SHR+P: 2210 ±
110* mmHg/s). Thus, although ageing female SHR did not
develop heart failure, chronic administration of the ACE
inhibitor, perindopril, attenuates ventricular hypertrophy and
improves ventricular function without decreasing systolic
blood pressure.
Abstract N° B136
Perindopril reverses cardiovascular remodelling in
young male spontaneously hypertensive rats
Julian de Looze, Andrew Fenning, Vincent Chan,
Lindsay Brown. School of Biomedical Sciences,
The University of Queensland, Brisbane, Qld, Australia
ACE inhibitors may have beneficial effects on end-organ
damage in hypertension independently of their effect on
blood pressure per se. To further define this proposal, we
investigated the effect of an oral 1 mg kg–1 daily dose of
perindopril for 12 weeks on left ventricular structure and
function in the 6–9-month-old male SHR. At this age, male
SHR are hypertensive with ventricular hypertrophy and in-
creased collagen deposition but no signs of heart failure
when compared to age-matched normotensive male Wistar–
Kyoto rats. Monthly measurement of blood pressure by tail-
cuff plethysmography demonstrated marginal decreases in
systolic blood pressure, with treated rats remaining signifi-
cantly hypertensive. Echocardiographic assessment of in
vivo cardiac function revealed that perindopril prevented the
early development of diastolic dysfunction in the SHR over
the course of the study. Isolated heart perfusion studies per-
formed using the Langendorff technique showed perindopril
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treatment normalised diastolic stiffness of the SHR left ven-
tricle to control levels, with corresponding functional impro-
vement such as an increased developed pressure compared to
untreated hearts. Picrosirius red staining showed decreased
interstitial collagen content of the left ventricle following
treatment in the SHR. These results provide further evidence
that ACE inhibition reverses cardiac remodelling and its
functional consequences independent of lowering blood
pressure, possibly related to inhibition of tissue rather than
circulating ACE.
Abstract N° B137
Hypertrophic effects of angiotensin II and endothelin-I
are mediated by leptin in rat neonatal ventricular
myocytes
Venkatesh Rajapurohitam, Daniel M. Purdham,
Morris Karmazyn. Department of Physiology and
Pharmacology, University of Western Ontario, London,
Ontario, Canada
Leptin is a 16 kDa product of the obesity gene secreted
primarily by adipocytes. Leptin’s main function was origi-
nally attributed to regulating energy homeostasis via its di-
rect effect on the hypothalamus. We recently identified car-
diomyocytes as a target for the direct hypertrophic effects of
leptin and suggested that leptin may be a biological link
between obesity and cardiovascular pathologies. Activation
of the renin–angiotensin and endothelin systems is associa-
ted with development of cardiovascular diseases and plasma
renin levels are elevated in obese individuals. We determined
possible interaction between these factors in mediating hy-
pertrophy in cultured neonatal rat ventricular myocytes.
Twenty-four hours treatment with leptin (3.1 nM), angioten-
sin II (AngII, 100 nM) or endothelin-1 (ET-1, 10 nM) signi-
ficantly increased cell area by 29%, 32% and 30%, respecti-
vely. Surprisingly, the hypertrophic effects of all three agents
was prevented by leptin receptor (OBR) antibodies whereas
the AT-1 receptor blocker (Sar1–Ile8)-AngII or the ETA re-
ceptor blocker BQ123 were ineffective against leptin-
induced hypertrophy. Both AngII and ET-1 significantly in-
creased leptin levels in the culture medium by three and
fivefold, respectively. Moreover, gene expression of the long
form of OBR (OBR-b) but not the short form (OBR-a) was
increased by both AngII and ET-1 by 172% and 331%,
respectively. In contrast, leptin had no effect on either AngII
or ET-1 receptor mRNA levels. Our studies suggest that
leptin and leptin receptors mediate at least in part, the hyper-
trophic effects of both AngII and ET-1 in cultured neonatal
myocytes.
Abstract No B138
Angiotensin converting enzyme {ACE} inhibitor
{Lisinopril} improves semen quality : a preliminary
report
Basil Okeahialam, C.C. Ekwempu. Departments of
Medicine and Obstetrics and Gynaecology Jos University
Teaching Hospital, Jos, Nigeria
ACE inhibitors have many pharmacological effects.
Little, if any, is manifested in the reproductive system.
However in 1999, Mbah presented an anecdotal case report
of the ability of Lisinopril to improve semen quality. He had
in the course of treating 2 hypertensives having azoospermia
and infertility with Lisinopril recorded improvement in se-
men quality, recording pregnancy in the wife of one.
We decided to conduct a prospective study on males with
poor semen quality from infertile couples. They were given
Zestril brand of Lisinopril at 2.5 mg daily for 3 months, and
followed up for cardiovascular effects and changes in semen
quality.
From 2001 when the study commenced, 15 cases were
seen. 10 did not return for evaluation, but 2 came to report
later that their wives had conceived and delivered. The 5 who
returned for evaluation are the subject of this preliminary
report. In all, there was no untoward cardiovascular effect.
Positive changes in indices of semen quality were recorded in
all, but none reported conception in their wives during the
period. One of them was hypertensive and was continued on
Zestril in higher dose for blood pressure control. His semen
quality continued to improve until he reported conception in
his spouse.
Infertility puts great stress on the the afflicted. We recom-
mend further research to enunciate the mechanism of this
effect and suggest that ACE inhibitors {Lisinopril} be given
in low doses to oligospermic men in infertile couples.
Abstract N° B139
Detection of abnormalities in the diabetic heart using
MRI
Irina V. Smirnova a, Raj Loganathan a, Lisa Stehno-Bittel a,
Mehmet Bilgen b. a Department of Physical Therapy and
Rehabilitation Sciences, University of Kansas Medical
Center, Kansas City, KS, USA. b Department of Molecular
and Integrative Physiology, Hoglund Brain Imaging Center,
University of Kansas Medical Center, Kansas City, KS,
USA
Cardiovascular complications, including diabetic cardio-
myopathy, are the major cause of fatalities in diabetes. Dia-
betic cardiomyopathy is expressed in part through fibrosis
and left ventricular (LV) hypertrophy. This increases myo-
cardial stiffness leading to heart failure. In order to search for
curative interventions, precise evaluation of the diabetic
heart pathology is extremely important. Magnetic resonance
imaging (MRI) is a technique that is ideally suited for the
assessment of heart disorders due to its dimensional accu-
racy, high resolution, and 3D properties. Streptozotocin in-
jected Sprague–Dawley rats were used as a model of type I
diabetes. Changes in heart rate and stress test measures
confirmed cardiac abnormalities in the diabetic animals. In-
creases in heart to body weight ratio and in EKG R wave
heights were suggestive of LV hypertrophy. Masson tri-
chrome staining revealed significant accumulation of colla-
gen, an indication of fibrosis, in diabetic rats compared to
non-diabetics. To further characterize the LV changes in
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diabetic rats we performed high resolution cardiac MRI
using a 9.4 T scanner. In diabetic rats compared to controls,
MRIs demonstrated increased LV wall volume, suggestive of
LV hypertrophy; increased LV wall pixel intensity, sugges-
tive of the presence of fibrosis; and decreased T2 relaxation
time, suggestive of biomechanical changes in the diabetic
tissue, perhaps due to presence of fibrosis. Also, the diame-
ters of LV chamber in completely collapsed hearts were
dramatically increased in diabetes indicating decreased com-
pliance of tissue. Together the data suggest that LV hypertro-
phy and fibrosis may be a major factor underlying structural
and functional abnormalities of diabetic heart.
Abstract N° B140
Signalling pathways involved in development of
diabetes-induced cardiac dysfunction in the globally
ischemic heart
Ibrahim F. Benter a, Mariam Yousif a, Jasbir S. Juggi b,
Saghir Akhtar c. a Department of Pharmacology, Faculty of
Medicine, Kuwait University, Kuwait. b Department of
Physiology, Faculty of Medicine, Kuwait University,
Kuwait. c Centre for Genome-based Therapeutics, Welsh
School of Pharmacy, Cardiff University, Cardiff
We studied the roles of Ras-GTPase, tyrosine kinases
(TKs) including epidermal growth factor receptor (EGFR),
and PI3-kinase in global ischemia and reperfusion (I/R) in a
perfused diabetic rat heart model. Diabetes was induced by a
single intraperitoneal injection of 55 mg/kg body weight
streptozotocin. Recovery of cardiac function, measured as
left ventricular developed pressure (Pmax) and left ventricular
end-diastolic pressure (LVEDP), after 40 min episode of
global ischemia followed by a 30 min reperfusion was signi-
ficantly worse in perfused diabetic rat hearts as compared to
non-diabetic controls. Pre-treatment of rats with Ras-GTPase
inhibitor FPTIII (232 ng/min for 6 d), TKs inhibitor genistein
(1 mg/kg/d for 6 d), or PI3-kinase inhibitor LY294002
(1 mg/kg/d for 6 d) significantly enhanced cardiac recovery
in terms of left ventricular contractility. In contrast, hearts
from diabetic rats pre-treated with EGFR inhibitor AG1478
(578 ng/min for 6 d) produced detrimental effects on reco-
very of cardiac function:
These data suggest that EGFR is involved in signaling
pathways leading to recovery from cardiac ischemia, whe-
reas activation of Ras-GTPase-, TKs-, or PI3-kinase-
mediated signaling pathways are critical in the development
of cardiac dysfunction due to I/R in the diabetic heart.
Abstract N° B141
Atrial natriuretic peptide levels in experimental
diabetes
Erzsebet Kocsis, Ildiko Posa, Ferenc Horkay, Miklos Toth,
G. Gottsegen. National Institute of Cardiology, Budapest,
Hungary
Diabetes mellitus may lead to a cluster of cardiovascular
complications including altered cardiac endocrine activity. In
the present study, we aimed to investigate levels of atrial
natriuretic peptide (ANP) and amino terminal fragment of
proANP (NTproANP) in systemic plasma and pericardial
fluid of diabetic dogs. Metabolically healthy (H, n = 9) and
alloxan-diabetic (i.v. 560 µmol/kg; DM, n = 6) mongrel dogs
of either sex were used. The chest was opened under pento-
barbital (133 µmol/kg nembutal, i.v.) anesthesia and an infla-
table balloon was placed into the right atrium. As a stimulus
for ANP secretion, right atrial pressure was increased by
balloon inflation (by 7–9 cm H2O for 20 min). Systemic
blood and pericardial fluid samples were taken at baseline
and every 10 min during the 60-min study period. Natriuretic
peptide levels were determined by radioimmunoassay. Peri-
cardial ANP levels proved to be higher than systemic plasma
levels (2.2-fold in DM, 2.7-fold in H). Elevated baseline
NT-proANP levels were measured in plasma of diabetic dogs
compared to metabolically healthy controls (DM: 0.47 ±
0.03, P < 0.01 vs. H: 0.31 ± 0.03 pmol/l). In response to
elevation in right atrial pressure, ANP and NT-proANP levels
increased (ANP: 26.34 ± 3.31 P < 0.01 vs. 39.37 ±
6.01 pmol/l and NT-proANP: 0.31 ± 0.03 P < 0.05 vs. 0.42 ±
0.04 pmol/l) in metabolically healthy controls only. Howe-
ver, we failed to prove significant differences in pressure-
stimulated peptide levels between the two investigative
groups. The above results may lead to the conclusion that
elevated basal NT-proANP levels and diminished natriuretic
peptide secretory responsiveness indicate a deterioration in
cardiac function in diabetes.
Abstract N° B142
Expression of connective tissue growth factor is
increased in the diabetic myocardium and associated
with increased left ventricular chamber stiffness
T. Ramanathan a, X. Zheng a, G. Gallagher a, X. Wang b,
S.M. Twigg b, S. Hunyor a. a Cardiac Technology Centre,
Royal North Shore Hospital, Sydney, NSW, Australia. b
Discipline of Medicine, University of Sydney, Sydney,
NSW, Australia
Upregulation of the profibrotic protein connective tissue
growth factor (CTGF) may lead to left ventricular (LV)
diastolic dysfunction in diabetes. However the relationship
between CTGF expression and LV chamber stiffness has not
been determined. Hence, we sought to characterise this rela-
tionship in experimental diabetes. Open-chest anaesthetised





Non-diabetic 47 ± 4 532 ± 28
Diabetic 15 ± 2 * 1050 ± 49 *
Diabetic + FPTIII 25 ± 2 ** 782 ± 23 **
Diabetic + LY294002 29 ± 3 ** 734 ± 41 **
Diabetic + genistein 37 ± 2 ** 544 ± 34 **
Diabetic + AG1478 9 ± 2 ** 975 ± 51
Data (mean ± SEM) recorded at 30 min reperfusion
* Significant as compared to non-diabetic.
** Significant as compared to diabetic.
2552004 ISHR World Congress / Journal of Molecular and Cellular Cardiology 37 (2004) 161-375
ume relationship following 12 months untreated
streptozotocin-diabetes. Chamber stiffness was calculated as
the slope of the linearised LV end-diastolic pressure–volume
relationship, myocardial collagen content was determined by
hydroxyproline assay and CTGF expression was determined
by blinded semi-quantitative analysis of immunostained sec-
tions. Diabetes increased the slope of the linearised LV end-
diastolic pressure–volume relationship (0.00024 ± 0.00010
diabetes vs. 0.00016 ± 0.000032 control P < 0.05) reflecting
increased chamber stiffness. LV collagen content was signi-
ficantly higher in diabetic animals (31.0 ± 3.1 µg/mg dry
tissue) compared to controls (23.9 ± 5.0 µg/mg dry tissue) (P
< 0.01). CTGF expression increased 29.8% in diabetes (P =
0.002) and correlated with chamber stiffness (r = 0.62, P <
0.05). This study demonstrated for the first time a clear
relationship between increased chamber stiffness and CTGF
upregulation in experimental diabetes. Combined with its
known profibrotic effect, this data further implicates CTGF
in the induction of diastolic dysfunction by diabetes and
substantiates CTGF as a potential molecular target to prevent
and treat diabetic cardiomyopathy.
Abstract N° B143
Effects of experimental diabetes on the
endothelin-induced ventricular arrhythmias in dogs
I. Pósa a, F. Horkay a, L. Seres a, R. Skoumal a,
R. de Châtel b,c, M. Tóth a,b,c, E. Kocsis a. a Gottsegen
National Institute of Cardiology, Budapest, Hungary. b
Molecular Genetic Research Group of the Hungarian
Academy of Sciences, Budapest, Hungary. c 1st Department
of Internal Medicine, Semmelweiss University, Budapest,
Hungary
Endothelin (ET) is known to have direct arrhythmogenic
effect in the mammalian heart. Diabetes mellitus (DM) is
accompanied by a series of endothelial and cardiac dysfunc-
tions, however little is known about ET-induced direct ar-
rhythmias in DM. Therefore, we infused ET (33 pmol/min)
into the left anterior descending coronary artery of 28 mon-
grel dogs, and measured basic hemodynamic parameters,
coronary flow and ECG. DM was induced by alloxan and
experiments were done 8 weeks later. Metabolically healthy
dogs served as controls (C). In a further control group, local
hyperglycemia (HG) was induced by intracoronary glucose
infusion (HG). The electrophysiological parameters were
comparable between the groups. This was followed by the
occurrence of ventricular premature beats, coupled extra-
beats and later sustained ventricular tachycardia. Most of the
experiments were terminated by ventricular fibrillation. The
onset of arrhythmias was shorter in DM dogs as compared to
C and HG dogs (18 ± 8 min vs. 24 ± 8 and 30 ± 28 min, P <
0.05). However, there was no difference in the number of
ventricular fibrillations, and the total elapsed time until the
termination of the experiments. Therefore, the diabetic heart
seems to be more prone to ET-induced arrhytmias and this is
probably not a result of locally high glucose concentrations.
Abstract N° B144
Blockade or abrogation of angiotensin II AT1 receptor
suppressed accelerated diabetic atherosclerosis in
streptozotosin-induced diabetic apolipoprotein
E-deficient mice
Yoshiko Ihara, Minako Ishibashi, Kouta Funakoshi,
Gang Zhao, Qingwei Zhao, Kisho Ohtani, Ken-ichi Hiasa,
Shiro Kitamoto, Kensuke Egashira
Background. – Atherosclerotic complications represent a
leading cause of morbidity and mortality in diabetic patients.
Recent evidence suggests increased angiotensin II genera-
tion and its type 1 (AT1) receptor function in the arterial wall
of diabetic animals and humans. However, role of angioten-
sin II AT1 receptor in the mechanism of accelerated diabetic
atherosclerosis has not been clearly addressed.
Methods and results. – Diabetes was induced by injection
of streptozotosin in 8 to 9-week-old apolipoprotein (Apo)E-
deficient mice. These mice were treated with or without
angiotensin II receptor blocker (ARB), telmisartan, or ol-
mesrtan for 6 weeks. Non-diabetic ApoE-deficient mice were
used as controls. Diabetic animals showed a fourfold in-
crease in atherosclerotic lesions in the aorta (2.7 ± 0.5%, 8.7
± 2.3% (P < 0.01 vs. control), and 3.7 ± 0.4% (P < 0.01 vs.
diabetic), in the control, diabetic, and diabetic+ARB mice,
respectively). This was associated with increased expression
ofAT1 receptor and inflammation-promoting molecules such
as monocyte chemoattractant protein-1 in lipid- and
macrophage-rich lesions. Treatment with ARB did not affect
serum lipid profile, blood glucose, or blood pressure, but did
suppressed atherosclerotic plaque formation and decreased
inflammation and lipid deposition. Interestingly, AT1 recep-
tor lacking ApoE-deficient mice displayed similar suppres-
sion of accelerated diabetic atherosclerosis and inflamma-
tion.
Conclusion. – This study demonstrated the pivotal role of
angiotensisn II AT1 receptor in the mechanisms of diabetes-
associated acceleration of atherosclerosis. Blockade of AT1
receptor may function as anti-inflammatory therapy beyond
glycemic control.
Abstract N° B145
Improvement of vasorelaxation by endothelin receptor
antagonist CPU 0213 is mediated by suppression on
preproET-1 of the vascular wall in diabetic rats
De-Zai Dai, Li Sun, Min Ji. China Pharmaceutical
University, Nanjing 210009, China
Aim. – The endothelial lesion in diabetes could be related
to an excess of ET-1 which causes dysfunction of vasorelaxa-
tion. A novel endothelin receptor antagonist CPU 0213 a dual
blockader is tested to recover the impairment of vasorelaxa-
tion in the STZ induced diabetes.
Methods. – Rats were injected with STZ 60 mg/kg i.p.
developed sustained hyperglycemia in 4 weeks and treated
with CPU 0213 80 mg/kg p.o. and aminoguanidine (AGD)
100 mg/kg p.o. for 28 d, separately. The vasorelaxation to
acetylcholine, measurement of ET-1, mRNA of preproET-1
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in myocardium and thoracic aorta, iNOS and NO in serum
were conducted.
Results. – ET-1 raised significantly in serum in diabetic rat
by 39.5 and a reduction in ET-1 level was significant by CPU
0213 (–40.4%) and AGD (–30.0%). In the diabetic model the
mRNA abundance of preproET-1 was increased dramatically
in the myocardium (104%) and aortic wall (581%), respecti-
vely. CPU 0213 and AGD reduced preproET-1 mRNA in
myocardium (–42% and –28%, respectively) and thoracic
aorta (–83% and –80%). The iNOS mRNA increased in
diabetic aorta (305%) and was reduced by 0213 and AGD
(–70% and –38%). The iNOS activity in serum was elevated
in the model (865%), and reduced by 0213 and AGD (–81%
and –51%). The NO in serum was increased in model signi-
ficantly (96%) and reduced by 0213 and AGD (–16% and
–18%). The maximal vasorelaxation was reduced in the mo-
del (–69%), and improved by 0213 and AGD (151% and
125%).
Conclusion. – The novel endothelin receptor antagonist
CPU 0213 which improves significantly vasorelaxation of
the diabetic thoracic aorta is more effective to suppress over-
expression of preproET-1 mRNA in thoracic wall. (Suppor-
ted by a key project of National Science Foundation of China
No: 30230170.)
Abstract N° B146
PPAR-c agonist rosiglitazone reduces clinical
inflammatory responses in type 2 diabetes with
coronary artery disease after coronary angioplasty
X. Wang a, G. Wang a, J. Wei a, Y. Guan b, N. Jin a, J. Mao a.
a Institute of Vas Med, Peking University, 3th Hospital,
Beijing 100083, PR China. b Department of Physiology,
Basic Med Coll, Peking University, Beijing 100083, PR
China
Type 2 diabetes mellitus patients are at an increased risk
for coronary artery disease (CAD) and coronary restenosis
after angioplasty or stenting. Persistent chronic inflamma-
tory condition and metabolic disorder contribute importantly
to the pathogenesis of atherosclerosis and media many stages
of atheroma development from leukocyte recruitment to rup-
ture of plaque and restenotic lesions. Rosiglitazone (RSG),
an agonist of peroxisome proliferators activated receptor-c
(PPAR-c), is insulin-sensitizing antidiabetic agent and inhi-
bits restenosis in animal blood vessels. However, whether
RSG was benefit for diabetes with CAD patients after percu-
taneous coronary intervension (PCI), and if so, to explore the
mediating in a clinical trial. The diabetic CAD patients 70
undergone PCI were randomized receive RSG (4 mg/d) treat-
ment or served as control for 6 months. After 6 months RSG
treatment, the levels of fasting plasma glucose, fasting
plasma insulin, HbA1c and HOMA-IR were significantly
decreased in RSG group when compared with baseline va-
lues and control group. In addition, plasma levels of MCP-1,
CRP and hyper-responsiveness of low-dose LPS-induced
MCP-1 secretion from patient monocytes were also reduced
compared with baseline levels and control group. Further-
more, coronary events were significantly decreased in RSG
group when compared with control group after 6 months
follow-up. In conclusion RSG not only improves metabolic
disorders, but also reduces proinflammatory responses in
diabetic with CAD patients after PCI. Most importantly is
that RSG significantly reduces coronary events in study sub-
jects. These results indicate that PPAR-c agonist RSG may
protect vascular wall by anti-inflammation and anti-
metabolic disorders in diabetic CAD patients after PCI.
Abstract N° B147
Cardiovascular changes in the ageing growth hormone
deficient rat
Andrew Fenning a, Andrew Hoey b, Lindsay Brown a.
a School of Biomedical Sciences, The University of
Queensland, Toowoomba, Qld, Australia. b Department of
Biological and Physical Sciences, The University of
Southern Queensland, Toowoomba, Qld, Australia
Exogenous growth hormone has been implicated as a
potential novel therapy for patients with congestive heart
failure. This project has characterised the Lewis Dwarf (LD)
growth hormone deficient rat model from 6 to 18 months (M)
of age using echocardiography, isolated Langendorff heart
preparations, single-cell microelectrode electrophysiological
recordings and responses from isolated thoracic aortic rings
to determine if growth hormone deficiency initiates heart
failure. LD rats were moderately hypertensive (6 M, 148 ±
3*; 12 M, 157 ± 4*; 15 M, 162 ± 3*; 18 M, 161 ± 4* mmHg)
compared to age-matched Wistar (W) controls (6 M, 121 ± 3;
12 M, 126 ± 3; 15 M, 133 ± 2; 18 M, 129 ± 6 mmHg) with
decreased left ventricular internal dimensions in diastole
(LD: 6 M, 5.4 ± 0.3*; 12 M, 5.3 ± 0.1*; 15 M, 6.1 ± 0.1*;
18 M, 6.8 ± 0.2* mm; W: 6 M, 7.1 ± 0.1; 12 M, 8.2 ± 0.2;
15 M, 7.8 ± 0.3; 18 M, 7.9 ± 0.3 mm) and increased left
ventricular posterior wall thicknesses (LD: 6M, 1.87 ± 0.08*;
12 M, 1.87 ± 0.07*; 15 M, 1.89 ± 0.08*; 18 M, 1.76 ±
0.1* mm; W: 6 M, 1.76 ± 0.08; 12 M, 1.72 ± 0.07; 15 M, 1.77
± 0.08; 18 M, 1.89 ± 0.08 mm) indicative of concentric
cardiac hypertrophy. Fractional shortening, ejection fraction,
maximum ascending aortic blood flow velocity and maxi-
mum +dP/dt were all increased in the LD rat showing impro-
ved systolic function. LD rats showed prolonged action po-
tential duration (APD90: LD: 6 M, 47.5 ± 5.9*; 12 M, 52.9 ±
4.3; 15 M, 60.2 ± 5.3*; 18 M, 76.5 ± 7.2* mm; W: 6 M, 33.1
± 3.7; 12 M, 47.8 ± 5.9; 15 M, 49.9 ± 4.1; 18 M, 53.7 ±
5.6 ms). Additionally, maximal responses to noradrenaline,
acetylcholine and sodium nitroprusside were significantly
reduced in LD rats. Diastolic stiffness was unaltered between
the groups but increased with age. Thus, chronic growth
hormone deficiency produces compensated concentric car-
diac hypertrophy with improved left ventricular function
without symptoms of heart failure but vascular function is
dramatically reduced in the LD rat.
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Abstract N° B148
Rosiglitazone, a PPARc-activator, improves
cardiomyocytes contractile response to insulin in
spontaneously hypertensive rats
Hai F. Zhang, Rong Li, Ling Dong, Heng Ma, Xin L. Ma,
Feng Gao. Department of Physiology, Fourth Military
Medical University, Xi’an, China
To compare the effects of insulin on cardiomyocytes of
normal Wistar–Kyoto rats (WKY) and spontaneously hyper-
tensive rats (SHR), and further investigate whether rosiglita-
zone (ROSI), a peroxisome proliferators-activated receptor c
(PPARc) activator, modifies the sensitivity of SHR myocytes
to insulin. Male SHR were randomized to receive ROSI
(3 mg/kg/d, o.p.) or vehicle for 14 d. Single ventricular
myocytes were enzymatically isolated and field stimulated.
Myocyte shortening and intracellular Ca2+ transient were
assessed and compared with those of age- and sex-matched
WKY by a video-based motion edge detection system. Insu-
lin concentration dependently (at 10–6–10–8 mol/l) increased
the myocyte shortening of both WKY and SHR. At 10–
7 mol/l, insulin increased the peak twitch amplitude (PTA) of
WKY myocytes by 20.5% (n = 10, P < 0.05 vs. vehicle).
Compared with WKY, however, the response of SHR myo-
cytes to insulin reduced significantly as evidenced by de-
creased PTA (7.83 ± 0.55% vs. 10.17 ± 0.48% of WKY, n =
10, P < 0.01) and decreased maximal velocity of shortening
or relengthening (±dL/dt, n = 10, P < 0.05). After the treat-
ment with ROSI, the sensitivity of SHR myocytes to insulin
was augmented remarkably: PTA, +dL/dt and –dL/dt in-
creased by 31.2% (n = 10, P < 0.01), 23.7% and 21.6% (n =
10, P < 0.05), respectively. In addition, the Ca2+ transient
(fura-2 fluorescence intensity change) in ROSI-treated SHR
myocytes to insulin increased from 0.27 ± 0.02 to 0.43 ± 0.03
(n = 10, P < 0.01). Insulin has positive inotropic action on
normal rat cardiomyocytes, which is significantly blunted in
SHR. PPARc-activator ROSI enhances the insulin-induced
contractile effect on cardiomyocytes of SHR by increasing
intracellular Ca2+ transient.
Abstract N° B149
Mechanism of heart failure resulting from chronic
b-adrenergic stimulation
Carolyn Carr, Anthony Catchpole, Damian Tyler,
Mark Cole, Andrew Murray, Lisa Heather, Gillian Watson,
Vivyan Clarke-Newman, Kieran Clarke. University
Laboratory of Physiology, University of Oxford, Parks
Road, Oxford, OX1 3PT, UK
As the heart hypertrophies and fails, metabolic energy
stores become depleted through unknown mechanisms. We
have used non-invasive magnetic resonance imaging (MRI)
and isolated heart techniques to determine whether the
energy depletion results from increased workload or from
decreased mitochondrial ATP production. Male Wistar rats
(n = 16) were injected with the b-adrenergic agonist, isopro-
terenol (Iso), 5 mg/kg for 7 d, to induce cardiac hypertrophy.
In vivo cine MRI showed that the hearts of treated animals
had 25% increased left ventricular weight and 24% lower
cardiac output, with no changes in ejection fraction or stroke
volume. Plasma levels of glucose and triglycerides were
decreased by 38% and 36%, respectively, but the non-
esterified fatty acid levels were unchanged in Iso-treated
animals. Hearts were isolated and perfused in working mode
with Krebs–Henseleit buffer containing 11 mM glucose. The
hydraulic work performed by Iso-treated rat hearts was 42%
lower than controls. Protein levels of the insulin responsive
glucose transporter protein, GLUT4, were decreased by 26%
and levels of the mitochondrial uncoupling protein, UCP3,
were increased by 38% in the Iso-treated rat hearts compared
with controls. The observed decrease in GLUT4 and the
lower work performed by hearts perfused with glucose alone
suggest that the hypertrophied hearts were insulin resistant.
The increased UCP3 levels suggest that there would be in-
creased mitochondrial uncoupling and a consequent decrease
in cardiac efficiency in the presence of plasma fatty acids.
Thus the decreased energy stores in hypertrophied hearts are
probably due to decreased ATP production that limits the
cardiac work.
Abstract N° C1
Cardioprotective efficacy of zoniporide, a potent and
selective inhibitor of Na+/H+ exchanger isoform 1, in an
experimental model of cardiopulmonary bypass
Hugh Clements-Jewery a, Fiona J. Sutherland b,
Mary C. Allen b, W. Ross Tracey b, Metin Avkiran a. a Kings
College London, St Thomas’ Hospital, London, UK. b
Pfizer Global Research and Development, Groton, CT, USA
We determined (1) the inhibitory potency of zoniporide
against the native Na+/H+ exchanger isoform 1 (NHE1) ex-
pressed in adult rat ventricular myocytes and platelets, and
(2) the cardioprotective efficacy of zoniporide in isolated,
blood-perfused adult rat hearts subjected to cardioplegic ar-
rest, hypothermic ischaemia (150 min at 25 °C) and normo-
thermic reperfusion (60 min at 37 °C). In isolated myocytes,
zoniporide produced a dose-dependent inhibition of NHE1
activity, as measured by the rate of H+ efflux following
intracellular acidification (IC50 73 nM at 25 °C). A compara-
ble NHE1-inhibitory potency was retained at 37 °C. In pla-
telets, the rate of cell swelling, a surrogate index of NHE1
activity, was also inhibited by zoniporide (IC50 67 nM at
25 °C). In the isolated heart model, administration of zonipo-
ride (loading bolus of 1 mg kg–1 i.v. plus continuous infusion
of 1.98 mg kg—1 h–1 i.v.) to the support animal achieved a
free drug concentration of ≥1 µM. At this dose, relative to
vehicle treatment, zoniporide afforded improved preserva-
tion of left ventricular end-diastolic and developed pressures
and coronary perfusion pressure during reperfusion. Myocar-
dial myeloperoxidase activity was also attenuated by zonipo-
ride treatment, indicating reduced neutrophil accumulation.
These data show that zoniporide (1) is a potent inhibitor of
native NHE1 activity in ventricular myocytes and platelets,
and (2) affords significant cardioprotective benefit during
ischaemia and reperfusion in an experimental model that
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mimics several distinctive features of human cardioplegic
arrest with cardiopulmonary bypass.
Abstract N° C2
Myocardial protection by Na+/H+ exchanger inhibition
and ischemic preconditioning of rat heart
O.I. Pisarenko, I.M. Studneva, L.I. Serebryakova,
O.V. Tskitishvily. Cardiology Research Centre, Moscow,
Russia
This study was designed to compare the cardioprotective
efficacy of BIIB-722, a novel selective Na+/H+ exchanger
inhibitor (Boehringer Ingelheim Pharma, KG), and ischemic
preconditioning (IP) in a rat model of myocardial infarction.
The left anterior descending coronary artery (LAD) was
ligated for 40 min and then reperfused for 1 h (control).
BIIB-722 was infused intravenously (3 mg/kg) for 5 min
before LAD occlusion or at the first minute of reperfusion
(BIIBi or BIIBr group, respectively). IP was induced by two
cycles of 5-min LAD occlusion and 5-min reperfusion prior
to sustained ischemia. Myocardial infarct (MI) size was de-
termined by staining slices with triphenyltetrazolium chlo-
ride. Metabolic state and cell membrane damage of the area
at risk (AR) were assessed by ATP, phosphocreatine (PCr),
total creatine (RCr = PCr+Cr) and lactate contents after
reperfusion. The AR to the left ventricular weight ratio was
on average 32 ± 4% in all studied groups. The percentage
MI/AR ratios in BIIBr and IP groups did not differ and were
significantly lower than in the control (17 ± 2% and 15 ± 3%,
respectively vs. 43 ± 5%). This index was significantly higher
in BIIBi group (25 ± 2%) comparing with IP and BIIBr
groups but 1.7-fold lower than in the control. MI size limita-
tion was combined with better RCr preservation in BIIBr and
IP groups than in BIIBi one at the end of reperfusion (70 ±
5%, 75 ± 4% and 63 ± 5% of the initial value, respectively).
RCr content in the control was 58 ± 3% of the preischemic
value indicating pronounced sarcolemmal rupture. Both
BIIBr and IP groups showed significantly higher ATP and
PCr levels and lower lactate content comparing with these
indices in the control. BIIB-722 administration before sustai-
ned ischemia but did not affect metabolic state of the AR. The
results indicate that administration of Na+/H+ exchanger in-
hibitor on early reperfusion is much effective than before
ischemia. We believe that IP may inhibit Na+/H+ exchanger
during reperfusion to prevent myocardial damage.
Abstract N° C3
Intracellular acidosis stimulates ERK activity in adult
myocytes through a GPCR-, PKC- and
Src-independent mechanism
R.S. Haworth, M. Avkiran. Cardiovascular Research
Division, King’s College London, The Rayne Institute, St
Thomas’ Hospital, London SE1 7EH, UK
Intracellular acidosis has a profound effect on myocyte
function and viability. We have shown previously that intra-
cellular acidosis activates the ERK pathway in neonatal rat
ventricular myocytes (J Biol Chem 2003;278:31676–84).
Here, we examined acidosis-induced activation of the ERK
pathway and potential upstream mediators of this response in
adult rat ventricular myocytes (ARVM). After overnight cul-
ture, ARVM were transferred to bicarbonate-free Tyrode
solution for 90 min, and then exposed to 30 mM NH4Cl for
4 min. Intracellular acidosis was induced and maintained by
NH4Cl washout with Tyrode solution containing the NHE
inhibitor cariporide (3 µM). Intracellular acidosis induced a
robust (10-fold) increase in ERK activity (as determined by
western blotting with an antibody which recognises the phos-
phorylation of ERK1/2 by their upstream activator, MEK1)
in a rapid (peak within 3 min) and transient (return to basal by
10 min) manner. Acidosis-induced ERK activation was unaf-
fected by: (1) Adenovirus-mediated overexpression of regu-
lator of G protein signalling (RGS) proteins, to inhibit signal-
ling via Gq, Gi and G12/13 proteins. (2) Pharmacological
inhibition of protein kinase C with GF109203X (10 µM). (3)
Pharmacological inhibition of Src tyrosine kinases with PP2
(10 µM). In contrast, ERK activation was abolished by phar-
macological inhibition of MEK1 (U0126, 3 µM) or
adenovirus-mediated expression of a kinase-inactive domi-
nant negative MEK1 mutant. Our data indicate that, in
ARVM, intracellular acidosis increases ERK activity
through a GPCR-, PKC and Src-independent mechanism
mediated by MEK1.
Abstract N° C4
Caveolar Na/K-ATPase moonlights by interacting with
protein tyrosine kinases
Haojie Wang, Michael Haas, Jiang Tian, Man Liang,
Zijian Xie. Departments of Pharmacology and Medicine,
Medical College of Ohio, Toledo, OH 43614, USA
Binding of ouabain to Na/K-ATPase activates multiple
signaling pathways by stimulation of Src and other tyrosine
kinases. Since the a subunit of the pump contains two conser-
ved caveolin-binding motif, we aimed to test if the caveolar
Na/K-ATPase is involved in transmitting extracellular oua-
bain signal. GST pull-down assay showed that the a subunit
bound to the N-terminus of caveolin-1. Significantly, oua-
bain regulated this interaction in a time- and dose-dependent
manner and stimulated tyrosine phosphorylation of
caveolin-1. When added to the isolated membrane fractions,
ouabain increased tyrosine phosphorylation of proteins from
the isolated caveolae, but not other membrane fractions.
Consistently, ouabain induced the formation of a Na/K-
ATPase/Src/caveolin complex in the isolated caveolae prepa-
rations as it did in live cells. Finally, depletion of either
cholesterol by methyl b-cyclodextrin or caveolin-1 by siRNA
significantly reduced the caveolar Na/K-ATPase and Src.
Concomitantly, cholesterol depletion abolished ouabain-
induced recruitment of Src to the signaling pump. Like de-
pletion of caveolin-1, it also blocked the effect of ouabain on
ERKs, which was restored after cholesterol repletion.
Clearly, the caveolar Na/K-ATPase represents the signaling
pool of the pump that interacts with Src and transmits the
ouabain signals. Supported by NIH grants HL-36573, HL-
67963, and HL-63238.
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Abstract N° C5
Contractile function is depressed in the
phospholemman knockout mouse heart
J.R. Bell a, K. Dighe a, W. Fuller a, P. Eaton a, L. Jia b,
A.L. Tucker b, M.J. Shattock a. a Centre for Cardiovascular
Biology and Medicine, King’s College London, London,
UK. b Department of Internal Medicine, University of
Virginia, VA, USA
Phospholemman (PLM) is the primary cardiac sarcolem-
mal substrate for PKA and PKC, and may regulate cell
volume. Like other FXYD proteins, PLM has also been
implicated in the modulation of Na/K-ATPase activity. We
have recently shown that unphosphorylated PLM may exert a
tonic inhibition on Na/K-ATPase activity. We have investiga-
ted cardiac function in PLM knockout (KO) mice. Isolated
hearts were aerobically perfused in Langendorff mode for
30 min and left ventricular developed pressure (LVDP)
measured. PLM KO hearts exhibited a significantly reduced
LVDP compared with wild type (29 ± 9 vs. 96 ± 5 mmHg; n
= 4, P < 0.05), with no difference in coronary flow. This
depressed contractility was also seen in vivo. In anaethetised,
ventilated open-chest mice (n = 8/group), an LV Millar
conductance catheter was inserted via the cardiac apex and
pressure–volume loops recorded at various preloads.
These studies suggest PLM plays a significant role in the
regulation of cardiac contractile function and are consistent
with an elevated Na/K-ATPase activity in the KO heart. This
in turn may reduce intracellular sodium concentration and
hence indirectly reduce intracellular calcium concentration
and contractility.
Abstract N° C6
Isoform specific regulation of cardiac Na/K ATPase by
phospholemman
W. Fuller, P. Eaton, B.dZ. Silverman, J. Deng, J.R. Bell,
M.J. Shattock. Centre for Cardiovascular Biology and
Medicine, King’s College, London
Regulation of the Na/K ATPase (NKA) by protein kinases
is tissue and model specific. There is a well-established
functional link between PKA and cardiac NKA, but the NKA
a1 subunit is not a PKA substrate in vivo. The aim of this
study was to investigate the relationship between NKA, PKA
and phospholemman (PLM, the primary substrate for PKA
and PKC in cardiac sarcolemma) in isolated guinea pig
ventricular myocytes and homogenates of Langendorff-
perfused rat hearts. NKA activity in homogenates and sub-
cellular fractions of hearts perfused aerobically and made
ischemic for up to 30 min was determined by measuring
ouabain-sensitive phosphate generation from ATP at 37 °C.
NKA activity in isolated myocytes was measured using the
perforated patch technique, and currents due to NKA a1 and
a2 (Ia1 and Ia2) distinguished by their sensitivity to dihy-
droouabain. In sarcolemmal membranes prepared from
Langendorff-perfused hearts, ischemia caused a substantial
increase in NKA activity (from 2.4 ± 0.4 in aerobic controls
to 7.2 ± 0.5 µmol phosphate/min/g wet weight after 30 min
ischemia, n = 5), which was blocked by treatment with the
PKA selective inhibitor H89 (1 µmol/l) prior to ischemia. In
voltage clamped myocytes, PKA activation with forskolin
(1 µmol/l) caused a significant H89-sensitive increase in Ia1
of 36 ± 15% (n = 6), but no change in Ia2. PLM was
phosphorylated but NKA a1 subunit was not following PKA
activation in ischemic Langendorff-perfused hearts and
forskolin-treated myocytes. PLM was found associated with
NKA a1 and b1 but not a2 subunits by both co-
immunoprecipitation and immunofluorescence. Therefore,
PLM is an integral part of the NKA enzyme complex in the
heart and provides a functional link between PKA and NKA.
Its role is analogous to that of phospholamban in regulating
the sarcoplasmic reticulum calcium ATPase: phosphoryla-
tion of PLM leads to disinhibition of NKA.
Abstract N° C7
Dobutamine stimulates rubidium ion uptake in pig
hearts in vivo: 87Rb-MRS study
Valery V. Kupriyanov, Bo Xiang, Jiankang Sun,
Olga Jilkina. Institute for Biodiagnostics, National Research
Council, Winnipeg, Canada
We have previously shown using 87-rubidium MRI that
the adrenergic agonist, dobutamine (Dob), stimulate Rb+
uptake in isolated pig hearts. In the present work we studied
whether Dob can increase Rb+ uptake rate in vivo. Open-
chest domestic pigs (n = 14) were used under general anaes-
thesia. The surface coil was placed against the anterior left
ventricular wall to obtain 87Rb spectra. RbCl (188 mM) was
infused at the rate of 1.35 ± 0.14 mmol/kg/h without or with
Dob (0.6 mg/kg/h) over a 60-min period and then infusions
were terminated for 60 min. Hearts were arrested, excised
and analysed for RbCl content. 87Rb spectra were obtained
every 5 min using a Bruker Avance spectrometer interfaced
with Magnex 7T, 40-cm horizontal bore magnet. Dob in-
creased the rate constant and Rb+ influx rate (twofold) at the
similar plasma [Rb+] (Table 1) and tissue/plasma Rb ratios
(38 ± 9).
Heart rate (HR) and blood systolic pressure (BSP) in-
creased by 52 and 19% from 106 ± 9 bpm and 78 ± 7 mmHg,
respectively. Stimulation of Rb+ uptake by Dob is consistent
Wild type KO
dP/dt max (mmHg/s) 8032 ± 302 4548 ± 230 *
dP/dt min (mmHg/s) –7928 ± 227 –5033 ± 233 *
Ejection fraction (%) 73.5 ± 4.7 59.6 ± 6.0
Stroke work (mmHg·µl) 598 ± 55 396 ± 70 *
Tau-Weiss (ms) 7.64 ± 0.13 9.67 ± 0.25 *
Ventricle/body weight ratio (×102) 2.78 ± 0.07 3.27 ± 0.17 *
* P < 0.05.
Table 1
Group k × 103 (min–1) Flux (%/min) Plasma [Rb+] (mM)
Dob 36 ± 11.7 4.8 0.51 ± 0.19
Control 13 ± 2.4 2.5 0.73 ± 0.24
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with the activation of Na+/K+ ATPase previously observed in
isolated hearts. However the 50% increase in HR and dou-
bling of coronary flow (BSP increase and vasodilatation)
could also contribute to this effect.
Abstract N° C8
ANP activates the sarcolemmal sodium pump via nitric
oxide synthase
Maged William a,b, Alvaro Garcia a, Elisha Hamilton a,c,
Henning Bundgaard a, Helge Rasmussen a,c. a Cardiology,
Royal North Shore Hospital, Sydney, NSW, Australia. b
Cardiology, Gosford Hospital, Gosford, NSW, Australia.
c Department of Medicine, University of Sydney, Sydney,
NSW, Australia
We reported that atrial natriuretic peptide (ANP) at phy-
siological cardiac tissue concentration (~10 nM) activates the
Na+–K+ pump in rabbit ventricular myocytes by activating
cGMP dependent protein kinase-G. Given a reported absence
of particulate guanylyl cyclase (GC) in ventricular myocytes,
we tested the hypothesis that the ANP effect on the pump was
mediated by soluble guanylyl cyclase (sGC). We examined
the effect of 10 nM ANP on the cardiac sarcolemmal Na+–K+
pump by voltage clamping single rabbit ventricular myocy-
tes. Electrogenic Na+–K+ pump current (Ip) was identified as
the shift in holding current induced by 100 µM ouabain.
Pipette solutions included Na+ in a concentration of 10 mM.
Ip of control myocytes was 0.35 ± 0.02 pA/pF (n = 9) while Ip
of myocytes exposed to 10 nM ANP was 0.54 ± 0.03 pA/pF
(n = 7, P &ks; 0.001). We inhibited sGC by enclosing 10 µM
1h-[1,2,4]oxadiazole [4,3-a]quinoxaline-1-one (ODQ).
ODQ abolishes ANP-induced pump stimulation (Ip = 0.28 ±
0.02 pA/pF, n = 7). We examined if nitric oxide synthase
(NOS) linksANP to the Na+–K+ pump by including 10 µM of
the NOS-inhibitor L-N-monomethyl-arginine (L-NAME) in
pipette solutions. L-NAME induced a decrease in Ip in
control myocytes not exposed to ANP (Ip = 0.20 ± 0.2 pA/pF,
n = 5) and abolished ANP-induced pump stimulation (Ip =
0.20 ± 0.06 pA/pF, n = 5). We concluded that ANP activates
the Na+–K+ pump by a mechanism that involves activation of
sGC by NO as a result of NOS activation.
Abstract N° C9
Camp regulation of HERG K+ channel expression
Bian, Jinsong. National University of Singapore, Singapore
The timing and rate of cardiac repolarization is governed
by alterations of K+ channels including the rapidly activating
delayed rectifier current (IKr) which is produced by the
HERG gene. cAMP signaling is likely to provide a link
between stress and arrhythmias (hereditary long QT syn-
drome (LQTs) and acquired) by regulating of HERG K+
channel activity. Although HERG currents regulated by
cAMP have been studied extensively, little is known about its
effect on channel proteins involved in trafficking and expres-
sion. In the present study, we found that cAMP increased
HERG K+ channel abundance dose dependently in HEK293
which stably expressed HERG K+ channel. Treatment of
other transfected ion channels such as KvLQT1, Kir2.1,
Kv1.4 and Kv1.5 with the same CMV promoter with 50 µM
cpt-cAMP for 24 h did not change their abundances, sugges-
ting that the cAMP effect is specific to the HERG channel
protein. To determine whether the effect of cAMP depends
on de novo protein synthesis or not, we investigate whether
the new synthesized nuclear factors are required for the effect
of cpt-cAMP on the transcription of HERG gene. Treated
with 500 µg/ml cycloheximide (CHX) for 30 min to inhibit
protein synthesis did not abolish the effect of cpt-cAMP on
HERG abundance. Mutation of PKA phosphorylation sites in
HERG channel attenuated, but did not abolish, the effect of
cAMP, suggesting that PKA phosphorylation of HERG K+
channel may, at least partially, contribute to the channel
trafficking and expression. Moreover, treatment of rabbit
cardiac myocyte with cpt-cAMP for 6 h also significantly
increased ERG/Ikr expression. H-89, a PKA inhibitor, signi-
ficantly attenuated the effect of cAMP. These data suggested
that elevation of intracellular cAMP level in cardiac myocyte
may also alter cardiac ERG/Ikr expression. So in summary,
in the present study we demonstrated for the first time that
cAMP/PKA activity is a potential post-translational regula-
tor of cardiac HERG expression.
Abstract N° C10
Role of Ikur for action potential shape and contractility
in human atrial tissue from patients in atrial
fibrillation or in sinus rhythm
E. Wettwer a, O. Hála b, T. Christ a, J.F. Heubach a,
D. Dobrev a, M. Knaut c, A. Várro b, U. Ravens a.
a Department of Pharmacology and Toxicology, TU
Dresden, Germany. b Department of Pharmacology and
Pharmaco-therapy, Medical University Szeged, Hungary.
c Cardiovascular Centre Dresden, Germany
The ultrarapid outward current IKur is a major repolarizing
current in human atrium and a potential target for selectively
treating atrial arrhythmias. Here we have investigated the
effects of selective block of IKur by low concentrations of
4-aminopyridine (4-AP) or the biphenyl derivative AVE-
0118 on right atrial action potentials (AP) in trabeculae from
patients in sinus rhythm (SR) or with chronic atrial fibrilla-
tion (AF). AP duration at 90% of repolarization (APD90) was
shorter in AF than in SR (300 ± 16 ms, n = 6 vs. 414 ± 10 ms,
n = 15), whereas APD20 was longer (35 ± 9 ms in AF vs. 5 ±
2 ms in SR, P < 0.05 for both). Exposure of trabeculae to
4-AP, 5 µM, elevated the plateau phase to more positive
potentials from –21 ± 3 to –6 ± 3 mV in SR and from 0 ± 3 to
+12 ± 3 mV in AF The same concentration shortened APD90
from 414 ± 10 to 350 ± 10 ms in SR but prolonged APD90
from 300 ± 16 to 320 ± 13 ms in AF. AVE 0118 induced
similar effects. Computer simulations of selective IKur block
in human atrial APs predicted substantial secondary in-
creases in ICa,L and in the outward rectifiers IKr and IKs with
smaller changes in AF than in SR. The indirect effect on ICa,L
was supported by a concentration-dependent positive inotro-
pic response to 4-AP in the absence of direct effects on ICa,L.
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In accordance with the model predictions block of IKr with
E-4031 converted APD shortening effects of selective IKur
block in SR into APD prolongation like in AF. We conclude
that whether inhibition of IKur prolongs or shortens APD in
human atria depends on the disease status of the atria and
involves conductance of IKr.
Abstract N° C11
Transient opening of the mitochondrial KCa channel is
protective in the human adult but not neonatal
myocardium
M. Baghai, D.R. Anderson, C.B. Austin, J.M. Jennings,
N. Alphonso, M.J. Shattock. King’s College and Guy’s
Hospital, London, UK
We have investigated whether transient exposure to
NS1619 (a KCa opener) can protect both the human adult and
neonatal myocardium and if KCa channels play a role in
ischemic preconditioning (IPC). Right atrial trabeculae (n =
6/group), were obtained from adult (65 ± 12 years) and
neonatal (<1 month) patients undergoing cardiac surgery.
Trabeculae were isolated and superfused at 37 °C, field
stimulated at 1 Hz, stretched to Imax and allowed to stabilise
for 120 min. Ischemia was simulated by switching to hy-
poxic, substrate-free buffer and rapidly pacing at 3 Hz. Tra-
beculae were subjected to either 60 min simulated
ischemia/120 min reperfusion (I/R) or this protocol preceded
by IPC (3 min I/15 min R) or pretreatment protocols. Pre-
treatments included: NS1619 (30 µM) in the presence or
absence of the KCa antagonist paxilline (PAX, 1 µM) or the
antioxidant N-acetyl cysteine (NAC, 4 mM). Post-ischemic
recovery of function (PIR; % baseline) was measured. In
separate studies, mitochondrial flavoprotein oxidation
(MFO) was measured as an indirect index of mitochondrial
KCa channel opening. Following I/R alone, PIR was 19 ± 3%
and 48 ± 7% in the adult and neonates, respectively. This was
significantly (P < 0.05) improved in the adult by both IPC
(PIR 70 ± 6%) and NS1619 (53 ± 4%) but not in the neonatal
myocardium (51 ± 5% and 50 ± 3% with IPC and NS1619,
respectively). In the adult both NAC and PAX, abolished this
protection and NS1619 induced a reversible increase in MFO
from 12 ± 3% to 64 ± 11%. Thus we have shown a novel
mechanism by which the human adult but not neonatal myo-
cardium can be ‘preconditioned’ by the transient activation
of mitochondrial Ca-activated K channels using NS1619, a
process not implicated in IPC. This protection appears to be
mediated via mitochondrial oxidation and a free-radical-
dependent mechanism. Understanding this pathway may
provide alternate therapeutic options.
Abstract N° C12
Sex and strain differences in adult mouse cardiac
repolarization: importance of androgens
Judith Brouillette a,b, Eric Lizotte a,b, Katy Rivard a,
Céline Fiset a,b. a Research Center, Montreal Heart Institute,
Montréal, Québec, Canada. b Faculty of Pharmacy,
University of Montreal, Montréal, Québec, Canada
We previously demonstrated that compared to CD-1 male,
both female and castrated male mice of the same strain
display prolonged repolarization time associated with a spe-
cific decrease in the ultrarapid delayed rectifier K+ current
density that can be explained by a lower expression of Kv1.5.
These data strongly suggested that gender differences obser-
ved in mice are mainly due to the action of androgens. Since
previous studies have reported that male mice of the C57BL
strain are considered chronically androgen deficient, we
compared testosterone levels in different strains of mice and
observed that effectively only the mice of the C57BL/6 strain
had very low levels of testosterone; the others strains exami-
ned (FVB, C3H and CD-1) having normal levels of male sex
hormones. We therefore took advantage of this particularity
of the C57BL/6 mice to further confirm the role of male sex
hormones in the regulation of ventricular repolarization. We
verified that C57BL/6 male mice exhibit similar ventricular
repolarization than female mice but delayed repolarization
compared to the CD-1 male mice which have physiological
levels of male sex hormones. Furthermore, we showed that
androgen replacement in the C57BL/6 male mice as well as
in the castrated CD-1 male mice fastens ventricular repolari-
zation. Results obtained in this study provide strong evidence
that androgen is a major regulatory factor of cardiac repola-
rization and that special attention should be paid to the
hormonal status of the animal used when studying hormonal
regulation of cardiac repolarization.
Abstract N° C13
Molecular mapping of the mammalian sinoatrial node
Halina Dobrzynski a, Jue Li a, Vladimir P. Nikolski b,
Igor R. Efimov b, Mark R. Boyett a. a School of Biomedical
Sciences, University of Leeds, Leeds, UK. b Department of
Biomedical Engineering, Case Western Reserve University,
Cleveland, OH, USA
The sinoatrial node (SAN) is known to be heterogeneous,
and can be divided into centre and periphery. Our aim was to
delineate these two regions, and to construct an anatomically
and molecularly detailed 3-D model of the SAN. Techniques
used were: (1) Fluorescent optical imaging for detection of
the leading pacemaker. (2) Histological staining for detailed
anatomy and cell orientation. (3) Immunocytochemistry,
confocal imaging and quantitative real-time PCR for distri-
bution of: (a) markers (neurofilament, NF-M, and atrial na-
tuiretic peptide, ANP), (b) connexins responsible for electri-
cal coupling (Cx40, Cx43, Cx45), (c) pacemaking channel
subunits responsible for If (HCN1 and HCN4), (d) the Na
+
channel subunit responsible for INa (NaV1.5), and (e) an
inward rectifier K+ channel subunit responsible for IK,1
(Kir2.1). (4) Computer modeling. Our results show that in
the centre, cells are not uniformly arranged (as compared to
atrial muscle), and they do not express ANP, Cx43 and
NaV1.5, but they do express NF-M, HCN1 and HCN4. In the
centre, Cx45 is highly, but Cx40 is poorly, expressed. In the
periphery, there is intermingling and interdigitation of SAN
and atrial cells, and ANP is not expressed, but NF-M, Cx40,
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Cx43, Cx45, NaV1.5, HCN1 and HCN4 are expressed. Our
preliminary data also show that Kir2.1 is expressed in the
periphery, but not in the centre. The regional differences in
the distribution of connexins and ion channels reflect the
different functions of the SAN: the function of the centre is to
be the leading pacemaker, and the function of the periphery is
to drive the atrial muscle.
Abstract N° C14
If channel inhibitor ivabradine lowers heart rate in
mice with enhanced sympathoadrenergic activities
Xiao-Jun Du, Xinheng Feng, Xiao-Ming Gao,
Tze Ping Tan, Helen Kiriazis, Anthony M. Dart. Baker
Heart Research Institute, Melbourne, Vic., Australia
Ivabradine selectively reduces heart rate (HR) by inhibi-
ting the cardiac pacemaker If current, thus prolonging the
duration of spontaneous depolarisation in the sinus node.
HR-reducing activity of ivabradine under conditions of an
enhanced sympathoadrenergic drive were investigated by
testing the effects of repeated oral administration in mice
with sympathoadrenergic activation due to restrain-
associated stress, cardiac-restricted overexpression of b2-
adrenergic receptors (b2AR), or b-agonist administration.
HR and left ventricular fractional shortening (FS) were deter-
mined by echocardiography. Initial experiments showed that
the conscious restrained state was associated with stress-
mediated sympathetic activation whilst sympathetic wi-
thdrawal occurred under anesthetized conditions. In non-
transgenic (NTG) mice, oral treatment with ivabradine lead
to dose-related increase in the plasma level of ivabradine.
Ivabradine at 10 and 20 mg/kg/d reduced HR by about
10–20% under both conscious (stressed) and anaesthetised
states while FS was unchanged by the treatment. Ivabradine
at 10 and 20 mg/kg/d was similarly effective in reducing HR
by about 15% in the b2AR transgenic (TG) mice. Further, in
anesthetized NTG mice, ivabradine at 10 mg/kg/d reduced
the maximal HR increase in response to the b-agonist isopro-
terenol at 4 µg/kg i.p. (428 ± 26 vs. 580 ± 15 bpm, P < 0.01)
without modifying the response of contractile parameters
(FS: 55 ± 2% vs. 61 ± 2%, P = NS). These data indicate that
oral administration of ivabradine in mice reduces HR while
ventricular performance is maintained. This specific HR re-
ducing action of ivabradine is well preserved under condi-
tions that are associated with significant activation of the
sympathoadrenergic system.
Abstract N° C15
Signal-averaged P-wave after cardioversion of atrial
fibrillation: a marker of electrophysiological
remodeling
J. Bytesnik, M. Skalska, V. Vancura, J. Kautzner. Institute
for Clinical and Experimental Medicine, Prague, Czech
Republic
Prolonged P wave in the P wave signal-averaged electro-
cardiogram (PSAECG) may indicate an impaired intra- and
interatrial conduction. The aim of the study was to evaluate
the influence of the duration of an atrial fibrillation (AF)
episode on the parameters of PSAECG just after the cardio-
version (CV) to sinus rhythm and the relation of the duration
to the basic echocardiographic parameters. We evaluated 38
consecutive patients (29 months, age 62 ± 12 years) after
successful electrical CV of AF persistent more than 1 month
(Group A) and 22 patients (16M, age 63 ± 14 years) after CV
of acute AF with duration less than 48 h (Group B). We
measured the signal-averaged P wave duration (SA-P) and
the root mean square voltage of the terminal 20 ms of the
signal-averaged P wave (RMS 20), using MAC 5000, Mar-
quette. The measurements were performed 0.5–2 h after CV.
Left atrial diameter (LAD) and left ventricular ejection frac-
tion (LVEF) were evaluated by 2D-echocardiography.
Both groups were clinically comparable in the LVEF,
amiodarone treatment and presence of mitral valve disease.
Longer duration of an AF episode leads to longer duration of
the P wave in PSAECG after the CV, what can reflect more
profound remodeling of the atria caused by AF. Question
remains, whether SA-P is an independent variable or if it




T. Podzuweit a, D. Vogelezang a, S. Thomas a, N. Tribulova
b, M. Manoach c. a Max-Planck-Inst., Bad Nauheim, FRG.
b Institute for Heart Research, Bratislava, SK. c Department
of Physiology, TA University Medical School, Tel Aviv, IL,
USA
Ventricular fibrillation (VF) is a menacing and often fatal
arrhythmia that requires instant defibrillation. Presently, the
sole method of defibrillation is electric shock. We searched
for alternative means, using young domestic pigs, and fo-
cussed on drug-induced ventricular defibrillation (DVD).
Landrace pigs aged 5–10 d (n = 12) were anaesthetized with
pentobarbitone, i.v. and ventilated. Following sternotomy,
the heart was exposed in a pericardial cradle. ECG and aortic
pressure were recorded. VF was induced by bipolar electrical
stimulation of the ventricular epicardium (100 Hz, 15 V,
0.1 ms duration). Three conditions were studied, A: no treat-
ment, B: intravenous infusion of vehicle and C: infusion of a
drug mix, consisting of dibenzepine (7.5 mg/kg) and adrena-
line (2.5 µg/kg) dissolved in 2 ml isotonic saline. Vehicle or
drug were infused 15–75 s after the onset of VF and distribu-
ted by cardiac massage. In control experiments with or wi-
thout infusion of vehicle, none of the animals survived. As
VF ensued, blood pressure fell precipitously and never reco-
vered. However, demise could be consistently averted by
Group A Group B P value
LAD (mm) 44.8 ± 6.2 37.3 ± 5.1 <0.001
SA-P (ms) 173.3 ± 46.8 132.2 ± 21.3 <0.001
RMS 20 (ms) 3.2 ± 1.8 4.1 ± 3.2 NS
Noise (uV) 0.48 ± 0.21 0.46 ± 0.16 NS
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infusing a defibrillatory drug mix consisting of dibenzepine
and adrenaline. During and following drug infusion, ventri-
cular electrical activity slowed and synchronized until VF
ceased and sinus rhythm resumed. Electric shock was not
required. In the wake of DVD, the VF threshold increased
markedly. When VF was induced repeatedly in the same pig,
it was of short duration and sinus rhythm ensued sponta-
neously within 2–3 min. DVD succeeded in all pigs studied.
The present study provides the first report of consistent DVD
in young domestic pigs, indicating that VF is a potentially
reversible condition. Complementary experiments revealed
that the prototypic drug regimen, consisting of the tricyclic
antidepressant dibenzepine and adrenaline, may promote
spontaneous VD by increasing sarcoplasmic reticulum Ca2+
uptake.
Abstract N° C17
Long term follow up of patients undergoing
electrophysiological study on amiodarone
K.C. Roberts-Thomson, P.J. Psaltis, P. Kee, G.D. Young.
Department of Cardiology, Royal Adelaide Hospital,
Adelaide, SA, Australia
We conducted a retrospective study comparing outcomes
in patients who were inducible vs. non-inducible for ventri-
cular tachycardia (VT) at electrophysiological study (EPS)
whilst on amiodarone. EPS involved one to three extrastimuli
at two right ventricular sites during two paced cycle lengths.
Episodes were defined as documented VT/ventricular fi-
brillation (VF), appropriate defibrillator therapy or sudden
cardiac death. Mean follow up was 48 months. Thirty-four
patients had inducible VT at EPS and 15 patients were non-
inducible; 30/34 patients in the inducible group received an
automatic cardioverter defibrillator as did 3/15 patients in the
non-inducible group, two of whom had episodes. There was
no significant difference between the two groups in amioda-
rone dose, aetiology of cardiac disease, left ventricular func-
tion, or angiotensin converting enzyme inhibitor use. Beta
blocker use was higher in inducible VT group (P = 0.47). The
inducible VT group had significantly higher incidence of
episodes than the non-inducible group (27/34 patients vs.
3/15 patients, P < 0.001). Sudden cardiac death occurred in
one patient in the non-inducible group. There was no diffe-
rence in mortality between the two groups (8/34 inducible
patients died vs. 3/15 non-inducible patients). In patients on
amiodarone inducible VT is a good predictor of future episo-
des. Non-inducibility defines a group at lower risk of future
arrhythmic events.
Abstract N° C18
Nickel and ryanodine effects on sinus venosus
pacemaker activity of the heart in young and adult
frogs
Vladimir A. Golovko. Institute of Physiology, Komi Science
Centre, Ural Division RAS, Syktyvkar, Russia
The aim of the work was to investigate the role of current
via Na–Ca exchangers and sarcoplasmic reticulum (SR) in
the modulation of generation rate of action potentials (APs)
in the cells of sinus venosus of young (3-months old, group I)
and adult (>1.5-years old, group II) frogs, Rana temporaria.
Comparative analysis of the electrophysiological parameters
of AP cells showed that pacemaker cells of sinus venosus
differ according to frequency: 57 ± 4 beats per minute (bpm,
group I, n = 15) and 44 ± 3 bpm (group II, n = 14) at 20 °C. In
a control solution, the amplitude of APs cells in the adults
was larger by 20 mV, threshold potential was larger by 16 mV
and diastole duration (DD) was 21% longer than in young
frogs (P < 0.05). Nickel (100 µmol/l) did not change the rate
of spontaneous AP generation in the adult hearts. IC50 was
observed at 200 ± 50 µmol/l (n = 7) and a block of AP was
observed at Ni2+ equal to 400 ± 50 µmol/l (n = 6). In the
young, IC50 for Ni
2+ was registered at 500 ± 50 µmol/l
according to a 15 min exposure. After 25 min of exposure,
ryanodine (Ry, 3 µmol/l) decreased the frequency of AP
generation in the adults by 43% and the young ones showed
an 11% increase compared to the control. Negative chrono-
tropic effect in adult frogs was observed due to the increase
of DD by 46% and DD velocity reduction from 16 to 7 mV/s.
Increase of the external Ry concentration (20 µmol/l) com-
pletely blocked APs generation in the adults at the 7th min of
exposure. In young frogs, the decrease of AP rate by 5% was
registered at the 25th min. It was followed by the increase of
APs amplitude by 15 mV, APD90 showed a 19% decrease and
DD increased by 18% in the average. To conclude, in sinus
venosus of the young current via Na–Ca-exchanger channels
and Ca2+ releasing from SR are less dominating factors in the
modulation of AP generation rate than in adult frogs.
Work was supported by Russian Fund BR project 01-04-
49668.302.
Abstract N° C19
GLUT1 and GLUT4 localisation by immunogold
electron microscopy
K.A.B. Davey a, R. Southworth a, A. Warley b,
P.B. Garlick a. a Imaging Sciences, GKT School of
Medicine, London, UK. b Analytical Electron Microscopy,
GKT School of Medicine, London, UK
Western blotting provides the relative distribution of
transporters between endosomal and plasma membrane frac-
tions, while immunogold electron microscopy enables the
exact localisation of the transporters within the tissue to be
visualised. Hearts (n = 3) were perfused with Krebs buffer for
2 h. Western blots of GLUT1 and GLUT4 showed relative
distributions of 86.3 + 6.4% and 28.5 + 8.3% (mean + SEM)
in plasma membranes, respectively. Such data have pre-
viously been assumed to represent sarcolemmal GLUT
content. A second group of hearts (n = 3) was perfused for 2 h
and then fixed by perfusion with 2% formaldehyde + 0.2%
glutaraldehyde. Cryosections of 70 nm were cut and double
labelled with primary antibodies against GLUT1 and
GLUT4, followed by secondary antibodies with 10 and
15 nm gold particles attached for each transporter, respecti-
vely. Labelling was quantified using stereological techniques
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to count gold distribution relative to membrane length or
compartment size.
From the data above, we have shown that 65% of GLUT1
resides in the capillary plasma membrane, where GLUT4 is
absent; GLUT4 was mainly found in vesicles associated with
the T-tubules. These data suggest that, in heart, GLUT1 is
responsible for the transport of glucose from the bloodstream
into the interstitium; GLUT4 and the remaining GLUT1 are
responsible for the transport of this glucose into the myocyte
via the T-tubules and sarcolemma.
Abstract N° C20
Effect of clenbuterol treatment on cardiac contractility
in rats
Renee Cornford-Nairn a, Martin Sillence b, Andrew Hoey a.
a Centre for Biomedical Research, University of Southern
Queensland, Toowoomba, Queensland, Australia. b School
of Agriculture, Charles Sturt University, Wagga Wagga,
Australia
The b2-adrenoceptor agonist clenbuterol has a marked
anabolic effect in skeletal muscle caused by protein accre-
tion. However, in cardiac muscle, clenbuterol has been
shown to cause cardiac hypertrophy, but the functional chan-
ges in cardiac contractility have not been reported previously.
Male Wistar rats (commencing at 80 g body weight) were
administered clenbuterol in feed at a rate of 25 mg/kg feed
for 10 d. This dose caused an increased body growth rate,
ventricular hypertrophy and tachycardia relative to control
rats (P < 0.05). In tissue bath studies, the isolated right atria
had a higher basal rate of contraction and lowered potency to
(–)-isoprenaline (P < 0.05) indicative of b-adrenoceptor
downregulation. In the left atria, (–)-isoprenaline had a lower
potency, but a higher efficacy paralleled by an increased
efficacy to calcium (P < 0.05) relative to left atria in control
rats. In contrast, left ventricular papillary muscles from
clenbuterol treated rats showed a lowered potency and effi-
cacy to (–)-isoprenaline, accompanied by a reduced efficacy
to calcium (P < 0.05). Normalisation of the (–)-isoprenaline
responses relative to the calcium responses revealed no dif-
ference in the efficacy of (–)-isoprenaline between clenbute-
rol treated and control rats. In conclusion, clenbuterol causes
differential regulation of contractility in different cardiac
chambers with enhance atrial, but impaired ventricular
contractility.
Abstract N° C21
Effects of interleukin-2 on the mechanical restitution
and post-rest contraction in rat ventricular papillary
muscle
Guo-hua Lin a, Hai-long Ru a, Chun-mei Cao b, Qiang Xia b.
a Department of Physiology, Hangzhou Normal College
Medical School, Hangzhou, China. b Department of
Physiology, Zhejiang University School of Medicine,
Hangzhou, China
Previous studies demonstrated that interleukin-2 (IL-2)
has negatively inotropic effect on cardiomyocyte. To deter-
mine whether application of IL-2 alters function of sarco-
plasmic reticulum, we measured mechanical restitution and
post-rest potentiation in isolated rat papillary muscles, which
were paced at 0.5 Hz. Mechanical restitution curves were
constructed by interpolating extra-systoles at different test
intervals following a train of steady-state beats. Post-rest
potentiation was obtained after pause of 5, 10, 30, 60, 120
and 300 s. In control group, the maximal post-rest potentia-
tion was reached after 60–120 s of rest and the maximal
potentiation factor was 2.36 ± 0.23. IL-2 at 200 U/ml de-
creased the steady-state force of contraction to 56.4 ± 7.2%
of pre-drug control. But the time constant of recovery of
steady-state force was not altered following administration
of IL-2. Post-rest potentiation in relation to the pre-rest
control value in the presence of IL-2 was similar to that in the
absence of IL-2, but the potentiation was enhanced when
compared with the pre-drug control value. In papillary mus-
cle treated with IL-2, the maximal post-rest potentiation
occurred later and the potentiation factor after 300 s was 4.72
± 0.58 times that at the steady state. Recirculation fraction of
calcium which was calculated from the decay of post-rest
potentiation was 0.78 ± 0.09 in control and 0.59 ± 0.08 after
IL-2 treatment. We conclude that IL-2 decreases the function
of sarcoplasmic reticulum, which suggests that an impaired
function of sarcoplasmic reticulum may contribute to the
negative inotropic effect of IL-2.
Abstract N° C22
Involvement of calcium, calmodulin and PLC in the
epidermal growth factor-induced activation of
Ral-STAT3 pathway in smooth muscle cells
Richard R. Clough a, Rajinder P. Bhullar a,b. a Deparment of
Oral Biology, University of Manitoba, Winnipeg, Manitoba,
Canada. b Department of Biochemistry and Medical
Genetics, University of Manitoba, Winnipeg, Manitoba,
Canada
Epidermal growth factor (EGF) activates c-Src through
the Ras/RalGEF/Ral pathway, leading to activation of
STAT3. Since Ral activation is partly Ca2+/calmodulin-
dependent, we used rat aorta smooth muscle cells (A7r5) to
study if EGF-induced activation of Ral, c-Src and STAT3 is
Ca2+/calmodulin-dependent, and if Ca2+/calmodulin-
regulated Pyk-2 is involved in this pathway. Pull-down of
activated Ral showed that the EGF-induced activation of Ral
is Ca2+-, calmodulin- and PLC-dependent in A7r5 cells.
Location Labelling density
(mean + SEM, n = 3)
GLUT1 Capillary membrane 0.43 + 0.09 (golds µm–1)
Sarcolemma 0.19 + 0.07 (golds µm–1)
T-tubule membrane 0.04 + 0.02 (golds µm–1)
GLUT4 Capillary membrane Non-detectable
Sarcolemma 0.12 + 0.09 (golds µm–1)
T-tubule membrane 0.07 + 0.01 (golds µm–1)
Membrane-associated vesicles 3.16 + 0.42 (golds µm–2)
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Immunoblotting of cell lysates with antibodies to phospho-
rylated Pyk-2, c-Src and STAT3 showed that Pyk-2 is activa-
ted by EGF, and that EGF-induced activation of Pyk-2, c-Src
and STAT3 in A7r5 cells depends on calmodulin and PLC,
but only minimally on calcium. Therefore, Pyk-2 is involved
in novel signal transduction pathways, and calmodulin plays




The response of the neonatal cardiac myocyte to
endotoxin exposure
Diane L.M. Hickson-Bick, Chad Jones L. Maximilian Buja.
Department of Pathology and Laboratory Medicine,
University of Texas Medical-Houston, USA
Exposure of the heart to bacteriological agents, exempli-
fied by endotoxin, leads to myocyte and cardiac dysfunction
and death. The mechanisms involved in this response involve
the induction of inflammation with subsequent cardiac and
whole body responses necessary to resolve the inflammatory
response. We have observed that the neonatal cardiac myo-
cyte has an innate resistance to cell death and accompanying
cardiac dysfunction associated with lipopolysaccharide
(LPS) exposure. Exposure of neonatal rat cardiac myocytes
to low, non-toxic doses of endotoxin leads to a rapid degra-
dation of IjBa and a translocation of NFjB to the nucleus
where it can activate cardioprotective genes like iNO syn-
thase. Production of TNFa by the myocytes is also increased
in response to endotoxin. Activity of cyclooxygenase-2
(COX-2) increases rapidly and falls to baseline within 2 h.
Lipoxygenase (5-LOX) rapidly falls in the neonatal myocyte
in response to endotoxin. Thus, there appears to be a limited,
rapidly resolved, inflammatory response to endotoxin by the
neonatal cardiac myocyte. The role of cytochrome P450 in
detoxifying pro-inflammatory prostaglandins is well known
and has been implicated in protective mechanisms following
endotoxin exposure of other tissues. Cytochrome P450s of
the CYP4 gene subfamily are functionally conserved and
selective for omega hydroxylation of arachidonic acid, syn-
thesizing the biologically actives HETEs and EETs. We have
observed that expression of CYP4F isoform increases in the
neonatal rat cardiac myocyte in response to endotoxin (50-
fold within 1.5 h) showing a temporal pattern inverse to that
observed for COX-2 and 5-LOX suggesting that CYP4F is
inactivating inflammatory leukotrienes and prostaglandins.
Supported by the US Army (TATRC) DREAMS project.
Abstract N° C24
Modulation of human endothelial cell function by
HIV-1 protease inhibitors
Krishna C. Agrawal. Department of Pharmacology, Tulane
University Health Sciences Center, New Orleans, LA
70112, USA
HIV-1 protease inhibitors (PIs) as part of the highly active
antiretroviral therapy (HAART) have been shown to induce
insulin resistance and cardiovascular diseases (CVD) in HIV-
1-infected patients. However, the molecular mechanisms in-
volved in PI-induced endothelial dysfunction have not been
delineated. We have hypothesized that PI-induced inhibition
of insulin signaling can decrease eNOS gene expression and
production of NO coupled with an increase in ROS produc-
tion within the vasculature, which might play a significant
role in chronic endothelial injury. Furthermore, we have
hypothesized that the presence of inflammatory cytokine,
TNFa, associated with HIV-1 infection, exacerbates the PI-
induced effects. A combination of indinavir, zidovudine and
efavirenz at therapeutic concentrations induced a significant
decrease in eNOS gene expression in human aortic endothe-
lial cells (HAECs) within 24 h. This inhibition was synergi-
zed in the presence of TNFa (0.2 U/ml) and was reversed
upon stimulation with insulin (100 mU/ml). The intracellular
NO levels were decreased by approximately 80% in the
presence of TNFa (1 U/ml). Indinavir alone or in HAART
combination induced leukocyte recruitment (1.5–2.5-fold)
and increased cell surface expression (2–5 fold) of cell adhe-
sion molecules (CAMs). CAM-specific antibodies inhibited
TNFa-induced endothelial-leukocyte adhesion. These data
suggest that the pathogenic consequences of endothelial cell
activation and leukocyte infiltration due to inhibition of NO
production can result in a local inflammatory response lea-
ding to chronic endothelial injury and CVD in HIV-1-
infected patients.
Abstract N° C25
Effect of roxithromycin in patients following coronary
angioplasty and stenting: a case control study
Anil Grover, Idris Ahmed Khan, Rajesh Vijayvergiya,
Ajay Bahl. Department of Cardiology, PGIMER,
Chandigarh 160 012, India
Chronic inflammation is the underlying pathologic pro-
cess in atherosclerotic coronary artery disease (CAD). Va-
rious infectious agents are found to be associated with chro-
nic inflammation—Chlamydia pneumoniae is one among
them. We studied the 6 months clinical and angiographic
follow-up of CAD patients, who underwent coronary angio-
plasty ± stenting and treated with roxithromycin—an anti-
Chlamydia antibiotic. Thirty patients each of acute coronary
syndrome, who had at least two coronary lesions on coronary
angiography—one is ≥70%, dilated with angioplasty ± sten-
ting and other <70%, no intervention done—were included
in both case and control groups. All patients in case group
were given roxithromycin 150 mg twice a day for 6 weeks, in
addition to conventional treatment, while in control group no
antibiotic was given. At 6 months of follow-up, all patients
were assessed for acute coronary syndrome, stent restenosis
and progression of insignificant coronary lesions. Twenty-
seven cases and 30 controls underwent follow-up coronary
angiography at 6 months. Three patients in case group were
excluded from the study—two had side effect of roxithromy-
cin and one died on day 3 of myocardial infraction (MI)
because of ventricular septal disease (VSD).
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Six weeks of roxithromycin therapy has favorable but
insignificant effects on ACS at 6 months of follow-up in
patients, who underwent angioplasty ± stenting with no si-
gnificant effect on stent restenosis or lesion progression. The
favorable effect may be a result of plaque stabilization.
Abstract N° C26
Study of invasiveness of Group A Streptococcus in
epithelial and endothelial cells: proposal for a novel in
vitro model
Archana Bhatnagar a, Eva Medina b, Manfred Rhode b,
Shamim Ahmad a, Anil Grover a, G.S. Chhatwal b.
a Department of Cardiology, Division of Experimental
Medicine and Biotechnology, PGIMER, Chandigarh 160
012, India. b Department of Microbial Pathogenesis, GBF,
Germany
Attachment of Group A Streptococci (GAS) to the host
cell is the most important step in colonization of understan-
ding of pathogenic mechanisms in the disease. Our study was
carried out with some rheumatogenic strains of GAS and
their interaction with epithelial cell line, HEp-2, and the
endothelial cell line, Endo. The adhesion assay was perfor-
med by incubation of bacteria on monolayer of the cells,
which were then lysed and plated to look for colonies formed
by adhering bacteria. The invasion assay was performed
similarly except for the treatment with antibiotics to remove
adhering live bacteria. The GAS are capable of invading
endothelial cells several times more than the epithelial cells.
These observations are being given a new direction by crea-
ting a new experimental model of rheumatic heart disease in
vitro. Porcine aortic/pulmonary valves are being acellulari-
zed by using Triton-X. Endothelial cells as well as myofibro-
blast cells will then be isolated in parallel from human saphe-
nous veins and expanded in vitro. Specimens of the surface
of the acellular matrix will be seeded with myofibroblast
cells and endothelial cells. The tissue engineered valve will
then be cultured with GAS, sensitized serum and lymphocy-
tes of acute rheumatic fever/rheumatic heart disease patients
to see the pathological lesions.
Abstract N° C27
Seroprevalence of anti-Chlamydia pnemoniae and
anti-Helicobacter pylori IgG antibodies in coronary
artery disease patients
Rajesh Vijayvergiya a, Anil Grover a, Ajay Bahl a,
Archana Bhatnagar a, Meera Sharma b, Malkiat Singh b,
Madhu Khullar c. a Department of Cardiology, Post
Graduate Institute of Medical Education and Research,
Chandigarh 160 012, India. b Department of Medical
Microbiology, Post Graduate Institute of Medical Education
and Research, Chandigarh 160 012, India. c Department of
Experimental Medicine, Post Graduate Institute of Medical
Education and Research, Chandigarh 160 012, India
Recent studies have shown the association of Chlamydia
pnemoniae (CP) and Helicobacter pylori (HP) infection with
coronary artery disease (CAD). We correlated the seropreva-
lence of IgG antibody titers for CP and HP in angiographi-
cally proven CAD cases and compared it with controls. IgG
antibody titers were determined by ELISA method for HP in
90 cases and 30 controls, and also for CP in 75 cases and 15
controls. Both the groups were matched for demographic
variables and conventional CAD risk factors. HP group: the
IgG titer for HP was positive in 42.2% cases and 23.3%
controls. The difference was found to be marginally signifi-
cant (P = 0.06) with likelihood ratio of 3.60. Multifactorial
logistic regression analysis after considering conventional
CAD risk factors showed statistically significant (P < 0.04)
association with correlation coefficient of 1.11 and odds ratio
of 3.05. CP group: the IgG titer for CP was positive in 52.0%
cases and 20.0% controls. The difference was statistically
significant (P = 0.02) with likelihood ratio of 5.5. Multifac-
torial logistic regression analysis after considering conven-
tional CAD risk factors showed statistically significant (P =
0.03) association with correlation coefficient of 1.52 and
odds ratio of 4.58. The seropositivity in both groups was not
related with the type of clinical presentation like unstable
angina, chronic stable angina and acute myocardial infarc-
tion. Logistic regression analysis between two groups
showed independent association of anti-CP and anti-HP anti-
bodies with CAD (correlation coefficient 0.03, P = 0.78).
Serologically, infection with HP and CP is significantly and
individually associated with CAD.
Abstract N° C28
Identification of genes associated with persistent atrial
fibrillation using oligonucleotide microarrays
Joachim B. Grammer, Johannes Böhm, Rüdiger Lange,
Robert Bauernschmitt. German Heart Center, Munich,
Germany
High-density microarrays capable of evaluating thou-
sands of mRNAs are ideal for transcriptome analysis and
identification of genes implicated in disease. Our aim was to
compare the gene expression pattern in right atria of patients
suffering from persistent atrial fibrillation (AF) (>6 months,
n = 17) to that of patients in sinus rhythm (SR, n = 20). Right
atrial appendages were obtained during cardiac surgery and
total RNA was isolated and subsequently converted into
cDNA. Then, Cy3- and Cy5-labeled cRNA was generated
from both patient groups and hybridized to Pan 10K microar-
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ning 9850 gene-specific oligonucleotides. We have identified
differential expression of certain key genes previously found
to be linked with persistent AF as well as new, potentially
important genes involved in AF pathophysiology. The most
intriguing changes among the upregulated genes in AF atria
were observed as with genes associated with extracellular
matrix remodeling (collagen genes COL3A1 and COL1A2,
MMP-9, osteopontin), cell survival (BH3 interacting domain
death agonist; serine/threonine kinase 17a apoptosis indu-
cing; secreted frizzled-related protein 4), the contractile ap-
paratus (myosin genes MYH7 and MYL3) and the CXC-
chemokine receptor 4. Among the downregulated genes were
several interferon-stimulated proteins (ISG15, IFIT1, IFIT4,
MX1), protein kinase isoforms (myosin light chain kinase
isoform 6; protein kinase c epsilon) and MMP-25. To inde-
pendently validate expression ratios obtained by microar-
rays, a subset of genes was selected to measure relative
expression levels by semiquantitative RT-PCR, which confir-
med the array results. This is the first study to define at the
global level the transcriptome profile of atrial tissue in pa-
tients with persistent AF and provides new insights into the
pathophysiology of this most common arrhythmia.
Abstract N° C29
Function of ADP-ribosylation factor 1 gene in cardiac
hypertrophy
Lan-Ying Chen, Li Xu, Jun-Ming Liu, Jian Zhang.
Cardiovascular Institution and Fu Wai Hospital, Chinese
Academy of Medical Sciences and Peking Union Medical
College, Beijing, 100037, PR China
ADP-ribosylation factor 1 (ARF1) is a member of small
G-protein family that plays a role in vesicular trafficking. In
the present study, we showed that the expression of the ARF1
was increased in the hypertrophied hearts caused abdominal
aortic banding, an in vivo model for cardiac hypertrophy. To
understand the biological significances of such increase, the
ARF1 gene was over-expressed in cardiomyocytes by an
adenoviral vector. We demonstrated that the over-expression
of ARF1 gene promoted the cardiac myocytes growth by
increases of total protein contents and cardiomyocytes areas,
increased expressions of PKC-e, PKC-b1 and PKC-a, and
activated the proliferation of cardiac fibroblasts without
stretch. Such effects were further augmented when stretch
was applied. On the other hand, the opposite effects were
observed when the ARF1 expression was decreased by anti-
sense against ARF1, or when ARF1 activity was prohibited
by brefeldin A treatment. The expressions of PKC-b2,
PKC-d, ERK1/2, JNK1/2, p38, p53, Bax, Bcl2 or Fas were
not affected by over-expression or down-regulation of ARF1.
Thus, our data suggested that ARF1 promoted cardiomyocy-
tes growth via the branches of PKC signaling pathway, likely,
PKC-e, PKC-b1 and PKC-a, during cardiac hypertrophy.
Abstract N° C30
Arrhythmogenic effects of arsenic trioxide in patients
with acute promyelocytic leukemia and
electro-physiological study in isolated guinea pig
papillary muscles
K. Yamazaki, H. Terada, H. Satoh, A. Uehara, H. Katoh,
H. Hayashi. Department of Medicine III, Division of
Cardiology, Hamamatsu University School of Medicine,
Hamamatsu, Japan
Arsenic trioxide (As2O3) is a new promising regimen for
relapsed acute promyelocytic leukemia (APL). Poisoning of
As2O3 has been shown to cause arrhythmia, such as torsade
de pointes (TdP). This study was carried out in order to
evaluate an incidence of arrhythmias during As2O3 therapy,
and clarify the mechanism of arrhythmogenesis. ECGs were
monitored throughout As2O3 therapy in 20 patients. As2O3
(0.15 mg/kg) increased the QTc interval (445 ± 7 to 517 ±
17 ms, P < 0.01), the QTc dispersion (43 ± 4 to 73 ± 9 ms, P
< 0.01) and the transmural dispersion of repolarization (110
± 5 to 122 ± 6 ms, P < 0.05). Non-sustained ventricular
tachycardias and a TdP were observed in five and one pa-
tients, respectively. Action potential and isometric contrac-
tion were measured from guinea pig right ventricular pa-
pillary muscles. As2O3 (350 µM) prolonged action potential
duration (APD90: 150 ± 11 to 195 ± 12 ms, P < 0.01, n = 5)
and increased developed tension (28 ± 8 to 43 ± 14 mg, n =
5). APD prolongation showed the dose- and reverse-use
dependency. In addition, prolonged exposure to As2O3 cau-
sed rigor contracture, after contraction, triggered activity and
electro-mechanical alternans. Lowering extracellular K+
concentration (3.0 mM) and lowering rate of stimulation rate
(0.1 Hz) caused marked prolongation of APD, leading to
early after depolarization and triggered activity. Tetrodotoxin
(3 µM) and butylated hydroxytoluene (50 µM), an inhibitor
of lipid peroxidation, prevented APD prolongation partially.
The prolongation of APD and Ca2+ overload by As2O3 can
explain the prolongation of QT interval and arrhythmogene-
sis. The effects of APD prolongation by As2O3 might be, at
least, due to block Ikr and increase INa for its reverse-use
dependent effect and inhibition by tetrodotoxin, respectively.
The lipid peroxidation could be responsible for these effects.
Abstract No C32
Modulation of doxorubicin-induced cardiac
dysfunction in toll-like receptor-2 knockout mice
Tetsuro Shishido, Naoki Nozaki, Hiroki Takahashi,
Yasuchika Takeishi, Isao Kubota. Yamagata University,
Yamagata, Japan
Toll-like receptor-2 is involved in inflammatory response
and expressed in the heart. Recent studies have demonstrated
that TLRs are activated by endogenous signals such as oxi-
dative stress, which contributes to doxorubicin (Dox)-
induced cardiac dysfunction. Thus, we hypothesized that
TLR-2 had potential role for pathogenesis in Dox-induced
cardiac dysfunction. Myocardial lipid peroxidation was si-
gnificantly increased after Dox (Dox 20 mg/kg, intraperito-
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neally injection), but no significant difference was found
between WT and KO mice. After Dox-injection, NF-kappaB
activation was decreased by 80 % in KO mice compared with
WT mice. production of pro-inflammatory cytokines was
attenuated in KO mice. Numbers of TUNEL positive nuclei
and Dox-induced caspase-3 activation were decreased by
36.1 % and 26.7 %, respectively (p < 0.01), in KO mice
comprared with WT mce. Cardiac function evaluated by
echocardiography was preserved in KO mice compared with
WT mice. Consequently, survival rate was significantly hi-
gher in KO mice than in WT mice 10 days after Dox treat-
ment (11 % vs. 46 %, p < 0.05). These findings suggest that
toll-like receptor-2 may play an important role in the regula-
tion of inflammatory and apoptotic mediators in the heart
following doxorubicin.
WT-Con WT-Dox KO-Dox
Interleukin-6 (pg/mg protein) 1.0 ± 1.0 11.2 ± 3.3 ** 2.0 ± 0.4 ##
TNF-alpha (pg/mg protein) 0.2 ± 0.2 3.0 ± 0.4 ** 1.4 ± 0.8 * ##
Fractional shortening (%) 40.0 ± 0.4 27.7 ± 1.0 ** 34.1 ± 1.6 ** ##
Data were expressed mean ± SEM. * P < 0.05, ** P < 0.01 vs WT-Con.
# P < 0.05, ## P < 0.01 vs WT-Dox.
Abstract N° C33
Doxorubicin-induced cardiac dysfunction: the nitric
oxide-peroxynitrite-poly(ADP-ribose) polymerase
connection
Pal Pacher a, Peter Bai b, Lucas Liaudet b, Jon G. Mabley b,
Csaba Szabo b. a NIH, NIAAA, Bethesda, MD, USA.
b Inotek Pharmaceuticals, Beverly, MA, USA
Dysregulation of nitric oxide and increased oxidative
stress have been implicated in the cardiotoxicity of doxoru-
bicin (DOX), a commonly used antitumor agent. Peroxyni-
trite is a reactive oxidant produced from nitric oxide and
superoxide in various forms of cardiac injury. Oxidant-
induced cell injury triggers the activation of nuclear enzyme
poly(ADP-ribose) polymerase (PARP), which in turn contri-
butes to cardiac and vascular dysfunction in various patho-
physiological conditions including diabetes, reperfusion in-
jury, heart failure and circulatory shock. Recently we have
demonstrated increased oxidative and nitrosative stress, me-
talloproteinase and PARP activation in the heart following
DOX administration. Here we show the effect of a novel
peroxynitrite decomposition catalyst and ultrapotent PARP
inhibitor, on DOX-induced cardiac dysfunction. Mice recei-
ved a single injection of DOX (25 mg/kg i.p.) or three equal
doses of 9 mg/kg every 10 d. Left ventricular function was
measured 5 or 25 d after DOX administration using Millar’s
new Aria pressure–volume conductance system. Both acute
and chronic administration of DOX-induced high mortality
and a significant decrease in mean BP, left ventricular systo-
lic pressure, +dP/dt, –dP/dt, stroke volume, stroke work,
ejection fraction and cardiac output. Treatment with a novel
peroxynitrite decomposition catalyst or ultrapotent PARP
inhibitor reduced DOX-induced mortality and markedly im-
proved cardiac function. Peroxynitrite neutralization or
PARP inhibition did not interfere with DOX’s antitumor
effect. Thus, peroxynitrite and PARP activation plays a key
role in the pathogenesis of DOX-induced cardiac failure.
Targeting peroxynitrite formation or PARP may represent a
new cardioprotective strategy after DOX exposure, or in
other conditions which are associated with peroxynitrite for-
mation and PARP activation, including myocardial
ischemic/reperfusion injury.
Abstract N° C34
A novel ultrapotent poly(ADP-ribose) polymerase
inhibitor improves cardiac and endothelial dysfunction
associated with aging-induced heart failure
Pal Pacher a, Rita Benko b, AnneVaslin b, Jon G. Mabley b,
Lucas Liaudet b, George Hasko b, Mark Kollai b,
Csaba Szabo b, Anita Marton b. a NIH, NIAAA, Bethesda,
MD, USA. b Inotek Pharmaceuticals, Beverly, MA, USA
Increased production of reactive oxygen and nitrogen spe-
cies has recently been implicated in the pathogenesis of
cardiac and endothelial dysfunction associated with atheros-
clerosis, hypertension and aging. Oxidant-induced cell injury
triggers the activation of nuclear enzyme poly(ADP-ribose)
polymerase (PARP), which in turn contributes to cardiac and
vascular dysfunction in various pathophysiological condi-
tions including diabetes, reperfusion injury, circulatory
shock and aging. Here we investigated the effect of a novel
ultrapotent PARP inhibitor, INO1001, on cardiac and endo-
thelial dysfunction associated with aging using Millar’s new
Aria pressure–volume conductance system and isolated aor-
tic rings. Young (3-months old) and aging (24-months old)
Fischer rats were treated for 2 months with vehicle or the
ultrapotent PARP inhibitor INO1001. In the vehicle-treated
aging animals there was a marked reduction of both systolic
and diastolic cardiac function and loss of endothelial relaxant
responsiveness of aortic rings to acetylcholine. Treatment
with INO1001 remarkably improved cardiac performance in
aging animals and also Ach-induced, NO-mediated vascular
relaxation. In addition to the beneficial effects of chronic
treatment with PARP inhibitor, 1-h in vitro incubation of
aortic rings from aging rats with INO1001 was also able to
improve the endothelial dysfunction. Thus, pharmacological
inhibition of PARP may represent a novel approach to im-
prove cardiac and endothelial dysfunction associated with
aging.
Abstract No C35
A novel ultrapotent poly(ADP-ribose) polymerase
inhibitor improves cardiac and endothelial dysfunction
associated with aging-induced heart failure
Pal Pacher, NIH, NIAAA, Bethesda, MD, USA ;
Rita Benko, AnneVaslin, Jon G Mabley, Lucas Liaudet,
George Hasko, Mark Kollai, Csaba Szabo, Anita Marton,
Inotek Pharmaceuticals, Beverly, MA, USA
Increased production of reactive oxygen and nitrogen spe-
cies has recently been implicated in the pathogenesis of
cardiac and endothelial dysfunction associated with atheros-
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clerosis, hypertension and aging. Oxidant induced cell injury
triggers the activation of nuclear enzyme poly(ADP-ribose)
polymerase (PARP), which in turn contributes to cardiac and
vascular dysfunction in various pathophysiological condi-
tions including diabetes, reperfusion injury, circulatory
shock and aging.
Here we investigated the effect of a novel ultrapotent
PARP inhibitor, INO1001, on cardiac and endothelial dys-
function associated with aging using Millar’s new Aria
pressure-volume conductance system and isolated aortic
rings. Young (3 months old) and aging (24 months old) Fis-
cher rats were treated for 2 months with vehicle or the ultra-
potent PARP inhibitor INO1001. In the vehicle-treated aging
animals there was a marked reduction of both systolic and
diastolic cardiac function and loss of endothelial relaxant
responsiveness of aortic rings to acetylcholine.
Treatment with INO1001 remarkably improved cardiac
performance in aging animals and also Ach-induced, NO-
mediated vascular relaxation. In addition to the beneficial
effects of chronic treatment with PARP inhibitor, 1-h in vitro
incubation of aortic rings from aging rats with INO1001 was
also able to improve the endothelial dysfunction.
Thus, pharmacological inhibition of PARP may represent
a novel approach to improve cardiac and endothelial dys-
function associated with aging.
Abstract N° C36
Prognostic value and pathologic correlation of
echocardiographic indices in mice with
cardiomyopathy
D.U. Xiao-Jun, Xiao-Ming Gao, Helen Kiriazis,
Xin Heng Feng, Anthony M. Dart. Baker Heart Research
Institute, Melbourne, Australia
Echocardiography is commonly used in studies on mice
but its prognostic value and correlation with morphometric
measures are yet to be assessed. We studied male non-
transgenic (NTG, n = 26) and transgenic (TG n = 72) mice
with cardiomyopathy due to cardiac overexpression of b2-
adrenergic receptors (b2AR) by performing echocardiogra-
phy at 12 months of age and then monitor them for survival
for a further 3-month period, a time period when heart failure
(HF) and premature death occur in this model. We determi-
ned left ventricular (LV) dimension (r), fractional shortening
(FS), wall thickness (h), LV mass and Doppler-derived aortic
flow (AF) velocity and cardiac output. Autopsy was perfor-
med to determine organ weights and pathological events. HF
was considered by chronic atrial thrombi, chest fluid accu-
mulation and increased wet weights of lungs, atria and the
right ventricle (RV). Weights of lungs, RV and atria were
correlated well with each other (r = 0.79~0.83). TG mice had
reduced FS (0.22 vs. 0.36, P < 0.01) and LV dilatation
(diastole: 5.0 vs. 4.2 mm, systole: 4.0 vs. 2.7 mm, both P <
0.01). During the 12–15-month period, none of NTG but
71% of TG animals died of either HF or non-HF reason
(arrhythmia). To explore the use of echo indices in predicting
survival and HF death, TG mice were re-grouped based on
various echo indices. Using the ratio of (FS × (h/r)), we
identified a subgroup of mice with the lowest ratio (1.5 ± 0.4
vs. 6.2 ± 1.7 in NTG, mean ± S.D.) and the highest total
mortality and HF death. M-mode-derived parameters (FS, r)
were correlated well with weights of RV, atria and lungs (r =
0.48~0.66) whereas correlations between the organ weights
and Doppler AF parameters were poor. The correlation
between M-mode and AF-derived indices was in general
poor. In conclusion, M-mode echo parameters are able to
identify cardiomyopathy mice with severe HF and poor pro-
gnosis but Doppler flow measurements have limited value.
Abstract N° C37
Effects of ACEI and ARB on changes in
dystrophin-related glycoproteins in the failing heart
Kouichi Tanonaka a, Masaya Takahashi a,
Hiroyuki Yoshida a, Miki Koshimizu a, Teruhiko Toyo-oka b,
Satoshi Takeo a. a Department of Pharmacology, Tokyo
University Pharm. Life Sci., Tokyo, Japan. b Department of
Organ Pathophysiology, Int. Med., Tokyo University Hosp.,
Tokyo, Japan
Dystrophin-related glycoproteins (DRG) are considered
to play an important role in the regulation of myocardial
contractility. Recently, we have shown that a-sarcoglycan
(SG) and dystrophin (DSP) of the viable left ventricle (LV) in
the failing rat heart decreased after myocardial infarction
(MI). In the present study, effects of an angiotensin
I-converting enzyme inhibitor (ACEI) trandolapril (Tra) and
an angiotensin II type 1 receptor blocker (ARB) candesartan
(Can) on the changes in DRG were examined. MI was indu-
ced by permanent occlusion of the left coronary artery. Tra
(3 mg/kg/d) or Can (1 mg/kg/d) was administered from the
2nd to 8th week after MI. Long-term treatment with Tra or
Can improved hemodynamic parameters of the MI rat at the
8th week, associated with preservation of a-SG and DSP.
Other SGs in the viable LV did not alter throughout the
experiment, regardless of treatment with or without these
agents. MI also induced a sustained increase in both m- and
m-calpains. Tra and Can attenuated increases in these pro-
teases of the viable LV after MI. In contrast, Tra and Can did
not affect mRNA expression of DRG. m-calpain activity of
cytosolic fraction of the viable LV increased. Tra and Can
attenuated MI-induced increase in the protease activity.
These results suggest that ACEI and ARB preserve myocar-
dial DRG after MI via an attenuation of the increase in
protease activity in the failing heart, leading to an improve-
ment of cardiac contractile function after MI.
Abstract N° C38
Pitavastatin inhibits cardiac hypertrophy in rat model
of progressive renal injury
Hiroki Takahashi, Yasuchika Takeishi, Isao Kubota.
Yamagata University, Yamagata, Japan
Cardiac hypertrophy, observed in many patients with
chronic renal failure, is a major risk factor for cardiovascular
death. The aim of the present study was to examine the
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effects of pitavastatin (PITAVA) on cardiac hypertrophy in a
progressive renal injury rat model by subtotal nephrectomy
(SNx). Since we previously reported that angiotensin II (AII)
played a pivotal role in cardiac hypertrophy of SNx rats, we
first investigated the effects of PITAVA on AII-induced acti-
vation of extracellular-signal regulated kinase (ERK) and
serum response element (SRE) DNA-binding activity using
neonatal rat cardiomyocytes. The phosphorylation activity of
ERK was measured by western blotting. DNA-binding acti-
vity of SRE, found in the promoter of several immediate-
early response gene, was measured by dual-luciferase assay.
The ERK activation by AII (10 µM) was attenuated by the
pre-treatment with PITAVA (10 µM) for 1 h (2.19 ± 0.33-fold
vs. 1.31 ± 0.30-fold, P < 0.05). AII-induced increase of SRE
DNA-binding activity was also inhibited by PITAVA (2.60 ±
0.62-fold vs. 1.34 ± 0.13-fold, P < 0.05). We next examined
the effect of PITAVA on hypertrophied heart of SNx rats.
Treatment with PITAVA (3 mg/kg/d) prevented ERK activa-
tion and cardiac hypertrophy in SNx rats without changes in
blood pressure. These data suggest that PITAVA has a bene-
ficial effect on cardiac hypertrophy in renal failure through
preventing the activation of ERK.
Abstract N° C39
Time course and regional distribution of myocyte
hypertrophy after myocardial infarction in rabbits
Celina Morales, Susana G. Pérez, Silvina Monroy Germán
E. González, Manuel Rodrı́guez, Ricardo J. Gelpi.
Department of Pathology, Cardiovascular Pathophysiology
Institute, University of Buenos Aires, Argentina
Compensatory hypertrophy of myocytes (CHM) involves
post-infarct ventricular remodelling. However, it has not
been described the temporal and regional distribution of this
hypertrophy. For this reason, we evaluate temporal and regio-
nal distribution of the CHM in remote myocardium of the
infarcted hearts. The left coronary artery of 40 rabbits was
ligated and rabbits were sacrificed at 2, 4, 6, 8, 12, 14, 18, 26,
35 and 56 d post-ligature (n = 4 each group). Two rabbits
were used as control and four were sham operated. Transver-
sal diameter and cross-sectional area of myocyte were
measured using an image analyser software. We evaluated 70
myocytes from each group. Septum remote zones and right
ventricle (RV) were evaluated in two slices: One slice inclu-
ded the infarct area and in the other slice the infarct area was
absent. The average infarct size was 25.1 ± 3.8%. The diame-
ter (µ) and the cross sectional area (µ) of the myocytes in the
remotes zones of the septum increased in both slices, but they
were significantly higher in the slice with infarct and peaked
in the 26th day (21.9 ± 0.54 and 289 ± 8 in the slice with
infarct vs. 16.8 ± 0.48 and 195 ± 5 in the slice without infarct,
P < 0.05). After that these measurements started to decrease
slowly. Diameter and the cross-sectional area in both slices of
the RV were significantly lower than in the septum slice (14.8
± 0.2 and 173 ± 4 in the RV of the slice with infarct, and 12.9
± 0.3 and 119 ± 6 in the RV of the slice without infarct, P <
0.05 vs. septum slice wit infarct). Our data suggests that
development of compensatory hypertrophy in myocardial
infarction includes the participation of at least two compo-
nents: (1) the time course of the infarct and (2) the regional-
loading conditions.
Abstract N° C40
Effects of acute and chronic oral administration of
amiodarone on arrhythmias induced by
ischemia/reperfusion in canine model
Yoshinobu Nagasawa, Keitaro Hashimoto, Jianguang Chen.
Department of Pharmacology, University of Yamanashi,
Yamanashi, Japan
We previously reported that intravenous infusion of amio-
darone (6.67 mg/kg/h) did not suppress the ventricular fi-
brillation (VF) induced by coronary ligation/reperfusion
(ischemia/reperfusion, IR) in in vivo dogs. In this study, we
examined effects of acute and chronic oral administration of
amiodarone on arrhythmias induced by IR in in vivo dogs.
Thirty-one female beagle dogs (8.0–12.5 kg/mg) were divided
into four groups: amiodarone (40 mg/kg, p.o., 2 h before the
operation)-treated, placebo (p.o., 2 h before the operation)-
treated, amiodarone (40 mg/kg, once daily for 4 weeks, p.o.)-
treated, and placebo (once daily for 4 weeks, p.o.)-treated
groups. Dogs were anesthetized with pentobarbital sodium
and artificially ventilated. The chest was opened, and the left
anterior descending coronary artery was ligated for 30 min,
and then reperfused. The occurrence of arrhythmias was exa-
mined during the ischemic and reperfusion period. As shown
in Fig. 1, both acute and chronic oral administration of amio-
darone suppressed the extrasystoles induced by coronary liga-
tion (P < 0.05) and VF induced by IR (P < 0.05). In conclu-
sion, acute and chronic oral administration of amiodarone are








Sham 16.5 ± 0.44 1.69 ± 0.05 1.64 ± 0.04 1.00 ± 0.14
SNx 23.3 ± 1.26* 2.11 ± 0.06 * 2.07 ± 0.04 * 2.27 ± 0.32 *
SNx +
PITAVA
18.4 ± 0.93 ** 1.90 ± 0.05 ** 1.69 ± 0.06 ** 1.21 ± 0.35 **
LVW/TL: left ventricular weight to tibial length ratio; IVSd: diastolic
interventricular septal thickness; PWd: diastolic posterior wall thickness.
ERK activity is shown as fold increase over sham. Data are reported from
seven animals for each.
* P < 0.01 vs. sham.
** P < 0.05 vs. SNx.
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Abstract N° C41
Dietary supplementation of vitamin E and a-lipoic acid
upregulates cell growth and signaling genes in rat
myocardium
Sue Marsh a, Steven Mason b, Leigh Ward b,
Jeff Coombes a. a School of Human Movement Studies, The
University of Queensland, Australia. b School of Molecular
and Microbial Sciences, The University of Queensland,
Australia
The efficacy of antioxidant supplementation in the preven-
tion of cardiovascular disease appears equivocal, however
the use of a more potent antioxidant combination than those
traditionally used may exert a more positive effect. We have
shown previously that supplementation of vitamin E and
a-lipoic acid increases cardiac performance during post-
ischemia reperfusion in older rats and increases Bcl-2 levels
in endothelial cells. The purpose of this study was to examine
the effect of vitamin E and a-lipoic acid supplementation on
expression of genes associated with cell signaling and
growth in the myocardium.Young male rats received either a
control (n = 7) or vitamin E and a-lipoic acid supplemented
diet (n = 8) for 14 weeks. RNA from myocardial tissue was
then amplified and samples were pooled within groups and
competitively hybridized to 8.5 K oligonucleotide rat mi-
croarrays. The relative expression and variance of each gene
was then compared to the control sample. Animals that recei-
ved the antioxidant-supplemented diet exhibited upregula-
tion (>1.5×) of 13 genes in the myocardium with two genes
downregulated. Upregulated genes include those involved in
cell growth and maintenance (LynB, Csf1r, Akt2, Tp53),
transcription regulation (Dbp), cell signaling (LynB, Csf1r)
and signal transduction (Pacsin2, Csf1r). Downregulated ge-
nes encode thyroid (Thrsp) and F-actin binding proteins
(Nexilin). Therefore, supplementation of rats with vitamin E
and a-lipoic acid has an effect on myocardial genes; further
experiments will determine the implications of these fin-
dings.
Abstract N° C42
Chronic effects of probucol on development of right
ventricular failure
F. Farahmand, P.K. Singal. Institute of Cardiovascular
Sciences, University of Manitoba, Canada
Background. – The treatment of right heart failure (RHF)
is challenging due to the limited treatment options available.
In fact for these patients there is no cure available in modern
medicine. Since heart failure evolves through time, one of the
solutions lies in targeting molecular mechanism involved in
this process. Oxidative stress is known to play a role in the
pathogenesis of heart failure. We have already shown a cause
and effect relationship between RHF and oxidative stress. In
this study, we examined the chronic effects of probucol, an
antioxidant and lipid lowering drug on oxidative stress and
development of RHF.
Methods. – Pulmonary hypertension (PH) and secondary
RHF was created in rats by monocrotaline (MCT; 60 mg/kg
i.p.). This is similar to clinical condition in patients with RHF
secondary to PH. Probucol (cumulative dose, 120 mg/kg
body weight) was given (i.p.) in 12 equal injections after
MCT over 2 weeks. At 6 weeks post-treatment, animals in all
groups were assessed by echocardiography, including
measurements of pulmonary artery (PA) flow velocity; right
ventricular (RV) outflow tract dimensions/aortic dimensions
ratios and hemodynamics (RV systolic pressure, RVSP).
Myocardial antioxidant enzymes and lipid peroxidation were
also analyzed.
Results. – Based on the Doppler echocardiography at
6 weeks the ratio of RV outflow tract dimensions to aortic
dimensions, RVSP and PA velocity (PV) increased in the
MCT group compared with the controls. These echocardio-
graphic and hemodynamic findings were correlated with
interventricular septum (IVS) wall thickness and leftward
displacement of IVS without change in left ventricle (LV)
free wall. MCT treatment decreased glutathione peroxidase
activity and increased lipid peroxidation. Probucol treatment
prevented: sever bulging of IVS into LV; increase in the ratio
of the (RV) outflow tract dimensions to aortic dimensions;
increase in RVSP and increase in PV. Probucol improved
glutathione peroxidase activity and reduced lipid peroxida-
tion.
Conclusion. – Considering the cause and effect rela-
tionship between oxidative stress and development of RHF
and that probucol effectively prevent PH and RHF in an
experimental model of RHF, it is suggested that probucol
may prove effective for the treatment of RHF in patients.
(Supported by CIHR.)
Abstract No C43
Cardiovascular structural and functional adaptations
to group IIA sPLA2 inhibition
Scott Levick Stephen Taylor, David Fairliea and Lindsay
Brown, School of Biomedical Sciences, and aInstitute of
Molecular Biosciences, The University of Queensland,
QLD. Australia
Group IIA phospholipase A2 (sPLA2) enzymes are invol-
ved in inflammation by initiating the release of arachidonic
acid from the cell membrane. sPLA2 enzymes and other
components of the arachidonic acid cascade have been linked
to both replacement and reactive fibrosis, without direct
evidence of their involvement. This study has treated male
spontaneously hypertensive rats (SHR) and normotensive
age-matched Wistar-Kyoto rats (WKY) from 4-12 weeks of
age with KHO64 (5 mg/kg/day po), a selective group IIA
sPLA2 inhibitor to determine whether products of the arachi-
donic acid cascade play a role in the cardiovascular changes
associated with the development of genetic hypertension.
The sPLA2 inhibitor prevented the increases in perivascular
(WKY 12 wk 18.2 ± 1.4, n = 6 ; SHR 12 wk 26.9 ± 1.3,
n = 5 ; + KH064 18.8 ± 2.1 %, n = 5) and interstitial fibrosis
(WKY 12 wk 4.8 ± 0.4, n = 6 ; SHR 12 wk 8.5 ± 0.88,
n = 5 ; + KH064 5.3 ± 0.4 %, n = 6) that are associated with
hypertension. KHO64 had no effect on cardiac hypertrophy
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as shown by echocardiographic analysis of left ventricle
posterior wall thickness (WKY 12wk 1.53 ± 0.06, n = 12 ;
SHR 12 wk 1.77 ± 0.08, n = 11 ; + KHO64 1.81 ± 0.09 mm
n = 9) and chamber diameter (WKY 12 wk 7.15 ± 0.16,
n = 12 ; SHR 12 wk 6.78 ± 0.21, n = 12 ; + KH064
6.67 ± 0.25 mm, n = 8). Increased systolic blood pressure
was partially prevented in SHR rats by KHO64 (WKY 12 wk
142 ± 3, n = 14 ; SHR 12 wk 199 ± 5, n = 10 ; + KH064
169 ± 5 mmHg, n = 9). Endothelial function was reduced in
KHO64 treated rats as shown by a reduced maximal response
to acetylcholine in isolated thoracic aortic rings. Therefore,
the arachidonic acid cascade may be important in the deve-
lopment of fibrosis in the heart but not in the development of
cardiac hypertrophy.
Abstract N° C44
Blockade of anandamide hydrolysis reverses
hypertension through activation of cardiac and
vascular CB1 receptors
Pal Pacher, Sándor Bátkai, George Kunos. NIH, NIAAA,
Bethesda, MD, USA
Background. – Endocannabinoids are novel lipid media-
tors with hypotensive activity that have been implicated in
cardiovascular regulation. Here we document an endocanna-
binergic tone in hypertension, and show that potentiation of
this tone by inhibiting the metabolic inactivation of the endo-
cannabinoid anandamide normalizes the elevated blood pres-
sure and cardiac contractility of hypertensive rats.
Methods and results. – Using the Millar pressure–volume
system in rats with three different models of hypertension we
find that cannabinoid-1 receptor (CB1) antagonists markedly
increase blood pressure and left ventricular contractile per-
formance. In contrast, preventing anandamide inactivation
by treatment with an inhibitor of fatty acid amidohydrolase
or anandamide transport reduces blood pressure, cardiac
contractility and vascular resistance to levels in normotensive
rats, and these effects are reversed by CB1 antagonists. In
normotensive control rats, the same parameters remain unaf-
fected by any of these treatments. CB1 agonists lower blood
pressure much more in spontaneously hypertensive rats
(SHR) than in normotensive Wistar Kyoto rats (WKY), and
the expression of CB1 is increased in heart and aortic endo-
thelium of SHR compared to WKY.
Conclusion. – We conclude that upregulation of vascular
and cardiac CB1 in hypertension unmasks an endocannabi-
nergic negative inotropic and vasodilator tone, and enhan-
cing this tone by blocking anandamide hydrolysis can nor-
malize blood pressure. Targeting the endocannabinoid
system offers novel therapeutic strategies in the treatment of
hypertension.
Abstract N° C45
PKC activates NAD(P)H oxidase in human failing
heart
Sachin Gupte, Brian Marks, Elias Zias *, Mohan Sarabu,
Michael Wolin. Department of Physiology and
Cardiovascular Surgery, New York Medical College, NY,
USA. * Corresponding author.
NAD(P)H oxidase is one of the major sources of supe-
roxide anion (O2
–) in cardiovascular system. In recent stu-
dies, we have found that O2
– determined by lucigenin (5 µM)
chemiluminescence is increased in the homogenate of human
failing hearts (FH; n = 7) vs. non-FH by fivefold. superoxide
dismutase (SOD) (200 U/ml) and DPI (10 µM), a flavopro-
tein inhibitor, both reduced O2
– by 25–40%. Further, charac-
terization indicated that O2
– was derived from flavoprotein-
dependent enzymes, which mainly consumed NADPH,
because addition of NADPH (100 µM) and NADH (100 µM)
increased O2
– by 60- and 15-fold, respectively, in an apocy-
nin (100 µM) and DPI (10 µM) inhibitable manner. Incuba-
tion of FH homogenates with a PKC inhibitor, staurosporine
(10 µM), almost completely abolished O2
– production. Thus,
these data suggest that PKC activated NAD(P)H oxidases
and O2
– generation in heart failure.
Abstract N° C46
Evidence for a role of reactive oxygen species in
angiotensin II-induced left ventricular hypertrophy in
vivo
Reka Skoumal, Istvan Szokodi, Balazs Sarman,
Rudolf deChâtel, Zoltan Lako-Futo, Gabor Foldes,
Lajos Papp, Heikki Ruskoaho, Miklos Toth. 1st Department
of Internal Medicine, Semmelweis University, Budapest,
Hungary. Heart Institute, University of Pecs, Pecs, Hungary.
Department of Pharmacology and Toxicology, University of
Oulu, Oulu, Finland
In vitro studies have suggested that reactive oxygen spe-
cies (ROS) are important mediators of cardiomyocyte hyper-
trophy. We studied the effect of dimethylthiourea (DMTU), a
hydroxyl radical scavenger, on angiotensin II (Ang II)-
induced left ventricular hypertrophy. Male Sprague–Dawley
rats (n = 27) were infused with Ang II (33 µg/kg/h) via
subcutaneously implantated osmotic mini-pumps in the pre-
sence and absence of a daily intraperitoneal injection of
DMTU (50 mg/kg/d) for 6 d. Total RNA was isolated from
left ventricular tissue and mRNA levels were measured by
northern blot. Ang II infusion increased left ventricular
weight/body weight (LVW/BW) ratio (2.63 ± 0.18 vs. 2.09 ±
0.11; Ang II vs. control, P < 0.01). DMTU treatment signifi-
cantly attenuated the effect of Ang II on LVW/BW ratio (2.37
± 0.16, P < 0.01). In contrast to the attenuation of the increase
in LVW/BW ratio, DMTU had no significant effect on Ang II
induced increases in the mRNA levels of atrial natriuretic
peptide (12.7-fold vs. 15.7-fold; Ang II vs. Ang II + DMTU;
P = NS), B-type natriuretic peptide (3.5-fold vs. 4.5-fold; P =
NS), skeletal alpha-actin (3.9-fold vs. 3.7-fold; P = NS),
collagen I (1.8-fold vs. 2.2-fold; P = NS), and fibronectin
(1.4-fold vs. 1.8-fold; P = NS). The present results suggest
that ROS significantly contributes to the development of left
ventricular hypertrophy in vivo as the Ang II induced in-
crease in LVW/BW ratio was substantially attenuated by
DMTU. Moreover, the hydroxyl radical scavenger appears to
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have a selective effect on protein synthesis since it did not
affect the increased expression of key genes associated with
cardiac hypertrophy.
Abstract N° C47
Dietary fish oil attenuates cardiac hypertrophy and
improves cardiac function in a murine model of
systemic carnitine deficiency
Ryotaro Takahashi, Kenji Okumura, Yasushi Numaguchi,
Hideo Matsui, Toyoaki Murohara. Department of
Cardiology, Nagoya University Graduate School of
Medicine, Nagoya, Japan
The juvenile visceral steatosis (JVS) mouse, a murine
model of systemic carnitine deficiency, develops cardiac
hypertrophy with lipid accumulation. Fish oil (FO) or n-3
fatty acids may exert their beneficial effects on the patholo-
gical cardiac hypertrophy by modifying the fatty acid com-
position of myocardial 1,2-diacylglycerol (DAG), a lipid
second messenger that activates protein kinase C (PKC). We
investigated the effect of dietary FO on the hypertrophied
heart in JVS mice. Both JVS and control mice were fed a FO
diet (containing 10% FO) or a standard diet from 4 weeks of
age. At 8 weeks of age, the ventricular-to-body weight ratio
in JVS mice was 2.7-fold higher than that in controls (P <
0.01) and was reduced by 22% by dietary FO (P < 0.01 vs.
JVS mice). In JVS mice, myocardial DAG levels were 2.3-
fold higher than in controls (P < 0.01) with an increase in
C18:1n-7,9 and C18:2n-6 fatty acids (both P < 0.01 vs.
controls); dietary FO reduced both fatty acid species (P <
0.05 and P < 0.01 vs. JVS mice, respectively) without chan-
ging the total DAG levels. Membrane translocation of car-
diac PKCa, b2, and e in JVS mice was greater than that in
controls (P < 0.01, P < 0.05, and P < 0.05, respectively), and
was reduced to control levels by dietary FO (P < 0.01, P <
0.05, and P < 0.05 vs. JVS mice, respectively). From 8 to
10 weeks of age, JVS mice exhibited a progressive decline in
left ventricular fractional shortening, which was maintained
in FO treated JVS mice (P < 0.01). In conclusion, dietary FO
may attenuate cardiac hypertrophy with improvement of
cardiac function in JVS mice via modification of molecular
species composition of myocardial DAG and consequent
inhibition of PKC translocation.
Abstract N° C48
Limits to the beneficial effects of dietary flaxseed in
prolonged hypercholesterolemic conditions
C.M.C. Dupasquier, A.-M. Weber, B.P. Ander,
E.A. Kroeger, J.S.C. Gilchrist, A. Lukas, G.N. Pierce.
National Centre for Agri-Food Research in Medicine, St.
Boniface General Hospital Research Centre, University of
Manitoba, Winnipeg, Canada
We have shown that dietary flaxseed supplementation
preserves vascular function and reduces the progression of
atherosclerotic lesions during 6 and 8 weeks of hypercholes-
terolemic conditions. It is unclear however, if flaxseed re-
mains beneficial in more prolonged hypercholesterolemic
conditions. Male New Zealand White (NZW) rabbits were
assigned to a control group (regular chow), a 10% flaxseed
supplemented diet, a 0.5% cholesterol supplemented diet, or
a 0.5% and 10% flaxseed supplemented diet for 16 weeks of
feeding. The aorta and carotids were analyzed en face for
atherosclerotic lesion coverage. Aortic cross-sections were
stained with oil red O and Hematoxylin and analyzed for
thickness of intimal lesions. Aortic vascular response to KCl,
norepinephrine (NE), and acetylcholine (Ach) was exami-
ned. Plasma cholesterol levels were significantly increased
with cholesterol feeding. Vascular contractile activity was
impaired by cholesterol. The cholesterol-flax and cholesterol
groups had decreased contractile responses to KCl and NE,
and a decreased relaxation response to ACh as compared to
the control and flax groups. Dietary cholesterol stimulated
atherogenesis. Flaxseed added to the high cholesterol diet
significantly increased the area of aortic and carotid atheros-
clerotic lesions as compared to the three other groups. The
cholesterol-flax group also had increased intimal plaque thic-
kness as compared to lesions in the cholesterol fed group. In
conclusion, the combination of dietary flaxseed with choles-
terol did not deter atherogenesis or correct the contractile
abnormalities. Dietary flaxseed does not provide a protective
effect in prolonged conditions of severe hypercholesterole-
mia.
This study was supported by CIHR, the Heart and Stroke
Foundation of Canada, NSERC, and Polar Foods, Inc.
Abstract N° C49
Platelet aggregation in rats fed a hempseed
supplemented diet
M.N. Landry a, A.L. Edel a, C.M.C. Dupasquier a,
A. Al-Khalifa b, B.P. Ander a, G.N. Pierce a. a National
Centre for Agri-Food Research in Medicine, St Boniface
Hospital Research Centre, University of Manitoba,
Winnipeg, Canada. b College of Medicine and Medical
Science, Arabian Gulf University, Bahrain
N-3 polyunsaturated fatty acids (PUFA) are known to be
antithrombotic because they reduce platelet aggregation.
However, n-6 PUFAs are suggested to have pro-thrombotic
effects. Hempseed is a unique food enriched in both linoleic
acid (LA), an n-6 PUFA, and alpha linolenic acid (ALA), an
n-3 PUFA. The purpose of our study was to determine if
chronic dietary supplementation with hempseed can alter
platelet aggregation. Sprague–Dawley (S–D) rats were admi-
nistered a regular diet or one supplemented with either 5%
hempseed, 10% hempseed, 10% hempseed cake (lipid deple-
ted), or 1% palm oil for 6 or 12 weeks. The extent and rate of
ADP-induced platelet aggregation was recorded with a
chrono-log aggregometer. LA and ALA levels in the plasma
and diets following 6 weeks of feeding were analyzed by gas
chromatography. Proximate analysis of the diets was also
conducted. Dietary and plasma LA and ALA levels were
significantly increased in the two hempseed supplemented
groups. After 6 weeks of dietary intervention, there were no
differences in the extent and rate of ADP-induced platelet
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aggregation in any of the groups. However, after 12 weeks of
dietary intervention, hempseed supplementation reduced the
extent and rate of platelet aggregation in comparison to rats
consuming a regular diet. In summary, our data would argue
against a detrimental effect of elevated n-6 fatty acids on
platelet aggregation. Extended dietary supplementation with
hempseed provides protective effects against platelet aggre-
gation.
This study was supported by CIHR, the Heart and Stroke
Foundation of Canada, NSERC, and Hemp Oil Canada.
Abstract N° C50
Dietary flaxseed limits atherosclerotic development in
the LDLr-KO mouse
C.M.C. Dupasquier, A.L. Kostenuk, B.K.h. Yeganeh,
J.T. Wigle, M.H. Moghadasian, G.N. Pierce. National
Centre for Agri-Food Research in Medicine, St Boniface
Hospital Research Centre, University of Manitoba,
Winnipeg, Canada
Flaxseed, the richest plant source of the omega-3 fatty
acid alpha-linolenic acid (ALA), has been reported to have
inhibitory effects on atherosclerosis in rabbits. The mecha-
nism for this beneficial effect is unclear. The purpose of our
work was to re-examine the anti-atherogenic capacity of
flaxseed in a more optimal model—the low-density-
lipoprotein receptor deficient (LDLr-KO) mouse. LDLr-KO
mice were administered a regular diet (RG), a 10% flaxseed
supplemented diet (FX), or an atherogenic diet containing
2% cholesterol, alone (CH) or supplemented with 10%
flaxseed (CF), 5% flaxseed (CF5), 1% flaxseed (CF1), 10%
low-ALA flaxseed (CX), or 5% coconut oil (CS) for
24 weeks. Plasma cholesterol and triglyceride levels were
measured enzymatically. The whole aorta and cross-sections
at the aortic sinus were analyzed for atherosclerotic lesion
coverage. Tissue sections were stained with oil red O and
hematoxylin. Dietary cholesterol supplementation elevated
plasma cholesterol levels. The CH group had significantly
greater plasma cholesterol levels than all groups. CF5 had
lower plasma cholesterol levels than all other atherogenic
groups. The addition of 5% and 10% flaxseed to an athero-
genic diet reduced plasma triglyceride levels as compared to
the CS group. Dietary cholesterol stimulated atherogenesis.
The CF and CF5 groups had a reduced area of aortic athero-
sclerotic lesions. The CF5 group also had less severe lesions
at the aortic sinus. In summary, the addition of 5% and 10%
dietary flaxseed to an atherogenic diet reduced plasma cho-
lesterol and triglyceride levels and deterred the development
of atherogenesis. The high ALA content of flaxseed appears
to be providing these beneficial effects. Dietary flaxseed
provides preventative effects on atherosclerotic develop-
ment.
This study was supported by CIHR, the Heart and Stroke
Foundation of Canada, NSERC, and Polar Foods Inc.
Abstract N° C51
Influence of dietary hempseed on arrhythmia
generation by ischemia/reperfusion
M.A. Prociuk, A.L. Edel, N.T. Gavel, A. Lukas,
G.N. Pierce. National Centre for Agri-Food Research in
Medicine, St. Boniface General Hospital Research Centre,
Departments of Physiology and Pharmacy, University of
Manitoba, Winnipeg, Canada
Polyunsaturated fatty acids (PUFAs) have been suggested
to induce both beneficial and detrimental effects on the car-
diovascular system. Specifically, the omega-3 family has
been identified for its anti-arrhythmic effects while the
omega-6 family has been suggested to be pro-arrhythmic.
Hempseed contains a ratio of 3:1 of omega-6: omega-3
PUFA. It is not yet known what influence the two kinds of
PUFAs have on arrhythmia generation when consumed as a
dietary supplement. In the present study, male New Zealand
White (NZW) rabbits were maintained for 8 weeks on a
regular diet or a diet supplemented with one of either 10%
hempseed (HP), 0.5% cholesterol (OL), 10% hempseed +
0.5% cholesterol (OLHP), 10% delipidated hempseed (SC)
or 5% coconut oil (CO). At 8 weeks, blood samples were
collected by venipuncture and plasma analyzed by gas chro-
matography for the lipid profile. The highest levels of linoleic
and alpha-linolenic acid were found in the OLHP group. The
hearts were excised and subjected to ischemia/reperfusion by
Langendorff technique. During global ischemia, the inci-
dence of arrhythmias was highest in the OL group. The
duration of ischemia-induced tachycardia was longest in the
OLHP and SC groups. The duration of fibrillation was lon-
gest in the OL and SC groups. The incidence of reperfusion-
induced arrhythmias was highest in the SC group. The dura-
tion of reperfusion-induced tachycardia was longest in the
OLHP group while fibrillation was longest in the HP group.
These results demonstrate the influence dietary hempseed
has on arrhythmia generation which may be achieved tho-
rough its unique PUFA composition.
Supported by CIHR, Heart and Stroke Foundation, and
Hemp Oil, Canada.
Abstract N° C52
The effects of dietary hempseed on platelet aggregation
under hypercholesterolemic conditions
M.A. Prociuk, A.L. Edel, N.T. Gavel, J.A. Austria,
C.M.C. Dupasquier, B.P. Ander, G.N. Pierce. National
Centre for Agri-Food Research in Medicine, St Boniface
Hospital Research Centre, University of Manitoba,
Winnipeg, Canada
Hempseed is a unique food enriched in both omega-6 and
omega-3 polyunsaturated fatty acids (PUFA), such as lino-
leic acid (LA) and alpha-linolenic acid (ALA), respectively.
The purpose of our study was to determine if chronic dietary
supplementation with hempseed would alter platelet aggre-
gation in animals with high circulating cholesterol levels.
Male New Zealand White (NZW) rabbits were assigned to a
regular diet (RG), or a diet supplemented with either 10%
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hempseed (HP), 0.5% cholesterol (OL), 0.5% cholesterol +
10% hempseed (OLHP), 10% delipidated hempseed (SC), or
5% coconut oil (CO) for 8 weeks. The extent and rate of both
collagen- and adenosine diphosphate (ADP)-induced platelet
aggregation was recorded with a chrono-log aggregometer.
Plasma LA and ALA levels were analyzed by gas chromato-
graphy. Plasma LA and ALA levels were significantly in-
creased with hempseed supplementation (HP and OLHP).
Cholesterol feeding enhanced plasma LA and ALA levels in
the OLHP group. The extent and rate of platelet aggregation
induced by both ADP and collagen was significantly lower
with hempseed supplementation (HP and OLHP) than with
cholesterol feeding. Hempseed cake supplementation did not
reduce platelet aggregation. The combination of cholesterol
and hempseed resulted in less collagen-induced aggregation
than the OL, SC, HP, and CO groups. In summary, hempseed
supplementation increases plasma PUFA levels. Hempseed
reduces the extent and rate of platelet aggregation even in the
presence of high circulating cholesterol. Delipidated
hempseed does not elevate plasma PUFA levels or prevent
platelet aggregation, suggesting that the PUFA content in
hempseed provides the beneficial antithrombotic effects.
Supported by CIHR, NSERC, Heart and Stroke Founda-
tion of Canada and Hemp Oil Canada.
Abstract N° C54
A flaxseed-supplemented diet greatly enhances omega-3
fatty acid content in rabbit tissues
B.P. Ander, A.L. Edel, M.A. Kopilas, J.A. Austria,
T.G. Maddaford, A.R. Weber, P. Rampersad,
J.S.C. Gilchrist, A. Lukas, G.N. Pierce. Division of Stroke
and Vascular Disease, Institute of Cardiovascular Sciences
and National Centre for Agriculture–Food Research in
Medicine, Department of Physiology, Faculties of
Medicine, Pharmacy and Dentistry, University of Manitoba,
Winnipeg, MB, Canada
Epidemiological studies relate diets rich in omega (x)-3
polyunsaturated fatty acids (PUFA) to decreased incidences
of cardiovascular disease and mortality. The extent of incor-
poration of these beneficial fats into body tissues through
food consumption is uncertain. In this study, male New
Zealand White rabbits were fed 125 g/d of either regular
rabbit chow or a diet containing 10% ground flaxseed—a
seed highly enriched with the x-3 PUFA, a-linolenic acid
(ALA). Heart, aorta, liver, kidney, brain and blood were
collected from the animals after 8 weeks of feeding. Fatty
acids were extracted from tissues and analyzed by gas chro-
matography. Incorporation of ALA and its metabolic pro-
ducts eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) was most significant in the heart, which had 4.9
± 1.2 mg ALA/g tissue compared to only 0.8 ± 0.1 mg ALA/g
tissue in the control group. Similar trends were observed in
all other tissues, but to a much lesser extent in the brain.
Arachidonic acid (x-6) was decreased in all tissues obtained
from the flax-supplemented group and the ratio of x-6:x-3
fatty acids was dramatically lowered in the tissues compared
to controls. Thus, consumption of dietary flaxseed appears to
be an effective means to increase x-3 content in body tissues.
These tissue stores of x-3 fatty acids could protect against
arrhythmias, thrombosis, and other potentially fatal events.
This study was supported by CIHR, Heart and Stroke
Foundation of Canada, Flax Council of Canada and Polar
Foods, Inc.
Abstract N° C55
Dietary fatty acids alter phospholipid composition in a
murine model of AngII induced cardiac hypertrophy
C.E. Huggins a, P.L. McLennan b, T. Pedrazzini c, S. Pepe d.
a L.M.D Delbridge, University of Melbourne, Melbourne,
Australia. b University of Wollongong. c University of
Lausanne. d Baker Medical Research Institute
Elevated endogenous angiotensin II (AngII) is associated
with cardiac growth (independent of blood pressure) and
impaired cardiac performance. In various contexts cardio-
protection can be enhanced by increasing the myocardial
phospholipid omega-3:omega-6 polyunsaturated fatty acid
(x-3:x-6 PUFA) ratio. Membrane fatty acid composition
impacts on lipid–protein interactions, and alteration of mem-
brane structure and fluidity affects membrane protein func-
tion and membrane mediator-derived signalling. The goal of
this study was to determine (1) if AngII induced hypertrophy
alters membrane phospholipid fatty acid composition and (2)
whether dietary lipid manipulation can impact on membrane
phospholipid fatty acid composition to increase the x-3:x-6
ratio in this murine model. Mature female (34–38 weeks)
wildtype (WT) and transgenic cardiac AngII-overexpressing
mice (TG) were fed a diet enriched with either x-3 PUFA
(7% fish oil + 3% olive oil) or x-6 PUFA (5% sunflower oil +
5% olive oil) for 4 weeks. The percentage of x-3 and x-6
PUFA and the ratio of x-3:x-6 PUFA in cardiac phospholi-
pids were analysed by gas chromatography (see Table 1).
These findings indicate that cardiac AngII induced growth
results in altered phospholipid composition which can be
advantageously modulated by dietary manipulation to in-
crease the x-3:x-6 ratio.
Abstract N° C56
Dietary modification of hypertension induced cardiac
damage
Megan Elliott a, Peter McLennan a, Peter Howe b.
a Department of Biomedical Science, Smart Foods Centre,
University of Wollongong; b Department of Physiology,
University of Adelaide, Adelaide, Australia
Table 1
x-6 diet x-3 diet
WT TG WT TG
% w-3 24.5 ± 0.7 21.9 ± 1.3 * 48.7 ± 0.5 # 46.5 ± 0.6 *,#
% w-6 27.0 ± 0.5 33.1 ± 0.8 * 8.8 ± 0.08 # 7.4 ± 0.2 *,#
x-3:w-6 0.91 ± 0.04 0.66 ± 0.05 * 5.9 ± 0.2 # 6.32 ± 0.2 *,#
* P < 0.05 when compared to WT.
# P < 0.05 when compare to x-6 diet.
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A cardioprotective role for n-3 fatty acids has been well
established by epidemiological, experimental and clinical
research. Moderate reductions in the blood pressure (BP) of
hypertensive patients have been reported but decreased rein-
farction, increased survival from cardiac events and impro-
ved peripheral flow response are consistently observed,
hence the effects of n-3 fatty acids on hypertension may be
achieved by end organ protection. Hypothesis: n-3 fatty acids
have a time dependent effect on target organ damage with
longer feeding times related to higher levels of protection.
Eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) offer different levels of protection. Ten-week-old
stroke prone spontaneously hypertensive rats (SHRSP) were
fed either an olive oil (OO) control diet for 12 weeks or one of
five test diets (1) 8 weeks OO 4 weeks fish oil (FO), (2)
4 weeks OO 8 weeks FO, (3) 12 weeks FO, (4) 12 weeks EPA
and (5) 12 weeks DHA. Histological analysis of myocyte
hypertrophy, coronary vasculature hypertrophy and collagen
deposition was performed.All FO fed animals showed mode-
rate time dependent decreases in BP. No significant reduction
was seen in cardiac hypertrophy. FO fed rats showed time
dependent reductions in collagen deposition, myocyte cross-
section area (CSA) and coronary artery hypertrophy. Compa-
rison of EPA and DHA showed greater protective effect of
DHA on collagen deposition and myocyte CSA.
This study shows n-3 fatty acids provide cardio-protection
in hypertensive animals independently of BP change. Protec-
tion is time dependent and greater with DHA alone than FO
or EPA.
Abstract N° C57
A comparative effect of fish oil, flaxseed oil, and hemp
seed oil supplementation on selected parameters of
cardiovascular health in healthy volunteers
N. Kaul, R. Kreml, M. Landry, A. Austria, A.E. Edel,
E. Dibrov, S. Hirono, M.E. Zettler, G.N. Pierce. National
Centre for Agri-Food Research in Medicine, St. Boniface
Research Center, Winnipeg, Canada. Department of
Physiology, University of Manitoba, Winnipeg, Canada
The effects of three dietary oils (fish oil, flaxseed oil, and
hemp oil supplementation) given in concentrations expected
to be self-administered in the general population were exa-
mined in healthy volunteers in terms of providing potential
cardiovascular health benefits. Eighty-six healthy male and
female volunteers completed a 12-week double blinded, pla-
cebo controlled, trial. They were randomly assigned to any
one of the four groups. Subjects were orally supplemented
with two 1-g capsules of placebo, fish oil, flaxseed oil or
hemp seed oil per day for 12 weeks. The lipid parameters
(TC, HDL-C, LDL-C and TG) did not show any significant
differences among the four groups. Oxidative modification
of LDL showed no increase in lag time over the 12-week
period. Both collagen and thrombin induced platelet aggre-
gation showed no statistical difference amongst the four
groups studied. Similarly C-reactive protein (CRP) and tu-
mor necrosis factor-alpha (TNF-a) levels at baseline and
after supplementation showed no significant changes. From a
consumer’s perspective, ingesting two capsules of any of
these oils in an attempt to achieve cardiovascular health
benefits may not provide the desired or expected result over a
3-month period.
Supported by CIHR and NSERC.
Abstract N° C58
Molecular mechanisms for cardioprotective effects of
Curcuma longa on myocardial apoptosis, cardiac
function and antioxidant milieu in an ischemia
reperfusion model of myocardial infarction
S.K. Gupta. Department of Pharmacology, All India
Institute of Medical Sciences, New Delhi 110 029, India
The present study investigated the effect of Curcuma
longa (Cl), a medicinal herb on myocardial injury, apoptosis,
antioxidant status and cardiac functional recovery in rats
subjected to 45 min of ischemia followed by 1 h of reperfu-
sion. In the control ischemia reperfusion (I/R) group, signi-
ficant myocardial injury, cardiac apoptosis as evidenced by
TUNEL-positive nuclear staining, depressed hemodyna-
mics, decline in myocardial antioxidant status and elevation
in lipid peroxidation was observed as compared to sham
control. However, myocardial injury produced after I/R was
significantly reduced in the Cl-treated group. Cl treatment
maintained the antioxidant reserve of the myocardium by
augmenting endogenous antioxidant enzyme activities, inhi-
biting lipid peroxidation and restoration of the antioxidant
status of the myocardium. Our results indicate that cardiose-
lective overexpression of bcl-2 and downregulation of bax
protein exerts a cardioprotective effect after myocardial I/R,
and this effect is probably mediated via an anti-apoptotic
action of Cl. The beneficial effects also translated into the
functional recovery of the heart. Histopathological examina-
tion reconfirmed the protective effects of Cl on the myocar-
dium. The results of the present study demonstrate that admi-
nistration of Cl provided significant protection against
myocardial injury and this may be attributed to its antioxi-
dant and anti-apoptotic properties.
OO 12 FO EPA DHA
BP
(mmHg)
241 ± 1 * 219 ± 2.5 217 ± 2.2 218 ± 1.6
CSA
(mm2)
0.43 ± 0.01 * 0.36 ± 0.02 0.36 ± 0.03 0.34 ± 0.02 **
Collagen
(%)
23.01 ± 3.20 * 14.70 ± 4.93 13.39 ± 3.59 10.28 ± 2.28 ***
* P < 0.05 compared to OO.
** P = 0.059.
*** P < 0.05 compared to FO.
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Abstract N° C59
Effects of sour cherry seed extract in isolated
ischemic/reperfused mouse heart
Norbert Nagy, Arpad Tosaki. Department of Pharmacology,
Health and Science Center, University of Debrecen,
Debrecen, Hungary
The effects of sour cherry seed flavonoids were evaluated
for their contribution to post-ischemic recovery in isolated
mouse hearts subjected to ischemia/reperfusion. Mice were
orally treated with various doses (1, 5, 10, and 30 mg/kg/d) of
flavonoid-rich extract of sour cherry seeds for 10 d. One day
after the last treatment, animals were anesthetized, hearts
were isolated in “working mode” and subjected to 30 min
ischemia followed by 2 h reperfusion. The recovery of post-
ischemic cardiac function including heart rate (HR), coro-
nary flow (CF), aortic flow (AF), and aortic pressure (AOP)
were registered. In mice treated with 10 and 30 mg/kg/d of
sour cherry flavonoid-rich extract, after 60 min of reperfu-
sion, AOP was significantly improved from its untreated
control value of 75 ± 4 to 98 ± 6 mmHg (P < 0.05) and 119 ±
6 mmHg (P < 0.5), respectively. The same improvement in
post-ischemic recovery of HR, CF, and AF was also obser-
ved. Lower concentrations (1 and 5 mg/kg/d) of the extract
failed to significantly improve the recovery of cardiac func-
tion. The incidence (%) of reperfusion-induced ventricular
fibrillation (VF) was also reduced from its drug-free value of
83–50% and 33% in mice treated with 10 and 30 mg/kg/d of
extract, respectively. However, this protection against VF,
because of the relatively low numbers of hearts (n = 6, and
nonparametric distribution) in each group, was not at a signi-
ficant level. In summary, sour cherry seed flavonoid-rich
extract possesses protective effect against reperfusion-
induced injury through its abilities to improve post-ischemic
cardiac function.
Abstract N° C60
Relationship between clinical effects of injection sheng
mei on chronic heart failure and its concentration in
plasma
X. Zeng. Chengdu No 2 Hospital, China
Background. – In the previous studies, we found that
sheng mei may be of value for long-term treatment in patients
with chronic heart failure. In order to improve its clinical
effect and to reduce side effects, it is necessary to study the
relationship between its effect and its concentration in
plasma in patients with congestive heart failure (CHF).
Methods and results. – The study in 59 patients with class
III–IV chronic heart failure was performed. All patients were
given conventional therapy for CHF consisting digitalis, diu-
retics, nitrates, beta blockers and ACE inhibitors for 2 weeks,
and were randomly divided into three groups: sheng mei
60 ml/d (n = 20) or sheng mei 30 ml/d (n = 20) or placebo (n
= 19). After 4 week sheng mei therapy, data of left ventricular
ejection fraction (LVEF) 6 min walking test and Mennesota
Living with Heart Failure score were assessed again and
sheng mei concentration in plasma was measured by HPLC.
Plasma samples were pretreated by protein precipitation with
methanol and centrifuged at 17 000 rpm for 10 min. Re of
sheng mei was determined in 60 or 30 ml/d group using a uB
and pank C18 column (10u, 300 3.9 mm I.D.) with a mobile
phase of acetonitrile mixed with 0.02 mol/l phosphoric acid
water solution in plasma were 8 ng/ml after injection of 50 µl
of sample. The average recovery of gengsen Re of sheng mei
in plasma was 96.5%. The results showed that increase in
LVEF and exercise capacity and improvement of quality of
life in 60 ml group were more remarkabe than those in 30 ml
group which corresponded to change plasma concentration
in sheng mei (0.33 µg/ml vs. 0.1 µg/ml, P < 0.01). And
increase in exercise capacity and improvement of quality of
life in 30 ml group were more apparent than that in placebo.
There was not any apparent side effect among three groups.
Conclusions. – Monitoring sheng mei concentration in
plasma may be helpful in treating the patients with chronic
heart failure by using sheng mei.
Abstract N° C61
Evaluation of cardiovascular and cardioprotective
effects of Terminalia arjuna
Jagriti Bhatia a, S.K. Bhattacharya b, P. Mahajan a,
S. Dwivedi a,b. a All India Institute of Medical Sciences,
New Delhi 110 029, India. b University College of Medical
Sciences and GTB Hospital, Delhi 110 095, India
The bark of Terminalia arjuna (TA) possesses beneficial
cardiovascular effects, Hence, the present work was underta-
ken to screen the effect of aqueous extract (AqE) of TA on
the isolated-perfused rabbit’s heart preparation and
isoproterenol-induced myocardial necrosis in rats, The effect
of different doses of the AqE in the dose range 1–2048 µg
was observed at different time intervals of the isolated-
perfused rabbit’s heart preparation. The AqE increased the
force of contraction and decreased the heart rate at and above
the dose of 64 µg and increases the coronary flow rate above
the dose of 512 µg significantly. The cardioprotective effect
of AqE of TA was evaluated in the Wistar rats. The rats were
divided into four groups of 10 each. Group 1 was the saline
control. In groups 2, 3 and 4, myocardial necrosis was indu-
ced with isoproterenol (ISO; 85 mg/kg, s.c.) on the last 2 d of
pretreatment of animals with saline (i.p.), propranolol
(2 mg/kg, i.p.) or TA (150 mg/kg, p.o.) respectively for 9 d.
The effect of treatment on electrocardiographic changes and
blood pressure in all the groups was recorded 24 h after the
last injection of ISO. AqE of TA produced significant hypo-
tension (60.25 ± 1.1 vs. 98.2 ± 2.03 mm of Hg in group 1; P
< 0.001). A significant reduction in the J-point elevation was
also noted (0.68 ± 0.1 vs. 1.36 ± 0.19 mm in group 2; P <
0.02). However, ISO led to a significant increase in the heart
rate in AqE-treated rats (301.5 ± 7.19 vs. 252.8 ±
4.75 beat/min in group 1; P < 0.001). The results of the
present study indicate that the AqE of TA enhances coronary
flow, lowers blood pressure and also reduces the intensity of
ISO-induced myocardial necrosis in experimental animals.
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Abstract N° C62
Cardioprotective effects of hydro-alcoholic extract of
Withania somnifera on isoproterenol-induced
myocardial infarction in rats
D.S. Arya, I. Mohanty, S.K. Ojha, M. Nandave, S.K. Gupta.
Department of Pharmacology, All India Institute of Medical
Sciences, New Delhi 110 029, India
The present study evaluated the cardioprotective potential
of hydro-alcoholic extract of Withania somnifera (Ws) an
Indian medicinal plant against isoproterenol (ISP)-induced
myocardial infarction in rats. Rats were administered Ws at
doses of 25, 50 and 100 mg/kg, orally for 4 weeks and
randomly divided into three groups: sham, ISP control and
Ws treatment. On 29th and 30th day ISP (85 mg/kg) was
administered subcutaneously to the ISP control and Ws treat-
ment groups. On the 31st day after recording hemodynamics,
hearts were processed for histopathological and biochemical
studies. In ISP group left ventricular dysfunction as eviden-
ced by decrease in heart rate, left ventricular peak positive
and negative pressure change and elevated left ventricular
end-diastolic pressure was observed. In addition a significant
decrease in glutathione (GSH), activities of superoxide dis-
mutase (SOD), catalase (CAT), creatinine phosphokinase
(CPK) (P < 0.05) and lactate dehydrogenase (LDH) (P <
0.01) as well as increase in lipid peroxidation marker malon-
dialdehyde (MDA) level (P < 0.01) was observed in ISP
control as compared to sham group. The treatment with Ws
significantly reduced the myocardial injury subsequent to
ISP-induced necrosis. The cardioprotection may be due to
augmentation of endogenous antioxidants, maintenance of
the myocardial antioxidant status and significant restoration
of the altered hemodynamics. Histopathological assessment
further confirmed the cardioprotective effects of Ws. Ws at
dose of 50 mg/kg was found to be most effective in restoring
hemodynamic and biochemical alterations as compared to
dose of 25 and 100 mg/kg of Ws.
Abstract N° C63
Dietary substitution of sesame oil regulates changes in
lipid composition and hematological indices in
hypertensive patients
Sankar, Devarajan. Annamalai University, Tamil Nadu,
India
The current study was conducted to find out the effective-
ness of sesame oil as sole edible on lipid composition and
hematological indices in hypertensive patients medicated
with nifedipine, a calcium channel blocker. The study group
comprised of 200 hypertensive patients administered with
nifedipine (10–30 mg/d) as antihypertensive medication. Of
200 patients, 125 patients were supplied with sesame oil
(idhayam gingelly oil), which comes to 35 g of oil/d/person
and directed to use the oil in place of other edible oils for
60 d. Seventy-five patients were treated only with nifedipine
for 60 d. Lipid profile (total cholesterol (TC), low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), TC/HDL-C ratio and triglycerides),
plasma and RBC membrane fatty acid composition and he-
matological parameters (RBC, WBC, hemoglobin, platelets
and prothrombin time) were analyzed at basal and after
substitution of sesame oil and the drug, nifedipine for 60 d.
Plasma level of TC, LDL-C and TC reduced significantly
while HDL-C elevated significantly upon the substitution of
sesame oil. TC/HDL-C also reduced. Saturated fatty acids
content of plasma and RBC reduced where as monounsatu-
rated fatty acids and polyunsaturated fatty acids content
increased significantly. Hemoglobin levels showed signifi-
cant elevation. Platelets and prothrombin time altered signi-
ficantly during the oil substitution. These results indicate that
sesame oil influenced beneficially in the modulation of lipids
and hematological parameters, suggesting that dietary subs-
titution of sesame oil is added advantageous to hypertensive
patients.
Abstract N° C64
Myocardial salvaging effect of Moringa oleifera in
isoproterenol induced myocardial infarction
M. Nandave, S.K. Ojha, D.S. Arya, S.K. Gupta. Department
of Pharmacology, All India Institute of Medical Sciences,
New Delhi 110 029, India
The present study evaluated cardioprotective potential of
hydro-alcoholic extract of Moringa oleifera (Mo) on the
basis of histopathological and biochemical parameters
against isoproterenol (ISP)-induced myocardial infarction in
rats. Wistar albino rats (150–200 g) were divided into five
groups: sham control, ISP control, and Mo treatment groups.
Mo was administered at doses of 100, 200 and 400 mg/kg,
orally for 30 d. On day 29th and 30th the rats of ISP control
and Mo treatment groups were administered ISP (85 mg/kg),
subcutaneously at an interval of 24 h. On the 31st d hemody-
namic parameters were recorded and the hearts were subse-
quently removed and processed for histopathological and
biochemical studies. Myocardial damage determination was
done by direct staining using tri-phenyl tetrazolium chloride
(TTC) in phosphate buffer saline. Myocardial enzyme lactate
dehydrogenase (LDH), markers of oxidative stress: reduced
glutathione (GSH), superoxide dismutase (SOD), and
thiobarbituric-acid reactive substances (TBARS) were esti-
mated. Histopathological examination was done for all
groups. On morphological examination normal saline control
group exhibited myocardial tissue stained brick red (Forma-
zan of TTC and LDH) in contrast to ISP group which showed
patches of unstained regions (leakage of LDH from myocar-
dial tissue due to oxidative stress). Infarct like lesions were
produced in ISP-treated group with the accompanying fall in
LDH, GSH, SOD and rise in lipid peroxidation marker
TBARS as compared to normal saline group, which is statis-
tically significant (P < 0.05). Significant improvement (P <
0.05) of biochemical parameters and histopathological asses-
sment in Mo-treated groups confirmed the protective effects
of Mo on the myocardium. Mo at 200 mg/kg dose was found
to be the most optimal in functional recovery of the heart and
favorable restoration of biochemical and histopathological
alterations.
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Abstract N° C65
Cardioprotective effect of an indigenous drug:
glycyrrhiza glabra in experimentally induced
myocardial infarction
S.K. Ojha, M. Nandave, D.S. Arya, S.K. Gupta. Department
of Pharmacology, AIIMS, New Delhi 110 029, India
In the present study cardioprotective potential of glycyr-
rhiza glabra (Gg) has been evaluated against isoproterenol
(ISP)-induced myocardial ischemia. Gg was administered at
doses of 100, 300, 600 and 900 mg/kg orally for 30 d to
Wistar albino male rats randomly divided in sham and ISP
control and Gg treatment groups using lisinopril as standard.
On 29th and 30th d, ISP (85 mg/kg) was administered sub-
cutaneously at an interval of 24 h. On 31st day, hemodynamic
parameters were recorded and the hearts were subsequently
excised and processed for biochemical and histopathological
studies. A significant decrease in glutathione (GSH) (P <
0.05), activities of SOD, catalase (CAT), creatinine phospho-
kinase (CPK) and lactate dehydrogenase (LDH) (P < 0.01) as
well as increase in malondialdehyde (MDA) level (P < 0.01)
was observed to be restored by Gg treatment in comparison
to the ISP and sham-treated groups. However, no significant
change was observed in the activity of GSHPx and protein
levels. Left ventricular dysfunction was evidenced as a de-
crease in heart rate, left ventricular rate of peak positive and
negative pressure change and elevated left ventricular end-
diastolic pressure in the ISP control group. Gg significantly
restored heart rate and left ventricular function in comparison
to ISP and lisinopril group. The significance of these results
are implicated in relation to cardioprotective effects of Gg in
ISP induced myocardial ischemia. Among the different doses
studied, Gg at 100 mg/kg dose produced maximum cardio-
protective effect. Restoration of endogenous antioxidants as
well as significant restoration of the altered hemodynamic
parameters may contribute to its cardioprotective effect.
Abstract N° C66
Cardiovascular effects of danshen extract and its
magnesium tanshinoate B enriched form
S.W.S. Leung, R.Y.K. Man. Department of Pharmacology,
The University of Hong Kong, HKSAR, China
The Chinese medicine, danshen, is the dried root and
rhizome of Salvia miltiorrhiza Bunge (Labiatae) and has
been used as a health supplement to protect against the
development of hypertension and myocardial infarction. One
of its major active water-soluble components is magnesium
tanshinoate B (MTB). The present study examines and com-
pares the cardiovascular effects of the water-soluble extract
of danshen (SME) and its MTB enriched form containing
70% of MTB (MTB70) in anaesthetized rats. Rats were
subjected to intravenous infusion of saline and phenylephrine
to produce a basal state of normal and elevated blood pres-
sure, respectively. Different doses of SME, MTB70 or its
vehicle were then injected intravenously in rats and their
effects on blood pressure were monitored. Our results indi-
cate that both SME and MTB70 transiently reduce blood
pressure in a dose-dependent manner. Independent of the
initial blood pressure state, SME caused a smaller reduction
in blood pressure than MTB70. While the effect of SME was
similar in rats infused with saline or phenylephrine, MTB70
reduced blood pressure to a greater extent in rats infused with
phenylephrine compared to those infused with saline. From
these findings, it appears that MTB is one of the major
components responsible for the cardiovascular effects of
danshen, and its beneficial cardiovascular effect is enhanced
in conditions with elevated blood pressure. In view of the
highly variable content of danshen extract, standardization of
danshen preparation is essential to ensure consistent pharma-
cological actions. Therefore, our data suggests that the
amount of MTB might be employed as a standard reference
for the preparation of danshen as a therapeutic agent, espe-
cially in the treatment of cardiovascular disorders.
Abstract N° C67
Comparison of vasodilatation between quercetin and
rutin in the isolated rat thoracic aorta
X.M. Zhou a,b, H.D. Jiang c, H. Yao a, C.M. Cao a, Q. Xia a.
a Department of Physiology, Zhejiang University School of
Medicine, Hangzhou. b Department of Physiology, Jiaxing
College Medical School, Jiaxing. c College of
Pharmaceutical Sciences, Zhejiang University, Hangzhou,
China
To determine the possible difference in vascular effect of
rutin and quercetin (Que), we investigated the vasodilatation
of rutin and Que on the isolated rat thoracic aorta rings. Rutin
at range of 10–150 µmol/l caused dose-dependent vasore-
laxation in endothelium-intact rings preconstricted with phe-
nylephrine (PE, 10 µmol/l), but had no effect in aorta rings
without endothelium. Que (10–150 µmol/l) caused
endothelium-independent relaxation of aorta rings precons-
tricted with PE in a dose-dependent manner. Pretreatment
with l-NAME (0.1 mmol/l), an inhibitor of nitric oxide syn-
thase, abolished the vasorelaxation by rutin, but did not
influence the vasodilating effect of Que in endothelium-
intact rings. Pretreatment with methylene blue (10µ mol/l) as
well as 1H-[1,2,4]-oxadiazole-[4,3-a]-quinoxalin-1-one
(ODQ, 100 µmol/l), inhibitors of guanylyl cyclase, canceled
the vasorelaxation both by Que and rutin. Administration of
indomethacin (10 µmol/l), an inhibitor of cyclooxygenase,
attenuated the vasodilatation of Que, but did not affect the
vascular effect of rutin. The results indicate that the vasore-
laxation by rutin in rat aorta ring is mediated by nitric oxide-
guanylyl cyclase pathway, while the vascular effect of Que is
via cyclooxygenase-dependent pathway, suggesting glycosyl
groups in the structure of rutin may be the determinant factor
in the different vascular effect. (Supported by TCM Bureau
of Zhejiang Province, G20010358.)
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Abstract N° C68
Mechanisms responsible for the acute relaxation of
porcine left anterior descending coronary artery by
diosgenin
A.L.S. Au a, C.C. Kwok a, A.T.C. Lee a, Y.W. Kwan a,
M.M.S. Lee b, R.Z. Zhang c, S.M. Ngai d, S.M.Y. Lee e,
G.W. He c, K.P. Fung b,e. a Department of Pharmacology,
Faculty of Medicine, The Chinese University of Hong
Kong, Shatin, Hong Kong SAR, PR China. b Department of
Biochemistry, Faculty of Medicine, The Chinese University
of Hong Kong, Shatin, Hong Kong SAR, PR China. c
Department of Surgery, Faculty of Medicine, The Chinese
University of Hong Kong, Shatin, Hong Kong SAR, PR
China. d Department of Biology, Faculty of Medicine, The
Chinese University of Hong Kong, Shatin, Hong Kong
SAR, PR China. e Institute of Chinese Medicine, The
Chinese University of Hong Kong, Faculty of Medicine,
Shatin, Hong Kong SAR, PR China
The objective of this study was to determine the in vitro
vasodilating effect of diosgenin, a plant-derived sapogenin
(phytoestrogen) that is structurally similar to progesterone,
in porcine resistance left anterior descending coronary artery
(tertiary branch, O.D. ~ 500 µm). In 5-hydroxytryptamine
(3 µM) pre-contracted preparation, diosgenin caused a
concentration-dependent, endothelium-independent relaxa-
tion (0.03–1 µM) with a maximum relaxation of ~72% at
1 µM. Diosgenin-elicited relaxation was not altered by ICI
182,780 and mifepristone. The iberiotoxin-sensitive, Ca2+-
activated K+ (BKCa) current of single vascular myocytes
record was markedly enhanced by diosgenin, 17b-oestradiol
and progesterone. KT 5823 (300 nM) pre-treatment eradica-
ted the enhancement of BKCa amplitude by these three com-
pounds. In oestrogen competition essay using human breast
cancer cell (MCF-7 cells), diosgenin (0.001–10 µM) did not
interact with nuclear oestrogen receptor and no competition
with 3[H]-oestradiol binding was observed. In conclusion,
diosgenin possesses an endothelium-independent coronary
artery relaxation effect via the protein kinase G signalling
cascade and activation of the BKCa channel. In addition,
neither the oestrogen nor progesterone receptors are involved
in mediating diosgenin-elicited vascular response.
Abstract N° C69
Cholesterol-enriched diet leads to increased oxidative
stress and cardiac dysfunction in apoB100 transgenic
mice
Tamás Csont a, Péter Bencsik a, Erika Bereczkib,
Csaba Csonka a, Annamária Ónody a, Gabriella Fodor a,
Zoltán Giricz a, Miklós Sántha b, Péter Ferdinandy a.
a Department of Biochemistry, University of Szeged,
Szeged, Hungary. b Institute of Biochemistry, Biological
Research Center, Cardiovascular Research Group,
University of Szeged, Szeged, Hungary. *Corresponding
authors.
Hypercholesterolemia is a major factor in the develop-
ment of arteriosclerosis, however, its direct myocardial ef-
fects are poorly understood. To determine the direct effect of
hypercholesterolemia on cardiac performance and oxidative
stress, wild type and apoB100 transgenic mice were fed 2%
cholesterol-enriched or normal diet for 18 weeks. Cardiac
performance was assessed in isolated working hearts. There
was no significant difference in aortic flow between wild-
type and apoB100 transgenic mice fed normal diet (0.24 ±
0.02 vs. 0.26 ± 0.02 ml/min/g body weight). In cholesterol-
fed groups, aortic flow was not affected in wild types, howe-
ver, it was decreased in apoB100 transgenic (0.22 ± 0.02 vs.
0.14 ± 0.03 ml/min/g body weight, P < 0.05). Cholesterol-
enriched diet increased cardiac superoxide generation as-
sessed by lucigenin-enhanced chemiluminescence assay in
apoB100 transgenic mice (from 23 ± 9 to 73 ± 19 cpm/mg, P
< 0.05) but not in wild types (22 ± 7 vs. 26 ± 5 cpm/mg). The
peroxynitrite decomposition catalyst FeTPPS (20 mg/kg i.p.
injections 24 and 1 h prior to isolation of the heart) attenuated
the decrease in aortic flow in apoB100 transgenic mice fed
cholesterol-enriched diet (0.23 ± 0.02 ml/min/g body wei-
ght). We conclude that hypercholesterolemia induced by
cholesterol-enriched diet leads to increased oxidative stress
and subsequent cardiac dysfunction in the hearts of apoB100
transgenic mice.
Abstract N° C70
Effect of chronic carnitine supplementation on
myocardial metabolism and function in uraemia
Veena Reddy, Sunil Bhandari, Anne-Marie L. Seymour.
Department of Biological Sciences, University of Hull, UK
Cardiac complications are the major cause of mortality in
patients with chronic renal failure. Secondary carnitine defi-
ciency frequently occurs in chronic uraemia and can lead to
impaired myocardial fatty acid metabolism. In addition,
myocardial carnitine deficiency has been associated with
cardiac hypertrophy and heart failure. The aim of this study
was to determine the impact of chronic carnitine supplemen-
tation on cardiac function and oxidative fluxes in experimen-
tal uraemia using 13C NMR spectroscopy. Uraemia was indu-
ced in male Sprague–Dawley rats via a two-stage 5/6
nephrectomy. l-Carnitine was administered (5 mM,
0.25 µl/h) over a 3-week period by means of subcutaneous
mini-osmotic pumps. Three weeks after surgery, hearts were
perfused in the isovolumic mode with Krebs–Henseleit buf-
fer containing physiological concentrations of substrates in-
cluding 5 mM 1-13C glucose and 0.3 mM U-13C palmitate.
Following carnitine supplementation, palmitate oxidation in-
creased significantly in uraemic hearts compared to its
controls, and was associated with a small increase in rate
pressure product (RPP). Carnitine supplementation also re-
sulted in a significant improvement in haematocrit in urae-
mia. In conclusion, chronic carnitine supplementation im-
proves long chain fatty acid oxidation and function in the
uraemic heart.
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Abstract N° C71
Acute carnitine supplementation modifies cardiac
efficiency
Veena Reddy, Sunil Bhandari, Anne-Marie L. Seymour.
Department of Biological Sciences, University of Hull, UK
Cardiac complications are the major cause of mortality in
patients with chronic renal failure. Secondary carnitine defi-
ciency frequently occurs in chronic uraemia and can impair
myocardial fatty acid metabolism. In addition, myocardial
carnitine deficiency has been associated with cardiac hyper-
trophy and heart failure. The aim of this study was to deter-
mine the impact of acute carnitine supplementation on car-
diac function and oxidative fluxes in experimental uraemia
using 13C NMR spectroscopy. Uraemia was induced in male
Sprague–Dawley rats via a two-stage five or six nephrec-
tomy. Six-weeks post surgery, hearts were perfused in the
isovolumic mode with Krebs–Henseleit buffer containing
physiological concentrations of substrates including 0.3 mM
U-13C palmitate, ± 5 mM l-carnitine. Despite comparable
cardiac function and substrate selection, myocardial oxygen
consumption (MVO2) was significantly lower in both control
and uraemic hearts, following acute carnitine supplementa-
tion. This resulted in a marked increase in cardiac efficiency
(rate pressure product (RPP)/MVO2). In conclusion, acute
carnitine supplementation enhances cardiac efficiency in
both control and uraemic hearts.
Abstract N° C72
PPARa, free fatty acids and mitochondrial UCP3 in
mouse heart
Andrew J. Murray, Marcello Panagia, David Hauton,
Geoffrey F. Gibbons, Kieran Clarke. University of Oxford,
Oxford, UK
Diabetic patients have been shown to have abnormal car-
diac energetics, which correlated with high levels of plasma
free fatty acids (FFAs). We hypothesized that the high plasma
FFAs had increased uncoupling protein 3 (UCP3) levels in
heart by activating the nuclear transcription factor peroxi-
some proliferator-activated receptor a (PPARa). To test this
hypothesis we used western blotting to measure UCP3 in
mitochondria isolated from the hearts of PPARa null mice
and mouse models of diabetes. In the PPARa null mouse,
cardiac levels of UCP3 were 33% lower than in controls,
suggesting that cardiac UCP3 was indeed under PPARa
control. In confirmation, treatment with the PPARa-specific
agonist, WY-14,643, did not alter UCP3 levels in PPARa null
mice, but increased UCP3 levels in control mice by 54%. In
the type 2 diabetic (db/db) mouse, which had 50% higher
plasma FFA levels than control mice, cardiac levels of UCP3
were increased 38%. Streptozotocin (STZ) injection, which
increased circulating FFAs by 91%, increased cardiac UCP3
levels by 50% in control mice, but not in PPARa null mice.
We conclude that cardiac UCP3 levels were increased by
high concentrations of plasma FFAs, controlled via PPARa.
High levels of UCP3 decrease cardiac efficiency (work/O2
consumption) and may underlie the energetic deficiency of
the diabetic heart.
Abstract N° C73
Plasma free fatty acids and energy depletion in failing
human hearts
Andrew J. Murray a, Russell E. Anderson b,
Gillian C Watson a, George K. Radda a, Kieran Clarke a.
a University of Oxford, Oxford, UK. b Karolinska Hospital,
Stockholm, UK
In vivo 31P NMR spectroscopy of the failing human heart
has shown a decreased phosphocreatine/ATP ratio, indica-
ting a lowered energy status. The extent of this energy deficit
correlated inversely with plasma free fatty acid (FFA) levels.
We propose that the energetic defect in heart failure origina-
tes from increased mitochondrial uncoupling and decreased
substrate availability caused by high circulating FFA concen-
trations, which increase mitochondrial uncoupling protein
(UCP) and decrease insulin-sensitive glucose transporter,
GLUT4, levels in human heart. Plasma samples, for the
measurement of FFA concentrations, and right atrial appen-
dage and skeletal muscle biopsies were obtained from 39
patients undergoing coronary artery bypass surgery. Immu-
noblotting was used to quantify UCP2 and UCP3 levels in
isolated cardiac mitochondria and GLUT4 protein levels in
whole tissue. Positive correlations were found between fas-
ting plasma FFA concentrations and cardiac UCP2 (r = 0.64;












30.2 ± 13 24.9 ± 6.3 30.4 ± 6.2 29.9 ± 2.4
Palmitate oxidation (%) 26.3 ± 8.1 29.9 ± 7.7 22.3 ± 4.2 31.1 ± 7.3 *
Haematocrit (%) 39.1 ± 2.2 31.4 ± 3.1 39 ± 4.2 36 ± 3.4 **
* Compared to its control; P ≤ 0.05.












24.2 ± 0.4 21.6 ± 0.2 28.3 ± 2.2 23.6 ± 3.0
MVO2 (µmol/min/g dry
heart weight)
17.7 ± 0.8 16.9 ± 2.9 11.5 ± 1.2
*
10.9 ± 2.2 *
Cardiac efficiency × 103 1.4 ± 0.2 1.4 ± 0.2 2.6 ± 0.3 * 2.6 ± 0.4 *
* P < 0.05 compared to corresponding baseline group.
Mouse model (n = 5) Plasma FFAs (mM) Relative cardiac
levels of UCP3
Control 0.35 ± 0.03 1 ± 0.13
PPARa null 0.27 ± 0.05 0.67 ± 0.05 *
Control + WY-14,643 0.43 ± 0.01 1.54 ± 0.18 *
PPARa null + WY-14,643 0.38 ± 0.02 0.60 ± 0.08 *
Type 2 diabetic (db/db) 0.53 ± 0.02 ** 1.38 ± 0.03 **
Control + STZ 0.67 ± 0.07 ** 1.5 ± 0.04 *
PPARa null + STZ 0.80 ± 0.06 ** 0.67 ± 0.05 *
* P < 0.05 compared with control.
** P < 0.01 compared with control.
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correlations were found between plasma FFA concentrations
and GLUT4 in cardiac (r = 0.58; P < 0.0001) and skeletal
muscle (r = 0.53; P < 0.001). This study indicates that the
energy deficient state, characteristic of human heart failure,
may result from two main factors; firstly, increased mito-
chondrial UCPs that cause less efficient ATP synthesis, and
secondly, depleted GLUT4 that decreases the availability of
glucose as an energy-producing substrate for the heart.
Abstract N° C74
Translocation of glucose transporters and hexokinase
in response to insulin and no-flow ischaemia in the
heart
K.A.B. Davey a, R. Southworth b, A. Warley a,
P.B. Garlick a. b Imaging Sciences and Analytical Electron
Microscopy, GKT School of Medicine, London, UK. *
Corresponding author.
Immunogold electron microscopy (IGEM) provides spa-
tial information on intracellular protein location beyond the
distributions provided by western blotting. We have used
IGEM to characterise the response of myocardial GLUT 1
and 4 and hexokinase (HK) I and II to ischaemia and insulin.
Hearts (n = 3/group) were perfused with Krebs buffer for 1 h,
followed by a further 30 min of: control perfusion; insulin
stimulation (1IU/l); or no-flow ischaemia. Hearts were
perfusion-fixed (2% formaldehyde + 0.2% glutaraldehyde),
and cryosections were double-labelled for GLUT1 and 4 or
HKI and II. Labelling was quantified relative to membrane
length or compartment volume to give labelling density
(LD). HKI and GLUT1 remained unchanged in all groups.
Capillary membranes contained the majority of GLUT1
(0.41 ± 0.01 golds µm–1) while sarcolemmal and T-tubule
membranes each contained 0.12 ± 0.05 golds µm–1 (mean ±
SEM). HKI was located on the mitochondrial membranes
with an LD of 0.05 ± 0.01 golds µm–1. GLUT4 and HKII
distributions are summarised below:
Insulin- and ischaemia-mediated HKII binding to the mi-
tochondrial membrane allows HK direct access to mitochon-
drial ATP. The close proximity of many of the mitochondria
to either the T-tubules or the sarcolemma means that the
GLUT4-transported glucose can be delivered extremely rapi-
dly to the mitochondrial bound HKs.
Abstract N° C76
Insulin preserves endothelial-dependent coronary
function in a canine model of myocardial ischemia and
reperfusion
Feng Gao, Heng Ma, Jian H. Huo, Rong He, Ling Dong,
Jia Li, Hai F. Zhang, Xin L. Ma. Department of Physiology,
Fourth Military Medical University, Xi’an, China
Accumulating evidence has suggested that insulin is an
important endogenous vasomotion modulator in addition to
its classical actions to coordinate glucose homeostasis. The
objective of the present study was to evaluate whether insulin
exerts protective effect against reperfusion-induced coronary
endothelial dysfunction in dogs. Anesthetized dogs were
subjected to 45 min myocardial ischemia (MI) followed by
3 h of reperfusion (R), and randomized to receive vehicle (i.v.
infusion at the rate of 1.5 ml/kg/h beginning at 5 min before
R), glucose–insulin–potassium (GIK) or GK.At the end of R,
1.5–2 mm coronary segments distal to the site of occlusion
were removed, mounted and perfused in wire myographs.
Endothelium-dependent relaxations to acetylcholine (ACh,
10–1210–6 M) were determined in arteries pre-contracted by
endothelin (10–8 M). I/R induced a marked decrease in the
coronary responses to ACh (maximal relaxations: sham: 62 ±
7%, n = 5; I/R + vehicle: 40 ± 8%, n = 8, P < 0.05). This
impaired response was partially restored by the treatment
with GIK (53 ± 6%, P < 0.05 vs. vehicle, n = 10), but not GK
(37 ± 5%, P > 0.05 vs. vehicle, n = 10). Western blot showed
the enhanced phospho-eNOS expression (P < 0.01 vs. vehi-
cle, n = 3) of coronary arteries. Moreover, incubation of
coronary arterial segments with insulin (10–10 to 10–7 M)
elicited a concentration-dependent increase of nitric oxide
production in culture medium, with maximal increase of
132% (P < 0.01, n = 5). Taken together, these data shows that
GIK/insulin preserves the endothelial-dependent coronary
function during MI/R which is, partly at least, attributed to
the insulin-induced increase of endothelial release of nitric
oxide.
Abstract N° C77
Palmitate oxidation does not jeopardise function in the
ageing heart
Jessica Sample, John G.F. Cleland,
Anne-Marie L. Seymour. Department of Biological
Sciences and Cardiology, University of Hull, UK
Recent evidence has shown that ageing predisposes the
heart to failure and an enhanced susceptibility to stress in-
jury. However, the underlying cellular mechanisms are
unclear. Metabolic studies in the failing hypertrophied heart
have identified a shift in substrate utilisation from fatty acids
to glucose. Adaptations in the ageing heart are thought to
parallel closely those observed in cardiac hypertrophy. The-
refore, the aim of this study was to investigate palmitate
oxidation in the ageing heart and determine whether metabo-
lic adaptations predispose the ageing heart to stress injury.
Oxidative flux using 13C NMR and cardiac function were
investigated in hearts from 6 months (n = 29) and 24 months
Location Control LD Insulin LD Ischaemia LD
GLUT4 (golds µm–1)
Sarcolemma 0.02 ± 0.02 0.05 ±0.04 0.16 ±0.04
T-tubule membranes 0.06 ± 0.01 0.15 ±0.01 0.17 ± 0.04
Vesicles (golds µm–2) 3.16 ± 0.52 1.36 ± 0.12 1.11 ± 0.20
HKII (golds µm–1)
Mitochondrial membranes 0.04 ± 0.04 0.08 ± 0.01 0.14 ± 0.05
Vesicles (golds µm–2) 9.25 ± 1.77 6.00 ± 1.91 6.92 ± 1.17
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(n = 23) rats. Hearts were perfused in an isovolumic mode
with buffer containing 3% albumin and a physiological mix-
ture of substrates including low (0.3 mM) (LP) or high
(1.2 mM) (HP) U-13C palmitate, ± 40 µg/l dobutamine (D).
Cardiac function and efficiency were preserved with age
under baseline conditions, HP and HP+D. However, there
was a significant decline (–18.0 ± 11.0%, P < 0.05) in
efficiency in the 6 month hearts perfused with HP+D with a
concurrent fall in developed pressure. Palmitate oxidation
was significantly greater in 24 month hearts perfused with LP
relative to 6 months, but at HP, palmitate oxidation was
significantly lower in the 24 month hearts. HP+D further
increased palmitate oxidation in the aged hearts.
Thus, alterations in palmitate oxidation do not jeopardise
cardiac function nor enhance susceptibility to dobutamine
induced stress in ageing hearts.
Abstract N° C78
Pyruvate augments phosphorylation potential and
glutathione redox state of arrested myocardium
Robert T. Mallet, Arti B. Sharma, E. Marty Knott, Jian Bi,
Rodolfo Martinez. Jie Sun University of North Texas Health
Science Centre, Fort Worth, TX, USA
Purpose. – The natural carbohydrate pyruvate increases
energy state, antioxidant defenses and contractile perfor-
mance of isolated and in situ hearts. We tested whether
pyruvate could restore energy and antioxidant reserves of
arrested myocardium during internal CPR and following
recovery of spontaneous circulation (ROSC).
Methods. – Open-chest, anesthetized beagles were sub-
jected to 5 min cardiac arrest and 5 min cardiac massage (80
compressions/min; aortic pressure 60–70 mm Hg), then defi-
brillated (5 J epicardial DC countershocks). Pyruvate (pyr) or
NaCl control was infused i.v. (0.125 mmol/kg/min) from
4 min arrest to 25 min ROSC. Energy metabolites (phospho-
creatine, creatine and inorganic phosphate), glutathione
(GSH) and glutathione disulfide (GSSG) were measured in
snap-frozen biopsies of the anterior wall to determine phos-
phocreatine phosphorylation potential (~PCr; M–1), a
measure of myocardial energy reserve, and glutathione redox
state (GSH/GSSG).
Results. – (Table 1: mean ± SEM, n = 6–8; *P < 0.05 vs.
pre-arrest; §P < 0.05 vs. NaCl): Cardiac arrest severely deple-
ted myocardial energy and GSH antioxidant reserves. CPR
partially restored energy and GSH redox states; pyruvate
increased energy state even further. At 25 min ROSC, pyru-
vate augmented myocardial contractility (+ dP/dt, mm Hg/s)
and GSH redox state.
Conclusion. – Pyruvate accelerates myocardial energetic
and antioxidant recovery during CPR and ROSC.
Abstract N° C79
Pyruvate supplementation ameliorates ex vivo cardiac
dysfunction in GLUT4 deficient mice
C.E. Huggins a, N. Khalil a, J. Proietto b, S. Pepe a,
L.M.D Delbridge a. a University of Melbourne, Melbourne,
Australia. b Alfred Hospital and Baker Heart Research
Institute, Melbourne, Australia. * Corresponding authors.
Deficiency of the insulin-stimulated GLUT4 transporter
impairs cardiomyocyte glucose uptake. Reduced availability
of glucose in the heart has been associated with development
of cardiac hypertrophy and contractile dysfunction in insulin
resistance. Pyruvate, a metabolic product of glycolysis and
an oxidizable fuel in the heart elicits a positive inotropic
response when administered after ischemia. The goal of this
study was to investigate if pyruvate could ameliorate cardiac
contractile dysfunction associated with GLUT4 deficiency in
the basal state. We investigated the GLUT4 knock-out
(GLUT4-KO) mouse model (cardiac specific) and littermate
controls, which show a global GLUT4 knock-down
(GLUT4-KD), and wild-type C56Bl/6 control mice (WT).
Left ventricular function was measured ex vivo in
Langendorff-mode perfused hearts using a fluid-filled bal-
loon and pressure transducer (MLT884) (Krebs–Henseleit
buffer, 37 °C). Under standardized diastolic pressure condi-
tions GLUT4-KO hearts showed significantly reduced deve-
loped pressure and rate of pressure decline compared to
GLUT4-KD and WT hearts (54 ± 12, 104 ± 8, 160 ±
6 mmHg, –1.9 ± 0.5, –3.4 ± 0.4, –4.67 ± 0.2 mmHg/ms, P <
0.05). Heart rate and rate of pressure development were
significantly reduced in GLUT4-KO compared to WT hearts
only (313 ± 33 vs. 413 ± 11 bpm, 3.9 ± 0.5 vs. 6.2 ±
0.4 mmHg/ms, P < 0.05). GLUT4-KO response to pyruvate
supplementation (5 mM) was significantly enhanced compa-
red to GLUT4-KD and WT mice. GLUT4-KO mice showed
a 22% increase in developed pressure, a 12% increase in rate
of pressure development and a 32% increase in rate of pres-
sure decline on addition of pyruvate. Our findings suggest
pyruvate supplementation ameliorates cardiac dysfunction
associated with GLUT4 deficiency, by bypassing the glyco-
lysis pathway and restoring cardiac energy reserves and sub-
sequently enhancing cardiac performance.
Abstract N° C80
Aspartic acid and mannitol enhance efficacy of the St.
Thomas cardioplegic solution
O.I. Pisarenko, V.A. Shulzhenko, I.M. Studneva,
A.A. Timoshin. Cardiology Research Centre, Moscow, Russia
The aim of this work was to assess effects of a modified St.
Thomas’ Hospital cardioplegic solution (MSTS) on postis-
% Palmitate oxidation
n 0.3 mM (LP) 1.2 mM (HP) 1.2 mM (HP+D)
24 months 5 38.0 ± 8.7 63.6 ± 4 74.5 ± 6.9
6 months 6 25.4 ± 7.1 * 82.3 ± 7.6 n.d.
P < 0.05, 6 m vs. 24 m LP; P < 0.001, 6 m vs. 24 m HP; * n = 11.
+dP/dt ~PCr GSH/GSSG
Pre-arrest 3200 ± 130 174 ± 19 23 ± 2
5 min arrest – 3.0 ± 0.8 * 9.3 ± 0.9 *
CPR + NaCl – 30 ± 6 * 15 ± 2 *
CPR + pyr – 63 ± 15 *,** 20 ± 1
ROSC + NaCl 2410 ± 170 * 176 ± 31 20 ± 3
ROSC + pyr 3290 ± 260 ** 238 ± 24 * 32 ± 3 **
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chemic metabolic and functional recovery of isolated rat
heart. The St. Thomas’ Hospital cardioplegic solution no. 2
(pH 7.8 ± 0.1 at 22 °C) was used as a control (STS). MSTS
additionally contained 21.5 mM aspartic acid and 20.0 mM
mannitol, pH was 7.6 ± 0.1 at 22 °C. Osmolarity of both
cardioplegic solutions was 340 ± 5 mOsm. After 20 min
initial perfusion according to Neely the hearts were subjected
to 40-min normothermal total ischemia followed by 30-min
reperfusion. Cardioplegic solutions were infused prior to
ischemia at rate of the initial coronary flow for 5 min at room
temperature. After ischemia MSTS treated hearts exhibited
1.4-fold less lactate accumulation and significantly better
preservation of ATP and phosphocreatine (PCr) compared
with these indices in control. By the end of reperfusion the
hearts of MSTS group completely recovered coronary flow
(to 98 ± 3% of the initial value vs. 77 ± 3% in the control, P
< 0.02) and showed better restoration of cardiac work and
pressure–rate product (to 64 ± 3% and 72 ± 6% of the initial
values, respectively, vs. 12 ± 2% and 24 ± 5% and in the
control, P < 0.01). The hearts treated with MSTS recovered
contents of PCr and lactate to the preischemic values and
restored ATP level up to 65.2 ± 4.6% of initial one comparing
with 40.5 ± 3.2% in the control at the end of reperfusion. The
hearts protected by MSTS showed a markedly reduced for-
mation of (5,5′-dimethyl-1-pyrroline-N-oxid)-OH, a hy-
droxyl radical adduct at the early reperfusion assessed by
spin-trap measurements. Therefore in an isolated rat heart
model MSTS provides substantially superior protection
against ischemia/reperfusion stress compared to STS.
Abstract N° C81
Measurement of IMP in purine mixtures
Sylvia Thomas, Thomas Podzuweit. Max-Planck Institute,
Bad Nauheim, Germany
Ischaemia induced catabolism of adenine and guanine
nucleotides produces an array of purine nucleotides, nucleo-
sides and bases, analysis of which provides information
about the enzymatic reactions involved. Most purines can be
quantitated by reversed phase high performance liquid chro-
matography (RP-HPLC) with UV absorbance. A problem is
the measurement of small amounts of inosine 5′-
monophosphate (IMP) in the presence of ATP as both nu-
cleotides co-elute. We searched for a method that allows
accurate assay of IMP without changing the HPLC condi-
tions. We noticed that ATP and ADP are acid labile. Both
nucleotides were readily dephosphorylated in 6% perchloric
acid (PCA). Acid hydrolysis affected primarily the gamma
and beta phosphates. Under the conditions chosen, the mono-
phosphates AMP and IMP were stable. The AMP content of
acidic extracts increased with time due to hydrolysis of its
precursor ADP. The IMP content remained constant. IMP
was neither formed nor degraded in acid milieu. Importantly,
deamination of AMP–IMP did not occur. The acid hydrolysis
of ATP was temperature dependent. Dephosphorylation was
complete after 8 h at 37 °C and 24 h at ambient temperature.
These observations facilitate the measurement of IMP in
tissue extracts by RP-HPLC. The following procedure is
recommended. Specimens were extracted in 6% PCA. Fol-
lowing centrifugation, the acid supernatants were divided.
One part was neutralized with 5 N KOH. The other part was
kept 24 h at room temperature. Analysis was by RP-HPLC.
The neutralized supernatant was analysed directly (all puri-
nes) and the acid extract next day (IMP). The present study
provides a method for the measurement of IMP in complex
purine mixtures by RP-HPLC, which is known for deficient
separations of ATP and IMP. To obviate modifications of the
chromatographic conditions, the co-eluting ATP was hydro-
lysed with 6% PCA prior to HPLC. As PCA is commonly
used for tissue extractions, it is important to recognize that
the preservation of acid labile nucleotides for subsequent
analysis requires instant neutralisation.
Abstract N° C82
Inihibition of aldose reductase prevents carotid artery
restensosis in diabetic rats
Sanjay Srivastava, Aruni Bhatnagar. Division of Cardiology,
Department of Medicine, and Institute of Molecular
Cardiology, University of Louisville, Louisville, KY 40202,
USA
Diabetes is a significant risk factor for cardiovascular
disease and a predictor of restenosis, but the mechanisms by
which diabetes affects vascular response to injury remain
unknown. We tested the hypothesis that aldose reductase
(AR) activity is a key determinant of diabetic vascular res-
ponses to injury. The study group consisted of 20 non-
diabetic and 20 diabetic rats. Diabetes was induced by a
single injection of streptozotocin (55 mg/kg, i.p.). Six weeks
after streptozotocin treatment left carotid artery of non-
diabetic and diabetic animals were injured by balloon wi-
thdrawal. One day before the injury and throughout the
observation time, 10 rats in each group were gavage-fed with
AR-inhibitor tolrestat. Ten days after the injury, the injured
arteries of streptozotocin-diabetic rats displayed >35% grea-
ter abundance of AR as compared to the injured carotid
arteries of non-diabetic rats. In diabetic rats, intimal expan-
sion was >30% higher at 10 d of injury and >50 higher at 21 d
of injury as compared to the corresponding non-diabetic rats.
Ten days after the injury, a greater number of cells (30–50%)
in 10-d old diabetic neointima were stained with antibodies
against proliferating cell nuclear antigen (PCNA), a-actin,
and activated NF-∏B. At 21 d after the injury, PCNA, a-actin
and AR staining of the diabetic neointima were comparable
to non-diabetic rats. Treatment with the AR inhibitor tolrestat
decreased neointima formation and the number of PCNA,
a-actin, and activated NF-jB-positive cells in diabetic le-
sions. In injured carotid arteries, tolrestat treatment increased
the abundance of protein adducts with the lipid peroxidation
product—4-hydroxy trans-2-nonenal. These results suggest
that vascular inflammation and responses to injury are exag-
gerated during diabetes and that these responses are preven-
ted by inhibiting AR.
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Abstract N° C83
NRF1 Inhibits USF1- dependent induction of the
cardiac isoform of acetyl-CoA carboxylase
S. Makaula a, T. Adam a, N. Manga b, M. Young a,
M.F. Essop a. a Hatter Institute, UCT, South Africa.
b Institute of Molecular Medicine, Houston, TX, USA. *
Corresponding author.
Previous studies have shown that 5′-AMP activated pro-
tein kinase (AMPK) is upregulated with hypoxia. Moreover,
AMPK inhibits the cardiac-enriched acetyl-CoA carboxy-
lase isoform (ACCb), an indirect inhibitor of mitochondrial
fatty acid uptake. To further delineate its regulation in the
heart, we measured in vivo ACCb gene expression with
hypoxia and found it was significantly reduced (P < 0.05).
However, the transcriptional mechanisms directing ACCb
gene expression are poorly understood. Since AMPK activa-
tes nuclear respiratory factor 1 (NRF1), we hypothesized that
hypoxia diminishes ACCb gene expression by NRF1 activa-
tion. To evaluate this, we transiently transfected a 1317 bp
human ACCb promoter-luciferase construct (pPbII-1317)
with an NRF1 expression vector into H9c2 myoblasts. Inte-
restingly, NRF1 co-transfection diminished basal pPbII-
1317 induction by 55 ± 6% (P < 0.001). To rule out interfe-
rence of endogenous muscle-type trans-activators, we co-
transfected pPbII-1317 and upstream stimulatory factor 1
(USF1), a putative trans-activator of ACCb, into null-
background CV-1 fibroblasts and HepG2 hepatic cell lines.
Here, NRF1 inhibited USF1-dependent induction of pPbII-
1317 by ≥65% (P < 0.01). Moreover, transfection studies
using deletion constructs suggest that a putative NRF1 regu-
latory region is situated between +65 and –93 bp of theACCb
promoter region. We therefore propose that NRF1 may be a
novel repressor of ACCb gene expression during hypoxia.
Abstract N° C84
Low flow myocardial ischaemia: a metabolic balancing
act
R. Southworth, K.A. Davey, P.B. Garlick. Imaging
Sciences, Guy’s Hospital, London, UK
The energy balance involved in maintaining cell viability
during myocardial hibernation remains poorly understood;
increased 18FDG6P seen in clinical PET scans suggests that
glucose flux is crucial. Using PANDA (PET And NMR Dual
Acquisition) and immunogold electron microscopy (IGEM),
we have constructed an “energetic profile” of an isolated
heart model that, we have shown previously, exhibits many of
the clinical hallmarks of hibernation. Rat hearts (n = 4/group)
were perfused (Krebs +250 MBq 18FDG +11 mM glucose
+/– 0.4 mM oleate) for 40 min at 100% flow and 3 h at 10%
flow; 18FDG scans and 31P NMR spectra were acquired
throughout. Hearts were then fixed and the distribution of
GLUT 1, GLUT 4 and hexokinase I and II determined by
IGEM. The rate of 18FDG6P accumulation in ischaemic
tissue was the same as (glucose only, G) or higher than
(glucose+oleate, G + O) control tissue despite receiving 10%
of the flow (23 ± 2 vs. 11 ± 2 cps/g/min, G + O vs. control, P
< 0.05). In G hearts, pH decreased to 6.76 ± 0.02 and did not
recover; PCr decreased to 287 ± 9%, recovering to 39 ± 7% at
3 h and Pi increased to 467 ± 88% of preischaemic values. In
G + O hearts, pH decreased to 6.88 ± 0.02, but recovered to
6.98 ± 0.05; PCr decreased to 42 ± 14% but recovered to 68 ±
12% and Pi increased to 220 ± 53%. In response to ischae-
mia, GLUT1 did not move but GLUT4 moved from the
cytosolic vesicles to the sarcolemma and the T-tubules in all
hearts, with a larger change in the presence of oleate. In G +
O hearts, ischaemia increased sarcolemmal and T-tubule
GLUT 4, from undetectable to 0.18 ± 0.06, and from 0.05 ±
0.02 to 0.15 ± 0.04 golds µm–1, respectively. Concomitantly,
GLUT4 in cytosolic vesicles decreased from 4.38 ± 0.84 to
1.88 ± 0.30 golds µm–2. In G hearts, ischaemia translocated
hexokinase II to the mitochondria, thus increasing glycolytic
through put; this effect was not observed in the presence of
oleate. We conclude that there is sufficient O2, even at 10%
flow, to enable fatty acid oxidation; this contributes signifi-
cantly to the maintenance of both cellular energy levels and
intracellular pH.
Abstract N° C85
Preischemic intracellular glycogen as a determinant of
cardioprotective effect of ischemic preconditioning
H.-D. Kim. Department of Anatomy and Cell Biology,
Sungkyunkwan, University School of Medicine, Suwon
440-746, South Korea
Relation between preischemic intracellular glycogen
(PIG) and ischemic preconditioning (IPC) effect was as-
sessed in isolated Langendorff-perfused rabbit (1.7 kg body
weight) hearts. Hearts were subjected to 45 min global ische-
mia (I) followed by 120 min reperfusion (R), with IPC (5 min
I and 10 min R, n = 10) or not (control, n = 9). PIG content
(µmol/g tissue, mean ± S.E.), left ventricular function, lac-
tate, high-energy phosphate derivatives (HEPd) and cell via-
bility (assessed by formazan production) considered for sta-
tistical analyses. Baseline PIG before 45 min I and before
IPC were 16.12 ± 73 and 15.34 ± 63 mg/l, respectively;
lactate and HEPd were not significantly different between
groups. IPC increased recovery of LV function and cell
viability. However, these cardioprotective effect of IPC was
abolished by concurrent low PIG (10.00 ± 50 by 5 mg/l
sodium acetate, n = 10, P < 05 vs. baseline) or high PIG
(23.58 ± 1.41 by 1 unit/l insulin, n = 10, P < 01 vs. baseline)
before IPC. These results indicate that PIG before IPC may
be a key determinant for the cardioprotective effect of IPC.
Abstract N° C86
Diabetes, the hexosamine biosynthesis pathway and
protein O-glycsoylation in the heart
Norbert Fulop, Peipei Wang, Richard B. Marchase,
John C. Chatham. University of Alabama at Birmingham,
USA
The hexosamine biosynthesis pathway (HBP) consumes
2–4% of the glucose transported into the cell leading to
protein O-glycosylation. Increased flux through the HBP as
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well as increased protein O-glycosylation have been implica-
ted in diabetic complications; however, little is known about
the HBP in the heart. Therefore, we measured the level
UDP-GlcNAc, a metabolite of the HBP, in hearts from 12-
week-old male Zucker diabetic fatty (ZDF) rats and Lean
non-diabetic littermates. UDP-GlcNAc levels are increased
from 60 ± 7 in Lean to 112 ± 7 arbitrary units in the ZDF
group (P < 0.05). To evaluate the level of protein
O-glycosylation, we used CTD110 an antibody that is speci-
fic for O-GlcNAc, on protein extracts from ZDF and lean
hearts. The level of O-GlcNAc in ZDF group was clearly
increased compared to Lean (88 ± 8 vs. 65 ± 5 O.D. units; P
< 0.05). To determine the impact of altered HBP flux, hearts
from ZDF rats were perfused ± azaserine (Aza, 20 µM), an
HBP inhibitor, and hearts from Lean rats were perfused ±
glucosamine (GlcN, 5 mM), which increases HBP flux. All
hearts were subjected to low flow ischemia (30 min,
0.3 ml/min) and 60 min reperfusion. In the absence of treat-
ment, functional recovery as % of pre-ischemic level was
higher in the ZDF group compared to the Lean group (90 ±
7% vs. 74 ± 8%; P < 0.05). However,Aza reduced recovery of
the ZDF group (69 ± 6%; P < 0.05) whereas GlcN improved
recovery of the Lean group (94 ± 7%; P < 0.05). These data
show that diabetes increases HBP flux and O-glycosylation
in the heart and that this may account for the increased
recovery of function in the ZDF group following ischemia.
Abstract N° C87
Increased carbohydrate oxidation and decreased fatty
acid oxidation do not improve cardiac function after
ischemia
Peipei Wang, Steven G. Lloyd, John C. Chatham.
Department of Medicine, University of Alabama,
Birmingham, Birmingham AL, USA
A shift from fatty acid to carbohydrate oxidation in the
heart has been reported to decrease ischemic injury. Howe-
ver, many of these reports are based on studies where glucose
is the only available carbohydrate. Therefore, we investiga-
ted whether increasing carbohydrate oxidation was protec-
tive when physiologically relevant concentrations of lactate
(1 mM) and pyruvate (0.1 mM) as well as glucose and
palmitate (0.3 mM) were available. Hearts from male Spra-
gue–Dawley rats were isolated, perfused and assigned to one
of three groups: (1) Control, glucose 5 mM, insulin
50 µU/ml; (2) +dichloroacetate (DCA), 5 mM; and (3) glu-
cose 30 mM and insulin 1000 µU/ml (HG/HI). All hearts
were subjected to low flow ischemia (30 min, 0.3 ml/min)
and 60 min reperfusion. Substrate oxidation rates were deter-
mined during reperfusion using 13C-NMR glutamate isoto-
pomer analysis. Total carbohydrate oxidation increased from
45 ± 4% of total substrate oxidation in control group to 86 ±
3% in the DCA group (P < 0.01). However, the recovery of
rate pressure product (RPP) was similar in both Control and
DCA groups (73 ± 11% and 74 ± 5%, respectively). Surpri-
singly in the HG/HI group carbohydrate oxidation was only
46 ± 2%, which was not significantly different from control.
However, % recovery of RPP was improved to 86 ± 2% (P <
0.05 vs. control). These data suggests that in the presence of
other carbohydrates, a shift from fatty acid to carbohydrate
oxidation may not be associated with improved recovery of
function following LFI.
Abstract N° C88
Oxidative and non-oxidative metabolic substrate fluxes
in normal and ischemic rat heart
Steven G. Lloyd, PeiPei Wang, Huadong Zeng,
John C. Chatham. Department of Medicine, University of
Alabama, Birmingham, Birmingham AL, USA
During acute occlusion of a coronary artery, collateral
vessels may provide 10–20% of baseline flow in the infarct
zone. However, our understanding of energy metabolism du-
ring such low flow ischemia is relatively limited. Therefore,
we developed a method using 1H/13C NMR spectroscopy and
oximetry to quantify the oxidation of up to four exogenous
substrates plus oxidative and non-oxidative glycogen metabo-
lism, during severe low flow ischemia (LFI, 0.3 ml/min).
Isolated rat hearts were perfused for 30 min under control and
LFI conditions with insulin and 13C-labeled lactate, pyruvate,
palmitate, and glucose. The results (see Table 1) show that
despite a ~50-fold reduction in substrate delivery and oxygen
consumption, during LFI oxidative metabolism accounted for
~30% of total ATP synthesis. During control perfusion, lactate
oxidation was the major source of ATP; however in LFI this
shifted to a combination of oxidative and non-oxidative gly-
cogen metabolism. These results demonstrate the importance
of oxidative energy metabolism for ATP production even
during very LFI. We believe that this approach will be valua-
ble for studies into mechanisms related to the protective effect
of increasing cardiac carbohydrate utilization.
Abstract N° C89
Effects of simultaneous antegrade and retrograde
cardioplegia on myocardial water content, cellular
compartments, and energy metabolism
Ganghong Tian, Bo Xiang, Gang Li, Tomas A. Salerno,
Roxanne De Slauriers. Institute for Biodiagnostics, NRC,
Winnipeg, Canada
We have demonstrated in our previous study that simulta-
neous antegrade/retrograde cardioplegia (SARC) improves
myocardial blood perfusion in jeopardised regions as well as
in normal region of the myocardium. The present study was
to assess the effects of SARC on myocardial water content,
the volumes of the intracellular and extracellular compart-
ments, and myocardial energy metabolism. Four isolated pig
hearts were subjected to 20-min control perfusion and 2-h
Table 1
Total, non-oxidative and oxidative, ATP synthesis rates (µmol/min/g wet
weight) in the control (con) and LFI groups
Total Non-oxidative Oxidative % oxidative
Control 21 ± 1 1.3 ± 0.2 20 ± 1 97 ± 9
LFI 1.5 ± 0.3 1.0 ± 0.2 0.5 ± 0.1 33 ± 7
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SARC. Throughout the experiment, myocardial water
content was monitored using near infrared (NIR) spectros-
copy with a NIR probe positioned over the anterior wall of
the left ventricular wall. The volume of the intracellular and
extracellular compartments and high-energy phosphates of
the hearts were followed using 31P MR spectroscopy in
conjunction with the chemical markers for the total water
space (dimethyl methylphosphonate, DMMP) and extracel-
lular space (phenylphosphonic acid, PPA). NIR spectra
showed a significant increase in water peak (62 ± 15%)
during the 2-h SARC, suggesting severe tissue edema. 31P
MR spectra exhibited significant increase in the levels of
DMMP and PPA, which translates to significant expansion of
both intracellular (35%) and extracellular (50%) compart-
ments. However, the levels of high-energy phosphates (ATP
and PCr) remained at normal levels throughout 2-h SARC.
We conclude that although SARC increases tissue water
content and enlarges the cellular compartments, it sustains
normal myocardial energy metabolism. The effect of SARC-
induced edema on cardiac contractile function, however,
remains to be investigated.
Abstract N° C90
Regional flow, oxygenation and optical tracer kinetics
assessed by near-infrared imaging in the in vivo pig
hearts
Valery Kupriyanov, Stephen Rempel-Nighswander,
Bo Xiang, Anthony Shaw. Institute for Biodiagnostics,
National Research Council, Winnipeg, Canada
We used near-infrared spectroscopic (NIRS) imaging to
assess flow dependence of heart oxygenation, mapping oxy-
to deoxy-(hemoglobin (Hb) + myoglobin (Mb)) ratios (O/D)
and intravascular tracer, indocyanine green (ICG). In open-
chest pigs nominal flow through the left anterior descending
artery was reduced to 0 (n = 6), 20 ± 1 and 44 ± 5% by
variable 90-min occlusion and restored afterwards (to 219 ±
71%) for 120 min. ECG-gated NIRS images of the heart were
obtained using a CCD-array camera with a liquid crystal
tunable filter, which acquired reflectance spectra in the range
of 650–1050 nm for each of 256 × 256 pixels (0.4 mm2).
Deoxy-, and oxy-(Hb+Mb) contents were calculated using a
spectral fitting algorithm based on their absorption spectra
between 650–890 nm. To visualize flow distribution ICG
bolus (8.3 mg/5 ml) was injected i.v. at each step of the
protocol and gated images were acquired at 800 nm every
beat over 60 s period. The ratio of ICG wash-in velocity to
equilibrium absorbance (V/Atail) was calculated. O/D and
V/Atail decreased as flow reduced in the area at risk (Table 1).
Thus oxy/deoxy measurements detected regional flow below
44% while ICG kinetics detected flow below 20%.
Abstract N° C91
Regional oxidative metabolism in complete left bundle
branch block
Taketsugu Tsuchiya, Masanobu Namura, Masatoshi Ikeda,
Shinichiro Fujita, Naohiro Yoshida, Akira Izawa,
Takahiro Higuchi. Kanazawa Cardiovascular Hospital
The recent reports discuss about that homogenization of
myocardial glucose and oxidative metabolism results in suc-
cessful cardiac resynchronization therapy (CRT) in heart
failure (HF) with complete left bundle branch block
(CLBBB). We have three responders to CRT, who also
showed homogenization of oxidative metabolism. Inhomo-
geneity of myocardial metabolism might be the independent
predictor of cardiac reverse remodeling. On the other hand,
regional metabolism in isolated CLBBB has been uncertain.
We evaluate the oxidative regional metabolism in patients
with CLBBB by measuring the monoexponential clearance
rate of [11C] acetate (kmono) with positron emission tomogra-
phy (PET). Serial CLBBB patients with HF (group A, seven
cases, five males, age 68 ± 9 years), CLBBB without HF
(group B, 12 cases, five males, age 68 ± 10 years) and HF
patients without CLBBB (group C, seven cases, five males,
age 66 ± 18 years) that consulted our hospital from January to
September 2003 underwent PET estimation. We also did
PET estimation in five volunteers (group D, five males, age
35 ± 5 years). The kmono lateral to septum ratio of groupA and
B were similar (1.18 ± 0.42 and 1.16 ± 0.10) but higher than
group C and D (0.96 ± 0.08 and 1.00 ± 0.13). Patients with
CLBBB have inhomogeneity of myocardial oxidative meta-
bolism despite of whether they have HF or not. So further
work should be necessary to clarify the relation between
improvement of HF and metabolic homogenization that CRT
results in.
Abstract N° C92
Glucagon-like peptide-1 mediated cardiac protection
against ischemia/reperfusion injury involves multiple
pro survival pathways
Amal K. Bose a, Mihaela M. Mocanu a, Richard D. Carr b,
Derek M. Yellon a. a The Hatter Institute, UCL, London,
UK. b Novo Nordisk A/S, Bagsvaerd, Denmark.
* Corresponding author.
We have shown previously that GLP-1 protects against
myocardial infarction in both in vivo and in vitro rat model.
The present study aimed to elucidate the mechanisms by
which such protection occurred. We used a Langendorff
perfused rat heart model of 30 min regional ischemia and
120 min reperfusion. The end point was the measurement of
the infarction developed in the risk zone using triphenyl-
tetrazolium chloride. The values were expressed as percenta-
ges of the area at risk (I/R%); 0.3 nM GLP-1 and 20 mg/l
valine pyrolidide (VP), an inhibitor of GLP-1 breakdown,
were added 15 min prior to ischemia and continued throu-
ghout the experiment. Our results showed that GLP-1 signi-
ficantly reduced infarct size (26.7 ± 2) vs. control (58.7 ± 4.1)
and VP alone (52.6 ± 4.7) (P < 0.001). This protection was
Step (n) Flow (%) D(O/D) vs. 0 flow V/Atail
Occlusion (5) 20 0.10 ± 0.28 0.32 ± 0.34
Occlusion (4) 44 0.76 ± 0.32 1.20 ± 0.39
Normal (9) 100 1.63 ± 0.58 1.60 ± 0.49
Reflow (9) 219 2.25 ± 0.92 1.80 ± 0.58
288 2004 ISHR World Congress / Journal of Molecular and Cellular Cardiology 37 (2004) 161-375
abolished by the GLP-1 receptor antagonist Exendin-9-39
(57.3 ± 3.8, P < 0.001) suggesting a receptor mediated
trigger. The c-AMP inhibitor Rp-cAMP also abolished the
protection (57.5 ± 5.0) suggesting the involvement of a
cAMP dependent pathway. Furthermore the protection was
abolished by the PI3kinase inhibitor LY294002 (43.4 ± 3.9)
as well as by the p42/44 MAPK inhibitor UO126 (48.3 ± 8.6)
implicating both these pro survival pathways in the cardio-
protection mediated by GLP-1. This study demonstrates that
GLP-1 protects the myocardium from ischemia reperfusion
injury via activation of a number of cellular pro survival
signaling pathways.
Abstract N° C93
Differential generation of superoxide and cytosolic
nadph by bovine pulmonary vs. coronary artery
Sachin A. Gupte, Pawel M. Kaminski, Beverly C. Floyd,
Michael S. Wolin. Department of Physiology, New York
Medical College, NY 10595, USA
Systemic and pulmonary circulatory systems have been
known to show physiologically different phenotypic charac-
teristics. However, the underlying biochemical differences
have not been sorted out. In this study, we demonstrate that
bovine pulmonary artery (PA) generated twofold more luci-
genin (5 µM) chemiluminescence detectable superoxide than
coronary artery (CA). A thromboxane receptor agonist,
U46619 (100 nM) which activates protein kinase C (PKC),
increased superoxide by 1.3-fold and 1.5-fold in the CA and
PA, respectively. Furthermore PDBu (10 µM), a PKC ago-
nist, elevated the superoxide production by fivefold in CA vs.
12-fold in PA. In addition, we have found that PA generates
4.2-fold more NADPH, which is one of the co-factor for
NAD(P)H oxidase, and 7.5-fold more NADP+ than the CA.
The pentose phosphate pathway (PPP) is the primary source
of cytosolic NADPH in many cell types and glucose-6-
phosphate dehydrogenase (G-6-PD) is a rate limiting enzyme
of PPP. Thus, examination of G-6-PD activity in PA and CA
indicated that in the PA G-6-PD was 1.5-fold more active
than in CA. Similarly, G-6-PD protein was 1.6-fold greater in
the PA than CA. Thus, PA differ from CA in that they have
higher levels of G-6-PD activity, NADPH and superoxide.
Abstract N° C94
Agonist-mediated control of adenosine receptor
transcripts in multiple cell types
Kevin J. Ashton, Grant A. Pritchard, Kirsty Holmgren,
John P. Headrick. Heart Foundation Research Centre,
Griffith University, Australia
Adenosine receptors are crucial in cardiovascular control
and cardioprotection. However, nothing is known regarding
control of their cellular expression. Using quantitative real-
time PCR we investigated agonist-mediated control of ade-
nosine receptor (ADOR) gene expression in Jurkat T-cells
and U397 and THP-1 monocyte cultures. Data reveal that
adenosine selectively modulates ADOR levels. Adenosine
(50 µM) or A1AR agonist (50 nM CPA) both reduced
ADORA1 and ADORA2A expression (2–3-fold) in Jurkat
cells after 4 h of stimulation. A3AR agonism (100 nM Cl-IB-
MECA) down-regulated ADORA1 and ADORA2A levels
(12- and 4-fold, respectively), whereas A2AAR agonism
(10 nM CGS21680) down-regulated ADORA1 (~3-fold) wi-
thout modifying ADORA2A. Conversely, ADORA2B expres-
sion was modestly enhanced by all agonists. Unfortunately
accurate ADORA3 quantitation in these cell types was limi-
ted due to its low expression. Both phosphotidylinositide
3-kinase (PI3-K) and MEK/ERK dependent pathways main-
tain ADORA1 and ADORA2A transcription, since inhibition
(100 nM wortmannin, 50 µM PD98059) virtually abolished
ADORA1 and ADORA2A expression. In contrast, MEK/ERK
represses ADORA3, since PD98059 enhanced expression
>4-fold. MEK/ERK signalling also counters stimulatory ef-
fects of adenosine on ADORA2B and ADORA3. These data
indicate that: (i) ADOR mRNA levels are differentially regu-
lated via receptor agonism; (ii) PI3-K and MEK/ERK depen-
dent paths maintain ADORA1 and ADORA2A expression;
(iii) MEK/ERK activity represses ADORA3 expression and
counters induction of ADORA2B and ADORA3 by adeno-
sine. Further studies with PKC, PKA, Raf-1 and tyrosine
kinase inhibitors, and in U937 and THP-1 cells, reveal trans-
criptional responses involve multiple signalling paths and
vary in different cell types.
Abstract N° C95
Targeted deletion of A2A adenosine receptors attenuates
post-ischemic coronary flow without altering cardiac
contractility
R. Ray Morrison a, Catherine Ledent b, S. Jamal Mustafa c.
a Department of Pediatrics, East Carolina University,
Greenville, NC 27858, USA. b University Libre de
Bruxelles, Brussels, Belgium. c Department of
Pharmacology, East Carolina University, Greenville, NC
27858, USA
The relative roles of A2 adenosine receptor subtypes in
regulation of coronary flow (CF) and myocardial contracti-
lity following ischemia–reperfusion remain incompletely
understood. To examine the effects of targeted deletion of
A2A adenosine receptors (A2AAR) on coronary vascular and
functional responses to ischemia–reperfusion, constant-
pressure perfused isolated hearts from A2AAR knockout
(A2AKO) mice and their respective wild-type (WT) litterma-
tes underwent 20 min of global ischemia followed by 40 min
of reperfusion. In the first 3 min of reperfusion A2AKO and
WT hearts had equal post-ischemic hyperemia (181 ± 17 and
168 ± 13% change from pre-ischemic baseline, respectively,
n = 4, n.s.). However, beginning at 5 min of reperfusion, CF
in A2AKO hearts was ~35% lower than WT hearts and this
reduction was sustained for the duration of reperfusion (CF at
40 min 82 ± 5 and 127 ± 17% of baseline, respectively, n = 4,
P < 0.05). Left ventricular developed pressure (LVDP) and
diastolic pressure (DP) were the same in A2AKO and WT
hearts throughout reperfusion (LVDP at 40 min 79 ± 4 and 73
± 4% of baseline, respectively, n = 4, n.s.; DP at 40 min 6 ± 3
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and 13 ± 7 mmHg, n = 4, n.s.). Taken together, these data
support the conclusion that targeted deletion of A2AAR atte-
nuates post-ischemic CF without altering contractile func-
tion in isolated murine hearts. That recovery of LVDP and
DP are preserved independent of attenuated CF in A2AKO
hearts raises the possibility that contractile function is sup-
ported by alternative adenosine receptor subtype(s) in this
model.
Supported by NIH KO8 HL074001 and HL 27339.
Abstract N° C96
Mechanisms of postischemic cardiac release of TNFa:
insights from knockout mice
Bernhard F. Becker, Jan-Christian Reil, Stefanie Gilles,
Ulrich Welsch, Stefan Zahler. Departments of Physiology
and Anatomy, University of Munich, Germany
Reperfusion of the human heart after bypass surgery is
accompanied by release of tumor necrosis factor-alpha
(TNFa) in two phases: acutely (first min of reperfusion) and
delayed (after about 60 min).An identical time-course is seen
when TNFa is liberated from isolated hearts of rat or mouse.
This study assessed TNFa release in isolated hearts of mice
after 15 min of global ischemia, comparing IL-6–/– (H.
Drexler, MHH Hannover), MMP-7–/– (L. Matrisian, Nas-
hville, TN), mast-cell deficient kitw/w–v (L. Hueltner, GSF
Munich), TNFa-R1–/– (K. Pfeffer, TU Munich) and wild-
type mice, the latter without and with infusion of cyclohexi-
mide or matrixmetalloprotease(MMP)-inhibitor II. Samples
of coronary effluent and interstitial transudate were analyzed
for cytokine by ELISA. Cytokine release from TNFa-R1–/–
hearts showed a similar two-peak pattern to wild-type
controls, so that autostimulation via TNF-receptor 1 does not
seem obligatory. Immunohistology demonstrated TNFa pre-
dominantly in cardiac mast cells of wild-type mice. Release
of TNFa from mast cell-deficient hearts was absent during
early reperfusion but increased with duration of reperfusion.
Pertinently, kitw/w–v mice revealed TNFa localized to tissue
macrophages and endothelial cells in the heart. Therefore,
mast cells supply most of the TNFa released immediately
upon reperfusion, but are not the only source in the murine
heart. Surprisingly, the pattern of TNFa release of IL-6–/–
mice was similar to that of kitw/w–v mice, i.e. there was no
early peak. This may be explained by the fact that IL-6 is an
important factor for the maturation of mast cells. Indeed, the
mast cells in IL-6–/– hearts stained only poorly. MMP-7–/–
mice lacked the late TNFa peak. Infusion of MMP-inhibitor
II, a specific inhibitor of the metalloproteases 1, 3, 7 and 9, or
of cycloheximide, a protein synthesis inhibitor, likewise sup-
pressed the late peak. Thus, the second phase of TNFa
release after about 1 h of reperfusion is due to de-novo
synthesis, and may involve cleavage of membrane bound
TNFa by MMP-7. Experiments using regional ischemia sug-
gest that cardiomyocytes and not mast cells are the source.
Supported by the Deutsche Forschungsgemeinschaft
(SFB 469).
Abstract N° C97
Over pressure load induce production of tumor
necrosis factor-a
Shiying Li *, Xinhai Ni, Aimin Dang, Guozhang Liu.
Beijing Union Medical College, FuWai Hospital, Beijing
100037, China. * Corresponding author.
To observe whether TNF-a is involved in the process of
myocardium hypertrophy induced by overpressure in vivo.
Coarctation of the abdominal aorta was performed on male
Sprague–Dawley rats weighing 180–200 g. Sham-operated
controls underwent an identical procedure except for the
placement of the silver clamp. Cardiac hypertrophy was
evaluated by IVSTd and LVPWd at 1 and 3 months after
coartation by M dimensional echocardiography. Immunohis-
tochemistry study was used to detect TNF-a expression level
in myocardium. Electrophoretic motif shift assay EMSA was
used to screen for the probable promoter of TNF-a. Left
ventricular (LV) wall thickness was assessed by echocardio-
graphy once a month after the operation. Three months later,
aorta coarctation rats develop significantly left ventricular
hypertrophy compared with those of sham operation (IVSTd:
2.68 ± 0.40 and 2.46 ± 0.37 mm, respectively; LVPWd: 2.70
± 0.37 and 2.29 ± 0.36 mm, respectively; P < 0.05). But left
ventricular wall thickness had no difference between
1 month coarctation and sham operation rats (IVSTd: 2.68 ±
0.40 and 2.46 ± 0.37 mm, respectively; LVPWd: 2.70 ± 0.37
and 2.29 ± 0.36 mm, respectively; P > 0.05). The myocar-
dium TNF-a was negative in non-coarctation rats’ myocar-
dium, but it was persistently positive in all over-pressure load
rats’ hearts despite of hypertrophy or not. EMSAs showed
that nuclear extract of all overload myocardium specifically
bound with two upstream oligonucleotides of TNF-a, which
is –619 to –591cat tcc ctc tgg ggc tgc ccc att ctc ctc and –508
to –481ctc aga caa ggg ggc ttt ccc tcc tca ac. Aortic coarcta-
tion increase heart pressure load, as well it activate neuro-
endocrine system. The expression of TNF-a is earlier than
the morphorism hypertrophy and persistently exists in the
hypertrophy myocardium, suggesting TNF-a participate in
the remodeling process. The sequences of –619z –591 and
–508z –481 in the upstream of TNF-a contain the potential
sites that switch on the expression of TNF-a in over-
pressured myocardium.
Abstract N° C98
Angiotensin II stimulate the production of TNF-a in
cultured cardiac myocytes of neonatal rat
Shiying Li *, Xinhai Ni, Xi Chen, Bianmei Han,
Aimin Dang, Guozhang Liu. Beijing Union Medical
College, FuWai Hospital, Beijing 100037 China. *
Corresponding author.
To observe the production of TNF-a in cardiac myocytes
stimulated with Angiotensin II. In primary cultured rat myo-
cytes, we use 10–7 M Angiotensin II) (AngII)) or 100 ng/ml
lipopolysaccharide (LPS) to stimulate the cardiac myocytes
for 24 or 48 h. Using immunohistochemistry to observe
TNF-a in situ. We performed RT-PCR to detect TNF-a
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mRNA in different myocytes. TNF-a immunohistochemistry
staining was negative in control myocytes, but it was positive
in myocytes treated with AngII or LPS. With the prolonga-
tion of the treating time, there was a tendency that the stai-
ning granule was more obvious. TNF-a mRNA level was
detected by RT-PCR, same tendency was noticed that the
optical dense ratio TNF-a PCR product was obviously in-
creased in AngII or LPS treated myocytes, and the quantity
was elevated with the continuation of the stimulation. Both
protein level and mRNA levels of TNF-a were very low in
the control cultured newborn rat myocytes but they were
obviously increased in AngII treated myocytes, which sug-
gested that TNF-a may be a effector of AngII in myocytes.
Abstract N° C99
Investigation of urotensin-II converting enzyme activity
in human cells and blood
F.D. Russell a, P. Kearns b, I. Toth b, P. Molenaar a.
a Department of Medicine, University of Queensland, Qld
4067, Australia. b School of Pharmacy, University of
Queensland, Qld 4067, Australia
Human urotensin-II (UII) is an 11 amino acid peptide
produced by cleavage of 124 and 139 amino acid residue
isoforms of a prohormone. While “urotensin converting en-
zyme” (UCE) activity is required for biological activity, the
endogenous UCE has not been investigated. This study in-
vestigated UCE in human cultured epicardial mesothelial
cells obtained from the right atrium of patients with coronary
artery disease (n = 3) and venous blood from healthy indivi-
duals (n = 3). Cells were incubated in medium containing
Tris–HCl with or without CaCl2 (1 mM) and EDTA (2 mM)
(37 °C for 3 h). UCE activity was determined by measuring
conversion of a 25 amino acid C-terminal fragment of the
prohormone (CTF-pUII) to UII using mass spectrometry.
The putative cleavage site contains dibasic residues, a com-
mon recognition sequence for broad range convertases, and a
recognition sequence for the trans-Golgi endoprotease, furin.
UII was readily detected at pH 7.0 in the superperfusate of
cells incubated with 10 µM CTF-pUII and permeabilised
with 0.1% triton X-100, but not in the superperfusate of
non-permeabilised cells, indicating the presence of intracel-
lular enzyme(s). UCE activity was inhibited at pH 5.0, and at
pH 7.0 when cells were incubated in Ca2+-free medium in the
presence of EDTA. The characteristics of UCE activity in
cells was similar to that determined for 2 U/ml recombinant
furin in a cell-free system. UCE activity was detected in
blood samples incubated with CTF-pUII, and was inhibited
by 35 µM aprotinin. Similar aprotinin-sensitive activity was
observed when CTF-pUII was incubated with 0.05 mg/ml
trypsin in a cell-free system. These findings identified UCE
activity in human epicardial mesothelial cells that was
mainly associated within intracellular compartments, and
resembled the characteristics of furin. Aprotinin-sensitive
UCE activity was detected in blood, consistent with the
presence of a serine protease such as trypsin.
Abstract N° C100
Urotensin II regulates mesenteric micro-circulation in
rats
Xiuhua Liu *, Fengying Liu, Lirong Cai, Sheng Sun.
Department of Pathophysiology, PLA General Hospital,
Beijing, China. * Corresponding author.
Urotensin II, a cyclic neuropeptide, confers potent cardio-
vascular effects including depression of cardiac function and
vessel contraction. To investigate the effects of human uro-
tensin II on in vivo mesenteric microcirculation, 24 adult SD
rats were randomly divided into the following groups:
control, human urotensin II (10–6 mol/l), noradrenaline(10–
6 mol/l), and human urotensin II (10–6 mol/l) + NA(10–
6 mol/l). The intestinal loop was mounted on the stage of an
intravital microscope equipped with a TV camera. Video
images of microcirculation were stored by a video cassette
recorder. Changes of internal diameter and microcirculatory
velocity of microvessels were measured using the ImagePro
software. The blood flow in intestinal wall was measured
with PIMII laser Doppler perfusion imager. The findings
were that the internal diameters of arterioles and venules
decreased by 34.1% and 41.7% in human urotensin treated
rats, respectively. The blood flow in intestinal wall increased
1 min after treated with human urotensin II and up to high
peak at 5 min (6.4 ± 1.1 perfusion unit vs. control 4.2 ± 0.9 ,P
< 0.05). However, microcirculatory velocities of arterioles
and venules have no significant changes in human urotensin
II group. The study shows that urotensin II contracts mesen-
teric microvessels and increase microcirculatory blood per-
fusion to intestinal wall in rats.
Keywords: Peptide; Microcirculation; Small intestine
Abstract N° C101
Effects of human urotensin II on pia mater
microcirculation in rats
Xiuhua Liu *, Lirong Cai, Fengying Liu, Sheng Sun.
a Department of Pathophysiology, PLA General Hospital,
Beijing, China. * Corresponding author.
Urotensin II is a cyclic neuropeptide confers potent car-
diovascular effects including depression of cardiac function
and vessel contraction. To determine whether human Uroten-
sin II has effects on cerebral microcirculation, we separated
32 rats into four groups received either normal saline, human
Urotensin II , noradrenaline , and Urotensin II with noradre-
naline groups. For recording of microcirculation images in
pia mater , skull windows were performed and mounted on
the stage of an intravital microscope equipped with a TV
camera. Video images of microcirculation were stored by a
video cassette recorder. Temporal changes in internal diame-
ter and microcirculatory velocity of microvessels were
measured using the ImagePro software. Blood flow in cere-
bral tissue was measured with PIMII laser Doppler perfusion
imager. It was found that human Urotensin II decreased the
internal diameters of arterioles and venules by 27.7% and
42.4%, respectively. The blood flow in meninges increased
by 52% in human Urotensin II treated rats. However, both
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microcirculatory velocities in arterioles and venules have no
significant changes in human Urotensin II group. We
conclude that human Urotensin II contracts microvesseles in
pia mater and increases microcirculatory blood perfusion to
cerebral tissue in rats. We suggested that Urotensin II may
regulate cerebral microcirculation.
Keywords: Peptide; Microcirculation; Brain
Abstract N° C102
Macrophage colony-stimulating factor MCSF-1 and
proto-oncogene c-fms expression on mitral valves
during experimental bacterial endocarditis
Walter B. Eichinger, Joachim B. Grammer, Bo Zhao,
Juliane Brückner, Erwin Lankes, Florian Botzen-hardt,
Rüdiger Lange, Robert Bauernschmitt. German Heart
Center, Munich, Germany
MCSF-1 and its receptor c-fms are essential factors for
mobilizing and activating mononuclear phagocytes in the
inflammatory response. Only little information is available
about MCSF-1-triggered activation of monocytes via the
c-fms-pathway on diseased heart valves. In an experimental
model mitral valves of seven untreated rabbits were compa-
red to seven animals after mitral valve surgery and to seven
animals after mitral valve surgery plus bacteremia with Sta-
phylococcus aureus. The surgical intervention consisted of a
Dacron patch being sewed to the anterior leaflet of the valve
causing an endothelial lesion and a mild valve insufficiency.
Six hours after the intervention, valve tissues were explanted
and mRNA expression was analyzed by RT-PCR. The results
of the control group were set as 100% and up- or downregu-
lation in the surgery groups are presented as relative values.
After mitral valve surgery MCSF-1 mRNA increased to 166
± 29% (P < 0.001), whereas c-fms was downregulated to 67 ±
13% (P < 0.05) compared to control. After mitral valve
surgery in combination with bacteremia MCSF-1 mRNA
expression further increased to 263 ± 69% (P < 0.01) com-
pared to the surgery group. The c-fms mRNA nearly reached
baseline values after surgery plus bacteremia (81 ± 31%,
n.s.). MCSF-1 upregulation promotes monocyte activation in
traumatized heart valve tissues. A further upregulation was
documented during the development of bacterial endocardi-
tis with S. aureus. We for the first time demonstrated basal
c-fms expression on heart valve tissue. The downregulation
after surgical manipulation may be interpreted as negative
feedback loop to locally increased MCSF-1 concentrations.
The mechanism of the MCSF-1/c-fms pathway in heart valve
tissue during inflammatory processes has to be further eva-
luated in detail.
Abstract N° C103
Cardioprotective mechanisms of melatonin against
adriamycin-induced cardiotoxicity in rats
Nari Kim a,b, Dang Van Cuong a,b, Euiyong Kim a,
Jin Han a,b. a Department of Physiology and Biophysics,
College of Medicine, Inje University, Busan 614-735,
Korea. b Molecular Cell Physiology Research Center,
College of Medicine, Inje University, Busan 614-735, Korea
In the present study, we evaluated the effect of melatonin
administration on adriamycin-induced cardiotoxicity in rat.
We measured malondialdehyde (MDA) content as an index
of lipid peroxidation and lactate dehydrogenase (LDH) re-
lease as an indicator of lethal cell injury. Serious adriamycin-
induced lethality was observed in rat with a single intraperi-
toneal injection in a dose-dependent manner. A single
injection of adriamycin (25 mg/kg, intraperitoneal injection)
resulted in a lethality rate of 86%, which was reduced to 20%
with melatonin treatment (10 mg/kg subcutaneous injection
for 6 d). The severe body weight loss caused by adriamycin
was also significantly attenuated by melatonin treatment. The
adriamycin-induced MDA formation and LDH release were
also significantly prevented by melatonin. A cell damage
induced by adriamycin was not evident after melatonin treat-
ment. Melatonin prevented adriamycin-induced nuclear
DNA fragmentation, mitochondrial depolarization and gluta-
thion depletion without changes of reactive oxygen species
content. These data indicate that melatonin prevents
adriamycin-induced cardiotoxicity and thus it may be used in
combination with adriamycin to reduce the free radical-
mediated cardiotoxicity.
Abstract N° C104
Peripartum cardiomyopathy: correlation between
cholesterol, C-reactive protein and left ventricular
dysfunction
O. Forster, E. Libhaber, J. Kachope, H. Abbasi,
A. Pappachan, F. Peters, MR. Essop, K. Sliwa. Department
of Cardiology, Chris Hani Baragwanath Hospital Soweto,
University of the Witwatersrand Johannesburg, South Africa
Heart failure is characterised by activation of inflamma-
tory cytokines possibly due to increased endotoxin levels.
Lipoproteins are non-specific endotoxin buffers. We ana-
lysed the correlation between serum cholesterol level,
C-reactive protein level and left ventricular dysfunction in
patients with peripartum cardiomyopathy (PPCM). Single
centre, prospective study of 100 patients with newly dia-
gnosed PPCM. Clinical assessment, echocardiography and
cardiac scintigraphy were done at baseline and after 6 months
of treatment. CRP and serum cholesterol were measured at
baseline only. Fifteen patients died and eight were not availa-
ble for follow up. Total serum cholesterol was 4.2 ±
0.9 mmol/l, while CRP was 10.8 ± 13.2 mg/l with 45% of
patients having values >10 mg/l. We documented an inverse
correlation between CRP and total serum cholesterol (rs =
–0.29, P = 0.01). Total serum cholesterol also correlated
inversely with left ventricular end-diastolic diameter (rs =
–0.35, P = 0.0009) and end-systolic diameter (rs = –0.38, P =
0.0001). The correlation between baseline serum cholesterol
and ejection fraction was positive (rs = 0.36, P = 0.0006). In
PPCM low serum cholesterol levels are associated with ele-
vated CRP levels at baseline and more severe left ventricular
dysfunction after 6 months of treatment.
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Abstract N° C105
A lack of effects of nicotinic acid on plasma lipids and
atherosclerosis in apo E-KO mice
A. Jolodar, B. Yeganeh, C. Dupasquier, A. Gutsol,
C. Mueller, G.N. Pierce, M.H. Moghadasian. Department of
Human Nutritional Sciences and NCARM, University of
Manitoba, Canada
Pharmacological doses of nicotinic acid may reduce coro-
nary events due to its beneficial effects on plasma lipoprotein
profiles. The aim of the present study was to investigate
whether administration of nicotinic acid beneficially modi-
fies plasma lipoprotein profiles and subsequently prevents
atherosclerosis in apolipoprotein E deficient mice (apo
E-KO). Two groups of mice were fed with a cholesterol-
enriched diet (0.2% w/w) with (treated group (n = 8) or
without (control group, n = 7) supplementation with nicotinic
acid (0.5% w/w) for 4 months. Plasma lipid levels (total
cholesterol, triglycerides) were measured using standard en-
zymatic methods. At the end of the study, the hearts and
aortas were collected, and the extent and severity of atheros-
clerotic lesions in the aortic roots were examined by a num-
ber of histological and morphometrical techniques. Treat-
ment with nicotinic acid neither significantly changed
plasma lipid levels nor reduced the extent of atherosclerosis
in the aortic roots, as compared to controls. Supported by
Manitoba Medical Services Foundation and NCARM.
Abstract N° C106
Ankle brachial blood flow index—a possible
physiological tool to predict atheroslerosis
N.S. Verma, M. Bajpai. Department of Physiology,
K G Medical University, Lucknow, India
Forearm hyperemia, carotid intima thickness, Ankle Bra-
chial Pressure Index are subclinical markers associated with
coronary artery disease. Ankle Brachial Index is the ratio of
systolic pressure as measured at the ankle and arm by the
Doppler.It has been used to detect atherosclerosis. In the
present study Imdedance Cardiovasograph (BARC, Mum-
bai) has been used to measure Blood Flow Index (BFI) at
ankle and upper arm by Impedance Plethysmography. In our
study there is 90% sensitivity, 96% specificity and a positive
predictive value of 94% for atherosclerosis and a significant
(P < 0.0001) association with coronary artery disease. This
method being non-invasive, quick and easy has a high patient
acceptability and is an accurate and reliable indicator of
atherosclerosis.
Abstract N° C107
Role of various adhesion and activation molecules in
patients with coronary artery disease
Anil Grover a, Rajesh Vijayvergiya a, Ajay Bahl a,
Girish Dwivedi a, Archana Bhatnagar b, Yash Paul Sharma a,
S Majumdar b. a Department of Cardiology, Post Graduate
Institute of Medical Education and Research,
Chandigarh-160 012, India. b Experimental Medicine, Post
Graduate Institute of Medical Education and Research,
Chandigarh-160 012, India. * Corresponding authors.
Chronic inflammation is the underlying pathologic pro-
cess in development of atherosclerotic coronary artery di-
sease (CAD). Chronic inflammatory response is associated
with the generation of cytokines, which results in increased
expression of various adhesion and activation molecules. We
estimated levels of various adhesion and activation molecu-
les in peripheral and coronary sinus blood samples in angio-
graphically proven CAD cases and compared it with normal
coronary arteries controls. Various molecules like CD3 (T
cell surface receptor), CD11 (receptor for ICAM), CD19 (B
cell surface receptor), CD25 (interleukin-2 receptor), CD54
(intercellular adhesion molecule-1), and CD69 (early activa-
tion marker), were estimated in peripheral and coronary
sinus blood samples in 20 cases and compared it with 20
controls. Both groups were matched for demographics and
conventional CAD risk factors. Significant elevation of CD3,
CD11b, CD25, CD54 and CD69 were found both in coronary
sinus and peripheral blood samples in cases compared to
controls (P < 0.05). No significant difference was noted for
CD11a, CD11c and CD19 (P > 0.1). Only CD11b, CD11c,
CD54 and CD69 were elevated in coronary sinus compared
to peripheral blood in cases (P < 0.05), while in controls
CD11a, CD11b, CD25, CD54 and CD69 were elevated in
coronary sinus compared to peripheral blood (P < 0.05).
Adhesion and activation molecules like CD25, CD54, CD69,
CD3, and CD11b were elevated in CAD patients. There is not
much of incremental benefit in estimating various molecules
in coronary sinus compared to peripheral blood.
Abstract N° C108
Fenofibrate paradoxically increases plasma total
cholesterol levels but not HDL-cholesterol levels in apo
E-KO mice
B. Yeganeh, A. Jolodar, C. Mueller, A. Gutsol S. Hourihane,
M.H. Moghadasian. Department of Human Nutritional
Sciences and NCARM, University of Manitoba, Winnipeg,
Canada
Fibrates may reduce coronary events due to beneficial
effects on plasma lipoprotein profiles. The aim of the present
study was to investigate whether administration of fenofi-
brate beneficially modifies plasma lipoprotein profiles and
subsequently prevents atherosclerosis in apolipoprotein E
deficient mice (apo E-KO). Two groups of mice received a
cholesterol-enriched diet (0.2% w/w) with (treated group (n
= 8) or without (control group, n = 7) supplementation with
fenofibrate (0.1% w/w) for 4 months. Plasma concentrations
of total cholesterol, HDL-cholesterol, and triglyceride levels
were measured at the baseline and 4-week intervals during
the study period; non-HDL-cholesterol levels were calcula-
ted by subtracting HDL-cholesterol values from total choles-
terol values. The hearts and aortas were collected, and the
extent and severity of atherosclerotic lesions in the aortic
roots were examined by a number of histological and mor-
phometrical techniques. Fenofibrate significantly increased
plasma concentrations of total cholesterol without reducing
plasma triglyceride or increasing HDL-cholesterol concen-
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trations as compared to controls. Treatment with fenofibrate
did not result in the prevention of atherosclerosis in the aortic
roots of the mice.
Supported by Manitoba Medical Service Foundation and
NCARM.
Abstract N° C109
Genetic polymorphism of apolipoprotein E in coronary
artery disease patients of north India
Narayan Bhat a, Rajesh Vijayvergiya a, Anil Grover a,
Ajay Bahl a, Madhu Khullar b. a Department of Cardiology,
Post Graduate Institute of Medical Education and Research,
Chandigarh-160012, India. b Experimental Medicine, Post
Graduate Institute of Medical Education and Research,
Chandigarh 160012, India. * Corresponding author.
Genetic predisposition is considered to be an important
risk factor for coronary artery disease (CAD). We studied the
genetic polymorphism of apolipoprotein E in patients with
established coronary artery disease in north India. A total of
150 subjects in three groups were studied: group I—50 pa-
tients with established CAD; group IIA—50 age and sex
matched controls without any family history of CAD; group
IIB—age and sex matched controls, who were first degree
relatives of patients with CAD. Fasting blood samples were
collected from all subjects and lipid profile was analyzed.
The genomic DNA was isolated from the leukocytes and
amplified. The Apo E genotyping was carried out by Hixon
and Vernier method. Group I and IIB subjects had higher total
cholesterol (TC) and low density cholesterol (LDL) compa-
red to group IIA. Group I patients had significantly lower
high density cholesterol (HDL) than group IIA and IIB sub-
jects. There was no significant difference in triglycerides
(TG) levels or in distribution of apo E genotypes between the
three Groups. The apo E 3/3 genotype was the most common
among all the three groups. The apo E 4/3 genotype was
significantly higher in group I compared to group IIA (18%
vs. 4%). Among the alleles, e3 allele carriers were the highest
in all the three groups. The e4 allele carriers were more than
doubled in CAD (20%) compared to e3 allele carriers (8.2%)
and e2 allele carriers (10.9%), but the value did not reach
statistical significance. The e4 allele was more prevalent in
group I (CAD) than group IIA or group IIB. There was no
positive correlation between e4 allele and elevated TC or
LDL-C. e4 allele carriers had significantly higher TG levels
than e3 or e2 allele carriers. The e4 allele carriers had 3.5
times higher odds (95% CI- 1.2–9.4) to develop CAD com-
pared to subjects without e4 allele. Subjects with CAD had
higher prevalence of apo E4/3 genotype and e4 allele. There
was no positive correlation between e4 allele and elevated
total cholesterol or LDL cholesterol.
Abstract N° C110
Profile of North Indian patients with dilated
cardiomyopathy and MyBPC: a preliminary study
Ajay Bahl, Anil Grover, Rajesh Vijayvergiya,
Archana Bhatnagar. Division of Experimental Cardiology,
Department of Cardiology, Post Graduate Institute of
Medical Education and Research, Chandigarh 160 012,
India
The study was aimed at a 25 base pair deletion in MyBPC,
which has been described in the Indian population but is not
present in Caucasians. This polymorphism results in alter-
nate splicing of exon 33 and therefore can be a prevalence of
the 25 base pair deletion in intron 32 of MyBPC in these
patients. Patients with left ventricular ejection fraction less
than 40% in the absence of a secondary cause were included
in this study. DNA was extracted from whole blood and PCR
of intron 32 of MyBPC carried out. The PCR product was run
on 2.5% agarose gel to detect the presence of the deletion.
Thirty-five patients with idiopathic dilated cardiomyopathy
were studied. The mean age was 43.2 ± 15.4 years (range
13–77 years), 22 were females. Out of these, four each were
hypertensive (11%) and diabetic (11%). Two patients (6%)
had peripartum cardiomyopathy and one had a history dilated
cardiomyopathy affecting several members of family. Three
(8.6%) patients were in NYHA Class I, 22 (62.9%) in Class
II, eight (22.9%) in Class III and two (5.7%) in Class IV. Two
(6%) patients were in atrial fibrillation, eight (23%) met the
voltage criteria for left ventricular hypertrophy, six (17%)
had left bundle branch block, four (11%) had bifascicular
block, two (6%) had complete heart block, one (3%) had
right bundle branch block while only one (3%) had a com-
pletely normal ECG. Echocardiogram was carried out in all
patients. The left ventricular ejection fraction was 30.9 ±
6.9% (range 18–40%). Twenty of these patients were inves-
tigated for a 25 base pair deletion in intron 32 of MyBPC.
This deletion has only been reported in Indians. One (5%)
was found to carry the polymorphism. Seventy control sub-
jects were also studied, of these three (4.2%) were found to
carry this deletion. This polymorphism has a prevalence of
4.2% in control subjects; it is therefore unlikely to cause
dilated cardiomyopathy but its role, as a disease-modifying
factor needs further studies.
Abstract N° C111
Acute treatment with statins not chronic treatment
attenuates infarct in an isolated rat heart model
Kwabena Mensah, Christopher A. Efthymiou,
Michaela Mocanu, Derek M. Yellon. The Hatter Institute
and Centre for Cardiology, University College London
Hospitals and Medical School, London, UK
Chronic treatment with statins (HMG Co-A reductase
inhibitors) have been shown to improve survival following
myocardial infarction. This benefit has been primarily attri-
buted to its cholesterol lowering effects. However patients
treated chronically with statins have been shown to have a
lower incidence of heart disease than individuals with com-
parable cholesterol levels. Statins are known to have a num-
ber of pleiotropic effects that may be beneficial in vascular
occlusive disease such as inhibition of smooth muscle proli-
feration and platelet aggregation, anti-inflammatory effects,
enhancement of endothelial function. One other pleiotropic
294 2004 ISHR World Congress / Journal of Molecular and Cellular Cardiology 37 (2004) 161-375
effect is its ability to recruit the phosphatidyl inositol 3-OH
kinase (PI3 kinase)/Akt pathway, one of the pro-survival
pathways. In this regard, it has also been recently shown that
atorvastatin can limit infarct size if given prior to the point of
reperfusion an effect which is mediated via its ability to
recruit the PI3 kinase/Akt/eNOS cascade. The aims of this
study were to determine whether chronic treatment with
statins could limit infarct size and secondly to determine
whether additional acute statin treatment would be beneficial
in the presence of chronic statin therapy. Sprague–Dawley
rats (SDR) were gavaged daily for 2 weeks with either 1%
methylcellulose vehicle (group 1), atorvastatin 20 mg/kg
(group 2), atorvastatin 40 mg/kg (group 3) or atorvastatin
80 mg/kg (group 4) after which time the hearts were isolated
and subjected to 35 min of regional ischaemia on a Langen-
dorff apparatus followed by 120 min of reperfusion. Two
further groups, group 5 and 6, consisted of SDR gavaged for
2 weeks with 20 mg/kg atorvastatin as with group 2 (group 5)
and 80 mg/kg atorvastatin as with group 4 (group 6) and also
subjected to 35 min of ischaemia with a further 50 µmol of
atorvastatin given acutely for the first 15 min of reperfusion.
The results of this study shows that atorvastatin given chro-
nically did not limit infarct size measured by infarct to risk
(I/R) ratio compared to controls (I/R ratio 54.6% ± 6.4%) at
20, 40 or 80 mg/kg (I/R ratio 58.4 ± 3.3%, 42.4 ± 8.5% and
58.4 ± 5.1%, respectively). A further acute dose of 50 µmol
produced a significant reduction in infarct size (P < 0.05)
after chronic gavage with 20 and 80 mg/kg of atorvastatin
(I/R ratio 25.67 ± 5.4% and 24 ± 6.6%, respectively). We
conclude from these results that although chronic treatment
with statins confers long-term protection in cardiovascular
disease, this does not appear to be mediated via a limitation in
infarct size. However, a further acute dose of statin at reper-
fusion reduces infarct size despite chronic treatment with a
statin. This may provide us with a new and novel therapeutic
use of statins.
Abstract N° C112
Atorvastatin reduces infarct size acutely in an isolated
rat heart model
Kwabena Mensah, Christopher A. Efthymiou,
Michaela Mocanu, Derek M. Yellon. The Hatter Institute
and Centre for Cardiology, University College London
Hospitals and Medical School, London, UK
Statins have been shown to be of great benefit in the
treatment of coronary heart disease. This has been attributed
mainly to their cholesterol lowering effect. However, statins
are known to have pleiotropic effects. One such effect may
occur as a result of their ability to recruit the PI3-kinase/Akt
pathway, the pro-survival pathway. This pathway is central to
the protection afforded by ischaemic preconditioning. We
therefore hypothesized that statins could reduce infarct size if
used as a preconditioning mimetic.
Methods. – Male Sprague–Dawley rats were anaesthe-
tised, the hearts isolated and mounted on a Langendorff
apparatus. They were then stabilized for 35 min during which
time they received 50 µmol atorvastatin for 10 min followed
by 10 min of washout prior to ischaemia/reperfusion (Group
A). There were three further groups: Group B received
10 min of vehicle followed by washout; Group C received
atorvastatin with wortmannin, the PI3-kinase inhibitor, and
Group D received wortmannin alone. Atorvastatin given acu-
tely at a dose of 50 µmol was found to reduce infarct size
significantly compared to controls reducing the infarct to risk
(I/R) ratio from 44.3 ± 2.5% to 22.2 ± 6.6%. This protective
effect was abrogated by the PI3K inhibitor wortmannin (I/R
ratio 53.0% ± 2.6%). Wortmannin alone had no effect on
infarct size (I/R ratio 58.0 ± 6.3%). Atorvastatin given as a
preconditioning mimetic reduces infarct size in an isolated
perfused rat heart model of ischaemia/reperfusion injury and
this protection is mediated via the PI3-kinase signalling pa-
thway. This is the first time that a statin has been shown to
precondition the myocardium and could lead to new and
novel uses of these agents in the treatment of ischaemic heart
disease.
Abstract N° C113
Short-term pre-treatment with atorvastatin reduces
infarct size in an isolated rat heart model of
ischaemia/reperfusion injury
Kwabena Mensah, Amal Bose, Mihaela Mocanu,
Derek M. Yellon. The Hatter Institute and Centre for
Cardiology, University College London Hospitals and
Medical School, London, UK
Statins have been shown in numerous studies to be of
benefit in the long-term treatment of ischaemic heart disease.
However, a number of studies have shown that short-term
treatment with statins can be beneficial. This beneficial effect
is thought to be due to inhibition of inflammation and endo-
thelial dysfunction by preventing activation and extravasa-
tion of neutrophils. The aim of this study was to observe the
effect of pre-treatment with statins on the heart in isolation.
Male Sprague–Dawley rats were gavaged for 1 d with
methylcellulose 1% vehicle (Group 1), 1 d with 20 mg/kg
atorvastatin (Group 2), 3 d with methylcellulose 1% (Group
3) or 3 d with atorvastatin 20 mg/kg. After 2 weeks they were
anaesthetised, the hearts isolated and mounted on a Langen-
dorff apparatus. After a period of stabilisation, the hearts
were subjected to 35 min of regional ischaemia followed by
2 h of reperfusion. Infarct size was then determined using
methylene blue and TTC staining. Infarct size was signifi-
cantly reduced (P < 0.05) after oral gavage for 1 d with
atorvastatin from an infarct to risk zone ratio (I/R) of 56.4% ±
2.3% after 1 d of methylcellulose gavage to 38.9 ± 3.1%. The
same was true after 3 d gavage with infarct reduced from 61.3
± 3.8% after methylcellulose gavage to 39.3 ± 2.4% after
gavage with atorvastatin (P < 0.05). Short-term pre-treatment
with statins reduces infarct size in an isolated rat heart model
of ischaemia/reperfusion suggesting that the protective effect
of this treatment is not entirely due to a reduction in inflam-
mation but may be in part due to activation of an intrinsic
protective mechanism within the myocardium.
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Abstract N° C114
Rosuvastatin prevents cardiovascular remodelling
without lowering blood pressure in DOCA-salt
hypertensive rats
David Loch a, Andrew Hoey b, Lindsay Brown a.
a The University of Queensland, Brisbane, Qld, Australia.
b The University of Southern Queensland, Toowoomba, Qld,
Australia
The pleiotropic responses of the statins represent novel
mechanisms for the treatment of hypertension and heart
failure, as well as hyperlipidaemia. This project investigated
cardiac remodelling in DOCA-salt hypertensive rats treated
with rosuvastatin (20 mg/kg/d in 10% Tween 20) by oral
gavage for 32 d, commencing 4 d before surgery. Male
8 week old Wistar rats were uninephrectomised and treated
with deoxycorticosterone acetate (DOCA, 25 mg every 4th
day sc) and 1% NaCl in the drinking water for 4 weeks;
uninephrectomised (UNX) rats served as controls (n >
6/group). Rosuvastatin did not alter systolic blood pressure,
but decreased left ventricular weight/body weight in DOCA
rats (3.05 ± 0.10 vs. 2.68 ± 0.10; UNX: 1.81 ± 0.04 vs. 1.92 ±
04 mg/kg). Diastolic stiffness was lowered from 24.4 ± 0.6 to
21.5 ± 0.5 in treated DOCA-salt rats, whilst UNX rats
remained unchanged (21.4 ± 0.4 vs. 21.9 ± 0.4). Rosuvastatin
treatment normalised left ventricular interstitial collagen
content in DOCA-salt rats (DOCA: 4.39 ± 0.59 vs. 2.61 ±
0.39; UNX: 2.58 ± 0.16 vs. 2.38 ± 0.31% area). Action
potential duration at 90% of repolarisation in isolated
papillary muscle preparations was reduced from 114.4 ± 3.3
to 95.2 ± 3.1 ms with treatment in DOCA-salt rats (UNX:
45.99 ± 0.99 vs. 51.36 ± 3.91 ms). Thus, rosuvastatin
prevented increases in cardiac stiffness and collagen
deposition and attenuated both cardiac hypertrophy and
action potential prolongation in the DOCA-salt model of
hypertension in rats without altering systolic blood pressure.
Abstract N° C115
Preconditioning ischemia favorably attenuates platelet
aggregation: insight into molecular mechanisms
Matthew Linden, Alan D. Michelson, A.L. Frelinger III,
Marc Barnard, Mark Furman, Karin Przyklenk. University
of Massachusetts Medical School
There is extensive evidence that brief antecedent precon-
ditioning (PC) ischemia limits infarct size. Recent studies
have further revealed that PC ischemia also improves vessel
patency in models of coronary artery injury + stenosis (I + S)
mimicking unstable angina, presumably by as-yet unknown,
favorable effects of the PC stimulus on subsequent platelet
aggregation. To address this issue, anesthetized dogs recei-
ved 10 min PC ischemia + 10 min reflow or a matched
control period, after which I + S (resulting in cyclic varia-
tions in coronary flow, caused by repeated formation/
dislodgement of platelet thrombi) was initiated. Coronary
flow was monitored for 3 h following I + S, and blood
samples were obtained at baseline and 2 h post I + S for
blinded measurement, by flow cytometry, of multiple ar-
chetypal molecular indices of platelet activation/aggregation,
including formation of neutrophil-platelet aggregates
(NPAs), fibrinogen binding (FB), and surface expression of
P-selectin (P-sel).
Abstract N° C116
Increased platelet-derived microparticles in the
coronary circulation of patients undergoing coronary
angioplasty
J.A. Craft a, P.P. Masci b, M.S. Roberts b, T.A. Brighton c,
P. Garrahy d, S. Cox d, N.A. Marsh e. a Department of
Biological and Physical Sciences, University of Southern
Queensland, Toowoomba, Qld, Australia. b Department of
Medicine, University of Queensland, Princess Alexandra
Hospital, Australia. c Department of Clinical Haematol
Cancer Care Centre, St. George Hospital, Australia.
d Department of Cardiology, University of Queensland,
Princess Alexandra Hospital, Australia. e Adelaide Graduate
Centre, University of Adelaide, Australia
Platelet-derived microparticles (PMPs) that are produced
during platelet activation are capable of adhesion and aggre-
gation. Endothelial trauma which occurs during percuta-
neous transluminal coronary angioplasty (PTCA) may sup-
port PMP adhesion and contribute to subsequent
development of restenosis. We have previously reported an
increase in platelet-derived microparticles in peripheral arte-
rial blood with PTCA. This finding raised concerns regarding
the role of PMPs in restenosis, and therefore in this study, we
have monitored PMP levels in the coronary circulation. The
study population consisted of 19 angioplasty patients. Paired
coronary arterial and sinus samples were obtained following
heparinisation, following contrast administration, and subse-
quent to all coronary arterial intervention. PMPs were iden-
tified with an anti-CD61 (glycoprotein IIIa) antibody using
flow cytometry. There was a significant decrease in arterial
platelet-derived microparticles from heparinisation to
contrast administration (P = 0.001), followed by a significant
increase to the end of PTCA (P = 0.004). However, there was
no significant change throughout the venous samples. These
results indicate that the higher level of PMPs after PTCA in
arterial blood remained in the coronary circulation. This may
have implications for the development of coronary restenosis
post-PTCA, although this remains to be determined.
Controls (n = 9) Preconditioned (n = 9)
Baseline Post I + S % Baseline Post I + S %
NPAs 6.5 ± 0.8 9.5 ± 1.1 158 ± 21 6.9 ± 0.9 7.0 ± 0.7 107 ± 8 *
FB 1.8 ± 0.3 2.9 ± 0.4 177 ± 24 2.3 ± 0.3 2.8 ± 0.6 112 ± 14 *
P-sel 2.3 ± 0.3 4.1 ± 0.4 197 ± 23 2.6 ± 0.6 3.4 ± 0.5 148 ± 14 **
Formation of neutrophil-platelet aggregates and fibrinogen binding were
both abrogated (* P = 0.03), P-selectin expression was attenuated (** P =
0.09), and, as expected, coronary flow was better maintained (mean of 53 ±
5% vs. 23 ± 5% of baseline; P < 0.01) in the PC group vs. controls. These
data provide the first molecular insight into the mechanisms by which brief
antecedent PC ischemia favorably attenuates subsequent platelet activation
and, thus, improves coronary patency in the unstable angina model.
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Abstract N° C117
Effect of roxythromycin on arterial vasoactivity
M. Berman a, E. Hochhauser b, E. Raanani a, L. Kapustin b,
Y. Chepurko b, D. Hasdai c, D.A. Vidne a. a Cardiothoracic
Surgery and Cardiology Department, Cardiac Research
Laboratory, Tel Aviv University, Israel. b FMRC, Rabin
Medical Center, Petah Tikva, Tel Aviv University, Israel
Background. – Inflammatory disease can damage vascu-
lar functioning and advance atherosclerosis. Coronary events
and a high flow of the brachial artery have been reported in
patients treated with macrolides.
Objective. – To determine the function of the macrolide,
roxythromycin (RX) on arterial vasoactivity.
Methods. – Vascular rings were obtained from human and
rat internal mammary arteries (IMA), attached to a force
transducer and immersed into organ chambers with oxygena-
ted Krebs–Henseleit (KH) solution. Vascular integrity in
response to norepinephrine (NE), acetylcholine (ACh), so-
dium nitroprusside (SNP) was investigated. After restabiliza-
tion, 10–6 M NE, 10–7–10–4 M RX, followed by 10–5 M SNP,
were added. The mechanism of RX action was tested in rats
using solutions containing KH; KH + L-NAME, nitric oxide
(NO) production inhibitor; KH + calcium ionophore (Ca);
KH + indomethacin, a prostaglandin inhibitor; KH + gliben-
clamide; KH + 5-hydroxydecanoic acid, membrane and mi-
tochondrial K channel inhibitors (10–6 M each).
Results. – IMA and rat aorta exhibited similar contraction
and relaxation rates in response to NE, RX, and ACh. RX
relaxation (4 ± 1 to 15 ± 3%) was dose dependent and similar
to ACh, lower than SNP. Relaxation was significantly redu-
ced in the presence of Ca, L-NAME, 5-HD (P < 0.005).
Glibenclamide and indomethacin had no effect on relaxation.
Conclusion. – RX relaxation is mediated by calcium,
mitochondrial K ATP channels and NO production. Thus,
RX offers a therapeutic advantage, for cardiac patients nee-
ding macrolide treatment.
Abstract N° C118
Would aging impair cerebral oxygenation during
orthostatic stress?
Xiangrong Shi, Hong Guo, Frederic Schaller, Nancy
Tierney. Departments of Integrative Physiology and Internal
Medicine, University of North Texas Health Science Center
at Fort Worth, TX 76107, USA
The purpose of this study was to test the hypothesis that
cerebral perfusion during orthostatic stress was compro-
mised by aging. Lower-body negative pressure (LBNP) –15,
–30, and –50 Torr was applied to simulate orthostatic stress in
eight elderly (E, 71 ± 2 years, 74.5 ± 5.4 kg and 1.68 ±
0.03 m) and seven young (Y, 27 ± 2 years, 70.2 ± 5.9 kg and
1.72 ± 0.03 m) healthy volunteers. During the test stroke
volume (SV), cardiac output (CO, thoracic impedance), sys-
temic arterial pressure (SAP, Tonometer), systemic oxygen
saturation (SO2S, Oximeter), and regional cerebral oxygen
saturation (RO2S, near-infrared spectroscopy) were conti-
nuously recorded. Baseline SAP was significantly higher in
E (132 ± 4/73 ± 4 mmHg) than Y (117 ± 3/63 ± 2 mmHg),
whereas SV and CO were significantly lower in E (54.5 ±
4.0 ml and 3.21 ± 0.30 l/min) than Y (84.2 ± 7.1 ml and 5.44
± 0.51 l/min). Though SO2S was significantly lower in E than
Y (95.0 ± 0.6 vs. 96.6 ± 0.6%), there was no statistical
difference in RO2S between the groups (E vs. Y: 67.0 ± 3.8
vs. 69.2 ± 3.3%). LBNP significantly decreased SV and CO
in both groups, indicating a central hypovolemia during or-
thostatic stress. During LBNP SO2S remained constant, whe-
reas RO2S significantly decreased (to 61.6 ± 2.4 and 63.6 ±
3.9% in E and Y, respectively, at –50 Torr), suggesting cere-
bral under-perfusion. Decrease in RO2S in terms of unit
decrease in CO or SV appeared to be greater (P < 0.05) in E
thanY (5.71 ± 0.75 vs. 3.04 ± 0.14%/l/min or 0.25 ± 0.04 vs.
0.15 ± 0.01%/ml). We concluded that aging impaired cere-
bral oxygenation during central hypovolemia, which would
explain orthostatic intolerance of the elderly.
(This Study is supported in part by NIH grant R01-
HL65613).
Abstract N° C119
Acute negative inotropic effect of b2AR-blockers
through p38-MAPK signaling pathway in human
ventricular myocytes
Z. Zheng, H. Gong, M. Petrou, L.Q. Yang, S.E. Harding.
NHLI, Imperial College School of Medicine, London, UK
Our previous studies have shown that b2AR-blockers
could acutely depress the contraction of failing human myo-
cytes and that the effect was mediated primarily through the
inhibitory guanine nucleotide binding protein, Gi. The pre-
sent work continued to investigate the mechanism of this
effect. Consistent with our previous results, acute treatment
with 3 µM ICI 118,551—a specific b2AR blocker—
produced a significant depression of contraction in both
failing human myocytes and b2AR-overexpressing rat myo-
cytes. This negative inotropic effect could be prevented by
pretreatment with SB 203580 (10 µM), a specific p38-
MAPK inhibitor (basal 100%; ICI 64.8 ± 3.6%, P < 0.01 vs.
basal; SB 106 ± 3%; SB + ICI 102 ± 5%; n = 14, 14, 6, 6
human myocytes, respectively, 6–8 mM Ca2+). In addition,
western blot showed that the phosphorylated p38-MAPK
protein levels increased significantly in ICI 118,551-treated
samples from CABG patients (arbitrary units: –ICI: 10.2 ±
2.4; +ICI: 17.8 ± 2.5, P < 0.01; n = 6). Overexpression of
b2AR for 48 h using adenovirus (Ad.b2AR-GFP, 500 MOI)
in rat myocytes raised basal cAMP levels but the basal
contraction amplitude was lower than control (Ad.GFP).
Amplitude in b2AR-overexpressing cells could be restored to
levels even higher than those of control cells following treat-
ment with PTX, which indicates that the negative effect is Gi
dependent. The negative effect of b2AR overexpression was
not reduced by the p38-MAPK inhibitor (% cell shortening:
control 5.04 ± 0.58%; +b2AR 3.08 ± 0.31%, b2AR + SB 3.08
± 0.36%, P < 0.05, vs. control; n = 10 cells). We have
therefore demonstrated that the p38-MAPK signaling pa-
thway plays an important role in the acute negative inotropic
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effect of b2AR-Gi coupling in rat and human ventricle.
However, the negative inotropic effect of b2AR overexpres-
sion per se in rat is Gi- but not p38-MAPK-dependent and
occurs despite an increase in cyclic AMP.
Abstract N° C120
Opposing roles of p38 MAPK and ERKS pathway in
b-AR-mediated secretion of IL-6 in mouse cardiac
fibroblasts
Feng Yin, Chide Han, You-Yi Zhang. Institute of Vascular
Medicine, Peking University Third Hospital and Key
Laboratory of Molecular Cardiology, Ministry of Education,
beijing, China
We recently reported that cardiac fibroblasts, but not car-
diomyocytes, are served as the predominant source of IL-6 in
response to b-adrenoceptor (b-AR) stimulation in mouse
myocardium. The present study investigated the molecular
mechanism of b-AR-mediated secretion of IL-6 in mouse
cardiac fibroblasts. Treatment of cells with isoproternol
(ISO, b-AR agonist) induced a time-dependent accumulation
of IL-6 secretion, which was completely inhibited by pre-
treatment with ICI118551 (b2-AR antagonist). Cholera toxin
and foskolin treatment for 12 h significantly induced IL-6
secretion. PDE inhibitor also elevated b2-AR-mediated IL-6
production significantly. However, no effect was observed by
protein kinase A (PKA) inhibitors. ISO-induced IL-6 pro-
duction was also markedly reduced by pretreatment with an
L-type Ca2+ channel antagonist nifedipine. Moreover, ISO-
induced secretion of IL-6 was significantly elevated by inhi-
biting Gi, phosphoinositide 3-kinase (PI3K), or MEK1 with
pertussis toxin (PTX), LY294002, or PD98059, respectively,
but was completely abolished by inhibiting p38 MAPK with
SB203580. Most importantly, SB203580 pretreatment also
completely reverse the elevated levels of IL-6 mediated by
PTX, LY294002 and PD98059. Meanwhile, the phospho-
rylation of p38 MAPK induced by b-AR stimulation was
significantly enhanced by pretreatment with PTX and
LY294002. Taken together, the present study shows for the
first time that cAMP and calcium influx, but not PKA, are
critically involved in b2-AR-mediated secretion of IL-6 in
mouse cardiac fibroblasts, and that the secretion of IL-6 is
regulated positively by p38 MAPK and negatively by Gi-
PI3K-ERKs signaling cascade. This work was supported by
the Major State Basic Research Development Program of PR
China (G2000056906) and by grant from the National
Science Foundation of China (30270540).
Abstract N° C121
Ceramide-dependent inhibition of nuclear protein
import in vascular smooth muscle cells
R.S. Faustino, M.N. Landry, N. Gavel, A.K. Kostenuk,
J.M. Ellis, G.N. Pierce. Division of Stroke and Vascular
Disease, Department of Physiology, St. Boniface Research
Centre, University of Manitoba, Winnipeg, Man., Canada
Ceramide has anti-mitogenic actions. The purpose of this
study was to determine if the anti-proliferative effects of
ceramide may be due to an effect on nuclear protein import.
Nuclear protein import is a process critical to cell growth.
The permeabilized cell assay was used to examine nuclear
protein import in vascular smooth muscle cells (VSMCs).
Exogenous cytosol pre-treated with 1 and 10 µM ceramide
significantly inhibited nuclear import. This inhibition was
reversed upon the addition of SB-202190, a p38 MAP kinase
blocker, and PD-98059, a MEK antagonist. Nuclear protein
import was also significantly inhibited in situ after microin-
jection of ceramide into vascular smooth muscle cells. This
was again reversed by the addition of SB-202190. CAS is a
critical protein that modulates nuclear protein import by
regulating the nuclear/cytoplasmic cycling of importin alpha
in the cell. Ceramide treatment eliminated the localization of
CAS at the nuclear periphery in control cells. Treatment of
cells with ceramide ± SB-202190 or 20 µM PD-98059 cau-
sed a redistribution of CAS back to the nuclear rim. This was
also observed for importin alpha. In conclusion, ceramide
inhibits nuclear protein import in VSMCs via an inhibition of
p38 and MEK kinase activity. CAS appears be a target of
MAP kinase activity and it mediates the inhibitory effects of
ceramide on nuclear protein import. Supported by CIHR and
NSERC.
Abstract N° C122
Lysophosphatidylcholine stimulates nuclear protein
import
R.S. Faustino, L.N.W. Stronger, M.N. Landry,
M.P. Czubryt, D.A. Ford, M.A. Prociuk, G.N. Pierce.
Division of Stroke and Vascular Disease, St. Boniface
Research Centre, University of Manitoba, Winnipeg, Man.,
Canada. Department of Biochemistry and Molecular
Biology, St. Louis University Health Science Center, St.
Louis, USA
Lysophosphatidylcholine (LPC) stimulates vascular
smooth muscle cell proliferation, but its mechanism of action
is unclear. Import of proteins from the cytoplasm into the
nucleus of a given cell is integral to the regulation of gene
expression. We hypothesized that LPC exerts its effects
through alterations in nuclear protein import. A cytosolic
nuclear import cocktail was treated with LPC for varying
lengths of time. LPC caused a dose- and time-dependent
increase in import. This effect was not observed with other
lysophosphatidyl species. Lysoplasmenylcholine also stimu-
lated import. LPC did not stimulate import when incubated
with the nuclei, suggesting the nuclear pore complex itself
did not directly mediate its effects. Instead, the cytosolic
mechanism of action of LPC was found to be through an
augmentation of GTP hydrolysis via activation of the MAP
kinase pathway. LPC stimulated RanGAP, a RanGTPase
activating protein and a critical regulatory component of
nuclear protein import. We conclude that LPC may alter gene
expression and cell proliferation through striking effects on
nuclear protein import via cytoplasmic activation of Ran-
GAP. Supported by CIHR and NSERC.
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Abstract N° C123
MAPKS in adriamycin cardiomyopathy and heart
failure and their modulation by probucol
Huiquan Lou, Igor Danelisen, Pawan K. Singal. Department
of Physiology, Institute of Cardiovascular Sciences,
University of Manitoba, Winnipeg, Man., Canada
Phosphorylation of ERK1/2, p38 and JNK mitogen-
activated protein kinases (MAPKs) in adriamycin-induced
cardiomyopathy (AIC), along with the modulatory effects of
antioxidant, probucol (PROB) was studied in rats. Male rats
were administered with adriamycin (ADR, cumulative dose,
15 mg/kg) with and without PROB (120 mg/kg). The animals
were assessed clinically and hemodynamically and the hearts
were collected at different post-treatment durations. Phos-
phorylation of ERK1/2, showed a biphasic response with an
increase to 167% at 1 h, 209% at 2 h and peaking at 513% at
4 h. At 24 h, the activity decreased to 197% of control and at
3 weeks, was 66.8% of the control. Phosphorylation of p38
showed a steady increase through 2, 4, 24 h and 3 weeks
(119%, 138%, 140% and 148%). Increase in phosphoryla-
tion of JNK also showed a graduate rise through 1, 2, 4, 24 h
and 3 weeks (116%, 124%, 127%, 141% and 148%). PROB
modulated these ADR-induced changes in all three MAPKs.
ADR depressed myocardial function, caused heart failure as
well as mortality. These changes were also completely pre-
vented by PROB. It is suggested that all three MAPKs are
involved in the AIC in both early and late stages. Modulation
of these changes in signaling pathways, as well as complete
prevention of AIC by antioxidant PROB may suggest that
these changes may be mediated by adriamycin-induced oxi-
dative stress (Supported by Heart and Stroke Foundation).
Abstract N° C124
Fibroblast growth factor 2 mediates
isoproterenol-induced cardiac hypertrophy through
specific MAPK and PKC pathways
Stacey House, Jo El Schultz, Betty Glascock,
Thomas Kimball, Thomas Doetschman. University of
Cincinnati College of Medicine, Cincinnati, OH, USA
Fibroblast growth factor 2 (FGF2) has been shown to
affect growth and differentiation in some tissues and to be
required for cardiac hypertrophy in vivo. FGF2 has been
shown in vitro to signal throught the mitogen-activated pro-
tein kinase (MAPK) and protein kinase C (PKC) pathways to
affect cell survival and growth. In order to ascertain which of
these pathways might mediate FGF2’s role in cardiac hyper-
trophy in vivo, we have utilized mice with a targeted ablation
of the FGF2 gene (FGF2 KO). FGF2 KO and wildtype mice
at 10–12 weeks of age were treated with isoproterenol
(60 mg/kg/d) or saline via subcutaneous mini-osmotic pump
implants for 2 weeks to induce a hypertrophic response.
Isoproterenol-treated wildtype animals exhibited marked
cardiac hypertrophy, whereas this response was significantly
attenuated in FGF2 KO mice. Echocardiography
revealed significantly decreased fractional shortening in
isoproterenol-treated wildtype mice but not in FGF2 KO
mice suggesting that the absence of FGF2 protects against
the maladaptive cardiac dysfunction seen in cardiac hyper-
trophy. Western blot analysis of the MAPK and PKC pa-
thways was then performed on isoproterenol or saline-treated
FGF2 KO or wildtype mouse hearts. These studies revealed
ERK-MAPK activation in isoproterenol-treated wildtype
hearts but not in isoproterenol-treated FGF2 KO hearts. Si-
milar results were obtained for some PKC isoforms. Together
these data suggest that FGF2 is integral to the hypertrophic
response induced by isoproterenol and that this response is
mediated through specific MAPK and PKC pathways.
Abstract N° C125
Inhibition of phenylephrine-induced cardiac
hypertrophy by a carbonic anhydrase inhibitor: a
pathological pathway linking CAII, NHE1 and AE3fl
Bernardo V. Alvarez a, Ying Xia b, Morris Karmazyn b,
Joseph R. Casey a. a Department of Physiology, University
of Alberta, Edmonton, AB, Canada. b Department of
Physiology and Pharmacology, University of Western
Ontario, London, ON, Canada
Cardiac hypertrophy (CH) contributes to heart failure, a
major cause of death by cardiovascular disease. Carbonic
anhydrase II (CAII), which catalyses the reversible CO2
hydration, is expressed in early stages of cardiac develop-
ment. CAII activates transport activity of Na+/H+ exchanger
1 (NHE1) and anion exchangers (AE). Stimulation of
a-adrenergic receptors (a1R) also activates NHE1 transport
activity in isolated cardiomyocytes (CM). AE3fl (SLC4) and
SLC26A6 (SLC26) are the predominant anion exchangers in
the heart. The effect of the a1R agonist, phenylephrine
(PHE) on anion transport mediated by AE3fl and SLC26A6
was studied in HEK293 cells individually co-transfected
with AE3fl/a1aR, or SLC26A6/a1aR, cDNAs. Cells were
loaded with BCECF-AM and intracellular pH measured.
PHE (10 µM) increased anion exchange activity of AE3fl by
70% ± 9 (n = 3; P < 0.05), but inhibited anion transport by
SLC26A6 by 65% ± 3 (n = 4; P < 0.05). Cardiomyocyte
hypertrophy (CMH) in cultured neonatal rat cardiomyocytes
was induced by PHE (10 µM). PHE increased cell surface
area by 42% ± 6; atrial natriuretic factor (ANF) and CAII,
mRNA expression increased by 66% ± 9, and 61% ± 9,
respectively (n = 4; P < 0.05). The CA inhibitor,
6-ethoxyzolamide (ETZ, 100 µM), completely abolished the
PHE-induced CMH (cell size 94% ± 2 of control, n = 4). ETZ
also normalized ANF and CAII expression. Taken together,
we conclude that CAII,AE3fl and NHE1 are associated in the
hypertrophic phenomenon in cardiomyocytes.
Abstract N° C126
Crucial roles of cardiac alpha1B-adrenoceptor on
contractile functions in both physiological and
pathophysiological conditions
Yoshihisa Nasa a, Akito Tanoue b, Ryo Oikawa a,
Yuji Kawahara a, Takashi Tomabechi a, Rie Ishii a,
Satoshi Takeo a, Taka-aki Koshimizu b, Gozoh Tsujimoto c.
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a Department of Molecular and Cellular Pharmacology,
Tokyo Univ. Pharm. Life Sci. b Deparment of Molecular and
Cellular Pharmacology, Natl. Center Child Health Devel.
Res. Inst. c Deparment of Genom. Drug Discov. Sci.,
Pharmceutical Science, Kyoto University
Currently, the cardiovascular phenotype of alpha1B-
adrenoceptor (1B-AR) single knockout (KO) mice has revea-
led no significant alterations in cardiovascular parameters. To
address the functional roles of cardiac 1B, we evaluated the
phenotype of 1BKO mice.As compared with wild-type (WT)
control, the basal blood pressure and HR of 1BKO were
similar, whereas fractional shortening and cardiac output
were low when assessed by echocardiography. Under anes-
thesia the measurement by a direct catheterization method
revealed lower LVDP and dP/dt in this KO mouse. LV mass
index by echocardiography, actual heart weight, and cross-
sectional area of cardiomyocytes of the 1BKO were smaller
than those of WT. Although cardiac hypertrophy was evident
after pressure overload stress, there was no significant diffe-
rence in contractile and morphological parameters. In the
isolated perfused hearts, phenylephrine-induced positive
inotropic response was comparable, whereas the postische-
mic recovery of LVDP was low in the 1BKO hearts. The
results provide evidence that cardiac 1B-AR plays an impor-
tant role in the maintenances of heart function under both
physiological and pathophysiological status.
Abstract N° C127
Alterations in alpha adrenoreceptor density and
localization after mechanical left ventricular unloading
with the Jarvik flowmaker assist device
Alina Grigore, Brian Poindexter, William Vaughn, Nancy
Nussmeier, O.H. Frazier, John Cooper, Igor Gregoric,
L. Maximilian Buja, Roger Bick. Departments of
Cardiovascular Anesthesiology and Cardiopulmonary
Transplantation, The Texas Heart Institute at St. Luke’s
Episcopal Hospital, Houston, TX, USA. Department of
Pathology, University of Texas Medical School at Houston,
Houston, TX, USA
Left ventricular assist devices can improve myocardial
performance. We hypothesized that mechanical unloading
would result in favorable alterations in alpha one adrenore-
ceptor (a1AR) density and distribution in patients with low-
output syndrome and left ventricular failure.
Methods. – Myocardial a1AR density and localization
were compared at the time of Jarvik flowmaker insertion and
removal in 13 patients with heart failure. Snap frozen sec-
tions were probed with fluorescent markers for a1ARs. De-
convolution microscopy produced planar images, which
were reconstructed as three-dimensional renditions. Samples
were examined with tagged Prazosin for visualization of
a1ARs. Receptor density, determined by pixel numbers, was
measured, and localization of receptors was determined in
reconstructed, deconvoluted and stacked sections.
Results. – We found a statistically significant increase (P
< 0.05) in left ventricular a1AR density after mechanical left
ventricular unloading with a continuous-flow pump. These
findings were complemented by alterations in the distribu-
tion of the a1AR (i.e. perivascular vs. intra-myocytic) from a
clumped pattern before LVAD insertion to a homogenous
appearance at the time of LVAD explantation. The alterations
were more consistent with the normal physiological state of
ventricular myocardium.
Conclusion. – Mechanical unloading of the heart with a
continuous-flow pump significantly increases a1AR density
and normalizes their distribution.
Abstract N° C128
Two alpha1-adrenoceptors regulating vasopressor
response have differential roles in postural hypotension
Akito Tanoue. National Research Institute for Child Health
Development, Japan
Alpha1-adrenoceptors (ARs) have a prominent role in
regulating vascular tone and are targets for antihypertensive
therapy. They contain three subtypes (1A, 1B and 1D-AR),
and functional role of each AR subtype is still uncertain.
Although non-selective AR blockers have been widely used
to control hypertension, their adverse effect, postural hypo-
tension, limits their safe use and subtype-selective AR bloc-
kers could reduce such an unwanted effect. To study the role
of individual AR subtypes, we created mice lacking the 1B-
and/or 1D-AR and studied hemodynamic and vasocontrac-
tile responses. Both 1D knockout (1DKO) and 1BD-AR
double KO (BDKO), but not the 1BKO mice, had a signifi-
cantly lower level of basal blood pressure than did wild-type
(WT) mice. All mutants showed reduced catecholamine-
induced pressor and vasoconstriction responses. However, a
tilt-induced postural hypotensive response was more promi-
nent in the 1BKO and WT mice treated with prazosin than in
mice lacking the 1D. We show that both 1B and 1D-ARs
mediate vasopressor responses to catecholamines, but
1B-AR is more closely related to the tilt-induced postural
change in blood pressure. Our study provides evidence for
the clinical efficacy of drugs that are highly selective for the
different ARs subtypes.
Abstract N° C129
Effects of aging in mouse heart expressing
constitutively active a1B-adrenergic receptors
Helen Kiriazis, Xinheng Feng, Xiao-Ming Gao,
Xiao-Jun Du. Baker Heart Research Institute, Melbourne,
Vic., Australia
Cardiac-directed overexpression of wild-type a1B-
adrenergic receptor (AR) (26–43-fold) results in dilated car-
diomyopathy and premature death at 9 months of age and
suppression of b1-AR signalling. To investigate whether this
heart failure phenotype is due to chronic activation of the
a1B-ARs, transgenic mice (Milano et al. PNAS
1994;91:10109–13) expressing constitutively active
a1B-AR by twofold in the heart (TG) and their non-
transgenic (NTG) littermates were non-invasively studied at
6, 9, 12 and 15 months of age using M-mode and Doppler
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echocardiography. Fractional shortening (FS) was signifi-
cantly increased in TG vs. NTG mice (Table). Notably, the
ratio of left ventricular (LV) early and atrial filling flow
velocities (E/A) was reduced and the deceleration time (DT)
of the E-wave was prolonged in TG mice. This LV diastolic
dysfunction was evident at 6 months of age and persisted at
the advanced ages. LV mass, estimated via echocardiography
and normalised for body mass (LVM/BM), was not signifi-
cantly different between TG and NTG mice, a finding that
was verified at autopsy. Catheterisation experiments at
15 months revealed unchanged LV contractility at baseline
and blunted responses to b-agonist stimulation for heart rate
and –dP/dt in TGs. In summary, unlike cardiac overexpres-
sion of wild-type a1B-ARs, expression of constitutively ac-
tive a1B-AR does not impart detrimental effects leading to
premature death.
Abstract N° C130
mTld alters subcellular localization of a1A-adrenergic
receptors
Qi Xu, Tan Zhang, Zhizhen Lu, Qide Han, Youyi Zhang.
Institute of Vascular Medicine, Peking University Third
Hospital and Reference Laboratory of Education Ministry
on Molecular Cardiology, Beijing, China
It has been recognized that non-G-proteins interact with
G-protein-coupled receptors. However, whether such inte-
raction occurs to a1-adrenergic receptors (a1AR) remains
unclear. We screened pretransformed human cDNA library
using a1AAR C terminal as bait, and obtained the CUB
domain of mTld, known as an extracellular matrix protease.
We then studied the interaction between a1AAR and mTld
both in yeast and mammalian cells. In yeast cells, the colony-
lift filter assay (X-gal) indicated that CUB5 domain of mTld
interacted well with the C terminal of a1AAR, but not the
cytoplasmic tails of either a1BAR or a1DAR. Immunopreci-
pitation also confirmed the coupling of a1AAR and mTld in
HEK293 cells. With immunofluorescence assay, we obser-
ved that a1AAR expressed both on the cell surface and intra-
cellularly in HEK293 cells in the absence of mTld, whereas
in cells with mTld, a1AAR were accumulated in certain
cytoplasmic compartments and could not be detected on the
cell surface. Radioligand binding showed that the density and
affinity of a1AAR were not affected by mTld. However,
whole-cell ELISA assay revealed that the cell surface a1AAR
in HEK293 cells in the presence of mTld were only 56 ± 6%
of that in cells transfected with a control vector, LacZ. Fur-
thermore, in cells without mTld, there was a rapid agonist-
induced internalization of cell surface receptor. In cells co-
expressing mTld, however, the cell surface a1AAR increased
initially followed by progressive decline in response to
a1AAR stimulation. Collectively, this study is the first to
demonstrate a specific interaction of mTld with a1AAR. Such
interaction does not change receptor expression, but signifi-
cantly alters the subcellular localization of a1AAR and the
time-course of agonist-induced a1AAR internalization.
Abstract N° C131
Cardiac myocyte intracellular calcium handling and
contractility in alpha 1A-adrenergic receptor
overexpressing mice
J.C. Tan a,b, A.C. McMahon a,b, R.M. Graham a,
M.P. Feneley a,b. a Victor Chang Cardiac Research Institute,
St. Vincent’s Hospital. b Department of Cardiology, St.
Vincent’s Hospital
Previous in vivo studies have shown that transgenic mice
which overexpress the a1A-adrenergic receptor (A1A1) have
enhanced cardiac contractility but no evidence of hypertro-
phy. However the contractile profile of cardiac myocytes in
these mice is unknown. Intracellular calcium (Ca2+i) han-
dling and contractility (% cell shortening) were compared in
single cardiac myocytes from wild-type (WT, n = 7) and
A1A1 (n = 7) mice using indo-1 loaded, electrically paced
cells. Responses to increasing concentrations of pheny-
lephrine (PE) were also measured. Basal calcium transients
were not different between WT and A1A1, but cell shorte-
ning was significantly reduced in A1A1 (WT, 6 ± 1% vs.
A1A1, 3 ± 2%, P < 0.01). With increasing [PE], [Ca2+]i and
cell shortening increased significantly in A1A1 but WT cells
were unresponsive. Plotting fractional cell shortening against
fractional change in [Ca2+]i indicated that the increased cell
shortening at higher [PE] in A1A1 is a result of increased
[Ca2+]i, and not due to increased sensitivity to calcium. These
data suggest that the in vivo phenotype can be explained by
the increased density of a1A-adrenergic receptors in the pre-
sence of circulating catecholamines.
Abstract N° C132
Sex dependent differences in cardiac myocyte
hypertrophy
Ruchi Patel a, Rebecca Ritchie b, Igor Wendt a. a Department
of Physiology, Monash University, Clayton, Vic., Australia.
b Baker Heart Research Institute, Melbourne, Vic., Australia
Cardiac hypertrophy is a major risk factor for
cardiovascular-related morbidity and mortality. There is evi-
dence for sex differences in the incidence of cardiac hyper-
Group E/A ratio DT (ms) FS (%) LVM/BM
(mg/g)
NTG
6 months 2.11 ± 0.11 32 ± 1 35 ± 1 3.3 ± 0.1
12 months 2.09 ± 0.19 33 ± 2 35 ± 1 3.6 ± 0.1
TG
6 months 1.31 ± 0.06 * 48 ± 2 * 44 ± 2 * 3.6 ± 0.1
12 months 1.26 ± 0.05 * 44 ± 1 * 40 ± 2 * 3.8 ± 0.2








0 5 10 15 2 0 2 5 3 0 3 5 4 0 4 5 5 0
WT                          A1A1
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trophy, and the presence of oestrogen and androgen receptors
in cardiac myocytes raises the possibility that sex hormones
may influence how the heart responds to conditions that lead
to the development of cardiac hypertrophy. The aim of the
present study was to examine possible sex differences in the
response of isolated cardiac myocytes to hypertrophic
agents. Cultures of both adult and neonatal rat cardiac myo-
cytes were studied, with the hypertrophic response to
angiotensin-II (AngII), endothelin-1 (ET-1) and pheny-
lephrine (PE) assessed by increases in protein synthesis.
Cardiac myocytes from either males or females were separa-
tely harvested by enzymatic digestion and established in
culture, prior to treatment with the hypertrophic agents in
[3H]-phenylalanine spiked media. [3H]-phenylalanine incor-
poration into protein (a marker of myocyte hypertrophy) was
normalised to total DNA to account for differences in cell
numbers between cultures. In cultures of adult cardiac myo-
cytes there was a significant difference between male and
female cells in the hypertrophic response to AngII and PE,
with the male cells exhibiting a greater response. The res-
ponse to ET-1 was not significantly different between the
sexes. In contrast, all three hypertrophic stimuli elicited ro-
bust responses in neonatal cardiac myocytes, with no signi-
ficant sex differences. These results suggest that in the neo-
nate, prior to exposure of the heart to circulating sex steroids,
there are no sex differences in the heart’s hypertrophic res-
ponsiveness. In the adult, however, after exposure to the
normal circulating sex hormone levels of the sexually mature
animal, sexual dimorphism in hypertrophic responsiveness
develops. This has important clinical implications, in that
development of, and optimal treatment for, cardiac hypertro-
phy may differ between the sexes.
Abstract N° C133
Gonadectomy and testosterone replacement influence
intracellular Ca2+ in male rat cardiac myocytes
Claire Curl a,b, Ben Canny a, Lea Delbridge b, Igor Wendt a.
a Department of Physiology, Monash University, Vic. 3800,
Australia. b Department of Physiology, University of
Melbourne, Vic. 3010, Australia
It is becoming increasingly evident that many aspects of
cardiac phenotype show important physiological differences
between the sexes, suggesting that sex steroid hormones may
serve as long-term modulators of myocardial function. The
present study investigated the effects of 4 weeks gonadec-
tomy (GDX), with or without testosterone (T) replacement,
on intracellular Ca2+ ([Ca2+]i) in male rat cardiac myocytes.
Cardiac myocytes were freshly isolated by collagenase di-
gestion and loaded with fura-2 for monitoring [Ca2+]i. Values
for the amplitude of the Ca2+ transient recorded in myocytes
stimulated at 0.5 Hz in 1.5 mM Ca2+ solution are given in the
table, along with the Ca2+ transient decay time constant and
extent of shortening (*denotes value is significantly different
from sham, †denotes value is significantly different from
testosterone replaced animals; n = 12–14 cells; N = 5–7
animals in each group).
These results show that testosterone promotes increased
levels of intracellular Ca2+ and contractility in cardiac myo-
cytes. This raises the possibility that testosterone may,
through influencing intracellular Ca2+ handling, play a role in
modulating cardiac performance in males and thereby contri-
bute to sex-dependent differences in cardiac function and
disease.
Abstract N° C134
Effect of sex hormone levels on the non-genomic action
of 17b-estradiol in rat mesenteric arteries
Wendy Keung, Ricky Y.K. Man. Department of
Pharmacology, The University of Hong Kong, HKSAR,
China
The lower incidence of cardiovascular events in women
has been attributed to the beneficial effects of the female sex
hormone estrogen. The effects of estrogen on the cardiovas-
cular system include both genomic and non-genomic mecha-
nisms. However, how these two effects interact is not well
understood. Sprague–Dawley rats (8 weeks old) were or-
chiectomized (male), ovariectomized (female) or sham-
operated and treated with vehicle or 17b-estradiol for 14 d.
Rats were then sacrificed and isometric tension of the mesen-
teric arteries were measured in organ bath setup. Acute admi-
nistration (30 min) of a physiological concentration of 17b-
estradiol (1 nM) caused a decrease in contraction to
phenylephrine in male but not in female rat mesenteric arte-
ries. However, this non-genomic effect was present when
female rats were ovariectomized and treated with vehicle. In
both sham-operated and ovariectomized female rats treated
with 17b-estradiol, the non-genomic effect was not present.
Sham-operated, vehicle-treated rats exhibited this non-
genomic effect. However, orchiectomy with vehicle treat-
ment abolished this effect. The non-genomic effect was also
lost in sham-operated and orchiectomized male rats treated
with 17-estradiol. The present study suggests that the reduc-
tion of contraction in the arteries by acute administration of
17b-estradiol is dependent on the levels of chronic circula-
ting sex hormones. This non-genomic effect appears to be
enhanced by testosterone and inhibited by estrogen. The
rapidity of this action and the low concentration required
(1 nM) to elicit this effect suggest that it is a receptor-
mediated response.
Abstract N° C135
Effect of testosterone on the secretion of
adrenomedullin and endothelin in cultured endothelial
cells
Xue-Wei Xu *, Xiao-Ying Li. Department of Geriatric
Cardiology, Chinese PLA General Hospital, Beijing
100853, China
Sham GDX GDX + T
Ca2+ transient amplitude (nM) 179 ± 17 102 ± 18 *,† 187 ± 20
Decay time constant (ms) 279 ± 23 455 ± 80 *,† 277 ± 19
Extent of shortening (%) 7.8 ± 1.8 2.7 ± 0.6 *,† 7.2 ± 1.3
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To investigate the effect of testosterone on the secretion of
adrenomedullin (ADM) and endothelin (ET) in cultured en-
dothelial cells. Incubated endothelial cells with different
concentration of testosterone (0, 2, 10, 50 and 100 ng/ml) for
24 h, then collected the cells and cultured medium respecti-
vely, radioimmunoassay was carried out to measure the
content of ADM and ET in cells and in cultured medium
respectively.
Results. – (1) The levels of ADM in cultured medium in
testosterone groups (2, 10, 50 and 100 ng/ml) were 34.29 ±
4.2 (vs. control group, P < 0.05), 44.65 ± 4.8 (vs. control
group, P < 0.001), 78.29 ± 8.07 (vs. control group, P <
0.001), 70.98 ± 10 pg/ml (vs. control group, P < 0.001)
respectively, but the content of ADM in cells in any groups
were no statistically different. (2) Likely ADM, ET in cultu-
red medium was also higher than in control group except at
concentration 2 ng/ml of testosteorne group, the content of
ET in cells was no difference between these groups.
Conclusion. – Testosterone can promote the secretion of
ADM and ET (testosterone’s concentration higher than
2 ng/ml) in cultured endothelial cells, through which testos-
terone may have an effect on the blood pressure.
Abstract N° C136
Effects of exogenous testosterone on atherosclerosis in
castrated rabbits
Wu Qiang, Li Xiao-Ying, Xu Xue-Wei. Department of
Geriatric Cardiology, Chinese PLA General Hospital,
Beijing 100853, China
To study the effect of serum testosterone level on experi-
mental atherosclerosis in castrated rabbits. Forty-five male
New Zealand white rabbits were randomized and then the
castrated rabbits were randomized to hypotestosteronemia
group, physitestosteronemia group, hypertestosteronemia
group, placebo group and sham operation group. The castra-
ted rabbits in the first three groups were intramuscularly
injected testosterone undecanoate 3, 6 and 12 mg/kg once
every 2 weeks, respectively, since the operation, whereas the
placebo group and the sham-operated rabbits did not receive
any testosterone. All animals were fed a cholesterol-rich diet
during the 16-week treatment period. Blood samples were
collected for determination of serum levels of total testoste-
rone (TT), estradiol (E2), lipids, lipoproteins and apolipopro-
teins at the 1st week before treatment and 16th week after
injection. At the end of study, the aortic of the second part
rabbits was analyzed morphmetrically and immunohistologi-
cally and the aortic cholesterol content were determined
chemically. The average serum lipids, atherogenic lipopro-
teins and apolipoproteins, such as total of cholesterol (TC),
triglycerides (TG), low density lipoprotein cholesterol
(LDL-C), apolipoprotein B (ApoB), etc. and the cholesterol
content (mmol/g) and intimal thickening in the proximal
aortic arch were significantly higher in the placebo, exoge-
nous hypotestosteronemia and hypertestosteronemia groups
than those in the sham operated and the exogenous hysites-
tosteronemia groups. Exogenous testosterone, at physiologi-
cal level seems have a good effect on the serum lipids,
lipoproteins, lipoproteins and atherosclerosis in castrated
male rabbits, whereas the endogenous or enexogenous hypo-
testosteronemia and hypertestosteronemia may have not.
Abstract N° C137
Set recruitment and chromatin remodeling are
epigenetic components responsible for myocardial gene
profiles in the hypertrophied and failing heart
Xiao-Jun Du, Shirley Moore, Hari Kn, Xiao-Ming Gao,
Helen Kiriazis, Assam El-Osta. Baker Heart Research
Institute, Melbourne, Vic., Australia
Histone modifications remodel chromatin structure and
transcription activity. Hypertrophied and failing myocar-
dium are characterized by profound changes in gene trans-
cription and molecular remodeling and it was not known
whether an epigenetic program is involved in myocardial
gene regulation during heart failure. We studied
acetylation/deacetylation or methylation states of histone
tails and correlated these marks with transcriptional state of
selected genes in hypertrophied and failing hearts of C57B6
mice with transverse aorta constriction (TAC) for 16 weeks.
Mice with TAC developed severe left ventricular hypertro-
phy (179 ± 11 vs. 95 ± 4 mg), chamber dilatation (4.8 ± 0.3
vs. 3.4 ± 0.1 mm) and failure (fractional shortening: 22 ± 3
vs. 36 ± 2%, all P < 0.01 vs. sham-operated group, SHAM).
Real-time RT-PCR showed enhanced (a-MHC, ANF) or sup-
pressed (a-MHC, SERCA2, a1AR) expression. Soluble
chromatin fractions derived from cross-linked SHAM and
TAC hearts were immunoprecipitated with antibodies
against acetyl-H3, acetyl-H4, histone deacetylase 1
(HDAC1), or histone H3-K4 methylation using specific chro-
matin immunoprecipitation (ChIP) assays and real time-PCR
to determine particular promoter sites. Chromatin from ac-
tive gene sets were enriched in acetyl-H3 and H4 together
with a concomitant release of HDAC1 in TAC vs. SHAM
hearts, and the opposite occurred for the down-regulated
gene sets. H3-K4 is known to activate transcription. We
observed that the H3-K4 histone methyltransferase Set7 is
mobilised onto transcriptionally competent genes (a-MHC
and ANF). Interestingly, these epigenetic changes are rever-
sible 6 weeks following removal of aorta banding. In sum-
mary, our results suggest that a coordinated and ordered
response to hypertrophy and failing heart is the active remo-
deling of chromatin, and that mobilization of the epigenome
is critical in regulating gene activity in heart disease.
Abstract N° C138
Gene expression profiling reveals distinct sets of genes
altered during hormonally and metabolically induced
cardiac hypertrophies
A.A. Domenighetti a,c, M. Ritchie b, G. Smyth b,
T. Pedrazzini c, J. Proietto d, L.M.D. Delbridge a.
a Department of Physiology, Melbourne University,
Australia. b WEHI Bioinformatics Group, Australia.
c Division of Hypertension, CHUV, Switzerland. d The
Royal Melbourne Hospital, Australia
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Today there is still a lack of diagnostic indicators and
prognostic markers that might direct individualized clinical
management of cardiac diseases induced by multifactorial
metabolic and neuro-humoral disturbances. cDNA high-
density microarray assays were used to explore changes in
cardiac expression of ~15,000 clones in: (1) the cardiac
angiotensin II-overproducing transgenic TG1306/1R mouse
and (2) the insulin-resistant cardiomyopathic muscle-
specific GLUT4-KO (knock-out) mouse. In TG1306/1R, we
report the (>2-fold) upregulation of 51 known genes and 26
ESTs (e.g. Hsd17b4, Tia1, Aogn, Col15a1, Mmp7, Calr,
Rab18), with a (>2-fold) downregulation of 11 known genes
and 14 ESTs (e.g. Nxf2, Grid2). In GLUT4-KO, we report
the (>2-fold) upregulation of 24 known genes and 17 ESTs
(e.g. Ndr4, Nppb, Gapd, S100a6, Cdh22, Ftl1), with a (>2-
fold) downregulation of 25 known genes and 11 ESTs (e.g.
Atp2a2, Tpm1, Atp5, Fabp3). Among the genes altered in
both mouse strains, we found Esterase 22, mitochondrial
ribosomal protein S16 and cytochrome c oxidase I (downre-
gulated in both mouse strains), as well as Hcapg, ICOS
ligand and CD2 antigen binding protein 2 (downregulated in
TG1306/1R, but upregulated in GLUT4-KO). Altered ex-
pression of the genes identified in this study may assist to
systematically characterize molecular events pertaining to
complex multifactorial diseases such as diabetic cardiomyo-
pathy and hormonally-induced cardiac hypertrophy.
Abstract N° C139
Gene expression profiling of human heart failure
Masako Tsubakihara a,b, C.C. Liew b, Paul D. Allen b,
Cristobal dos Remedios a. a University of Sydney, Sydney,
NSW, Australia. b Brigham and Women’s Hospital, Boston,
MA, USA
Heart failure (HF) is a major cause of mortality in the
Western world. Despite our increasing understanding of the
development and progression of HF from human studies and
animal models, the molecular mechanisms underlying this
disease are still not understood. In order to investigate these
molecular mechanisms we have examined gene expression
profiles of 58 patients with end-stage HF and 24 non-
diseased, donor hearts using Affymetrix Human Genome
U133 2.0 plus gene arrays and cardiovascular-specific Car-
dioChip cDNA arrays. HF patients with different aetiologies,
including: idiopathic dilated cardiomyopathy (13 cases);
viral-induced dilated cardiomyopathy (seven); familial di-
lated cardiomyopathy (five); familial hypertrophic cardi-
omyopathy (six); post-partum dilated cardiomyopathy (five);
ischemic cardiomyopathy (22); and anthracycline-induced
cardiomyopathy (six) were examined. This enabled us to
observe changes in gene expression due to different aetiolo-
gies of HF, and characterized distinct sets of genetic and
biological pathways to provide an insight in understanding
the pathways involving HF. We have also distinguished the
genomic profiles of the seven types of HF using hierarchical
cluster analysis. One of challenges we face when examining
human tissues compared to animal models is that individual
genetic background differences and epigenetic factors, such
as history of smoking, diet, drinking, and medications, may
affect gene expression as much as the disease itself. To
address this problem, detailed clinical data were obtained
and the effects of epigenetic factors on the gene expression
were examined. This is the largest gene expression profiling
analysis undertaken to date and will provide valuable infor-
mation on the nature of human HF.
Abstract N° C140
Relationship between MTHFR gene polymorphism and
peripheral arterial occlusive disease
Jianwei Liu, Jing Liu, Ling Ye, Xiaoying Li. Institute of
Geriatrics, Chinese PLA General Hospital, Beijing 100853,
China
Methylenetetrahydrofolate reductase (MTHFR) is a
speed-limiting enzyme of homocysteine (Hcy). The decrease
of MTHFR activity, which was caused by C677T mutation in
MTHFR gene, may lead to an elevated level of plasma Hcy.
Hyperhomocysteinemia may speed up the progress to arte-
riosclerosis and appears to be an independent risk factor for
peripheral vascular occlusive disease. This study aims at
exploring the relationship between MTHFR gene polymor-
phism and the risk to peripheral arterial occlusive disease
(POAD) in the elderly of Beijing community. Polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) was carried out. One hundred control subjects
(NC group), 83 patients with peripheral arterial occlusive
disease (POAD group) were screened to assess the polymor-
phism of MTHFR gene. The frequencies of three genotypes
were C/C (homozygous normal), 31%; C/T (heterozygous),
50%; T/T (homozygous mutant), 19% in NC group and
13.3%;51.8%;34.9% in POAD group respectively. The fre-
quencies of allele T were 44% and 60.8%, respectively. The
frequencies of homozygous T/T and allele T in POAD group
were significantly higher than those in NC. C677T mutation
in MTHFR gene is associated with the risk to peripheral
arterial occlusive disease in the elderly of Beijing commu-
nity.
Abstract No C142
Monte Carlo simulation demonstrating the regression
dilution bias of the risk estimation of high blood
pressure on cardiovascular events and mortality
Moshe Leshnoa,b,MD, PhD and Uri Goldbourta PhD.
aSackler Faculty of Medicine, Tel Aviv University, Israel.
bFaculty of Management, Tel Aviv University, Israel
The random fluctuations in systolic blood pressure (SBP)
or diastolic blood pressure (DBP) may lead to underestima-
tion of the odds ratio of developing disease, associated with
blood pressure, using logistic regression. For example, the
true association between SBP and cardiovascular (CV) mor-
tality may be underestimated using only one measurement of
blood pressure. A correction of the estimates can be granted,
given at least two measurements of blood pressure (BP) i.e.
risk estimations are more precise based on at least two mea-
surements of BP than based on only one measurement.
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The Israeli Ischemic Heart Disease (IIHD) project was a
longitudinal investigation of cardiovascular disease among
10,059 male civil servant and municipal employees in Israel.
Participants underwent clinical evaluation in 1963, 1965 and
1968. Using bootstrapping we randomly divided the popula-
tion 1,000 times into two sets, termed the in-sample set and
the out-sample set. We calculated the 10th and 90th percen-
tiles of the SBP measured in 1963 in the in-sample set, and
estimated the odds ratio (OR) of the cardiovascular mortality
rate in the two sets, using the same 10th and 90th percentiles
of the SBP in the out-sample set. We found that OR for CV
mortality, based on the in-sample set, underestimated the true
OR obtained in the out-sample set. The correction of the
regression dilution factor estimate was 1.64 (CI = 1.61-
1.64). Specifically, the OR for CV mortality over a 21-year
follow-up, associated with an increase of 20 mmHg of SBP
was estimated based on one SBP measurement to be 1.51
(CI = 1.46-1.55), whereas the —true » OR for CV mortality
over a 21-year follow-up was 1.96 (CI = 1.94-1.98). This
underestimation can be corrected using at least two measure-
ments of SBP. In addition we demonstrate the regression
dilution bias using Monte Carlo simulation.
Abstract No L1
Sarcomeric proteins as centers of multiplex functions
in signaling and mechano-transduction in the
myocardium
R. John Solaro, College of Medicine, University of Illinois
at Chicago, Chicago, IL 60612
Apart from their critical role in generating tension and
shortening, cardiac sarcomeres actively participate in impor-
tant mechanisms that determine cardiac function in health
and disease. I will present experiments aimed at testing the
following three hypotheses : 1) Modifications of the sarcom-
eric response to calcium are essential elements in the control
of the extent and rate of tension development by cardiac
myocytes, and their rates of shortening and relengthening. 2)
Signaling and functional changes at the level of the sarcom-
ere are integral elements in the cascade of reactions associ-
ated with compensated hypertrophy and the transition to
failure. 3) The Z-disk functions not only as a physical anchor
for the myofilaments, cytoskeletal proteins, and membrane
proteins, but also as a pivot point for the reception, transduc-
tion, and transmission of mechanical and biochemical sig-
nals. Approaches to these hypotheses include mutagenesis,
transgenesis, and in vitro exchange of sarcomeric proteins.
This lecture honors the memory of Keith Reimer, who did
seminal work in ischemic injury. I will present data demon-
strating that increased myofilament response to calcium is
able to blunt effects of reperfusion injury.
Abstract No L2
The damaged heart
Piero Anversa, Daniele Torella, Daria Nurzynska, Marcello
Rota, Brian Whang, Konrad Urbanek, Bernardo
Nadal-Ginard, Annarosa Leri, Jan Kajstura, New York
Medical College, Valhalla, New York, USA
Cardiac stem cells and early committed cells (CSCs-
ECCs) are present throughout the myocardium, express
c-Met and IGF-1 receptors and through a feed-back loop
respond by secreting the corresponding ligands, HGF and
IGF-1. HGF mobilizes CSCs-ECCs and IGF-1 promotes
their survival and proliferation. Therefore, HGF and IGF-
1 were injected in the heart of infarcted mice to favor, respec-
tively, translocation of CSCs-ECCs from the surrounding
myocardium to the dead tissue, and to enhance their viability,
growth and differentiation within the damaged area. The new
myocardium contained arterioles, capillaries and function-
ally competent myocytes, which with time increased in size,
ameliorating ventricular performance at healing and long
thereafter. Myocardial regeneration induced by growth fac-
tors rescued animals with infarcts up to 86 % of the ventricle,
which are commonly incompatible with life and improved
survival. Thus, the heart has an endogenous reserve of CSCs-
ECCs that can be activated to reconstitute lost myocardium
after infarction and obviate the need to introduce exogenous
stem cells.
Abstract No L3
Use of gene therapy for cardioprotection
Roberto Bolli, Institute of Molecular Cardiology, University
of Louisville, Louisville, KY
The heart has evolved an adaptive response of stress,
termed late preconditioning (PC), which confers powerful
and sustained protection against ischemia/hyperfusion in-
jury. Previous work by us and others has shown that late PC is
underlain by a genetic reprogramming of the heart, i.e., by
the upregulation of a cluster of stress-responsive cardio-
protective proteins, such as iNOS, HO-1, COX-2 and ec-
SOD. Based upon this work, we tested the feasibility of
transferring these genes to the heart to achieve a permanent
preconditioned-like state.
From the inception of our work on late PC, our goal has
been to exploit the mechanism of late PC to achieve a chronic
preconditioning-like state that could afford long-term, possi-
bly permanent, cardioprotection in patients at risk for coro-
nary artery disease. A number of studies performed in our
laboratory now show that cardiac transfer of iNOS, COX-2,
HO-1 and ecSOD affords robust and sustained protection
against lethal ischemia/reperfusion injury in mice and rab-
bits. While most of these studies were performed with first-
generation adenoviral vectors, we are now using recombi-
nant adeno-associated viral vectors (rAAV) to overcome the
two major limitations of first-generation vectors, namely, the
short duration of expression and the inflammatory response.
Our data show that rAAV-mediated gene transfer is feasible
and results in long-term genetic reprogramming of the heart,
which confers a protective phenotype. These studies demon-
strate that gene therapy can be used to achieve chronic
prophylactic cardioprotection and lay the groundwork for
novel therapeutic approaches to myocardial ischemia/
reperfusion injury predicated upon the over expression of the
proteins that are responsible for late PC.
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Abstract No L4
Cardiac channelopathy : a bridge from the gene to
clinical practice
Masayasu Hiraoka. Dept of Cardiovascular Diseases,
Medical Research Institute, Tokyo Medical and Dental
University, Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
Recent advances in molecular genetics and electrophysi-
ologic method have disclosed the genetic abnormalities in
cardiac ion channels as pathological basis for inherited ar-
rhythmic disorders : cardiac channelopathy. Congenital long
QT syndrome is caused by mutations of ion channel genes.
At present, seven chromosomal loci and mostly ion channel
genes have been identified. They are classified as LQT1 —
LQT7. LQT1 is the most frequent form and is caused by
mutations in KvLQT1 (or KCNQ1), which encodes Iks.
LQT2 is the next prevalent type and is caused by mutations in
HERG (KCNH2), encoding Ikr. Mutations of these genes
underlie various degrees of current suppression (loss of func-
tion). We have observed different sites of mutations in HERG
demonstrating various mechanisms of current suppression in
Japanese LQT2 patients including activation and inactivation
abnormalities, and trafficking defects. LQT3 is far less fre-
quent than the other two forms and is caused by mutations in
SCN5A, encoding human cardiac Na+ channels. Mutations of
SCN5A exhibit persistent Na+ current providing the gain of
function to prolong QT intervals. Other forms (LQT4-LQT7)
are quite rare. Brugada syndrome is a unique form of idio-
pathic ventricular fibrillation (IVF), exhibiting ST segment
elevation in right precordial leads of ECG and is also caused
by mutations in SCN5A. Mutant Na+ channels found in Bru-
gada syndrome show either no expressed currents or de-
creased functions mainly due to altered inactivation proper-
ties. A single mutation in SCN5A is shown to exhibit clinical
phenotypes of both LQT3 and Brugada syndrome. We also
demonstrated the SCN5A mutation, S1710L, in a patient with
IVF without showing typical ECG changes of Brugada syn-
drome. The functional abnormality of S1710L has close
similarity to that of other type of mutations in SCN5A caus-
ing the progressive cardiac conduction disturbances. Thus,
Na+ channelopathy may bring a new disease entity of cardiac
pathogenesis. Catecholaminergic polymorphic ventricular
tachycardia is caused by mutation in ryanodine receptor
gene. (RyR2).
Abstract No L5
Janice Pfeffer Distinguished Lecture : Cardiac
dyssynchrony and resynchronization
David A. Kass, Johns Hopkins Medical Institutions
Baltimore, MD, USA
The failing heart reflects the conspiracy of multiple abnor-
malities of the myocyte, molecular signalling, cellular/
chamber remodelling, load, and neurohumoral stimulation.
Recently added to this long list is the presence of dyssyn-
chronous contraction from conduction delay. Cardiac dys-
synchrony is induced by routine single-site pacing, and in
normal hearts results in a modest decline in cardiac function
and energetic efficiency. However, its impact in failing hearts
is exacerbated, and clinical studies have shown that creating
dyssynchrony in patients where none previously existed can
worsen heart failure. Importantly, the reverse — resynchro-
nizing by of left- or bi-ventricular stimulation improves
symptoms, reduces hospitalizations and mortality in patients
with severe heart failure. Dyssynchronous ventricles are ef-
fectively polarized into two regions ; an early activated terri-
tory that contracts against little load and largely pre-stretches
the remote myocardium, and a late activated area that gener-
ates higher stress and also wastes work by re-stretching the
early stimulated region. Dilated failing hearts enhance both
geographic and temporal separation of these regions, en-
hancing the impact of dyssynchrony. Cardiac resynchroniza-
tion (CRT) improves contractile coordination and thereby
systolic function and efficiency, often leading to reverse
remodelling.
At the basic level, dyssynchrony alters local and transmu-
ral electrical conduction and repolarization in the late acti-
vated lateral wall. When combined with failure, more intense
changes in the expression of calcium handling proteins,
stress kinases, gap junction proteins, and myocyte dysfunc-
tion are observed localized to the high stressed lateral en-
docardium. New studies are assessing the impact of varying
site and delivery method to CRT efficacy, and expanding our
exploration into molecular and cellular signalling changes
and impact that CRT has on these abnormalities.
Abstract No S1A
Controversies in adult stem cell plasticity
Malcolm Alison, Imperial College London, UK
A large body of evidence now supports the idea that
certain adult stem cells, particularly those of bone marrow
origin, can engraft alternative locations (e.g. non-
haematopoietic organs), particularly when the recipient or-
gan is damaged and transdifferentiate in to phenotypes ap-
propriate to their new location. Hence there is considerable
excitement in using HSCs in cell based therapies and as
vectors to deliver therapeutic genes. However the field is not
without its detractors. The reason for this is twofold, 1)
certain instances of so-called plasticity have now been attrib-
uted to cell fusion between bone marrow cells (or their
myeloid/monocytic descendants) and cells of the recipient
organ, and 2) several remarkable claims have not been able to
be confirmed, most recently the inability to show that puri-
fied HSCs can contribute to the healing of a myocardial
infarction. This last observation is particularly noteworthy
given the number of Medical Centres embarking upon the
injection of autologous bone marrow to assist in myocardial
healing after infarction.
Certain criteria should be met before claims that stem cells
can cross their apparent lineage barriers are accepted, in
particular they should be functional and in continually re-
newing tissues they should be able to proliferate. In the
context of renal injury and in epidermis we have shown
proliferation of bone marrow-derived cells with an appropri-
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ate epithelial phenotype, and even clonal expansion of such
cells to contribute to whole Epidermal Proliferative Units
(EPUs). We have also shown that bone marrow contributes to
vasculogenesis (endothelium and smooth muscle). We have
also shown that intestinal subepithelial myofibroblasts (niche
cells of the crypt) are bone marrow derived, as are myofibro-
blasts in a variety of other organs, moreover bone marrow
contributes to the tumour desmoplastic response. Bone mar-
row cells also make a significant contribution to the hepatic
myofibroblast population that is instrumental in causing the
hepatic scarring of cirrhosis.
Abstract No S1B
The reality of myogenic stem cells
Miranda D Grounds, School of Anatomy and Human
Biology, the University of Western Australia, Perth,
Australia
Transplantation into the heart of autologous muscle pre-
cursor cells (myoblasts) routinely derived from primary cul-
tures of mature skeletal muscle appears to alleviate the dam-
age caused by necrosis of cardiomyocytes. The potential
clinical use of stem cells as a superior source of myoblasts for
transplantation therapy for heart repair and gene replacement
in myopathies is an area of intense investigation. The two
main sources of such putative (autologous) stem cells are (1)
within skeletal muscle tissue as either a sub-population of
satellite cells (conventional muscle precursors on the surface
of myofibres) or the interstitial connective tissue, and (2)
from non-muscle tissue such as bone- marrow, the dermis or
thymus. The intrinsic and extrinsic factors controlling com-
mitment of such cells into myoblasts or their conversion into
cardiomyocytes and their expansion in vivo are critical issues
to consider. The key question is the extent to which such stem
cells might be harnessed for clinical purposes and whether
any of them represent a superior source of myoblasts for
heart repair.
Abstract No S1C
Plasticity of adipose tissues : cardiac and vascular
potential
L. Casteilla, V. Planat-Benard, UMR 5018, UPS/CNRS,
IFR31 Toulouse, JS Silvestre, U541, Paris, France
Adipose tissue development and remodelling are closely
associated with the growth of vascular network. We hypoth-
esized that adipose tissue may contain progenitor cells with
cardiogenic and angiogenic potential and that therapy based
on adipose tissue-derived progenitor cells administration
may constitute a promising cell therapy. Firstly, we demon-
strate that rare beating cells with cardiomyocyte features can
be identified after culture of murine adipose stroma cells
without addition of 5-azacytidine. The cardiomyocyte phe-
notype is identified by morphological studies, immunohisto-
logical confocal analysis, expression of specific cardiac
markers and electrophysiological and functional analyses.
Second, we demonstrate that cultured human SVF cells
differentiate into endothelial cells, incorporate into vessels
and promote both post-ischemic neovascularization in Nude
mice and vessel-like structures formation in Matrigel plug.
These cells are as efficient as bone marrow mononuclear
cells to reconstitute neo-vessels. In vitro, these cells can
spontaneously express the endothelial cell markers
CD31 and von Willebrand factor when cultured in semi-solid
medium. Interestingly, dedifferentiated mature human adipo-
cytes have the potential to rapidly acquire endothelial pheno-
type in vitro and to promote neovascularization in ischemic
tissue and vessel-like structures formation in Matrigel plug
suggesting that cells of endothelial and adipocyte phenotypes
may have a common precursor. This study demonstrates, for
the first time, that adipocytes and endothelial cells have a
common progenitor.
Taken together, these results highlight the concept that
cells from adipose tissue represent a suitable new cell source
for therapeutic angiogenesis in ischemic disease and for heart
regeneration after heart failure.
Abstract No S2B
Cardiac lim proteins and mechanical stress sensing
Masahiko HOSHIJIMA, MD PhD, Department of Medicine
and Institute of Molecular Medicine, University of
California San Diego
Cardiac myocytes respond to mechanical stretch stimuli
by triggering downstream signals for cell growth and sur-
vival. Inadequate stress sensing may lead to the development
of various forms of cardiomyopathies and to trigger the
abnormal remodelling of surviving myocardium in the inf-
arcted heart, which is chronically exposed to high wall stress.
Although the involvement of stretch activated channels and
cell adhesion complex proteins has been propose, the mo-
lecular components of the cardiac muscle stretch sensor have
remained uncertain. Our group recently identified a selective
role for muscle LIM protein (MLP), a Z disc protein, in
sensing passive stretch in cardiomyocytes via biological and
physiological studies in MLP deficient mouse cardiac
muscle. MLP interacts with and co-localizes with telethonin
(T-cap), a titin interacting protein. Based on our understand-
ing that other Z disc associated cardiac LIM proteins includ-
ing ALP and ZASP/Cypher/Oracle are also linked to dilated
cardiomyopathy (DCM) in human and rodents, we propose
cardiac titin/Z disc structure and associated LIM proteins
constitute in vivo cardiomyocyte stretch sensor machinery,
and that defects in the complex can lead to human DCM and
associated heart failure.
Abstract No S2C
A Molecular Switchboard : Communicating with
myofilaments through the actin capping protein CapZ
Glen Pyle, University of Guleph, Canada
The cardiac Z-discs have traditionally been viewed as
passive structural elements of myocytes. However, recent
studies have expanded the function of cardiac Z-discs to
include roles in intracellular signalling and regulation of
muscle mechanics. Using the Z-disc component actin cap-
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ping protein (CapZ), we have investigated its impact on
intra-cellular communication pathways thought to be in-
volved in the development of heart failure, as well as its
ability to regulate myofilament function. We have exploited
two experimental models in our investigations : a transgenic
mouse line deficient in cardiac CapZ ; and a procedure
whereby CapZ is extracted from wild-type myofilaments
with PIP2. Both models have yielded similar results. We have
found that a reduction in cardiac CapZ enhances myofila-
ment Ca2 + sensitivity and increases isometric force develop-
ment by 60 %. The downregulation of CapZ attenuates the
inhibition of myofilament activation by PKC-oII, a putative
messenger in the development of heart failure. Finally, we
have found that type 1 protein phosphatase — which nor-
mally increases both maximum isometric tension and myo-
filament Ca2 + sensitivity — decreases myofilament activa-
tion when CapZ levels are reduced. Together these results
strongly support the concept that the Z-discs are active regu-
lators of cardiac function by virtue of their ability to control
intracellular signalling systems and myofilament activation.
The vital role of CapZ in a signalling pathway though to
promote heart failure, coupled with its apparent ability to
dampen force development suggests that the therapeutic ma-
nipulation of this Z-disc protein may be a viable treatment
option for the management of cardiac dysfunction.
Abstract No S2D
Deciphering the multiple roles of actin filament
capping proteins in thin filament length regulation
Carol C. Gregorio, Ryan E. Mudry and Abigail S.
McElhinny. Dept. of Cell Biology and Anatomy, University
of Arizona, USA
Actin (thin) filament length regulation and stability are
essential for striated muscle function. To identify the mecha-
nisms required for this process we have taken the approach of
deciphering the physiological significance of specific actin
filament capping proteins at the pointed and barbed ends
(Z-line) with their binding proteins. For example, to deter-
mine the role of the actin filament pointed end capping
protein, tropomodulin1 (Tmod1) with tropomyosin, we gen-
erated monoclonal antibodies against Tmod1 that specifi-
cally disrupted its interaction with tropomyosin in vitro.
Perturbing this interaction in chick cardiac myocytes caused
a dramatic loss of the thin filaments, as revealed by immun-
ofluorescence deconvolution microscopy. Real-time imaging
of live myocytes expressing GFP-a-tropomyosin and micro-
injected with the function-blocking antibodies revealed that
the thin filaments depolymerized from their pointed ends. In
a thin filament cell permeabilization reconstitution assay,
stabilization of the filaments with phalloidin or jasplakino-
lide, prior to the addition of the function blocking antibodies
prevented the loss of thin filaments. As a complementary
approach, we also expressed a recombinant N-terminal frag-
ment of Tmod1 containing the tropomyosin binding site.
Again, a loss of actin filaments was observed, likely due to a
dominant-negative mechanism. These studies indicate that
the interaction of Tmod1 with tropomyosin is critical for thin
filament stability. These data, together with previous studies,
indicate that Tmod1 is a multifunctional protein. Its actin
filament capping activity is responsible for maintaining actin
length, by preventing elongation from the pointed ends ; the
tropomyosin binding activity stabilizes actin-thin filaments
by preventing depolymerization of the thin filaments.
Abstract No S2E
The role of a novel Z-disc protein family, calsarcins, in
striated muscle function and disease
N. Frey, Dept. of Cardiology, University of Heidelberg,
Germany
Signaling by the calcium-dependent phosphatase cal-
cineurin profoundly influences growth and gene expression
of cardiac and skeletal muscle. Calcineurin binds to a novel
family of muscle-specific proteins, calsarcins, which are
tethered to the Z-disc of the sarcomere, a focal point for
pathological signalling in human cardiomyopathies and mus-
cular dystrophies. We now show that calsarcin-1 negatively
modulates the functions of calcineurin, such that calcineurin
signaling is enhanced in cardiac and skeletal muscle of
calsarcin-1 null mice. As a consequence of inappropriate
calcineurin activation, calsarcin-1 mutant mice display an
excess of slow skeletal muscle fibers. Moreover, despite the
absence of hypertrophy or an overt cardiac phenotype,
calsarcin-1 mutant mice exhibit a marked induction of the
—fetal gene program » and an enhanced cardiac growth
response to biomechanical stress. In contrast, cardiac adap-
tation to other types of stress signals, such as chronic cat-
echolamine stimulation, is unaffected in calsarcin-1 null
mice. These findings reveal important roles for calsarcins as
modulators of calcineurin signaling and the transmission of a
specific subset of stress signals leading to cardiac remodel-
ling in vivo.
Abstract No S3A
Cell death and cytosolic CA2 + overload : cause or
consequence of mitochondrial dysfunction ?
Paolo Bernardi, Department of Biomedical Sciences and
Venetian Institute of Molecular Medicine, University of
Padova, Italy
Mitochondria are central to apoptotic Ca2 + signalling. A
key switch between cell survival and cell death is the mito-
chondrial permeability transition pore (PTP), a high conduc-
tance channel that may open in response to mitochondrial
Ca2 + uptake. Matrix Ca2 + is a permissive factor for pore
opening, yet Ca2 + alone may not be sufficient. In fact, the
PTP open-closed transitions are modulated by additional
factors that may critically affect the outcome of an identical
Ca2 + signal. Addition of A23187 should mimic the Ca2 +
overload taking place under pathological conditions. Unex-
pectedly, however, we found that addition of A23187 to
MH1C1 cells caused a slow mitochondrial depolarization
and death of about 30 % of cells, findings that are inconsis-
tent with the expected consequences of cellular Ca2 + over-
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load. Here I will show that addition of A23187 causes a fast
but only transient rise of [Ca2 + ]c, which is sequentially
followed by a rapid increase of cPLA2 activity and then by
PTP opening, the latter event occurring when [Ca2 + ]c had
already returned to nearly basal levels. We identified the
proapoptotic signal triggered by A23187 as free arachidonic
acid, whose levels could be further increased by treatment
with the lipoxygenase inhibitor MK886 plus the cyclooxyge-
nase inhibitor indomethacin. These findings identify cPLA2
as the mechanistic link between A23187-dependent pertur-
bation of Ca2 + homeostasis and the effector mechanisms of
cell death. Whether cytosolic Ca2 + overload can bypass the
otherwise necessary activation of cPLA2 is under active in-
vestigation.
Abstract No S3B
PTP and ischemia-reperfusion injury
Fabio Di Lisa, Departmentof Biochemistry, University of
Padova, Italy
The viability of the ischemic myocardium is jeopardized
by alterations, such as ATP decrease and elevation in intrac-
ellular [Ca2 + ], that are related to derangements in mitochon-
drial function. Besides these established notions, the elucida-
tion of the apoptotic cascade and the availability of novel
methodologies for in situ studies prompted a renovated inter-
est in mitochondria. The characterization of mitochondrial
channels provided a contribution that is particularly relevant
to cardiovascular research.
Here we focus on the role of the permeability transition
pore in ischemia reperfusion injury by analyzing (i) the
methodological requirements for its characterization in iso-
lated cells and intact organs ; (ii) the consequences of its
opening highlighting the derangements in NAD+ metabo-
lism ; (iii) the contribution to necrosis and apoptosis ; (iv) the
possible relationship with the formation or reactive oxygen
species.
Abstract No S3C
The inner mitochondrial membrane proteins altered
with preconditioning : complexity and novel proteins
revealed by proteomics
Jennifer van Eyk. JHU Bayview Proteomic Center,
Baltimore, Maryland, USA
Alteration of the mitochondrial proteome and correspond-
ing changes in mitochondrial function has been implicated in
a variety of degenerative diseases, heart disease, aging and
cancer. The heart can be protected against severe ischemia
either through preconditioning, induced by either brief tran-
sient ischemia or pharmacologically using adenosine or dia-
zoxide. Although adenosine and diazoxide are potent PC
agents they are known to work via different molecular path-
ways. Adenosine stimulates a complex signaling cascade that
includes activation of PKC while diazoxide is proposed to act
specifically on the KATP channels. Our hypothesis is com-
mon proteome changes would represent key protein(s) in-
volved in induction of PC. Isolated rabbit myocytes were
treated for 60 minutes with either drug and various subpro-
teomes (myofilament, mitochondria, cytoplasmic) were ana-
lyzed by 2 dimensional gel electrophoresis (pH 4-7, 6-11 and
3-10).The protein alterations converged on to the mitochon-
drial proteins involved in TCA or the oxidative phosphoryla-
tion pathway. Surprisingly, the inner mitochondrial proteome
is not well established, in part, due to the hydrophobic nature
and basic isoelectric point of these membrane proteins. Com-
bining 2DE (pH 4-7, 6-11 and 3-10) and 2 dimensional liq-
uid chromagraphy (Beckman, pH 4-8.5) we identified over
200 proteins, 20 of which were post translationally modified,
was created of the proteins associated with and spanning the
mitochondrial inner membrane. Further subfractionation us-
ing Nabicarbonate to enriched for transmembrane mitochon-
drial inner transmembrane proteins revealed an additional
40 proteins. Several novel channels and associated proteins
of unknown function were identified and functional roles are
being investigated.
Abstract No S3D
Limitation of electron flow during ischemia and
mitochondrial and myocardial protection
Edward J. Lesnefsky. Cardiology Section/Medical Service,
Louis Stokes VA Medical Center, Cleveland, OH 44106,
USA
Mitochondria are sources and targets of oxidative damage
during myocardial ischemia. In the isolated, perfused rabbit
heart, ischemia damages the distal electron transport chain
(ETC), decreasing the contents of cardiolipin and cyto-
chrome c, leading to a decrease in the rate of oxidation
through cytochrome oxidase. In isolated mitochondria in
vitro, limitation of electron flow into complex III by the
complex I inhibitor rotenone blunted the production of reac-
tive oxygen species during the oxidation of complex I sub-
strates. We asked if blockade of electron flow immediately
before in situ ischemia would limit damage to the distal ETC.
Treatment immediately before ischemia with rotenone at-
tenuated ischemic mitochondrial damage, preserving the
contents of cardiolipin, cytochrome c, and respiration
through cytochrome oxidase. Rotenone treatment before is-
chemia preserved mitochondrial oxidative function in the
aged rat heart, a model of enhanced ischemic damage. Treat-
ment of the isolated rat heart before ischemia with amytal, a
reversible complex I inhibitor at the rotenone site, also pre-
served mitochondrial oxidative function at the end of is-
chemia. Thus, limitation of electron flow during ischemia is a
robust mechanism to minimize ischemic damage to the distal
ETC. Ischemic damage to the distal ETC augments the pro-
duction of reactive oxygen species, a likely mechanism for
the oxidant burst that occurs at the onset of reperfusion.
Limitation of electron flow during ischemia preserves mito-
chondrial function at the end of ischemia. Preservation of
mitochondrial function following ischemia is likely to trans-
late into myocardial protection during ischemia and reperfu-
sion.
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Abstract No S3E
Mitochondrial criticality : role of mitochondrial ion
channels and ROS
Brian O’Rourke, Sonia Cortassa and Miguel A. Aon.
Institute of Molecular Cardiobiology. The Johns Hopkins
University, Baltimore MD
Synchronization of mitochondrial function is an impor-
tant determinant of cell physiology and survival, yet little is
known about the mechanism of interorganellar communica-
tion. We have recently observed that coordinated cell-wide
oscillations in the mitochondrial energy state of heart cells
can be induced by a highly localized perturbation of a few
elements of the mitochondrial network, indicating that mito-
chondria represent a complex, self-organized system. The
oscillations were associated with bursts of mitochondrial
reactive oxygen species (ROS) production, but did not in-
volve the classical permeability transition pore or intracellu-
lar Ca2 + overload. Propagated synchronized oscillations
were abolished by inhibiting mitochondrial complex III-
derived reactive ROS, by increasing ROS scavenger levels, or
by inhibiting mitochondrial anion channels, suggesting that
an inner membrane, superoxide-permeable, anion channel
opens in response to free radicals. To investigate the mecha-
nism of intramitochondrial synchronization, we have applied
percolation theory to demonstrate that a global phase transi-
tion (mitochondrial depolarization) occurs when a critical
density of mitochondria accumulate reactive oxygen species
(ROS) above a threshold to form an extended spanning clus-
ter. The scaling and fractal properties of the mitochondrial
network at the edge of instability agree remarkably well with
the idea that mitochondrial network is organized as a perco-
lation matrix, with ROS as a key messenger. The mechanism
of the oscillator is further explored in a newly developed
computational model describing how the balance between
mitochondrial ROS production and intracellular ROS scav-
enging determine the dynamics and stability of the mito-
chondrial energy state of cardiac cells. Our findings indicate
that the mitochondria can be viewed as a network of oscilla-
tors that may constitute a ROS-dependent signalling system.
Abstract No S4A
Sodium/bicarbonate cotransport current in the
configuration of the cardiac action potential
Ernesto Alejandro Aiello. Centro de Investigaciones
Cardiovasculares. Facultad de Ciencias Médicas,
Universidad Nacional de La Plata, La Plata, Argentina
The Na+/HCO3
- cotransport (NBC) contributes to 40-
50 % of total acid extrusion in ventricular myocardium.
There are at least two electrogenic isoforms of the NBC in
the heart, NBC1 and NBC4. Measuring Na+-dependent
bicarbonate-sensitive currents with perforated-patch we
were able to demonstrate the existence in the heart of an
electrogenic NBC with a HCO3
- :Na+ stoichiometry ratio of
2 :1. This electrogenic NBC produces an anionic current
which is outward (hyperpolarizing and repolarizing current)
at potentials positive to the reversal potential of the NBC.
Since the determined reversal potential for this electrogenic
NBC is close to —95 mV, when the myocytes are exposed to
a solution containing a physiological concentration of bicar-
bonate a hyperpolarization of resting membrane potential
together with a shortening of action potential duration are
observed. Thus, the electrogenic NBC participates in the
configuration of the cardiac action potential, being this effect
usually masked by the wide use of non-bicarbonate solution
in electrophysiological recordings. The role of NBC in
ischemic-reperfusion injury, heart failure and generation of
arrhythmias remains to be determined. However, there is
increasing evidence that involves this transporter as one of
the Na+-loading mechanisms during reperfusion.
Abstract No S4B
Pathophysiological and protective roles of katp
channels in ischemia/reperfusion : re-evaluation using
katp channel-knockout mice
Haruaki, Nakayaa, Masashi Suzukia, Toshiaki Satoa,
Takashi Mikib & Susumu Seinob. aChiba University
Graduate School of Medicine, Chiba ; and bKobe University
Graduate School of Medicine, Kobe, Japan
To elucidate the pathophysiological roles of ATP-sensitive
(KATP) channels in ischemia/reperfusion, we conducted
functional experiments using Kir6.x knockout (KO) mice.
The KATP channel current could be recorded in ventricular
cells of Kir6.1 KO but not Kir6.2 KO mice. The action poten-
tial duration was shortened during no-flow ischemia in
coronary-perfused ventricular muscle preparations of wild-
type (WT) but not Kir6.2 KO mice. The mitochondrial KATP
(mitoKATP) channel function, evaluated by flavoprotein oxi-
dation, was preserved in both Kir6.2 KO and Kir6.1 KO
ventricular cells, suggesting that neither Kir6.1 nor Kir6.2 is
a component of mitoKATP channel. However, ischemic pre-
conditioning failed to reduce the infarct size in Kir6.2 KO
mice, indicating that sarcolemmal KATP (sarcKATP) chan-
nels composed of the Kir6.2 pore subunits play an important
role in cardioprotection, at least, in mice. Kir6.1 KO mice
showed sudden cardiac death resulting from myocardial is-
chemia associated with spontaneous ST elevation and atrio-
ventricular block in ECG. Functional analysis of vascular
smooth muscles of WT and Kir6.1 KO mice revealed that
sarcKATP channels having the Kir6.1 pore subunit are im-
portant in the regulation of vascular tone. Thus sarcKATP
channels having a distinct pore-forming subunit play a cru-
cial role in the cardiovascular system.
Abstract No S4C
Factors involved in the antiarrhythmic and
proarrhythmic effects of thyroid hormones (TH).
Narcis Tribulova, Hai Lin a, Issei Imanagaa, Vlado Knezlb,
Shingo Sekic, Mordechai Manoachd. Inst. Heart Res.,
Bratislava, SR, aFukuoka Univ.,Fukuoka, JP, bInst. Pharm.,
Bratislava, SR, cJikei Univ., Tokyo, JP, 4Tel Aviv Univ., Tel
Aviv, IL
Acute or chronic intercellular channel connexin (Cx) al-
terations and abnormal Ca handling are crucial in the devel-
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opment of lethal arrhythmias (VF). Recently we have shown
that TH up-regulate Cx43 and attenuate Ca overload in neo-
natal heart cells. Further studies were aimed to examine
whether acute or prolonged TH-treatment can affect arrhyth-
mogenic factors, susceptibility of the heart to VF and its
ability for self-defibrillation (SVD). Results showed that
acute administration of TH : a) decreased previously elevated
intracellular free Ca 2 + in aged rat and guinea pig hearts,
while higher dosage abolished Ca overload transiently fol-
lowed by its dramatic increase ; b) prevented electrically-
induced VF in guinea pig heart. Prolonged TH treatment : a)
increased susceptibility of young but not old rat hearts to VF
and facilitated SVD in the latter ; b) decreased of
Cx43 expression and its phosphorylation isoforms (P2 and
P3) in young rat hearts, while to much lesser extend in old
one. The results indicate that TH can modulate both,
Ca2 + (nongenomic effect) and Cx-43 (genomic effect) in the
rat and guinea pig hearts. These effects can be involved in
antiarrhythmic or proarrhythmic potentials of TH that are
dose- and age-dependent.
Abstract No S4D
Role of the gap junction in cardiac arrhythmias
Issei Imanagaa, Hai Lina, Koichi Ogawab. Department of
Physiologya, Department of Anatomyb, School of Medicine,
Fukuoka University, Fukuoka 814-0180 Japan
In the cardiac muscle, the gap junctions greatly contribute
to electrical cell coupling. Then dysfunction of the gap junc-
tion impairs conductivity and can be one of arrhythmogenic
factors. The physiological function of the gap junction de-
pends on phosphorylation of the connexins which composes
the gap junction channel since the connexin is phosphopro-
tein. In this study, alterations of phosphorylation of Cx43 in
aconitine (alkaloid) - induced atrial and ventricular fibrilla-
tion were examined on adult guinea-pig and rat hearts.
Atrial and ventricular fibrillation were induced within
about 10 min after application of aconitine (10-7M) on Lan-
gendorff perfusion and continued for 30 to 40 min after
wash-out of aconitine. At the beginning of the fibrillation,
dephosphorylation of Cx43 was observed in Westernblot and
it was augmented as the fibrillation was lasing. Confocal-
image-analysis of Cx43 in the immuno-histochemistry re-
vealed less immninoreactive particles at the intercalated disk
in the fibrillating heart. The pathological hearts, such as
ischemic or diabetic in which phosphorylation of Cx43 was
impaired and expression of Cx43 was reduced, were suscep-
tible to the fibrillation. Dephosphorylation of Cx43 is possi-
bly one of arrhythmogenic substrata.
Abstract No S4E
Gap junction remodeling and altered connexin
expression in human cardiac diseases
Sawa Kostin, Max-Planck-Institute, Department of
Experimental Cardiology, Bad Nauheim, Germany
Central to the organizational pattern of cell-to-cell current
transfer are the myocardial tissue architecture and special-
ized junctions responsible for electrical coupling, the gap
junctions. Recent experimental and clinical studies have em-
phasized that altered distribution of gap junctions and
changes in the expression of their constituent connexins may
lead to abnormal coupling between cardiomyocytes and
likely contribute to arrhythmogenesis. Thus, in the diseased
ventricle, disturbed patterns of gap junction distribution have
reportedly been noted in myocytes bordering regions of
healed myocardial infarcts, small areas of replacement fibro-
sis and myocardial inflammation. The most consistently ob-
served quantitative alteration in ventricular connexin expres-
sion involves down regulation of connexin 43. This reduction
of connexin 43 is found irrespective of whether heart failure
is due to idiopathic dilated, inflammatory, ischemic or
pressure-overload heart disease. In contrast, the compen-
sated stage of left ventricular hypertrophy in patients with
aortic stenosis is characterized by increased connexin 43 ex-
pression which may constitute an important part of the im-
mediate adaptive response of the heart to increased work-
load. In the diseased atria, disturbed patterns of gap junction
organization and changes in connexin 43 and connexin
40 expression have been implicated in the initiation and
maintainance of atrial fibrillation. Taken togther, these data
indicate that alterations in gap junctions and connexins are
typical features of myocardial remodeling that may play an
important role in the development of pro-arrhythmic sub-
trates in a variety of forms of human heart diseases.
Abstract No S4F
Ionic and molecular mechanisms of acquired QT
prolongation in association with complete
atrioventricular block
Itsuo Kodamaa, Yukiomi Tsujib, Tobias Opthofc,
Kenji Yasuia, Jong-Kook Leea, Stanley Nattelb. aDepartment
of Circulation, Research Institute of Environmental
Medicine, Nagoya University, Nagoya, Japan, bDepartment
of Medicine, Montreal Heart Institute Research Center,
Montreal, Canada, cDeparment of Medical Physiology,
University Medical Center Utrecht, the Netherlands
Bradyarrhythmias resulting from complete atrioventricu-
lar block (AVB) are known to predispose to acquired
long-QT syndrome (LQTS) and torsade de pointes (TdP).
The underlying mechanisms remain to be clarified. We cre-
ated a rabbit and a mouse model with chronic AVB
(n = 34 and 20), which showed prominent QT prolongation,
high incidence of spontaneous TdP (71 % in rabbits), and
cardiac hypertrophy. Ventricular myocytes from rabbits at
3 weeks of AVB showed a marked prolongation of action
potential duration (by 61 % at 0.5 Hz). Both rapidly- (IKr)
and slowly- (IKs) activating components of delayed rectifier
K+ current in AVB myocytes were significantly smaller than
controls (by 50-55 %). Peak amplitude of L-type Ca2 + cur-
rent (ICa,L) and transient outward current (Ito) appeared to be
unchanged, whereas the inward rectifier K+ current (IK1)
significantly increased in AVB myocytes compared with con-
trols. KCNH2 mRNA and KCNQ1 mRNA were downregu-
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lated in AVB rabbits (by 48-55 %). KCNH2 protein and
KCNQ1 protein amounts were reduced in parallel with their
mRNAs, whereas KCNE1 protein expression was un-
changed. Kir2.1 protein was upregulated (by 45 %). In mice
with AVB for 10 days, gene profiling with microarray analy-
sis in ventricular muscle revealed downregulation of mRNA
expression for Kv4.2 and Kir 2.1. Complete AVB causes
arrhythmogenic modulation of K+ channel expression prob-
ably through a volume overload to the ventricles. Although
the modulation is species- and model-dependent, the pheno-
types closely resemble the clinical characteristics of congeni-
tal LQTS. These results provide new insights into the ionic
and molecular mechanisms of chronic bradycardia-induced
LQTS.
Abstract No S18B
Cardiac hypertrophy : role played by the
NA + /H + exchanger
Irene L. Ennis. Centro de Investigaciones Cardiovasculares,
La Plata. Argentina
Cardiac hypertrophy has been established as one of the
most powerful predictors for cardiovascular morbidity and
mortality. In the last years, there have been impressive
progress in the understanding of the mechanism(s) of myo-
cardial hypertrophy and good evidence has emerged about
the main role played by Na + /H + exchanger (NHE) activity
in many, if not all, types of CH. The sarcolemmal NHE,
through the electroneutral exchange of intracellular H+ for
extracellular Na+, constitutes a main cell proton-extruding
mechanism. The NHE-1 isoform is the most abundant in
myocardium an has a major role in the regulation of cardiac
function particularly under pathological conditions. More-
over, its enhanced activity has been linked to the deleterious
effects of ischemia/reperfusion. Therefore, NHE inhibition
seems to be a potential novel therapeutic strategy to interfere
with the hypertrophic process independently of load mecha-
nisms and also beneficial in the treatment of
ischemia/reperfusion injury. About the mechanism by which
the activation of the NHE-1 can underlie the development of
cardiac hypertrophy the hypothesis is that elevated activity of
this exchanger will increase Na+ influx to the cell therefore
increasing its cytosolic concentration. This, in turn will
favour the reverse mode of operation of the Na+/Ca2 + ex-
changer leading to a secondary increase in Ca2 + i. The notion
that the increase in Ca2 + i is a primary signal for cardiac
hypertrophy is supported by numerous studies since it can
activate several intracellular signaling pathways like PKC
and Ca-calmodulin dependent phosphatase (calcineurin) and
kinases (CaMKs) involved in the hypertrophic response. On
the other hand, the link between Na+ influx, activation of
PKC-ooand oooand hypertrophy has been also demon-
strated.
Abstract No S18C
Lysophospholipid and AKT signaling pathways in
cardiac hypertrophy and protection
Joan Heller Brown, Chun-Yang Xiao, Dominic Del Re,
Christopher Means and Shigeki Miyamoto, University of
California San Diego, USA
Lysophospholipids including sphingosine-1-phosphate
(S1P) and lysophosphatic acid (LPA) are biological media-
tors that signal through G-protein coupled receptors Cardi-
omyocytes from rats and mice express multiple subtypes of
receptors for both of these ligands i.e. S1P1,2,3,5 and LPA1,2,3
receptors. LPA and S1P are weak inducers of hypertrophy in
neonatal rat ventricular myocytes, perhaps as a result of their
relatively limited ability for Gaq-mediated phospholipase C
activation. In contrast both are highly efficacious activators
of the small G-protein RhoA. While Rho has been implicated
in hypertrophy induced by GPCR activation, we have also
determined that this small G-protein regulates PI3 kinase
dependent Akt activation. In cells from mice in which the
S1P2 and S1P3 receptor subtypes are deleted, Rho activation
by S1P is inhibited. Infarct size following in vivo ischemia-
reperfusion (IR) is significantly increased in these S1P recep-
tor knockout mice, coincident with decreased Akt activation.
We suggest that S1P released during I-R confers cardiopro-
tection via activation of Rho and/or Akt pathways. The
mechanisms underlying Akt-induced protection appear to
include mitochondrial PT pore inhibition.
Abstract No S18D
Distinct components of the Jak/STAT signaling
pathway are involved in the onset of myocardial
hypertrophy and ischemia and in cardioprotection
M.A.Q. Siddiqui, Eduardo Mascareno, Yueling Guo, and
Daniel Beckles Center for Cardiovascular and Muscle
Research, Department of Anatomy and Cell Biology, State
University of New York, Downstate Medical Center,
Brooklyn, NY 11203
It is well established that binding of the vasoactive peptide
angiotensin II (AngII) to its receptors triggers induction of
several intracellular signaling pathways, notable among
them is the Jak/STAT pathway. We have previously identified
the components of the Jak/STAT signaling pathway that are
activated in rat heart subjected to hypertrophy associated
stimuli an ischemia/reperfusion. The activated STAT pro-
teins cause stimulation of the renin-angiotensin system
(RAS) via their role in transcription regulation of the pro-
moter of the pro-hormone angiotensinogen (ANG). To dem-
onstrate the regulatory linkage between the Jak/STAT signal-
ing and activation of localized and systemic RAS in an
animal context, we produced transgenic mice harboring
ANG promoter containing the wild type or mutant STAT
target site (St-domain) fused to the luciferase reporter. We
show here that administration of AngII, a positive feedback
agonist of RAS, to the mice resulted in prominent expression
of luciferase in the liver and the heart of animals containing
the wild type St-domain but not in mice harboring mutant
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St-domain. AngII induced signaling caused the activation of
STAT proteins, the pattern of which was distinct in the heart
relative to that of liver. The inducible function of STAT
protein appears to be mediated by physical association of
p300 with STAT5B in the liver and STAT3 and STAT5A in
the heart. In parallel, mice were subjected to transaortic
constriction which resulted in development of pressure over-
load hypertrophy. The hypertrophic response followed the
activation of signaling events manifested by prominent acti-
vation of Jak/STAT, MAPK and P13 kinase pathways. We
observed that the expression of SOCS3, a negative regulator
of Jak2, was also increased. Thus, these findings point to the
differences in the signaling mechanisms in the circulating
and localized RAS reflecting their distinct functional in-
volvement in the cardiovascular system. The activation of
Jak/STAT pathway plays a dual role, one that affords the
development of pressure overload hypertrophy and perhaps
the activation of the negative feedback loop for cell survival.
Abstract No S18E
Role of metalloporphyrins in therapeutics of
cardiovascular complications during hypoxic stress
Ramesh Chandra, Anju Katyal and Anita Talwar,
Dr. B.R. Ambedkar Centre for Biomedical Research,
University of Delhi, Delhi 110007, India
Hypoxia challenges the uptake, transfer and delivery of
oxygen thus affecting the essential components of the cardio-
respiratory system of the body. In addition, pressure overload
of the right ventricle, induced experimentally by hypoxia or
pulmonary artery banding is known to increase hemoxyge-
nase (HO-1) expression. HO also plays a critical role in
cellular homeostasis by regulating the availability of heme.
This substantiates the critical role of hemoxygenase in car-
diovascular adaptation. A series of metalloprophyrins can be
of immense value in exploring the role of haemoxygenase
during hypoxia. The main aim of the current study was to
study the role of hemoxygenase in cardiovascular adaptation
during hypoxia and whether metalloporphyrin treatment can
prove beneficial for management of hypoxia. Cardiovascular
variables were monitored using DS telemetry technique in
conscious rats. Increase in Heart rate, MAP with progressive
hypoxia showed a significant decrease following pretreat-
ment with CrMP. Furthermore, we have studied the expres-
sion of HO-1, the inducible isozyme in chronic hypoxic rats.
It was concluded out of the five metalloporphyrins studied,
CrMP, at a concentration of 5 µM, was a selective inhibitor of
HO activity and was the most useful metalloporphyrin for the
conditions tested. Thus, CrMP would appear to be a valuable
chemical probe in modulating HO mediated effects of
chronic hypoxia on cardiovascular variables.
Abstract No S18F
Shift and cleavage of myocardial dystrophin (DYS) is a
common pathway to advanced heart failure (AdHF)
Teruhiko Toyo-okaa, Tomie Kawadab, Masashi Urabec,
Fujiko Masuia, Takashi Ebisawaa, Asaki Tezukaa, Kuniaki
Iwasawaa, Jutta Schaperd, Mikio Nakazawab, and Keiya
Ozawa3.1University of Tokyo, bNiigata University, cJichi
Medical School, Tochigi, Japan ; dMax-Planck-Institute,
Bad Nauheim, Germany
AdHF is the leading cause of death and the progression
mechanism of cardiac dysfunction should be clarified to
establish its prevention and/or treatment. In TO-2 hamsters
with hereditary dilated cardiomyopathy (DCM), we have
identified the responsible gene (d-SG) in Dys-associated
proteins. The same gene mutation was detected in human
families. Present analyses reveal the age-dependent cleavage
and translocation of myocardial Dys from sarcolemma (SL)
to myoplasm, increased SL permeability in situ and close
relation between the loss of Dys and hemodynamic indices.
In addition, the amount of Dys was surprisingly correlated
with the animal’s survival rate. The Dys disruption is not an
epiphenomenon but directly precedes the AdHF, because
long-lasting transfer of the missing d-SG gene to the degrad-
ing cardiomyocytes in vivo ameliorated all of the pathologic
features and animal’s prognosis. Furthermore, Dys disrup-
tion occurs with both acute HF after isoproterenol toxicity,
chronic HF after the coronary ligation in rats and AdHF in
human DCM that required cardiac transplantation. The Dys
cleavage in animal models and humans supports a novel
scheme of the SL instability and Dys proteolysis in all
3 types of HF. The hereditary HF is curable with potential
gene therapy, when the responsible gene is identified and
precisely corrected with biological inert rAAV vector.
Abstract No S19A
The molecular basis for the atypical o-adrenoceptor
pharmacology of CGP12177A
BD Popp, BA Evans & RJ Summers. Dept of
Pharmacology, Monash University, Vic 3800, Australia
The aryloxypropanolamine CGP12177A originally devel-
oped as a o1/o2-adrenoceptor (AR) agonist was later demon-
strated to be a o3-AR agonist and more recently an agonist at
the putative o4-AR. Agonist responses to CGP12177A occur
in heart or adipose tissue which express high concentrations
of o1-AR and in cells expressing recombinant o1-AR. Studies
in o1-AR knockout mice suggest that o4-AR are a form or
state of the o1-AR although the molecular basis for the
actions remains unknown. We have examined whether the
o1-AR interacts with receptor activity modifying proteins
(RAMPs) to produce a receptor with an altered phenotype.
CHO K1 cells stably expressing o1-AR were transfected with
RAMPs 1,2 or 3 and used 48 hrs later. Immunohistochemis-
try showed that RAMPs 2 and 3 but not RAMP1 were ex-
pressed at the cell surface. [125I] CYP binding was unaffected
by expression of RAMPs as was competition for binding by
isoprenaline, propranolol or CGP12177A. cAMP production
by cells co-expressing RAMP 1,2 or 3 in response to isopre-
naline (o1-AR) or CGP12177A (atypical response) was un-
changed. Although there is evidence that RAMPs interact
with o1-AR (Bouvier pers communication) this does not
appear to influence the binding characteristics or ability to
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generate cAMP. Another possible explanation for altered
phenotype is the formation of o1-AR homo and heterodimers
which have been demonstrated by co-immunoprecipitation
and bioluminescence resonance energy transfer (BRET). Co-
expression of o1-AR containing GFP2 or Rluc produced a
BRET signal which was reduced by co-expression of un-
tagged o1-AR or a peptide corresponding to transmembrane
6 (TM6) of the o1-AR. Current studies suggest that co-
expression of o1-AR and TM6 increased the response of cells
to CGP12177A and also to the o1-AR agonist isoprenaline.
In conclusion, formation of complexes with RAMPs or re-
ceptor dimerisation do not appear to explain the formation of
alternative phenotypes of the o1-AR. However, interactions
at an alternative site, production of a ligand specific state or
alternative ligand binding of a phosphorylated receptor re-
main feasible mechanisms.
Abstract No S19B
Human heart b1- and b2-adrenoceptors (AR) ; high and
low affinity states
Kaumann, A.J. Department of Physiology, University of
Cambridge, CB2 3EG, UK
The identification of 2 b1-AR states was prompted by the
characteristic effects of non-conventional partial agonists
(NCPA). NCPA cause cardiostimulant effects at concentra-
tions considerably greater than those that antagonize the
effects of catecholamines. The density of both sites is de-
creased in failing hearts. Twelve clinically used b-blockers
have consistently higher affinity for the H-site than the L-site.
The Arg389Gly polymorphism can reduce the catecholamine
responsiveness but hardly affects the (-)-CGP12177 respon-
siveness and does not modify the affinity of clinically used
b-blockers for the b1-AR H-site. Mutation of the b1-AR
Asp138 to Glu138 reduces catecholamine agonist potency
10,000-fold but (-)-CGP12177 potency only 6-fold, abolish-
ing the (-)-bupranolol-evoked antagonism of the catechola-
mine effects but not of the (-)-CGP12177 effects. Thus,
b1-AR binding partners are clearly different for NCPA and
catecholamines. Human myocardial b2-AR mediate in-
creases of contractility and hastening of relaxation, consis-
tent with coupling to Gs protein. Activation of feline and
murine b2-AR, however, does not hasten relaxation although
causes increases in contractility. The lack of lusitropic effects
is presumably due to dual coupling of b2-AR to Gs and Gi
proteins, Gi preventing the manifestation of the Gs/cyclic
AMP-dependent protein kinase (PKA) pathway that leads to
phosphorylation of proteins involved in relation. In human
b2-AR overexpressed \\ 126\\200-fold in murine heart (TG4
mice), low adrenaline concentrations increase contractility
but 1000-fold higher concentrations cause pertussis toxin-
sensitive cardiodepression, effects mirrored by equivalent
changes of PKA activity. On the other hand, noradrenaline
does not cause cardiodepression and increases contractile
force and PKA activity at both low and high concentrations.
These results are simulated with a model for 2 b2-AR states
activated by adrenaline, one with high affinity (H) coupled to
Gs, the other with low affinity (L) coupled to Gi. Noradrena-
line only activates b2-AR through Gs. These H and L states
appear to differ from the high (GTP-sensitive) and low affin-




Weizhong Zhu, Su-Hyun Jo, Chakir Khalid,
Veronique Leblais, Rui-Ping Xiao. LCS, National Institute
on Aging, NIH, USA
Coexisting cardiac b-adrenergic receptor (bAR) subtypes,
mainly b1AR and b2AR, activate different signaling cascades
with b1AR coupling to Gs and b2AR to Gs and Gi pathways.
As a result, b1AR activation induces myocyte apoptosis,
whereas b2AR activation protects heart cells from assaulting
factors, including enhanced b1AR stimulation, hypoxia, and
reactive oxygen species. Inhibition of b2AR-activated Gi-
Goo-PI3K-Akt pathway converts b2AR stimulation to apop-
totic. Furthermore, we have demonstrated that sustained
b1AR stimulation promotes myocyte apoptosis by activation
CaMKII, independently of PKA signaling. Overexpressing a
cardiac CaMKII isoform, CaMKII-oC, markedly exagger-
ates b1AR apoptotic effect. These findings indicate that
CaMKII constitutes a novel PKA-independent linkage of
b1AR stimulation to cardiomyocyte apoptosis that has been
implicated in the overall process of chronic heart failure.
These studies on bAR subtype signaling elucidate mecha-
nisms underlying the beneficial effects of bAR blockers in
patients with chronic heart failure, might also delineate ratio-
nale for combining selective b1AR blockade with b2AR
activation as a potential therapy for chronic heart failure.
Abstract No S19D
b-adrenergic signaling in the heart — novel insights
about mechanisms of cardiac hypertrophy and fibrosis
Stefan Engelhardt, Molecular Cardiobiology Group,
Rudolf-Virchow-Center, University of Wuerzburg, Germany
Chronic b-adrenergic stimulation leads to cardiac hyper-
trophy, fibrosis and heart failure in experimental models and
contributes to the progression of heart failure in humans. The
pathways mediating the detrimental effects of chronic
b-adrenergic stimulation are only partly understood. In order
to identify these pathways, we are making use of different
strategies. We are analyzing the function of known candidate
genes in vivo in transgenic animal models and thereby iden-
tified abnormal calcium handling as a critical step underlying
the detrimental effects of chronic b1-adrenergic signaling.
Alternative approaches aim at identifying novel candidate
genes involved in b-adrenergically mediated cardiac hyper-
trophy and fibrosis. We are making use of gene arrays to
search for differentially regulated genes early in the course of
cardiac hypertrophy and validate their importance in the
b-adrenergic growth response through the generation of
transgenic animal models for these candidate genes. In addi-
tion, we are trying to elucidate mechanisms underlying car-
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diac fibrosis. There is increasing evidence pointing towards
communication between cardiomyocytes and fibroblasts me-
diated through secreted factors. To identify such factors, we
undertook a yeast-based genetic screening approach to iden-
tify genetically encoded factors by which cardiomyocytes
might signal to cardiac fibroblasts.
In conclusion, novel mechanisms involved in b-adrener-
gically mediated cardiac hypertrophy and fibrosis will be
discussed.
Abstract No S19E
Place of b3-adrenoceptors among other b-adrenoceptor
subtypes in the regulation of the heart function
Gauthier-Erfanian Chantal, INSERM, U 533, France
The sympathetic system knowledge is a basic element in
the understanding of numerous physiological and physio-
pathological phenomena. In the heart, at least three popula-
tions of b-adrenoceptors (b-AR) potentially modulate the
cardiac function. The effects of b1- and b2-AR are well
established both in human and other mammals. Their stimu-
lation produces positive chronotropic and inotropic effects.
We have demonstrated the functional presence of b3-AR in
human heart. Stimulation of the b3-AR produced a negative
inotropic effect. The inhibition of contractility involved the
inhibitory G protein, Gi/o and results from the production of
nitric oxide (NO) by the endothelial isoform of NO synthase
and an increase in intracellular cGMP level. Compared to b1-
and b2-AR, the b3-AR presents a relative in vitro and in vivo
lack of desensitization following activation with agonists.
These features suggest that the expression of b3-AR in heart
may have pathophysiological significance. Recently, we
have described opposite regulation for b1-AR and b3-AR in
the human failing heart. Beside the classically observed b1-
AR, an upregulation of b3-AR was reported. Despite in-
creased b3-AR expression, the negative inotropic effect was
mildly reduced in failing heart tissue compared with re-
sponses observed in nonfailing samples because of concur-
rent alterations in post-receptor coupling mechanisms, espe-
cially decreased eNOS expression. Nevertheless, the
reduction in b3-AR response is less than that obtained with
b1-AR stimulation. Therefore, the functional loss of cat-
echolamine positive control of cardiac contractility during
heart failure may result from a shift in the balance between
b1-AR-mediated positive and b3-AR-mediated negative ino-
tropic pathways. The efficiency of some b-blockers used in
the treatment of heart failure, could result from on action on
b3-adrenoceptors. As we have descived the presence of
b3-AR in vessels, the mechanism responsible for the benefi-
cial effects of blocking b-AR activation could be actually due
to the effects of these agents on the vasculature. Thus,
b-blockers with vasodilator action (b-blockers of 3rd genera-
tion) may be more efficient to treat heart failure than non-
vasodilatory ones, because arteriolar and venous dilatation
would reduce afterload and preload respectively, in the fail-
ing heart.
Abstract No S20A
Development of molecular therapy to treat ischemic
arterial disease
Ryuichi Morishita, Division of Clinical Gene Therapy,
Osaka University
Regenerative medicine is emerging as a potential strategy
for the treatment of cardiovascular disease such as peripheral
arterial disease (PAD). Especially, most fruitful strategy is to
stimulate blood vessel formation, so called angiogenesis.
Recently, the efficacy of therapeutic angiogenesis using
VEGF gene transfer has been reported in human patients
with critical limb ischemia and myocardial ischemia. As we
reported the potent angiogenic activity of hepatocyte growth
factor (HGF) in animal study, we planed a prospective open-
labeled clinical trial of gene therapy (TREAT-HGF) by intra-
muscular injection of naked plasmid DNA in patients with
PAD who had failed conventional therapy as phase I/IIa trial.
In this trial, gene transfer was performed in 22 patients by
intramuscular injection of naked plasmid DNA encoding
human HGF. ABI (ankle-brachial pressure index) was sig-
nificantly increased at 2 months after injection, and increase
in ABI over 0.1 was observed in 11 of 17 patients. Reduction
of pain scale (over 2cm in visual analog scale) was observed
in 8 of 13 patients, while the reduction in ulcer size (> 25 %)
was observed in 11 of 18 ulcers. Currently, severe adverse
effects related to gene transfer could not be detected in any
patient. Of importance, different from VEGF, no edema for-
mation could be observed throughout the gene therapy peri-
ods. Overall, the present results indicated that intramuscular
injection of naked plasmid DNA encoding human HGF
cDNA resulted in a significant improvement of clinical
symptom or increase in ABI in 18 patients out of 22 patients.
In addition, HGF gene transfer also induced angiogensis in
myocardium. Naked plasmid DNA as drug delivery system is
useful to treat cardiovascular disease such as PAD. Currently,
phase III trial in Japan, and phase II trial in USA to treat PAD
using HGF gene are underway.
Abstract No S20B
Calreticulin regulates angiogenesis
Nasrin Mesaeli. Division of Stroke & Vascular Disease,
St. Boniface G. H. Research Centre and University of
Manitoba, Winnipeg, MB, Canada R2H 2A6
The Sarco/endoplasmic reticulum (SR/ER) membrane is
one of the most important intracellular organelles. It is in-
volved in the control of virtually every aspect of cellular
function including Ca2 + transport and storage, protein and
lipid synthesis, protein modification and folding. Calreticulin
(CRT) is a SR/ER resident protein. It plays an important role
in chaperoning the newly synthesized proteins and regulation
of intracellular Ca2 + homeostasis. Previously we showed
that gene targeted deletion of CRT is embryonic lethal with
main defect in the cardiovascular development. We have also
demonstrated that at early mouse development CRT gene is
highly expressed in the heart and blood vessel. CRT gene is
down regulated in the cardiomyocytes of newborn mice. To
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investigate the in vivo role of CRT in the vessel wall we
generated transgenic mice overexpressing CRT in the vascu-
lar smooth muscle cells. Overexpression of CRT resulted in
increased coronary artery angiogenesis, increased vessel
wall permeability, coronary aneurysm and formation of vas-
cular tumor. Other phenotypes of these transgenic mice in-
clude enlarged heart, congested lungs and defects in the
kidney (necrosis in severe cases). Immunohistological analy-
sis of the vascular wall of these mice showed that the ob-
served defects are due to altered extracellular matrix (ECM)
composition. We conclude that CRT affects angiogenesis by
regulating enzymes affecting ECM degradation.
Supported by the Canadian Institute for Health Research.
Abstract No S20C
New approaches to treat cardiovascular diseases
targeting NFkB
Isobe M, Morishita Ra, Suzuki J. Department of
Cardiovascular Medicine, Tokyo Medical and Dental
University, aOsaka University Medical School, Japan
Nuclear factor-kappa B (NFkB), a multipotential tran-
scriptional factor, has been reported to play a significant role
in the coordinated transcription of a variety of inflammatory
molecules. Therefore, blocking the activation of NFkB may
inhibit gene expression of essential inflammatory molecules.
Inflammation is one of the key pathophysiological processes
leading to the development of acute cardiac rejection, graft
arteriopathy, myocarditis, arterial intimal hyperplasia,
ischemia/reperfusion injury, ventricular remodeling, and
heart failure. This investigation was attempted to test the
hypothesis that NFkB blockade with a « decoy » against the
cis element or new IkB inhibitors (IMD0354/1041) which
blocks NFkB activation could prevent progression of these
cardiovascular diseases. Mice hearts were heterotopically
transplanted. Scrambled decoy-transfected allografts were
acutely rejected, while NFkB decoy prolonged their survival.
While severe cell infiltration and intimal thickening with
enhancement of inflammatory factors were observed in un-
treated or scrambled decoy treated allografts at day 28, NFkB
decoy attenuated these changes. Experimental autoimmune
myocarditis was developed by immunizing rats with purified
porcine cardiac myosin. NFkB decoy was infused into the rat
coronary artery on day 0 or day 14 and harvested them on
day 21. The ratios of myocarditis-affected areas to the ven-
tricular cross sectional area of all treatment groups were
significantly lower than that of control group. Also, in a rat
model of coronary ischemia/reperfusion, IMD0354 signifi-
cantly reduced myocardial infarct size at 24 hours in associa-
tion with reduction in inflammatory cytokines and chemok-
ines. IMD1041 improved survival rate and late left
ventricular remodeling at 28 days after occlusion of rat left
anterior descending artery in association with reduction in
fibrosis and serum levels of BNP. These data indicate that
NFkB is critically involved in the development of a variety of
cardiovascular diseases. Treatment targeting NFkB is prom-
ising in the prevention of these diseases.
Abstract No S20D
Cardiac adenosine receptors & protein kinase C
James G. Dobson, Jr. and Richard A. Fenton, Dept. of
Physiology, University of Massachusetts Medical School,
Worcester, MA 01655 U.S.A.
Adenosine is involved in regulation of the coronary circu-
lation. In addition adenosine displays antiarrhythmogenic,
angiogenic, antiadrenergic and inotropic effects in the heart.
The cardiac antiadrenergic effects of adenosine are brought
about by adenosine A1 receptor (A1R) activation that fosters
a negative feedback modulation of b1-adrenergic mediated
contractile and metabolic responses in the myocardium. On
the other hand, adenosine A2a receptor (A2aR) stimulation
elicits a positive inotropic response in various in vitro and in
vivo cardiac preparations. The importance of protein kinase
C (PKC) in the antiadrenergic and inotropic actions of ad-
enosine were investigated using isolated ventricular myo-
cytes stimulated to contract and changes in sarcolemmal
length were determined to assess contractile performance.
The A1R agonist chlorocyclopentyladenosine (CCPA) re-
duced the contractile response caused by the b1-adrenergic
agonist isoproterenol. The PKC inhibitor, chelerythrine
(CHEL), prevented the CCPA reduction of the isoproterenol
contractile response. However, CHEL did not prevent the
positive inotropic response elicited by anA2aR agonist CGS-
21680. Since PKC epsilon (PKCe) is a major isoform in the
rat myocardium subsequent studies were performed where
PKCe was over-expressed in ventricular myocytes. Over-
expression of PKCe enhanced the CCPA reduction of the
isoproterenol elicited contractile response. In addition stimu-
lation of myocytes with CCPA caused a translocation of
PKCe to the t-tubular system as evidenced by using a GFP-
tagged PKCe. Administration of a specific PKCe inhibitor
peptide prevented the antiadrenergic effect of CCPA. In sum-
mary protein kinase C epsilon appears to play an important
role in the A1R mediated antiadrenergic action of adenosine
in the heart. The results also suggest that PKC is not involved
in the cardiac contractile response caused by A2aR stimula-
tion.
Abstract No S20E
Modulation of nuclear protein import in vascular
smooth muscle cells by lipids
G.N. Pierce, R.S. Faustino, M.N. Landry, M.P. Czubryt.
Division of Stroke & Vascular Disease, St. Boniface
Hospital Research Centre, Department of Physiology,
Faculties of Medicine and Pharmacy, University of
Manitoba, Winnipeg, MB, Canada
Cell proliferation is a key process during organ develop-
ment and during pathological conditions like cancer and
atherosclerosis. The growth of the cells is closely regulated
by proteins that are transported into the nucleus to turn genes
on or off. RNA exits the nucleus to initiate protein transla-
tion. The transportation of molecules in and out of the
nucleus, therefore, becomes critical to the process of growth.
Factors that regulate nucleocytoplasmic transport become
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extremely important modulatory factors in cell growth and
proliferation. However, little is currently known of the cyto-
plasmic factors that have the capacity to alter transport of
molecules through the nuclear pore complex in vascular
smooth muscle. We have examined the capacity for lipids to
influence nuclear protein import in vascular smooth muscle
cells using a standard cell permeabilized methodology and a
fluorescent marker protein to measure the movement. We
have also used the technique of cell micro-injection to exam-
ine the capacity of these lipids to affect protein import into
the nucleus. Our results will be summarized to show that
some of these lipids stimulate import whereas others inhibit
it. The MAPK pathway appears to function as a central
intracellular effector of these actions. Stimulation of its activ-
ity by specific lipids can either stimulate or inhibit import
depending upon its activation and its cytoplasmic targets.
Nuclear protein import appears to be a complex, multi-
pathway, highly regulated process that may provide mecha-
nistic insight into cell proliferation under conditions of nor-
mal development and during conditions of accelerated
growth like atherosclerosis.
Supported by CIHR and NSERC.
Abstract No S21A
The role of MMPS and the plasminogen system in the
LV remodeling process after myocardial infarction
Esther Creemers, The Netherlands
Matrix metalloproteinases (MMPs) are a large family of
proteinases with a central role in the degradation of extracel-
lular matrix components, a requirement for cell migration
and tissue remodeling. Recent evidence implicates the MMP
family as a mediator of cardiac diseases, in particular in left
ventricular (LV) dilatation and the development of heart
failure in both human and animal studies. To elucidate the
role of MMPs in the healing and remodelling process of the
heart after myocardial infarction (MI) we have performed
3 different interventions (pharmacological MMP inhibition,
TIMP-1 knock-out and plasminogen knock-out mice) in the
MI model in mice. In the first study, the broad-spectrum
MMP inhibitor GM6001 (100 mg/kg/day) was administered
to mice undergoing MI. GM6001 treatment led to a reduction
in LV dilatation, less thinning of the infarcted wall, and
improved systolic function at 14 days post-MI. In a second
study the role of TIMP-1, an endogenous inhibitor of MMPs,
was investigated in the post-MI remodelling process. In that
study, enhanced MMP activity caused diastolic dysfunction
after infarction, as was evidenced by a greater degree of LV
dilatation and increased filling pressures. In addition, TIMP
deficient mice showed reduced collagen levels in the non-
infarcted myocardium and exhibited a greater hypertrophic
response. Systolic function was not changed in the TIMP-
1 deficient MI group compared to the wild-type MI group. In
the third study, the plasminogen system, which is an endog-
enous activator of MMPs, was identified as a key regulator in
the control of infarct healing. In this regard, infarct healing
was abolished in plasminogen deficient mice, as inflamma-
tory cells did not migrate into the infarcted myocardium,
necrotic cardiomyocytes were not removed and scar tissue
was not being formed until at least 5 weeks post-MI. In these
scarless infarcted plasminogen deficient hearts, LV dilatation
was not affected but systolic function was depressed after
stressing the hearts with dobutamine. Gelatinolytic activity
of MMP-2 and MMP-9 was reduced the plasminogen defi-
cient hearts, suggesting that the the effect of plasminogen on
infarct healing is mediated through the activation of MMP-
s.Together, these studies have contributed to the recent view
that MMP inhibitors could potentially be used as therapy for
patients with both acute and chronic MI, to improve postinf-
arction remodeling and prevent the development of heart
failure.
Abstract No S21B
Cardiac remodeling in hyperhomocysteinemia and
diabetes : a NO and ECM connection
Tyagi SC. Department of Physiology and Biophysics,
University of Louisville School of Medicine, KY 40202
Accumulation of oxidized-matrix between endothelial
and muscle is associated with endocardial endothelial (EE)
dysfunction in diabetes mellitus (DM). High levels of circu-
lating homocysteine (Hcy) are associated with oxidative
stress and DM. These high levels of Hcy (hyperhomocys-
teinemia, HHcy) have a negative correlation with peroxi-
some proliferator activated receptor (PPAR) expression. The
hypothesis is that Hcy exacerbates diabetes by antagonizing
PPAR. Previous studies have demonstrated that Hcy de-
creases bioavailability of endothelial nitric oxide (eNO),
generates nitrotyrosine, activates latent matrix metallopro-
teinase (MMP), and instigates EE dysfunction. PPAR*
ligands ameliorate endothelial dysfunction by competing
with Hcy. Here we have demonstrated that EE dysfunction in
DM is due to increased levels of reduced oxygen species
(ROS), Hcy, nitrotyrosine, MMP activity, collagenolysis, and
decreased levels of eNO in response to antagonizing PPAR*.
To determine whether the Hcy induces oxidative stress by
antagonizing PPAR* in DM, DM is created by alloxan to
wildtype and heterozygous cystathionine * synthase (hyper-
homocysteinemic) mice. To induce PPAR*, ciglitazone was
administered in drinking water. Cardiac ROS and eNO were
measured by dichlorofluorescin, and by estimating
nitrate/nitrite, respectively. Total collagen and fragments
were measured by Western analysis using anti-collagen anti-
body. Levels of collagenolytic MMP were measured using
collagen-gel zymography. The cardiac inhibitor of metallo-
proteinase was measured by reverse zymography. The re-
sponses to acetylcholine, bradykinin, and nitroprusside in
cardiac rings from HHcy-DM mice were measured in tissue
myobath. The results elucidate intra- and extracellular
mechanism by which Hcy amplifies DM and have therapeu-
tic ramifications for diabetic cardiomyopathy.
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Abstract No S21C
Intracellular action of MMP-2 and TIMP-4 in the
oxidatively stressed heart
Richard Schulz, University of Alberta, Edmonton, Alberta,
Canada
Matrix metalloproteinases (MMPs) are conventionally
known as proteases which are activated by proteolysis of
their zymogen form at the cell membrane. They are then
released from cells to degrade extracellular matrix proteins.
Their activity is regulated at several levels, including direct
inhibition by endogenous tissue inhibitors of metalloprotein-
ases (TIMPs). However, recent evidence shows that the zy-
mogen form of MMPs is activated by peroxynitrite. In the
first minutes of reperfusion following myocardial ischemia, a
burst of peroxynitrite is generated in the myocardium. More-
over, pro-inflammatory cytokines also increase peroxynitrite
levels in the heart. This may activate MMPs without loss of
the propeptide domain and inactivate TIMPs. We therefore
assessed whether there is an imbalance between MMPs and
TIMPs in two models of the oxidatively stressed heart.
In isolated rat hearts subjected to ischemia-reperfusion
injury we found that there is activation of MMP-2 and release
from the heart as a consequence of the injury. TIMP-4 is also
rapidly lost from the heart. In situ zymography, however,
reveals an imbalance between MMPs/TIMPs and enhanced
proteolytic activity in the reperfused heart. MMP inhibitors
functionally protect the heart from either ischemia-
reperfusion injury or exposure to pro-inflammatory cytokine
stress. We found that MMP-2 and TIMP-4 are localized to
the thin myofilaments of the cardiomyocyte. MMP-2 co-
localizes with troponin I (TnI), the regulatory element of
actin-myosin force generation. MMP-2 readily degrades TnI
in vitro and in vivo in both ischemic-reperfused and in
cytokine-stressed hearts.
Our working hypothesis is that MMPs are activated inside
the cardiomyocyte by peroxynitrite. TnI is a proteolytic tar-
get of MMP-2 and is an early effector of peroxynitrite-
induced cardiac injury. Inhibition of MMP activity is a novel
therapeutic target approach to prevent myocardial injury due
to oxidative stress.
Abstract No S21D
In vivo activation and broad-spectrum inhibition of
matrix metalloproteinases
Ricardo A. Garcia. Dept. of Medicine, University of
California San Diego
Activation of matrix metalloproteinases (MMPs) in the
heart facilitates cardiac remodeling and progression to fail-
ure. Considerable efforts have therefore been devoted to-
wards unraveling the processes by which MMPs are acti-
vated. Despite these efforts, surprisingly little is known about
the biomechanical mechanisms underlying in vivo activation
of MMPs in the heart. Our group has employed atrial-
ventricular epicardial pacing to induce abnormal wall motion
of the ventricular myocardium. We hypothesized that re-
gional abnormal wall motion of the left ventricle would
stimulate activation of MMPs. Atrial-ventricular pacing re-
sulted in abnormal motion at a left ventricular (LV) pacing
site yielding early shortening and late systolic lengthenin-
g.Assessment of global myocardial MMP activity showed a
seven-fold increase in substrate cleavage (p < 0.02) at the LV
pacing site relative to a remote site of the left ventricle distal
to the pacing site. Gelatin zymography revealed increases of
fifty-fold in 92kDa MMP-9 activity (p < 0.001) and ten-fold
in 84 kDa MMP-9 activity (p < 0.01) at the LV pacing site
relative to the remote site, whereas MMP-2 activity was
unaffected. Abnormal wall motion was associated with a
two-fold increase in myocardial collagen degradation
(p < 0.03) and with increases in plasmin activity (\\ 126\\two-
fold ; p < 0.05) and inflammatory infiltrate (\\ 126\\two-fold ;
p < 0.02) relative to the remote site. Our results indicate that
regional dyskinesis induced by epicardial activation is suffi-
cient to stimulate significant MMP activity in the heart,
suggesting that abnormal wall motion is a major stimulus for
MMP activation. As an adjunct to these studies, we have also
explored the molecular mechanisms of MMP inhibition by
broad-spectrum MMP inhibitors. We have employed
hydrogen/deuterium exchange mass spectrometry to investi-
gate inhibition by the broad-spectrum MMP inhibitor doxy-
cycline. Model studies with the MMP-7 reveal two putative
doxycycline-binding sites (residues 145-155 ; residues 231-
243) of similar affinity that flank the zinc-binding domains of
the enzyme. Examination of the X-ray crystal structure of
MMP-7 shows that the doxycycline-binding site at residues
231-243 is positioned within the active site cleft adjacent to
the catalytic zinc atom. Inhibitor binding occurs in the ab-
sence of major changes in structure. These results suggest a
mode of MMP inhibition by doxycycline that could involve
interactions with the catalytic zinc atom.
Abstract No S22A
SERCA2 and CSQ2 transcriptional regulation in
cardiomyocytes
A. Zarain-Herzberg, R. Juárez-Rubí, G. Álvarez-Fernández,
A.B. Medina-Pérez. Dept. Bioquímica y Biología
Molecular, Facultad de Medicina, UNAM, México
The sarcoplasmic reticulum (SR) Ca2 + -ATPase
(SERCA2) and calsequestrin (CSQ2) are two proteins that in
cardiocytes play a key role in Ca2 + transport, storage and
release during the contraction/relaxation cycle. The
SERCA2 transcription is up-regulated by thyroid hormone
and down-regulated during cardiac hypertrophy and failure.
The sequence of the SERCA2 gene proximal promoter is
conserved among mammals and is highly G + C-rich, it con-
tains a TATA-box, an E-box/USF sequence and a CAAT-box
which are part of the endoplasmic reticulum stress response
element (ERSE), four Sp1 binding sites that play a role in the
hypertrophic response, and one thyroid hormone receptor
site (THR). There are two distal conserved regulatory regions
(-410 to -661 bp and from -919 to -1410 bp) that have puta-
tive sites for : THR. GATA-4, Nkx-2.5/Csx, OTF-1, USF,
MEF-2, SRF, PPAR and AP-2. Transfection experiments
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demonstrate that the human proximal promoter region is
necessary for high level of expression in cardiac myocytes,
response to thyroid hormone, calcium and glucose metabo-
lites, as well to PKC isoforms. he human CSQ2 gene consists
of 11 exons that span 78 kb and has very similar organization
compared to the rabbit and mouse CSQ2 genes. The proxi-
mal 5’-regulatory region contains one Sp1 site, one TATA-
box, one CArG-box and 3 CAAT-boxes. Transfection of neo-
natal cardiocytes with CSQ2 promoter constructs containing
the -582 kb to -3.1 kb region increases 3- to 4-fold transcrip-
tion of the gene. This region contains several MyoD, MEF2,




as a mechanism to limit Ca2 + overload
C. Mundiña-Weilenmanna, L. Vittonea, M. Saida, E.
Kraniasb, A. Mattiazzia. aCentro de Investigaciones
Cardiovasculares, Fac Cs Médicas, La Plata, Argentina and
bDept of Pharmacology and Cell Biophysics, Univ of
Cincinnati College of Medicine, Cincinnati, USA
Phosphorylation of phospholamban (PLN) relieves its in-
hibitory effects on SERCA2a activity resulting in : a) in-
creased sarcoplasmic reticulum (SR) Ca2 + uptake rate,
which accelerates myocardial relaxation ; and b) increased
SR Ca2 + load and release, which modulates myocardial
contractility. The physiological significance of the phospho-
rylation of PLN at Thr17 by CaMKII remains unclear. While
b-adrenergic agonists consistently increase Ser16 phosphory-
lation (PKA site), an increase in Thr17 phosphorylation is not
always found by this intervention. We have shown that Thr17
phosphorylation, independently of that of Ser16, requires the
increase in intracellular Ca2 + together with the inhibition of
phosphatases, two conditions met by the b-adrenergic stimu-
lation and experimentally, by the perfusion of high Ca2 +
with phosphatase inhibitors or acidic pH. We studied PLN
phosphorylation in the perfused heart under two pathological
situations in which increased intracellular Ca2 + co-exits
with acidic pH : reperfusion after ischemia and recovery
from hypercapnic acidosis. PLN was phosphorylated at
Thr17, independently of Ser16, at the onset of reflow and
immediately after hypercapnia was settled. The mechanical
recovery after both, the ischemic and acidic insults, was
impaired when the increase in Thr17 phosphorylation was
abolished by CaMKII inhibition. Studies in transgenic ani-
mals with Thr17 mutated toAla confirmed these results : mice
with mutated PLN have lower contractile and delayed relax-
ation recoveries after ischemia than mice with non-mutated
PLN. Although phosphorylation of PLN at Thr17 may not be
sufficient to prevent myocardial injury, it may provide a
mechanism to limit the intracellular Ca2 + overload in patho-
logical situations.
Abstract No S22C
Molecular control of SR Ca2 + release
Silvia Guatimosim, Long-Sheng Song, Eric A. Sobie & W.
J. Lederer. Institute of Molecular Cardiology, Medical
Biotechnology Center, Univ. Maryland Biotech. Institute,
Baltimore, MD USA
Ca2 + sparks are the elementary unit of Ca2 + release from
the sarcoplasmic reticulum (SR) in heart muscle. The Ca2 +
sparks are triggered nearly synchronously during the cardiac
action potential to produce the [Ca2 + ]i transient. New find-
ings related to the triggering of Ca2 + sparks and Ca2 + spark
restitution will be presented. The discussion will re-examine
how Ca2 + sparks are controlled in normal and diseased
myocardium.
Abstract No S22D
Control of the Ca spark during E-C coupling
Mark B. Cannell & C. Soeller Dept. Physiology, School of
Medicine and Health Sciences, University of Auckland,
Park Rd, Auckland New Zealand
Cardiac E-C coupling has been resolved at the micro-
scopic level as Ca sparks (Cheng et al., 1993) which show
that we must consider the local micro-environment surround-
ing the channels that regulate calcium release in order to
explain E-C coupling in the heart. Several fundamental ques-
tions about cardiac E-C coupling remain unclear e.g. : (1)
How many sarcoplasmic reticulum (SR) ryanodine receptors
(RyR) are activated during a Ca spark ? (2) If SR release is
regulated entirely via —calcium — induced calcium re-
lease » how does this process terminate ? (3) Why is it so
hard to model/explain the observed spatial dimensions of the
Ca spark ? In order to clarify how E-C coupling works, we
combine structural data obtained at the limitS of light mi-
croscopy and EM with computer models for movements of
calcium that give rise to the Ca spark.
Methods for determining the Ca flux underlying the Ca
spark should be able to help answer question 1 —provided
we can also estimate the flux underlying the gating of a single
RyR. The second question is being addressed by computer
modelling to examine the necessary roles of SR depletion
and coupled gating of RyRs in the junctional space. Our
modelling and data analysis also indicated that during the
genesis of Ca spark the region of release appears to extend
and this may be due to the development of a microscopic
wave of RyR activation within the junction and some recent
immunocytochemical results support the idea that the t-SR
junction can be spatially extended. Other regions show mul-
tiple release sites at close spacing which raises the possibility
that, under some circumstances, SR release may involve
more than one site although fully regenerative release in the
form of a Ca wave does not develop.
Référence
Cheng et al., Science 262, 740-744 (1993).
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Abstract No S22E
Beta-adrenergic modulation of cardiac ryanodine
receptors
Nancy A. Benkusky, Emily F. Farrell, Ming-Tao Jiang, aAna
M. Gómez, & Héctor H. Valdivia. University of Wisconsin,
Madison, WI 53706 and aINSERM, Montpellier, France
b-adrenergic stimulation of ventricular myocytes results
in activation of PKA and subsequent phosphorylation of
target proteins. Phospholamban (PLB) and the ryanodine
receptor (RyR) are the most important substrates for PKA in
the sarcoplasmic reticulum (SR). In general, PKA phospho-
rylates substrates to increase the force (inotropism) or the
rate (chronotropism) of contraction. In line with this general
role, PLB phosphorylation results in acceleration of Ca2 + -
ATPase activity and increased SR Ca2 + load, which in turn
augments Ca2 + release and force of contraction. The func-
tional effect of PKA-phosphorylation of RyRs has been more
controversial, however, and the apparently contradicting re-
sults reported in the literature make it difficult to integrate
b-adrenergic modulation of RyRs with a clear inotropic re-
sponse. Here we used antibodies directed against the most
important PKA site of cardiac RyR (RyR2-S2809), single
RyR channel recordings, and Ca2 + sparks to assess the effect
of b-adrenergic stimulation on RyR activity. Western blots of
cardiac homogenates using the phospho-specific antibody
revealed that RyRs are phosphorylated in vivo to a basal
level. 32P-o-ATP-phosphorylated SR showed that an endog-
enous Ca2 + - and calmodulin-dependent protein kinase II
(CaMKII) is likely to mediate this basal level of phosphory-
lation since RyRs appear to be poor substrates for PKA.
Furthermore, immunoblot analyses with the phospho-
specific antibody showed that stimulation of isolated ven-
tricular myocytes with 300nM isoproterenol (Iso) in the
absence of Ca2 + produced poor phosphorylation of RyRs,
but Iso stimulation with Ca2 + resulted in higher phosphory-
lation. These results indicate that b-adrenergic stimulation of
RyRs involves the participation of CaMKII and is condi-
tioned to an [Ca2 + ]i elevation. [
cH]Ryanodine binding as-
says, which may be used as an index of the activity of the
channel, showed that PKA or the endogenous CaMKII mod-
estly inhibit RyR activity, whereas acid phosphatase (AcPh),
a protein phosphatase of broad spectrum that readily dephos-
phorylates RyRs, increases RyR activity. In line with these
results, direct application of PKA or CaMKII to RyRs recon-
stituted in lipid bilayers also modestly inhibited channel
activity, but AcPh caused a dramatic increase of channel
activity. Again, the modest effect of PKA and CaMKII and
the greater effect of AcPh in binding and lipid bilayer assays
suggest that the basal level of RyR phosphorylation is rela-
tively high, leaving a few phosphorylation sites free. In
isolated saponin-permeabilized ventricular myocytes loaded
with fluo-4, dephosphorylation by the endogenous phos-
phatase PP1 increased the size of Ca2 + sparks in
thapsigargin-treated cells, implying that the observed effects
resulted from direct activation of RyRs. Taken together, the
results indicate that PKA and CaMKII phosphorylation de-
creases RyR activity. Hence, a potential mechanism whereby
RyR phosphorylation contributes to the positive inotropic
response of b-adrenergic stimulation is one in which phos-
phorylation of RyRs decreases Ca2 + « leak » from the SR,
which in turn increases SR Ca2 + load and, like PLB, in-
creases force of contraction.
Abstract No S22F
Therapeutic potential of sodium-calcium echange
inhibitors
Larry V. Hryshko, Candace Lee, and Neeraj Visen. Institute
of Cardiovascular Sciences, University of Manitoba,
Winnipeg, Manitoba, Canada, R2H 2A6
The cardiac Na+-Ca2 + exchanger has been implicated as a
major contributor to the cellular toxicity associated with
ischemia-reperfusion injury. Specifically, in response to the
elevation of intracellular Na+ occurring during ischemia and
reperfusion, there is an impairment of Ca2 + efflux and/or an
augmentation of Ca2 + influx via this transporter. Depending
upon severity, the resultant Ca2 + overload can trigger func-
tional impairment of cardiac performance, arrhythmias, and
cell death. In this scenario, inhibition of Na+-Ca2 + exchange
appears to be a promising target for cardioprotection. Here,
we describe the inhibitory properties of newer Na+-Ca2 +
exchange inhibitors (KB-R7943 and SEA0400) that exhibit
remarkable cardioprotective effects against ischemia-
reperfusion injury. Both agents functionally interact with the
intrinsic ionic regulatory mechanisms of the cardiac Na+-
Ca2 + exchanger. Moreover, the inhibitory potency of
SEA0400 is increased as intracellular Na+ is increased. This
inhibitory profile leads to an apparent transport mode selec-
tivity for these agents whereby inhibition of the reverse
transport mode (i.e. Ca2 + influx) is favored. These attributes
provide nearly ideal characteristics when considering their
potential utility as cardioprotective agents against ischemia-
reperfusion injury.
Abstract No S23A
Chronic chymase inhibition prevented cardiac fibrosis
and improved diastolic dysfunction in the progression
of heart failure
Matsumoto T, Wada A, Ohnishi M, Tsutamoto T, Fujii M,
Yamamoto T, Takayama T, Dohke T and Horie M.
Cardiovascular and Respiratory Medicine, Shiga University
of Medical Science, Japan
Angiotensin-II (Ang-II) which plays a crucial role in the
cardiac remodeling process is generated via angiotensin-
converting enzyme (ACE), however, an alternative genera-
tion pathway, chymase, which is stored in the mast cells also
exists in the heart. We have revealed chymase pathway is
activated inMsevere stage of heart failure (HF), despite ACE
pathway is activated throught the progression of HF. How-
ever, the role of chymase in left ventricular (LV) function has
not been fully elucidated as yet. We evaluated the effects of a
specific chymase inhibitor, (Chy-I), on changes in cardiac
structures, Ang-II levels and the expression of several failing
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heart related genes in dogs with tachycardia induced HF.MIn
HF, the number of chymase-positive cells and cardiac Ang-II
concentrations increased in the LV compared with the nor-
mals, however, Chy-I significantly decreased them. Despite
no significant differences in LV systolic function compared
with the HF group, Chy-I significantly decreased LV filling
pressure, shortened the time constant of relaxation and up-
regulated the expression of sarcoplasmic reticulum Ca2 + -
ATPase mRNA. Chy-I also decreased collagen type I and III
mRNA and decreased cardiac collagen deposits compared
with theMHF group. Cardiac chymase may be involved in
diastolic dysfunction rather than systolic dysfunction, via
modification of Ca2 + handling as well as suppression of
collagen accumulation in HF.
Abstract No S23B
Angiotensin II-induced oxidative stress as a possible
mediator of contractile dysfunction in the failing heart
Martin G. Vila Petroff, Centro de Investigaciones
Cardiovasculares, La Plata
The peptide Angiotensin II (Ang II) exerts both positive
and negative contractile actions in the heart via distinct
mechanisms, and the net effect on contraction is determined
by the relative magnitudes of the opposing pathways. The
components of Ang II signaling, underlying its positive con-
tractile actions, have been examined in detail and are cur-
rently well understood. In contrast, the mechanisms underly-
ing the negative inotropic effect are presently a largely
uncharted territory. Because in heart failure the circulating
levels of Ang II are increased, the balance between positive
and negative inotropic actions could be upset. Thus, under
these circumstances the Ang II-induced negative inotropic
effect could be enhanced and contribute to the contractile
dysfunction observed in these pathological condition. Ang II
triggers several mechanisms, any of which could potentially
reduce myocardial contractility. In this scenario, p38 MAPK
has been recently recognized as a downstream target of the
renin-angiotensin pathway and redox-sensitive intermediates
have been implicated in Ang II-mediated p38 MAPK activa-
tion. Furthermore, coupling of Ang II receptors to NAD(P)H
oxidase, resulting in superoxide formation and p38 MAPK
activation has been recognized in ventricular myocytes.
Moreover, in experiments with transgenic mice, it has been
demonstrated that the cardiac-specific activation of
p38 MAPK markedly attenuates cardiac contractility. These
results suggest a previously unrecognized link between Ang
II, NAD(P)H oxidase-reactive oxygen species generation,
p38 MAPK-mediated negative inotropic effect and heart fail-
ure induced contractile dysfunction.
Abstract No S23D
Chronic b-adrenoceptor blockade prevents progression
of heart failure in ageing SHR
Vincent Chan, Kathleen Wilsona, Darryl Burstowa, Andrew
Hoeyb and Lindsay Brown. School of Biomedical Sciences,
The University of Queensland, aThe Prince Charles
Hospital, Chermside and bDepartment of Biological &
Physical Sciences, The University of Southern Queensland,
QLD, Australia
Although once a contraindication, b-adrenoceptor block-
ade is now an established treatment to prolong survival in
human heart failure. This project has determined changes in
cardiac structure and function in 15 month old male normo-
tensive Wistar-Kyoto (WKY) and spontaneously hyperten-
sive rats (SHR) treated with metoprolol (M ; 30-80 mg/kg po
for 24 weeks ; *p < 0.05vsWKY ; **p < 0.05vsSHR). The
increased left ventricular weight in SHR was reduced by
metoprolol (WKY 2.37±0.08, SHR 4.53±0.06*, SHR + M
3.69±0.26** mg/g bwt). In ageing SHR, metoprolol pre-
vented the following changes : cardiac dilatation (LV internal
diameter WKY 7.90±0.30, SHR 8.96±0.32*, SHR + M
7.48±0.37** mm), decreased fractional shortening (WKY
59.5±2.8, SHR 40.4±2.9*, SHR + M 67.7±3.9** %) and in-
creased mitral valve flow (E/A) ratio (WKY 1.19±0.01, SHR
3.64±0.69*, SHR + M 2.24±0.28**). In isolated hearts, me-
toprolol reversed both the increased cardiac stiffness (WKY
28.8±1.4, SHR 38.3±4.1*, SHR + M 31.5±1.4**) and the
increased interstitial collagen deposition (WKY 4.4±1.3,
SHR 15.6±2.0*, SHR + M 5.9±0.9** % of area) and pre-
vented further increases in APD90. Further, metoprolol
markedly improved survival at 21 months. Thus, chronic
metoprolol treatment attenuated the pathological structural
and functional changes during the progression of heart fail-
ure in the ageing SHR.
Abstract No S23E
Pharmacologic inhibition of poly(adenosine
diphosphate-ribose) polymerase is a promising new
approach for the therapy of various forms of heart
failure
Pal Pacher, NIH, NIAAA, Bethesda, MD, USA. Csaba
Szabo, Inotek Pharmaceuticals, Beverly, MA, USA
Acute and chronic myocardial ischemia and ischemic
cardiomyopathy are major causes of hospitalization, morbid-
ity and mortality worldwide. The mechanism of myocardial
injury has been extensively studied, and there is accumulat-
ing evidence for the key role of oxidative and nitrosative
stress in this process.
Oxidant induced cell injury triggers the activation of
nuclear enzyme poly(ADP-ribose) polymerase (PARP),
which in turn contributes to cardiac and vascular dysfunction
in various pathophysiological conditions including reperfu-
sion injury, heart transplantation, diabetic cardiomyopathy,
drug induced and chronic heart failure. Accordingly, neutral-
ization of peroxynitrite or pharmacological inhibition of
PARP protect against cardiovascular dysfunction.
A multitude of novel PARP inhibitors are in various stages
of preclinical or clinical development, many with potency
that greatly exceeds the prototypic agents successfully used
in earlier animal studies. The remarkable efficiency of new
PARP inhibitors against various forms of myocardial injury
in animal models strongly suggests that these agents show
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considerable promise and hope in the treatment of cardiovas-
cular disorders in humans.
Abstract No S23F
Cell transplantation for the treatment of heart failure :
active contributor or passive bystander ?
Peter Whittaker, Emergency Medicine Department,
University of Massachusetts Medical School, Worcester,
MA, USA
Immature muscle cells transplanted into the scar formed
after myocardial infarction can not only survive, but also
develop and grow. Nevertheless, if such cells are to make a
useful active contribution to cardiac function, the trans-
planted tissue must be organized in an appropriate manner.
Despite the encouraging results published documenting ap-
parent enhancement of function, this crucial architectural
imperative in the transplant process has received little atten-
tion. In rat hearts, the bolus injection of neonatal cardiac
muscle cells and fibroblasts into an infarct resulted, 6 months
later, in a highly disorganized musculature containing large
amounts of collagen. Such organization is unlikely to provide
active functional improvement and could even, under some
circumstances, be detrimental. However, the presence of the
transplant tissue did minimize or prevent paradoxical sys-
tolic bulging of the infarct, which was consistent with a
passive benefit. Thus, while cell transplantation leading to
active functional improvement is the ultimate goal, there may
also be some advantage to be gained from implantation of
elements specifically designed to strengthen and thicken the
infarct. The fabrication of polymer nanofibers, including
collagen, using the techniques of electro-spinning provides a
potential source for such material. In addition, it may be
possible to use fabricated nanofibers to serve as guides to
train transplanted cells to align in the desired orientation. The
application of such tissue engineering approaches to address
the architectural problems associated with cell transplant
may provide a rational basis for the treatment of heart failure.
Abstract No S24A
Oxidant signals and cardioprotection : dual role in
susceptibility to ischemia/ reperfusion injury
T. Ravingerova, J. Neckara, P. Simoncikova, M. Barancik,
O. Pechanovab, A. Ziegelhöffer, F. Kolara. Inst Heart Res,
bInst Norm Pathol Physiol, SAS, Bratislava, Slovak
Republic,
a
Inst Physiol AS CR, Prague, Czech Republic
Myocardial ischemia/reperfusion alters cellular redox sta-
tus and results in a burst of free radicals (FR) including those
derived from O2 and NO traditionally viewed as cardiotoxic.
Over the last decade, however, FR have become recognised
as important triggers of cell signaling mechanisms leading to
cardioprotection. Treatment with antioxidants and/or inhibi-
tion of NO synthesis appears to be cardioprotective only in
non-adapted hearts exhibiting myocardial dysfunction or ar-
rhythmias, but it abrogates protective response in the hearts
preconditioned by a short-term ischemic stress. Oxidative
load is a common feature of a number of chronic processes
associated with remodeling, hypertrophy and functional dis-
orders on the one hand, but on the other hand, it contributes to
development of long-term adaptation that increases ischemic
tolerance. Chronic high altitude hypoxia, despite its negative
cardiac effects, leads to adaptation that renders rat hearts
more resistant to ischemia, and protection is blunted by
antiradical interventions. Similarly, long-term adaptation of
rats during chronic L-NAME-induced hypertension associ-
ated with an enhanced production of FR resulted in an im-
proved postischemic contractile recovery and suppression of
reperfusion-induced arrhythmias, in conjunction with an in-
creased ERK1/2 activity, and the effect was reversed by mito
K(ATP) blocker 5-HD. It is concluded that FR may play a
dual role in the heart. Being deleterious in the myocardium
exposed to ischemia/ reperfusion alone and contributing to
low ischemic tolerance in the non-adapted heart, they might
be also implicated in cardioprotection conferred by both,
short-term and long-term adaptation. Potential downstream
mechanisms may involve mito K(ATP) opening and/or acti-
vation of certain MAPK cascades.
Abstract No S24B
Redox regulation of vascular cell function
Shane R. Thomas, John F. Keaney, Jr. and Roland Stocker,
Centre for Vascular Research, University of New South
Wales, Australia and Whitaker Cardiovascular Institute,
Boston University, USA
Endothelial nitric oxide synthase (eNOS) and heme
oxygenase-1 (HO-1) have properties that may protect against
vascular disease. Nitric oxide (NO) produced by eNOS is an
important molecule required for maintenance of vascular
homeostasis. Vascular disease is characterized by impaired
NO bioactivity due, in part, to excess production of reactive
oxygen species. While the implications of superoxide anion
on NO bioactivity have been studied, the effect of hydrogen
peroxide (H2O2) in this regard is less clear. We observed that
H2O2 activates eNOS activity in aortic endothelial cells, and
this was dependent on the ability of H2O2 to induce cell-
signaling pathways involving Src, phosphoinositide 3-kinase
and Akt kinases that alter eNOS phosphorylation at the regu-
latory amino acid residues Ser-1177 and Thr-495. Despite
promoting eNOS activity H2O2 impaired agonist-stimulated
endothelial-derived NO bioactivity and relaxation of rabbit
arterial rings. This impairment appeared to result from H2O2-
induced, iron-dependent oxidative inactivation of NO, high-
lighting an additional mechanism by which oxidative stress
may impact on NO bioactivity in vascular diseases. Induction
of HO-1 inhibits proliferation of vascular smooth muscle
cells (VSMC) and intimal thickening after arterial injury. We
observed that inhibition of intimal thickening and VSMC
proliferation in balloon-injured rabbit aortas by the antioxi-
dant drug probucol was associated with induction of HO-1 in
VSMC. Probucol also induced HO-1 in cultured VSMC, and
pharmacologic or molecular inhibition of HO-1 induction
resulted in a loss of the drug’s ability to inhibit VSMC
proliferation. These findings may explain how probucol in-
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hibits restenosis and highlight HO-1 as a redox-sensitive
target for therapeutic intervention against occlusive vascular
disease. Together, these studies provide new information on
how oxidants and antioxidants regulate the function of vas-
cular cells relevant to vascular disease.
Abstract No S24C
Role of cytokines in redox regulation in the ischemic
heart
Naoki Makino, Masahiro Sugano, Keiko Tsuchida, Shinji
Sato. Division of Molecular and Clinical Gerontology,
Medical Institute of Bioregulation, Kyushu University,
Beppu, Japan
Circulating and cardiac TNF-a levels are increased during
myocardial ischemia in experimental animals and in patients
with ischemic heart disease and advanced heart failure.
Soluble TNF-a receptor 1 (sTNFR1) is an extracellular do-
main of TNF-a receptor 1 and an antagonist to TNF-a. We
have examined whether or not sTNFR1 improves cardiac
function after myocardial infarction in rats. Rat sTNFR1
cDNA was produced by RT-PCR and cloned into the TA
expression vector. Male Wistar rats (250-300g) were sub-
jected to left coronary artery (LCA) ligation. Immediately
after LCA ligation, a total of 200ug of the sTNFR1 (n = 26)
or LacZ plasmid (n = 26) was injected into three different
sites in the left ventricular wall. The vector-derived sTNFR1
transcripts and protein expression were detected from 1 day
to 21 days after the sTNFR1 plasmid injection. At 1, 7,
14 and 21 days after LCA ligation, TNF-a bioactivity in the
heart was higher in rats receiving LacZ plasmid than in
sham-operated rats, whereas sTNFR1 plasmid significantly
suppressed the increase in TNF-a bioactivity. At 21 days
after LCA ligation, the LV diastolic dimension (LVDd) was
significantly lower and the fractional shortening (FS) was
significantly higher in the rats treated with the sTNFR1
plasmid than in those treated with the LacZ plasmid (LVDd :
9.4 ± 0.4 mm vs. 11.0 ± 0.5, FS : 19.0 ± 1.0 % vs. 6.4 ± 0.6.
n = 8 in each group, mean ± SEM). The LV end diastolic
pressure was also significantly lower in the rats treated with
the sTNFR1 plasmid than in those treated with the LacZ
plasmid (10.5 ± 0.6 mmHg vs. 14.4 ± 1.1, n = 8). In addi-
tion, the sTNFR1 expression plasmid had significantly re-
duced the infarct size at 21 days after LCA ligation
(16.6 ± 1.8 % vs. 23.5 ± 2.5 (LacZ plasmid), n = 8 in each
group). In myocardial infarction, the TNF-a bioactivity in the
heart increased from the early stage of infarction and re-
mained elevated. This elevation is thought to be partially
responsible for the impairment of LV function and the in-
crease in infarct size.
Abstract No S24D
Thioredoxin is a negative regulator of cardiac
hypertrophy
Junichi Sadoshima, Cardiovascular Research Institute, New
Jersey Medical School, Newark, New Jersey, USA
Thioredoxin 1 (Trx1) has redox sensitive cysteine residues
and acts as an anti-oxidant in cells. However, the extent of
Trx1 contribution to overall cellular anti-oxidant mecha-
nisms is unknown in any organs in vivo. We generated trans-
genic mice with cardiac specific over-expression of a domi-
nant negative (DN) mutant (C32S/C35S) of human Trx1
(Tg-DN-Trx1), where the activity of endogenous Trx was
significantly diminished. Markers of lipid peroxidation and
oxidative DNA damage were significantly increased in hearts
from Tg-DN-Trx1 compared with those from non-transgenic
littermates (NTg). Tg-DN-Trx1 exhibited cardiac hypertro-
phy with maintained cardiac function at baseline. Intraperi-
toneal injection of N-2 mercaptopropionyl glycine, an anti-
oxidant, normalized cardiac hypertrophy, suggesting that
oxidative stress plays an important role in mediating cardiac
hypertrophy in Tg-DN-Trx1. Thoracic aortic banding caused
significantly greater increases in myocardial oxidative stress
and enhanced the extent of cardiac hypertrophy in Tg-DN-
Trx1 than in NTg. By contrast, transgenic mice with cardiac
specific overexpression of wild type Trx1 did not show car-
diac hypertrophy at baseline but exhibited reduced levels of
hypertrophy and oxidative stress in response to pressure
overload. Studies on the signalling mechanism indicated that
Trx1 directly associate with Ras, thereby negatively regulat-
ing the Ras-ERK pathway in cardiac myocytes. These results
for the first time demonstrate that endogenous Trx1 is an
essential component of the cellular anti-oxidant mechanisms
and plays a critical role in regulating oxidative stress in the
heart in vivo. Furthermore, inhibition of endogenous Trx1 in
the heart primarily stimulates cardiac hypertrophy both un-
der basal conditions and in response to pressure overload
through redox-sensitive mechanisms.
Abstract No S24E
Redox signaling in mending the broken hearts
Das DK, Cardiovascular Research Center, University of
Connecticut School of Medicine, Farmington, Connecticut,
USA
Reactive oxygen species (ROS) play a crucial role in the
pathophysiology of ischemic heart disease by causing car-
diac dysfunction and cell death. Several redox-sensitive anti-
and pro- apoptotic transcription factors including NFoB and
AP-1 progressively and steadily increase in the heart as a
function of the duration of ischemia and reperfusion. When
the heart is preconditioned to ischemic stress by repeated
short-term ischemia and reperfusion, NFoB remains high
while AP-1 is lowered to almost baseline value. The anti-
apoptotic gene Bcl-2 is downregulated in the ischemic/
reperfused heart, while it is upregulated in the adapted myo-
cardium. Cardioprotective abilities of the preconditioning
are abolished when heart is pre-perfused with N-acetyl cys-
teine, a scavenger for ROS, suggesting the role of ROS in
redox signaling. Mammalian heart is protected by several
lines of defense, which include among others, redox-
regulated proteins, thioredoxin and glutaredoxin. Reperfu-
sion of ischemic myocardium results in the downregulation
of thioredoxin 1 (Trx 1) expression, which is upregulated in
the preconditioned myocardium. The increased expression of
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Trx 1 is completely blocked with an inhibitor of Trx 1,
CDDP, which also abolishes cardioprotection afforded by
ischemic adaptation. The cardioprotective role of Trx 1 is
further confirmed with transgenic mouse hearts overexpress-
ing Trx 1. The Trx 1 overexpressed mouse hearts displayed
significantly improved post-ischemic ventricular recovery
and reduced myocardial infarct size and apoptosis as com-
pared to the corresponding wild-type mouse hearts. Taken
together, preconditioning appears to potentiate redox signal-
ing, which converts the —death signal » into —survival
signal ».
Abstract No S25A
From contraindication to general acceptance : the
mechanisms of the clinical response to beta-blockers in
heart failure
Finn Waagstein MD PhD FESC Sweden
In the early seventies major opinion leaders in cardiology
suggested that long-term inotropic stimulation of the failing
heart should be the state of the art treatment. This proposal
was based on experimental studies of heart failure models,
myocardial biopsies from human failing hearts and plasma
samples showing low content of noradrenalin in tissue and
high levels of circulating catecholamine. Retrospectively
however these data could also be interpreted in the opposite
manner concluding that myocardial protection by reducing
overload would be a better alternative. For the next two and a
half decades unfortunately the first interpretation was pre-
vailing. Our own clinical observations in patients with acute
myocardial infarction with heart failure receiving intrave-
nous selective beta-blockade indicated that the metabolic
unloading by reduction in heart rate and blood pressure was
well tolerated and lead to reduction of ischemia and eventu-
ally to smaller infarcts and decreased mortality. The same
principle was therefore applied to chronic heart failure with
tachycardia. By stepwise slow titration of beta-blockers the
sudden withdrawal of sympathetic stimulation was avoided
and only small transient depression of heart function was
observed during the first month followed by gradually im-
provement over the next 6 to 12 months. The excellent toler-
ability for beta-blockade has finally been confirmed by major
placebo —controlled trials also showing marked reduction in
morbidity and mortality as well as improved wellbeing. The
working hypothesis for the beneficial effect of beta-blockers
in heart failure from the very beginning was to improve the
myocardial energy balance by reducing the metabolic load
and energy waste caused by strong sympathetic stimulation.
Myocardial efficiency was improved and the ratio between
myocardial phosfocreatine and ATP was restored to normal
values. Moreover it was noticed that inflammatory cytokines
and neurohormones including angiotensin, endothelin-1 and
noradrenalin was reduced after beta-blockade. Some of the
conditions leading to heart failure are characterized by in-
creased sympathetic tone such as hypertension and type-II
diabetes and beta-blockade seems therefore a logical treat-
ment concept already in the early stages of heart failure or
left ventricular dysfunction. MR- studies with gadolinium
enhancement has shown that the amount of hibernating myo-
cardium is predictive of functional improvement. Polymor-
phism of the beta1-receptor may also play a role for outcome.
Conclusion : There is now a strong rationale for the use of
beta-blockade in heart failure treatment in addition to block-
ade of renin-angiotensin-aldosteron-system.
Abstract No S25B
Restoration of calcium-handling proteins after
b-blocker treatment in heart failure patients
Ken Margulies. Cardiovascular Research Center, Temple
University School of Medicine, Philadelphia, PA 19140,
U.S.A.
Beta-adrenergic receptor blockers (BB) are established as
highly effective disease modifying drugs for patients with
chronic congestive heart failure. Although typical target
doses of BB can acutely worsen cardiac performance and
exacerbate heart failure, numerous studies have demon-
strated that gradual dose-titration and sustained administra-
tion of BB usually results in improved cardiac function
among patients with both ischemic and nonischemic cardi-
omyopathies. Though incompletely understood, the mecha-
nisms of improved contractility and reverse remodeling in-
duced by BB seem to involve improvements in beta-
adrenergic signal transduction and alterations in the
abundance of calcium handling proteins. In particular, nu-
merous studies demonstrate that BB therapy increases sarco-
plasmic reticulum ATPase (SERCA) mRNA and protein
abundance in failing hearts and several studies have corre-
lated function and/or prognosis with changes in SERCA
abundance during BB therapy. While reported changes in
other calcium handling proteins have been less consistent,
studies to date suggest that changes in phospholamban and
ryanodine receptor abundance and/or phosphorylation also
contribute to improved myocardial function during sustained
BB therapy in heart failure.
Abstract No S25C
Does b-blocker-mediated stimulation of gi contribute to
recovery mechanisms ?
Sian E. Harding, Cardiac Medicine, NHLI, Imperial College
London, SW3 6LY, UK
b-blockers not only prevent the worsening of heart failure
but promote recovery in terms of increased cardiac output.
We have shown that b2AR-selective b-blockers can activate
the coupling of the receptor to Gi. Acutely, this produces a
negative inotropic effect in failing (but not non-failing) hu-
man ventricular myocytes. Similar negative effects of
b-blockers are seen when conditions in rat myocytes are
adjusted to resemble those in failing human heart by overex-
pression of the b2AR, Gi or the Na
+/Ca2 + -exchanger. Addi-
tionally, overexpression of the human b2AR per se has a
biphasic time-dependent effect on contraction, increasing
basal amplitudes at 24 h but reducing them below control
values at 48 h. This implies a switch from constitutive Gs
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coupling at early time points to later tonic coupling of the
b2AR through Gi to a negative inotropic mechanism. This
sequence recapitulates effects observed in the transgenic
mouse overexpressing the human b2AR. There are several
mechanisms by which chronic stimulation of Gi could pro-
mote recovery. First, desensitisation of tonic Gi-mediated
negative inotropic effects may occur when this pathway is
continually stimulated. Application a specific b2AR-blocker
for 48h to rat myocytes overexpressing the b2AR increased
contractility. Second, there are a number of Gi-coupled path-
ways whose activation may be protective to the myocyte in
terms of apoptosis and hypertrophy, including PI3kinase and
MAPKinase. Gi-mediated activation by b-blocker stimula-
tion of the b2AR has the potential to contribute to the recov-
ery process, and may explain the superior effect of the b2AR-
selective carvedilol.
Abstract No S25D
Metoprolol and carvedilol : pharmacological
differences and their impact on the clinical use in
patients with chronic heart failure
Christoph Maacka, Michael Kindermannb, Michael Böhmb.
a The Johns Hopkins University, Baltimore, MD, USA.
b Universität des Saarlandes, Homburg, Germany
b-Adrenoceptor (b-AR) blockers improve ventricular
function and survival in patients with chronic heart failure. It
is presently debated whether carvedilol, a non-selective b1-
/b2-AR-blocker with vasodilating properties, is superior to
the b1-AR selective compound metoprolol. Besides their
different AR selectivity, carvedilol and metoprolol differ
profoundly regarding b-AR binding and b-AR-G-protein
interaction. In human myocardium, metoprolol inactivates
b-ARs (inverse agonism) to a higher degree than carvedilol.
This has important implications for myocardial b-AR regu-
lation in heart failure patients. Furthermore, carvedilol dis-
plays much slower on- and off-kinetics of b-AR binding
compared to metoprolol in intact human myocardium. Meto-
prolol induces a monophasic rightward shift of isoproterenol
concentration-response curves, whereas carvedilol induces a
biphasic one. This suggests that in contrast to metoprolol,
carvedilol is not a competitive antagonist and thus may not
interact with the orthostheric, but rather an allosteric site of
b-ARs. The clinical implications of the slow kinetics and
allosteric binding of carvedilol was tested in healthy volun-
teers that were treated with either carvedilol or metoprolol
succinate for 11 days. Dobutamine stress-echocardiography
was performed before, during and 44 hours after withdrawal
of treatment. While both b-AR blockers reduced
dobutamine-responses of various hemodynamic parameters
during treatment, after withdrawal of b-blockers, the re-
sponses were restored in metoprolol-, but not in carvedilol
treated subjects despite complete plasma elimination of
b-blockers. These differences in b-AR kinetics have impor-
tant clinical implications for patients with chronic heart fail-
ure that require inotropic support due to cardiac decompen-
sation. Furthermore, the fact that carvedilol provides b-AR
blockade far beyond its plasma elimination may contribute to
its beneficial effects in the treatment of chronic heart failure.
Abstract No S25E
Paradoxical pharmacology-the way forward ?
Bond RAa, Callaerts-Vegh Zsa, Dudekula Na. Shardonofsky
FR b, aUniversity of Houston, b Baylor College of Medicine,
Houston, TX, USA
Asthma is a chronic inflammatory airway disease in which
b2-adrenoceptors (b2-AR) act as the major bronchodilating
system. b2-AR agonists are current drugs of choice, how-
ever, they may be less effective when given chronically and
morbidity may be increased. b-blockers are contraindicated
due to their deleterious acute effects. These effects of b-AR
agonists and antagonists are analogous to what was the para-
digm in heart failure before chronic b-blocker use. In our
murine model of asthma, we observe that acute (15 min)
treatment (TX) with the b2-AR inverse agonist, nadolol,
increased airway resistance (Raw) while chronically
(28 days) Raw was significantly reduced. In contrast, b-AR
agonist TX with salbutamol reduces Raw acutely, but is
chronically ineffective. b-AR density measured by radioli-
gand binding correlates with the in vivo Raw data.
Figure 1 : Airway responsiveness in murine model of
asthma : 15 min TX with salbutamol or 28 d with nadolol
decrease Raw significantly compared to sensitized mice. Val-
ues are mean ± s.e.m. of n = 8-25 animals in each group
(*P < 0.05 comp. to Sensitized, ANOVA. Note Y-axis is dif-
ferent for the 15 min nadolol).
Table 1. – 15 min treatment with salbutamol or alprenolol
significantly increased Bmax (fM mg
-1 protein) to control
values, while 28 d with carvedilol or nadolol increased Bmax
values significantly for ß-AR receptors in lung membranes.
Values are mean ± s.e.m. of n = 3-5 animals in each group
(*P < 0.05 comp. to Sensitized, Student’s t-test). Samples
were run in triplicate.
Treatment 15 minutes 28 days
Ctrl 286.8 ± 88.02 * 286.8 ± 88.02
Sensitized 109.2 ± 9.72 109.2 ± 9.72
Salbutamol 256.5 ± 29.24 * 97.0 ± 23.02
Alprenolol 299.5 ± 12.19 * 179.2 ± 53.05
Carvedilol 86.3 ± 19.42 904.1 ± 43.46 *
Nadolol 181.9 ± 48.28 785.5 ± 154.8 *
Abstract No S26A
Vascular tissue engineering : challenges and
opportunities
Robert M. Nerem, Georgia Institute of Technology, Parker
H. Petit Institute for Bioengineering and Bioscience,
Atlanta, GA, USA
Tissue engineering will need to move from the repair of
tissues that for the most part are structural in nature to a focus
on the vital organs. For the heart, where a key component is
the epicardial coronary arteries, the replacement of such
vessels requires the development of a tissue-engineered
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small-diameter blood vessel substitute. This has been a
—holy grail » for cardiovascular tissue engineering, and in
this, there are a number of critical issues. First is the issue of
providing an —endothelial-like », non-thrombogenic inner
lining. There are a variety of endothelialization strategies
being pursued, with possibilities including the use of (i)
autologous cells, either from adipose tissue or circulating
progenitor cells, (ii) allogeneic cells, and (iii) embryonic
stem cells. A second critical issue is the matrix, including
engineering in the appropriate mechanical properties, not
just sufficient strength but visco-elastic properties that match
those of native vessels. Approaches here range from incorpo-
rating intact elastin scaffolds derived from xenogeneic tis-
sues to the genetic engineering of smooth muscle cells in
order to enhance elastin production and assembly. Third,
when a tissue-engineered blood vessel substitute is im-
planted into a host, an important issue is the variety of
biological responses that will take place. In this one must
confront not only such issues as thrombosis and remodeling,
but in addition the immunological barrier. In order to address
the wide clinical need, it will be important to have off-the-
shelf availability. If allogeneic cells are to be employed, this
will require the engineering of immune acceptance. This is
perhaps the biggest challenge if we are to move vascular
tissue engineering from benchtop research to the patient
bedside.
Abstract No S26B
Myocardial vascular regeneration using human
progenitor cells of endothelial and mesenchymal
lineage
Silviu Itescu, Departments of Medicine and Surgery,
Columbia-Presbyterian Medical Center, New York, USA
Congestive heart failure remains a major public health
problem, and is frequently the end result of cardiomyocyte
apoptosis and fibrous replacement after myocardial infarc-
tion, a process referred to as left ventricular remodelling. In
response to ischemic insult, adult cardiomyocytes undergo
cellular hypertrophy, nuclear ploidy, and a high degree of
apoptosis. Although most myocytes seem to be terminally
differentiated, recent studies suggest that a few cardiomyo-
cytes retain the ability to proliferate and regenerate in re-
sponse to ischemic injury. The dividing myocytes can be
identified on the basis of immunohistochemical staining of
proliferating nuclear structures such as Ki67 and cell surface
expression of specific cardiomyocyte lineage markers.
Whether these cells are derived from a resident pool of
cardiomyocyte stem cells or are derived from a renewable
source of circulating bone marrow-derived stem cells that
home to the damaged myocardium remains to be determined.
More importantly, the signals required for homing, in situ
expansion and differentiation of these cells are, at present,
unknown. Gaining an understanding of these issues would
open the possibility of manipulating the biology of endog-
enous cardiomyocytes in order to augment the healing pro-
cess after myocardial ischemia. Bone marrow-derived endot-
helial precursors resembling embryonic angioblasts can
induce infarct bed neovascularization after experimental
myocardial infarction, resulting in induction of proliferation
and regeneration of endogenous cardiomyocytes, and sus-
tained improvement in cardiac function. Regeneration of
functional cardiac muscle after an ischemic insult to the heart
could also be achieved by implanting exogenous donor-
derived or allogeneic cells such as fetal or embryonic cardi-
omyocyte precursors or bone marrow-derived mesenchymal
stem cells. It is reasonable to anticipate that cell therapy
strategies for ischemic heart disease will need to incorporate
(1) a renewable source of proliferating, functional cardi-
omyocytes, and (2) strategies to generate a network of capil-
laries and larger size blood vessels for supply of oxygen and
nutrients. The common mesenchymal origin of cardiomyo-
cytes and supporting vascular structures such as pericytes
and smooth muscle cells has spurred efforts to identify mes-
enchymal lineage precursors in various mammalian species
including humans which could serve as substrate for exog-
enous regeneration of these cells. Recent data have been
obtained which suggest that mesenchymal precursors can be
precisely identified in vivo on the basis of perivascular ana-
tomical location and expression of specific surface markers,
and that these cells can be immunoselected to high purity by
monoclonal antibodies directed to these markers. Combining
ex vivo expanded mesenchymal lineage cells with cells of
endothelial lineage allows for building of capacitance vessels
and arteriogenesis, and may result in both effective neovas-
cularization and myogenesis.
Abstract No S26C
Differentiation of macrophages into myofibroblasts
Julie H. Campbell, Jane Mooney, David Sester and Gordon
R. Campbell, University of Queensland, Brisbane QLD
4072, Australia
Polyethylene tubing implanted into the peritoneal cavity
of mice, rats, rabbits and dogs becomes encapsulated with
multiple layers of myofibroblasts and collagen and a single
outer layer of mesothelial cells. When the tubular capsule of
living cells is transplanted as an autologous vascular graft,
the myofibroblasts further differentiate into smooth muscle-
like cells and the mesothelial cells function as ’endothelium’.
The aim of the study was to determine the cellular origin of
the myofibroblasts that form the capsule. Foreign bodies
were implanted into the peritoneal cavity of C57BL/6 and
c-fms EGFP mice (in which only cells of myeloid origin, ie
macrophages, fluoresce green), then the tissue capsule that
formed around the foreign body harvested at different time
points. Cells within the peritoneal cavity and those compris-
ing the capsule were isolated for analysis of EGFP (enhanced
green fluorescent protein) transgene and expression of other
cell markers using flow cytometry and immunofluorescence
microscopy. The recruited cells were mainly rounded mac-
rophages, confirmed by their expression of F4/80 and
CD11b, that consisted of two subsets, EGFP-high and EGFP-
low. The EGFP-low subset also expressed Ly6C/G (Gr1).
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The two subsets of EGFP + ve cells comprised greater than
85 % of the cells of the capsule at day 2, with 75 % of the
cells EGFP-high and 10 % EGFP-low. The relative propor-
tion of EGFP-low increased over the next few days such that
by day 7, when the cells had become spindle-shaped, there
were equal numbers of EGFP-high and -low. Co-expression
of EGFP and the myofibroblast marker a-smooth muscle
actin was observed in the spindle-shaped cells by day 10.
In conclusion, cells that encapsulate a foreign body in the
peritoneal cavity and differentiate into myofibroblasts are of
myeloid (monocyte/ macrophage) origin. This suggests that
peritoneal monocyte/ macrophages are capable of trans-
differentiation into smooth muscle-like cells in the develop-
ment of an artificial artery.
Abstract No S26D
Tissue engineering heart valves : from concepts to
constructs
Patricia M. Taylor, Heart Science Centre, Harefield
Hospital, NHLI, Imperial College London, U.K.
Replacement tissue valves continue to have limitations
due to their inability to grow, limited durability and suscep-
tibility to infection. Creation of a tissue-engineered cardiac
valve populated with viable cells, thus having the potential to
grow and repair offers a promising alternative. The success-
ful tissue-engineering of a valve will rely on the production
of a construct that resembles the unique cellular and load
bearing characteristics, exhibit similar dynamic properties
and replicate as closely as possible the structure and biologi-
cal properties of the native valve. The choice of cell type to
populate the scaffold, the composition of the scaffold and the
dynamic conditions used during development will all play a
vital role in its success.
Valve interstitial cells are a heterogeneous and dynamic
population of specific cell types. Many express smooth
muscle a-actin, genes encoding structural components of the
cardiac and skeletal contractile apparatus and the skeletal
muscle-specific regulatory gene myogenin. When seeded in
collagen gel, valve interstitial cells display a characteristic
force generation profile, where the force generated is in-
versely related to cell density and they do not display ten-
sional homeostasis. These characteristics may be vital for a
fully functioning valve and may also provide a template for
identifying potential sources of cells for tissue-engineered
valve constructs. We are currently studying the phenotype,
functional responses and the effect of mechanical force on
cells from other sources in order to identify and/or direct
suitable candidate cells for the constructs. Ideally the cells
should not be immunogenic and studies investigating the
immunogenicity of candidate cells will also be discussed.
The scaffolds are produced from type I collagen using a
technique known as rapid prototyping, whereby a negative
mould of a computer program design is printed out in micro-
beads to create a 3-D structure. The cells populating the
construct should respond to the haemodynamic environment
in a manner that will promote valve function. Mechanical
forces can induce changes in gene expression, cell morphol-
ogy and cell metabolism. Using a novel bioreactor, we can
accurately reproduce a wide range of haemodynamic pres-
sures and flow rates, enabling us to determine the optimal
conditions for construct production. Preliminary experi-
ments are underway to evaluate the mechanical strength of
seeded constructs and to determine how cells affect the me-
chanical properties of the scaffold and how haemodynamic
forces affect the integrity of the construct.
The desired goal of any successful tissue-engineered heart
valve will be to produce a construct that closely replicates the
structure and function of the native valve. Knowledge of the
complex mechanisms of cell-cell interaction and cell-matrix
interaction is essential and is now beginning to be investi-
gated and understood at the molecular level.
Abstract No S26E
Grafting of engineered heart tissue to repair infarcted
myocardium
Wolfram-H. Zimmermann, Thomas Eschenhagen, Institute
of Pharmacology, University Hospital Hamburg-Eppendorf,
Hamburg, Germany
Cardiac tissue engineering may yield surrogate cardiac
tissue for the repair of diseased myocardium. Recently, we
developed a technology to construct Engineered Heart Tissue
(EHT) with structural and functional properties of native
myocardium from neonatal rat heart cells, collagen type I,
matrigel, and serum containing culture medium. EHTs can
be engineered in different sizes and geometries according to
in vivo demands. Here, we utilized large star-shaped EHTs
(diameter : \\ 126\\20 mm ; thickness : 1-4 mm) to test
whether EHTs can reconstitute heart muscle in rats with
transmural infarcts. Infarcts were generated by ligation of the
left descending coronary artery and EHTs were implanted
2 weeks thereafter. We assessed structural and functional
integration 4 weeks after EHT-grafting. Sham operated rats
served as controls. Hematoxylin&Eosin staining of paraffin
sections and confocal laser scanning microscopy of DAPI
labeled EHT-grafts revealed survival, differentiation, and
structural integration of EHT grafts into the native myocar-
dium. Multi-electrode epicardial mapping indicated electri-
cal coupling of EHT grafts to native myocardium. Echocar-
diography and nuclear magnetic resonance imaging
demonstrated that EHT grafts improved left ventricular wall
kinetics and systolic anterior wall thickening in rats with
myocardial infarcts. Thus, we conclude that EHT may be
utilized to repair infarcted and possibly otherwise damaged
myocardium in vivo.
Abstract No S26F
Myocardial tissue reconstruction by cell sheet
technology
Tatsuya Shimizu, Teruo Okano, Institute of Advanced
Biomedical Engineering and Science, Tokyo Women’s
Medical University
Regeneration therapy has currently emerged as one of the
most promising treatments for the patients suffering from
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severe heart failure. Direct transplantation of isolated myo-
blasts or bone marrow mononuclear cells, and recruitment of
stem cells from bone marrow by G-CSF administration have
been already clinically performed. As further advanced
therapy, research on fabricating three-dimensional (3-D) car-
diac grafts by tissue engineering technology has also now
begun. For creating functional myocardial tissue, critical
points are how to connect whole cardiomyocytes electrically
and how to grow enough vascularization within the con-
struct. We have exploited novel cell manipulation technique
to construct 3-D tissue by layering cell sheets without any
biodegradable scaffolds. Confluent neonatal rat cardiomyo-
cytes on temperature-responsive culture surfaces can be har-
vested as an electrically-communicated contiguous cell sheet
only by lowering temperature without any enzymatic diges-
tions. Both electrical and morphological communications are
developed between layered cardiomyocyte sheets, leading
simultaneous beating 3-D myocardial tissues. Layered cardi-
omyocyte sheets in vivo demonstrated synchronized beating,
1-year survival and characteristic structures of native heart
tissue including well-differentiated sarcomeres, gap junc-
tions and microvasculars. To overcome thickness limitation
due to primary insufficient oxygen permeation, multi-step
transplantation of triple-layered cell sheets were performed.
The latter graft synchronized with the former. No necrotic
tissue was observed within the overlaid grafts, because
neovascularization occurred step-by-step. Finally, 10-time
transplantations of triple-layer grafts have realized about
1 mm-thick functional myocardial tissue. In conclusion, cell
sheet technology should have enormous potential in myocar-
dial tissue engineering.
Abstract No S27A
Regulation of fatty acid oxidation in perfused hearts
from diabetic mice
David L. Severson, Faculty of Medicine, University of
Calgary, Calgary, AB Canada
Altered fatty acid metabolism in diabetic hearts may con-
tribute to cardiac dysfunction (lipotoxicity). We have exam-
ined the metabolism of palmitate complexed to albumin in
the perfusate of isolated perfused working hearts from both
type 1 (streptozotocin-induced insulin-deficient) and type 2
(monogenic db/db) mice. Rates of palmitate oxidation and
esterification (to triacylglycerol) were both markedly el-
evated in both models of diabetic hearts. Similar results were
obtained when diabetic hearts were perfusion with chylomi-
crons ; lipoprotein lipase-derived fatty acid oxidation and
esterification was also increased. Thus, fatty acid metabolism
was enhanced in diabetic hearts, irrespective of the fatty acid
source. Rates of cardiac fatty acid oxidation were normalized
in transgenic db/db-hGLUT4 mice with global over-
expression of the insulin-regulatable glucose (GLUT4)
transporter. In addition, fatty acid oxidation was normalized
in hearts from db/db mice after chronic oral administration of
a PPARgamma ligand (COOH, from Merck). COOH treat-
ment also enhanced insulin-stimulated glucose uptake in
isolated cardiomyocytes, providing evidence for insulin sen-
sitization in db/db hearts. The mechanism(s) responsible for
elevation of fatty acid oxidation rates in diabetic hearts
is(are) under investigation.
Abstract No S27B
Diabetes and cardiac carbohydrate metabolism
John C. Chatham, Dept. Medicine, University of Alabama at
Birmingham, Birmingham AL, USA
It is commonly believed that diabetes decreases cardiac
glucose oxidation and increases lipid oxidation. This shift
away from glucose towards lipids for energy metabolism has
been attributed to the development of contractile dysfunction
and increased sensitivity to ischemic injury. Recently we
have focused on the impact of Type-2 diabetes on the regula-
tion of cardiac metabolism using substrate mixtures that
include lactate and pyruvate at physiologically realistic con-
centrations as well as glucose and palmitate. In isolated
hearts from Zucker diabetic fatty rats (ZDF) perfused under
normoxic conditions, total carbohydrate oxidation was de-
creased by \\ 126\\50 % compared to non-diabetic controls ;
however, this was due entirely to \\ 126\\4-fold decrease in
lactate oxidation rates with no change in glucose oxidation.
On the other hand glycolytic lactate production was signifi-
cantly lower in the ZDF group. Even during low flow is-
chemia (30min at 0.3mls/min) and subsequent reperfusion,
there were no differences in glucose oxidation between the
two groups ; whereas, lactate oxidation remained depressed
in the ZDF group under all conditions. Interestingly, the
decrease in glycolysis observed during normoxia was not
present during ischemia or reperfusion. Furthermore, despite
the alterations in metabolism functional recovery follow is-
chemia was not depressed in the ZDF group. These data
suggest that in the presence of physiological substrate mix-
tures the shift from carbohydrates to fatty acids for oxidative
energy production may not be important in mediating the
adverse effects of diabetes on the heart.
Abstract No S27C
Alterations in malonyl coa control of fatty acid
oxidation in the diabetic heart
Gary D. Lopaschuk, University of Alberta, Canada
Alterations in energy substrate preference in the heart can
compromise cardiac function and decrease the ability of the
myocardium to withstand an ischemic episode. In uncon-
trolled Type I diabetes, myocardial fatty acid oxidation rates
markedly increase, resulting in a dramatic inhibition of glu-
cose oxidation. This increase in fatty acid oxidation is due
both to an increase in circulating fatty acid levels, as well as
alterations in malonyl CoA control of mitochondrial fatty
acid uptake. If mice are fed a high fat diet for a 10 week
period, they become obese and insulin-resistant. Hearts from
these mice show an energy substrate use profile that parallels
what is seen in the diabetic heart (i.e a switch towards to fatty
acid oxidation and a decrease in the contribution of glucose
oxidation to overall energy production). In both diabetic rat
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and obese mice hearts, the activity of malonyl CoA decar-
boxylase (MCD) increases. This results in a decrease in
malonyl CoA levels, and a resultant increase in fatty acid
oxidation rates. The increase in cardiac MCD in diabetes and
obesity appears to occur, in part, due to an increase in peroxi-
some proliferators-activated receptor a (PPARa) activity, an
important transcriptional regulator of fatty acid oxidative
enzymes in the heart. In support of this, overexpression of
PPARa in the mouse heart will increase fatty acid oxidation
and decrease glucose oxidation, similar to what is observed
in hearts from diabetic or obese mice. Part of this effect of
PPARa is mediated by an increase in MCD expression. This
suggests that inhibition of MCD may be a potential approach
to overcoming the alterations in fatty acid and glucose oxi-
dation that occur in the myocardium of diabetic and/or obese
individuals.
Abstract No S27D
Ketone bodies affect fatty acid utilization and gene
expression in cardiomyocytes from diabetic rats
Ger J. van der Vusse, Danny Hasselbaink, Andries Gilde and
Marc van Bilsen, Cardiovascular Research Institute
Maastricht, Maastricht, the Netherlands
It was explored whether chronic exposure of the heart to
both elevated extracellular ketone body and fatty acid (FA)
levels, as readily seen in STZ-induced type 1 diabetes, alters
FA utilization and the expression of FA handling genes in
cardiac muscle cells (CMC). CMC isolated from adult dia-
betic rat hearts showed increased uptake and oxidation rates
of extracellular FA. The ketone body acetoacetate, but not
beta-hydroxybyturate, nullified the diabetes-induced in-
crease in FA oxidation. The sensitivity towards the inhibitory
effect of acetoacetate, however, was similar in diabetic and
control cells. Chronic exposure of neonatal CMC to elevated
extracellular FA significantly induced the expression of a
panel of FA-handling genes, including FAT/CD36, FABP,
ACS, mCPT1 and LCAD. In the intact diabetic heart, how-
ever, mRNA levels of these proteins only showed a tendency
to increase, suggesting that other factors are apparently miti-
gating FA-induced gene expression. Beta-hydroxybutyrate
may play a role as this ketone body partly blocked the
FA-induced mCPT1 promoter activity in transfected neona-
tal CMC.
Abstract No S27E
Cardiac and skeletal muscle metabolism after chronic
PPARc activation in type 2 diabetes mellitus
Michaela Scheuermann-Freestone, Robin Buckingham,
Stefan Neubauer and Kieran Clarke. Laboratory of
Physiology and Department of Cardiovascular Medicine,
University of Oxford, Oxford and GlaxoSmithKline, UK
Despite normal cardiac function, patients with type 2 dia-
betes mellitus (DM) have impaired cardiac and skeletal
muscle high-energy phosphate metabolism. It is unknown
whether the energetic abnormalities can be rectified by im-
proving insulin sensitivity via activation of peroxisome
proliferator-activated receptor c (PPARc). To study this,
25 patients with DM, with normal cardiac function and with-
out cardiovascular disease, were randomised in a double-
blind fashion to receive either placebo or the PPARc agonist
Rosiglitazone (RSG, 8 mg od) for three months. Before and
after this treatment, fasting blood metabolites and cytokines
were measured, and cardiac function was assessed using
echocardiography. Cardiac energetics (phosphocreatine to
ATP ratio, PCr/ATP) were measured using 31P magnetic
resonance spectroscopy (MRS) at rest. Skeletal muscle ener-
getics (right gastrocnemius muscle) and tissue oxygenation
were measured at rest and during and after dynamic exercise
using MRS and near-infrared spectrophotometry, respec-
tively. Treatment with RSG for three months decreased insu-
lin resistance and significantly lowered plasma free fatty
acids (FFA, 0.3 ±0.1 vs. 0.5 ±0.1 with placebo, p < 0.01) and
highly-sensitive C-reactive protein levels (hs-CRP,
1.3 ±0.3 vs. 3.0 ±0.6 with placebo, p < 0.05). Whereas pla-
cebo did not change cardiac PCr/ATP ratios, treatment with
RSG increased PCr/ATP by 0.41 ±0.18 (vs.
—0.04 ±0.01 with placebo, p < 0.05), the increase in
PCr/ATP correlating with the decrease in hs-CRP (rb = 0.29,
p < 0.05). Neither treatment with placebo nor with RSG
changed exercise tolerance and skeletal muscle energetics.
However, a correlation between PCr recovery and FFA levels
became apparent after treatment with RSG, which was not
evident prior to treatment.In summary, treatment with RSG
improved cardiac energetics by lowering plasma FFA and
hs-CRP. Whereas skeletal muscle energetics were un-
changed, a new negative correlation between PCr recovery
and FFA was revealed. Thus, treatment with RSG may have
altered cardiac and skeletal muscle substrate utilisation and
improved inflammatory status with a beneficial effect on
cardiac energetics.
Abstract No S28A
Pathways regulating cellular mobilization in cardiac
hypertrophy
Thierry Pedrazzini, Division of Hypertension, University of
Lausanne Medical School, Lausanne, Switzerland
Cardiac remodeling is a common feature in patients suf-
fering from chronic hypertension or following myocardial
infarction. Recent evidence suggests the presence of undif-
ferentiated progenitors in many adult tissues. These cells
could be activated in injured organs and participate to the
healing process. In the present study, we investigated
whether the cardiac non-myocyte population contained a
subset of precursor cells with a capacity to differentiate into
functional cardiomyocytes. We isolated proliferative non-
myocyte cells from the neonatal heart, and demonstrated
that, when cultured under the appropriate conditions, these
cells could give rise to spontaneously beating cardiomyo-
cytes. Interestingly, a significant percentage of neonatal un-
differentiated non-myocyte cells express the stem cell mark-
ers Sca-1 and c-kit. In a second part, we search for humoral
factors that might regulate the differentiation process. The
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Fibroblast growth factor-2 (FGF-2) is known as a differentia-
tion factor. In additon, we have shown previously that mice
deficient for FGF-2 expression suffer from dilated cardi-
omyopyathy. We then tested whether the absence of FGF-
2 could affect cardiogenesis. The capacity of non-myocyte
cells lacking FGF-2 to differentiate into cardiomyocytes was
significantly reduced as compared to wild type cells. More-
over, the subset of Sca-1 positive cells in the undifferentiated
non-myocyte population markedly increased in FGF-
2 knockouts, suggesting that the absence of FGF-2 interfered
at an early time point with cardiogenesis. Together, these
results indicate the presence in the heart of a population of
undifferentiated precursors that might be recruited for tissue
repair. In addition, the mobilization and differentiation pro-
cess of this particular cell subset appeared to require the
presence of FGF-2.
Abstract No S28B
Growth induction and contractile dysfunction in the
heart — a variable phenotype
Lea M D Delbridge, Department of Physiology, University
of Melbourne, Australia
Significant progress has been made recently in the devel-
opment of genetic models of cardiac hypertrophy in which
intrinsic enlargement of the heart is observed in a normoten-
sive setting. In this context, non-load dependent aspects of
excitation-contraction coupling dysfunction in hypertrophy
may be identified. We have investigated and compared poly-
genic in-bred and uni-gene targeted transgenic models of
hypertrophy, where cardiac growth is linked with various
metabolic and endocrinologic manipulations. Whilst distur-
bances in cardiomyocyte Ca and pH homeostasis are usually
evident, the nature of the alterations in these ionic fluxes and
effect on contractility is model-specific. We have recently
reported the development of a novel polygenic rat strain of
primary cardiac hypertrophy derived from a cross of Fisher
(F344) and SHR (Physiol Genomics 9 :43-48, 2002). Our
new Hypertrophic Heart Rat (HHR) strain exhibits cardiac
and cardiomyocyte hypertrophy in the absence of hyperten-
sion. In parallel we have co-developed a Normal Heart Rat
(NHR) strain with small hearts and low blood pressure as a
control strain. We have investigated transgenic and gene-
knockout models to explore the role of trophic and metabolic
factors in inducing cardiac hypertrophy. Our studies of a
transgenic cardiac-specific angiotensinogen-over expressing
mouse and a cardiac-specific glucose Glut4 transporter Cre-
Lox KO mouse have revealed that similar functional adapta-
tions can be linked with quite different alterations in myocyte
calcium handling in hypertrophy. Our gene expression pro-
filing studies indicate that in contrasting models of cardiac
hypertrophy, altered mitochondrial metabolic function
emerges as a major ’common denominator’ associated with
cellular dysfunction.
Abstract No S28C
Regulation of PKA targeting by AKAPs in failing
hearts
Ruehr M, Zakhary D, Desnoyer, R, Moravec, C.S., Young,
J,B., McCarthy, P., Bhat, M., Ma, J., a Damron, D.S., Scott,
J.D.,b Bond, M. c. Cleveland Clinic Foundation, Howard
Hughes Medical Inst, Vollum Inst, Oregon Health Sciences
Univ, b Univ Med and Dentistry of NJ Jersey-RWJ Sch,a
Univ Maryland Sch Med., USA
Impaired signaling of the b-adrenergic pathway is closely
linked to development of heart failure. Many studies have
focused on altered signaling at the level of the o-adrenergic
receptor (o-AR), but there is now increasing evidence for
defects distal to the o-AR. We investigated regulation of
PKA-dependent substrate phosphorylation by protein kinase
A (PKA) targeting to PKA substrates via A-kinase anchoring
proteins (AKAPs). Using surface plasmon resonance, we
showed that affinity of different cardiac AKAPs for PKA can
increase up to 250 fold upon phosphorylation of serine 96 of
the regulatory subunit of PKA, RII, by the catalytic subunit,
C. In failing vs non-failing human hearts, we showed de-
creased phosphorylation of RII by C, implying decreased
targeting of PKA near PKA substrates by AKAPs. In sepa-
rate experiments, we investigated the effect of altered affinity
of PKA binding to AKAPs by expressing either muscle-
specificAKAP (mAKAP) or its inactive prolinated derivative
(mAKAP- P) in CHO cells expressing the type I ryanodine
receptor (RyRI). We activated adenynlyl cyclase by forskolin
and determined the effect of disruption of PKA targeting to
the RyR by mAKAP-P expression. Results showed that when
PKA targeting to AKAPs is abrogated, both RyR phosphory-
lation and the size of the caffeine releasable Ca2 + pool, are
decreased. These findings, together with our observation of
decreased RII phosphorylation in failing vs non-failing hu-
man hearts, and decreased phosphorylaton of other PKA
substrates (troponin-I and myosin binding protein C) imply
reduced affinity of RII for mAKAP during heart failure. We
conclude that decreased PKA targeting by AKAPs contrib-
utes to decreased phosphorylation of PKA substrates and
thus impaired contractile function of failing hearts.
Abstract No S28D
Ca homeostasis in the hypertrophied and failing heart
Donald M. Bers, Dept of Physiology, Loyola University
Chicago, Maywood IL, USA
Progression from hypertrophy to heart failure (HF) is
accompanied by contractile dysfunction and increased pro-
pensity for life-threatening arrhythmias. Both effects may be
related directly to altered cellular Ca handling in ventricular
myocytes. In HF the twitch Ca transient (D[Ca]i) which is a
main cause of systolic dysfunction. The lower D[Ca]i can be
attributed largely to reduced SR Ca content ([Ca]SRT) and
3 factors may contribute. First, there is reduced SR Ca-
ATPase function in HF which reduces net SR Ca uptake
during the cardiac cycle (consequently reducing SR Ca avail-
ability and also contributing to diastolic dysfunction). Sec-
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ond, increased expression and function of Na/Ca exchange
(NCX) favors Ca extrusion from the cell during relaxation
(competing with SR Ca uptake, but also limiting the extent of
diastolic dysfunction). Third, there may be enhanced dias-
tolic Ca leak from the SR in HF, which would also reduce SR
Ca availability (& this could be mediated by either CaMKII
or PKA effects on the RyR). Relative contributions of these
systems may vary with HF etiology. Triggered arrhythmias
including early and delayed after depolarizations (EADs &
DADs) are prominent initiators of arrhythmias in HF. DADs
are due to spontaneous SR Ca release and consequent activa-
tion of Ca-dependent transient inward currents (Iti). DADs
are normally associated with SR Ca overload, so at first
glance they would seem unlikely in HF. However, we have
shown that Iti is directly attributable to NCX current, and the
higher NCX expression means that there will be a greater Iti
for a given SR Ca release. In addition, there is a down-
regulation of the inwardly rectifying K current (IK1), which
normally stabilizes the resting membrane potential. Thus any
Iti will lead to a greater DAD amplitude, making it much
more likely to induce a propagating arrhythmogenic action
potential. We also show that preserved b-adrenergic respon-
siveness in HF, allows the SR Ca content to reach levels
required to induce spontaneous SR Ca release, Itis, DADs and
action potentials. Thus, altered Ca handling contributes to
both contractile dysfunction and arrhythmogenesis in HF.
Abstract No S28E
Anti-arrhythmic actions of calmodulin kinase
inhibition
Yuejin Wu, Michelle S.C. Khoo, Mark E Anderson,
Vanderbilt University Medical Center, 383 PRB,
2220 Pierce Avenue, Nashville, TN 37232-6300, USA
Disturbances in intracellular Ca2 + are associated with
cardiac arrhythmias and the Ca2 + and calmodulin-
dependent protein kinase II (CaMK) is a central molecular
signal for regulating cellular Ca2 + homeostasis. CaMK ac-
tivity is also up-regulated in patients and in diverse animal
models of structural heart disease, while transgenic over-
expression of CaMK causes cardiac hypertrophy, dilation
and premature death. Taken together, these findings lead us to
hypothesize that CaMK is a pro-arrhythmic signaling mol-
ecule and a potential target for anti-arrhythmic therapy. Here
we present data from isolated cardiomyocytes showing that
CaMK increases L-type Ca2 + channel openings and that
increasing cellular Ca2 + can activate Na+/Ca2 + exchanger
current by a CaMK-dependent mechanism. CaMK inhibition
can suppress afterdepolarizations, cellular arrhythmia
mechanisms linked to L-type Ca2 + channels and Na+/Ca2 +
exchanger currents. Furthermore, pharmacological and ge-
netic CaMK inhibition successfully reduces arrhythmias in
two murine models of structural heart disease (one due to
CaMKIV over-expression and the other due to calcineurin
over-expression) and significantly reduces mortality in mice
with severe cardiomyopathy, due to calcineurin over-
expression. These findings support the concept that CaMK
inhibition is a pro-arrhythmic signal and serve as a proof of
concept that CaMKII inhibition can suppress cardiac ar-
rhythmia
Abstract No S29A
Fat as an endocrine organ
John B Prins. University of Queensland and Princess
Alexandra Hospital, Brisbane, Australia
Adipose tissue is an important endocrine organ, produc-
ing, or regulating production of, numerous hormones in-
volved in energy metabolism and the cardiovascular system.
Collectively, these hormones have been termed adipokines.
Included in the former group are leptin, adiponectin, TNFo
and steroid hormones, all of which influence energy metabo-
lism and insulin sensitivity and which are involved in the
pathogenesis of the Metabolic Syndrome The latter group of
hormones includes PAI-1, TGF and members of the renin-
angiotensin system. These hormones have more direct effects
on the cardiovascular homeostasis, including BP regulation,
myocardial structure/function, endothelial function and
thrombotic diathesis. The role of these hormones in the
pathogenesis of the metabolic syndrome will be discussed,
with particular emphasis on cardiovascular disease. A num-
ber pharmaceutical therapies based on regulation or manipu-
lation of adipokine levels or production are currently under
trial. It is hoped that these strategies will efficacious in
targeting the multiple manifistations of the metabolic sy-
drome.
Abstract No S29B
Obesity and coronary artery disease
Trisha O’Moore-Sullivan. Department of Diabetes and
Endocrinology, Princess Alexandra Hospital, Brisbane.
School of Medicine, University of Queensland, Brisbane,
Australia
Although a relationship between obesity and coronary
artery disease (CAD) has long been recognised, the precise
nature of this relationship remains unclear. Central obesity
has been shown to correlate more closely with CAD than
excess total fat mass. There is a strong association between
central obesity and many of the traditional risk factors for
CAD such as type 2 diabetes mellitus, hypertension and
dyslipidaemia. It remains debatable whether obesity per se is
an independent risk factor for CAD, however evidence sug-
gests that obesity confers risk for CAD over and above that
due to its association with the traditional risk factors. It is
likely that other emerging risk factors associated with obesity
and the metabolic syndrome are contributing. These factors
include hyperinsulinism/insulin resistance, and a prothrom-
botic and proinflammatory state, as well as other hormones
secreted by adipose tissue.
The recognition that adipose tissue is a highly active
endocrine organ has led to interest in the role of adipose
tissue-derived hormones and cytokines in CAD in obesity.
Obesity is associated with increased levels of TNF-alpha,
IL-6, and PAI-1. CRP is also elevated in obesity and has been
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shown to strongly correlate with CAD. More recently it has
been shown that —adipokines » such as adiponectin and
leptin not only play a role in mediating insulin sensitivity and
energy balance, but also contribute to the regulation of car-
diovascular function. Adiponectin appears to be anti-
inflammatory and anti-atherogenic and levels are low in
obese and insulin resistant individuals. Leptin is elevated in
obese individuals and may be an independent risk factor for
the development of cardiovascular disease.
Thus, the relationship between obesity and CAD is also
influenced by both traditional and several less traditional risk
factors.
Abstract No S29C
Obesity cardiomyopathy : pathogenesis, clinical
recognition and management
Martin A. Alpert, M.D., St. John’s Mercy Medical Center,
St. Louis, Missouri, USA
Obesity, particularly morbid obesity is associated with a
variety of alterations in cardiac performance and morphol-
ogy. Excessive adipose accumulation produces augmenta-
tion of circulating blood volume. This in association with a
decrease in systemic vascular resistance leads to an increase
in cardiac output. Since heart rate changes little with increas-
ing fat accumulation, the rise in cardiac output is due prima-
rily to augmented stroke volume. These hemodynamic alter-
ations produce dilatation of the left ventricular (LV) which
predisposes to an increase in left ventricular wall stress.
Eccentric LVH (LVH) occurs in an attempt to normalize wall
stress. Eccentric LVH predisposes to LV diastolic dysfunc-
tion. If LV wall stress remains high (inadequate hypertro-
phy), LV systolic function may ensue. Concurrent systemic
hypertension and morbid obesity produces a hybrid form of
eccentric-concentric hypertrophy. Obesity cardiomyopathy
is a term used to describe congestive heart failure that occurs
due to the aforementioned alterations in cardiac structure and
function. In such individuals LV failure predominates. Right
ventricular failure occurs primarily due to LV failure. Pulmo-
nary arterial hypertension due to obesity/hypoventilation
may contribute to the development of right ventricular fail-
ure. Many of the hemodynamic, morphologic and clinical
manifestations of obesity cardiomyopathy are reversible with
substantial weight loss.
Abstract No S29D
Fat, salt and hypertension : the leptin-cardiorenal axis
Daniel Villarreal, MD, FACC, FAHA, FIACS, Division of
Cardiology, SUNY Upstate Medical University, Syracuse,
New York
Leptin is a recently isolated circulating peptide hormone
that is primarily synthesized and secreted by adipocytes. A
major function of this hormone is the control of energy
balance by binding to receptors in the hypothalamus, leading
to reduction in food intake, as well as elevation in tempera-
ture and energy expenditure. In addition, increasing pharma-
cological evidence suggests that Leptin, through its direct
and indirect actions, may play an important role in cardiovas-
cular and renal functions.
In the systemic vasculature, leptin appears to produce both
vasoconstriction indirectly via central nervous system activa-
tion, as well as vasodilation ; this latter effect mediated by an
endothelial mechanism consistent with NO. In chronic hy-
perleptinemic conditions, however, these potential balanced
effects of leptin on peripheral vascular resistance may not
remain, and there is information to suggest that in these
situations leptin may be hypertensinogenic.
The Kidney is among the tissues that express the leptin
receptor and numerous studies have recently reported that
leptin produces a robust natriuresis and diuresis in the normal
rat. These findings acquire additional relevance when it is
considered that feeding (and consequent intravascular
sodium-volume expansion) is associated with an increased
secretion of leptin into the circulation, and this hormone, in
turn, may be an important natriuretic factor facilitating post-
prandial sodium-volume regulation. Moreover, the concept
of a physiologically relevant natriuretic action of leptin is
further emphasized by more recent studies, indicating that
blockade of endogenous leptin significantly attenuates so-
dium and volume excretion in the rat.
Thus, while the relevance of endogenous leptin needs
further clarification, it appears to be a potential pressure and
volume regulating factor, and may function pathophysiologi-
cally as a common link to obesity and hypertension.
Abstract No S29E
Obesity hypertension and the heart
Efrain Reisin,M.D., Louisiana State University Health
Science Center, New Orleans, Louisiana, USA
In Addition to a genetic pre-disposition, several endo-
crinic, metabolic mechanisms have been linked to the devel-
opment of obesity hypertension. These include : insulin re-
sistance and hyper-insulinemia, increased serum aldosterone
levels, salt sensitivity and possibly increased leptin levels.
Hemodynamic studies have shown expanded plasma volume
and cardiac output in the presence of increased peripheral
vascular resistance, which induces structural changes in the
heart characterized by concentric-eccentric left ventricular
hypertrophy. The hemodynamic alteration may also cause
increased renal blood flow and reduced renal vascular resis-
tance, expansion of the extracellular matrix, increased inter-
stitial hydrostatic pressure and increased compression of the
tubules. Weight reduction effectively controls blood pres-
sure, improves left ventricular hypertrophy and cardiac out-
put and may also benefit kidney function and renal damage.
Angiotensin-converting enzyme inhibitors and AP recep-
tor blockers may offer an efficient antihypertensive approach
in obese hypertensive patients.
Abstract No S30A
Adenoviral targeting of vascular nox isoforms :
therapies to attenuate hypertrophy and estenosis
Patrick J. Pagano, Hypertension and Vascular Research
Division, Henry Ford Hospital, Detroit, MI 48202-2689
332 2004 ISHR World Congress / Journal of Molecular and Cellular Cardiology 37 (2004) 161-375
Numerous studies report the existence of vascular
NAD(P)H oxidase components including p22-phox, p67-
phox, rac and gp91-phox and its homologues nox1 and nox4.
Early induction of a combination of these components in
different cell types suggests a complex interplay of vascular
reactive oxygen species (ROS) leading to medial hypertro-
phy and neointimal hyperplasia. Recently we showed that
systemic delivery of specific peptide inhibitor pf p47-
phox :gp91-phox interaction, gp91ds, decreases vascular su-
peroxide anion and medial hypertrophy in hypertension and
neointimal hyperplasia in response to balloon injury. We
have begun developing adenoviral strategies targeting this
oxidase inhibitor to the vasculature. In one study, we com-
pared the ability of an adventitially applied virus containing a
fibroblast-active promoter driving expression of the gp91ds
peptide inhibitor with an adenovirus expressing dominant
negative p67-phox (p67dn) to prevent neointima formation.
Rat common carotid arteries were transfected with Ad-CMV-
p67dn, gp91ds-expressing virus or control virus in pluronic
gel and injured using standard techniques by balloon angio-
plasty catheter. Fourteen days after injury, CCAs were
perfusion-fixed and analyzed by digital morphometry.
Neointimal hyperplasia (as measured by neointimal area)
was significantly lower with the gp91ds-expressing virus
could attenuate medial hypertrophy of the mouse CCA in
response to a 7-day infusion of angiotensin II in vivo. Im-
mounohistochemical staining for maker protein eGFP
showed that expression was limited to the adventitia (primary
with fibroblast) in CCAs from the gp91ds group. As ex-
pected, angiotensinII induced a medial hypertrophic re-
sponse and increased ROS levels. Both effects were inhibited
by the gp91ds-expressing virus but not by the control virus.
Thus our data seem to suggest that gp91-phox-based oxidaise
in adventitial fibroblasts plays a modulatory role in angio-
tensin II indused medial hypertrophy. Taken together, these
data may also suggest an important fundamental role vascu-
lar gp91-phox-based oxidases in vessel wall homeostasis and
vascular angiogenesis. Current studies are aimed at testing
novel inhibitors of the gp91-phox homologues nox1 and
nox4 to investigate the unique contribution of these isoforms
in various vascular cell types to both hypertrophy and hyper-
plasia.
Abstract No S30B
NAD(P)H oxidase-derived superoxide-a source of
oxidative stress or signaling in coronary artery and
myocardium ?
Sachin A. Gupte, Pawel M. Kaminski, Golam Rabbani,
Shimran George, Michael S. Wolin. Department of
Physiology, New York Medical College, NY, USA
Oxygen-derived free radicals (ODFR) are known to play a
role in modulating myocardial and vascular function. Al-
though the sources of ODFR in vasculature and myocardium
are uncertain, NAD(P)H oxidases in vessel wall and cardiac
myocytes appear to be a major site of superoxide (O2-)
generation. We have previously demonstrated that in the
heart, O2- inactivates NO, increases vasoconstrictive pros-
tanoids, activates PKC-dependent signaling, and elicits coro-
nary dysfunction. In addition, O2- damages mitochondria
and induces systolic and diastolic dysfunction. Lactate and
pyruvate modulates NAD(P)H oxidase-derived O2- in the
presence of inhibition of SOD causing vascular dysfunction
via suppression of guanylate cyclase activity and NO-elicited
relaxation. In contrast, H2O2-a product of O2- and SOD
interaction, activates vascular relaxation and protects the
heart from O2- and ischemia-reperfusion induced injury. Our
recent studies indicate NOX-2 and NOX-4, which have dis-
tinct localization patterns, are present in the bovine coronary
artery, and activation of NAD(P)H oxidase by PKC is medi-
ated by Src. Furthermore, H2O2 and not O2- derived from
NAD(P)H oxidase mediate PDBu-induced contraction.
Thus, we believe NAD(P)H oxidase-derived free radicals
activate both signaling and stress depending on their levels,
balances between endogenous antioxidant defense, and their
localization in the cell.
Abstract No S30C
Role of NADPH oxidase-derived O2
.- in cardiac
hypertrophy and failure
Ajay M Shah, Department of Cardiology, GKT School of
Medicine, King’s College London, UK
Oxidative stress is involved in the pathophysiology of
cardiac hypertrophy and heart failure through (a) direct del-
eterious effects, (b) modulation of redox-sensitive signalling
pathways, (c) inactivation of nitric oxide (NO). Although
there are several potential ROS sources in the cardiovascula-
ture, a family of NADPH oxidases (Noxs) has been recogn-
ised as especially important in vascular pathologies. We have
studied the roles of Noxs in the heart.
All the major components of the classic NADPH oxidase
are found in cardiomyocytes and endothelial cells (EC),
which co-express both the gp91phox (Nox2) and Nox4 cata-
lytic subunits of the oxidase. In pressure-overload LVH in
guinea-pigs, we found a progressive increase in LV NADPH
oxidase subunit expression and activity in parallel with
MAPK activation and evidence of ROS-mediated endothelial
and diastolic dysfunction. Myocardial NADPH oxidase ac-
tivity is also increased in human heart failure. To specifically
address the role of the Nox2-containing oxidase, we under-
took studies in gp91phox-/- mice. In a model of AngII-induced
in vivo cardiac hypertrophy (by subpressor infusion), in-
creases in LV NADPH oxidase activity were inhibited in
gp91phox-/- mice. In parallel, in vivo myocyte hypertrophy,
increases in ANF mRNA, and AngII-induced interstitial fi-
brosis were all markedly inhibited. These data provide the
first definitive evidence for an essential role of the Nox2
oxidase inAngII-induced cardiac hypertrophy and interstitial
fibrosis. By contrast, LV hypertrophy induced by aortic
banding was similar in wild-type and gp91phox-/- mice. Unex-
pectedly, NADPH oxidase activity was increased by aortic
banding in gp91phox-/- mice, which was attributable to in-
creased expression of Nox4. In addition, LVH was inhibited
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by antioxidant treatment in both wild-type and knockout
mice. However, gp91phox-/- mice had preserved contractile
function and reduced interstitial fibrosis after banding as
compared to banded wild-types. Taken together, the above
data suggest distinct roles for Nox2 versus Nox4 in different
components of the overall cardiac hypertrophic response.
Abstract No S30D
Regulation of non-phagocytic nadph oxidases
Botond Banfi M.D. Ph.D., University of Iowa, Dept. of
Anatomy and Cell Biology
Reactive oxygen species (ROS) have been shown to play
an important role in the regulation of blood pressure and in
the formation of atherosclerotic plaques. However, the
source of ROS in the vascular system remains to be eluci-
dated.
In the last few years, six homologues of the ROS-
generating subunit of the phagocyte NADPH oxidase
(gp91phox) have been discovered. They all belong to the same
family of enzymes, called NADPH oxidases (NOXes). Inter-
estingly, four members of that family have been detected in
the vasculature including NOX1, NOX2 (alias gp91phox),
NOX4 and NOX5. The expression of the individual NOX
enzymes is unequal throughout the vascular wall : endothe-
lial cells express NOX4, vascular smooth muscle cells ex-
press NOX1, NOX4, and NOX5, while NOX2 is found
mainly in macrophages and in the fibroblasts of the adventi-
tia. In order to unravel the in vivo function and the relative
importance of individual NOX enzymes in vascular- and
other tissues, we investigated their regulation. Our results
demonstrate that NOX1, similar to NOX2, is not a stand-
alone enzyme, but part of a multisubunit complex consisting
of a NOX Organizer (NOXO1) and a NOX Activator
(NOXA1) protein beside NOX1. NOX5 functions apparently
independently of any additional subunits. Indeed, NOX5
itself contains an in-built —activator subunit » : its unusually
long N-terminus possesses four EF-hands, Ca2 + binding
domains. Upon Ca2 + influx, Ca2 + is bound to the
N-terminus of NOX5, which, as a result, becomes able to
interact with the catalytic C-terminus and triggers superoxide
generation. In contrast, the regulation of NOX4 is largely
unknown. Currently it is regarded as a constitutively active
enzyme, which may require additional subunits to function.
Abstract No S30E
NAD(P)H oxidase-derived superoxide signaling - from
mouse to man
Rhian M Touyz MD, PhD. Clinical Research Institute of
Montreal, Univ. of Montreal, Canada.
Free radicals and radical-derived, nonradical reactive spe-
cies, originally thought to be cellular metabolic byproducts
are now considered as regulatory mediators in signaling
processes playing important roles in cell function. In physi-
ological conditions low, but measurable, levels of intracellu-
lar reactive oxygen species (ROS) are maintained by the
balance between pro-oxidant and anti-oxidant systems. In
vascular cells ROS are typically generated by tightly regu-
lated NAD(P)H oxidase, which is activated both constitu-
tively and in response to multiple stimuli, such as Ang II,
EGF, PDGF, thrombin and stretch. From studies in 47phox-/-
mice and humans, it is evident that phosphorylation of
p47phox, which initiates translocation of cytoplasmic sub-
units, is essential for assembly and activation of fully func-
tional NAD(P)H oxidase in endothelial and vascular smooth
muscle cells. PLD, PLA2, PKC, Rho and c-Src are upstream
regulators of the vascular oxidase and influence activation by
stimulating phosphorylation and translocation of NAD(P)H
oxidase subunits and by increasing gene and protein expres-
sion of p22phox, gp91phox/nox1/nox4, p47phox and
p67phox. Furthermore regulation by NOXO1 (Nox organiz-
ing protein 1) and NOXA1 (NoxActivating protein 1) may be
important. ROS function as important intracellular second
messengers to activate many downstream signaling mol-
ecules, such as MAP kinases, protein tyrosine phosphatases,
protein tyrosine kinases and redox-sensitive transcription
factors. Cell responses to redox signaling depends on the
specific species of free radical generated, the kinetics of ROS
formation and the cell compartment in which ROS are local-
ized. In the vasculature activation of redox-sensitive signal-
ing cascades leads to VSMC growth and migration, modula-
tion of endothelial function, expression of pro-inflammatory
mediators, modification of extracellular matrix, apoptosis
and anoikis. Furthermore, ROS increase cytoplasmic free
Ca2 + concentrations, decrease cytoplasmic free Mg2 + lev-
els, and alter intracellular pHi, major determinants of vascu-
lar reactivity and growth. Exact molecular mechanisms
whereby ROS influence signaling molecules remain elusive,
but oxidative modification of proteins, particularly protein
tyrosine phosphatases, is important. In addition, redox-
dependent processes are critically involved in vascular injury
associated with hypertension, as evidenced by findings in
mice deficient in gp91-/- or p47phox, experimental rat mod-
els of hypertension and in human essential hypertension.
Accordingly, ROS and the signaling pathways that they
modulate, provide putative targets to regress vascular remod-
eling, reduce peripheral resistance and prevent hypertensive
end organ damage. Here, we will discuss the role of
NAD(P)H oxidase-derived ROS as second messengers and
will focus on implications of these events in processes con-
tributing to arterial remodeling and vascular dysfunction in
hypertension.
Abstract No S30F
Role of oxygen free radicals in myocardial
ischemia-reperfusion
Takao Okada, Department of Physiology, Juntendo
University School of Medicine, 2-1-1 Hongo, Bunkyo-Ku,
Tokyo-113, Japan
The oxygen-centered radical, superoxide (O2
-), is gener-
ated during reperfusion and dismutated to hydrogen peroxide
(H2O2) which is converted to hydroxyl radical (OH
-). In
addition, O2
- reacts with NO and forms peroxinitrite
334 2004 ISHR World Congress / Journal of Molecular and Cellular Cardiology 37 (2004) 161-375
(ONOO-). These reactive species inhibit enzymes such as
creatine kinase, aconitase, glyceraldehydes dehydrogenase,
SERCA, etc. Moreover, OH- and ONOO- damages mito-
chondria and open transition pores, which elicit apoptosis or
even necrosis resulting in myocardial dysfunction and injury.
Our data indicates in vitro reperfusion of the heart with O2
-
induces systolic and diastolic dysfunction, which is mediated
by ONOO- and prostaglandins. O2
- decreases Ca2 + sensitiv-
ity to the myofilament, fractures mitochondria, and induces
DNA fragmentation. Although high concentrations (0.7-
1.0 mM) of H2O2 causes myocardial injury, in contrast
H2O2 prevents the myocardial dysfunction induced by O2
-,
and perfusion of the hearts with low concentrations (0.010-
0.20 mM) of hydrogen peroxide, which activates PKC and
mitochondrial KATP channels, protects the heart from reper-
fusion injury and induces pre-conditioning. Nevertheless, the
mechanisms that mediate the protective effects of hydrogen
peroxide are still elusive, since in our hands opening of
mitochondrial KATP channels appears to mediate O2
--
induced myocardial dysfunction and injury. Thus depending
upon the type of radical species, their concentration, and site
of their generation and action determines the role of free
radicals such as signaling or stress in the myocardium.
Abstract No S31A
Aldosterone and remodeling in the cardiovascular
system
Claude Delcayre. INSERM U572, Hopital Lariboisiere,
Paris, France
Clinical and experimental studies have established that
aldosterone plays a major role in the pathophysiology of
cardiovascular and renal diseases. The aldosterone receptor
antagonists spironolactone and eplerenone have demon-
strated specific effects, not related to their hypotensive prop-
erties, in hypertension or cardiac diseases. It appears that a
key action of these molecules is related to prevention or
treatment of end-organ damage. This, and the evidence of
aldosterone escape on long-term treatment with ACE inhibi-
tors in heart failure, in diabetic nephropathy and in some
forms of hypertension, will likely increase the clinical use of
aldosterone receptor antagonists.
The mechanisms of aldosterone actions in cardiovascular
system are not totally understood, but recent experimental
results allow us to draw a tentative scheme. It is now well
established that high levels of aldosterone induce fibrosis in
heart and vessels. Cardiac fibrosis in heart appears to be
triggered by activation of pericoronary inflammation, with a
possible involvement of oxidative mechanisms. All these
deleterious phenomena may be due to initial aldosterone-
induced changes in intracellular ionic homeostasis. On the
other hand, transgenic mice with moderately increased al-
dosterone specifically in heart display a major coronary dys-
function but no myocardiac structural or functional alter-
ations. Together, these observations indicate that coronary
vessels are a target of aldosterone in heart. Despite not being
demonstrated, it is possible that similar mechanisms may
occur in other target organs of aldosterone.
Abstract No S31B
Physiopathological role of the mineralocorticoid
receptor in the heart : use of conditional transgenic
model
Yannis Sainte-Marie, Antoine Ouvrard-Pascaud,
Aurélie Nguyen Dinh Cat, Jean-Pierre Bénitah,
Christelle Soukaseum, Khai Le Quang, Flavien Charpentier,
Fatima Mechta, Ahmed T. Beggah, Marie-Edith Oblin,
Claude Delcayre, Nicolette Farman, Brigitte Escoubet,
Frederic Jaisser. AVENIR INSERM, Collège de France,
Paris ; INSERM U637, CHU A. de Villeneuve,
Montpellier ; INSERM U533, Medicine Faculty, Nantes ;
INSERM U572, Lariboisiere Hospital, Paris ; Unit of Gene
Expression and Disease, Department of Developmental
Biology, Pasteur Institute, Paris ; INSERM U478, X.Bichat
Medicine Faculty, Paris ; U426-CEFI IFR02-AP-HP-Hopital
Bichat, Faculte X.Bichat, Paris, France
To assess the role of the mineralocorticoid receptor (MR)
in the heart independently of the kidney, we generate two
transgenic mouse models that allow spatio-temporal control
of MR expression in vivo. A first model allows conditional
expression of a 320bp murine MR antisense mRNA re-
stricted to cardiomyocytes. These mice develop dilated hypo-
kinetic cardiomyopathy. Heart/Body weight ratio is in-
creased, cardiac remodelling with extensive interstitial
fibrosis is observed. Neither inflammation nor apoptosis are
observed. Administration of spironolactone, an MR antago-
nist, to one mo old animal has a synergistic effect with MR
antisense expression. Most interestingly, the cardiopathy is
reversible if transgene expression is turned off in 2 mo old
animals. A second model allows conditional over-expression
of the human MR. These mice experience sudden death with
normal histology suggesting fatal arrhythmia. Administra-
tion of spironolactone prevents premature death. Electro-
physiological analyses performed on isolated cardiomyo-
cytes reveal an increase in the length of action potential
associated with an increase in whole Ca current. ECG analy-
ses indicated an increase in PR and QT intervals. These two
mirror models should help to understand the physiopatho-
logical role of the MR in the heart.
Abstract No S31C
Eplerenone, but not steroid withdrawal, reverses
cardiac fibrosis in doc/salt rats
Morag Young, Prince Henry’s Institute of Medical
Research, Melbourne, Australia
Effects of nonepithelial MR activation have been demon-
strated, in the context of inappropriate mineralocorticoid
(MC) for salt status, including vascular inflammation and
cardiac fibrosis. Eearly inflammatory responses in the coro-
nary vasculature of rats treated with MC plus salt is now a
well-characterised precursor of the appearance of fibrosis at
these sites. The enzyme inhibitor carbenoxolone (CBX) plus
salt has also been shown to produce an MR-mediated inflam-
matory response identical to MC administration. Oxidative
stress, via expression of NADPH oxidases, may account for
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these inflammatory and fibrogenic responses. We hypoth-
esised that when 11bHSD2 is inhibited, endogenous gluco-
corticoids (GC) bound to unprotected VSMC MR will simi-
larly increase the early NADPH oxidase expression. When
endogenous GC were allowed to activate VSMC following
administration of CBX, inflammatory and fibrotic responses
were identical, in terms of time course and extent, as those
seen in rats given DOC. DOC or CBX administration for
4 days saw a 2-fold increase in expression of the VSMC
specific subunits of NADPH oxidase ; macrophage infiltra-
tion was elevated at 4 and 16 days following either DOC or
CBX ; cardiac collagen deposition was also increased. All
responses induced by administration of CBX were inhibited
by the MR antagonist eplerenone. Secondly, we tested
whether established fibrosis and vascular damage could be
reversed by MR blockade or by steroid withdrawal. DOC
raised cardiac collagen accumulation at 4 wk, and higher at
8 wk. Rats given DOC for 4 wk and killed at 8 wk showed
levels of fibrosis identical to those killed at 4 wk, i.e. persis-
tently elevated above control. Rats given DOC for 8 wk, and
eplerenone for the second half of this period, showed cardiac
collagen levels indistinguishable from control. ED-1, os-
teopontin and COX-2 in coronary vessels showed similar
patterns of expression. These findings show (i) that MR
antagonists can not only prevent cardiac fibrosis when given
concomitantly, but can reverse established cardiac fibrosis
(ii) that the continued vascular inflammatory response and
fibrosis post DOC withdrawal is further evidence for a role
for GC activation of vascular MR under conditions of tissue
damage. Our findings provide further evidence that exog-
enous MC or endogenous GC can activate VSMC MR and
influence intracellular redox state which may account for the
early vascular inflammation that precedes onset of fibrosis.
Abstract No S31D
Nongenomic cardiovascular effects of aldosterone
AS Mihailidou, Department of Cardiology, Royal North
Shore Hospital and University of Sydney, Sydney, Australia
Aldosterone has rapid nongenomic effects in a variety of
tissues and it has been postulated that these actions are
mediated via a membrane receptor, distinct from the classical
mineralocorticoid receptor (MR) since they are neither
blocked by spironolactone nor mimicked by cortisol. Recent
studies in human vascular smooth muscle cells (vsmc) have
implicated the classical mineralocorticoid receptor (MR) in
at least some of the rapid nongenomic effects of aldosterone
(Alzamora et al., 2000). In these studies while spironolactone
did not block the acute effects of aldosterone on Na+/H+
exchange, the water soluble, open E-ring MR antagonist
RU28318 did. Cortisol alone was without effect, but when
the enzyme 11ohydroxysteroid dehydrogenase (11oHSD2)
was blocked by carbenoxolone, cortisol mimicked the ago-
nist effect of aldosterone.
Similarly, we have shown that the rapid nongenomic ef-
fects of aldosterone on cardiomyocyte Na+/K+/2Cl- and/or
Na+/K+ pump activity cannot be blocked by canrenone, but
are blocked by canrenoate (and spironolactone in vivo).
These effects of aldosterone can be mimicked by oPKC
agonist peptides, and blocked by oPKC blocking peptides,
but not by oPKC, oPKC or scrambled o agonist peptide. The
rapid effects of aldosterone on Na+/K+ pump activity are
maintained over 7 days aldosterone infusion in vivo, and
over the time of the cell isolation, but are reversed within
15 min by oPKC blockade. Since mineralocorticoid recep-
tors in cardiomyocytes are always occupied (but not acti-
vated) by much higher concentrations of free glucocorti-
coids, we also examined the effect of cortisol. Cortisol alone
was without effect, but cosuperfused with aldosterone,
blocked the acute nongenomic effect of aldosterone. Further
studies are in progress to define this complex action of
aldosterone in the heart.
Alzamora et al. (2000). Hypertension 35 : 1099-1104.
Abstract No S31E
Primary aldosteronism : a common cause of
hypertension with a genetic basis
Michael Stowassera,b, Albertina Soa, Richard Gordonb.
aPrincess Alexandra and bGreenslopes Hospital
Hypertension Units, Brisbane, Australia
At the Greenslopes Hospital Hypertension Unit (GHHU),
adoption of the policy in 1991 to screen all hypertensives (and
not just those with hypokalemia or resistant hypertension) by
aldosterone/renin ratio testing led to a tenfold increase in
detection rate of PAL (only 22 % hypokalemic) and a fourfold
increase in rate of removal of aldosterone-producing ad-
enomas (APAs ; 44 % hypokalemic) leading to cure of hyper-
tension in 60 % and improvement in all remaining operated
patients. The GHHU reported a prevalence of PAL of 8.5 %
among 199 consecutively referred normokalemic hyperten-
sives and 12.5 % among 52 antihypertensive drug trial volun-
teers. The combined GHHU/Princess Alexandra Hospital Hy-
pertension Unit PAL series stands at over 1000 patients
diagnosed, and over 260 aldosterone-producing tumors re-
moved. Reliable detection requires that (1) the diagnosis is
considered in all hypertensives, (2) samples are collected un-
der standardised conditions of diet, posture and time of day, (3)
medications known to alter the ratio are avoided or their effects
taken into account, and (4) reliable methods (such as fludro-
cortisone suppression testing) are used to confirm PAL. Adre-
nal venous sampling is the only dependable way to differenti-
ate APA from bilateral adrenal hyperplasia. The availability of
laparoscopic adrenalectomy and a new selective aldosterone
receptor antagonist (eplerenone) represent important advances
in management. Elucidation of the genetic mutation respon-
sible for a familial, glucocorticoid-remediable form of
PAL (an ACTH-regulated « hybrid » 11beta-hydroxylase/
aldosterone synthase gene) and development by the GHHU of
a PCR-based diagnostic test has greatly facilitated detection
and led to a fuller appreciation of phenotypic diversity and
aldosterone regulation in that subtype. The identification of
mutations causing another, more common familial variety of
PAL described by the GHHU in 1991 should further aid in the
detection of this specifically treatable condition.
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Abstract No S31F
Impact of aldosterone on cardiovascular disease
Gail K. Adler, Harvard Medical School, Boston,
Massachusetts, USA
There are compelling new studies in animals and humans
suggesting aldosterone has adverse cardiovascular effects
that are in addition to its well-known renal actions on sodium
and potassium balance, plasma volume and blood pressure.
Two studies of patients with congestive heart failure, Ran-
domized Aldactone Evaluation Study (RALES) and
Eplerenone Post-Acute Myocardial Infarction Heart Failure
Efficacy and Survival Study (EPHESUS), demonstrated
marked benefits on mortality when mineralocorticoid recep-
tor blockade was added to standard therapy. In studies of
patients with essential hypertension, mineralocorticoid re-
ceptor blockade reduced left ventricular hypertrophy, pro-
teinuria and blood pressure. Beneficial effects of MR antago-
nists on myocardial necrosis, cardiac fibrosis, stroke,
proteinuria, and vascular remodeling have been demon-
strated in different animal models. In a rodent model of low
nitric oxide availability and high angiotensin II, mineralocor-
ticoid receptor blockade reduced vascular inflammation,
myocardial necrosis and proteinuria. This protection by min-
eralocorticoid receptor antagonists occurred in the absence
of elevated plasma aldosterone levels, was independent of
changes in blood pressure, and did not appear to be mediated
by plasminogen activator inhibitor-1 or by the potassium
sparing effects of mineralocorticoid receptor blockade. Vas-
cular inflammation and dysfunction appears to be one early
event in aldosterone-mediated injury, and may be an impor-
tant mechanism underlying aldosterone’s widespread contri-
butions to cardiac damage, cerebrovascular disease and
nephropathy.
Abstract no S32A
Adenosine receptor agonism and nhe inhibition limit
post-ischaemic coronary dysfunction
Amanda Zatta, John P. Headrick, Heart Foundation
Research Centre. Griffith University Gold Coast, Australia
We studied effects of ischaemia-reperfusion (I/R) on coro-
nary function in mouse hearts. After 20 min ischaemia and
30 min reperfusion endothelial function was selectively im-
paired : I/R inhibited coronary sensitivity to the endothelial-
dependent/independent 2-chloroadenosine (pEC50 =
7.5 ± 0.1 vs. 8.4 ± 0.1 in non-ischaemic) and endothelial-
dependent ADP (pEC50 = 6.8 ± 0.1 vs. 7.6 ± 0.1 in non-
ischaemic) without altering responses to endothelial-
independent nitroprusside. Reactive hyperaemia, NO/EDHF
and KATP channel dependent in control hearts, was also
attenuated by I/R. Coronary dysfunction was unaltered
by anti-oxidant therapy (300 µM MPG + 150 U/ml
SOD + 600 U/ml catalase) or endothelin antagonism
(200 nM PD142893), but was effectively reduced by ago-
nism of A3 adenosine receptors (100 nM Cl-IB-MECA) and
inhibition of Na+/H+ exchange (10 or 50 µM BIIB-513). Ef-
fects of A3 agonism and NHE inhibition wer enot additive.
Antagonism of A1 adenosine receptors also worsened vascu-
lar dysfunction. These data indicate post-ischaemic coronary
dysfunction is reduced by intrinsic activation of A1 receptors,
exogenous A3 agonism and NHE inhibition. NHE inhibition
and A3 agonism may share common signalling.
Abstract No S32B
Comprehensive in vivo assessment of cardiac function
in mice by pressure-volume analysis
David A. Kass Johns Hopkins Medical Institutions
Baltimore, MD. USA
The explosion of research utilizing murine models that
involve genetically engineered protein changes has high-
lighted the need for rigorous and comprehensive tools to
assess the impact they have on cardiac function. To this aim,
we first developed a miniaturized pressure-volume conduc-
tance catheter to assess function in these small hearts. Com-
bined with physiological anesthesia, proper ventilation, and
rapid instrumentation methods, in vivo murine heart function
can be fully assessed at heart rates (500-600 min-1) and
contractility (dP/dtmax of often 14,000 mmHg/s or higher)
typical of intact conscious animals.
The method involves use of a 1.8F multi-electrode cath-
eter with a single (or dual) pressure sensor. It is often placed
via an apical stab under direct visualization as this facilitates
proper and rapid placement. The catheter volume signal is
based on the local introduction of high frequency low ampli-
tude current. It is calibrated to a directly assessed aortic flow
(Doppler or ultrasound probe) and by a saline-injection or
dual-frequency method to derive absolute volume. The
mouse heart is well suited to this method as the current field
is locally distributed, so there is minimal effect of conduc-
tance from structures external to the heart.
From simultaneous pressure-volume data, one can accu-
rately assess systolic and diastolic function parameters, re-
laxation, the impact of varying preload and afterload on these
parameters, force frequency dependencies, pharmacologic
interventions, and many other features of cardiac function.
The method is not suitable for chronic repeated analysis,
although ongoing efforts to miniaturize telemetry systems
recently developed for rats may make this feasible in the
future.
Abstract No S32C
Cardiac metabolism, function and efficiency recordings
in ex vivo mouse hearts
Ellen Aasum, University of Tromsø, Norway
The use of genetically engineered mouse models in car-
diovascular research has led to the establishment of miniatur-
ized (in vivo and ex vivo) techniques for assessment cardiac
physiology. Experimental conditions (pre- and afterload,
heart rate, substrate availability etc.) can be easily controlled
in ex vivo systems, and several parameters are therefore still
best measured on isolated hearts. Thus, the isolated perfused
mouse heart model (both isovolumetric and working heart
preparations) is now in use in several labs, despite technical
challenges related to the small size of the heart.
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We have established a working isolated mouse heart
model, where measurements of cardiac mechanics (left ven-
tricular (LV) pressure, cardiac output) can be combined with
measurements of cardiac metabolism (radiolabelled sub-
strates) and myocardial oxygen consumption (fibre-optic
probe). Using this approach, the association between cardiac
function and metabolism can be studied in various mouse
models.
Cardiac work in the above model is, however, limited to
external work. The development of the new 1.4 French
pressure-volume catheter provides a direct high-fidelity mea-
surement of LV pressure and volume and, from them, esti-
mates of pressure-volume area (PVA), which is representa-
tive of the total (internal + external) work of the heart.
Moreover, cardiac efficiency is the relationship between car-
diac work (PVA) and oxygen consumption (MVO2). We have
demonstrated that the substrate supply significantly influ-
ences the PVA-MVO2 relationship in murine hearts, and
believe that this methodology can be applied to various
models requiring phenotypic assessment of the relationship
between metabolism, contractile performance and cardiac
efficiency.
Abstract No S32D
Echo-doppler evaluation of heart function in small
animals
Brigitte Escoubet, INSERM U426, IFR02, University of
Paris 7, France
Echo-Doppler assessment of heart function is in small
animals (rat, mice) is a major progress in experimental
projects. The advantages of this procedure are 1) the wide
availability of the equipment and of competence for perform-
ing the examination, 2) the non invasive character of the
procedure allowing to assess in vivo cardiac function and to
repeat assessment over time thus allowing to quantify pro-
gression or regression of cardiac disease.
The disadvantages of the procedure are 1) the cost of
equipment, 2) the operator-dependent character of the results
obtained, 3) time consuming examination. Echo-Doppler can
be conducted in a way similar to that in human with the
assessment of cardiac size and myocardial function (systolic
and diastolic) including new development of echocardio-
graphy such as tissue Doppler. Valvular disease can also be
studied. In all cases, technical limitations due to the size of
the animal and the high heart rate must be taken into account.
Needs are of new devices and developments in order to
improve reproducibility and sensitivity and to develop new
parameters.
Abstract No S33A
Coronary microembolization – signal transduction of
contractile dysfunction
Gerd Heusch, Rainer Schulz, Michael Haude, Raimund
Erbel, University of Essen, Germany
Coronary microembolization in patients with spontaneous
or peri-interventional atherosclerotic plaque rupture has re-
cently been identified as a potential cause of arrhythmias,
contractile dysfunction and microinfarction. In anesthetized
dogs with intracoronary embolization of 3.000 microspheres
(diameter 42 µm) per ml and min coronary inflow, there is a
rapid decrease in coronary blood flow with subsequent reac-
tive hyperemia. Regional contractile function is also de-
creased and then recovers over several minutes almost back
to normal. Subsequently a secondary profound progressive
contractile dysfunction develops over several hours, in the
absence of changes in myocardial blood flow, i.e. a charac-
teristic perfusion-contraction mismatch. The total amount of
microinfarction is about 2 % of the area at risk, and apoptotic
cardiomyocytes are less than 0.1 %. However, there is a
marked inflammatory response with leukocyte infiltration
and TNFa accumulation. TNFa gene expression is enhanced
in cardiomyocytes surrounding the microinfarcts. TNFa is
causal for the observed contractile dysfunction, as evidenced
by the prevention of progressive dysfunction by intravenous
TNFa-antibodies before microembolization. The TNFa-
initiated signal transduction cascade further involves NO
and – as a more distal effector – sphingosine. In chronically
instrumented dogs the progressive contractile dysfunction
following microembolization recovers back to control over
6-7 days. Methylprednisolone, even when given 30 min after
coronary microembolization, fully prevents the progressive
contractile dysfunction. Microembolized myocardium is
characterized by reduced coronary and inotropic reserves.
Early clinical studies in patients with coronary interventions
confirm the reduction of coronary reserve with microembo-
lization and the causal.
Abstract No S33B
Heart failure by coronary microembolization
Hani N. Sabbah, Henry Ford Health System, Detroit,
Michigan, USA
Embolization of plaque contents of platelet-thrombus into
the microvasculature has been reported in patients with acute
coronary syndrome. Mechanical crushing and fragmentation
of culprit coronary lesions during PCI has emerged as a
major cause of coronary microembolization. Until recently,
however, the consequences of coronary microembolizations
on LV function and on the development of ventricular ar-
rhythmias have been seriously underappreciated. In anesthe-
tized dogs, repetitive injections of 42 µm spheres into the left
circumflex coronary artery was shown to markedly decrease
LV systolic posterior wall thickening and to reduce both
coronary flow reserve as well as LV inotropic reserve. Stud-
ies in our laboratory showed that repetitive coronary embo-
lizations with \\ 126\\90 µm polystyrene latex microspheres
in both the left anterior descending and left circumflex coro-
nary artery over the course of several weeks can lead to the
formation of transmural micro-infarcts and to the gradual
development of LV systolic and diastolic dysfunction and to
the emergence of malignant ventricular arrhythmias. We also
showed that discontinuation of coronary microembolizations
once LV dysfunction is established invariably leads to pro-
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gressive worsening of LV function and remodelling that
ultimately culminates in the syndrome of heart failure (HF).
At the global level, development of HF in these animals is
characterized by progressive decline in LV ejection fraction,
cardiomegaly, LV hypertrophy, exercise intolerance, func-
tional mitral regurgitation and increased and sustained acti-
vation of the sympathetic and renin-angiotensin systems. At
the cellular level, dogs with HF manifest interstitial fibrosis,
cardiomyocyte apoptosis and abnormal cardiac sarcoplasmic
reticulum calcium cycling. At the molecular level, dogs with
HF manifest most if not all of the molecular maladaptations
described in patients with HF including induction of the fetal
gene program. Conclusions : While these studies represent
an extreme consequence of coronary microembolizations,
they nonetheless point to the serious adverse outcomes that
can develop as a result of microembolization-mediated coro-
nary microvascular obstructions.
Abstract No S33C
No-reflow and coronary microvascular dysfunction in
acute myocardial infarction
Masatsugu Horia, Hiroshi Itob, Shinsuke Nantoc. aOsaka
University Graduate School of Medicine, Department of
Internal Medicine and Therapeutics, bSakurabashi Watanabe
Hospital, cKansai Rousai Hospital, Japan
No-reflow after coronary reperfusion is often observed in
patients with anterior acute myocardial infarction (AMI).
No-reflow is detected by myocardial contrast echocardio-
graphy (MCE) and frequently associated with early systolic
retrograde flow and accelerated deceleration of flow velocity
during diastole. Approximately 20 % of the pts with TIMI
grade 2 flow after coronary angioplasty showed no-reflow on
MCE. The patientts without no-reflow showed better out-
come and less complications. Multivariate analysis demon-
strated that pre-infarction angina within 48 hrs before symp-
tom onset (ischemic preconditioning), number of Q waves on
ECG, wall motion score and TIMI flow grade 0 at initial
CAG are related to the no-reflow phenomenon. The causes of
the no-reflow may be multiple. After PCI we aspirate more
atheromatous plaque from patients with no-reflow than pa-
tients without no-reflow, and aspiration of the gruel derived
from atheroma improved the no-reflow. Intracoronary ad-
ministration of verapamil and nicorandil attenuated no-
reflow and improved regional wall motion, indicating that
microvascular function was improved by these pharmaco-
logical interventions. We conclude that no-reflow often ob-
served in AMI represents the coronary microvascular dys-
function partially induced by microvascular embolization
and functional dysintegrity which should be prevented or
treated for better outcome of this disease.
Abstract No S33D
Role of NO and EDHF during ischemia reperfusion
injury in coronary microcirculation
Toyotaka Yada, Kawasaki Medical School, Japan, Hiroaki
Shimokawa, Kyushu University, Japan, Fumihiko Kajiya,
Okayama University, Japan
Background : (1) Recent studies in vitro have demon-
strated that endothelium-derived hydrogen peroxide (H2O2)
is an endothelium-derived hyperpolarizing factor (EDHF) in
animals and humans. We tested our hypothesis that
endothelium-derived H2O2 plays an important role in coro-
nary autoregulation. (2) Recent studies have demonstrated
that Rho-kinase is substantially involved in the pathogenesis
of cardiovascular diseases, however, it remains to be exam-
ined whether it is also involved in ischemia/reperfusion (I/R)
injury. We examined whether Rho-kinase is involved in myo-
cardial ischemia/reperfusion (I/R) injury and if so, whether
NO is involved. Methods and Results : (1) We evaluated
vasodilator responses of canine (n = 41) subepicardial small
coronary arteries (> 100ƒÊm) and arterioles (< 100ƒÊm)
with an intravital microscope in response to acetylcholine
and to a stepwise reduction in coronary perfusion pressure
(from 100 to 30 mmHg) before and after inhibition of NO
synthesis (L-NMMA 200ƒÊM,IC) under cyclooxygenase
blockade (ibuprofen, 12.5mg/kg,IV). After L-NMMA, the
coronary vasodilator responses were attenuated mainly in
small arteries (P < 0.05), whereas combined infusion of
L-NMMA plus catalase (400,000U/kg IC) inhibited the va-
sodilator responses of both-sized arteries (P < 0.05). The
arteriolar responses were also comparable after catalase plus
L-NMMA. Coronary venous adenosine concentrations were
increased in response to decreasing perfusion pressure after
L-NMMA alone, L-NMMA plus catalase (P < 0.05), but
were not further increased after catalase alone. (2) Canine
subepicardial small arteries and arterioles were observed by
microscope during myocardial I/R. Myocardial I/R signifi-
cantly impaired coronary vasodilation to acetylcholine, as
did L-NMMA, whereas hydroxyfasudil, a specific Rho-
kinase inhibitor, preserved the response. Vasoconstriction by
L-NMMA was significantly improved by hydroxyfasudil.
Hydroxyfasudil significantly reduced the size of myocardial
infarction induced by I/R. Conclusions : (1) H2O2 is an
endogenous EDHF in vivo and plays an important role in
coronary autoregulation as a compensatory mechanism for
NO and adenosine. (2) Hydroxyfasudil exerts cardioprotec-
tive effects on I/R injury in vivo, for which NO-mediated
mechanism may be involved.
Abstract No S34A
Lessons from the toad pacemaker cells ; role of
intracellular calcium
David G. Allen and Yue-kun Ju, Department of Physiology,
University of Sydney, NSW 2006, Australia
Conventionally pacemaker function is attributed to a se-
ries of voltage- and time-dependent inward currents. In the
last decade evidence that intracellular calcium [Ca2 + ]i modi-
fies the firing rate has accumulated rapidly. We showed that
interventions which increased [Ca2 + ]i accelerated the firing
rate and vice-versa. A possible mechanism is provided by the
Na+/Ca2 + exchanger which removes Ca2 + and generates an
inward current (INa/Ca)which contributes to the pacemaker
currents. For instance ryanodine, a drug which prevents sar-
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coplasmic reticulum (SR) Ca2 + release, can slow or stop the
spontaneous firing. In this type of model, the acceleration
due to sympathetic stimulation is because the increased
[Ca2 + ]i which drives a larger INa/Ca. Further interest arises
from the discovery that pacemaker cells exhibit spontaneous
brief Ca2 + releases (Ca2 + sparks) which precede the rise of
the action potential. Where these sparks occur close to sur-
face membrane they may drive a local INa/Ca which further
contributes to pacemaker currents.
These new results suggest that Ca2 + -driven currents are at
least as important as the voltage-sensitive currents in deter-
mining pacemaker activity. Many interventions which affect
pacemaker function e.g. ischaemia, ATP probably do so at
least in part by altering Ca2 + handling.
Abstract No S34B
Calcium cycling in the heart is a general mechanism of
chronotropy and inotropy
Edward G. Lakatta, Victor Maltsev, Tatiana Vinogradova.
NIA, Gerontology Research Center, Baltimore, Maryland
Excitation induced Ca2 + cycling into and out of the cyto-
sol via the sarcoplasmic reticulum (SR) Ca2 + pump, ryano-
dine receptor (RYR) and Na+-Ca2 + exchanger (NCX) pro-
teins, and modulation of this Ca2 + cycling by b-Adrenergic
Receptor stimulation (bARs), governs the strength of ven-
tricular myocyte contraction and the cardiac contractile re-
serve. Recent evidence indicates that heart rate modulation
and chronotropic reserve via bARs also involve intracellular
Ca2 + cycling by these very same molecules. Specifically,
sinoatrial nodal pacemaker cells (SANC), even in the ab-
sence of surface membrane depolarization, generate local-
ized, rhythmic, submembrane Ca2 + oscillations via SR Ca2 +
pumping-RYR Ca2 + release. During spontaneous SANC
beating, these rhythmic, spontaneous Ca2 + oscillations are
interrupted by the occurrence of an Action Potential (AP),
which activates L-type Ca2 + channels to trigger SR Ca2 +
release, unloading the SR Ca2 + content and inactivating
RYRs. During the later part of the subsequent diastolic depo-
larization (DD), when Ca2 + pumped back into the SR suffi-
ciently replenishes the SR Ca2 + content, and Ca2 + -
dependent RYR inactivation wanes, the spontaneous release
of Ca2 + via RYRs again begins to occur. The local increase in
submembrane [Ca2 + ] generates an inward current via NCX,
enhancing the DD slope, modulating the occurrence of the
next AP, and thus the beating rate. bARs increases the sub-
membrane Ca2 + oscillation amplitude and reduces their pe-
riod (the time from the prior AP triggered SR Ca2 + release to
the onset of the local Ca2 + release during the subsequent
DD). This phase shift in spontaneous sub-membrane Ca2 +
release by âARs causes the DD modulation by NCX current
to occur at earlier times following a prior beat, promoting the
sooner arrival of the next beat and thus, an increase in the
spontaneous firing rate. Ca2 + cycling via the SR Ca2 + pump,
RyR and NCX, and its modulation by bARs is, therefore, a
general mechanism of cardiac chronotropy and inotropy.
Abstract No S34C
IF and sino-atrial node pacemaking
Annalisa Bucchi, Mirko Baruscotti and Dario DiFrancesco
Laboratory of Molecular Physiology and Neurophysiology,
Department of Biomolecular Sciences and Biotechnology,
University of Milano, Italy
Normal cardiac pacing is driven by the spontaneous activ-
ity of sino-atrial node (SAN) cells, chracterized by the pres-
ence of a slow diastolic (« pacemaker ») depolarization
phase of the action potential. Several independent results,
including If inhibition by specific heart-rate reducing agents
such as ivabradine, indicate that activation of the If current
plays a key role in the generation and autonomic control of
the pacemaker depolarization, operated through a cAMP-
dependent, Ca2 + independent mechanism of rate regulation.
Disruption of SR Ca2 + release in SAN myocytes slows
spontaneous rate and strongly reduces bAR-induced rate
acceleration, which has been taken to indicate that the target
of bAR-modulation of pacemaking is the intracellular Ca2 +
regulatory process. However, abolishement of SR Ca2 + tran-
sients (by incubation of SAN cells with ryanodine) does not
impair cAMP-dependent rate acceleration mediated by If ;
also, reduction of Ca2 + transients slows rate by depolarizing
the action potential threshold, while bAR-stimulation accel-
erates rate by increasing the rate of diastolic depolarization,
in agreement with the hypothesis that it is caused by an
increased degree of If activation.
These and other data suggest that rather than being di-
rectly involved in pacemaking, normal Ca2 + homeostasis is
necessary for the bAR-cAMP-If rate-controlling mechanism
to function properly.
Supported by MIUR- FISR 02.00652.ST97 and COFIN
2001055324 to DD.
Abstract No S34D
Sinoatrial node heterogeneity and pacemaking
M.R. Boyett, H. Dobrzynski, J. Tellez, I.D. Greener, J. Li,
M. Yamamoto, H. Honjo and R. Billeter. School of
Biomedical Sciences, University of Leeds, Leeds LS2 9JT,
UK
The pacemaker activity of the sinoatrial (SA) node is a
function of the ion channels expressed in the SA node and we
are using immunohistochemistry, real-time PCR and in situ
hybridisation to map the distribution of ion channel mRNAs
and proteins in and around the SA node of the rabbit and rat.
Results are reported below for mRNA abundance in the SA
node measured using real-time PCR. All results reported are
in relation to atrial muscle and are significant (P < 0.05 ;
n = 7 rabbits). The large and medium conductance connexin
isoforms (Cx40 and Cx43) were less abundant in the SA
node, whereas the small conductance Cx45 was of equal
abundance. The pattern of expression of connexins in the SA
node explains the weak electrical coupling in the SA node.
The cardiac Na+ channel isoform, Nav1.5, was less abundant
in the SA node. The lack of Nav1.5 explains the slow up-
stroke of the SA node action potential. Interestingly, the
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neuronal Na+ channel isoform, Nav1.1 (protein detected by
immunohistochemistry), was of equal abundance in the SA
node. We have shown that block of Nav1.1 slows pacemaking
(S.K.G. Maier et al. Proc.Natl.Acad.Sci.U.S.A. 100 :3507-
3512, 2003). We have obtained evidence of a L-type Ca2 +
channel isoform switch : whereas Cav1.2 was less abundant
in the SA node, Cav1.3 was more abundant. We have also
obtained evidence of a switch in the isoform responsible for
the transient outward current : whereas Kv1.4 was less abun-
dant in the SA node, Kv4.2 was more abundant. Two other
K+ channels (ERG and KvLQT1) were more abundant in the
SA node. The funny current, If, plays an important role in the
pacemaker potential in the SA node and, as expected, two ion
channels responsible for If (HCN1 and HCN4) were more
abundant in the SA node. The ryanodine receptor (RYR2) has
been implicated in pacemaking and RYR2 was less abundant
in the SA node.
Abstract No S34E
Future directions : gene therapy to enhance
pacemaking
Richard B. Robinson, Columbia University, New York NY,
USA
Electrophysiological and pharmacological studies over
past decades have provided insight into the ionic basis of
cardiac pacemaker function. Recent molecular and genetic
advances have raised the possibility for targeted gene thera-
peutic approaches to rhythm disorders. We recently have
explored the feasibility of developing a biological pace-
maker, either by introducing pacemaker channel (HCN)
genes into myocardial cells in the intact canine heart or by
genetically engineering adult human mesenchymal stem
cells (hMSCs) to express these same genes and then integrat-
ing the hMSCs into the cardiac syncytium. In the former
studies, the HCN2 pacemaker channel gene isoform was
placed in an adenovirus (Adv) and injected directly into left
atrial tissue or, via catheter, into the left bundle branch of the
ventricular conducting system. Approximately 1 week later
we recorded ECGs during vagal stimulation to suppress
normal sinus rhythm and AV conduction. Both Adv studies
resulted in pacemaker activity in HCN2 injected animals that
differed significantly from that of control animals (injected
with a GFP Adv or saline). More recent studies have non-
virally transfected hMSCs with the HCN2 gene. The hMSCs
normally express connexins 40 and 43 and can functionally
couple to each other and to myocytes in culture. HCN2-
transfected hMSCs express a large If-like current but are not
otherwise excitable. HCN2-expressing hMSCs, but not GFP-
expressing hMSCs, increase the spontaneous rate of co-
cultured neonatal myocytes, and when injected into the in
situ canine heart result in a stable escape rhythm during
transient AV block. Thus, both adenoviral and cell based
over-expression of HCN2 channels create a biological pace-
maker in the in situ heart.
Abstract No S35A
New paradigms in estrogen signaling with particular
reference to cardiovascular function
Jan-Åke Gustafsson, Department of Medical Nutrition,
Karolinska Institute, NOVUM, S-141 86 Huddinge,
Sweden
The discovery that estrogen signaling is mediated by two
partially antagonistic principles, estrogen receptors a and b,
is gradually changing our understanding of estrogen action in
different organs and systems in the body. It has since long
been appreciated that estrogens have an impact on cardiovas-
cular function but great controversies exist regarding the
details of estrogen regulation of heart and vessels. This lec-
ture will address some of these issues and attempt to offer
some explanations for unresolved inconsistencies.
Abstract No S35B
Novel selective agonists as tools to dissect biological
functions of eralpha and erbeta
Prelle K, Hegele-Hartung C, Hillisch A, Kosemund D,
Kaufmann U, Muhn P, Peters O, Fritzemeier KH
Estrogens exhibit physiological effects mainly through
two different nuclear estrogen receptors (ERs). ERb is pre-
dominatly expressed in ovarian granulosa cells, prostate,
vascular tissue, intestine and specific brain regions, whereas
pituitary, uterus and liver express ERa at high levels. Data
from various lines of ERb knockout mice showing different
degrees of female subfertility or infertility due to reduced
follicular maturation and ovulation rate imply that ERb plays
an important role in the control of ovarian function and
folliculogenesis. The stimulatory activity of estrogens on
granulosa cell growth was demonstrated in diverse studies in
rodents. Less information is available on direct effects of
estrogen on the human ovary. However, a number of primate
studies indicate that estrogen-free or reduced intraovarian
estrogen levels are associated with reduced rates of meiotic
maturation and fertilization. Additional information on the
function of ERa and ERb will be provided by the application
of subtype-selective-ER agonists. Based on the crystal struc-
ture of the ERa ligand-binding domain steroidal ligands were
designed to bind preferentially to either ERa or ERb and
were tested in vitro using transactivation assays. This ap-
proach directly led to highly ER isotype-selective (\\
126\\200 fold) and potent ligands (50 % of E2). To unravel
physiological effects, in vivo experiments were performed
using the ERa- and ERb-selective ligands. In ovariectomized
rats the ERa ligand induced uterine growth and caused bone-
protective effects, while the ERb ligand exhibited estrogen-
like effects on these parameters only at high doses. Therefore
estrogen effects on the uterus, pituitary, bone and liver may
be primarily mediated via ERa. In hypophysectomized ani-
mals, the ERb agonist caused stimulation of early folliculo-
genesis and a decrease in follicular atresia, accompanied by
an increase in the number of ovulated oocytes. In contrast,
the ERa agonist had little or no effect on these parameters
implying that direct estrogen effects on follicular develop-
ment are mediated primarily by ERb.
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Abstract No S35C
Modulation of cardiac hypertrophy by selective
estrogen receptor agonists and serms
Theo Pelzer MD, Department of Medicine ; University of
Würzburg, Germany
The biological effects of estrogens are transmitted by two
different estrogen receptor subtypes, ERa and ERb, which
posses redundant, divergent or even opposing functions in
several organ systems. Thus, the function of estrogens in
cardiovascular disease cant be understood and preventive
treatment strategies cant be developed without understanding
the biological function of both receptor subtypes, which is
still largely unknown. The recent synthesis of subtype-
selective ERa and ERb agonists has provided an additional
tool to dissect the biological function of both estrogen recep-
tors which complements already existing genetic mouse
models to study functional differences between ERa and
ERb. The task ahead is to apply these tools to animal models
of human heart disease. Cardiac hypertrophy, which in-
creases with age and with declining estradiol serum levels, is
effectively attenuated by non-selective ERa and ERb ligand
such as 17b-estradiol. Therefore, the development of cardiac
hypertrophy appears as an established model to evaluate
existing and innovative ER ligands. This presentation will
provide insight into the effects of subtype-selective estrogen
agonists and selective estrogen receptor modulators
(SERMs) on cardiac hypertrophy, function and gene expres-
sion via an integrative approach of small animal physiology,
functional cardiac imaging (MRI, PET) and cardiac gene
expression and includes very recent and unpublished data on
novel ER ligands.
Abstract No S35D
Estrogens block cardiac hypertrophy
Doevendans PA University Medical Centre Urrecht, The
Netherlands
Important gender related differences have been observed,
when comparing cardiac mass and hypertrophy. In female
cardiac mass increases after the menopause, suggesting an
important role for sex hormones in hypertrophy suppression.
In female mice we assessed the hypertrophic response upon
transverse aortic banding in the presence or absence of estro-
gen (E2) replacement. In this model a marked reduction of
the hypertrophic response was observed in the E2 substituted
animals. Hypertrophy reduction was p38 and ANF depen-
dent. The role of ANF, ANF receptor (guanylyl cyclase A
receptor), cGMP and cGMP dependent protein kinase in
blocking hypertrophy was further substantiated in in vitro
studies using isolated neonatal rat ventricular myocytes
(NRVM). In NRVM induced cGMP activity was observed
upon E2 treatment. In addition, the hypertrophic response
induced by endothelin and phenylephrine treatment was
blocked as shown by smaller cell surface and protein content.
The hypertrophy suppressive effect of E2 was inhibited by
adding ANF antibody to the medium, reducing the bioavail-
ability of ANF and by blocking of the cGMP dependent
protein kinase by KT-5823. In the next series of studies in
either estrogen receptor (ER) a or b deficient animals band-
ing was performed showing the requirement of functional
ERb for E2 to block hypertrophy. The analysis of the molecu-
lar pathways is ongoing using also microarray technology to
unravel changes in gene expression, comparing the various
experimental groups.
Conclusion : E2 blocks cardiac hypertrophy in vivo and in
vitro by the induction of ANF expression and activation of
cGMP. Blocking hypertrophy is dependent on the presence
of functional ER.
Abstract No S36A
Oxidant stress and vascular function : insights from
the human heart
David Gutterman, MD, Yanping Liu, MD PhD, Ossama
Abu-Hatoum, MD, Hiroto Miura, MD PhD Cardiovascular
Center, Medical College of Wisconsin, VA Medical Center,
Milwaukee, WI USA
Reactive oxygen species (ROS) play an important role in
modulating vascular tone. Most prominent in this regard is
the marked reduction in functional activity of nitric oxide
during conditions associated with increased superoxide for-
mation such as atherosclerosis or its risk factors. In these
conditions alternative mechanisms of dilation involving an
endothelial derived hyperpolarization factor (EDHF) often
compensate for loss of nitric oxide. In the human coronary
microcirculation, EHDF may actually be a ROS derived from
superoxide, hydrogen peroxide. Other ROS derived from
superoxide (i.e. peroxynitrite) impair EDHF-mediated dila-
tion by inhibiting activity of the effector potassium channels
present on underlying vascular smooth muscle. This presen-
tation will highlight the complex influence of ROS on vaso-
motor function in the human coronary microcirculation, fo-
cusing on the role of hydrogen peroxide as an EDHF, and
elucidating the mechanism of ROS-mediated inhibition of
hyperpolarization-mediated vasodilation in diabetes and
other risk factors for atherosclerosis.
Abstract No S36B
Endothelial dysfunction and vascular disease
Chris R. Triggle, School of Medical Sciences, RMIT
University, Bundoora, Victoria, Australia & Smooth Muscle
Research Group, University of Calgary, Calgary, Canada
The endothelium is the source of a number of important
vasoactive factors and plays a critical role in the regulation of
cardiovascular function. The most important endothelium-
derived factor in the macrovasculature is nitric oxide (N0)
whereas in the microvasculature another factor, or cellular
process, termed EDHF (Endothelium-Derived Hyperpolariz-
ing Factor) appears to be of at least equivalent importance to
NO. Endothelial dysfunction, defined as a reduced
endothelium-dependent vasorelaxation to acetylcholine, is a
common feature and early indicator of cardiovascular dis-
ease in both humans and animals. Endothelial dysfunction is
seen both in the macro- and microvasculature and may be
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linked to the reduced contribution of both NO and EDHF. We
have studied endothelial function in blood vessels from hu-
mans and mice with type II diabetes. A common feature of
endothelial dysfunction in type II diabetes is that the bio-
availability of NO is reduced and that endothelial function
can be at least partially restored by acutely providing tetrahy-
drobiopterin, a key co-factor for eNOS. In our studies of
blood vessels from the db/db mouse [which develops insulin
resistance, hyperinsulinemia and severe hyperglycaemia] we
have found that elevated oxidative stress, most likely second-
ary to the hyperglycaemia, is the major contributor to endot-
helial dysfunction and that oral treatment with sepiapterin, a
precursor of tetrahydrobiopterin, restores endothelial func-
tion without affecting the metabolic abnormalities. In addi-
tion, treatment of db/db mice with a PPARc agonist also
restores endothelial function as well decreases blood glucose
levels. These data suggest that dietary supplements designed
to improve NO bioavailability may prove to be a valuable
adjunct for the treatment of type II diabetics and improving
cardiovascular function.
Abstract No S36C
Infection and atherosclerosis – what role for
antibiotics ?
Sandeep Gupta, Whipps Cross and St Bartholomew’s
University Hospitals, London, UK
Interest in human antibiotic trials in the context of C
pneumoniae infection and atherosclerosis was triggered by
publication of the first two pilot clinical studies in 1997 – one
from UK ; the other from Argentina. These small studies
suggested a potential benefit of antimicrobial therapy in
patients with coronary heart disease (CHD). A series of
studies examining the effects of antibiotic prescribing and
cardiovascular events ensued. Results have been mixed.
More recently, exposure to antichlamydial antibiotics during
the 3 months after acute MI was associated with a better
survival. ACADEMIC, CLARICOR, ANTIBIO and ISAR-
3 studies have been inconsistent in showing a positive effect
with antibiotics – but it is possible that a sub-group of pa-
tients may be deriving benefit. The anti-chlamydial agents,
particularly the macrolides used in early antibiotic interven-
tion studies could be acting through non-antimicrobial ef-
fects (such as anti-inflammatory responses) thereby halting
the progression of atherogenesis or atherothrombosis. Inter-
estingly, other broad-spectrum antibiotics with anti-
chlamydial activities such as tetracyclines inhibit macroph-
age matrix metalloproteinases and may also hypothetically
stabilise the atherosclerotic plaque. Several large-scale trials
of anti-chlamydial antibiotic therapy in various subsets of
patients with CHD are currently underway. These include
WIZARD, ACES, AZACS, PROVE-IT and CLAINF. Some
25,000 patients in total have now been recruited and ran-
domised to receive antibiotic or placebo and are currently
being followed up for adverse cardiovascular events. Results
from some these trials will be discussed.
Abstract No S36D
The sphingosine kinase / sphingosine-1-phosphate
phosphohydrolase system as an endogenous regulator
of microvas-cular function – focus on the modulation of
rhoa signalling
Steffen-Sebastian Bolz, Institute of Physiology,
Ludwig-Maximilians-University, Munich, Germany
Exogenously applied sphingosine-1-phosphate (S1P)
elicits a RhoA/Rho kinase-dependent vasoconstriction in re-
sistance arteries (RA), and hence may play a role in the
development of hypertension. In vivo, production and degra-
dation of S1P is controlled by two enzymes, respectively,
sphingosine kinase (Sphk1) and S1P phosphohydrolase
(SPP1). To study the role of S1P as an endogenous modulator
of microvascular tone, we employed a genetic approach to
alter the expression/activity of these enzymes in the smooth
muscles cells of isolated RA.
Overexpresssion of Sphk1 augmented resting tone in RA.
When Sphk1 was co-expressed with dom. – neg. mutants of
RhoA or Rho kinase (N19RhoA ; KD1A), resting tone was
abolished, indicating a RhoA/Rho kinase-dependent mecha-
nism. Expression of a dom.-act. mutant of RhoA (L63RhoA)
also increased tone, further implicating a RhoA/Rho kinase-
dependent mechanism. Pressure-induced vasoconstriction
(myogenic response, MR) was augmented by Sphk1, but was
inhibited by the expresssion of the inactive Sphk1 mutant
(hSkG82D) or by coexpression of Sphk1 with N19RhoA or
KD1A. Overexpression of L63RhoA moderately enhanced
the MR.
Expression of dom.-act. SPP1 reduced basal tone, the MR,
calcium sensitivity of the contractile apparatus and vasocon-
striction induced by exogenous S1P. Conversely, antisense-
mediated reduction in SPP1 expression enhanced basal tone,
the MR, calcium sensitivity and exogenous S1P-mediated
vasoconstriction.
The pronounced, opposing effects of altering Sphk1 or
SPP1 activity highlight their importance as regulators of
microvascular tone, presumably through control of S1P bio-
availability. Therefore, these enzymes represent novel targets
for the pharmacological treatment of hypertension.
Abstract No S36E
Anti-inflammation therapy targeting monocyte
chemoattractant protein-1,as novel strategy to treat
cardiovascular disease
Kensuke Egashira, M.D., Ph.D. Department of
Cardiovascular Medicine, Faculty of Medicine, Kyushu
University, Fukuoka, Japan
Clinical challenges for cardiovascular disease, which need
new therapeutic options, include restenosis, atherosclerotic
events resulting from plaque rupture, post-transplantation
arteriosclerosis, ischemia-reperfusion injury and so on.
Emerging evidence suggests that an inflammatory process is
involved in the pathogenesis of such intractable diseases. In
particular, inflammatory responses to arterial injury, which
cause continuous recruitment and activation of monocytes
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mainly through activation of the monocyte chemoattractant
protein-1 (MCP-1) pathway, have a central role in restenosis
and atherogenesis. We recently devised a new anti-
inflammation (MCP-1) therapy by transfecting an
N-terminal deletion mutant of the MCP-1 gene into skeletal
muscles. This mutant MCP-1 lacks the N-terminal amino
acid 2 to 8, called 7ND, and works as a dominant-negative
inhibitor of MCP-1. We demonstrated that 7ND gene transfer
suppressed monocyte infiltration/activation after arterial in-
jury and attenuated restenotic changes after balloon injury or
stent placement. Stent-based or adenovirus-mediated local
transfection of 7ND gene reduced in-stent neointimal forma-
tion but did not affect process of endothelial regeneration or
tissue repair, suggesting that local transfection strategy is a
practical and promising means for prevention of in-stent
restenosis in animals including monkeys. Furthermore, 7ND
gene transfer not only attenuated the initiation of atheroscle-
rotic lesions, but also limited progression of pre-existing
atherosclerotic lesions and changed the lesion composition
into a more stable phenotype, i.e., containing fewer macroph-
ages, less lipid, more smooth muscle cells and collagen in
hypercholesterolemic mice and monkeys. Vascular inflam-
mation mediated by MCP-1 might create a positive feedback
loop to enhance restenotic and atherosclerotic changes
through activating lesional monocytes. We also reported that
7ND gene transfer attenuated ischemia-reperfusion injury,
post-transplantation arteriosclerosis, and left ventricular re-
modeling and failure after myocardial infarction. In conclusion, blockade
of MCP-1 with 7ND gene transfer is effective not only in reducing experi-
mental restenosis, atherosclerosis, and plaque destabilization leading to
acute coronary syndrome, but also in attenuating other forms of cardiovas-
cular diseases. Our finding in nonhuman primates has significant clinical
significance, implying that this anti-inflammation strategy targeting MCP-
1 might be a promising therapy against human restenosis and atherosclerotic
complications.
Abstract No S37A
Pathophysiological significance of adrenomedullin in
the cardiovascular system
Tanenao Eto, Johji Kato, Kazuo Kitamura, Miyazaki
Medical College, University of Miyazaki, Japan
Adrenomedullin (AM) has a wide range of biological
actions including vasodilatation, natriuresis, diuresis, inhibi-
tion of aldosterone secretion and inhibition of cardiac hyper-
trophy and fibrosis. Ten years has passed since AM was
discovered as a novel vasodilator peptide. During this de-
cade, much research, basic and clinical, has been done to
clarify its role in the homeostasis of cardiovascular functions,
and a substantial amount of data has been accumulated in this
field. Both the organs and tissues belonging to the cardiovas-
cular system, such as the myocardium and vascular wall,
were found to produce AM. AM is present in the bloodstream
in picomolar concentrations and plasma AM levels were
found to be progressively elevated in patients with hyperten-
sion, myocardial infarction and heart failure in association
with severities of the diseases. In addition, its biological
actions are closely related to the homeostasis of cardiac and
vascular functions. Based upon these findings, AM is consid-
ered a humoral or locally acting factor modulating the devel-
opment and progression of various cardiovascular diseases.
For example, AM likely functions to counteract the elevation
in blood pressure and progression of target organ damage in
hypertension. AM also appears to be acting against progres-
sion of heart failure through its natriuretic action and inhibi-
tion of the renin-angiotensin-aldosterone system. Our recent
studies showed that AM administration during an early pe-
riod of acute myocardial infarction ameliorated chronic pro-
gression of cardiac remodeling and heart failure. Research on
AM now seems to be entering a new phase, with clinical
benefits to be examined and specified. It appears certain that
further data will be provided as to the clinical application of
AM in diagnosing or treating patients with cardiovascular
diseases.
Abstract No S37B
Adrenomedullin and adrenomedullin receptor-ramp
interactions modulate cardiac function
Dominic J. Autelitano, Cryptome Pharmaceuticals, PO Box
6492 St.Kilda Rd. Central, Melbourne, VIC 8008, Australia
Co-expression of the potent hypotensive peptide
adrenomedullin (AM) with its receptor in the heart leads to
localized actions on cardiac function. Modulation of cardiac
AM signaling may come about as a consequence of altered
expression or function of either AM, AM receptor or one or
more of the receptor activity modifying proteins (RAMPs)
that are required for AM receptor activity.
In cultured rat neonatal cardiac myocytes (MC), hypertro-
phy was associated with down-regulation of AM gene ex-
pression and peptide secretion, however, addition of exog-
enous AM inhibited the hypertrophic response as determined
by protein :DNA ratio and the transcriptional activation of
ANP and MLC-2 reporter gene expression.
In whole rat heart and in MC, RAMP2 expression pre-
dominates over RAMP1 with little or no detectable RAMP3
expression. Using a CRE-Luc reporter to determine AM
receptor activity, we showed that AM signaling in MC is
dependent upon Calcitonin Receptor-Like Receptor (CRLR)
and RAMP2 expression. RAMP3 mRNA was shown to be
rapidly induced in MC by serum and phorbol esters and
adenovirus-mediated expression of RAMP3 in MC led to
enhanced AM-mediated signaling.
Thus AM signaling in the heart is potentially regulated by
modulating both AM and RAMP expression.
Abstract No S37C
Autocrine and paracrine functions of adrenomedullin
in myocardium
McDermott BJ & Bell D. Centre for Cardiovascular
Research, Queen’s University Belfast, Northern Ireland
A possible direct role for adrenomedullin (AM), produced
locally within the heart, in the attenuation of cardiac growth
has been implied. Increased cardiac mass can be attributed
either to growth of cardiomyocytes or proliferation of non-
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myocytes. On account of the documented attenuation of the
proliferation of cardiac fibroblasts by AM, utilisation of
isolated cardiomyocytes is essential to dissect out the effects
of the peptide that are intrinsic to the myocytes themselves.
Increased plasma levels of AM correlate positively with left
ventricular hypertrophy (LVH) and the severity of heart fail-
ure. The hypothesis that AM may constitute an endogenous
defence mechanism to attenuate ventricular hypertrophy and
cardiac decompensation was tested by investigating the ef-
fects of AM on growth (protein turnover, phenotypic gene
expression) of healthy rat ventricular cardiomyocytes in vitro
both under basal conditions and in response to hypertrophic
growth stimuli. Complete attenuation of phorbol-12-
myristate-13-acetate (PMA)-stimulated protein synthesis
was observed at concentrations of AM ≥ 10-8M. Secretion of
endogenous AM was increased in these cells in response to
growth stimuli. In experimental models of hypertension-
induced LVH, gene expression of AM in myocytes increased
(x3) after nitric oxide synthase inhibition in the rat and this
was accompanied by a modest increase in expression of the
receptor activity modifying protein (RAMP)-3, which was
observed also in the spontaneously hypertensive rat (SHR). It
appears that the cardiac AM system at the level of the myo-
cyte is upregulated in the hypertrophic state with possible
consequence for anti-remodelling actions in myocardium.
Abstract No S37D
Adrenomedullin gene delivery protects against
cardiovascular remodeling and apoptosis
Lee Chao and Julie Chao. Dept of Biochemistry and
Molecular Biology, Medical University of South Carolina,
Charleston, SC 29425, USA
We investigated the potential roles of adrenomedullin
(AM) in cardiovascular remodeling and apoptosis by somatic
gene delivery. We showed that a single intravenously injec-
tion of the human AM gene induces a prolonged delay in
blood pressure rise and reduction of left ventricular mass,
cardiomyocyte diameter and interstitial fibrosis in several
hypertenisve animal models. Local AM gene delivery signifi-
cantly inhibited arterial thickening, promoted re-
endothelialization in rat artery after balloon angioplasty. In a
rat model of myocardial ischemia/reperfusion injury, local
AM gene delivery significantly reduced myocardial infarc-
tion, occurrence of sustained ventricular fibrillation and apo-
ptosis without affecting hemodynamics, and these protective
effects were abolished by an AM antagonist, calcitonin gene-
related peptide, CGRP(8-37). These AM’s effects were ac-
companied by increased phospho-Akt and Bad and Bcl-
2 levels, but reduced NAD(P)H oxidase activities,
superoxide levels, p38 MAPK activation, Bax levels and
caspase activities in the ischemic heart. In cultured cardi-
omyocytes, AM also attenuated apoptosis induced by
hypoxia/reoxygenation, which was accompanied by in-
creased phospho-GSK-3b, but reduced GSK-3 and caspase-
3 activities. AM’s effects on anti-apoptosis and increased cell
viability were blocked by dominant-negative Akt but not by
inhibitor of GSK-3b and caspase-3. These results indicate
that AM attenuates cardiovascular remodeling and apoptosis
by suppression of oxidative stress and activation of Akt
signaling pathways. These findings provide new insights into
the role of AM as an anti-oxidant in protection against car-
diovascular dysfunction.
Abstract No S37E
Potential for targeting adrenomedullin mechanisms in
heart failure
Chris Charlesa, Miriam Rademakera, Mark Richardsa and
Gary Nichollsb. aChristchurch Cardioendocrine Research
Group, Christchurch, New Zealand and bDept Medicine,
University of United Arab Emirates, UAE
Evidence suggests that adrenomedullin plays a role in
pathophysiology of heart failure. Circulating concentrations
of adrenomedullin are elevated in cardiovascular disease in
proportion to severity of cardiac and hemodynamic impair-
ment. Raised plasma adrenomedullin levels following acute
cardiac injury and in heart failure provide prognostic infor-
mation on adverse outcomes. Administration of adrenom-
edullin in experimental and human heart failure induces
reductions in arterial pressure and cardiac filling pressures,
and improves cardiac output, in association with inhibition of
plasma aldosterone (despite increased renin release) and aug-
ments renal glomerular filtration and sodium excretion. Fur-
thermore, adrenomedullin in combination with other thera-
pies (angiotensin-converting enzyme inhibition and
augmentation of the natriuretic peptides) results in hemody-
namic and renal benefits greater than those achieved by the
agents separately. Manipulation of the adrenomedullin sys-
tem holds promise as a therapeutic strategy in cardiac dis-
ease.
Abstract No S38A
How to assemble myofibrils in the developing
vertebrate heart and how to deal with them during cell
division
Elisabeth Ehler, King’s College London, London SE1 1UL,
UK.
Development of contractile force in the heart depends on
the assembly of sarcomeric proteins to para-crystalline struc-
tures, the myofibrils. This process was investigated in devel-
oping embryonic chick and mouse hearts by confocal mi-
croscopy of triple-stained whole mount preparations. All
sarcomeric proteins investigated so far are already expressed
long before the first periodic contractions occur and the
assembly of the myofibrils happens within hours in the em-
bryonic heart. No stress fibre-like structures, typically seen in
cultured cardiomyocytes, have been observed during myofi-
brillogenesis in the embryonic heart. The first organised
complexes that can be observed involve Z-disk components
and occur in close association with the plasma membrane. A
cytoskeletal framework seems to exist that consists of the
Z-disk protein alpha-actinin, the M-band protein myomesin
and the elastic titin filaments stretching in-between and is
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essential for the integration of thin and thick filaments, re-
spectively.
Embryonic heart growth is achieved by cell division. This
is not performed by a stem-cell like population, but fully
differentiated cardiomyocytes can enter the cell cycle, disas-
semble their myofibrils and go through mitosis including
cytokinesis. Interestingly, disassembly of myofibrils happens
in a biphasic fashion, with Z-disks and thin filaments being
disassembled before M-bands and thick filaments. After cy-
tokinesis rapid reassembly can be seen. This costly process
might provide an additional explanation, why cardiomyo-
cytes cease to divide after birth in vertebrates.
Abstract No S38B
Myofibril inducing RNA (MIR) rescues mutant
salamander heart by promoting myofibrillogenesis
C. Zhanga, X.P. Huanga, S.L. Lemanskia, D.K. Dubeb and
L.F. Lemanskia. aDepartment of Biomedical Sciences,
Florida Atlantic University, Boca Raton, FL 33431 ;
bDepartment of Medicine, Upstate Medical University,
Syracuse, NY 13210
Recessive cardiac mutant gene c in axolotls (Ambystoma
mexicanum) is a natural occurring genetic mutation that
provides an excellent model for studying heart development
and muscle gene regulation. Mutant embryonic hearts that
lack tropomyosin and organized myofibrils and fail to beat
can be rescued by organ-culturing with normal anterior endo-
derm, a known heart muscle inductor tissue, or the medium
conditioned by normal anterior endoderm, or RNA mol-
ecules from a MIR (Myofibril Inducing RNA) gene origi-
nally deduced from the active RNA in endoderm-conditioned
medium. The RNA from this gene is capable of promoting
tropomyosin synthesis and myofibrillogenesis in mutant
hearts. RT-PCR shows that MIR RNA is present in embryos
at early stages. Two proteins (30 and 12 kDa) are known to
interact with MIR RNA. We found a point mutation (G-- > T)
in mutant RNA resulting in an altered protein binding pattern
and a failure to promote tropomyosin synthesis and myofibril
formation in mutant hearts. The genomic sequence was iden-
tified and indicates a putative promoter at the 5’ end of the
gene which contains a well conserved TATA box, Oct-
binding sites, etc. on the positive strand and some tissue
specific transcription factors’ (MyoD, TEF-1) binding sites
on the negative strand. These suggest there may exist a
mechanism to control tissue-specific expression during em-
bryogenesis in skeletal and cardiac myocytes. Testing the
promoter using red fluorescence protein as a reporter gene in
organ-cultured hearts has confirmed the driving ability of the
promoter. Double stranded MIR RNA has been applied to the
cultured normal whole embryonic hearts and proved to be
effective in inhibiting a heart beat and myofibril formation,
indicating the MIR gene is essential for myofibrillogenesis
and heart development. (NIH HL58435, HL61246 and AHA
Grants to LFL).
Abstract No S38C
Role of a novel tropomyosin in vertebrate heart
development
Dipak K. Dube a,b, Christopher R. Denz a,b,
Syamalima Dubea, Larry F. Lemanskic, Aruna Narshid and
Robert W. Zajdelb. aDepartment of Medicine, b Department
of Cell and Developmental Biology, SUNY Upstate
Medical University at Syracuse, Syracuse, New York, USA ;
c Florida Atlantic University, Boca Raton, Florida, USA ;
dSchool of Life Sciences, University of Birmingham,
Birmingham, UK
Our long term objective is to understand the mechanisms
of myofibrillogenesis in relation to cardiogenesis as well as
to various cardiovascular disease such as Familial Hyper-
trophic Cardiomyopathy (FHC) and Dilated Cardiomyopa-
thy (DCM). Tropomyosin (TM) is one of the five proteins
comprising the thin filaments of sarcomeres. Various mis-
sense mutations in TM have been implicated in FHC &
DCM. One of the limitations in TM research is the complex-
ity of its isoform diversity. We have recently discovered a
novel TM isoform, TPM1k, expressed predominantly in car-
diac tissues. Due to the occurence of multiple isoforms of
TM, it is not clearly understood how various missense muta-
tions in TPM1, one of the four TM genes in vertebrates, affect
cardiac but not skeletal muscles. We have found that the new
isoform TPM1k of the TPM1 gene is expressed mainly in
cardiac tissues via alternate splicing. TPM1k contains exons
1a,2a (instead of 2b as in TPM1a, the known striated muscle
specific isoform), 3,4,5,6b,7,8,& 9a/b. The Mexican axolotl
(Ambystoma mexicanum) is very useful for studying the role
of TPM1k in myofibrillogenesis in situ and in vivo. Some
Mexican axolotl carry a genetic mutation in gene ’c’. Ho-
mozygous embryos (c/c) form hearts that are deficient in TM,
lack organized myofibril, and fail to beat. The mutant hearts
can be rescued with exogenous TM. We are exploring
whether both TPM1a and TPM1k take part in cardiac myofi-
brillogenesis in vivo and play a role in cardiac disease such as
FHC.
This work was supported by the American Heart Associa-
tion.
Abstract No S38D
Troponin I gene regulation during heart development
Xupei Huang, Dept of Biomedical Science, Center for
Molecular Biology and Biotechnology, Florida Atlantic
University, Boca Raton, FL 33431, USA
Troponin I (TnI) gene family has been used as a model to
study the regulation of gene expression during the differen-
tiation and maturation of cardiac muscle tissues. Two major
TnI genes are expressed in the mammalian heart under the
control of a developmentally regulated program. Fetal TnI,
which is identical to slow skeletal TnI (ssTnI), is expressed
first and predominates throughout embryonic and fetal devel-
opment. After birth, ssTnI is downregualted and eventually
disappears in the adult heart. Meanwhile cardiac TnI (cTnI)
is upregulated and becomes predominant in the adult heart.
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TnI may become depleted in ischemic, infarct and failing
hearts. TnI deficiency can result in diastolic dysfunction. We
have investigated TnI isoform switching during heart devel-
opment in normal mouse hearts and in cardiac TnI gene
knockout hearts. The effects of thyroid hormone on TnI gene
regulation have also been studied both in cultured cells and in
whole animals. Very recently, the up-stream part of mouse
ssTnI has been identified. Analysis of the sequence with a
Genomatix software package has revealed several potential
regulatory domains and binding sites. The results from trans-
fection assays have indicated that conserved GA-rich se-
quences, an Oct binding site and a CCAAT box within the
first 300 bp upstream of the transcription start site are critical
for the gene expression. An inhibitory domain has been
revealed within the sequence between – 1700 to – 1780. The
inhibitory effect seems more significant in C2C12 Myoblast
cells than that in CHO cells, suggesting that some inhibitory
factors existed inside of muscle type cells. Our experimental
results have enhanced our understanding of the mechanism
underlying TnI gene regulation during heart development.
Abstract No S38E
C-protein and cofilin in myofibril formation and
maintenance
Naruki Sato and Takashi Obinata. Dept. of Biology, Chiba
Univ, Chiba 263-8522, Japan
Assembly of actin and myosin into filaments and their
precise alignment into sarcomeric structures is a major pro-
cess of myofibril formation. Myosin- and actin-binding pro-
teins are deeply involved in this process. Cardiac myosin-
binding protein C (MyBP-C), also known as C-protein, is one
of the major myosin-binding proteins localizing at A-bands
of myofibrils. MyBP-C has myosin- and connectin (titin)-
binding domains in the C-terminal side of the molecule and
actin- and myosin-binding domains in the N-terminal side.
We found that two MyBP-C variants are generated from a
single gene in both chicken and mice. An alternative spliced
form of mouse cardiac MyBP-C, MyBP-C (+), includes extra
10 amino acids in the C-terminal connectin/titin-binding do-
main. This spliced form has a decreased binding affinity to
myosin filaments and connectin/titin in vitro and does not
localize to A-bands in cardiac myocytes. When MyBP-C (+)
was expressed in chicken cardiac myocytes, sarcomere struc-
tures were disorganized, suggesting that it exerts dominant
negative effects on sarcomeric organization. Of particular
interest is that expression of MyBP-C (+) is scarcely detect-
able in ventricle through cardiac development, but its expres-
sion gradually increases in atria and becomes the dominant
form after 6 m after birth. The age dependent MyBP-C (+)
expression may lead to sarcomere disorganization partly at
least and decreased heart activity in the aged animal. Cofilin
is an actin-binding protein that plays a critical role in actin
filament dynamics in a variety of cells. We observed that
excess of cofilin in cardiac myocytes or myotubes leads to
disruption of actin filaments followed by actin-cofilin rod
formation in the cytoplasm. On the other hand, cofilin ex-
pression in cultured muscle cells was suppressed by applying
an anti-sense method, bundles of actin filaments were formed
and ordered assembly of actin into sarcomeric structures was
significantly suppressed. These results indicate that cofilin
plays a critical role for the regulated assembly of actin in the process of
myofibril formation.
Abstract No S39A
Group B coxsackievirus persistence in cardiac cells and
heart via a novel deletional mechanism
K-S Kima, NM Chapmana, S Tracya, WH Barryb. a
Department of Pathology and Microbiology, University of
Nebraska Medical Center, Omaha NE USA ; b Division of
Cardiology, University of Utah Medical Center, Salt Lake
City UT USA
The group B coxsackieviruses are among the primary
causes of acute inflammatory cardiomyopathies, conditions
than often lead to dilated cardiomyopathy and heart failure.
Enteroviral RNA can be detected in 20-25 % of cardiomyo-
pathic hearts but infectious virus is isolable only from pedi-
atric cases. In humans and in mouse models of cardiomyopa-
thy, enteroviral RNA can persist for weeks to months in the
absence of detectable cytopathic virus. We demonstrate that
coxsackievirus B3 (CVB3) -inoculated primary mouse car-
diomyocyte lysates or homogenized heart tissue from CVB3-
inoculated mice do not induce cytopathic effects (CPE) in
tissue culture, yet viral RNA is readily detected by RT-PCR
in the cultures. Sequence analysis of cDNA derived from this
RNA demonstrated variable deletions at the 5’ end ranging
from 7-49 nucleotides. These deletions have been cloned into
an infectious CVB3 cDNA ; these produce progeny infec-
tious virus that replicated very slowly and induced no detect-
able cytopathic effect in culture. Although normal enterovi-
rus replication produces ≥ 40 fold more positive strand RNA
than minus strand, these viruses display a positive/negative
strand ratio of only 1.5/1. Inoculation of mice with the termi-
nally deleted virus strains show viral RNA detectable in
hearts days after inoculation, demonstrating that the dele-
tions do not ablate infectivity in vivo. This evolution of a
novel defective enterovirus quasispecies in vivo provides a
mechanism by which to explain long-term viral persistence
in human cardiomyopathies in the absence of cytopathic
virus.
Abstract No S39B
Receptors for enteroviruses : their role in pathogenesis
and their normal function in the heart
Jeffrey M. Bergelson, The Children’s Hospital of
Philadelphia
Viruses initiate infection by attaching to specific receptor
molecules on the cell surface. Coxsackie B viruses and
adenoviruses— the major agents of viral heart disease—
both interact with a single protein, the Coxsackievirus and
Adenovirus Receptor (CAR) ; attachment to CAR may ex-
plain viral tropism for cardiac muscle. I will discuss the role
of CAR and other receptors in the pathogenesis of viral
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infection, and present new evidence indicating that CAR is
essential for normal cardiac development.
Abstract No S39C
From expression profiling to biological validation in
coxsackievirus infections : how far to leap, when, and
where ?
Bruce M. McManus, Brad Spiller, Tracy Deischer, Honglin
Luo, Caroline Cheung, Timothy Triche, Bobby Yanagawa,
The James Hogg iCAPTURE Centre for Cardiovascular &
Pulmonary Research, St. Paul’s Hospital-University of
British Columbia, Canada
Coxsackievirus B3 (CVB3) is the primary causative agent
of viral myocarditis, an inflammatory disease of heart
muscle. We have utilized mRNA differential display, cDNA
array and Affymetrix oligonucleotide arrays, in an integrative
manner, to identify differential transcriptional events at
viremic, inflammatory and reclamative stages in CVB3-
infected hearts. Gene expression changes were investigated
in the context of histological evidence of injury and dysfunc-
tion, the latter measured with 2D echocardiography. Gene
expression profiles were selected for further validation at
both mRNA and protein levels using semi-quantitative RT-
PCR and immunohistochemistry, respectively. We observed
acute increases in complement-related genes C2, C3, C4 and
factor B (fB), and further that mice null for fB and C2,
deficient in both classical and alternative complement cas-
cades, have increased myocardial injury, inflammation and
infectious virus particles. These investigations into the patho-
biological role of complement pathways in viral myocarditis
illustrate our strategy to gain biological understanding from
high throughput transcriptional studies. Other notable
differentially-regulated genes include host survival genes,
peripheral-type benzodiazepine receptor and S100 proteins,
and remodeling genes like muscle LIM protein, cathepsins
and serine protease inhibitors serpins, just to name a few. We
also utilized Affymetrix oligonucleotide arrays to identify
genomic changes in cultured cells post-CVB3 infection.
Such studies have led to a better understanding of the balance
between mitochondria-mediated apoptosis signalling and
pro-survival PI3K/Akt signalling triggered by virus infec-
tion. Thus, our expression profiling studies have guided us in
novel directions, allowing us to better understand viral patho-
genesis, organ injury and dysfunction in enteroviral heart
disease.
Abstract No S39D
Inflammation and therapeutic strategies for viral heart
diseases
Akira Matsumori, MD, PhD.Department of Cardiovascular
Medicine, Kyoto University Graduate School of Medicine,
Kyoto, Japan
Recent studies suggest that hepatitis C virus is involved in
development of myocarditis and cardiomyopathies. Our pre-
liminary study showed that interferon therapy was beneficial
for the treatment of myocardial diseases associated with
hepatitis C virus infection. Elevated levels of circulating
cytokines have been reported in patients with myocarditis
and cardiomyopathies, and various cytokines have been
shown to depress myocardial contractility in vitro and in
vivo. A transcription factor, NF-kB is activated by viral
infections, and this activation, leads to the coordinated ex-
pression of cytokines, and the further amplification and per-
petuation of the inflammatory response. NF-kB is therefore
an obvious target for new types of anti-inflammatory treat-
ment. We found that pimobendan and a new NF-kB inhibitor
suppressed cytokine production, and prevented development
of encephalomyocarditis virus (EMCV) myocarditis. We
have shown that angiotensin II is increased, and NF-kB is
activated in EMCV myocarditis, and that inflammatory re-
sponses and NF-kB activation are attenuated in angiotensin
II type I receptor (AT1) knock-out mice, and in mice treated
with an AT1 antagonist. We have also shown that mast cells
play an important role in the pathogenesis of viral myocardi-
tis, and an anti-allergic drug that stabilizes mast cells is
useful for the treatment of viral myocarditis. Cytokine gene
therapy which inhibits inflammatory response by viral IL-
10 and IL-1ra using recently developed method of electropo-
ration has been shown to be effective in EMCV myocartidis.
Abstract No S39E
The Role of Ubiquitination in Viral Pathogenesis : A
Therapeutic Opportunity ?
Honglin Luo The James Hogg, Centre for Cardiovascular
and Pulmonary Research, Department of Pathology and
Laboratory Medicine, St. Paul’s Hospital University of
British Columbia, Vancouver, British Columbia
Viral myocarditis and its main sequela, dilated cardiomy-
opathy, are the most prevalent causes of morbidity and mor-
tality worldwide, particularly in children. Coxsackievirus B3
(CVB3) is the primary causative agent of viral myocarditis.
The ubiquitin/proteasome pathway is a major intracellular
protein degradation pathway in mammalian cells. In addi-
tion, this pathway has also been found to be involved in a
variety of intracellular functions, including cell proliferation,
cell death, and inflammatory responses, processes important
in the progression of many diseases. We recently demon-
strated that the ubiquitin/proteasome pathway plays a critical
role in CVB3 replication. Cell culture experiments using
HeLa cells and murine cardiomyocytes showed that inhibi-
tion of the ubiquitin/proteasome pathway decreased CVB3
viral RNA and protein levels, and inhibited CVB3 progeny
release. These results strongly suggest that inhibition of the
ubiquitin/proteasome pathway may represent a novel thera-
peutic approach against viral myocarditis. To explore the
potential mechanisms by which the ubiquitin-proteasome
pathway regulates viral replication, we further studied the
impact of proteasome inhibitors on mitogen-activated pro-
tein kinase phosphatase (MKP-1) protein expression and
extracellular signal-regulated kinase (ERK) phosphoryla-
tion. We have previously reported that the ERK signaling
pathway is activated during CVB3 replication and activation
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of ERK is required for CVB3 replication and contributes to
virus-medicated pathogenesis. Recent studies have sug-
gested that MKP-1, which dephosphorylates and inactivates
ERK signaling, can be regulated post-translationally via the
ubiquitin-proteasome pathway. We found that proteasome
inhibition led to a loss of ERK phosphorylation in a dose-
dependent manner, which is correlated with an induction of
the MKP-1. Blockade of MKP induction using either MKP-
1 anti-sense or MKP-1 short-interfering RNA attenuated the
loss of ERK phosphorylation, and subsequently increased
viral replication. Our results suggest that inhibition of the
ERK signaling pathway contributes, as least in part, to pro-
teasome inhibitor reduction of coxsackievirus replication.
Data will also be presented on the role of proteasome inhibi-
tion in viral replication, in host protein degradation and in
virus-mediated myocardial damages in a well-established
murine myocarditis model. Taken together, our data ? ? ?
Abstract No S40A
Plasma potassium regulation by skeletal muscle
Clausen T, Dept. of Physiology, University of Aarhus,
Århus, Denmark
The skeletal muscles contain the largest single pool of K+
in the body (2600 mmol), 45x the K+ content of the extracel-
lular phase and 185x the K+ contained in blood plasma. The
action potentials eliciting muscle contractions cause a rapid
release of K+ from the muscle cells. During intense exercise,
the K+ leaking out of the working muscles is sufficient to
double the K+ concentration of arterial blood plasma within
one min and to limit further contractile performance
(Clausen, Physiol. Rev., 2003). The hyperkalemia is often
followed by hypokalemia, and both events carry a risk for
cardiac arrest. The net uptake of K+ into skeletal muscle is
mediated by the Na+,K+-pump. It can be calculated that if all
Na+,K+-pumps in the skeletal muscles run full speed, all K+
will be cleared from the extracellular phase in 28 s. Several
factors promote Na+,K+-pump mediated uptake of K+ into
skeletal muscle (excitation, insulin, catecholamines, theo-
phylline, calcitonin gene related peptide, amylin and IGF-I).
Therapeutic use of insulin or b2 agonists carries the risk of
inducing hypokalemia. Hypokalemia may also arise during
acute myocardial infarction, intense pain, hypoglycemia or
sepsis, reflecting Na+,K+-pump stimulation induced by el-
evated plasma catecholamines. Conversely, inhibition of the
Na+,K+-pumps as induced by digitalis intoxication leads to
hyperkalemia. The clearance of K+ from plasma depends on
the content of functional Na+,K+-pumps in skeletal muscle.
When the content of Na+,K+-pumps is upregulated by train-
ing, exercise-induced hyperkalemia is diminished. Con-
versely, when the Na+,K+-pump content is downregulated as
in cardiac insufficiency, myotonic dystrophy and McArdle
disease, exercise-induced hyperkalemia is more pronounced
and may cause fatigue.
Abstract No S40B
Potassium handling during exercise
Michael J. McKenna. Centre for Aging, Rehabilitation,
Exercise and Sport ; School of Human Movement,
Recreation and Performance, Victoria University of
Technology, Melbourne, Australia
Potassium is released from contracting skeletal muscle
cells. As a consequence, muscle intracellular [K+] is reduced,
accompanied by large [K+] increases in muscle interstitial
fluid, and in venous and arterial blood. These changes in
muscle are likely to be important factors in muscle fatigue.
During heavy exercise, muscle interstitial [K+], measured by
microdialysis, may rise more than 2-fold ; muscle-venous
plasma [K+] may also double, whilst arterial plasma [K+]
may reach 6 - 7 mM or even higher in some chronic diseases.
These increases in circulating [K+] are regulated by numer-
ous factors including muscle Na+,K+ pump content and ac-
tivity, muscle blood flow, type of contraction (isometric ver-
sus dynamic), upper versus lower limb exercise, fibre
composition of muscles recruited, hormonal responses, train-
ing status, health status and numerous medications. During
exercise K+ is continually released from contracting muscle,
but cleared by non-contracting muscle. Hence total muscle
mass may affect circulating [K+] during exercise. Thus in
chronic disease, including heart failure, a loss of muscle mass
may diminish the capacity to clear plasma K+. Furthermore,
muscle Na+,K+ pump content declines with chronic inactiv-
ity, and may exaggerate K+ loss from contracting muscles.
Together these result in an exaggerated rise in plasma [K+]
during exercise, which is also magnified by digoxin or beta-
blockers. The Na+,K+ pump maximal activity in muscle is
also impaired with fatigue, which may further exacerbate K+
loss from contracting muscles. This appears to be indepen-
dent of training status, even though muscle Na+,K+ pump
content is enhanced and plasma [K+] reduced by training.
Thus K+ disturbances in muscle are an important factor in
fatigue and exercise limitation, especially in patients with
chronic disease.
Abstract No S40C
Potassium handling during treatment of heart disease
Helge H Rasmussen, Department of Cardiology,
Royal North Shore Hospital, Sydney, Australia
Total body K+, and hence presumably intracellular K+, are
reduced in congestive heart failure (HF) while intracellular
Na+ levels are raised, at least in the heart. Since cellular ion
regulation is pivotal in HF it is of interest how treatment
affects membrane Na+ and K+ transport. Trials have ad-
dressed neurohumoral abnormalities in HF -abnormal angio-
tensin II, aldosterone, catecholamine, endothelin and natri-
uretic peptide levels. We examined how pharmacological
intervention directed at neurohumoral abnormalities affects
the sarcolemmal Na+-K+ pump by measuring electrogenic
pump current (Ip) in myocytes isolated from rabbits. In vivo
treatment of rabbits with the angiotensin converting enzyme
(ACE) inhibitor captopril or the angiotensin receptor antago-
3492004 ISHR World Congress / Journal of Molecular and Cellular Cardiology 37 (2004) 161-375
nist losartan caused an increase in Ip. The increase was
abolished by in vitro exposure to angiotensin II. Infusion of
aldosterone via osmotic minipumps to achieve serum levels
similar to those seen in HF induced a decrease in Ip and an
increase in intracellular Na+ concentration. Abnormalities
were abolished by co-treatment with an aldosterone antago-
nist. We examined the effect of exposing myocytes to atrial
natriuretic peptide (ANP) in vitro. ANP in concentrations
near the estimated normal interstitial concentration caused
pump stimulation. Stimulation was lost with a higher con-
centration of ANP expected to be « seen » by myocytes in
HF, particularly during treatment with neutral endopeptidase
inhibitors. The loss of stimulation was mediated by activa-
tion of protein kinase A (PKA). We have not directly exam-
ined the effect of catecholamines on the pump. However, we
have found that activation of PKA (a key messenger activated
by beta adrenergic receptors) with cAMP causes pump inhi-
bition. Finally, exposure of myocytes to endothelin causes
pump stimulation. ACE inhibitors/angiotensin receptor an-
tagonists, beta blockers and aldosterone antagonists have
proven efficacy in HF while neutral endopeptidase inhibitors
and endothelin antagonists have no effect or are harmful.
Thus, there is a perfect correlation between clinical efficacy
of treatment and effects on Na+-K+ pump activity.
Abstract No S40D
In vivo assessment of the k homeostasis in hypo- and
hyperkalemia in animals
Henning Bundgaard, Department of Cardiology, The Heart
Centre, Rigshospitalet, University of Copenhagen,
Copenhagen, Denmark
Myocardial and skeletal muscle Na,K-pump regulations
have extensively been elucidated in various diseases and
conditions. The physiological impact of these regulations is
not necessarily obvious as a number of other - attenuating or
enhancing - regulations may take place in parallel. An impor-
tant effect of changes in Na,K-pump concentration and/or
activity is alterations of the potassium (K) homeostasis. A
straight forward interpretation of for example a reduction in
skeletal muscle Na,K-ATPase concentration would be a re-
duction in skeletal muscle K uptake and a reduced tolerance
to K exposure. However, in vivo this may not be the case. On
this basis we developed an animal model to assess the K
homeostasis in vivo using intravenous infusions of large KCl
doses. During infusions plasma K is measured and immedi-
ately after the infusions are ceased skeletal muscle or myo-
cardial tissues are harvested for ion measurements. Selective
K depletion reduces skeletal muscle Na,K-ATPase and K and
increases Na and Mg. K supplementation has the opposite
effects. In the heart K depletion causes a minor decrease in K,
and increases Na,K-ATPase and Mg concentration and show
a tendency to an increase in Na. Again, K supplementation
has the opposite effects. K depletion increases the tolerated K
dose 2-4 fold, whereas K supplementation only induced a
change after fasting, which reduces skeletal muscle K con-
siderably in K supplemented animals. The increased K toler-
ance in K depleted animals was not the outcome of increased
renal K excretion. Net skeletal muscle K uptake showed a
significant positive correlation with pre-infusion skeletal
muscle Na levels, whereas no significant correlation was
observed between net K uptake and skeletal muscle Na,K-
ATPase concentration. In the heart there was a negative
correlation between net myocardial K uptake and pre-
infusion K content as well as between K uptake and myocar-
dial Na,K-ATPase concentration. In conclusion, physiologi-
cal impact of changes in Na,K-ATPase concentration and/or
activity is difficult to predict, and integrated assessments in in
vivo studies – that takes parallel changes into account – seem
warranted.
Abstract No S40E
Potassium and sudden death
Keld Kjeldsen, Laboratory for Molecular Cardiology, The
Heart Centre, Rigshospitalet, University of Copenhagen,
Denmark
Nihilism has prevailed regarding potassium (K) in clinical
cardiology for the last decades. Moreover, whereas diuretics
are prescribed to a large fraction of heart failure patients,
K-supplementation is in some clinics given only relatively
rarely. Recent research however throws new light on
K-homeostasis. The myocardial Na,K-ATPase is of impor-
tance for K handling in the extracellular space (ECV) of the
myocardium - moreover myocardial ECV-K is influenced by
K coming by the blood stream. Here skeletal muscle Na,K-
ATPase is of importance. Thus, maintaining K in myocardial
ECV within safe limits requires optimum regulation of the
Na,K-ATPase. Accordingly its dysregulation may cause se-
vere local hyper- or hypokalemia. Moreover, during exercise
K leaks out of muscular cells and is then pumped back by the
Na,K-ATPase. Thus, plasma-K may within minutes increase
to around 8 mmol/l during activity and decrease even below
resting level during rest. Furthermore, these fluctuations are
modified by Na,K-ATPase regulation by e.g. physical condi-
tioning, disease and medicine. In diuretic treatment of human
subjects plasma-K is maintained for some time by mobilising
K from intracellular compartments - skeletal muscle Na,K-
ATPase and K-content is reduced. Similarly muscle magne-
sium (Mg) may be reduced. In heart failure patients myocar-
dial Na,K-ATPase is reduced. Thus, dysfunction of
extrarenal K-homeostasis may per se cause arrhythmia.
Moreover such dysfunction may disclose conditions that are
usually well tolerated but becomes dangerous when exposed
to hyper- or hypokalemia. Thus, in e.g. long QT-syndrome
caused by mutations in genes coding for potassium-channels,
exercise and hypokalemia may elicit syncope and sudden
death. Recently, aldosterone-antagonist has been added to
heart failure treatment showing significant reductions in mor-
tality. Furthermore, it has been given to patients with long
QT-syndrome. A part of the effect may be the outcome of
improved extrarenal K-homeostasis. In conclusion,
plasma-K and plasma-Mg may be normal despite K and Mg
depletion. Resting plasma-K should be kept high. Plasma-K
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is a dynamic parameter that should be assessed not only
during rest but probably also during e.g. exercise. Major
plasma-K shifts and dysfunction of the K- homeostasis per
se as well as in combination with preexisting disease may
cause arrhythmia, syncope and sudden death. Especially in
situations with syncope or sudden death during exercise, a
thorough evaluation of the K-homeostasis seems in demand.
In the area of aldosterone-antagonist trails, a trial comparing
the protective effect of optimum K-supplementation with
that of aldosterone-antagonism is in demand. Time has come
to fend off K nihilism in clinical practice.
Abstract No S40F
Potassium, ion channelopathies and genes in heart
diseases
Christiansen M Statens Serum Institut and Copenhagen
Heart Arrhythmia Research Center, Copenhagen, Denmark
The course of the action potential (AP) of the cardiomyo-
cyte is the result of a well orchestrated combination of sev-
eral ion channels conducting potassium, sodium and calcium
currents. Deviations from normal function of these channels
is the pathophysiological basis for diseases such as long –
and short - QT syndromes, Brugada syndrome, progressive
conduction disease, idiopathic ventricular fibrillation and
other genetic arrhythmic syndromes as well as many cases of
drug induced arrhythmia and AP changes seen in other car-
diac diseases. The sequencing of the human genome has
made it possible to identify the genes coding for the proteins
constituting the ion channels and, thus, to associate some
arrhythmias with specific genetic variants. Such arrhythmias
are characterised by variable expressivity and penetrance and
cardiac events may be rare. Potassium is an important regu-
lator of ion channel function, as hypokalemia may cause both
an increase in the electrochemical potassium gradient but
also a paradoxical reduction in the funtion of – among other-
s – the HERG channel conducting the rapid repolarising po-
tassium current (Ikr) and thus a reduction of the repolarisa-
tion reserve. This mechanism may result in the clinical
precipitation of arrhythmia in genetic arrhythmic syndromes
as well as the occurrence of arrhythmia during drug intake.
This calls for a careful control of extracellular potassium and
potassium reserves in conditions prone to arrhythmia. There
seems to be a link between the phenotypic presentation of
genetic arrhythmic syndromes and potassium status and the
recent finding of frequent genetic variants and polymor-
phisms in the ion channel genes SCN5A and KCNE2 suggests
that hypokalemia may also be of quantitative importance in
sudden infant (and adult) death syndrome.
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Abstract No S42A
Metabolic remodelling in cardiac hypertrophy - a
factor in heart failure ?
Anne-Marie L. Seymour, Dept Biological Sciences,
University of Hull, UK
Cardiac hypertrophy is an important yet independent risk
factor in heart failure. The adaptations that occur in hypertro-
phy result in a cellular remodelling of the heart, and, in
particular, in alterations in the profile of metabolism. Our
hypothesis is that these changes in fuel selection and utilisa-
tion predispose the hypertrophied heart to injury and subse-
quent failure.
Using experimental models of hypertrophy (hypertension,
uraemia and pressure overload), we have investigated the
relative contribution of 13C labelled substrates to oxidative
fluxes in the intact heart with 13C NMR spectroscopy. Hearts
were perfused in the isovolumic mode, with a physiological
mixture of substrates, including 0.3mM palmitate, 5mM glu-
cose, 1mM lactate and 0.1mM pyruvate, and 100µU/ml insu-
lin. In all cases, we observed a reduction in the myocardial
energy reserve (phosphocreatine to ATP ratio). Furthermore,
as the extent of hypertrophy increased, the heart demon-
strated a growing reliance on glucose and carbohydrate me-
tabolism, and a marked reduction in fatty acid oxidation. In
addition, a depletion of essential cofactors (such as carnitine
and creatine) and alterations in expression of metabolic en-
zymes and proteins were observed. Taken together, these
factors may contribute to the impaired functioning of key
energy generating steps. Our recent studies on isolated cardi-
omyocytes, using confocal microscopy, have indicated that
exposure to high palmitate concentrations can modify the
mitochondrial membrane potential, rendering the hypertro-
phied heart more susceptible to apoptosis and functional
deterioration. Currently we are investigating strategies (such
as carnitine supplementation) which can reverse or limit the
metabolic remodelling in cardiac hypertrophy and may have
the potential to delay or prevent the onset of heart failure.
Abstract No S42B
Metabolic phenotype of the hypertrophied heart
Michael F. Allard, Centre & Dept of Pathology and
Laboratory Medicine, UBC-St Paul’s Hospital, Vancouver,
Canada
Myocardium hypertrophies in response to a prolonged
elevation in workload. The type of workload determines if
the hypertrophy is adaptive or maladaptive, as demonstrated
by functional outcome from a subsequent acute stress, such
as ischemia-reperfusion. Hypertrophy due to exercise (physi-
ologic hypertrophy) is cardioprotective, while that due to
pathologic stimuli, such as hypertension (pathologic hyper-
trophy), is not. The pattern of substrate utilization (or meta-
bolic phenotype) of the heart is recognized as a determinant
of functional outcome after ischemia, so it is of interest to
know if the metabolic phenotype differs between Pathologic
and Physiologic Hypertrophy, both of which have dramati-
cally different post-ischemic outcomes. Fatty acid oxidation
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is impaired, glycolysis is accelerated, and the extent of
glycolytically-derived pyruvate oxidation is reduced in
Pathologic Hypertrophy. In contrast, fatty acid oxidation is
increased, glycolysis reduced, and the extent of glycolyti-
cally derived pyruvate oxidation enhanced in Physiologic
Hypertrophy. That the metabolic phenotype of Physiologic
Hypertrophy resembles that produced by metabolic modula-
tors, such as dichloroacetate or trimetazidine, both of which
are cardioprotective in normal and pathologically hypertro-
phied hearts, supports that concept that alterations in meta-
bolic phenotype contribute, at least in part, to the differing
post-ischemic outcomes of Physiologic and Pathologic hy-
pertrophy. Differences in expression of key proteins or en-
zymes that control myocardial substrate utilization do not
account for the differing metabolic phenotypes of Pathologic
and Physiologic Hypertrophy, indicating that other factors,
such as differences in protein phosphorylation, metabolite
control, or subcellular distribution, are responsible. A corol-
lary of this latter finding is that change in the content of
potentially relevant proteins or enzymes in a metabolic path-
way is insufficient by itself to draw meaningful conclusions
about metabolic flux in the intact organ and how it is con-
trolled.
Abstract No S42C
Myocardial insulin resistance impairs mitochondrial
function and the metabolic adaptation of the heart to
pressure overload hypertrophy
E. Dale Abel, University of Utah, Salt Lake City
Individuals with type 2 diabetes are at greater risk of
developing heart failure particularly when there is coexistent
cardiac hypertrophy and myocardial ischemia. We have
shown that impaired myocardial insulin signaling develops
in the hearts of various mouse models of obesity, type 2 dia-
betes and the metabolic syndrome. Myocardial insulin resis-
tance in these mice is associated with mitochondrial abnor-
malities that include reduced mitochondrial respiratory
capacity and uncoupling of oxygen consumption and oxida-
tive phosphorylation. To determine if myocardial insulin
resistance was sufficient to account for the mitochondrial
phenotypes observed in diabetic hearts, we generated trans-
genic mice with cardiomyocyte-restricted deletion of insulin
receptors (CIRKO). These mice revealed an age-related de-
cline in mitochondrial function. In young < 8-week-old
CIRKO mice state 3 respiration with pyruvate as a substrate
was reduced but respirations with a long-chain fatty acid
(FA) substrate were increased. This change in substrate pref-
erence was associated with increased generation of reactive
oxygen species, and mitochondrial uncoupling. Mitochon-
drial uncoupling and diminished ATP generation worsened
with age and the ability of the mitochondria to metabolize
fatty acids ultimately declined. Thus CIRKO mitochondria
eventually develop reduced oxidative capacity for glucose
and fatty acid substrates. When CIRKO mice were subjected
to pressure overload hypertrophy by transverse aortic band-
ing (TAB), CIRKO hearts developed an accelerated decline
in cardiac function. Hypertrophied wild type (control) hearts
maintained their function up to 4-weeks following TAB and
this was associated with an increase in rates of glycolysis and
glucose oxidation and increased expression of the GLUT1
glucose transporter. In contrast, glucose oxidation and glyco-
lytic rates and GLUT1 expression declined in banded
CIRKO hearts, and expression of uncoupling protein 2 in-
creased. These results indicate that an intact myocardial
insulin signaling pathway is required for the maintenance of
mitochondrial integrity and for the metabolic adaptations
that preserve myocardial function in the face of pressure
overload hypertrophy.
Abstract No S42D
Potential role of the circadian clock in metabolic
adaptation of the heart
Martin E. Young, University of Texas Health Science Center
at Houston, USA
Circadian clocks are defined as a set of proteins that
generate self-sustained transcriptional positive and negative
feedback loops with a free-running period of 24 hours. These
circadian clocks are intrinsic to the cell, and exist even when
cells are isolated and cultured in vitro. These intracellular
molecular mechanisms confer the selective advantage of
anticipation, allowing the cell to synchronize responsiveness
with diurnal variations in its environment. We have charac-
terized the circadian clock within the rat heart, exposing an
array of transcription factors whose expression fluctuates as
much as 60-fold over the course of the day. The heart is
exposed to dramatic diurnal variations in multiple environ-
mental influences, including workload, sympathetic activity,
hormonal stimulation, and substrate availability. In the latter
case, fatty acids, the primary fuel utilized by the heart,
oscillate approximately 2-fold within a 24 hour period. Pre-
vious studies show that a loss of synchronization between
fatty acid availability and fatty acid oxidative (FAO) capacity
results in intramyocellular accumulation of detrimental fatty
acid derivatives, and subsequent contractile dysfunction (i.e.
lipotoxicity). We therefore hypothesized that the circadian
clock within the heart allows anticipation of periods of in-
creased fatty acid availability by increasing FAO capacity.
Our data suggest that the circadian clock allows the heart to
anticipate periods of prolonged fasting, when the animal in
the wild is unsuccessful in foraging for food.
Abstract No S42E
Inhibition of myocardial fatty acid oxidation for the
treatment of heart failure
William C. Stanley. Case Western Reserve University,
Cleveland, USA
The chronically failing heart is metabolically abnormal in
both animal models and in patients. Little data are available
on the rate of myocardial glucose, lactate and fatty acid
metabolism and oxidation in heart failure patients, thus at
present, it is not possible to draw definitive conclusions about
cardiac substrate preference in the various stages and mani-
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festations of heart failure. Normal cardiac function is depen-
dent on a constant resynthesis of ATP by oxidative phospho-
rylation in the mitochondria. The healthy heart gets
60 – 90 % of its energy for oxidative phosphorylation from
fatty acid oxidation, with the balance from lactate and glu-
cose. There is some indication that in early stage compen-
sated heart failure there is normal or accelerated lipid oxida-
tion, and decreased glucose uptake and carbohydrate
oxidation compared to healthy age-matched individuals, and
that therapies that acutely switch the substrate of the heart
away from fatty acids result in improvement in left ventricu-
lar function. On the other hand, in advanced late stage heart
failure there is a clear downregulation of myocardial fatty
acid oxidation and accelerated glucose oxidation. We re-
cently found that that chronic treatment with inhibitors of
carnitine palmitoyltransferase I (oxfencine) or long chain
3-ketoacylthiolase (trimetazidine) improves cardiac function
and slow the progression of heart failure in dog and rat
models of heart failure, respectively. Thus manipulation of
myocardial substrate oxidation toward greater carbohydrate
oxidation and less fatty acid oxidation may improve ven-
tricular performance and slow the progression of clinical
heart failure. At present, this intriguing hypothesis requires
further evaluation.
Abstract No S43A
The effect of p38 MAP kinase on cardiac remodeling
and dysfunction - upper or downer ?
Shuxun Rena, Manxiang Lid, Scherise Mitchell, David
Kassd, Ju Chenc, Peipei Pingb and Yibin Wanga,b. aDivision
of Molecular Medicine ; bCardiovascular Research
Laboratories, David Geffen School of Medicine at UCLA,
Los Angeles, CA 90095 ; cInstitute of Molecular Medicine,
UCSD, Lo Jolla, CA 92093 ; dDivision of Cardiology, Johns
Hopkins University School of Medicine, Baltimore,
Maryland, USA
Development of heart failure involves pathological re-
modeling in myocardium, including changes in gene expres-
sion, interstitial fibrosis and loss of cardiac function. Activa-
tion of stress-activated protein kinase p38 has been
implicated in the onset of heart failure. To investigate the
functional role of p38 in cardiac remodeling, we established
transgenic animals with targeted and temporally regulated
activation p38 and knockout of p38a isoform in heart. Induc-
tion of p38 activity led to lethal restrictive cardiomyopathy in
transgenic heart, associated with loss of contractility, induc-
tion of extracellular matrix content and regulatory genes.
Treating the transgenic animals with p38 inhibitor
SB239068 reversed remodeling process and improved con-
tractile function and survival rate. At cellular level, activation
of p38 leads to repressed contractility without affecting SR
calcium cycling. Both in vitro and in vivo, p38 activity is
both sufficient and necessary to induce inflammatory gene
expression in myocytes. These data suggest that p38 activity
is a critical signaling component in stress induced cardiac
pathologies, including extracellular matrix remodeling and
contractile dysfunction. The underlying mechanisms may
involve inflammatory gene regulation and sarcomere modu-
lation. Our observation implicates p38 MAP kinase as a
potentially important therapeutic target for treating heart
failure.
Abstract No S43B
P38 MAPK, a kind or kallous kinase (symposium) role
in maliganant hypertension : appeaser, pleaser or
bystander
Robert Willette, GSK Pharmaceuticals, USA
Chronic inflammatory processes contribute to the patho-
genesis of atherosclerosis and represent a pathophysiologic
link to its major risk factors ; diabetes, obesity, hypertension
and dyslipidemia. Pro-inflammatory cytokines have been
implicated in a variety of important cellular processes asso-
ciated with vascular inflammation, i.e. cellular activation,
adhesion, infiltration, dedifferentiation, apoptosis and dys-
function. Thus, suppression of pro-inflammatory cytokines
in the vasculature has emerged as an attractive approach to
the treatment of cardiovascular disease. In this regard, the
inhibition p38 MAPK has been implicated as a compelling
target because of its role in the elaboration of pro-
inflammatory mediators as well as in the signal transduction
of initiated by pro-inflammatory cytokines, mechanical
stress, and reactive oxygen species (ROS). Numerous studies
performed in a variety of pre-clinical cardiovascular models
(hypertension, heart failure, restenosis and atherosclerosis)
suggest that activation of vascular p38 MAPK is associated
with endothelial dysfunction, ROS generation, adhesion,
macrophage activation, hypertension and vascular remodel-
ing. Chronic treatment with p38 MAPK inhibitors a elicit
dose-related improvement in survival, endothelial function,
renal function, blood pressure, stroke incidence, indices of
vascular ROS and inflammation in hypertension induced by
salt-sensitivity and NOS inhibition. In models of atheroscle-
rosis, p38 MAPK inhibitors reduced the formation of
atheroma and macrophage activity. Finally, p38 MAPK in-
hibitors reduce the enhanced cytokine and matrix metallo-
proteinase production observed in human carotid endarterec-
tomy cultures. The results support the role of vascular
inflammation in the pathogeneisis of atherosclerosis and at-
tendant cardiovascular disease and strongly suggest that inhi-
bition of the p38 MAPK signaling pathway is a valid phar-
macological approach to treatment.
Abstract No S43C
p38-MAPK activation during myocardial ischaemia.
slayer or redeemer
Michael S Marber, Masaya Tanno, Diana Gorog and
Mohamed Bellahcene. Department of Cardiology, The
Rayne Institute, Cardiovascular Division, King’s College
London, UK
The activation of p38-MAPK has been implicated in the
injury that follows ischaemia. Furthermore in recent studies
its activation has been associated with contractile dysfunc-
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tion. However under other circumstances p38-MAPK activa-
tion has been associated with protection. We have investi-
gated p38-MAPK under a variety of circumstances. During
ischaemia our findings suggest that the phosphorylation of
the T-G-Y activating motif is not by upstream kinases
(MKK3/6) but is sensitive to the p38-MAPK catalytic-site
inhibitor SB203580. This, together with other findings, is
consistent with the notion that activation during ischaemia is
by an autophosphorylation mechanism. These results con-
trast directly with the activation profile in response to TNF,
which is dependent on MKK3. During low flow in the iso-
lated perfused heart contractile dysfunction is accompanied
by p38-MAPK activation. However, despite a contractile
reserve, SB203580 does not improve contractile perfor-
mance. Once again these findings differ to those seen with
TNF. In the isolated heart perfused under constant pressure
conditions TNF reduces coronary flow and contractile per-
formance. These effects are attenuated by SB203580 or the
absence of MKK3. Similar, though less marked, findings are
seen under constant flow conditions and in isolated cardiac
myocytes. In combination these results suggest that both the
pattern and consequence of p38-MAPK activation may differ
by circumstance. If understood this allows the possibility of
circumstance specific inhibition of p38-MAPK to prevent the
detrimental, but perhaps not the beneficial, consequences of
p38-MAPK activation.
Abstract No S43D
P38MAPK – Role in myocardial mechanical and
metabolic function : modulation or mirage ?
Alexander S. Clanachan and Jagdip S. Jaswal University of
Alberta, Edmonton, Alberta, Canada
The p38MAPK cascade is activated by various stresses,
including ATP depletion, hypothermia-rewarming and
ischemia-reperfusion. In order to assess the role of
p38MAPK in stress-induced alterations in myocardial me-
chanical and metabolic function, we have studied the conse-
quences of its activation in isolated working rat hearts per-
fused with Krebs solution containing palmitate (1.2 mM),
glucose (11 mM) and insulin (100 mU/L).
Activation of p38MAPK (assessed by phospho-specific
immunoblot analysis and MAPKAPK2 activity) in hearts
that are subjected to cardioplegia (St Thomas’ II, 3 oC),
hypothermic storage (8 hr, 3 oC) and rewarming (10 min,
37 oC) is associated with an impaired recovery of mechanical
function during a subsequent period of normothermic reper-
fusion. The p38MAPK inhibitor, SB202190 (10 µM), when
present during normothermic reperfusion, greatly improves
recovery of mechanical function. Inhibition of p38MAPK by
SB202190 in reperfused hearts was confirmed by inhibition
of MAPKAPK2 activation. Thus, p38MAPK activation
worsens recovery of mechanical function of hearts following
prolonged hypothermia.
As p38MAPK is activated by ischemia and ATP depletion,
it may also act as an energy sensor that regulates substrate
metabolism. Activation of p38MAPK by adenosine in hearts
perfused aerobically following transient (2 x 10 min) is-
chemia is accompanied by a stimulation of AMPK phospho-
rylation and AMPK activity as well as an acceleration of
glycolysis and H+ production from glucose metabolism. This
stimulation of p38MAPK and AMPK, which occurs in the
absence of ischemia, did not affect rates of fatty acid oxida-
tion or glucose uptake. The ability of either SB202190
(10 µM) or SB203580 (10 µM) to prevent the adenosine-
induced increase in AMPK phosphorylation, as well as the
downstream acceleration of glycolysis, suggests that
p38MAPK lies upstream of AMPK in a signaling cascade
that regulates myocardial glucose metabolism.
Abstract No S43E
Therapeutic potential of p38 mapk inhibition in
cardiovascular disease
Henry Krum, NHMRC Centre of Clinical Research
Excellence in Therapeutics, Monash University, Melbourne,
Australia
p38 mitogen-activated protein kinase (MAPK) is acti-
vated in cardiac cells by a range of extracellular stimuli
including ischemia, hemodynamic stress and neurohormonal
factors such as angiotensin II, endothelin and phenylephrine.
In vitro, p38 MAPK may regulate myocyte apoptosis and
hypertrophy, inflammation and fibroblast proliferation.
Sustained p38 MAPK activation in the heart has been
associated with LV remodeling and dysfunction arising from
various etiologies in both humans and in animal models.
Cardiac myocyte-specific activation of p38 in transgenic
mice results in LV remodeling marked by interstitial fibrosis,
myocyte hypertrophy, systolic and diastolic dysfunction and
ultimately premature death. p38 MAPK activation is also
implicated in hypertensive cardiac hypertrophy and end-
organ damage in spontaneously-hypertensive stroke-prone
rats maintained on a high salt/high fat diet.
Our group has demonstrated highly significant beneficial
effects of the specific p38 MAPK a/b inhibitor RWJ
67657 on cardiac hemodynamics and echocardiographic pa-
rameters of LV remodeling following MI in the rat. These
benefits on LV structure and function were associated with
increased hypertrophy of myocytes in the peri-infarct and the
non-infarct zones, and reduced myocardial collagen and
a-smooth muscle actin (aSMA) immunoreactivity. In addi-
tion, RWJ 67657 protected cultured myocytes from apopto-
sis induced by hydrogen peroxide.
Taken together, these data support a key role for
p38 MAPK in pathological cell signaling in these processes
and its inhibition as a potential novel therapeutic strategy in
these settings.
Abstract No S44A
Molecular mechanism of myocardial angiogenesis
Nilanjana Maulik, University of Commenticut Medical
Centre, USA
Angiogenic therapy for the human heart is currently being
vigorously pursued. In the past ten years, alternative
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revascularization/ angiogenesis strategies have, progressed
from bench to bedside, focusing on the capillary sprouting
and/or growth of new vessels to replace the old. The results of
our study documented that ischemic preconditioning (IP) can
possess angiogenic potential and can improve myocardial
blood flow and cardiac function followed by severe ischemic
myocardial injury. Therefore, myocardial adaptation to inter-
mittent ischemia appears to be a highly promising approach
to induce angiogenesis in a rat model of myocardial infarc-
tion as evidenced by increased capillary and arteriolar den-
sity. This increased micro vascular growth was found to be
associated with a reduced infarct size and significant preser-
vation of contractile functional reserve. Pharmacological
cardiac stress testing with dobutamine revealed differences
in the extent of cardiac contractile reserve between ischemic
preconditioned (IPMI) and non-preconditioned (CMI) myo-
cardium subjected to myocardial infarction (MI). The IPMI
displayed significantly elevated contractile reserve compared
to CMI. In the present study IP triggered significant expres-
sion of VEGF and increased perfused capillary density along
with increased blood flow. In summary, we observed signifi-
cant improvements in regional myocardial function along
with increased capillary and arteriolar density following in-
duction of survival factors VEGF, Bcl2 and survivin in the
setting of fully established chronic rat myocardial infarction
model subjected to ischemic preconditioning. Again, tran-
sient suppression of Src activity within several days follow-
ing MI might reduce ischemia induced heart injury and
prevent long-term myocardial damage without disrupting
VEGF-mediated revascularization. Thus, co-administration
of or sequential gene therapy with VEGF, Bcl2 and survivin
might prove beneficial to enhance myocardial collateral
blood vessel function and may represent a new approach to
the treatment of cardiovascular disease.
Abstract No S44B
Endothelial progenitor cells for vascular regeneration
Takayuki Asahara MD, PhD, 1Kobe Institute of Biomedical
Research and Innovation 2Tokai University School of
Medicine
The regenerative potential of stem cells has recently been
under intense investigation. In vitro, stem and progenitor
cells possess the capability of self-renewal and differentia-
tion into organ-specific cell types. In vivo, transplantation of
these cells may reconstitute organ systems, as shown in
animal models of diseases. In contrast, differentiated cells do
not exhibit such characteristics. Human endothelial progeni-
tor cells (EPCs) have been isolated from the peripheral blood
of adult individuals, expanded in-vitro and committed into an
endothelial lineage in culture. The transplantation of these
human EPCs has been shown to facilitate successful salvage
of limb vasculature and perfusion in athymic nude mice with
severe hindlimb ischemia, while differentiated endothelial
cells (human microvascular endothelial cells) failed to ac-
complish limb-saving neovascularization.
Future studies will clarify the mechanisms and circum-
stances that may be responsible for modulating the contribu-
tion of vasculogenesis to postnatal neovascularization. Spe-
cifically in this regard, it is intriguing to consider the
possibility that certain angiogenic growth factors which are
acknowledged to promote both angiogenesis and vasculo-
genesis in the embryo, but have been assumed to promote
neovascularization exclusively by angiogenesis in the adult,
may in fact promote migration, proliferation, and mobiliza-
tion of EPCs from BM. The possibility that modulation of
vasculogenesis can be used therapeutically to augment as
well as inhibit neovascularization deserves further investiga-
tion.
Abstract No S44C
Cell transplantation to improve heart function : cells or
matrix ?
Ren-Ke Li, MD, PhD, Toronto General Hospital, Toronto,
Canada
Current attempts to regenerate the damaged myocardium
after myocardial infarction have focused on therapies di-
rected at increasing regional perfusion and salvaging viable
cardiomyocytes. Accumulating evidence suggests that im-
plantation of healthy muscle cells into the damaged myocar-
dium can prevent infarct thinning and chamber dilatation.
Cell transplantation has been suggested to encourage the
recruitment of stem cells from the bone marrow or from the
heart to repopulate the infarct region. These neo-myogenic
cells in the myocardial scar tissue prevent ventricular dilata-
tion and delay the onset of cardiac dysfunction. Early clinical
trials suggest encouraging results for cellular cardiomyo-
plasty. Although the beneficial effects of cell therapy for
myocardial regeneration after an infarction have led to phase
I clinical trials, the mechanism of benefit of this novel
therapy has not been elucidated. Stimulating neo-vessel for-
mation and engraftment of muscle cells within the scar may
contribute to the enhanced regional and global function.
However, the number of the cells, which survived implanta-
tion, is too small to account for the functional benefit. The
number of surviving cells may not be enough to replace the
cells lost during the infarction. An alternate explanation for
the benefit of cell transplantation may be the effect of the
engrafted cells on matrix remodeling. The extracellular ma-
trix plays an important role in the response to the infarction.
Disruption of the matrix network may contribute to the apo-
ptosis of cardiomyocytes leading to chamber dilation. Cell
transplantation may prevent infarct thinning and cardiac dila-
tation by altering the matrix response to infarction. We im-
planted smooth muscle cells into the heart and found that the
cells survived and altered matrix remodeling both within and
remote from the region of implantation. Matrix metallopro-
teinase activity decreased in the transplanted group as com-
pared to a control group. The matrix structure was main-
tained and ventricular dilatation was prevented. These data
suggest that implanted cells prevented ventricular dilatation
through an alteration of matrix metabolism, which is a pos-
sible mechanism by which cell transplantation improves
heart function.
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Abstract No S44D
Arteriogenesis – Haemodynamic and Cellular Aspects
Matthias Heil and Wolfgang Schaper, Max-Planck-Institute
for Physiological and Clinical Research- Dept. Of
Experimental Cardiology ; Benekestr. 2, 61231 Bad
Nauheim, Germany
Growth of collateral blood vessels is potentially able to
preserve structure and a variable degree of function in sub-
tended tissues in the presence of arterial occlusions. The
process of transformation of a small arteriole into a much
larger conductance artery is called arteriogenesis. Physical
forces are important triggers of arteriogenesis : Fluid shear
stress on the collateral endothelium markedly increases when
due to arterial occlusion a pressure gradient develops be-
tween the proximal and the distal end of a pre-existing
interconnecting anastomosis. This potentially activates en-
dothelial cells, reflected in the release of cytokines and
expression of adhesion molecules, and leads to monocyte
adhesion and infiltration. We could demonstrate that arterio-
genesis is enhanced by local delivery of the monocyte
chemoattractant MCP-1 and the MCP-1-CCR2-pathway
plays an essential role during the early phase of arteriogen-
esis. Within the perivascular space, monocytes subsequently
differentiate into macrophages with the production of growth
factors and proteases. Thereby, the second phase of arterio-
genesis is initiated which is stamped by induction of cell
proliferation and remodelling processes.The role of stem or
progenitor cells for arteriogenesis is currently under inten-
sive investigation. Increasing evidence is gained showing
that the paracrine function of bone marrow-derived cells like
release of arteriogenic growth factors, chemokines and pro-
teases is a pre-requisite for arteriogensis rather than their
incorporation into structures of the growing collateral vessel.
Abstract No S44E
Regulation of coronary vascular branching : role of
FGF2 and synectin
Thomas Chittenden, Ebo DeMuinck, Robert Palac, Eduard
Dedkov, Robert Tomanek and Michael Simons Dartmouth
Medical School and University of Iowa, USA
Fibroblast growth factors (FGF) have long been consid-
ered as key regulators of vascular branching. However, the
molecular mechanism of FGF1 and FGF2-dependent regula-
tion of branching are not well understood. Previously we
have demonstrated that syndecan-4 plays a major role in
FGf2 signaling. Synectin was isolated as a cytoplasmic part-
ner of syndecan-4 using yeast two hybrid screening. To elu-
cidate function of synectin (PDZ2 scaffold protein) in vivo,
we have generated synectin-/- mice. The synectin-/- mice are
viable, but are significantly smaller than wild type controls
(Table). Coronary angiography demonstrated reduced
branching of epicardial coronary arteries in the synectin-/-
mice compared to wild type (WT). To further address the
issues of intramural arterial branching, ventricular cross-
sections from the WT and synectin-/- mice were stained with
anti-alpha-smooth muscle actin antibody. The volume (Vv)
and surface (Sv) density of total alpha smooth muscle actin
positive profiles were measured per whole cross sections of
left ventricle. In agreement with angiography, quantification
of vascular density parameters demonstrated a significant
reduction in vascular density in synectin-/- mice. To assess
the impact of this reduced vascularity on myocardial func-
tion, left ventricular (LV) fractional shortening was exam-
ined using 2-D echocardiography. We observed a significant
reduction in LV function at rest. In conclusion, synectin gene
disruption results in reduced formation of myocardial coro-
nary arteries, decreased heart size and impaired left ventricu-
lar function. These results suggest that synectin could play an
important role in arterial branching.
synectin-/- WT Pvalue
Body weight (g) 16.7 ± 1.3 19.9 ± 0.5 0.03
Heart/body wt ratio 0.41 ± 0.05 0.53 ± 0.02 0.03
Vv (%) 0.57 ± 0.02 0.87 ± 0.06 0.01
Sv (%) 0.13 ± 0.01 0.17 ± 0.003 0.01
Fractional shortening (%) 56.8 ± 4.2 66.9 ± 1.8 0.04
Abstract No S45A
Regulation of coronary vascular branching : role of
FGF2 and synectin
Thomas Chittenden, Ebo DeMuinck, Robert Palac, Eduard
Dedkov, Robert Tomanek and Michael Simons Dartmouth
Medical School and University of Iowa, USA
Fibroblast growth factors (FGF) have long been consid-
ered as key regulators of vascular branching. However, the
molecular mechanism of FGF1 and FGF2-dependent regula-
tion of branching are not well understood. Previously we
have demonstrated that syndecan-4 plays a major role in
FGf2 signaling. Synectin was isolated as a cytoplasmic part-
ner of syndecan-4 using yeast two hybrid screening. To elu-
cidate function of synectin (PDZ2 scaffold protein) in vivo,
we have generated synectin-/- mice. The synectin-/- mice are
viable, but are significantly smaller than wild type controls
(Table). Coronary angiography demonstrated reduced
branching of epicardial coronary arteries in the synectin-/-
mice compared to wild type (WT). To further address the
issues of intramural arterial branching, ventricular cross-
sections from the WT and synectin-/- mice were stained with
anti-alpha-smooth muscle actin antibody. The volume (Vv)
and surface (Sv) density of total alpha smooth muscle actin
positive profiles were measured per whole cross sections of
left ventricle. In agreement with angiography, quantification
of vascular density parameters demonstrated a significant
reduction in vascular density in synectin-/- mice. To assess
the impact of this reduced vascularity on myocardial func-
tion, left ventricular (LV) fractional shortening was exam-
ined using 2-D echocardiography. We observed a significant
reduction in LV function at rest. In conclusion, synectin gene
disruption results in reduced formation of myocardial coro-
nary arteries, decreased heart size and impaired left ventricu-
lar function. These results suggest that synectin could play an
important role in arterial branching
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synectin-/- WT Pvalue
Body weight (g) 16.7 ± 1.3 19.9 ± 0.5 0.03
Heart/body wt ratio 0.41 ± 0.05 0.53 ± 0.02 0.03
Vv (%) 0.57 ± 0.02 0.87 ± 0.06 0.01
Sv (%) 0.13 ± 0.01 0.17 ± 0.003 0.01
Fractional shortening (%) 56.8 ± 4.2 66.9 ± 1.8 0.04
Abstract No S45B
The importance of metabolic substrates and
antioxidants in myocardial protection during cardiac
surgery
Franklin Rosenfeldt, Cardiac Surgical Research Unit, Alfred
Hospital, Baker Institute, and Monash University,
Melbourne, Australia
Myocardial energy production is a major determinant of
the outcome of cardiac surgery. Cardiac surgery involves
multiple stresses to the myocardium that impair energy pro-
duction : ischaemia/reperfusion, hypoxia/re-oxygenation
(oxidative stress) and aerobic (oxygen-demanding) stress.
These are commonly exacerbated by preoperative myocar-
dial impairment due to heart failure, infarction and old age.
Myocardial energy metabolism is enhanced by substrates
given at the time of surgery, aspartate, glutamate, TCA cycle
intermediates etc. A promising form of energy enhancement
is myocardial metabolic conditioning given preoperatively.
We and others have shown that energy production can be
enhanced and oxidative stress reduced, particularly at a mito-
chondrial level and in the elderly myocardium, by preopera-
tive use of coenzyme Q10, orotic acid and glucose insulin
potassium. Further reductions in oxidative stress can be
achieved by intraoperative leukocyte depletion. We have re-
cently combined in the preoperative period, metabolic and
antioxidant-mediated conditioning with holistic therapy us-
ing physical exercise and mental stress reduction. These
measures can be augmented by postoperative use of glucose-
insulin-potassium. Such simple and inexpensive multimo-
dality approaches can markedly enhance myocardial energy
metabolism and improve postoperative recovery particularly
in the elderly and energy- depleted myocardium.
Abstract No S45C
The Vascular endothelium as a therapeutic target for
surgical myocardial protection
Jakob Vinten-Johansen, Ph.D. FAHA, Division of
Cardiothoracic Surgery and Dept of Physiology ; Director,
The Cardiothoracic Research Laboratory ; Emory
University, Atlanta, Georgia USA
The coronary vascular endothelium is a major player in
regulation of blood flow, blood pressure, coagulation and the
inflammatory response. The pathogenesis of myocardial inf-
arction involves a well-scripted response by inflammatory
cells interacting with endothelium « primed » by ischemia
and activated by reperfusion, via the various mediators gen-
erated by this interaction, such as oxidants, pro-inflammatory
cytokines and proteases. This inflammatory response to myo-
cardial ischemia and reperfusion involving the endothelium
is exacerbated by extracorporeal circulation used in coronary
artery bypass surgery. Both regional ischemia and global
ischemia during cardioplegic arrest damage the endothe-
lium ; this damage is not avoided by use of cardioplegia
solutions without specific vasculoprotective additives.
Endothelium-specific, as well as broader spectrum anti-
inflammatory, therapeutic strategies that attenuate this endot-
helial damage have been developed for cardiac surgery.
Therapy such as adenosine, nitric oxide and its precursors,
inhibitors of adhesion molecules, and inhibitors of
endothelin-1 have proven of benefit in reducing the general-
ized inflammatory response to on-pump cardiac surgery and
the associated pathogenesis of myocardial infarction and
apoptosis after acute ischemia. Promising therapies to at-
tenuate endothelial dysfunction include insulin, cytokine in-
hibitors (TNFa inhibition), inhibitors of transcription fac-
tors, neutrophil inhibitors, and protease inhibitors. These
agents can be delivered either systemically or selectively to
the heart in the cardioplegic solution used to arrest the heart.
Therefore, the endothelium is far from being a pedestrian
« cellophane » wrapper for the myocardial vasculature, but
its central role in the pathogenesis of ischemia-reperfusion
injury during cardiac surgery offers the opportunity to target
a central mechanism of injury. Therefore, the cardioprotec-
tive armamentarium and cardioplegic solution formulation
should incorporate strategies to specifically protect the vas-
cular endothelium and inhibit its contributions to the
inflammatory/oxidant response to surgical ischemia-
reperfusion injury.
Abstract No S45D
Mitochondria as a target for myocardial protection
Andrew P. Halestrap, Department of Biochemistry,
University of Bristol, UK
Reperfusion of the ischemic heart causes opening of a
non-specific pore in the inner mitochondrial membrane,
known as the permeability transition pore (MPTP). This
causes mitochondria to become uncoupled and capable of
hydrolysing rather than synthesising ATP. Unrestrained, this
will lead to loss of ionic homeostasis and ultimately necrotic
cell death. Thus MPTP opening probably represents a critical
phase in the transition between reversible and irreversible
reperfusion injury. In support of this, we have demomstrated
that functional recovery of the Langendorff-perfused heart
from ischaemia inversely correlates with the extent of MPTP
opening. Furthermore, hearts are protected from reperfusion
injury by inhibiting the MPTP, either directly using the spe-
cific inhibitors Cyclosporin A and Sanglifehrin A, or indi-
rectly by decreasing reactive oxygen species (ROS) and
calcium loading (key inducers of pore opening) or by lower-
ing pHi. Pyruvate and propofol protect in this way and have
been shown to be effective in both the Langendorff and
working rat heart and in a pig model of reperfusion injury
that closely parallels routine open heart surgery. We have
shown that ischemic preconditioning (IPC) also leads to
inhibition of the MPTP, but this effect is indirect and prob-
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ably secondary to changes in calcium loading and ROS
production. Mitochondrial KATP channels (mitoKATP) have
been implicated in IPC, but our data suggest that the channel
openers and blockers routinelu used to support this hypoth-
esis, such as diazoxide and 5-hyroxy-decanoate, act through
other mechanisms independent of the putative mitoKATP.
Acknowledgements. – The numerous contributions of many col-
leagues and financial support from the British Heart Foundation are grate-
fully acknowledged.
Abstract No S45E
The endogenous cell defense : its possible role in
myocardial protection during cardiac surgery
Jarle Vaage, Dept of Surgery, Ulleval University Hospital,
Oslo, Norway
In experimental studies ischemic preconditioning inhibits
all aspects of ischemia-reperfusion injury : necrosis, apopto-
sis, cardiomyocyte and endothelial stunning, and arrhyth-
mias. In cardiac surgery preconditioning by short cycles of
clamping and declamping the aorta before cardioplegic arrest
increase cardiac index and reduce release of biochemical
markers of cardiomyocyte injury during the first 24 postop-
erative hours. Postoperative arrhythmias were also signifi-
cantly reduced. Unfortunately repeated clamping and dec-
lamping of the ascending aorta is not acceptable in routine
cardiac surgery due to the risk of atherosclerotic emboliza-
tion.
We have recently presented data that isolated heart from
rats and mice were preconditioned by the animals breathing
100 % oxygen for 30-60 minutes before heart harvesting.
The precondition was caused by oxidative stress and was as
powerful as ischemic preconditioning. Oxygen-induced
myocardial protection was dependent on the transcription
factor Nuclear factor kappa B, and it may easily be applied to
patients, but so far there are no such data.
A year ago the first paper appeared showing that short
episodes of ischemia and reperfusion in the first minutes of
reperfusion after a sustained ischemic injury, postcondition-
ing, was able to reduce the injury caused by ischemia and
reperfusion. Postconditioning reduced infarct size probably
by reducing oxidative injury. We have recently shown that
postconditioning is able to convert persistent ventricular fi-
brillation during reperfusion into regular beating.
If a pharmacological increase of the endogenous celle
defense is used, this is expected not only to protect the heart,
but may also cause a « whole body protection ». It is highly
unlikely that the exploitation of the endogenous cell defense
will not be a routine part of organ protection in the not so far
future.
Abstract No S46A
New insights into NHE regulation and function
Metin Avkiran. Centre for Cardiovascular Biology and
Medicine, King’s College London, The Rayne Institute, St
Thomas’ Hospital, London SE1 7EH, UK
The cardiac Na+/H+ exchanger (NHE) is a sarcolemmal
protein encoded by the NHE1 isoform of the multi-gene
NHE family. Based largely on experiments with selective
pharmacological inhibitors, NHE1 activity has been identi-
fied as a causal or permissive factor in the inotropic and
growth responses of myocardium to neurohormonal and me-
chanical stimuli, and in the development of myocardial in-
jury during ischemia and reperfusion and myocardial hyper-
trophy and remodeling during hemodynamic overload. Data
from recent clinical trials with cariporide, a selective NHE1
inhibitor, support an important role for NHE1 activity in
myocardial injury during ischemia and reperfusion in hu-
mans ; however, serious adverse effects preclude therapeutic
application of the treatment modality that was tested. Im-
proved understanding of the molecular signaling mecha-
nisms that regulate NHE1 activity in healthy and diseased
myocardium may lead to the development of new approaches
to its therapeutic manipulation. Recent studies in isolated
myocytes indicate that extracellular signal regulated kinases
1 and 2 (ERK1/2) and their downstream effector, the 90 kDa
ribosomal S6 kinase (p90RSK), play key roles in mediating
increased sarcolemmal NHE activity in response to diverse
stimuli, such as prolonged intracellular acidosis, stimulation
of G protein-coupled receptors, and oxidative stress. Investi-
gations are ongoing to determine the molecular mecha-
nism(s) of this regulation, including the roles of direct phos-
phorylation of the NHE1 regulatory domain at multiple sites
and altered interaction with accessory proteins.
Abstract No S46B
NHE in diabetes
D. Feuvray, A. Darmellah, D. Baetz, F. Prunier, S.
Tamareille, D. Mésangeau, CNRS UMR 8078 - Université
Paris-Sud XI, France
The cardiac sarcolemmal Na+-H+ exchanger (isoform-
1 of NHE) has recently gained considerable interest in the
context of myocardial damage. Previous studies have shown
that the streptozotocin-induced model of type-1 diabetes in
rats is associated with a decrease in NHE activity. However,
type-2 diabetes comprises the largest group of diabetic pa-
tients since it accounts for > 90 % of all cases of diabetes.
This led us to examine the activity of NHE in ventricular
myocytes from hearts of GK (Goto-Kakizaki) rats which
phenotype exhibits several typical features of metabolic,
hormonal and vascular disorders usually described in human
type-2 diabetes. Doppler echocardiography was used to as-
sess GK-diabetes alterations in cardiac phenotype in vivo.
The main results were a significantly increased LV mass and
LV dilation. Myocytes isolated from GK rat left ventricles
(LV), but not from right ventricles, exhibited significantly
greater sarcolemmal NHE activity (+ 100 %) than LV myo-
cytes isolated from control rats. This was not associated with
increased NHE1 protein expression but with upregulation of
the exchanger. In particular, this appeared to be mediated via
the MAPK(ERK)-dependent pathway since ERK phospho-
rylation was markedly increased in GK LV myocytes with
greater sarcolemmal NHE activity, an effect that was abol-
ished by the ERK inhibitor U0126, as was abolished the
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increase in NHE activity. However, an increase in basal
[Ca2 + ]i, as assessed by INDO measurements, may also con-
tribute to enhanced NHE activity. Altogether, our results
suggest a relationship between NHE activity and the devel-
opment of the hypertrophic process in LV myocardium of
type-2 diabetic GK rats.
Abstract No S46C
Role of NHE in myocardial remodelling and heart
failure
Morris Karmazyn, Dept of Physiology & Pharmacology,
University of Western Ontario, London, Ontario, Canada
Increasing evidence implicates NHE-1 as a candidate for
targeted intervention to attenuate the remodelling and hyper-
trophic processes contributing to heart failure (HF). NHE-
1 inhibitors including cariporide and EMD 87580 reduce
cardiomyocyte hypertrophy induced by various factors and
attenuate HF in vivo. With respect to the latter, this effect has
been shown to occur in various models of heart failure in-
cluding experimental myocardial infarction, hypertension as
well as in heart failure-prone transgenic mice overexpressing
Beta1 adrenergic receptors. Moreover, inhibiting NHE-
1 reverses the myocardial remodelling and HF processes
when treatment has been delayed by up to 6 weeks. The
beneficial effects of NHE-1 inhibition occurs independently
of either blood pressure lowering or infarct size reduction.
The cellular mechanisms for NHE-1 involvement remain to
be elucidated but it appears that NHE-1 is a downstream
mediator for numerous hypertrophic factors including angio-
tensin II, endothelin-1, aldosterone and alpha1 adrenoceptor
agonists and indeed NHE-1 blockade attenuates the hyper-
trophic effect of these agents. Thus, NHE-1 inhibition repre-
sents a potentially effective approach for reducing remodel-
ling and treating HF.
Abstract No S46D
Clinical trials with nhe inhibitors : where are we now
and where are we going ?
Robert M. Mentzer Jr., M.D., Department of Surgery,
University of Kentucky, USA
Since there is extensive preclinical evidence that sodium-
hydrogen exchange (NHE) inhibition is cardioprotective, the
purpose of this review is to examine the clinical findings to
date and develop an understanding regarding future direc-
tions. In an early study, Rupprecht et al randomized 100 pa-
tients to receive placebo or an NHE inhibitor (cariporide)
prior to reperfusion therapy for acute myocardial infarction
(AMI). The findings suggested that NHE inhibition might
result in enhanced functional recovery. In the first stage of the
ESCAMI trial, 433 patients were randomized to placebo or
low, intermediate, or high doses of eniporide prior to reper-
fusion therapy for AMI. In the second stage, 978 additional
patients were enrolled. While stage one results were encour-
aging, the stage two results failed to demonstrate a reduction
in infarct size or improved clinical outcomes. In the
GUARDIAN trial, 11,590 patients undergoing high-risk per-
cutaneous coronary intervention and coronary artery bypass
grafting (CABG) surgery were randomized to receive a pla-
cebo or one of three doses of cariporide. While GUARDIAN
failed to demonstrate an overall reduction in MI/death, a
subgroup analysis showed a 25 % relative risk reduction
(RRR) at 36 days in patients undergoing CABG surgery
(P = 0.027). In the EXPEDITION trial, 5761 patients were
randomized to receive cariporide or placebo. At 5 days, the
results showed an 18.3 % RRR in MI/death (P = 0.0003) and
a 23.8 % RRR in nonfatal MI (P = 0.000005). This finding
was offset by the observation of an imbalance in mortality
that favored cariporide (2.2 % versus 1.5 %, P = 0.028). Fu-
ture studies need to be directed towards whether it is possible
to dissociate the adverse effects from the beneficial effects of
cariporide and whether the adverse effects associated with
cariporide treatment is dose related, unique to cariporide, or a
manifestation of NHE inhibitors in general.
Abstract No S47B
The context of cvd among indigenous australians
ADH Brown, Menzies School of Health Research ; Inst. of
Advanced Studies, Charles Darwin University, Australia
CVD is the major cause of death of adults in Australia and
the biggest cause of deaths and of excess deaths for the
Aboriginal population of Australia. Age-adjusted CVD death
rates in Aboriginal people are almost 3 times as high as in the
non-Aboriginal population and age specific mortality differ-
entials are much greater between the ages of 25-54, where
Aboriginal deaths rates are 7-12 times that of non-
Aboriginals. Most developed countries have witnessed dra-
matic declines in ASDR’s from CVD. Yet these improve-
ments have not been witnessed equally among all population
groups. Transition from traditional to ‘Western’ lifestyles are
an important antecedent to an increase in prevalence of con-
ventional risk factors, and subsequent high rates of CVD,
renal impairment, impaired glucose tolerance and diabetes
among a number of Indigenous groups globally. Conven-
tional risk factors have an important role to play in explaining
differentials in CVD burdens. There is also interest in a
growing list of ‘novel’ risk factors (including homocysteine
and C-reactive protein) which have been shown to be at high
levels in a range of Aboriginal communities. The contribu-
tion of these factors to the burden of CVD in Indigenous
Australians is yet to be demonstrated. There are many barri-
ers to care for Aboriginal clients with established CVD.
Access to specialists, diagnostics and acute care is limited in
remote/regional areas where large Aboriginal groups reside.
Even when facilities are available, Aboriginal people are less
likely than non-Aboriginal people to receive cardiac proce-
dures. Aboriginal Australians utilise a range of health care
services differently, dominated by publicly provided ser-
vices, with under-utilization of Pharmaceutical, Medicare,
specialist and GP consultations. Numerous studies have also
confirmed that ‘psychosocial stress’ has important associa-
tions with CHD. The determinants of health among Aborigi-
nal Australians include poor housing, income inequality,
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poverty, low levels of education, poor environmental condi-
tions, high levels of stress and social dysfunction. Further,
the loss of land, culture, language and identity, racism, pre-
mature death, grieving, pain and loss have long been high-
lighted as fundamental causes of ill health. Through what
bio-psycho-social pathways these factors incur risk of CHD
and whether they contribute or account for the excess burden
of CVD among Indigenous population groups remains to be
qualified or quantified. Understanding the complex interac-
tive hierarchy of CVD aetiology and the large and expanding
CVD differentials experienced by Aboriginal Australians
stands as a critical target for future research, from the cell to
the community, and for clinical, public health, and health
service policy development.
Abstract No S47C
Cardiomyopathies in the tropics
CC.Kartha, Sree Chitra Tirunal Institute for Medical
Sciences and Technology, Trivandrum, Kerala, India
Cardiovascular diseases (CVDs) prevalent commonly in
the tropics are no different from those in the non-tropical
regions. Nevertheless, there are CVDs, which are almost
exclusively seen in the tropical countries. Cardiomyopathies
among them offer diagnostic and therapeutic challenges to
the inexperienced. Their pathogenic mechanisms are elusive
and for several of them causal factors are enigmatic. Differ-
ences in the diet, lack of nutritional essential elements, tradi-
tionally used local medicines, poisonous plants, parasites and
viruses endemic in tropical environs, have all been incrimi-
nated as causes for the difference in the epidemiologic pat-
tern of cardiomyopathies. Technological advances and avail-
ability of powerful diagnostic techniques in the last five
decades have led to a better understanding of the clinical
features and natural history of the tropical cardiomyopathies.
Causes and pathogenic mechanisms of some of them have
been identified. Much is now known about the immuno-
pathogenesis and genetic susceptibility in Chaga’s cardiomy-
opathy secondary to Trypanasoma Cruzi infection. En-
domyocardial fibrosis (EMF) has been clinically well
characterized and extensively investigated. Investigators in
Kerala have linked its causation to geochemical factors, spe-
cifically higher content of cerium, a lanthanide in the mona-
zite sands of coastal regions in Kerala. While divergent views
on causation of EMF persist, a common mechanism has been
proposed for pathogenesis of the lesions in the disease ;
endocardial endothelial injury leads to subendocardial fibro-
blast activation and collagen accumulation. In the next de-
cade, it is hoped that specific genetic and molecular basis of
cardiomyopathies in the tropics would be defined leading to
definitive information on causation and mechanisms.
Abstract No S47D
Alternative treatments for ventricular tachyarrhythmia
in developing countries
K.K. Talwar, R. Juneja, N. Naik, R. Yadav, M. Rohit.
Department of Cardiology, PGIMER, Chandigrah &
AIIMS, New Delhi, India
It is estimated than 50 % of the cardiac deaths are sudden,
and most result from ventricular tachyarrhythmia (VT). Im-
plantable cardioverter defibrillator (ICD) has improved in
both primary and secondary prevention trails ; it still remains
a costly and unaffordable modality for most of the needy
patients in developing countries. Optimized drug therapy and
radiofrequency catheter ablation could offer cost effective
alternative to ICD in developing countries. Currently the
conventional catheter ablation technique is mostly adjunctive
to drugs and ICD. Refinements in ablation techniques have
extended the indications of catheter-based ablation of VT,
especially with the use of CARTO and ENSITE. These tech-
niques are still evolving, and a combination of drugs and
radiofrequency ablation may prove to be an affordable alter-
native. The short-term experience of combined RFA using
CARTO and drugs in 10 such cases will be presented
Abstract No S47E
TTK-Chitra prosthetic heart valve for mitral
replacement
G.S.Bhuvaneshwar, Sree Chitra Tirunal Institute for
Medical Sciences and Technology, Trivandrum, India
Rheumatic heart disease is still a major cause for mitral
valve replacement in India and other developing countries. In
1981, it was estimated that 1.2 million children were at risk
of acquiring rheumatic disease in India – mostly from the
low socio-economic groups.
A project was initiated in the late 70’s for the development
of a low cost Indian valve ; at a time when little expertise and
facilities for biomedical research existed in the country. Just
like others, this project group had to go through a series of
3 failures, before a successful valve could be put into clinical
use. The tilting disc TTK-Chitra Heart Valve is made of an
integrally machined cobalt alloy cage, an ultra-high molecu-
lar weight polyethylene disc occluder and a polyester sewing
ring. The development included extensive in-vitro and in-
vivo preclinical evaluation in a sheep model. Between De-
cember 1990 and January 1995, 205 patients underwent iso-
lated mitral valve replacement in 6 institutions. 191 patients
were followed till September 1998 for a total of 767 patient
years. Twelve patients (1.6 %/py) developed valve thrombo-
sis, while embolic episodes occurred in 18 cases (2.4 %/py).
Other complications like bleeding, infective endocarditis,
paravalvular leak or structural dysfunction were negligible or
absent. Actuarial survival rates at 7 years and freedom from
the valve related complications were comparable to other
tilting disc models. Current clinical results indicate favour-
able performance even in poorly anti-coagulated patient
groups ; possibly as a result of it’s unique features like low
impact forces and absence of cavitation.
Abstract No S47F
Cardiovascular system in a problem-based curriculum
at the arabian gulf university
Pallab K. Ganguly, Professor and Chairman, Dept. of
Anatomy, Arabian Gulf University, Manama, Kingdom of
Bahrain
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The College of Medicine and Medical Sciences at the
Arabian Gulf University (AGU) adopted a problem-based
learning (PBL), student-centered curriculum since its estab-
lishment in 1982. The cardiovascular system (CVS) is stud-
ied, together with the respiratory system (Unit II) during the
pre-clerkship phase. Teaching and learning are carried out
through an integrated organ-system process with the faculty
members acting as facilitators to small group students. The
health problems cover the general themes such as function of
the heart as a pump including valves, development of the
heart and great vessels, coronary circulation, cardiac electri-
cal impulse generation and conduction and hemodynamics.
The Unit committee chooses the appropriate problems that
address not only the above themes/objectives but also pro-
vide the basis for important pathological processes and phar-
macological principles of treatment. The students learn labo-
ratory and professional skills as well as community medicine
such as burden of illness, risk factors, screening and health
education. Emphasis is given in students’ assessment to criti-
cal thinking, reasoning and problem solving. Since monitor-
ing and evaluation of a curriculum is considered integral to
fine-tuning and improvement of an educational system, stu-
dents’ perception of teaching cardiovascular system is con-
tinuously sought in order to identify where improvements
can be made. While some gaps are already identified, it is
generally believed that problem-based approach practised at
AGU is considered an interesting method to study cardiovas-
cular system.
Abstract No S48A
Exercise training for heart failure patients : factors
affecting mortality and morbidity and predicted
response to exercise training
Neil A Smart and Thomas H Marwick, Dept of Medicine,
PA Hospital, The University of Queensland, Brisbane,
Australia
Exercise training improves functional capacity and qual-
ity of life in CHF patients. Uncertainty about a survival
benefit, safety and availability of resources have prevented
optimal use of exercise therapy in this patients group.
Aims. – 1. Identify optimal form of delivery ; 2. Define
survival benefit. 3. Examine safety and efficacy. 4. Identify
sub-groups that benefit most. 5. Predict, from baseline data,
which patients will benefit, thus preventing unnecessary pa-
tient risk/discomfort and wasted resources.
Methods. – 1. A systematic review of 81 CHF exercise
training studies up to August 2003 was conducted. 2. Data
added from Piepoli, BMJ Dec 2003 of individual patient data
from 9 RCT studies. 3. A 16 week mechanistic study of
exercise training in CHF patients (EF < 35 %) was con-
ducted.
Results. – The review demonstrated mean increment in
Peak VO2 of 17 %. Both the review and analysis re-
ported > 80 % male subjects, predominantly middle aged \\
126\\60 yrs, LVEF\\ 126\\27 % and approximately 60 % is-
chemic. Only the meta-analysis was sufficiently precise to
produce a significant survival effect and a reduction in com-
posite end-points of deaths (p = 0.015, 95 % CI 0.46-0.92)
and hospitalizations (p = 0.011, 95 % CI 0.56-0.93), al-
though the review also suggests a survival benefit. There was
a hint that sub-groups such as age > 60yrs, LVEF < 27 %,
ischemic, Peak VO2 < 15ml/kg/min, NYHA Class III/IV and
exercise training duration > 28 weeks were more likely to
respond to training, although composite analyses were not
significant. No deaths were directly attributable to exercise in
over 60,000 pt/hours of exercise and one non-fatal, adverse
event can be expected every 3,300 pt/hours of training. In the
mechanistic study at 8 weeks, peak VO2 increased by 8.8 %
(12.4 ± 4.6 vs 13.5 ± 4.2, p = 0.26), and at 16 weeks, peak
VO2 increased by 26 % (12.4 ± 4.6 vs 15.0 ± 4.9, p < 0.001).
Change in peak VO2 at 16 weeks was associated with base-
line myocardial strain and strain rate. Change in 16 week
peak VO2 was predicted by baseline strain, baseline peak
VO2 and the absence of diabetes (r
2 = 0.56 ; p < 0.001), and
prediction was improved by inclusion of change of peak VO2
at 8 weeks in the model (r2 = 0.76, p < 0.001). Moreover,
myocardial parameters rather than LVEF and volumes were
altered by training in this study ; change in 16-week peak
systolic strain was predicted by baseline diastolic tissue ve-
locity and strain.
Conclusions. – Exercise training is safe and effective,
there is good evidence of a survival and morbidity benefit.
Sub-group analysis provided only limited evidence of who
will benefit most. Changes in functional capacity following
16 weeks exercise training may be predicted by baseline and
8-week functional capacity, and myocardial strain.
Abstract No S48B
Exercise, antioxidant supplementation and
cardioprotection
Jeff S. Coombes, School of Human Movement Studies,
University of Queensland, St Lucia, QLD, 4072
During exercise, skeletal muscle increases oxygen utilisa-
tion resulting in a potential source of oxidative stress. El-
evated oxidative stress has been implicated in the pathogen-
esis of cardiovascular disease with epidemiological data
reporting that individuals involved in large amounts of physi-
cal activity have higher rates of mortality. Antioxidant sys-
tems protect against exercise-induced oxidative stress how-
ever it is currently unclear whether exercising individuals
may benefit from supplementing the diet with additional
antioxidants. This presentation will summarise literature
concerning the production of reactive intermediates during
exercise and the adaptations this may cause. Although the
health benefits of regular exercise are well-documented, evi-
dence supporting the notion that high levels of physical
activity may have a detrimental effect on health will be
evaluated. Finally, the effects of antioxidant supplementation
on the cardioprotection and performance of exercising indi-
viduals will be discussed.
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Abstract No S48C
Exercise training and endothelium-derived vasoactive
factors, endothelin and no
Seiji Maedaa and Takashi Miyauchib. aInstitute of Health
and Sport Sciences and bInstitute of Clinical Medicine,
University of Tsukuba, Japan
Vascular endothelial cells play an important role in the
regulation of vascular activity by producing vasoactive fac-
tors, e.g., endothelin-1 (ET-1) and nitric oxide (NO). ET-
1 has a potent vasoconstrictor effect and a potent proliferat-
ing activity on vascular smooth muscle cells ; therefore,
ET-1 has been implicated in the progression of hypertension
and/or atherosclerosis. On the other hand, NO has a potent
vasodilative effect and has been proposed as having antiath-
erosclerotic property ; therefore, NO has been implicated in
the prevention of progression of hypertension and/or athero-
sclerosis. We investigated the effects of exercise training on
the production of ET-1 and NO in humans and animals. We
revealed that aerobic exercise training causes a decrease in
plasma ET-1 concentration and an increase in plasma NO
concentration (measured as the stable end product of NO,
i.e., nitrite/nitrate [NOx]) in young and older humans. The
plasma ET-1 concentration increased with age, and exercise
training reduced aging-induced increase in plasma ET-
1 concentration in older humans. In older humans, aerobic
exercise training also reduced their blood pressure. Thus,
these changes in endogenous ET-1 and NO production by
exercise training may contribute to the exercise training-
induced decrease in risk of developing hypertension and
atherosclerosis. Furthermore, we revealed that the produc-
tion of endothelial NO synthase (eNOS) in the aorta is in-
creased by exercise training in aged rats. In conclusion,
exercise training has favorable effects on the production of
endothelium-derived vasoactive factors, i.e., ET-1 and NO,
to decrease cardiovascular risk (i.e., prevention of progres-
sion of hypertension and/or atherosclerosis).
Abstract No S48E
Functional genomics of the remodeling heart : profiling
the cardio-protective effect of prior exercise training
Kessler-Icekson G, Freimann S, Eldar M, Shahar I,
Kaminsky N, Izik-Radom S, Scheinowitz M. Tel-Aviv
University, Tel-Aviv, Israel
We have previously shown that prior swimming exercise
training improves the outcome of acute MI as manifested at
the remodeling phase by better heart function, reduced scar
size and increased arteriole density. To elucidate molecular
mechanisms underlying this outcome we conducted hight-
hroughput expression analysis. Rats underwent a 7-week
exercise training (Ex) or remained sedentary (Sed). At
7 weeks, animals were subjected to acute MI and were sacri-
ficed 4h, 2d or 4w thereafter (ExMI4h, ExMI2d, ExMI4w,
SedMI4h, SedMI2d, SedMI4w). RNA of the viable left ven-
tricle was analyzed by DNA-microarrays. Out of 3,686 de-
tected transcripts, 1542 were regulated ± 1.5-fold or more in
at least one group. Global analysis of the expression profiles
indicated that early after MI the impact of infarction on the
genes expressed is stronger than that of training. At 4 weeks,
however, the prior-exercised hearts differed markedly from
their non-exercised counterparts. Twelve clusters of co-
regulated genes were identified. Fibrosis-related genes
peaked earlier in ExMI than in SedMI hearts. The tensile
force-regulated collagen XII clustered with the load-
dependent atrial natriuretic peptide, both being markedly
enhanced in SedMI hearts during remodeling. Expression of
genes involved in aerobic energy metabolism remained
higher in the exercised hearts. It is concluded that exercise
training conducted prior to acute MI reprograms the heart for
better tolerance of MI injury, diminished remodeling and
ameliorated energy metabolism, all contributing to the im-
proved heart function.
Abstract No S49A
Dilated cardiomyopathy in alpha-1-adrenergic receptor
knockout mice
Paul Simpsona,b, Timothy O’Connellc, MC Rodrigoa,b,
Philip Swigartb, Shuji Johoa, Shinji Ishizakaa, Susanna
Cotecchiae, Gregg Rokoshd, Elyse Fostera, William
Grossmana. University of California San Francisco USAa,
VA Medical Center San Francisco USAb, University of
South Dakota USAc, University of Louisville Kentucky
USAd, University of Lausanne Switzerlande
In the ALLHAT clinical trial in hypertension, an a1-
adrenergic receptor (AR) antagonist increased heart failure,
but the mechanisms are uncertain. Knockout (KO) of the two
main a1-AR subtypes, the a1A and the a1B (the ABKO)
causes reduced heart growth during post-natal development,
without changing resting blood pressure (J Clin Invest 111 :
1783, 2003). Here we tested the response of the ABKO to the
stress of pressure overload. Transverse aortic constriction
(TAC) caused \\ 126\\50 % mortality in ABKO mice vs 0 %
in wild type (WT) mice. Death in the ABKO was due to heart
failure. By echo in awake mice, the ABKO had worse dilated
cardiomyopathy than WT, with larger LV volume and lower
ejection fraction. The ABKO cardiomyopathy was not
caused by impaired hypertrophy per se, since heart and
myocyte size increased after TAC the same as in WT mice.
However, the ABKO heart after TAC had (1) failure of fetal
gene induction ; (2) increased fibrosis ; and (3) increased
apoptosis. Interestingly, ABKO myocytes were predisposed
to apoptosis even before TAC. We conclude that the a1A and
a1B ARs are required for an adaptive response to cardiac
stress. These results provide a plausible biological basis for
the adverse effects of a1-AR antagonists in clinical trials.
Abstract No S49B
Cardiovascular and metabolic changes in mice lacking
the alpha1b-adrenergic receptor subtype
Susanna Cotecchia, Rémy Burcelin and Bernard Thorens.
Institut de Pharmacologie et Toxicologie, Lausanne,
Switzerland
Three a1-adrenergic receptors (AR) subtypes (a1a, a1b
and a1d) are present in different mammalian organs in which
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they mediate a variety of effects such as vasoconstriction,
glycogenolysis and a number of behavioural responses. To
investigate the role of different a1-AR subtypes in vivo, we
created a knock out mouse model lacking the a1b-AR (a1b-
/-). In the a1b-/- mice the number of a1-AR was decreased by
74 %, 98 % and 42 % in the heart, liver, and cerebral cortex,
respectively. The a1b-/- mice displayed a 45 % reduction in
blood pressure response to phenylephrine, suggesting that
the a1b-AR mediates a portion of the vasopressor effect of
catecholamines. This effect might, at least in part, involve its
control on the vascular tone. To investigate the potential role
of the a1b-AR on glucose homeostasis, several parameters
related to whole body glucose metabolism were measured in
the a1b-/- mice. The a1b-/- mice displayed high hepatic
glycogen stores in fed and fasted states, hyperinsulinemia in
the fasted state, hyperleptinemia, insulin-resistance as well
as higher sensitivity to high fat diet-induced obesity. Interest-
ingly, treatment with atropine or methyl-atropine could re-
vert the hyperinsulinemia of the a1b-/- mice to levels similar
to those of control mice. This was also associated with
increased levels of hypothalamic NPY mRNA. Finally, the
results of the glucose turnover experiments indicated that the
a1b-/- mice were insulin resistant. Altogether these findings
indicate that, in the absence of the a1b-AR, the parasympa-
thetic system and the expression of the hypothalamic NPY
are increased resulting in hyperinsulinemia and insulin resis-
tance as well as favouring obesity and glucose intolerance
during the high fat feeding.
Abstract No S49C
Hypertension and a1-adrenergic receptor subtype
Gozoh Tsujimoto, Department of Genomic Drug Discovery
Science, Graduate School of Pharmaceutical Sciences,
Kyoto University, Japan
To study the functional role of individual a1-AR subtypes
in blood pressure regulation and the development of hyper-
tension, we created mice lacking the a1B-AR and/or a1D-AR,
and studied hemodynamic and vasocontractile responses in
these mutant mice. Both the a1D-AR knockout and a1B-
/a1D-AR double knockout, but not the a1B-AR knockout
mice, had a significantly lower level of basal blood pressure
than wild type mice by monitoring blood pressure. All mu-
tants showed reduced catecholamine-induced pressor and
vasoconstriction responses. We further examined blood pres-
sure changes in wild type and the mutant mice, which were
subjected to subtotal nephrectomy and dietary salt loading.
After 35 days of salt loading, blood pressure of the a1B-AR
knockout mice increased to a comparable level to wild type
mice, while blood pressure changes of a1D-AR knockout and
a1B-/a1D-AR double knockout mice were significantly at-
tenuated, which is attributable to a combination of decreased
vascular responsiveness and lower sympathetic nerve activ-
ity. Our data indicated that deletion of the functional a1B-AR
gene did not lead to an anti-hypertensive effect in this model
and that a1D-AR played a critical role in the development of
salt induced hypertension, showing differential contributions
of a1B- and a1D-ARs to development of hypertension.
Abstract No S49D
The role of alpha 1-adrenergic receptor subtypes in
hypertropy, inotropy and ischemic preconditioning
Boyd R. Rorabaugh, Sean A. Ross, Mike Zuscik, June Yun,
Mike Piascik, Paul Simpson, and Dianne M. Perez.
GlaxoSmithKline, University of Rochester, NEOUCOM,
University of Kentucky, VA Med Ctr San Francisco, and
The Cleveland Clinic Foundation
Systemic transgenic expression of the a1-Adrenergic Re-
ceptor (AR) subtypes was used to determine subtype-specific
roles in cardiovascular functions. Transgenic mice overex-
pressing a constitutively active mutant (CAM) a1B-AR had
enlarged hearts and diastolic dysfunction but did not transi-
tion to failure. Microarray analysis indicated increased
growth-related genes involving Src-related signaling path-
ways and a large inflammatory response. Cardiac gene ex-
pression was decreased for common failure-associated pro-
teins. In isolated hearts, a1B-AR overexpression did not
increase inotropy, suggesting that this subtype is not a major
factor in contractility but caused downregulation of the a1a-
AR, which suppressed phenylephrine-induced inotropy.
Hearts isolated from normal, CAM a1A-ARs or CAM a1B-
ARs, were preconditioned followed by 30 min ischemia and
reperfusion. Ischemic preconditioning significantly en-
hanced the post-ischemic recovery of normal hearts. Hearts
expressing CAM a1A-ARs recovered completely from
30 min ischemia without undergoing the preconditioning
protocol. Thus, the a1A-AR transgenic hearts were inherently
preconditioned. However, expression of CAM a1B-ARs pro-
vided no protection against ischemic injury. These data sug-
gests that a1A-AR, but not the a1B-AR, mediate ischemic
preconditioning.
Abstract No S49E
Genetic enhancenment of ventricular contractility
protects against pressure – overload-induced cardiac
dysfunction
aXiao-Jun Du, bLin Fang, aXiao-Ming Gao, aHelen Kiriazis,
aXinheng Feng, aElodie Hotchkins, bBryony Mearns,
bAngela Finch, bRobert M Graham. aBaker Heart Research
Institute, Melbourne & bVictor Chang Cardiac Research
Institute, Sydney, Australia
Background. – In response to pressure-overload cardiac
function deteriorates and may either progress to fulminant
heart failure and death, or may be restored to normal by the
development of hypertrophy. Here we questioned if genetic
enhancement of left ventricular (LV) contractility protects
against pathological overload.
Methods and Results. – Transgenic (TG) mice with
cardiac-restricted overexpression (66-fold) of the a1A-
adrenergic receptor (AR) and their non-TG littermates, were
subjected to transverse aorta constriction (TAC)-induced
pressure-overload for 12 weeks. TAC-induced hypertrophy
was similar in the non-TG and TG mice but the TG mice with
TAC were less likely to die of heart failure compared to the
non-TG animals (P < 0.05). The hypercontractile phenotype
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of the TG mice was maintained over the 12-week period
following TAC with LV fractional shortening being better
preserved than in the non-TG mice (42 ± 2 vs 29 ± 1 %,
P < 0.01). In the TG animals, b-AR-blockade with atenolol
for 11 weeks neither induced hypertrophy nor suppressed the
hypercontractile phenotype.
Conclusions. – The hypertrophic response to pressure-
overload is not altered by cardiac a1A-AR overexpression.
Moreover, a1A-AR-mediated enhancement of LV contractil-
ity protects against pressure-overload-induced cardiac dec-
ompensation and death.
Abstract N° S5A
Signaling Mechanisms of Preconditioning
James Downey, University of South Alabama, Mobile,
Alabama USA
Current evidence indicates that ischemic precondition-
ing’s protection is triggered by receptor-dependent opening
of mitochondrial ATP-sensitive potassium channels (mKATP)
that cause the mitochondria to generate reactive oxygen
species (ROS). The ROS then act as second messengers to
activate downstream protein kinases, including PKC, that
mediate the protection during the index ischemia. The ROS
hypothesis explains why a period of reperfusion must follow
a preconditioning ischemia because that is when the ROS are
produced. Timing studies indeed show that the critical time
for mKATP opening is prior to rather than during the index
ischemia. By utilizing an isolated cardiomyocyte model in
which we monitor ROS production in response to receptor
stimulation we have been able to map out the signal transduc-
tion pathway between the muscarinic receptor and the
mKATP. Using the preconditioning mimetic acetylcholine we
find that population of the muscarinic receptors causes acti-
vation of a metalloprotienase that liberates heparin-binding
epidermal growth factor (HB-EGF) from a membrane-bound
pro-HB-EGF. Occupation of the EGF receptor then activates
PI3-kinase. The phospholipid product causes activation of
Akt. Akt then activates eNOS through phosphorylation. The
eNOS makes nitric oxide that causes guanylyl cyclase to
make cGMP that in turn activates protein kinase G (PKG)
resulting in mKATP opening and ROS production. While it
appears that any Gi- or Gq- coupled receptor in the heart
muscle cell can trigger the preconditioned state, only ago-
nists for the adenosine A1 and A3, the bradykinin B2 and the
delta opioid receptors are released during a preconditioning
ischemia. There is even diversity among these 3 receptors as
adenosine receptors bypass the mKATP/ROS pathway and
only the opioids utilize the EGF receptor. These multiple
parallel pathways provide many opportunities for pharmaco-
logical preconditioning.
Abstract N° S5B
G-protein coupled receptor cross-talk : implications for
preconditioning
Jason N. Peart & Garrett J. Gross. Medical College of
Wisconsin
Ischemic preconditioning (IPC) is multifactorial with
many potential triggers and mediators. Activation of G
protein-coupled receptors (GPCRs) such as adenosine,
bradykinin and opioid receptors appear to be essential to
triggering IPC. Growing evidence suggests that GPCR cross-
talk between beta-adrenoceptors, adenosine, opioid and en-
dothelin receptors regulates cardiovascular function under
both normal and pathophysiological conditions. GPCR
cross-talk is well documented, however, its role in IPC is not
known. We have previously demonstrated that adenosine and
opioid receptors exhibit cross-talk in a rat model of myocar-
dial infarction whereby infarct abrogation elicited by opioid
and adenosine receptor agonists is reversed by adenosine and
opioid antagonists, respectively. Furthermore, simultaneous
activation of both opioid and adenosine receptors failed to
provide an additive effect suggesting a converging pathway.
Interestingly, in an isolated murine heart model of stunning
ìcross-talkî appears to be incomplete. That is, while opioid
receptor-mediated protection can be abolished via adenosine
receptor antagonism, opioid receptor blockade has little ef-
fect upon adenosinergic cardioprotection. Furthermore, pre-
liminary data obtained from western blot analysis indicate
that increased activation of phosphoERK following mor-
phine exposure is abolished with concomitant blockade by
the A1 adenosine receptor antagonist, DPCPX. These results
suggest that an intact CNS maybe required for receptor
cross-talk between adenosine and opioids.In addition, recep-
tor cross-talk may be explained by receptor dimerization.
Dimerization can occur among identical GPCRs and those
from distinct families. GPCR dimerization may effect recep-
tor activation, ligand binding and signaling. Understanding
the consequences of cross-talk and dimerization may provide
novel approaches to limiting the detrimental effects of car-
diac ischemia and reperfusion.
Abstract N° S5C
KATP channel deficit and cardiac maladaptation
Garvan C. Kane, Mayo Clinic College of Medicine,
Rochester, MN, USA
ATP-sensitive potassium (KATP) channels are evolution-
arily conserved plasma-membrane protein complexes,
widely represented in tissue beds with high metabolic activ-
ity. There, they are formed through the physical association
of the inwardly rectifying potassium channel pore, most
typically Kir6.2, and the regulatory sulfonylurea receptor
subunit, an ATP-binding cassette protein. Energetic signals,
received via tight integration with cellular metabolic path-
ways, are processed by the sulfonylurea receptor subunit that
in turn gates the nucleotide sensitivity of the channel pore
thereby controlling membrane potential dependent cellular
functions. Recent findings, elicited from genetic disruption
of channel proteins, have established in vivo the requirement
of intact KATP channels in the proper function of cardiac
muscle under stress. Indeed, in the heart where KATP chan-
nels were originally discovered, ablation of the channel com-
plex compromises cardioprotection under ischemic insult.
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New data further implicate the requirement of intact KATP
channels for the cardiac adaptive response to acute stress.
Moreover, KATP channels have been implicated in the adap-
tive cardiac response to chronic physiologic and pathophysi-
ologic hemodynamic stress, with KATP channel deficiency
affecting the structural remodeling response, rendering the
heart vulnerable to calcium-dependent maladaptation predis-
posing to heart failure. These findings are underscored by the
identification in humans that defective KATP channels in-
duced by mutations in ABCC9, the gene encoding the cardiac
sulfonylurea receptor subunit, confer susceptibility to dilated
cardiomyopathy. Thus, these results expand our understand-
ing of the requirement for intact, functioning sarcolemmal
KATP channels in the cardiac stress response.
Abstract N° S5D
KATP channels and long-lasting cardioprotection
Kolar F., Neckar J., Ostadal B. Inst. Physiol. AS CR and Ctr.
Exp. Cardiovasc. Res., Prague, Czech Republic
Adaptation to chronic hypoxia (CH) confers long-lasting
myocardial protection against all major end-points of acute
ischemia and reperfusion injury but its mechanism remains
obscure. We examined roles of mitochondrial KATP (mKATP)
channels, reactive oxygen species (ROS) and protein kinase
C (PKC) in myocardial infarct size-limiting effect of CH
(20-min coronary artery occlusion and 3-h reperfusion in an
open-chest model). Adult male Wistar rats exposed to inter-
mittent (8 h/day) hypobaric hypoxia of 5000 m or 7000 m for
5-6 weeks exhibited infarct size reduction by 15 % or 30 %,
respectively, compared to normoxic controls. This protective
effect persisted and was still significant 5 weeks after the last
hypoxic exposure (10 % reduction). Chronic antioxidant
treatment (N-acetylcysteine, 100 mg/kg daily before the hy-
poxic exposure) attenuated infarct size limitation by CH.
Similar blunting effect occurred in rats exposed to CH com-
bined with hypercapnia (4.1 % CO2 in the air) which lowers
oxidative stress. MKATP blocker (5-hydroxydecanoate,
5 mg/kg), administered before ischemia, completely abol-
ished the protective effect of CH, while mKATP openers
(diazoxide or BMS-191095, 10 mg/kg) limited infarct size in
normoxic but not in CH rats. Neither antioxidants (tempol,
100 mg/kg or melatonin, 10 mg/kg) nor PKC inhibitor (chel-
erythrine, 1 mg/kg), given before ischemia, affected CH-
induced cardioprotection. It is concluded that oxidative stress
associated with CH contributes to the development of in-
creased cardiac ischemic tolerance. The protective mecha-
nism involves the activation of mKATP channels but presum-
ably not ROS- and PKC-dependent pathways during acute
ischemia.
Supported by GACR 305/04/0465.
Abstract N° S5E
The importance of the reperfusion phase in ischaemic
preconditioning
Derek J Hausenloy & Derek M Yellon. The Hatter Institute,
University College London, UK
The actual mechanism through which ischaemic precon-
ditioning (IPC) protects the heart against ischaemia-
reperfusion injury is unclear. Our recent studies have demon-
strated that IPC can protect the heart against ischaemia-
reperfusion injury by modifying crucial events, which take
place during the first few minutes of reperfusion.
The opening of the mitochondrial permeability transition
pore (mPTP), during the first few minutes of reperfusion,
which occurs in response to the prevailing conditions of
oxidative stress, a high mitochondrial [Ca2 + ], and relative
ATP depletion, is a critical determinant of lethal reperfusion
injury. Our previous studies have demonstrated that pharma-
cologically inhibiting mPTP opening at the time of reperfu-
sion is cardio-protective, in both the animal and human heart.
We have demonstrated that IPC protects the heart by inhibit-
ing the opening of the mPTP, at the time of reperfusion. IPC
may inhibit mPTP opening : (1) by reducing oxidative stress
at the time of reperfusion ; (2) by rendering mitochondria
more resistant to mPTP opening at the time of reperfusion ;
or (3) through the activation of pro-survival kinases, such as,
PI3K-Akt and MEK1/2-Erk1/2, which we have termed the
Reperfusion Injury Salvage Kinase (RISK)-Pathway.
We have demonstrated that the pharmacological activa-
tion of this RISK-Pathway, during the first few minutes of
reperfusion, is cardio-protective. Interestingly, we have re-
cently found that IPC induces the activation of the RISK-
Pathway, at the time of reperfusion, and that the activation of
the pro-survival kinases, PI3K-Akt and MEK1/2-Erk1/2, at
this time, is essential for IPC-induced protection. We postu-
late that these kinases mediate protection by inhibiting mPTP
opening at the time of reperfusion. Interestingly, we have
also demonstrated that the recently described phenomenon of
ischaemic postconditioning, also protects the heart by acti-
vating components of the RISK pathway, at the time of
reperfusion.
In conclusion, our recent data suggests that IPC protects
the heart by modifying crucial events, which occur during the
first few minutes of reperfusion, and demonstrates the impor-
tance of the reperfusion phase in IPC.
Abstract N° S5F
KATP channels and preconditioning in the neonatal
heart : are they up to the job ?
MJ Shattock, M Mukaida, M Baghai, W Awad, DJ
Chambers, N Alphonso, CB Austin, DR Anderson, King’s
College, London, UK
We have previously described a developmental change in
the ability of the heart to be protected by ischemic precondi-
tioning (IPC). Protection is absent in 4-day old neonatal rats
but appears gradually over the first 3 weeks of life. In the
human myocardium, the same maturational response occurs
over the first post-partum year. In adult heart, the signalling
pathway underlying protection has been defined and there is
general agreement that it involves - G-protein coupled
receptors > ?PKC ? > KATP channels > mitochondrial
perturbation > oxidant stress > an elusive end-effector. In the
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adult heart, KATP channel activation has been shown to
mimic IPC-induced cardioprotection. However, we have
shown while nicorandil can dose-dependently shorten the
action potential in adult human myocardium, it is ineffective
in the neonate. Thus, we have investigated whether (i) KATP
channel openers (KCOs) can protect neonatal hearts ? (ii)
KATP channels are expressed in neonatal hearts ?, (iii) KATP
channels are functional in neonatal hearts, and (iv) whether
bypassing KATP channels (either at the level of the mitochon-
dria or down-stream) can invoke protection ? The KCOs
cromakalim (10-6-10-4) nicorandil (100µM) and diazoxide
(30-600µM) all failed to protect the immature heart while
conferring protection in the adult. Western blotting for Kir
6.1, Kir 6.2 and SUR2A, shows KATP channels are expressed
in neonatal heart and voltage-clamp data shows that they are
functional and their sensitivity to KCOs is, in fact, increased.
Bypassing the mitoKATP channel by opening Ca-activated
mitoK channels with NS1619 (30µM) protected adult human
heart (protection was blocked by the antioxidant NAC
(4mM)) but failed to protect the neonate. Preliminary studies
with H2O2 (1-10µM) suggest that transient oxidant stress
may protect the neonatal heart. These results suggest that, in
neonatal heart, the lesion in the protective signalling pathway
is down-stream from the KATP channel and may be related to
its inability to generate an oxidant stress.
Abstract N° S6A
Myocardial gene profiling during human cardiac
hypertrophy and failure
Hari S. Sharma, Theodorus H.F. Peters, Peter van der Speka
and Ad J.J.C. Bogersb. Cardiopulmonary & Molecular
Biology Laboratory, Departments of Pharmacology,
aBioinformatics and bCardiothoracic-Surgery, Erasmus MC,
University Medical Center, Rotterdam, The Netherlands
Right ventricular hypertrophy and failure are prominent
features in cyanotic congenital heart disease, tetralogy of
Fallot (TF). Patients with TF require primary cardiac surgery
at a very young age. To get an insight into the underlying
molecular mechanisms of right ventricular hypertrophy and
to identify gene(s) involved in TF, differential gene expres-
sion profile was assessed using high density DNA microarray
chip analysis on right ventricular biopsies from TF patients
who underwent primary correction (TF-1, mean age 0.8 yr,
n = 12). Employing quantitative immunohistochemistry, ex-
pression of VEGF, flk-1 and extracellular matrix (ECM) pro-
teins (collagens and fibronectin) as well as vessels counts and
myocyte cell size were evaluated in TF-1 and TF-2 (mean
age 30 yrs, n = 12) patients in relation to age matched con-
trols (n = 8). Among 236 genes showing altered expression
pattern in TF patients, VEGF (1.8 fold) and ECM markers
were clearly up-regulated (fibronectin, 2.4 ; collagen Ia,
7.5 and collagen III, 4.4 folds), flk-1 and most MMPs re-
mained unchanged except the levels of MMP-13 and 17 were
declined. TIMPS showed down regulated pattern. Staining of
VEGF in cardiomyocytes and of ECM proteins (fibronectin,
collagen I and III) in interstitial as well as in peri-vascular
area were increased (p < 0.01) in TF patients. Morphometric
analysis revealed enhanced vascular density (65 ± 9 vs.
33 ± 3 vessels/mm2 ; p < 0.05) with unchanged wall thick-
ness and enlarged myocyte cross sectional areas
(262 ± 21 vs. 81 ± 7mm2 ; p < 0.01) with linear correlation
(r = 0.92, p < 0.01) with the age in TF-1 patients. We con-
clude that the up-regulation of genes encoding VEGF and
ECM proteins are the key events contributing to right ven-
tricular hypertrophy and stunted angiogenesis in patients
with TF.
Abstract N° S6B
Molecular regulators of cardiac cell growth and cell
death
Kelly M. Regula and Lorrie A. Kirshenbaum, Institute of
Cardiovascular Sciences, St. Boniface Hospital Research
Centre, Department of Physiology, University of Manitoba,
Winnipeg, Manitoba, R2H 2A6
One of the most compelling issues to impact on contem-
porary cardiology, is arguably the phenomenon of pro-
grammed cell death or apoptosis. Studies in the nematode C.
elegans provided the first indication that determinants of cell
fate crucial for normal worm development were under ge-
netic influences of the ced-3 and ced-9 genes- which promote
or prevent cell death, respectively. Extrapolation of these
seminal findings led to the discovery of the mammalian
ced-3 and ced-9 homologues which broadly encompass a
family of cellular cysteine proteases known collectively as
caspases and the Bcl-2 proteins. In quiescent cells, caspases
exist as inactive zymogens that are readily activated by auto-
catalytic processes or by other caspases following a death
signal. The caspase dependent cleavage of intracellular sub-
strates results in the biochemical dismantling of the cell and
morphological features characteristic of apoptosis. Recently,
a mitochondrial death pathway for apoptosis has been pro-
posed. Perturbations to mitochondria resulting in the loss of
mitochondrial membrane potential DWm, permeability tran-
sition pore opening and the release of pro-apoptotic factors
by mitochondria including cytochrome c, Smac/Diablo, AIF,
and others are considered terminal events in the apoptotic
pathway. Bcl-2 and related family members are character-
ized by their ability to promote or prevent cell death. These
proteins exert their pro- or anti-apoptosis function by im-
pinging on components of cell death pathway that underlie
caspase activation, mitochondrial dysfunction or both. The
limited regenerative potential of the adult cardiac muscle
itself, together with the heightened and exciting possibility of
regenerating cardiac muscle with cardiac progenitor cells,
acknowledges the need for new strategies to suppress and/or
prevent inappropriate cardiac cell death in patients with is-
chemic heart disease or heart patients failure as a therapeutic
means of preserving cardiac pump function after injury.
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Abstract N° S6C
Mechanical stretch activates angiotensin II type
1 receptor without involvement of angiotensin II
Issei Komuro, Department of Cardiovascular Science and
Medicine, Chiba University Graduate School of Medicine,
Chiba, Japan
Angiotensin II (AII) type 1 (AT1) receptor plays a critical
role in the load-induced cardiac hypertrophy. We here dem-
onstrate anAII-independent mechanism ofAT1 receptor acti-
vation by mechanical stress. Without the involvement of AII,
mechanical stress not only activated extracellular signal-
regulated kinases (ERKs) in vitro but also induced cardiac
hypertrophy in vivo. Mechanical stretch induced association
of AT1 receptor with Jak2, and translocation of G proteins
into the cytosol. All of these responses were inhibited by the
treatment with an AT1 receptor blocker, candesartan. There-
fore, mechanical stress activates AT1 receptor independently
of AII, which is inhibited by an inverse agonist candesartan.
Abstract N° S6D
Hormonal regulation of the Na+/H+ exchanger in the
heart
Pérez, Néstor Gustavo. Centro de Investigaciones
Cardiovasculares, Facultad de Ciencias Médicas de La Plata
(UNLP) Argentina
The Na+/H+ exchanger (NHE) is a pH-regulatory protein
that is present in many different cell types including cardiac
myocytes. It removes one intracellular proton in exchange
for one extracellular sodium in response to intracellular aci-
dosis, but hormones and growth factors can also activate it,
possibly through protein kinases and other regulatory pro-
teins. In the myocardium, angiotensin II (AngII), endothelin
(ET), thrombin and a1-adrenergic stimulation were shown to
activate the NHE. Experiments performed by us suggest that
NHE activation is the central step for the positive inotropic
response to low concentrations of AngII. The enhanced activ-
ity of the NHE by increasing the intracellular Na+ concentra-
tion favors the reverse mode of the Na+/Ca2 + exchanger,
with the consequent increase in the Ca2 + T that determines
the increase in force. ET is an autocrine/paracrine factor that
mediates this effect.
Abstract N° S6E
Computer simulation of failing heart
Seiryo Sugiura, Toshiaki Hisada, Hiroshi Watanabe,
Jun-ichi Okada@ University of Tokyo
To integrate the vast amount of information acquired at
multiple levels of biological system, computational science
is now recognized as an indispensable tool. We have devel-
oped a fluid-structure interaction finite element model of the
human left ventricle contraction and relaxation of each struc-
tural element is driven by the molecular mechanism of exci-
tation contraction coupling of cardiac myocyte. Because the
structure (ventricular wall) and the fluid (blood) were formu-
lated by strong coupling strategy, the model could success-
fully reproduce not only the pressure-volume relation but
also the instantaneous flow distribution during the ejection
and filling of the ventricle. Furthermore, by introducing mo-
lecular abnormalities idenitfied in heart failure we could also
reproduce the hemodynamics as well as echocardiographic
finding of the failing heart. Other diseased conditions will
also be discussed in the presentation.
Abstract N° S7A
Stemming myocardial damage with stem cells : an
overview
M Ashraf, K Haider. Department of Pathology, University
of Cincinnati Medical Ctr, Cincinnati, Ohio, USA
Patients with heart failure remain a therapeutic challenge.
The contemporary therapeutic modalities including heart
transplant, assist devices and medical therapy have their
shortcomings and limitations. Cell transplantation and an-
giogenesis are novel and promising strategies at molecular
and cellular levels.
Transplantation of multiple adult stem cell types, espe-
cially skeletal myoblast and bone marrow derived stem cells,
into ischemic and infarction animal models has demonstrated
graft survival, cell fusion and improved myocardial function.
An interesting aspect of the studies has been the use of
transient immunosuppression or even no immunosuppres-
sion in some cases, leading to longer term survival of the
cellular graft.Human phase-1 studies have proven safety of
the procedure with encouraging results.
Another interesting aspect of stem cell research is cellular
angiogenesis. Transplantation of cells with inherent ability to
express angiogenic growth factors or genetic modulation of
donor cells to over-express angiogenic growth factors has
shown increased collateral formation and enhanced regional
blood flow in ischemically damaged myocardium. Combin-
ing cell transplantation and angiogenesis, it has been shown
that the donor cells survive and integrate with the host tissue
and may carry exogenous gene for cardiac muscle cells. This
combined strategy of cell transplantation with gene therapy
may be cardioprotective for the ischemic myocardium. Myo-
cardial regeneration with stem-cell transplantation and its
combination with angiogenesis potentially reverse the de-
pleted functional, hemodynamic and neurohormonal effects
that occur after myocardial infarction.
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Abstract N° S7B
Development of the cardiac conduction system
Antoon FM Moorman and Vincent Christoffels, Department
of Anatomy & Embryology, Academic Medical Center,
University of Amsterdam, The Netherlands
The conduction system is generally held responsible for
the rhythmic and coordinated electrical activity of the heart.
Because an adult type of ECG can already be derived from
very early embryonic hearts, it is often assumed that these
hearts have a conduction system, which, in turn, proofed
difficult to identify and led to much controversy. If we accept
that the most conspicuous features of the electrocardiogram
are caused by the electrical activity associated with the rapid
depolarisation of the atria and ventricles it is equally reason-
able to assume that the adult type of electrocardiogram in the
early heart finds its origin in the formation of the fast-
conducting working myocardium of the chambers rather than
in the formation of a conduction system.
Why certain areas of the heart tube do not develop into the
working myocardium of the chambers and contribute to the
formation of the cardiac conduction system is one of the key
questions of cardiac embryology. By our recent findings that
the transcriptional repressors Tbx2 and Tbx3 repress the
chamber-specific program of gene expression and chamber
formation in transgenic animals over-expressing these fac-
tors, we are beginning to understand these morphogenetic
processes. Detailed reconstructions of the developmental
patterns of expression of Tbx3 during development have
revealed, that Tbx3 is expressed in those areas of the heart
tube that do not become chamber, i.e. in the sinu-nodal
region, internodal region, atrioventricular junction, atrioven-
tricular bundle and bundle branches. These areas comprise
not only the conventional conduction system, but also the
highly controversial areas of the internodal region and the
entire atrioventricular junction. The pulmonary veins drain
directly upon the developing left atrium in a myocardial
region that has a « chamber » molecular phenotype
(Connexin40 positive) rather than an embryonic or nodal
phenotype not supporting the notion that the embryonic
(nodal) origin of the pulmonary myocardium explains ar-
rhythmias originating from this area.
Abstract N° S7E
Fasciclins induce differentiation of cardiac cushion
mesenchymal cells into valvular fibrous tissues
Roger Markwald and Simon Conwaya. Medical University
of South Carolina and University of Indianaa, USA
Cushion cells are endocardially derived cells that form
within primitive segments located at the inlet and outlet of
the ventricles. Cushion cells have potential to differentiate
into cardiac muscle, bone, bone marrow and cartilage but
normally give origin to valvular fibroblasts. Based on mi-
croarray analysis and studies with cultured MC3T3 cells, we
have proposed that fasciclin genes promote differentiation of
cushion cells into fibroblasts and/or inhibit their differentia-
tion into calcifying lineages. In vivo, cushion cells and their
fibroblastic progeny express 3 fasciclin proteins, periostin,
bigH3 and stabilin 2 during embryonic and fetal life while
periostin and bigH3 continue to be expressed into adult life.
Fasciclins are cell surface secreted proteins that modify cell-
:cell or cell :matrix interactions in invertebrates. Based on
antibody, in situ hybridization and promoter-reporter studies,
periostin expression in chick and mice embryos correlates
spatially and temporally with the Histogenic pattern of fi-
brous tissue (dense vs. loose) in future valve leaflets and with
the formation of tendinous suspensory cords. We used gene
targeting strategies to create two lines of periostin knockout
mice. We found that valve leaflets in newborn null mice were
variably affected, some (aortic leaflet) were totally hypoplas-
tic while others (mitral, tricuspid) exhibited a mixed pheno-
type of normal dense fibrous tissue interspersed with expan-
sions of undifferentiated mesenchyme. Additionally,
tendinous cords were absent and leaflets failed to delaminate
from the associated ventricular myocardium. Approximately
20 % of newborns died at day 12. To further assess function,
we developed adenoviral vectors to over express or inhibit
periostin expression. Infection of micromass cultures with
full length antisense virus prevented formation of
3-dimensional, dense, fibrous rings that normally develop in
this culture system. Instead, chondrogenic tissue developed.
To simulate a more in vivo like setting, we engineered tubular
scaffolds of aligned collagen which were seeded with fetal
cardiomyocytes and connected to a circulating bioreactor.
Embryonic chick cushions were attached to the luminal sur-
face of these pulsatile and contractile linear « hearts ». Over
time, they elongated into preleaflet-like structures which
expressed fasciclins. Infection with virus carrying full length
sense periostin cDNA engendered premature dense fibrous
tissue formation within virally infected cells whereas infec-
tion with full length, antisense vectors resulted in chondro-
genesis. These findings indicate fasciclins regulate valvulo-
genesis by promoting and sustaining differentiation of
cushion stem cells into a fibrogenic lineage. Supported by
NIH Grants : HL 33756, HL 53128.
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